{
  "cells": [
    {
      "cell_type": "markdown",
      "id": "1101434d",
      "metadata": {
        "id": "1101434d"
      },
      "source": [
        "\n",
        "# Build a Tool-Use ReAct Agentic AI System with LangGraph"
      ]
    },
    {
      "cell_type": "markdown",
      "source": [
        "## Problem Statement\n",
        "\n",
        "In this notebook, we will be building an Agentic AI system â€” HealthBuddy â€” using LangGraph with built-in utility functions. This system will act as an intelligent assistant that can:\n",
        "\n",
        "- Understand user queries about health\n",
        "- Research using web and arXiv tools\n",
        "- Recommend appropriate doctors based on user symptoms\n",
        "\n",
        "We will follow the **ReAct principle** (Reason + Act) to let the agent think, use tools when needed, observe results, and provide a well-formed final answer. Instead of relying on built-in LLM knowledge alone, the agent will use **external tools** to gather accurate and helpful information before responding.\n",
        "\n",
        "\n",
        "---\n",
        "\n",
        "### Objective:\n",
        "\n",
        "Our goals in this notebook are:\n",
        "\n",
        "- **Build a ReAct-based Tool-Use Agent using LangGraph with built-in utility functions like `create_react_agent()`**\n",
        "- Equip the agent with multiple tools (web search, arXiv search, doctor recommendation)\n",
        "- Handle user queries end-to-end â€” from interpreting intent to delivering a useful, cited, and grounded response\n",
        "- Simulate a multi-step reasoning and tool-using workflow\n",
        "\n",
        "By the end of this notebook, we will have a working agent that can research a health query, gather relevant information, and offer advice including suggesting a doctor â€” all through structured decision-making and tool usage.\n",
        "\n",
        "### Agent Architecture:\n",
        "\n",
        "The following figure shows the agent architecture including all the components and the overall workflow\n",
        "\n",
        "![](https://i.imgur.com/efDt1tq.png)\n"
      ],
      "metadata": {
        "id": "7itPJfyXgfas"
      },
      "id": "7itPJfyXgfas"
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "id": "9bf7b469",
      "metadata": {
        "id": "9bf7b469",
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "outputId": "f3abc925-1c83-4f59-f8ce-dace2ae5a1f2"
      },
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Collecting langgraph==1.0.2\n",
            "  Downloading langgraph-1.0.2-py3-none-any.whl.metadata (7.4 kB)\n",
            "Collecting langchain==1.0.5\n",
            "  Downloading langchain-1.0.5-py3-none-any.whl.metadata (4.9 kB)\n",
            "Collecting langchain-openai==1.0.2\n",
            "  Downloading langchain_openai-1.0.2-py3-none-any.whl.metadata (1.8 kB)\n",
            "Collecting langchain-community==0.4.1\n",
            "  Downloading langchain_community-0.4.1-py3-none-any.whl.metadata (3.0 kB)\n",
            "Collecting arxiv==2.3.0\n",
            "  Downloading arxiv-2.3.0-py3-none-any.whl.metadata (5.2 kB)\n",
            "Collecting pymupdf==1.26.6\n",
            "  Downloading pymupdf-1.26.6-cp310-abi3-manylinux_2_28_x86_64.whl.metadata (3.4 kB)\n",
            "Requirement already satisfied: langchain-core>=0.1 in /usr/local/lib/python3.12/dist-packages (from langgraph==1.0.2) (0.3.79)\n",
            "Collecting langgraph-checkpoint<4.0.0,>=2.1.0 (from langgraph==1.0.2)\n",
            "  Downloading langgraph_checkpoint-3.0.1-py3-none-any.whl.metadata (4.7 kB)\n",
            "Collecting langgraph-prebuilt<1.1.0,>=1.0.2 (from langgraph==1.0.2)\n",
            "  Downloading langgraph_prebuilt-1.0.2-py3-none-any.whl.metadata (5.0 kB)\n",
            "Collecting langgraph-sdk<0.3.0,>=0.2.2 (from langgraph==1.0.2)\n",
            "  Downloading langgraph_sdk-0.2.9-py3-none-any.whl.metadata (1.5 kB)\n",
            "Requirement already satisfied: pydantic>=2.7.4 in /usr/local/lib/python3.12/dist-packages (from langgraph==1.0.2) (2.11.10)\n",
            "Requirement already satisfied: xxhash>=3.5.0 in /usr/local/lib/python3.12/dist-packages (from langgraph==1.0.2) (3.6.0)\n",
            "Collecting langchain-core>=0.1 (from langgraph==1.0.2)\n",
            "  Downloading langchain_core-1.0.4-py3-none-any.whl.metadata (3.5 kB)\n",
            "Requirement already satisfied: openai<3.0.0,>=1.109.1 in /usr/local/lib/python3.12/dist-packages (from langchain-openai==1.0.2) (1.109.1)\n",
            "Requirement already satisfied: tiktoken<1.0.0,>=0.7.0 in /usr/local/lib/python3.12/dist-packages (from langchain-openai==1.0.2) (0.12.0)\n",
            "Collecting langchain-classic<2.0.0,>=1.0.0 (from langchain-community==0.4.1)\n",
            "  Downloading langchain_classic-1.0.0-py3-none-any.whl.metadata (3.9 kB)\n",
            "Requirement already satisfied: SQLAlchemy<3.0.0,>=1.4.0 in /usr/local/lib/python3.12/dist-packages (from langchain-community==0.4.1) (2.0.44)\n",
            "Collecting requests<3.0.0,>=2.32.5 (from langchain-community==0.4.1)\n",
            "  Downloading requests-2.32.5-py3-none-any.whl.metadata (4.9 kB)\n",
            "Requirement already satisfied: PyYAML<7.0.0,>=5.3.0 in /usr/local/lib/python3.12/dist-packages (from langchain-community==0.4.1) (6.0.3)\n",
            "Requirement already satisfied: aiohttp<4.0.0,>=3.8.3 in /usr/local/lib/python3.12/dist-packages (from langchain-community==0.4.1) (3.13.2)\n",
            "Requirement already satisfied: tenacity!=8.4.0,<10.0.0,>=8.1.0 in /usr/local/lib/python3.12/dist-packages (from langchain-community==0.4.1) (8.5.0)\n",
            "Collecting dataclasses-json<0.7.0,>=0.6.7 (from langchain-community==0.4.1)\n",
            "  Downloading dataclasses_json-0.6.7-py3-none-any.whl.metadata (25 kB)\n",
            "Requirement already satisfied: pydantic-settings<3.0.0,>=2.10.1 in /usr/local/lib/python3.12/dist-packages (from langchain-community==0.4.1) (2.11.0)\n",
            "Requirement already satisfied: langsmith<1.0.0,>=0.1.125 in /usr/local/lib/python3.12/dist-packages (from langchain-community==0.4.1) (0.4.40)\n",
            "Requirement already satisfied: httpx-sse<1.0.0,>=0.4.0 in /usr/local/lib/python3.12/dist-packages (from langchain-community==0.4.1) (0.4.3)\n",
            "Requirement already satisfied: numpy>=1.26.2 in /usr/local/lib/python3.12/dist-packages (from langchain-community==0.4.1) (2.0.2)\n",
            "Collecting feedparser~=6.0.10 (from arxiv==2.3.0)\n",
            "  Downloading feedparser-6.0.12-py3-none-any.whl.metadata (2.7 kB)\n",
            "Requirement already satisfied: aiohappyeyeballs>=2.5.0 in /usr/local/lib/python3.12/dist-packages (from aiohttp<4.0.0,>=3.8.3->langchain-community==0.4.1) (2.6.1)\n",
            "Requirement already satisfied: aiosignal>=1.4.0 in /usr/local/lib/python3.12/dist-packages (from aiohttp<4.0.0,>=3.8.3->langchain-community==0.4.1) (1.4.0)\n",
            "Requirement already satisfied: attrs>=17.3.0 in /usr/local/lib/python3.12/dist-packages (from aiohttp<4.0.0,>=3.8.3->langchain-community==0.4.1) (25.4.0)\n",
            "Requirement already satisfied: frozenlist>=1.1.1 in /usr/local/lib/python3.12/dist-packages (from aiohttp<4.0.0,>=3.8.3->langchain-community==0.4.1) (1.8.0)\n",
            "Requirement already satisfied: multidict<7.0,>=4.5 in /usr/local/lib/python3.12/dist-packages (from aiohttp<4.0.0,>=3.8.3->langchain-community==0.4.1) (6.7.0)\n",
            "Requirement already satisfied: propcache>=0.2.0 in /usr/local/lib/python3.12/dist-packages (from aiohttp<4.0.0,>=3.8.3->langchain-community==0.4.1) (0.4.1)\n",
            "Requirement already satisfied: yarl<2.0,>=1.17.0 in /usr/local/lib/python3.12/dist-packages (from aiohttp<4.0.0,>=3.8.3->langchain-community==0.4.1) (1.22.0)\n",
            "Collecting marshmallow<4.0.0,>=3.18.0 (from dataclasses-json<0.7.0,>=0.6.7->langchain-community==0.4.1)\n",
            "  Downloading marshmallow-3.26.1-py3-none-any.whl.metadata (7.3 kB)\n",
            "Collecting typing-inspect<1,>=0.4.0 (from dataclasses-json<0.7.0,>=0.6.7->langchain-community==0.4.1)\n",
            "  Downloading typing_inspect-0.9.0-py3-none-any.whl.metadata (1.5 kB)\n",
            "Collecting sgmllib3k (from feedparser~=6.0.10->arxiv==2.3.0)\n",
            "  Downloading sgmllib3k-1.0.0.tar.gz (5.8 kB)\n",
            "  Preparing metadata (setup.py) ... \u001b[?25l\u001b[?25hdone\n",
            "Collecting langchain-text-splitters<2.0.0,>=1.0.0 (from langchain-classic<2.0.0,>=1.0.0->langchain-community==0.4.1)\n",
            "  Downloading langchain_text_splitters-1.0.0-py3-none-any.whl.metadata (2.6 kB)\n",
            "Requirement already satisfied: jsonpatch<2.0.0,>=1.33.0 in /usr/local/lib/python3.12/dist-packages (from langchain-core>=0.1->langgraph==1.0.2) (1.33)\n",
            "Requirement already satisfied: packaging<26.0.0,>=23.2.0 in /usr/local/lib/python3.12/dist-packages (from langchain-core>=0.1->langgraph==1.0.2) (25.0)\n",
            "Requirement already satisfied: typing-extensions<5.0.0,>=4.7.0 in /usr/local/lib/python3.12/dist-packages (from langchain-core>=0.1->langgraph==1.0.2) (4.15.0)\n",
            "Collecting ormsgpack>=1.12.0 (from langgraph-checkpoint<4.0.0,>=2.1.0->langgraph==1.0.2)\n",
            "  Downloading ormsgpack-1.12.0-cp312-cp312-manylinux_2_17_x86_64.manylinux2014_x86_64.whl.metadata (1.2 kB)\n",
            "Requirement already satisfied: httpx>=0.25.2 in /usr/local/lib/python3.12/dist-packages (from langgraph-sdk<0.3.0,>=0.2.2->langgraph==1.0.2) (0.28.1)\n",
            "Requirement already satisfied: orjson>=3.10.1 in /usr/local/lib/python3.12/dist-packages (from langgraph-sdk<0.3.0,>=0.2.2->langgraph==1.0.2) (3.11.4)\n",
            "Requirement already satisfied: requests-toolbelt>=1.0.0 in /usr/local/lib/python3.12/dist-packages (from langsmith<1.0.0,>=0.1.125->langchain-community==0.4.1) (1.0.0)\n",
            "Requirement already satisfied: zstandard>=0.23.0 in /usr/local/lib/python3.12/dist-packages (from langsmith<1.0.0,>=0.1.125->langchain-community==0.4.1) (0.25.0)\n",
            "Requirement already satisfied: anyio<5,>=3.5.0 in /usr/local/lib/python3.12/dist-packages (from openai<3.0.0,>=1.109.1->langchain-openai==1.0.2) (4.11.0)\n",
            "Requirement already satisfied: distro<2,>=1.7.0 in /usr/local/lib/python3.12/dist-packages (from openai<3.0.0,>=1.109.1->langchain-openai==1.0.2) (1.9.0)\n",
            "Requirement already satisfied: jiter<1,>=0.4.0 in /usr/local/lib/python3.12/dist-packages (from openai<3.0.0,>=1.109.1->langchain-openai==1.0.2) (0.11.1)\n",
            "Requirement already satisfied: sniffio in /usr/local/lib/python3.12/dist-packages (from openai<3.0.0,>=1.109.1->langchain-openai==1.0.2) (1.3.1)\n",
            "Requirement already satisfied: tqdm>4 in /usr/local/lib/python3.12/dist-packages (from openai<3.0.0,>=1.109.1->langchain-openai==1.0.2) (4.67.1)\n",
            "Requirement already satisfied: annotated-types>=0.6.0 in /usr/local/lib/python3.12/dist-packages (from pydantic>=2.7.4->langgraph==1.0.2) (0.7.0)\n",
            "Requirement already satisfied: pydantic-core==2.33.2 in /usr/local/lib/python3.12/dist-packages (from pydantic>=2.7.4->langgraph==1.0.2) (2.33.2)\n",
            "Requirement already satisfied: typing-inspection>=0.4.0 in /usr/local/lib/python3.12/dist-packages (from pydantic>=2.7.4->langgraph==1.0.2) (0.4.2)\n",
            "Requirement already satisfied: python-dotenv>=0.21.0 in /usr/local/lib/python3.12/dist-packages (from pydantic-settings<3.0.0,>=2.10.1->langchain-community==0.4.1) (1.2.1)\n",
            "Requirement already satisfied: charset_normalizer<4,>=2 in /usr/local/lib/python3.12/dist-packages (from requests<3.0.0,>=2.32.5->langchain-community==0.4.1) (3.4.4)\n",
            "Requirement already satisfied: idna<4,>=2.5 in /usr/local/lib/python3.12/dist-packages (from requests<3.0.0,>=2.32.5->langchain-community==0.4.1) (3.11)\n",
            "Requirement already satisfied: urllib3<3,>=1.21.1 in /usr/local/lib/python3.12/dist-packages (from requests<3.0.0,>=2.32.5->langchain-community==0.4.1) (2.5.0)\n",
            "Requirement already satisfied: certifi>=2017.4.17 in /usr/local/lib/python3.12/dist-packages (from requests<3.0.0,>=2.32.5->langchain-community==0.4.1) (2025.10.5)\n",
            "Requirement already satisfied: greenlet>=1 in /usr/local/lib/python3.12/dist-packages (from SQLAlchemy<3.0.0,>=1.4.0->langchain-community==0.4.1) (3.2.4)\n",
            "Requirement already satisfied: regex>=2022.1.18 in /usr/local/lib/python3.12/dist-packages (from tiktoken<1.0.0,>=0.7.0->langchain-openai==1.0.2) (2024.11.6)\n",
            "Requirement already satisfied: httpcore==1.* in /usr/local/lib/python3.12/dist-packages (from httpx>=0.25.2->langgraph-sdk<0.3.0,>=0.2.2->langgraph==1.0.2) (1.0.9)\n",
            "Requirement already satisfied: h11>=0.16 in /usr/local/lib/python3.12/dist-packages (from httpcore==1.*->httpx>=0.25.2->langgraph-sdk<0.3.0,>=0.2.2->langgraph==1.0.2) (0.16.0)\n",
            "Requirement already satisfied: jsonpointer>=1.9 in /usr/local/lib/python3.12/dist-packages (from jsonpatch<2.0.0,>=1.33.0->langchain-core>=0.1->langgraph==1.0.2) (3.0.0)\n",
            "Collecting mypy-extensions>=0.3.0 (from typing-inspect<1,>=0.4.0->dataclasses-json<0.7.0,>=0.6.7->langchain-community==0.4.1)\n",
            "  Downloading mypy_extensions-1.1.0-py3-none-any.whl.metadata (1.1 kB)\n",
            "Downloading langgraph-1.0.2-py3-none-any.whl (156 kB)\n",
            "\u001b[2K   \u001b[90mâ”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”\u001b[0m \u001b[32m156.8/156.8 kB\u001b[0m \u001b[31m5.3 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n",
            "\u001b[?25hDownloading langchain-1.0.5-py3-none-any.whl (93 kB)\n",
            "\u001b[2K   \u001b[90mâ”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”\u001b[0m \u001b[32m93.8/93.8 kB\u001b[0m \u001b[31m5.9 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n",
            "\u001b[?25hDownloading langchain_openai-1.0.2-py3-none-any.whl (81 kB)\n",
            "\u001b[2K   \u001b[90mâ”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”\u001b[0m \u001b[32m81.9/81.9 kB\u001b[0m \u001b[31m7.9 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n",
            "\u001b[?25hDownloading langchain_community-0.4.1-py3-none-any.whl (2.5 MB)\n",
            "\u001b[2K   \u001b[90mâ”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”\u001b[0m \u001b[32m2.5/2.5 MB\u001b[0m \u001b[31m34.8 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n",
            "\u001b[?25hDownloading arxiv-2.3.0-py3-none-any.whl (11 kB)\n",
            "Downloading pymupdf-1.26.6-cp310-abi3-manylinux_2_28_x86_64.whl (24.1 MB)\n",
            "\u001b[2K   \u001b[90mâ”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”\u001b[0m \u001b[32m24.1/24.1 MB\u001b[0m \u001b[31m77.9 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n",
            "\u001b[?25hDownloading dataclasses_json-0.6.7-py3-none-any.whl (28 kB)\n",
            "Downloading feedparser-6.0.12-py3-none-any.whl (81 kB)\n",
            "\u001b[2K   \u001b[90mâ”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”\u001b[0m \u001b[32m81.5/81.5 kB\u001b[0m \u001b[31m6.8 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n",
            "\u001b[?25hDownloading langchain_classic-1.0.0-py3-none-any.whl (1.0 MB)\n",
            "\u001b[2K   \u001b[90mâ”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”\u001b[0m \u001b[32m1.0/1.0 MB\u001b[0m \u001b[31m59.9 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n",
            "\u001b[?25hDownloading langchain_core-1.0.4-py3-none-any.whl (471 kB)\n",
            "\u001b[2K   \u001b[90mâ”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”\u001b[0m \u001b[32m471.2/471.2 kB\u001b[0m \u001b[31m40.6 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n",
            "\u001b[?25hDownloading langgraph_checkpoint-3.0.1-py3-none-any.whl (46 kB)\n",
            "\u001b[2K   \u001b[90mâ”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”\u001b[0m \u001b[32m46.2/46.2 kB\u001b[0m \u001b[31m4.0 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n",
            "\u001b[?25hDownloading langgraph_prebuilt-1.0.2-py3-none-any.whl (34 kB)\n",
            "Downloading langgraph_sdk-0.2.9-py3-none-any.whl (56 kB)\n",
            "\u001b[2K   \u001b[90mâ”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”\u001b[0m \u001b[32m56.8/56.8 kB\u001b[0m \u001b[31m5.1 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n",
            "\u001b[?25hDownloading requests-2.32.5-py3-none-any.whl (64 kB)\n",
            "\u001b[2K   \u001b[90mâ”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”\u001b[0m \u001b[32m64.7/64.7 kB\u001b[0m \u001b[31m5.4 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n",
            "\u001b[?25hDownloading langchain_text_splitters-1.0.0-py3-none-any.whl (33 kB)\n",
            "Downloading marshmallow-3.26.1-py3-none-any.whl (50 kB)\n",
            "\u001b[2K   \u001b[90mâ”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”\u001b[0m \u001b[32m50.9/50.9 kB\u001b[0m \u001b[31m4.6 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n",
            "\u001b[?25hDownloading ormsgpack-1.12.0-cp312-cp312-manylinux_2_17_x86_64.manylinux2014_x86_64.whl (208 kB)\n",
            "\u001b[2K   \u001b[90mâ”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”\u001b[0m \u001b[32m208.3/208.3 kB\u001b[0m \u001b[31m18.6 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n",
            "\u001b[?25hDownloading typing_inspect-0.9.0-py3-none-any.whl (8.8 kB)\n",
            "Downloading mypy_extensions-1.1.0-py3-none-any.whl (5.0 kB)\n",
            "Building wheels for collected packages: sgmllib3k\n",
            "  Building wheel for sgmllib3k (setup.py) ... \u001b[?25l\u001b[?25hdone\n",
            "  Created wheel for sgmllib3k: filename=sgmllib3k-1.0.0-py3-none-any.whl size=6046 sha256=c4215a102fcba4544c46f5f791c900ae1c5089af8e4f973af8e9e6179658d590\n",
            "  Stored in directory: /root/.cache/pip/wheels/03/f5/1a/23761066dac1d0e8e683e5fdb27e12de53209d05a4a37e6246\n",
            "Successfully built sgmllib3k\n",
            "Installing collected packages: sgmllib3k, requests, pymupdf, ormsgpack, mypy-extensions, marshmallow, feedparser, typing-inspect, arxiv, langgraph-sdk, dataclasses-json, langchain-core, langgraph-checkpoint, langchain-text-splitters, langchain-openai, langgraph-prebuilt, langchain-classic, langgraph, langchain-community, langchain\n",
            "  Attempting uninstall: requests\n",
            "    Found existing installation: requests 2.32.4\n",
            "    Uninstalling requests-2.32.4:\n",
            "      Successfully uninstalled requests-2.32.4\n",
            "  Attempting uninstall: langchain-core\n",
            "    Found existing installation: langchain-core 0.3.79\n",
            "    Uninstalling langchain-core-0.3.79:\n",
            "      Successfully uninstalled langchain-core-0.3.79\n",
            "  Attempting uninstall: langchain-text-splitters\n",
            "    Found existing installation: langchain-text-splitters 0.3.11\n",
            "    Uninstalling langchain-text-splitters-0.3.11:\n",
            "      Successfully uninstalled langchain-text-splitters-0.3.11\n",
            "  Attempting uninstall: langchain\n",
            "    Found existing installation: langchain 0.3.27\n",
            "    Uninstalling langchain-0.3.27:\n",
            "      Successfully uninstalled langchain-0.3.27\n",
            "\u001b[31mERROR: pip's dependency resolver does not currently take into account all the packages that are installed. This behaviour is the source of the following dependency conflicts.\n",
            "google-colab 1.0.0 requires requests==2.32.4, but you have requests 2.32.5 which is incompatible.\u001b[0m\u001b[31m\n",
            "\u001b[0mSuccessfully installed arxiv-2.3.0 dataclasses-json-0.6.7 feedparser-6.0.12 langchain-1.0.5 langchain-classic-1.0.0 langchain-community-0.4.1 langchain-core-1.0.4 langchain-openai-1.0.2 langchain-text-splitters-1.0.0 langgraph-1.0.2 langgraph-checkpoint-3.0.1 langgraph-prebuilt-1.0.2 langgraph-sdk-0.2.9 marshmallow-3.26.1 mypy-extensions-1.1.0 ormsgpack-1.12.0 pymupdf-1.26.6 requests-2.32.5 sgmllib3k-1.0.0 typing-inspect-0.9.0\n"
          ]
        }
      ],
      "source": [
        "!pip install langgraph==1.0.2 langchain==1.0.5 langchain-openai==1.0.2 langchain-community==0.4.1 arxiv==2.3.0 pymupdf==1.26.6"
      ]
    },
    {
      "cell_type": "markdown",
      "source": [
        "## Load Necessary Dependencies"
      ],
      "metadata": {
        "id": "BORSQbHHsVsq"
      },
      "id": "BORSQbHHsVsq"
    },
    {
      "cell_type": "code",
      "source": [
        "import json\n",
        "from langchain_openai import ChatOpenAI\n",
        "from langchain_core.tools import tool\n",
        "from langchain_core.messages import SystemMessage, HumanMessage\n",
        "from langgraph.prebuilt import create_react_agent\n",
        "from IPython.display import display, Image, Markdown"
      ],
      "metadata": {
        "id": "QQ_lWEMZxSmO"
      },
      "id": "QQ_lWEMZxSmO",
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "markdown",
      "source": [
        "## Setup Authentication and LLM Client\n",
        "\n",
        "Here we authenticate and connect to necessary LLM using OpenAI Authentication"
      ],
      "metadata": {
        "id": "crTRTYdTKxGv"
      },
      "id": "crTRTYdTKxGv"
    },
    {
      "cell_type": "code",
      "source": [
        "import os\n",
        "import getpass\n",
        "\n",
        "# OpenAI API Key (for chat & embeddings)\n",
        "if not os.environ.get(\"OPENAI_API_KEY\"):\n",
        "    os.environ[\"OPENAI_API_KEY\"] = getpass.getpass(\"Enter your OpenAI API key (https://platform.openai.com/account/api-keys):\\n\")\n",
        "\n",
        "# Tavily API Key (for web search)\n",
        "if not os.environ.get(\"TAVILY_API_KEY\"):\n",
        "    os.environ[\"TAVILY_API_KEY\"] = getpass.getpass(\"Enter your Tavily API key (https://app.tavily.com/home):\\n\")"
      ],
      "metadata": {
        "id": "KbYgtNWOv4P_",
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "outputId": "1f372205-a233-476c-c569-c368b051cd0e"
      },
      "id": "KbYgtNWOv4P_",
      "execution_count": null,
      "outputs": [
        {
          "name": "stdout",
          "output_type": "stream",
          "text": [
            "Enter your OpenAI API key (https://platform.openai.com/account/api-keys):\n",
            "Â·Â·Â·Â·Â·Â·Â·Â·Â·Â·\n",
            "Enter your Tavily API key (https://app.tavily.com/home):\n",
            "Â·Â·Â·Â·Â·Â·Â·Â·Â·Â·\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "llm_client = ChatOpenAI(model_name=\"gpt-4o-mini\")"
      ],
      "metadata": {
        "id": "Sfd4PAxHxxRv"
      },
      "id": "Sfd4PAxHxxRv",
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "markdown",
      "source": [
        "## Preparing Database for Doctor Recommendations Tool\n",
        "\n",
        "In this section, we will create a small, in-memory database that contains information about doctors. This data will be used by our **Doctor Recommendation Tool**, which will help users find the right doctor based on their health query or symptoms.\n",
        "\n",
        "The database includes a list of doctors along with their:\n",
        "- Name\n",
        "- Specialization (e.g., Dermatology, Pediatrics, Cardiology)\n",
        "- Location\n",
        "- Availability\n",
        "- Contact information\n",
        "\n",
        "We are using a simple Python list of dictionaries to store the doctor data. This keeps it easy to understand and modify. In a real-world application, this would typically be replaced by a backend database like PostgreSQL, MongoDB, or an external API.\n",
        "\n",
        "We will build a tool later on to use this data to recommend doctors based on the user's needs â€” for example, suggesting a pediatrician for a childâ€™s fever or a cardiologist for chest pain."
      ],
      "metadata": {
        "id": "yOuACuleCIjE"
      },
      "id": "yOuACuleCIjE"
    },
    {
      "cell_type": "code",
      "source": [
        "# loading our doctors dataset\n",
        "doctors_db = [\n",
        "    {\"name\": \"Dr. Janet Dyne\", \"specialization\": \"Endocrinology (Diabetes Care)\", \"available_timings\": \"10:00 AM - 1:00 PM\", \"location\": \"City Health Clinic\", \"contact\": \"janet.dyne@healthclinic.com\"},\n",
        "    {\"name\": \"Dr. Don Blake \", \"specialization\": \"Cardiology (Heart Specialist)\", \"available_timings\": \"2:00 PM - 5:00 PM\", \"location\": \"Metro Cardiac Center\", \"contact\": \"don.blake@metrocardiac.com\"},\n",
        "    {\"name\": \"Dr. Susan D'Souza\", \"specialization\": \"Oncology (Cancer Care)\", \"available_timings\": \"11:00 AM - 2:00 PM\", \"location\": \"Hope Cancer Institute\", \"contact\": \"susan.dsouza@hopecancer.org\"},\n",
        "    {\"name\": \"Dr. Matt Murdock\", \"specialization\": \"Psychiatry (Mental Health)\", \"available_timings\": \"4:00 PM - 7:00 PM\", \"location\": \"Mind Care Center\", \"contact\": \"matt.murdock@mindcare.com\"},\n",
        "    {\"name\": \"Dr. Dinah Lance\", \"specialization\": \"General Physician\", \"available_timings\": \"9:00 AM - 12:00 PM\", \"location\": \"Downtown Medical Center\", \"contact\": \"dinah.lance@downtownmed.com\"}\n",
        "]"
      ],
      "metadata": {
        "id": "hmVstsSUCj4s"
      },
      "id": "hmVstsSUCj4s",
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "markdown",
      "source": [
        "## Create Tools for AI Agent\n",
        "\n",
        "In this section, we will define the tools that our AI Agent will use to perform specific tasks.\n",
        "\n",
        "LangChain makes it easy to create and register tools using the `Tool` class. A tool includes:\n",
        "- A name and description\n",
        "- The python function to be called\n",
        "- An input schema that tells the model what arguments it can use\n",
        "\n",
        "When tools are defined properly, they help the model solve more complex problems by letting it take actions and use external data. This makes the system more useful and reliable.\n",
        "\n",
        "### ðŸ§ª Example\n",
        "```python\n",
        "from langchain.tools import tool\n",
        "\n",
        "@tool\n",
        "def search_web(query: str) -> str:\n",
        "    \"\"\"Get live information for user queries from the web.\"\"\"\n",
        "    # assuming we have a google_search function implemented to search on google\n",
        "    return google_search(query)\n",
        "```\n",
        "\n",
        "These tools will allow the agent to retrieve information from our preloaded vector databases (web search and PubMed), as well as recommend doctors from our in-memory doctor database.\n",
        "\n",
        "The goal is to modularize the logic for different types of tasks into reusable components that can be invoked by the LLM when needed. These include:\n",
        "\n",
        "- A **Web Search Tool** that queries the web to get relevant information through web search\n",
        "- A **ArXiv Search Tool** that retrieves information from top research papers from arxiv.org relevant to the query  \n",
        "- A **Doctor Recommendation Tool** that finds suitable doctors based on user symptoms or needs\n",
        "\n",
        "This tool-based setup is essential for enabling agentic behavior, where the LLM reasons through a problem, decides which action to take, and requests to call the right tools to gather more information or perform a task.\n"
      ],
      "metadata": {
        "id": "lLmG5MF4_f_t"
      },
      "id": "lLmG5MF4_f_t"
    },
    {
      "cell_type": "code",
      "source": [
        "from langchain_community.utilities.tavily_search import TavilySearchAPIWrapper\n",
        "from langchain_community.retrievers import ArxivRetriever\n",
        "\n",
        "# Tool for web search on general health topics\n",
        "# Tavily Web Search\n",
        "tavily_search = TavilySearchAPIWrapper()\n",
        "\n",
        "@tool\n",
        "def search_web(query: str) -> list:\n",
        "    \"\"\"\n",
        "    Search the web for general or up-to-date information on healthcare topics.\n",
        "\n",
        "    Inputs:\n",
        "    - query (str): The search query string. Should describe the healthcare topic or information you want to find.\n",
        "\n",
        "    Outputs:\n",
        "    - list: A list of up to 3 formatted strings, each containing:\n",
        "        - Title of the search result\n",
        "        - Content extracted from the page\n",
        "        - Source URL\n",
        "    \"\"\"\n",
        "    results = tavily_search.raw_results(query=query, max_results=3, search_depth='advanced',\n",
        "                                        include_answer=False, include_raw_content=True)\n",
        "    docs = results['results']\n",
        "    docs = [doc for doc in docs if doc.get(\"raw_content\") is not None]\n",
        "    docs = ['## Title\\n'+doc['title']+'\\n\\n'+'## Content\\n'+doc['raw_content']+'\\n\\n'+'##Source\\n'+doc['url'] for doc in docs]\n",
        "    return docs\n",
        "\n",
        "\n",
        "# Tool for arXiv Search\n",
        "# arxiv search retriever\n",
        "arxiv_retriever = ArxivRetriever(\n",
        "    top_k_results=3,\n",
        "    get_full_documents=True,\n",
        "    doc_content_chars_max=20000\n",
        ")\n",
        "\n",
        "@tool\n",
        "def search_arxiv(query: str) -> list:\n",
        "    \"\"\"\n",
        "    Search arXiv for relevant scientific research papers and articles.\n",
        "\n",
        "    Inputs:\n",
        "    - query (str): The research topic or keywords to search for on arXiv.\n",
        "\n",
        "    Outputs:\n",
        "    - list: A list of up to 3 formatted strings, each containing:\n",
        "        - Title of the paper\n",
        "        - Summary of the paper\n",
        "        - Full content (truncated to maximum allowed characters)\n",
        "      Returns [\"No articles found for the given query.\"] if no matches are found.\n",
        "    \"\"\"\n",
        "    try:\n",
        "        results = arxiv_retriever.invoke(query)\n",
        "        if results:\n",
        "            articles = ['## Title\\n'+doc.metadata['Title']+'\\n\\n'+'## Summary\\n'+doc.metadata['Summary']+'\\n\\n'+'##Content\\n'+doc.page_content for doc in results]\n",
        "            return articles\n",
        "        else:\n",
        "            return [\"No articles found for the given query.\"]\n",
        "    except Exception as e:\n",
        "        return [f\"Error fetching arXiv articles: {str(e)}\"]\n",
        "\n",
        "\n",
        "@tool\n",
        "def recommend_doctor(query: str) -> dict:\n",
        "    \"\"\"\n",
        "    Recommend the most suitable doctor based on the user's symptoms or health-related query.\n",
        "\n",
        "    Inputs:\n",
        "    - query (str): A description of the patient's symptoms or healthcare needs.\n",
        "\n",
        "    Outputs:\n",
        "    - dict: A dictionary containing:\n",
        "        - \"recommended_doctor\": JSON-formatted details of the selected doctor from the `doctors_db`.\n",
        "          If the most suitable match cannot be determined, defaults to recommending the General Physician.\n",
        "    \"\"\"\n",
        "    doctors_list = str(doctors_db)\n",
        "    prompt = f\"\"\"You are an assistant helping recommend a doctor based on patient's health issues.\n",
        "\n",
        "                 Here is the list of available doctors:\n",
        "                {doctors_list}\n",
        "\n",
        "                Given the user's query: \"{query}\"\n",
        "\n",
        "                Choose the most suitable doctor from the list. Only pick one doctor.\n",
        "                Return only the selected doctor's information in JSON format (no markdown).\n",
        "                If not sure, recommend the General Physician.\n",
        "              \"\"\"\n",
        "    # qcom_llm = .,,,,,\n",
        "    response = llm_client.invoke(prompt)\n",
        "    return {\"recommended_doctor\": response}"
      ],
      "metadata": {
        "id": "vd5MS0gX-TCD"
      },
      "id": "vd5MS0gX-TCD",
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "markdown",
      "source": [
        "## Define Tools to be Used by the Agent\n",
        "\n",
        "In this section, we define the tools that our AI agent will use when reasoning through user queries. These include:\n",
        "\n",
        "- `search_web`: To fetch general health-related information from the internet.\n",
        "- `search_arxiv`: To retrieve scientific research papers from arXiv.org.\n",
        "- `recommend_doctor`: To recommend a suitable doctor based on the user's symptoms.\n",
        "\n",
        "These tools are already defined and registered using the `@tool` decorator. Here, we simply collect them into a list to be fed into the agent function later on.\n"
      ],
      "metadata": {
        "id": "kBNA9LD2MQPt"
      },
      "id": "kBNA9LD2MQPt"
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "id": "dfc8e72e",
      "metadata": {
        "id": "dfc8e72e"
      },
      "outputs": [],
      "source": [
        "# List of all tools that the LLM should be aware of\n",
        "# These tools were defined earlier using the @tool decorator\n",
        "tools = [search_web, search_arxiv, recommend_doctor]"
      ]
    },
    {
      "cell_type": "markdown",
      "source": [
        "## Define Agent Instructions Prompt\n",
        "\n",
        "To guide the LLM-based agent, we provide a custom system prompt that sets the role and behavior of the assistant.\n",
        "\n",
        "The prompt clearly instructs the agent to:\n",
        "- Act as a helpful healthcare assistant\n",
        "- Reason on input queries and do the following:\n",
        "  - Research the query using the most relevant tools (web, pubmed)\n",
        "  - Recommend a doctor only if appropriate\n",
        "\n",
        "This prompt plays a critical role in shaping how the agent reasons, decides when to call tools, and how to construct final responses. It supports ReAct-style behavior where the model reflects, takes actions (via tools), and continues reasoning."
      ],
      "metadata": {
        "id": "5hdJI9UPMWWi"
      },
      "id": "5hdJI9UPMWWi"
    },
    {
      "cell_type": "code",
      "source": [
        "# Instruction prompt for the overall Agent\n",
        "AGENT_PROMPT_TXT = r\"\"\"You are an agent designed to act as an expert in researching on medical symptoms\n",
        "and also recommend relevant doctors for booking appointments.\n",
        "Also remember the current year is 2025 and use the same for all search queries when no specific dates are mentioned.\n",
        "\n",
        "Given an input user query call relevant tools and give the most appropriate response.\n",
        "Follow some of these guidelines to help you make more informed decisions:\n",
        "  - If the user's query specifies recommending a doctor only then recommend an appropriate doctor\n",
        "  - If the user is researching on detailed and specific aspects around symptoms, treatments and other aspects related to healthcare\n",
        "  use both search_web and search_arxiv tools to get comprehensive information and then give a well-structured response\n",
        "  - If the user is just looking for general information around healthcare then web search is enough\n",
        "  - Use search_arxiv tool only if the query is related to information which might be found in research papers\n",
        "  - Response should include cited source links and \\ or arXiv Article Title, Publication Dates if available\n",
        "  - If recommending doctors then use the recommend_doctor and show detailed information in a nice structured way and recommend them to book an appointment via email\n",
        "  - Politely decline answering any queries not related to medical or healthcare information\n",
        "\"\"\"\n",
        "\n",
        "AGENT_SYS_PROMPT = SystemMessage(content=AGENT_PROMPT_TXT)"
      ],
      "metadata": {
        "id": "1e9-BJlvU8e1"
      },
      "id": "1e9-BJlvU8e1",
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "markdown",
      "source": [
        "## Create our Tool-Use AI Agent\n",
        "\n",
        "Using the tools, prompt, and LLM setup, we now create the actual **Tool-Use Agent** using LangChainâ€™s built-in `create_react_agent()` utility function.\n",
        "\n",
        "This creates a simple ReAct-style agent capable of:\n",
        "- Receiving a user query\n",
        "- Reasoning on next steps\n",
        "- Calling the appropriate tool(s) if needed\n",
        "- Observing tool outputs\n",
        "- Returning a final answer\n",
        "\n",
        "This step brings together everything weâ€™ve built so far: tools, instructions, and reasoning logic into a functioning agentic loop."
      ],
      "metadata": {
        "id": "WhkzHIRzMgrh"
      },
      "id": "WhkzHIRzMgrh"
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "id": "4af2257a",
      "metadata": {
        "id": "4af2257a",
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "outputId": "81f6cd63-a993-4104-a4b9-1450e6b6788c"
      },
      "outputs": [
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "/tmp/ipython-input-416506609.py:2: LangGraphDeprecatedSinceV10: create_react_agent has been moved to `langchain.agents`. Please update your import to `from langchain.agents import create_agent`. Deprecated in LangGraph V1.0 to be removed in V2.0.\n",
            "  healthbuddy_agent = create_react_agent(model=llm_client,\n"
          ]
        }
      ],
      "source": [
        "# Create our agent using tools, LLM and instruction prompt\n",
        "healthbuddy_agent = create_react_agent(model=llm_client,\n",
        "                                       tools=tools,\n",
        "                                       prompt=AGENT_SYS_PROMPT)"
      ]
    },
    {
      "cell_type": "markdown",
      "source": [
        "You can update this and use the `create_agent` function from LangChain agents only if you are using version > 1.0, in production if you are using version < 1.0 then you can continue using the above (recommended especially as LangChain 1.0 just came out and expect them to break more stuff!)"
      ],
      "metadata": {
        "id": "SCR9_OUTDJ10"
      },
      "id": "SCR9_OUTDJ10"
    },
    {
      "cell_type": "code",
      "source": [
        "from langchain.agents import create_agent\n",
        "\n",
        "healthbuddy_agent = create_agent(model=llm_client,\n",
        "                                 tools=tools,\n",
        "                                 system_prompt=AGENT_PROMPT_TXT) # just send prompt text directly here"
      ],
      "metadata": {
        "id": "ZVRfmxHcDYpC"
      },
      "id": "ZVRfmxHcDYpC",
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "markdown",
      "source": [
        "## View our Agent Flow\n"
      ],
      "metadata": {
        "id": "mdCJxfRuMrQe"
      },
      "id": "mdCJxfRuMrQe"
    },
    {
      "cell_type": "code",
      "source": [
        "display(Image(healthbuddy_agent.get_graph().draw_mermaid_png()))"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 266
        },
        "id": "T64bs4ieMt3R",
        "outputId": "9b359411-2a45-4d68-a206-92204d2a3233"
      },
      "id": "T64bs4ieMt3R",
      "execution_count": null,
      "outputs": [
        {
          "output_type": "display_data",
          "data": {
            "image/png": "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\n",
            "text/plain": [
              "<IPython.core.display.Image object>"
            ]
          },
          "metadata": {}
        }
      ]
    },
    {
      "cell_type": "markdown",
      "source": [
        "## Build Utility Function to Stream Agent Results\n",
        "\n",
        "We define a helper function to stream the step-by-step output of the agent. This makes it easier to trace:\n",
        "- What the agent doing in each step\n",
        "- Which tool it decides to call\n",
        "- What response it gets from that tool\n",
        "- How it forms the final reply\n",
        "\n",
        "Streaming output is helpful when evaluating multi-step reasoning and debugging tool use in real time."
      ],
      "metadata": {
        "id": "jQV4v8JANean"
      },
      "id": "jQV4v8JANean"
    },
    {
      "cell_type": "code",
      "source": [
        "# get agent streaming utils\n",
        "!gdown 1dSyjcjlFoZpYEqv4P9Oi0-kU2gIoolMB"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "6hj_ysrGVEU2",
        "outputId": "c42c91dc-6b0e-4685-d8a7-6df7583632be"
      },
      "id": "6hj_ysrGVEU2",
      "execution_count": null,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Downloading...\n",
            "From (original): https://drive.google.com/uc?id=1dSyjcjlFoZpYEqv4P9Oi0-kU2gIoolMB\n",
            "From (redirected): https://drive.google.com/uc?id=1dSyjcjlFoZpYEqv4P9Oi0-kU2gIoolMB&confirm=t&uuid=10da76d9-8717-4601-8001-eaabff652253\n",
            "To: /content/agent_utils.py\n",
            "\r  0% 0.00/6.45k [00:00<?, ?B/s]\r100% 6.45k/6.45k [00:00<00:00, 19.2MB/s]\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "from agent_utils import format_message\n",
        "\n",
        "# Utility function to call the agent and stream its step-by-step reasoning\n",
        "def call_agent(agent, query, verbose=False):\n",
        "\n",
        "    # Stream the agent's execution with the given query\n",
        "    for event in agent.stream(\n",
        "        {\"messages\": [HumanMessage(content=query)]}, # input prompt\n",
        "        stream_mode='values'  # Stream output as intermediate values\n",
        "    ):\n",
        "        # If verbose is enabled, print each intermediate message step-by-step\n",
        "        if verbose:\n",
        "            format_message(event[\"messages\"][-1])\n",
        "\n",
        "    # Display the final response from the agent as Markdown\n",
        "    print('\\n\\nFinal Response:\\n')\n",
        "    display(Markdown(event[\"messages\"][-1].content))\n",
        "\n",
        "    # Return the overall event messages for optional downstream use\n",
        "    return event[\"messages\"]\n"
      ],
      "metadata": {
        "id": "WrCBZs3YffCl"
      },
      "id": "WrCBZs3YffCl",
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "markdown",
      "source": [
        "## Test out our Agent!\n",
        "\n",
        "In this final section, we run a complete test of our Tool-Use AI Agent by passing it a sample health-related query.\n",
        "\n",
        "We observe how the agent:\n",
        "- Interprets the query\n",
        "- Decides which tool(s) to use (if any)\n",
        "- Executes tool calls\n",
        "- Streams the intermediate steps and final output"
      ],
      "metadata": {
        "id": "-5_CbU32NmaA"
      },
      "id": "-5_CbU32NmaA"
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "id": "5435f97e",
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 1000
        },
        "id": "5435f97e",
        "outputId": "3e6a14ba-e33e-495c-ac72-7ea1a78fb49d"
      },
      "outputs": [
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "\u001b[34mâ•­â”€\u001b[0m\u001b[34mâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€\u001b[0m\u001b[34m ðŸ§‘ Human \u001b[0m\u001b[34mâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€\u001b[0m\u001b[34mâ”€â•®\u001b[0m\n",
              "\u001b[34mâ”‚\u001b[0m what are the latest methods for diabetes management and recommend a doctor please                               \u001b[34mâ”‚\u001b[0m\n",
              "\u001b[34mâ•°â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â•¯\u001b[0m\n"
            ],
            "text/html": [
              "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #000080; text-decoration-color: #000080\">â•­â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€ ðŸ§‘ Human â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â•®</span>\n",
              "<span style=\"color: #000080; text-decoration-color: #000080\">â”‚</span> what are the latest methods for diabetes management and recommend a doctor please                               <span style=\"color: #000080; text-decoration-color: #000080\">â”‚</span>\n",
              "<span style=\"color: #000080; text-decoration-color: #000080\">â•°â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â•¯</span>\n",
              "</pre>\n"
            ]
          },
          "metadata": {}
        },
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "\u001b[31mâ•­â”€\u001b[0m\u001b[31mâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€\u001b[0m\u001b[31m âš™ï¸ Tool Request \u001b[0m\u001b[31mâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€\u001b[0m\u001b[31mâ”€â•®\u001b[0m\n",
              "\u001b[31mâ”‚\u001b[0m                                                                                                                 \u001b[31mâ”‚\u001b[0m\n",
              "\u001b[31mâ”‚\u001b[0m ðŸ”§ Tool Call: search_web                                                                                        \u001b[31mâ”‚\u001b[0m\n",
              "\u001b[31mâ”‚\u001b[0m    Args: {                                                                                                      \u001b[31mâ”‚\u001b[0m\n",
              "\u001b[31mâ”‚\u001b[0m   \"query\": \"latest methods for diabetes management 2025\"                                                        \u001b[31mâ”‚\u001b[0m\n",
              "\u001b[31mâ”‚\u001b[0m }                                                                                                               \u001b[31mâ”‚\u001b[0m\n",
              "\u001b[31mâ”‚\u001b[0m    ID: call_R6ToyLdkwnwp0Z0gh3CmH2mj                                                                            \u001b[31mâ”‚\u001b[0m\n",
              "\u001b[31mâ”‚\u001b[0m                                                                                                                 \u001b[31mâ”‚\u001b[0m\n",
              "\u001b[31mâ”‚\u001b[0m ðŸ”§ Tool Call: recommend_doctor                                                                                  \u001b[31mâ”‚\u001b[0m\n",
              "\u001b[31mâ”‚\u001b[0m    Args: {                                                                                                      \u001b[31mâ”‚\u001b[0m\n",
              "\u001b[31mâ”‚\u001b[0m   \"query\": \"diabetes management\"                                                                                \u001b[31mâ”‚\u001b[0m\n",
              "\u001b[31mâ”‚\u001b[0m }                                                                                                               \u001b[31mâ”‚\u001b[0m\n",
              "\u001b[31mâ”‚\u001b[0m    ID: call_gDSmwWfaAjB3pYaBAKXVmtau                                                                            \u001b[31mâ”‚\u001b[0m\n",
              "\u001b[31mâ•°â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â•¯\u001b[0m\n"
            ],
            "text/html": [
              "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #800000; text-decoration-color: #800000\">â•­â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€ âš™ï¸ Tool Request â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â•®</span>\n",
              "<span style=\"color: #800000; text-decoration-color: #800000\">â”‚</span>                                                                                                                 <span style=\"color: #800000; text-decoration-color: #800000\">â”‚</span>\n",
              "<span style=\"color: #800000; text-decoration-color: #800000\">â”‚</span> ðŸ”§ Tool Call: search_web                                                                                        <span style=\"color: #800000; text-decoration-color: #800000\">â”‚</span>\n",
              "<span style=\"color: #800000; text-decoration-color: #800000\">â”‚</span>    Args: {                                                                                                      <span style=\"color: #800000; text-decoration-color: #800000\">â”‚</span>\n",
              "<span style=\"color: #800000; text-decoration-color: #800000\">â”‚</span>   \"query\": \"latest methods for diabetes management 2025\"                                                        <span style=\"color: #800000; text-decoration-color: #800000\">â”‚</span>\n",
              "<span style=\"color: #800000; text-decoration-color: #800000\">â”‚</span> }                                                                                                               <span style=\"color: #800000; text-decoration-color: #800000\">â”‚</span>\n",
              "<span style=\"color: #800000; text-decoration-color: #800000\">â”‚</span>    ID: call_R6ToyLdkwnwp0Z0gh3CmH2mj                                                                            <span style=\"color: #800000; text-decoration-color: #800000\">â”‚</span>\n",
              "<span style=\"color: #800000; text-decoration-color: #800000\">â”‚</span>                                                                                                                 <span style=\"color: #800000; text-decoration-color: #800000\">â”‚</span>\n",
              "<span style=\"color: #800000; text-decoration-color: #800000\">â”‚</span> ðŸ”§ Tool Call: recommend_doctor                                                                                  <span style=\"color: #800000; text-decoration-color: #800000\">â”‚</span>\n",
              "<span style=\"color: #800000; text-decoration-color: #800000\">â”‚</span>    Args: {                                                                                                      <span style=\"color: #800000; text-decoration-color: #800000\">â”‚</span>\n",
              "<span style=\"color: #800000; text-decoration-color: #800000\">â”‚</span>   \"query\": \"diabetes management\"                                                                                <span style=\"color: #800000; text-decoration-color: #800000\">â”‚</span>\n",
              "<span style=\"color: #800000; text-decoration-color: #800000\">â”‚</span> }                                                                                                               <span style=\"color: #800000; text-decoration-color: #800000\">â”‚</span>\n",
              "<span style=\"color: #800000; text-decoration-color: #800000\">â”‚</span>    ID: call_gDSmwWfaAjB3pYaBAKXVmtau                                                                            <span style=\"color: #800000; text-decoration-color: #800000\">â”‚</span>\n",
              "<span style=\"color: #800000; text-decoration-color: #800000\">â•°â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â•¯</span>\n",
              "</pre>\n"
            ]
          },
          "metadata": {}
        },
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "\u001b[33mâ•­â”€\u001b[0m\u001b[33mâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€\u001b[0m\u001b[33m ðŸ”§ Tool Output \u001b[0m\u001b[33mâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€\u001b[0m\u001b[33mâ”€â•®\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m {'recommended_doctor': AIMessage(content='{\\n  \"name\": \"Dr. Janet Dyne\",\\n  \"specialization\": \"Endocrinology    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m (Diabetes Care)\",\\n  \"available_timings\": \"10:00 AM - 1:00 PM\",\\n  \"location\": \"City Health Clinic\",\\n          \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m \"contact\": \"janet.dyne@healthclinic.com\"\\n}', additional_kwargs={'refusal': None},                              \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m response_metadata={'token_usage': {'completion_tokens': 69, 'prompt_tokens': 387, 'total_tokens': 456,          \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 'completion_tokens_details': {'accepted_prediction_tokens': 0, 'audio_tokens': 0, 'reasoning_tokens': 0,        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 'rejected_prediction_tokens': 0}, 'prompt_tokens_details': {'audio_tokens': 0, 'cached_tokens': 0}},            \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 'model_provider': 'openai', 'model_name': 'gpt-4o-mini-2024-07-18', 'system_fingerprint': 'fp_560af6e559',      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 'id': 'chatcmpl-CZagubdp8I4HAmEaxeWCHMHunN4ST', 'service_tier': 'default', 'finish_reason': 'stop', 'logprobs': \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m None}, id='lc_run--9b801946-9fed-48bd-8fea-d170d63a3ca2-0', usage_metadata={'input_tokens': 387,                \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 'output_tokens': 69, 'total_tokens': 456, 'input_token_details': {'audio': 0, 'cache_read': 0},                 \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 'output_token_details': {'audio': 0, 'reasoning': 0}})}                                                         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ•°â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â•¯\u001b[0m\n"
            ],
            "text/html": [
              "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #808000; text-decoration-color: #808000\">â•­â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€ ðŸ”§ Tool Output â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â•®</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> {'recommended_doctor': AIMessage(content='{\\n  \"name\": \"Dr. Janet Dyne\",\\n  \"specialization\": \"Endocrinology    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> (Diabetes Care)\",\\n  \"available_timings\": \"10:00 AM - 1:00 PM\",\\n  \"location\": \"City Health Clinic\",\\n          <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> \"contact\": \"janet.dyne@healthclinic.com\"\\n}', additional_kwargs={'refusal': None},                              <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> response_metadata={'token_usage': {'completion_tokens': 69, 'prompt_tokens': 387, 'total_tokens': 456,          <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 'completion_tokens_details': {'accepted_prediction_tokens': 0, 'audio_tokens': 0, 'reasoning_tokens': 0,        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 'rejected_prediction_tokens': 0}, 'prompt_tokens_details': {'audio_tokens': 0, 'cached_tokens': 0}},            <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 'model_provider': 'openai', 'model_name': 'gpt-4o-mini-2024-07-18', 'system_fingerprint': 'fp_560af6e559',      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 'id': 'chatcmpl-CZagubdp8I4HAmEaxeWCHMHunN4ST', 'service_tier': 'default', 'finish_reason': 'stop', 'logprobs': <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> None}, id='lc_run--9b801946-9fed-48bd-8fea-d170d63a3ca2-0', usage_metadata={'input_tokens': 387,                <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 'output_tokens': 69, 'total_tokens': 456, 'input_token_details': {'audio': 0, 'cache_read': 0},                 <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 'output_token_details': {'audio': 0, 'reasoning': 0}})}                                                         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â•°â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â•¯</span>\n",
              "</pre>\n"
            ]
          },
          "metadata": {}
        },
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "\u001b[32mâ•­â”€\u001b[0m\u001b[32mâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€\u001b[0m\u001b[32m ðŸ¤– Assistant \u001b[0m\u001b[32mâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€\u001b[0m\u001b[32mâ”€â•®\u001b[0m\n",
              "\u001b[32mâ”‚\u001b[0m ### Latest Methods for Diabetes Management                                                                      \u001b[32mâ”‚\u001b[0m\n",
              "\u001b[32mâ”‚\u001b[0m                                                                                                                 \u001b[32mâ”‚\u001b[0m\n",
              "\u001b[32mâ”‚\u001b[0m The management of diabetes, particularly type 2 diabetes, has seen significant advancements, especially in the  \u001b[32mâ”‚\u001b[0m\n",
              "\u001b[32mâ”‚\u001b[0m areas of treatment, lifestyle intervention, and monitoring. Key updates in diabetes management as of 2025       \u001b[32mâ”‚\u001b[0m\n",
              "\u001b[32mâ”‚\u001b[0m include:                                                                                                        \u001b[32mâ”‚\u001b[0m\n",
              "\u001b[32mâ”‚\u001b[0m                                                                                                                 \u001b[32mâ”‚\u001b[0m\n",
              "\u001b[32mâ”‚\u001b[0m 1. **Lifestyle Interventions**:                                                                                 \u001b[32mâ”‚\u001b[0m\n",
              "\u001b[32mâ”‚\u001b[0m    - Lifestyle changes remain foundational in diabetes management, emphasizing diet and physical activity.      \u001b[32mâ”‚\u001b[0m\n",
              "\u001b[32mâ”‚\u001b[0m    - Intensive lifestyle interventions (ILI) can lead to significant improvements in glycemic control.          \u001b[32mâ”‚\u001b[0m\n",
              "\u001b[32mâ”‚\u001b[0m                                                                                                                 \u001b[32mâ”‚\u001b[0m\n",
              "\u001b[32mâ”‚\u001b[0m 2. **Medications**:                                                                                             \u001b[32mâ”‚\u001b[0m\n",
              "\u001b[32mâ”‚\u001b[0m    - **SGLT2 Inhibitors**: These drugs (e.g., empagliflozin) have shown substantial benefits in reducing        \u001b[32mâ”‚\u001b[0m\n",
              "\u001b[32mâ”‚\u001b[0m cardiovascular and kidney-related risks in patients with diabetes.                                              \u001b[32mâ”‚\u001b[0m\n",
              "\u001b[32mâ”‚\u001b[0m    - **GLP-1 Receptor Agonists**: Medications like semaglutide and tirzepatide not only help in glycemic        \u001b[32mâ”‚\u001b[0m\n",
              "\u001b[32mâ”‚\u001b[0m control but also promote weight loss and improve cardiovascular health.                                         \u001b[32mâ”‚\u001b[0m\n",
              "\u001b[32mâ”‚\u001b[0m    - **Resmetirom**: Recently approved for metabolic dysfunction-associated steatohepatitis (MASH), showcasing  \u001b[32mâ”‚\u001b[0m\n",
              "\u001b[32mâ”‚\u001b[0m a novel approach for liver health in diabetes patients.                                                         \u001b[32mâ”‚\u001b[0m\n",
              "\u001b[32mâ”‚\u001b[0m                                                                                                                 \u001b[32mâ”‚\u001b[0m\n",
              "\u001b[32mâ”‚\u001b[0m 3. **Technology in Care**:                                                                                      \u001b[32mâ”‚\u001b[0m\n",
              "\u001b[32mâ”‚\u001b[0m    - Continuous Glucose Monitoring (CGM) systems have enhanced the ability to manage blood glucose levels       \u001b[32mâ”‚\u001b[0m\n",
              "\u001b[32mâ”‚\u001b[0m effectively, facilitating timely interventions.                                                                 \u001b[32mâ”‚\u001b[0m\n",
              "\u001b[32mâ”‚\u001b[0m                                                                                                                 \u001b[32mâ”‚\u001b[0m\n",
              "\u001b[32mâ”‚\u001b[0m 4. **Screening and Management of Complications**:                                                               \u001b[32mâ”‚\u001b[0m\n",
              "\u001b[32mâ”‚\u001b[0m    - Regular screening for cardiovascular disease (CVD) and chronic kidney disease (CKD) is now recommended due \u001b[32mâ”‚\u001b[0m\n",
              "\u001b[32mâ”‚\u001b[0m to the intertwining relationships these conditions have with diabetes.                                          \u001b[32mâ”‚\u001b[0m\n",
              "\u001b[32mâ”‚\u001b[0m    - Enhanced understanding of the need for early intervention to prevent complications has led to more         \u001b[32mâ”‚\u001b[0m\n",
              "\u001b[32mâ”‚\u001b[0m comprehensive guideline recommendations.                                                                        \u001b[32mâ”‚\u001b[0m\n",
              "\u001b[32mâ”‚\u001b[0m                                                                                                                 \u001b[32mâ”‚\u001b[0m\n",
              "\u001b[32mâ”‚\u001b[0m 5. **Focus on Mental Health**:                                                                                  \u001b[32mâ”‚\u001b[0m\n",
              "\u001b[32mâ”‚\u001b[0m    - Increased acknowledgment of the psychological aspects of diabetes management, including routine screening  \u001b[32mâ”‚\u001b[0m\n",
              "\u001b[32mâ”‚\u001b[0m for diabetes distress and anxiety, emphasizing holistic patient care.                                           \u001b[32mâ”‚\u001b[0m\n",
              "\u001b[32mâ”‚\u001b[0m                                                                                                                 \u001b[32mâ”‚\u001b[0m\n",
              "\u001b[32mâ”‚\u001b[0m For a more detailed account of these methods, the [International Diabetes Federation (IDF) Recommendations for  \u001b[32mâ”‚\u001b[0m\n",
              "\u001b[32mâ”‚\u001b[0m Managing Type 2 Diabetes 2025](https://idf.org/media/uploads/2025/04/IDF_Rec_2025.pdf) and the [American        \u001b[32mâ”‚\u001b[0m\n",
              "\u001b[32mâ”‚\u001b[0m Diabetes Association Standards of Care 2025](https://diabetesjournals.org/care/issue/48/Supplement_1) provide   \u001b[32mâ”‚\u001b[0m\n",
              "\u001b[32mâ”‚\u001b[0m extensive insights.                                                                                             \u001b[32mâ”‚\u001b[0m\n",
              "\u001b[32mâ”‚\u001b[0m                                                                                                                 \u001b[32mâ”‚\u001b[0m\n",
              "\u001b[32mâ”‚\u001b[0m ### Recommended Doctor                                                                                          \u001b[32mâ”‚\u001b[0m\n",
              "\u001b[32mâ”‚\u001b[0m                                                                                                                 \u001b[32mâ”‚\u001b[0m\n",
              "\u001b[32mâ”‚\u001b[0m For diabetes management, I recommend the following healthcare professional:                                     \u001b[32mâ”‚\u001b[0m\n",
              "\u001b[32mâ”‚\u001b[0m                                                                                                                 \u001b[32mâ”‚\u001b[0m\n",
              "\u001b[32mâ”‚\u001b[0m #### Dr. Janet Dyne                                                                                             \u001b[32mâ”‚\u001b[0m\n",
              "\u001b[32mâ”‚\u001b[0m - **Specialization**: Endocrinology (Diabetes Care)                                                             \u001b[32mâ”‚\u001b[0m\n",
              "\u001b[32mâ”‚\u001b[0m - **Location**: City Health Clinic                                                                              \u001b[32mâ”‚\u001b[0m\n",
              "\u001b[32mâ”‚\u001b[0m - **Available Timings**: 10:00 AM - 1:00 PM                                                                     \u001b[32mâ”‚\u001b[0m\n",
              "\u001b[32mâ”‚\u001b[0m - **Contact**: [janet.dyne@healthclinic.com](mailto:janet.dyne@healthclinic.com)                                \u001b[32mâ”‚\u001b[0m\n",
              "\u001b[32mâ”‚\u001b[0m                                                                                                                 \u001b[32mâ”‚\u001b[0m\n",
              "\u001b[32mâ”‚\u001b[0m If you would like to book an appointment, please reach out to Dr. Dyne's office via the provided email address. \u001b[32mâ”‚\u001b[0m\n",
              "\u001b[32mâ•°â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â•¯\u001b[0m\n"
            ],
            "text/html": [
              "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #008000; text-decoration-color: #008000\">â•­â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€ ðŸ¤– Assistant â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â•®</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span> ### Latest Methods for Diabetes Management                                                                      <span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>                                                                                                                 <span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span> The management of diabetes, particularly type 2 diabetes, has seen significant advancements, especially in the  <span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span> areas of treatment, lifestyle intervention, and monitoring. Key updates in diabetes management as of 2025       <span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span> include:                                                                                                        <span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>                                                                                                                 <span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span> 1. **Lifestyle Interventions**:                                                                                 <span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>    - Lifestyle changes remain foundational in diabetes management, emphasizing diet and physical activity.      <span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>    - Intensive lifestyle interventions (ILI) can lead to significant improvements in glycemic control.          <span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>                                                                                                                 <span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span> 2. **Medications**:                                                                                             <span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>    - **SGLT2 Inhibitors**: These drugs (e.g., empagliflozin) have shown substantial benefits in reducing        <span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span> cardiovascular and kidney-related risks in patients with diabetes.                                              <span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>    - **GLP-1 Receptor Agonists**: Medications like semaglutide and tirzepatide not only help in glycemic        <span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span> control but also promote weight loss and improve cardiovascular health.                                         <span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>    - **Resmetirom**: Recently approved for metabolic dysfunction-associated steatohepatitis (MASH), showcasing  <span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span> a novel approach for liver health in diabetes patients.                                                         <span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>                                                                                                                 <span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span> 3. **Technology in Care**:                                                                                      <span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>    - Continuous Glucose Monitoring (CGM) systems have enhanced the ability to manage blood glucose levels       <span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span> effectively, facilitating timely interventions.                                                                 <span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>                                                                                                                 <span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span> 4. **Screening and Management of Complications**:                                                               <span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>    - Regular screening for cardiovascular disease (CVD) and chronic kidney disease (CKD) is now recommended due <span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span> to the intertwining relationships these conditions have with diabetes.                                          <span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>    - Enhanced understanding of the need for early intervention to prevent complications has led to more         <span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span> comprehensive guideline recommendations.                                                                        <span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>                                                                                                                 <span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span> 5. **Focus on Mental Health**:                                                                                  <span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>    - Increased acknowledgment of the psychological aspects of diabetes management, including routine screening  <span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span> for diabetes distress and anxiety, emphasizing holistic patient care.                                           <span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>                                                                                                                 <span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span> For a more detailed account of these methods, the [International Diabetes Federation (IDF) Recommendations for  <span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span> Managing Type 2 Diabetes 2025](https://idf.org/media/uploads/2025/04/IDF_Rec_2025.pdf) and the [American        <span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span> Diabetes Association Standards of Care 2025](https://diabetesjournals.org/care/issue/48/Supplement_1) provide   <span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span> extensive insights.                                                                                             <span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>                                                                                                                 <span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span> ### Recommended Doctor                                                                                          <span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>                                                                                                                 <span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span> For diabetes management, I recommend the following healthcare professional:                                     <span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>                                                                                                                 <span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span> #### Dr. Janet Dyne                                                                                             <span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span> - **Specialization**: Endocrinology (Diabetes Care)                                                             <span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span> - **Location**: City Health Clinic                                                                              <span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span> - **Available Timings**: 10:00 AM - 1:00 PM                                                                     <span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span> - **Contact**: [janet.dyne@healthclinic.com](mailto:janet.dyne@healthclinic.com)                                <span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>                                                                                                                 <span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span> If you would like to book an appointment, please reach out to Dr. Dyne's office via the provided email address. <span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">â•°â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â•¯</span>\n",
              "</pre>\n"
            ]
          },
          "metadata": {}
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "\n",
            "\n",
            "Final Response:\n",
            "\n"
          ]
        },
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<IPython.core.display.Markdown object>"
            ],
            "text/markdown": "### Latest Methods for Diabetes Management\n\nThe management of diabetes, particularly type 2 diabetes, has seen significant advancements, especially in the areas of treatment, lifestyle intervention, and monitoring. Key updates in diabetes management as of 2025 include:\n\n1. **Lifestyle Interventions**: \n   - Lifestyle changes remain foundational in diabetes management, emphasizing diet and physical activity.\n   - Intensive lifestyle interventions (ILI) can lead to significant improvements in glycemic control.\n\n2. **Medications**:\n   - **SGLT2 Inhibitors**: These drugs (e.g., empagliflozin) have shown substantial benefits in reducing cardiovascular and kidney-related risks in patients with diabetes.\n   - **GLP-1 Receptor Agonists**: Medications like semaglutide and tirzepatide not only help in glycemic control but also promote weight loss and improve cardiovascular health.\n   - **Resmetirom**: Recently approved for metabolic dysfunction-associated steatohepatitis (MASH), showcasing a novel approach for liver health in diabetes patients.\n\n3. **Technology in Care**:\n   - Continuous Glucose Monitoring (CGM) systems have enhanced the ability to manage blood glucose levels effectively, facilitating timely interventions.\n\n4. **Screening and Management of Complications**:\n   - Regular screening for cardiovascular disease (CVD) and chronic kidney disease (CKD) is now recommended due to the intertwining relationships these conditions have with diabetes.\n   - Enhanced understanding of the need for early intervention to prevent complications has led to more comprehensive guideline recommendations.\n\n5. **Focus on Mental Health**:\n   - Increased acknowledgment of the psychological aspects of diabetes management, including routine screening for diabetes distress and anxiety, emphasizing holistic patient care.\n\nFor a more detailed account of these methods, the [International Diabetes Federation (IDF) Recommendations for Managing Type 2 Diabetes 2025](https://idf.org/media/uploads/2025/04/IDF_Rec_2025.pdf) and the [American Diabetes Association Standards of Care 2025](https://diabetesjournals.org/care/issue/48/Supplement_1) provide extensive insights.\n\n### Recommended Doctor\n\nFor diabetes management, I recommend the following healthcare professional:\n\n#### Dr. Janet Dyne\n- **Specialization**: Endocrinology (Diabetes Care)\n- **Location**: City Health Clinic\n- **Available Timings**: 10:00 AM - 1:00 PM\n- **Contact**: [janet.dyne@healthclinic.com](mailto:janet.dyne@healthclinic.com)\n\nIf you would like to book an appointment, please reach out to Dr. Dyne's office via the provided email address."
          },
          "metadata": {}
        }
      ],
      "source": [
        "# Example usage\n",
        "query = \"what are the latest methods for diabetes management and recommend a doctor please\"\n",
        "result = call_agent(healthbuddy_agent, query, verbose=True)"
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "# inspect all agent events separately\n",
        "for event in result:\n",
        "    format_message(event)"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 1000
        },
        "id": "bx2x61NPE56t",
        "outputId": "65b7458e-57fd-4ab8-b212-be2c10543a4f"
      },
      "id": "bx2x61NPE56t",
      "execution_count": null,
      "outputs": [
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "\u001b[34mâ•­â”€\u001b[0m\u001b[34mâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€\u001b[0m\u001b[34m ðŸ§‘ Human \u001b[0m\u001b[34mâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€\u001b[0m\u001b[34mâ”€â•®\u001b[0m\n",
              "\u001b[34mâ”‚\u001b[0m what are the latest methods for diabetes management and recommend a doctor please                               \u001b[34mâ”‚\u001b[0m\n",
              "\u001b[34mâ•°â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â•¯\u001b[0m\n"
            ],
            "text/html": [
              "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #000080; text-decoration-color: #000080\">â•­â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€ ðŸ§‘ Human â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â•®</span>\n",
              "<span style=\"color: #000080; text-decoration-color: #000080\">â”‚</span> what are the latest methods for diabetes management and recommend a doctor please                               <span style=\"color: #000080; text-decoration-color: #000080\">â”‚</span>\n",
              "<span style=\"color: #000080; text-decoration-color: #000080\">â•°â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â•¯</span>\n",
              "</pre>\n"
            ]
          },
          "metadata": {}
        },
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "\u001b[31mâ•­â”€\u001b[0m\u001b[31mâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€\u001b[0m\u001b[31m âš™ï¸ Tool Request \u001b[0m\u001b[31mâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€\u001b[0m\u001b[31mâ”€â•®\u001b[0m\n",
              "\u001b[31mâ”‚\u001b[0m                                                                                                                 \u001b[31mâ”‚\u001b[0m\n",
              "\u001b[31mâ”‚\u001b[0m ðŸ”§ Tool Call: search_web                                                                                        \u001b[31mâ”‚\u001b[0m\n",
              "\u001b[31mâ”‚\u001b[0m    Args: {                                                                                                      \u001b[31mâ”‚\u001b[0m\n",
              "\u001b[31mâ”‚\u001b[0m   \"query\": \"latest methods for diabetes management 2025\"                                                        \u001b[31mâ”‚\u001b[0m\n",
              "\u001b[31mâ”‚\u001b[0m }                                                                                                               \u001b[31mâ”‚\u001b[0m\n",
              "\u001b[31mâ”‚\u001b[0m    ID: call_R6ToyLdkwnwp0Z0gh3CmH2mj                                                                            \u001b[31mâ”‚\u001b[0m\n",
              "\u001b[31mâ”‚\u001b[0m                                                                                                                 \u001b[31mâ”‚\u001b[0m\n",
              "\u001b[31mâ”‚\u001b[0m ðŸ”§ Tool Call: recommend_doctor                                                                                  \u001b[31mâ”‚\u001b[0m\n",
              "\u001b[31mâ”‚\u001b[0m    Args: {                                                                                                      \u001b[31mâ”‚\u001b[0m\n",
              "\u001b[31mâ”‚\u001b[0m   \"query\": \"diabetes management\"                                                                                \u001b[31mâ”‚\u001b[0m\n",
              "\u001b[31mâ”‚\u001b[0m }                                                                                                               \u001b[31mâ”‚\u001b[0m\n",
              "\u001b[31mâ”‚\u001b[0m    ID: call_gDSmwWfaAjB3pYaBAKXVmtau                                                                            \u001b[31mâ”‚\u001b[0m\n",
              "\u001b[31mâ•°â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â•¯\u001b[0m\n"
            ],
            "text/html": [
              "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #800000; text-decoration-color: #800000\">â•­â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€ âš™ï¸ Tool Request â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â•®</span>\n",
              "<span style=\"color: #800000; text-decoration-color: #800000\">â”‚</span>                                                                                                                 <span style=\"color: #800000; text-decoration-color: #800000\">â”‚</span>\n",
              "<span style=\"color: #800000; text-decoration-color: #800000\">â”‚</span> ðŸ”§ Tool Call: search_web                                                                                        <span style=\"color: #800000; text-decoration-color: #800000\">â”‚</span>\n",
              "<span style=\"color: #800000; text-decoration-color: #800000\">â”‚</span>    Args: {                                                                                                      <span style=\"color: #800000; text-decoration-color: #800000\">â”‚</span>\n",
              "<span style=\"color: #800000; text-decoration-color: #800000\">â”‚</span>   \"query\": \"latest methods for diabetes management 2025\"                                                        <span style=\"color: #800000; text-decoration-color: #800000\">â”‚</span>\n",
              "<span style=\"color: #800000; text-decoration-color: #800000\">â”‚</span> }                                                                                                               <span style=\"color: #800000; text-decoration-color: #800000\">â”‚</span>\n",
              "<span style=\"color: #800000; text-decoration-color: #800000\">â”‚</span>    ID: call_R6ToyLdkwnwp0Z0gh3CmH2mj                                                                            <span style=\"color: #800000; text-decoration-color: #800000\">â”‚</span>\n",
              "<span style=\"color: #800000; text-decoration-color: #800000\">â”‚</span>                                                                                                                 <span style=\"color: #800000; text-decoration-color: #800000\">â”‚</span>\n",
              "<span style=\"color: #800000; text-decoration-color: #800000\">â”‚</span> ðŸ”§ Tool Call: recommend_doctor                                                                                  <span style=\"color: #800000; text-decoration-color: #800000\">â”‚</span>\n",
              "<span style=\"color: #800000; text-decoration-color: #800000\">â”‚</span>    Args: {                                                                                                      <span style=\"color: #800000; text-decoration-color: #800000\">â”‚</span>\n",
              "<span style=\"color: #800000; text-decoration-color: #800000\">â”‚</span>   \"query\": \"diabetes management\"                                                                                <span style=\"color: #800000; text-decoration-color: #800000\">â”‚</span>\n",
              "<span style=\"color: #800000; text-decoration-color: #800000\">â”‚</span> }                                                                                                               <span style=\"color: #800000; text-decoration-color: #800000\">â”‚</span>\n",
              "<span style=\"color: #800000; text-decoration-color: #800000\">â”‚</span>    ID: call_gDSmwWfaAjB3pYaBAKXVmtau                                                                            <span style=\"color: #800000; text-decoration-color: #800000\">â”‚</span>\n",
              "<span style=\"color: #800000; text-decoration-color: #800000\">â•°â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â•¯</span>\n",
              "</pre>\n"
            ]
          },
          "metadata": {}
        },
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "\u001b[33mâ•­â”€\u001b[0m\u001b[33mâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€\u001b[0m\u001b[33m ðŸ”§ Tool Output \u001b[0m\u001b[33mâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€\u001b[0m\u001b[33mâ”€â•®\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m [\"## Title\\n[PDF] IDF Global Clinical Practice Recommendations for Managing Type 2 ...\\n\\n## Content\\nIDF       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Global Clinical Practice Recommendations for Managing Type 2 Diabetes 2025 IDF Global Clinical Practice         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Recommendations for Managing Type 2 Diabetes 2025 In Memoriam We are deeply saddened by the passing of          \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Professor Akhtar Hussain (IDF President 2022-2024), who served as Chair of this initiative and led its          \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m development. His leadership, dedication, and expertise significantly shaped this publication. We respectfully   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m dedicate this work to his memory.\\nCorrespondence Prof. Stephen Colagiuri (co-chair), University of Sydney,     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Sydney, Australia. stephen.colagiuri@sydney.edu.au; Prof. Antonio Ceriello (co-chair), IRCCS MultiMedica,       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Milan, Italy. antonio.ceriello@hotmail.it Acknowledgements International Centre for Professional Development in \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Health and Medicine (ICPDHM), Team â€“ Canada Bhavadharini Balaji, PhD - Lead medical writer, Alanna Grant, PhD - \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Senior medical writer and editorial support, Jenny Anawati, Vice President, Anatoly Langer, MD, MSc, FRCPS(C),  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m FACC, Chair, Vivianne Vinet, Chief Executive Officer, IDF Executive Office Lorenzo Piemonte (Belgium) Lucy      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Michaeloudis (France) Paraskevi Salpea (United States) Phil Riley (Belgium) Sameer Pathan (United Kingdom)      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Xango Bimont (France) Sponsorsâ€™ duality of interest This update of the 2005 International Diabetes Federation   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m (IDF) Global Guideline on type 2 diabetes was supported by educational grants from Sanofi and Servier.\\nThese   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m companies did not take part in any aspect of the development of these clinical practice recommendations.        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Copyright No part of this publication may be reproduced or transmitted in any form or by any means without the  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m written prior permission of the International Diabetes Federation. Requests to reproduce or translate this      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m publication should be e-mail at communications@idf.org.\\nÂ© International Diabetes Federation, 2025 ISBN         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 978-2-930229-97-3 Please cite this report as International Diabetes Federation. IDF Global Clinical Practice    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Recommendations for Managing Type 2 Diabetes â€“ 2025. https://idf.org/t2d-cpr-2025 Co-chairs: Antonio Ceriello   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m (Italy) Contributors: Tadej Battelino (Slovenia) A Enrique Caballero (USA) Juliana CN Chan (Hong Kong, China)   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Francesco Cosentino (Sweden) Amalia Gastadelli (Italy) Per-Henrik Groop (Finland) Akhtar Hussain (Norway) â€“ in  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m memoriam David Jenkins (Canada) Linong Ji (China) Stephen Colagiuri (Australia) IDF TECHNICAL WORKING GROUP     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Nebojsa Lalic (Serbia) Carolyn SP Lam (Singapore) Rayaz A Malik (Qatar) Roopa Mehta (Mexico) Viswanathan Mohan  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m (India) Renan MagalhÃ£es Montenegro Junior (Brazil) Ayesha A Motala (South Africa) Peter E.H. Schwarz (Germany)  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Luc Van Gaal (Belgium) Antonio PÃ©rez (Spain) Gojka Roglic (Switzerland) Banshi Saboo (India) Petar M SeferoviÄ‡  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m (Serbia) Jonathan Shaw (Australia) Wayne H-H Sheu (Taiwan, China) Nigel Unwin (UK) Daisuke Yabe (Japan) Jian    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Zhou (China) Project Development, Coordination, and Dissemination Sameer Pathan, Senior Manager at the          \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m International Diabetes Federation, served as project lead and coordinator for this publication, overseeing its  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m development, expert engagement, finalisation, and global dissemination.\\nExternal Reviewers: Adel El Sayed      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m (Egypt) Mohammed Eslam (Australia) Massimo Federici (Italy) Edward W Gregg (UK) James L Januzzi, Jr (USA)       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Alicia Jenkins (Australia) Anatoly Langer (Canada) Maddalena Lettino (Italy) Geltrude Mingrone (Italy) Bernard  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Omech (Uganda) Foreward Introduction Antonio Ceriello, MD & Stephen Colagiuri, MD Chapter 1 Detection of        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m diabetes and intermediate hyperglycaemia, and prevention of type 2 diabetes Chapter 2 Glycaemic control         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m assessment and targets in type 2 diabetes Chapter 3 Blood glucose-lowering therapies â€“ non-insulin options for  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m type 2 diabetes Chapter 4 Blood glucose-lowering therapies â€“ insulin options for type 2 diabetes Chapter 5      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Weight control in type 2 diabetes mellitus management Chapter 6 Cardio-renal protection in type 2 diabetes      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Chapter 7 Management of metabolic dysfunction-associated steatotic liver disease (MASLD) in type 2 diabetes Pg. \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 13 Pg. 9 Pg. 18 Pg. 34 Pg. 50 Pg. 62 Pg. 74 Pg. 86 Pg. 100 TABLE OF CONTENTS 9 Foreward IDF Global Clinical     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Practice Recommendations for Managing Type 2 Diabetes â€“ 2025 FOREWARD IDF Global Clinical Practice              \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Recommendations for Managing Type 2 Diabetes â€“ 2025 10 On behalf of the International Diabetes Federation       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m (IDF), it is my great pleasure to present this 2025 edition of the IDF Global Clinical Practice Recommendations \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m for Managing Type 2 Diabetes. These recommendations reflect our ongoing commitment to improving the lives of    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m people living with diabetes worldwide by equipping healthcare providers with the tools to help them deliver     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m high-quality, evidence-based care. Diabetes remains a serious and fast-growing public health challenge. The IDF \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Diabetes Atlas estimated that 589 million adults aged 20â€“79 years were living with diabetes in 2024 and that    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m this number is projected to reach 853 million by 2050. Type 2 diabetes mellitus (T2DM), which accounts for      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m between 90% and 95% of all diabetes cases, places a substantial burden on individuals, families, and healthcare \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m systems. Around half of all T2DM cases remain undiagnosed. If not managed, T2DM can lead to severe              \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m complications, including cardiovascular disease, chronic kidney disease, retinopathy, neuropathy, and liver     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m disease. With an early diagnosis and access to appropriate treatment and support, T2DM can be controlled and    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m its associated complications prevented or delayed. Furthermore, there is increasing evidence that remission of  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m T2DM may be possible in the early stages of the condition. Therefore, early detection, effective management,    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m and preventive strategies are imperative to address the burden T2DM places on individuals and their families.   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m The 2025 IDF global clinical practice recommendations have been updated to incorporate the latest evidence and  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m advancements in diabetes care. These recommendations provide a structured yet adaptable framework for           \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m healthcare professionals, ensuring they are equipped with practical guidance tailored to diverse clinical       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m settings. A key feature of these recommendations is their unique approach to distinguishing between optimal and \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m basic care strategies, allowing for context-specific adaptation while maintaining high standards of diabetes    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m management. This edition covers a broad range of critical topics, including epidemiology, glycaemic targets,    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m blood glucose management (both non-insulin and insulin therapies), weight control, cardio-renal health, and the \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m impact FOREWARD 11 Foreward of metabolic dysfunction-associated steatotic liver disease (MASLD) on diabetes     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m outcomes. These recommendations prioritise a person-centred approach, ensuring that care is aligned with the    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m individual needs, preferences, and circumstances of people living with diabetes. The development of these       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m recommendations has been a collaborative effort, bringing together leading experts from around the world. I     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m extend my heartfelt gratitude to the co-chairs of the Technical Working Group, Professor Stephen Colagiuri and  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Professor Antonio Ceriello, and to all the contributors, reviewers, and editors who have dedicated their time   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m and expertise to this initiative. I acknowledge the essential contribution of our past president, the late      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Professor Akhtar Hussain, whose vision and dedication were instrumental in shaping this project from the        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m outset. He would be extremely proud that this document has been produced and launched in time for our congress, \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m in keeping with his wishes. His contributions will remain a legacy in the field of diabetes care and education. \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Additionally, I extend my appreciation to the IDF Executive Office for their unwavering support in delivering   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m this document. The impact of these recommendations will be determined by their implementation. We urge          \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m healthcare providers, policymakers, and other key diabetes stakeholders to adopt and adapt these guidelines     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m within their local contexts, ensuring they lead to meaningful improvements in diabetes care. By working         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m together, we can alleviate the global burden of diabetes, prevent its complications, and move closer to         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m achieving universal health coverage and health equity for all those living with or at risk of diabetes. The     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m International Diabetes Federation remains steadfast in its goal to support healthcare professionals, empower    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m people living with diabetes, and drive innovation in diabetes care. We hope these recommendations will serve as \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m a valuable resource for all those working to improve diabetes management in primary care settings. Thank you    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m for joining us in this vital effort. Together, we can create a world where everyone has access to the care they \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m need to lead healthy, fulfilling lives. Professor Peter Schwarz IDF President, 2024â€“2027 13 Introduction        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Antonio Ceriello & Stephen Colagiuri IDF Global Clinical Practice Recommendations for Managing Type 2 Diabetes  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m â€“ 2025 STANDARDS OF CARE IDF Global Clinical Practice Recommendations for Managing Type 2 Diabetes â€“ 2025 14    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m The principles of T2DM care are as follows: o An holistic approach to delivering evidence-based care centred    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m around the person with diabetes, empowered through self-management education and support o A well-trained       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m multidisciplinary health professional team o Decision support systems (registries, reminders, audits, and       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m feedback) Diabetes is a major global health challenge, with an estimated 589 million adults in 2024 living with \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m diabetes, of whom almost one-in-two were undiagnosed. In addition, another 1.1 billion adults worldwide had     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m impaired glucose tolerance or impaired fasting glycaemia predisposing them to an increased risk of developing   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m type 2 diabetes mellitus (T2DM). These numbers are projected to increase significantly over the next two        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m decades.1 T2DM is the most common type of diabetes, accounting for over 90% of all diabetes worldwide, and is   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m associated with increased all-cause mortality and macrovascular and microvascular complications. There is       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m strong evidence that the T2DM burden can be reduced by controlling hyperglycaemia and associated risk factors,  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m diagnosing earlier, and preventing high-risk individuals from progressing to T2DM. The global burden of T2DM    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m continues to increase despite the wealth of existing evidence on diabetes care and prevention. Optimal diabetes \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m management is not reaching the majority of individuals who could benefit. Poor glycaemic control is common in   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m T2DM and does not meet the World Health Organization (WHO) goal of 80% of people with diagnosed diabetes        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m achieving good glycaemic control.2 INTEGRATED DIABETES CARE deliver care in the context of a chronic care model \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m which addresses the multifaceted challenges inherent to this complex condition. Structured diabetes care is an  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m essential aspect of integrated care and underscores the significance of systematic and organised processes,     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m including assessment as a crucial component of quality assurance. Regular evaluation of the person with T2DMâ€™s  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m progress and adherence to agreed care plans creates a foundation for data-driven decision-making. International \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Diabetes Federation guidelines The first International Diabetes Federation (IDF) Global Guideline for Type 2    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Diabetes was published in 20053,4 and an update for primary care physicians was published in 2017.5 Since then, \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m T2DM management has undergone considerable transformation marked by noteworthy developments. New medications    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m have emerged, offering a broader range of therapeutic options and a more personalised approach to care aligning \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m interventions with individual needs. Concurrently, tests for assessing and monitoring diabetes have evolved.    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m The integration of technology into diabetes care has transformed the interaction between individuals with T2DM  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m and their providers. Wearable devices, continuous glucose monitoring systems, and mobile applications are       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m available for the daily management of T2DM in well-resourced healthcare systems. Coupled with the adoption of   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m virtual care, including telemedicine and digital health platforms, these technological advancements have        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m expanded access to care, fostering engagement and facilitating ongoing monitoring and support. The IDF Global   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Clinical Practice Recommendations for Managing Type 2 Diabetes - 2025 IDF is a global umbrella organisation of  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m more than 240 national diabetes associations from 161 countries and territories, representing a diverse range   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m of health systems and populations. Developing global clinical practice recommendations which are relevant,      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m applicable, and equitable across these various healthcare settings presents a unique challenge. Clinical        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m guidance recommendations of national and international learned societies are formulated on the highest level of \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m available evidence in relatively well-resourced health STANDARDS OF CARE Providing this care requires a         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m comprehensive, integrated, individual-centred strategy supported by a health system structured to 15            \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Introduction systems with universal health coverage or at least coverage of essential health services. This     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m does not reflect global reality, with an estimated 4.5 billion people not covered by essential health services  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m and exposed to out-of-pocket health expenses and impoverishing financial hardship. Regrettably, the recent      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m global pattern is one of stagnating progress in service coverage with catastrophic health spending increasing   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m across all regions and most countries.6 In this context, current clinical guidance may be of limited practical  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m use in countries with resource-challenged health systems. This new IDF Global Clinical Practice Recommendations \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m for Managing Type 2 Diabetes - 2025 attempts to strike a balance, embracing the latest therapeutic and          \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m technological evidence while acknowledging the realities of providing diabetes care in a diverse global         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m healthcare environment. These guidelines aspire to provide healthcare professionals and policy makers with an   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m effective and contemporary framework for navigating the complexities of diabetes management that is sensitive   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m to resource, affordability, access, and equity. Levels of diabetes care and prevention approach All people with \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m or at risk of diabetes should have equitable and affordable access to the best available evidence-based,        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m cost-effective integrated diabetes care and prevention. However, it is widely recognised that many countries    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m and health systems around the world do not currently have the workforce or financial resources to provide this  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m level of diabetes care. An imperative in formulating IDF guidance is recognising the limitations and            \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m opportunities presented in the context of varying healthcare systems globally. This is pivotal in guiding       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m recommendations that cater to diverse settings, and which can evolve and be adapted to encourage and facilitate \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m healthcare system reform. The 2005 IDF guideline adopted a Levels of Care approach to formulate recommendations \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m for diabetes care and prevention to address the challenges of global variations in available healthcare         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m resources, expertise, and funding across different countries and localities.3,4 Unlike national guidelines      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m formulated for a particular healthcare system, this perspective is necessary to increase the global relevance   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m and applicability of IDF recommendations. To serve its global membership, the IDF has developed this global     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m guidance that is resource-, capacity-, and cost-sensitive while ensuring an appropriate level of care which     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m will improve outcomes relative to the current situation. Standards of diabetes care and prevention IDF clinical \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m and prevention recommendation advice is now based on two levels of standards of diabetes care and prevention    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m which recognise the diversity of global healthcare systems and inherent resource constraints. Optimal Careâ€¯sets \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m the standard for evidence-based care which would ideally be universally available and represents the most       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m desirable care to achieve best outcomes. This care requires well-resourced health systems which would usually   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m include some form of universal health coverage. It may be available to subgroups of the population in less      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m well-resourced health systems but is not generally available. It should be the aim of all healthcare systems to \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m achieve this standard of care. Basic Careâ€¯aims to achieve the main objectives of \\\"Optimal Care\\\" but is        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m provided in a healthcare setting with limited resources. It serves as a foundational level or starting point to \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m ensure that, even with limited resources, individuals receive essential care and establishes a pathway towards  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Optimal Care. IDF Global Clinical Practice Recommendations for Managing Type 2 Diabetes â€“ 2025 16 The intended  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m users of these guidelines are all healthcare professionals involved in the management of people with T2DM (and  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m those at risk of developing T2DM) and policy makers who are responsible for healthcare services to improve      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m individual and population health. The focus on policy makers is particularly important to ensure that           \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m healthcare and health system reform is implemented to provide universal optimal care. Methodology This guidance \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m focuses on recent advances in diabetes care and prevention. An IDF expert panel was appointed to guide the      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m development of these recommendations, which were formulated using an evidence-based consensus approach. The     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m process included proposing pertinent questions deemed most relevant for the effective management of individuals \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m with, or at risk of, T2DM. These questions were systematically categorised into various topics. Experts in      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m their respective field compiled evidence summaries for each section. The entire group convened to discuss the   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m synthesised evidence on the various topics and draft recommendations. A preliminary document was shared with    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m external reviewers for broader input. Feedback received was carefully reviewed, and revisions made to address   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m duplications and consolidate the evidence and recommendations. The International Centre for Professional        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Development in Health and Medicine (ICPDHM.com), a not-for-profit physician organisation based in Canada,       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m provided medical writing, editorial, and logistical support throughout the development. Acknowledgements The    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m IDF Global Clinical Practice Recommendations for Managing Type 2 Diabetes - 2025 was supported by educational   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m grants from Sanofi and Servier. These companies did not take part in any aspect of the development of these     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m clinical practice recommendations. Medical writing support was provided by, Bhavadharini Balaji, PhD and Alanna \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Grant, PhD of the International Centre for Professional Development in Health and Medicine (ICPDHM), Quebec,    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Canada. REFERENCES 1. International Diabetes Federation (IDF). IDF Diabetes Atlas, 11th edition. Brussels,      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Belgium: International Diabetes Federation, 2025. Available from: http://www.diabetesatlas.org. 2. World Health \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Organization. First-ever global coverage targets for diabetes adopted at the 75th World Health Assembly.        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Available from: https://www.who.int/news-room/                                                                  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m feature-stories/detail/first-ever-global-coverage-targets-for-diabetes-adopted-at-the-75-th-world-health-assemb \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m ly [Accessed February 2025]. Optimal Care Basic Care Definition Evidence-based care and prevention provided in  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m well-resourced settings Evidence-based care and prevention adapted for resource-constrained settings. Serves as \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m a starting point towards Optimal Care Target audience Healthcare professionals and policy makers in             \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m well-resourced settings Healthcare professionals and policy makers in resource-constrained settings             \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Accessibility All individuals with or at risk of diabetes Essential care for all individuals regardless of      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m resource limitations Scope â€¢\\tComprehensive â€¢\\tIndividual-centred â€¢\\tMultidisciplinary care â€¢\\tDecision support \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m systems â€¢\\tFocus on essential services and prioritised programmes â€¢\\tAdapted to challenges of local healthcare  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m settings â€¢\\tIndividual-centred â€¢\\tBest available multidisciplinary care approach Table 1. Standards of diabetes \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m care and prevention STANDARDS OF CARE 17 Introduction 3. IDF Clinical Guidelines Task Force. Global guideline   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m for type 2 diabetese. Brussels: International Diabetes Federation, 2005. IDF Clinical Guidelines Task Force.    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Global guideline for type 2 diabetes: Recommendations for standard, comprehensive, and minimal care. Diabet     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Med. 2006;23(6):579-93. 4. IDF Clinical Guidelines Task Force. Global guideline for type 2 diabetes:            \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Recommendations for standard, comprehensive, and minimal care. Diabet Med. 2006;23(6):579-93. 5. IDF Working    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Group. IDF clinical practice recommendations for managing type 2 diabetes in primary care. Available from:      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m https://idf.org/media/uploads/2023/05/ attachments-63.pdf [Accessed May 2024]. 6. World Health Organization.    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Tracking universal health coverage: 2023 global monitory report. Available from: https://www.who.int/           \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m publications/i/item/9789240080379 [Accessed February 2025]. 18 Detection of Diabetes and Intermediate           \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Hyperglycaemia, and Prevention of Type 2 Diabetes Chapter 1 SCREENING AND PREVENTION 19 Chapter 1               \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m RECOMMENDATIONS Optimal Care Basic Care Criteria for defining diabetes and intermediate hyperglycaemia WHO      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m criteria ADA criteria Diabetes Fasting plasma glucose (FPG) â‰¥7.0 mmol/L (126 mg/dL) â‰¥7.0 mmol/L (126 mg/dL) 2 h \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m plasma glucose* â‰¥11.1 mmol/L (200 mg/dL) â‰¥11.1 mmol/L (200 mg/dL) HbA1c â‰¥6.5% (48 mmol/mol) â‰¥6.5% (48 mmol/mol) \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Intermediate hyperglycaemia Impaired fasting glucose (IFG) Fasting plasma glucose 6.1â€“6.9â€¯mmol/L (110â€“125       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m mg/dL) 5.6â€“6.9 mmol/L (100â€“125 mg/dL) Impaired glucose tolerance (IGT) 2 h plasma glucose* 7.8â€“11.0 mmol/L      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m (140â€“199 mg/dL) 7.8â€“11.0 mmol/L (140â€“199 mg/dL) HbA1c â€“ 5.7%â€“6.4% (39â€“47 mmol/mol) Options for screening for    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m diabetes and intermediate hyperglycaemia Target group: determine locally Risk assessment: â€¢\\tRisk scores â€“      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m developed locally or adapted to local factors â€¢ Risk factors â€“ excessive weight, family history, gestational    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m diabetes history, etc.\\nBiochemical testing options: â€¢\\tFPG â€¢\\t2 h OGTT â€¢\\tHbA1c 1 h PG during 75 g OGTT is an  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m emerging option Select the screening protocol based on available resources and capacity to intervene (in those  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m identified as high-risk) with a diabetes prevention programme Diabetes prevention programmes for high-risk      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m individuals â€¢ Offer a locally developed or adapted 6â€“12-month structured lifestyle modification diabetes        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m prevention programme aiming for 5% weight loss if overweight/obese. â€¢ Consider metformin as additional          \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m intervention â€¢ Provide regular reassessment of individuals â€¢ Support the programme with data systems â€¢          \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Regularly monitor and evaluate the programme Consider the feasibility of implementing a community-based         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m lifestyle modification diabetes prevention programme Diabetes prevention population strategies Implement        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m population programmes to encourage healthier eating, increased physical activity, and healthy weight Consider   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m population programme to encourage healthier eating, increased physical activity, and healthy weight *Following  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m a 75 g oral glucose tolerance test.\\nADA, American Diabetes Association; FPG, fasting plasma glucose; HbA1c,    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m glycated haemoglobin; OGTT, oral glucose tolerance test; WHO, World Health Organization.\\nIDF Global Clinical   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Practice Recommendations for Managing Type 2 Diabetes â€“ 2025 20 SCREENING AND PREVENTION o Globally, there is a \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m high number of people with diabetes, which is predicted to continue to increase; almost one in two people       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m living with diabetes are undiagnosed. o Diabetes can be diagnosed by fasting plasma glucose, 2 h oral glucose   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m tolerance test (OGTT), and glycated haemoglobin (HbA1c) with universally agreed diagnostic criteria. However,   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m there is a lack of congruence between these measures. o Screening for undiagnosed diabetes will identify        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m individuals who will benefit from early treatment. o Intermediate hyperglycaemia (IH) (also referred to as      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m â€œprediabetesâ€) includes impaired glucose tolerance (IGT), impaired fasting glucose (IFG), and intermediate      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m HbA1c. The WHO and ADA criteria for defining IH differ for IFG and WHO does not have an HbA1c criterion. o The  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m prevalence of IH is higher than diabetes but varies with the screening test â€“ these tests lack congruence. IGT  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m can only currently be detected by a 2 h OGTT. o The 1 h OGTT test has recently been advocated as another        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m option. o Screening for IH identifies individuals who can benefit from interventions to prevent type 2 diabetes \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m mellitus (T2DM). o Strategies for diabetes prevention include the individual-based high-risk approach and the   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m population approach. o Structured lifestyle modification programmes are effective in preventing or delaying     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m T2DM in people with IGT but not isolated IFG. Data for HbA1c-detected IH are limited. Some medications can      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m prevent or delay T2DM. o Prevention strategies have been successfully translated in community or national       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m programmes in a number of countries. o The design of programmes has differed in relation to target group,       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m screening process and test, and intensity and method of delivery of the lifestyle intervention. Little data are \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m available on the impact on diabetes prevention, but weight reduction and increased physical activity are        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m encouraging. o A decision to implement a high-risk individual diabetes prevention programme should be guided by \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m local resources, health system capacity, and cost. Local design and adaptation are important. o Population      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m approaches aiming to reduce modifiable diabetes risk factors in the whole population include healthier eating,  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m regular physical activity, and preventing and managing overweight and obesity. o Encouragingly, there appears   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m to be a stabilisation or decline in diabetes incidence in many higher-income countries. KEY POINTS 21 Chapter 1 \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m BACKGROUND In 2024, an estimated 589 million adults aged 20 to 79 were living with diabetes, giving a           \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m prevalence of 11.1%. Almost one-in-two (42.8%; 251.7million) adults with diabetes were undiagnosed, with        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m considerable regional differences.1 In addition, the global prevalence of impaired glucose tolerance (IGT) was  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 12.0% and that of impaired fasting glucose (IFG) was 9.2%.1 Individuals with undiagnosed type 2 diabetes        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m mellitus (T2DM) and intermediate hyperglycaemia (IH) are at increased risk of adverse outcomes and premature    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m mortality. Type 2 diabetes is a silent, progressive disease with chronic hyperglycaemia often preceded by IH.   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Earlier detection of T2DM provides an opportunity to intervene with evidence-based care and studies over the    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m last three decades confirm that progression from IH to T2DM can be prevented or delayed. Tests used for the     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m early detection of diabetes and IH include fasting plasma glucose (FPG), 2 h PG during a 75 g oral glucose      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m tolerance test (OGTT), or glycated haemoglobin (HbA1c). Programmes for the detection of undiagnosed T2DM and    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m the prevention of progression to T2DM in high-risk individuals are well-accepted strategies to reduce the       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m burden of diabetes. GLOBAL CONSIDERATIONS The capacity to detect individuals with undiagnosed T2DM and IH and   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m implement diabetes prevention programmes varies considerably between countries and health services and systems, \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m especially in low- and middle-income countries (LMIC). The World Health Organization (WHO) periodically         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m conducts a country capacity survey on non-communicable diseases (NCDs) to assess the national-level response to \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m the NCD burden, which includes information on health system capacity for diabetes detection, treatment, and     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m care. The most recent survey in 2019 collected data from 160 countries; 75% reported having an operational      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m policy, strategy, or action plan for diabetes. Specific details on diabetes screening and prevention were not   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m reported. The percent of countries with guidelines utilised in at least 50% of healthcare facilities was 22%    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m for overweight/obesity and 33% for physical activity. Fifty-two percent of countries had an OGTT generally      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m available in 50% of their primary care facilities in the public and private health sector; 53% of countries had \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m HbA1c tests.2 The Pan American Health Organization separately reported its survey results and found that 33 of  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 35 countries (94%) had blood glucose measurement equipment, 22 of 35 countries (63%) had OGTT testing, and 18   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m of 35 countries (51%) had HbA1c testing generally available in 50% of public primary healthcare facilities.3 A  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m survey of individuals from LMICs showed that the reach of any diabetes prevention-related activities was low:   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 40% for physical activity counselling, 37% for weight loss counselling, 43% for dietary counselling, and 37%    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m for blood glucose screening. The lowest receipt of these activities was among people in low-income countries    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m and people with no formal education.4 EVIDENCE SUMMARY Criteria for diabetes and intermediate hyperglycaemia    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Criteria for diabetes and IH have evolved since the first WHO guidelines were published in 1965, with           \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m significant changes made by expert panels of WHO and the American Diabetes Association (ADA) to reflect         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m evolving evidence and its interpretation.5 Since there is no specific marker which unequivocally defines        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m diabetes, the diagnosis is based on cut-points derived from the relationship between various measures of        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m glycaemia associated with risk of diabetes microvascular complications, particularly retinopathy.5 Without a    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m true gold standard among the biochemical tests for diagnosing diabetes (FPG, 2 h OGTT PG, HbA1c), comparisons   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m of these tests are questionable. It has been suggested that the closest to a gold standard would be a           \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m combination of FPG, 2 h PG, and HbA1c assessments with confirmatory testing for all parameters, but this is not \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m feasible.6 This also applies to tests and comparisons of tests for IH. There are significant differences in the \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m attributes of tests used to diagnose diabetes and IH which influence the testing method adopted in different    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m health settings and services.7,8 These include requirement for fasting, global access and affordability,        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m analytic stability, biologic variation, and factors affecting the assay (Table 1.1). IDF Global Clinical        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Practice Recommendations for Managing Type 2 Diabetes â€“ 2025 22 SCREENING AND PREVENTION FPG OGTT HbA1c Fasting \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m required Yes Yes No Test preparation Fasting Pretest CHO intake Nil Convenience Reasonable Low Good Global      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m access and affordability Highest Intermediate Intermediate Pre-analytic stability Poor â€“ influenced by sample   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m handling Good Assay standardisation Not standardised Standardised but varies globally Biological variation      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Intermediate High Low Within-person variation High Low Acute factors affecting result Food intake, stress,      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m activity Not affected Other factors affecting results Diurnal variation Older age Medications                   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Haemoglobinopathies Altered red cell turnover, uraemia Ethnicity Diagnostic sensitivity (compared to OGTT)      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Lower Highest Lower Identifies IGT No Yes No Lifestyle prevention intervention effect Negative (for isolated    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m IFG) Positive (for IGT +/â€“ IFG) Limited data Table 1.1 Comparison of tests to diagnose diabetes and define      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m intermediate hyperglycaemia CHO, carbohydrate; FPG, fasting plasma glucose; IFG, impaired fasting glucose;      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m HbA1c, glycated haemoglobin; IGT, impaired glucose tolerance; OGTT, oral glucose tolerance test. Diabetes       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Criteria Definitions of diabetes are universally agreed, with both WHO and ADA adopting the same FPG, 2 h PG,   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m and HbA1c diagnostic values (Table 1.2). WHO criteria ADA criteria Diabetes Fasting plasma glucose (FPG) â‰¥7.0   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m mmol/L (126 mg/dL) â‰¥7.0 mmol/L (126 mg/dL) 2 h plasma glucose* â‰¥11.1 mmol/L (200 mg/dL) â‰¥11.1 mmol/L (200       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m mg/dL) HbA1c â‰¥6.5% (48 mmol/mol) â‰¥6.5% (48 mmol/mol) Intermediate hyperglycaemia Impaired fasting glucose (IFG) \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Fasting plasma glucose 6.1â€“6.9â€¯mmol/L (110â€“125 mg/dL) 5.6â€“6.9 mmol/L (100â€“125 mg/dL) Impaired glucose tolerance \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m (IGT) 2 h plasma glucose* 7.8â€“11.0 mmol/L (140â€“199 mg/dL) 7.8â€“11.0 mmol/L (140â€“199 mg/dL) HbA1c â€“ 5.7%â€“6.4%     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m (39â€“47 mmol/mol) *Following a 75 g oral glucose tolerance test. ADA, American Diabetes Association; HbA1c,      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m glycated haemoglobin; WHO, World Health Organization.\\nIn asymptomatic individuals, two abnormal values either  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m in the same setting or on separate occasions are recommended for clinical management.5 Table 1.2 Criteria for   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m defining diabetes and intermediate hyperglycaemia 23 Chapter 1 Prevalence Prevalence data for diabetes vary and \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m are influenced by the method used to identify individuals with diabetes, which may include diabetes based on    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m self-report, and/or taking diabetes-specific medication, and/or testing of people without known diabetes,       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m and/or testing people with self-report diabetes but not taking medication. Furthermore, there is a              \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m well-recognised lack of congruence between FPG, 2 h PG, and HbA1c tests in identifying individuals as having    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m diabetes.9 In 2024, the International Diabetes Federation (IDF) reported a global diabetes prevalence in        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 20â€“79-year-olds of 11.1% (589 million people), which was predicted to increase to 853 million by 2050. Diabetes \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m prevalence was similar in men and women, highest in those aged 75â€“79 years, higher in urban (12.7%) than rural  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m (8.8%) areas, and in high-income (12.4%) compared to low-income countries (6.1%). Regional differences were     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m also noted, with the highest prevalence in the Middle East and North Africa IDF region (19.9%) and the lowest   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m in the Africa IDF region (5.0%), and the largest numbers of people with diabetes in China (148 million) and     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m India (90 million).1 Methods for diabetes diagnosis included any of the three glucose measures, self-report,    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m medical record or clinic diagnosis, and extrapolations for countries without data.10 In 2022, the NCD Risk      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Factor Collaboration estimated that 828 million adults aged 18 years and older had diabetes, an increase of 630 \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m million from 1990, with the largest increases in low- and middle-income countries. The global age-standardised  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m diabetes prevalence was 13.9% for women and 14.3% for men. These estimates were based on defining diabetes as   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m an FPG â‰¥7.0 mmol/L (126 mg/dL) or an HbA1c â‰¥6.5% (48 mmol/mol), or taking medication for diabetes.11 Previously \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m undiagnosed diabetes In 2024, almost one in two (42.8%; 251.7 million) adults aged 20â€“79 years old living with  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m diabetes were undiagnosed. There were significant regional disparities in undiagnosed diabetes, and 86.9% of    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m all undiagnosed cases were in low- and middle-income countries. Low-income countries had the highest proportion \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m of undiagnosed cases (58.7%), followed by middle-income countries at 45.5%, and high-income countries at        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 28.9%.1 The lack of congruence between glycaemic measures impacts reported prevalence of undiagnosed diabetes.  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m An analysis of previously undiagnosed diabetes detected by an elevated FPG, HbA1c, or both reported that        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m globally 29% of individuals with screen-detected diabetes had an isolated elevated FPG, 37% had an isolated     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m elevated HbA1c, and 34% had elevated levels of both, with substantial variation across regions. In most low-    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m and middle-income regions, isolated elevated HbA1c was more common than isolated elevated FPG.12 Some of this   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m disparity may relate to ethnic variations in the FPG-HbA1c relationship.13 Intermediate hyperglycaemia          \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Intermediate hyperglycaemia, also referred to as â€œprediabetesâ€, includes impaired glucose tolerance (IGT),      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m impaired fasting glucose (IFG), and intermediate HbA1c. IGT was introduced in 1979 to describe a category of    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m increased risk of progressing to diabetes.14 IFG was introduced in 1997 to describe the FPG zone, which was     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m believed to equate to IGT.15 There are differences in the pathogenesis of IFG and IGT, with IGT associated with \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m muscle insulin resistance and defective insulin secretion, resulting in less efficient disposal of the glucose  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m load during the OGTT; IFG is associated with impaired insulin secretion and impaired suppression of hepatic     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m glucose output.16 Criteria WHO and ADA criteria are the same for IGT but are different for defining IFG (Table  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 1.2), with WHO using an FPG range of 6.1â€“6.9 mmol/L (110â€“125 mg/dL) and the ADA using an FPG range of 5.6â€“6.9   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m mmol/L (100â€“125 mg/dL). Based on an OGTT with measurement of both FPG and 2 h PG, IH can be subdivided into     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m those with isolated IFG, isolated IGT, and combined IFG/IGT. IFG and IGT are not clinical entities but rather   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m risk factors for future diabetes and adverse outcomes, and regression to normoglycaemia is common, ranging from \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 33% to 59% over 1â€“5 years of follow-up for IFG and 17% to 42% over 6â€“11 years of follow-up for IGT.17 In 2009,  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m an International Expert Committee (IEC) recommended using an HbA1c of 6.0%â€“6.4% (42â€“47 mmol/mol) to identify    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m people with IH.18 An HbA1c intermediate hyperglycaemia category termed â€œprediabetesâ€ was adopted by ADA in      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 2010, defined as an HbA1c of 5.7%â€“6.4% (39â€“47 mmol/mol).19 To date, WHO has not made a recommendation on HbA1c  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m for IH. Other groups IDF Global Clinical Practice Recommendations for Managing Type 2 Diabetes â€“ 2025 24        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m SCREENING AND PREVENTION such as the UK National Institute for Health and Care Excellence recommends an HbA1c   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m of 6.0%â€“6.4% (42â€“47 mmol/mol).20 Prevalence of intermediate hyperglycaemia In 2024, IDF estimated the global    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m prevalence of IGT was 12.0% and that of IFG was 9.2% among adults aged 20â€“79 years, with marked regional        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m differences. Age-adjusted IGT prevalence was highest in Southeast Asia region (13.8%) and lowest in Europe      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m region (5.9%). North America and the Caribbean region showed the highest IFG prevalence (13.6%) while Europe    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m had again the lowest (5.4%).1 There are significant differences in prevalence and congruence of IH identified   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m by different criteria, and overlap between the various biochemical tests is only moderate. Although IFG and     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m intermediate HbA1c were introduced to achieve alignment with IGT, individuals with IGT who also had ADA-IFG was \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 58%, WHO-IFG was 23%, and ADA-HbA1c was 32%.21 In addition, the percentage of people without IGT who have IFG   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m increases substantially with ADA-FPG versus WHO-FPG.22 The 2015â€“2016 US NHANES survey reported IH prevalences   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m ranging from 4.3% with IEC-HbA1c to 43.5% with ADA-IFG. If a combination of ADA-HbA1c, ADA-FPG, and 2 h PG was  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m used, the prevalence was 2.5% compared with 51.3% if any of the three tests was used.23 Progression to diabetes \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m All measures of IH predict progression to T2DM without intervention, and incident rates of T2DM increase with   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m longer periods of follow-up. Randomised controlled trials (RCTs) of diabetes prevention in people with IGT in   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Asia,24 Europe,25 India,26 and the United States27 reported a cumulative diabetes incidence of 23%â€“68% in the   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m control group in this high-risk group mostly defined by two abnormal OGTTs. A Cochrane review reported a        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m cumulative diabetes incidence in individuals with IGT of 13% after one year and 60% after 20 years follow-up.   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m The risk of diabetes was highest with combined IFG and IGT compared to people with normal glucose tolerance and \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m with isolated IGT. The cumulative diabetes incidence after 12 years follow-up was 31% for both ADA-IFG and      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m WHO-IFG; for ADA-HbA1c it was 31% at 10 years follow-up and 29% at 15 years follow-up for IEC-HbA1c.17 A recent \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Danish population study reported a 21% 5-year cumulative T2DM incidence for IEC-HbA1c.28 Older age is an        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m important consideration. A study of older adults with a high prevalence of ADA-FPG and ADA-HbA1c-defined IH     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m reported that regression to normoglycaemia or death was more frequent than progression to diabetes.29           \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Prediction of adverse outcomes The association between adverse outcomes and the various definitions of IH has   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m been examined in two systematic reviews. The first included 129 studies with 10,069,955 individuals30 and the   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m second included 106 prospective studies and nearly 1.85 million people from 27 countries.31 Overall, IH was     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m associated with a significantly increased risk of mortality, cardiovascular disease (CVD), stroke, and chronic  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m kidney disease compared with normoglycaemia across the different definitions of IH, albeit with some minor,     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m inconsistent differences. Summary There are considerable differences in prevalence with the various individual  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m tests for IH. Although the absolute reported prevalence varies, the pattern is consistent, with the highest     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m prevalences found with ADA-IFG, ADA-HbA1c, and IGT and the lowest with WHO-IFG and IEC-HbA1c.32, 33 Differences \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m in IH prevalences and progression to T2DM may reflect differences in pathophysiology and the myriad of          \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m ecological and external factors (e.g., environment, ecosystem, awareness, cultures, access to care, and         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m standard of care) as well as host factors (e.g., ancestry, ethnicity, sex, age, gender, genetics, life course   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m events, education, lifestyles, cognitive/psychological behaviours, coexisting risk factors, and comorbidities)  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m and their complex interactions. As such, context and phenotyping are important considerations in attempts to    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m improve the precision of risk assessment to maximise the impacts and cost-effectiveness of interventions.34, 35 \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m There are well-documented differences across ethnic groups based on OGTT, with Asians highly insulin-sensitive, \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Africans most insulin-resistant, and Caucasians in-between along the hyperbolic curve between glucose           \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m sensitivity and insulin secretion.36 Data from Uganda indicate that nearly one-third of people with incident    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m diabetes have a body mass index (BMI) <25 kg/m2, with a predominant phenotype of 25 Chapter 1 reduced           \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m pancreatic secretory function.37 These differences contribute to sub-phenotypes within the spectrum of          \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m dysregulation of glucose metabolism, which may stem from interethnic differences in biological responses,       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m influenced by differences in population-specific genetic and ecological factors.38 Screening for undiagnosed    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m diabetes and intermediate hyperglycaemia Screening for undiagnosed T2DM or for IH are commonly recommended      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m strategies. Earlier diagnosis and treatment reduce the risk of adverse outcomes, and identifying people with IH \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m provides an opportunity to prevent progression to diabetes. The usual approach to screening for undiagnosed     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m T2DM or IH is based on well-recognised clinical risk factors (e.g., increasing age, family history of diabetes, \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m overweight/ obesity, previous history of gestational diabetes, ethnicity) and/or using formal risk scores       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m composed of clinical information, followed by blood testing of glucose or HbA1c.39,40 Risk scores have been     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m demonstrated to enhance the performance of biochemical testing.32 Use of local data to develop a risk score to  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m estimate absolute risk prediction for diabetes may also increase precision. Testing method and frequency of     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m screening There are considerable differences in the performance of individual tests for IH and consequently     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m differences in country and international recommendations. If a decision is made to screen, the choice of test   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m procedure and frequency of testing will need to be determined by a countryâ€™s health services, taking into       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m account available resources. Within-country differences in recommendations underscore the lack of universal     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m consensus.7, 41 While guidelines recommend repeat testing to confirm a diagnosis of diabetes in an asymptomatic \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m individual, there are no guidelines regarding repeat testing to confirm IH.42 The 1 h OGTT â€“ a proposed new     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m approach to testing for intermediate hyperglycaemia Decades ago, the 2 h OGTT was a five-sample test with       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m glucose measured at 0, 30, 60, 90, and 120 minutes. Later the 30-, 60-, and 90-min samples were eliminated,     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m leaving the modern day OGTT with only FPG and 2 h PG. Recently, the value of the 1 h PG during an OGTT has been \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m revisited in an IDF Position Statement. Epidemiological data demonstrate the value of a 1 h PG â‰¥8.6 mmol/L (155 \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m mg/dL) in predicting diabetes and associated complications, even in people with otherwise normal glucose        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m tolerance, and a 1 h PG â‰¥11.6 mmol/L (210 mg/dL) for diagnosing T2DM. The IDF Position Statement suggests the 1 \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m h PG as a more sensitive and practical method than other current biochemical tests and calls for redefining     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m current diagnostic criteria for IH and T2DM by adding the 1 h PG as a diagnostic option.43 The evidence         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m supporting the utility of the 1 h PG during an OGTT is comprehensively detailed in the IDF Position Statement   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m and is therefore not reviewed further in this Chapter. In time, the 1 h PG OGTT may be adopted for detecting    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m IH. Using a 1 h OGTT may not necessarily overcome the practical and health system challenges of the 2 h OGTT,   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m even though it is a shorter test. An additional test for detecting IH may find increased prevalence rates and   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m incongruence in classifying individuals with IH evident with currently available tests. While it is likely that \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m individuals with an elevated 1 h PG will benefit from diabetes prevention interventions similar to those with   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m IGT, there are currently no supporting clinical trial data. Diabetes prevention There are two complementary     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m approaches to reducing the incidence of type 2 diabetes: o The individual-based high-risk approach with         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m interventions in higher risk individuals o The population approach to reduce diabetes risk factors across the   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m entire population The individual-based high-risk approach This strategy involves identifying individuals at     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m higher risk of developing T2DM by screening and testing for IH, followed by offering lifestyle interventions.   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Successful randomised diabetes prevention studies have targeted individuals with IGT, and a recent review       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m reported a lack of effect of lifestyle intervention in individuals with isolated IFG.44 However, the situation  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m may be different for IDF Global Clinical Practice Recommendations for Managing Type 2 Diabetes â€“ 2025 26        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m SCREENING AND PREVENTION pharmacological interventions to prevent diabetes for glucose- or HbA1c-defined IH.45, \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 46 There are limited data on the effectiveness of lifestyle intervention in individuals with IH identified by   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m HbA1c. The US Diabetes Prevention Program (DPP) evaluated treatment effects (in participants with IH identified \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m by HbA1c) on incident diabetes, defined by HbA1c â‰¥6.5% (48 mmol/mol). Lifestyle intervention and metformin      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m reduced diabetes incidence by 49% and 44%, respectively, during the DPP, and by 29% and 38%, respectively,      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m during the 10-year follow-up. In contrast to the superiority of the lifestyle intervention on glucose-defined   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m diabetes, metformin and lifestyle interventions had similar effects in preventing HbA1c-defined diabetes.47     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Interventions to prevent or delay development of T2DM in high-risk individuals review reported a significant    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m reduction in incident T2DM in people with IGT with or without IFG (but not in isolated IFG) who received diet   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m and exercise counselling.53 The lack of effect in IFG has been confirmed in a more recent systematic review of  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m data from other studies.44 Diabetes prevention or delay persists but decreases over time as demonstrated after  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 20 years in the China Da Qing Diabetes Prevention Study, with intervention participants having 3.6 fewer years  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m with diabetes. However, residual risk of progression to diabetes was high: 80% in the intervention group and    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 93% in the control group after 20 years.54 The Finnish DPS reported an ongoing reduction in incident T2DM over  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m the 13-year follow-up. The cumulative incidence of diabetes was 44% in the intervention group and 64% in the    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m control group, with an estimated five-year delay in deterioration from IGT to overt T2DM.55 The US Diabetes     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Prevention Program Outcomes Study also showed sustained diabetes prevention in the intervention versus control  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m group after 12 years.56 Emerging data from long-term observational studies of RCTs suggest a possible           \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m beneficial effect on vascular complications,57 including a lower risk of severe retinopathy after 20 years of   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m follow-up,58 and a significant 41% risk reduction in CVD and 29% reduction in all-cause death in the            \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m intervention group after 23 years.59 Pharmacotherapy Several studies have assessed the effect of various        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m glucose-lowering medications on T2DM prevention. A Cochrane review reported the superiority of metformin in     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m reducing incident T2DM compared with standard diet and exercise but it was not different compared with          \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m intensive diet and exercise, acarbose, thiazolidinediones, or when combined with intensive lifestyle compared   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m with intensive lifestyle alone.60 However, a recent RCT reported a 17% significantly lower risk of incident     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m T2DM with metformin plus lifestyle intervention compared with lifestyle intervention alone, but with more       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m adverse gastrointestinal side effects.61 Data on long-term outcomes are limited except for the US DPP which     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m showed no difference in microvascular complications in the metformin versus the comparative group after 15      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m years follow-up.62 Other agents which significantly reduced diabetes incidence include acarbose,63              \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m thiazolidinediones,45 glucagon-like peptide-1 receptor agonists,64 and sodium-glucose cotransporter-2           \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m inhibitors.46 Several systematic reviews and meta-analyses have demonstrated an association between incident    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m T2DM and diet or dietary components, including: o High glycaemic index (GI) foods and high glycaemic load (GL)  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m diets increase risk.48 o Consumption of foods and dietary components from plant-based sources, such as whole    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m grain products, fibre, vegetable fats, and plant proteins, reduces risk.49 o A higher intake of red meat,       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m processed meat, and sugar-sweetened beverages increases risk.50 o A high intake of vegetable fat lowers T2DM    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m incidence but total fat intake is not associated with incident T2DM.50 o Substituting plant protein for animal  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m protein may decrease T2DM risk.51 o Vegetarian diets are associated with reduced T2DM incidence.52 Randomised   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m controlled studies Diet and physical activity Lifestyle changes are effective in preventing or delaying the     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m development of T2DM. A Cochrane 27 Chapter 1 Community and national programmes Several programmes have          \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m translated the high-risk individual lifestyle-based T2DM diabetes prevention RCTs into large-scale community    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m and national prevention programmes. The US National Diabetes Prevention Program (US NDPP) US NDPP is a          \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m lifestyle intervention programme to prevent T2DM in at-risk people age â‰¥18 years old identified by HbA1c, FPG,  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m or OGTT, or previous gestational diabetes, or positive ADA risk test. The programme is overseen by the Centre   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m for Disease Control (CDC) and promotes â‰¥5% weight loss over one year delivered via in-person classes, distance  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m learning, online programming, or a combination of modalities. There are a total of 26 sessions and at least 22  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m must be completed for the individual to achieve CDC recognition for completing the programme. Analysis of       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 14,747 adults enrolled in the programme reported that 36% achieved the 5% weight loss goal (average weight loss \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 4.2%). As yet, incident T2DM has not been systematically evaluated.65 The Finnish National Diabetes Prevention  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Programme (FIN-D2D) FIN-D2D is a community-based lifestyle modification T2DM prevention programme delivered in  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m primary and occupational health care, predominantly through groups.66 Individuals are screened for high risk    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m with the Finnish Diabetes Risk Score (FINDRISC) and are then referred for OGTT. Evaluation of 2,730 individuals \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m with complete follow-up data showed that in those who lost 2.5%â€“4.9% body weight and â‰¥5% during the first year, \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m risk for incident medication-treated diabetes after 7.4 years was significantly reduced by 37% and 29%,         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m respectively, compared with those with stable weight. There were no significant differences in CVD events or    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m all-cause mortality.67 The UK National Health Service Diabetes Prevention Programme (NHS DPP) This programme is \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m offered to individuals aged â‰¥18 years with an HbA1c 6.0â€“6.4% (42â€“47 mmol/mol) or FPG 5.5â€“6.9 mmol/L (100â€“125    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m mg/dL) through 13 lifestyle modification education sessions delivered by face-to-face groups or a digital       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m service. An assessment of 17,252 individuals who completed the programme demonstrated a mean weight loss of 3.3 \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m kg and an HbA1c reduction of 0.19% (2.04 mmol/mol). T2DM incident was not reported.68 Australian Victorian      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Life! Taking Action on Diabetes Program This is a community-based diabetes prevention programme with            \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m individuals at risk of developing diabetes identified by a national risk score. An evaluation of 8,412          \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m participants who commenced a Life! Program (of whom 37% completed all six education sessions) showed an average \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m weight loss of 2.4 kg (2.7%) in completers and 1.4 kg weight loss in those attending 1â€“5 sessions.69            \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Middle-income countries A review of six RCTs of community-based lifestyle interventions included three studies  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m (Chennai and Kerala, India, and one from rural China) reported diabetes incidence in 1,921 individuals. The     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m review found a non-significant reduction in diabetes incidence at 12 months compared with controls. Significant \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m reductions were observed in weight (2.3 kg) and in FPG and HbA1c.70 A lifestyle diabetes prevention programme   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m in primary care settings in Thailand in 1,093 individuals with IGT reported a significant 28% reduction in      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m incident diabetes after two years compared with the control group, accompanied by body weight reduction of 1.5  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m kg in the intervention group and a 0.4 kg increase in the control group.71 South Africa Lifestyle Africa is a   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m culturally adapted version of the US DPP with a lifestyle intervention of 17 video-based group sessions         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m delivered by trained community health workers. An assessment of 494 enrolled participants reported a mean       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m weight change of 0.6% in the intervention group, not significantly different to the 0.4% in the control group.  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m However, HbA1c was significantly lower (mean difference 0.24% [2.58 mmol/mol]).72 The population approach       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Strategies to improve the health of the entire population by reducing modifiable risk factors for NCDs are an   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m integral part of T2DM prevention. Reducing population diabetes risk factors results in a small downward shift   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m in average population levels of diabetes risk, which can lead to a significant reduction in diabetes. This can  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m be achieved by encouraging a healthy diet and regular physical activity, preventing overweight and obesity, and \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m reducing other IDF Global Clinical Practice Recommendations for Managing Type 2 Diabetes â€“ 2025 28 SCREENING    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m AND PREVENTION health risks such as smoking, excessive alcohol intake, improving sleep, and minimising          \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m climate-related health effects. Common strategies to drive population change include increasing                 \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m health-promoting environments, embedding health-promoting activities in everyday life, education and social     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m media campaigns, and reducing marketing and the promotion of unhealthy foods, especially to children. Effective \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m societal strategies include legislation (e.g., sugar tax) to reduce consumption of sugar-sweetened beverages,   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m food reformulation, improved food labelling, and changing the physical environment (e.g., reduce pollution,     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m provide living and leisure space). Broader population-based measures are also important, including improving    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m general education, reducing poverty, ensuring food security, and raising health awareness â€“ all underpinned by  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m universal health coverage and a robust primary care and health system.38 These interventions can be             \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m incorporated in diabetes prevention programmes.66 Summary Randomised controlled studies have demonstrated the   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m effective prevention of T2DM in people with IGT across different populations but a lack of effect in people     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m with isolated IFG. The effect on incident diabetes persists but declines over time. Emerging evidence suggests  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m a decline in some adverse diabetes outcomes. Several countries and settings have translated this evidence into  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m community-based programmes, with differences in target population, method of identifying high-risk individuals, \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m and the intervention content and delivery. Overall, the degree of weight loss is less than in RCTs and data on  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m incident diabetes are lacking. Including strategies to reduce population diabetes risk is an important          \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m component of diabetes prevention programmes. Implementing diabetes prevention programmes Diabetes prevention    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m programmes should ideally include both high-risk and population strategies. Encouragingly, the incidence of     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m diagnosed diabetes appears to be stabilising or declining in many higher-income countries, with a reported      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m annual estimated change in incidence ranging from â€“1.1% to â€“10.8% since 2010. Multifaceted T2DM prevention      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m activities in individuals at high risk of T2DM and population-wide approaches may be factors in this            \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m observation.73 Population strategies require lobbying and influencing national policy makers. The focus of this \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m section is implementing programmes for high-risk individuals.\\nThe essential components of programmes targeting \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m high-risk individuals are universally agreed (Figure 1.1). However, there are a number of questions which need  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m to be considered in developing and implementing a community or Figure 1.1 Overview of high-risk type 2 diabetes \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m screening and prevention programmes â€ Programme content and delivery dependent on local resources. FPG, fasting  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m plasma glucose; HbA1c, glycated haemoglobin; OGTT, oral glucose tolerance test.\\n29 Chapter 1 Programme         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m delivery Established programmes have varied widely with respect to number of education sessions (ranging from   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 4â€“22), the way the programme is delivered (face-to-face individual or group, online), and the follow-up support \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m offered. Programmes have also differed with respect to training, qualifications, and accreditation of the       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m education trainers who deliver the programme. Awareness, enrolment, and retention In Finland, 25% of men and    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 48% of women reported being aware of the FIN-D2D programme in the area where it was being rolled out, compared  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m with 20% men and 36% of women in the control area.77 Community-based programmes have consistently highlighted   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m the challenge of enrolment and retention. In the Victorian Diabetes Program, over 29,000 individuals showed     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m interest in the programme, 15,000 were referred, approximately 8,500 commenced the programme, and 3,000         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m attended all six programme sessions.69 In the UK NHS Diabetes Prevention Programme by December 2018, nearly     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 325,000 people were referred, approximately 150,000 attended the initial assessment, and approximately 95,000   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m attended at least one of 13 group-based intervention sessions with approximately half completing the            \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m intervention (attending >60% of sessions).68 Attendance may be influenced by the mode of programme delivery,    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m with assessment of over 330,000 US National DPP participants showing that the average number of sessions        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m attended was highest for in-person participants (68%), online (57%), distance learning (55%), and combination   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m (49%), with a similar pattern for average weeks in the programme. Among participants who remained in the        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m programme for all sessions, average weight loss exceeded the programme goal of 5% for all delivery modes.78     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Results were similar for the South African programme â€“ average attendance across all sessions and groups was    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 54%, with 35% attending at least 75% of sessions across all groups.79 Scalability Scalability and reach remain  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m a challenge. The US National DPP has been successful in offering the programme to over 700,000 at-risk          \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m participants since it began in 2012 but there are an estimated nearly 100 million Americans with IH. One        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m approach which has been taken to improve reach is to incorporate diabetes prevention national diabetes          \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m prevention programme for high-risk individuals.\\nRisk assessment and screening Most programmes target a         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m specific age group for screening rather than offering universal screening but differ in the selected age, which \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m is decided based on local risk and resources. Many guidelines suggest initial screening with a risk score to    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m identify high-risk individuals. Developing or adapting a risk score using local data may increase predictive    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m precision. Screening for high risk is complex and challenging on a large scale. The strongest evidence for      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m successful lifestyle intervention is for people with IGT, which can only be diagnosed by an OGTT.44 However,    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m OGTT screening has practical limitations for both the health system and participants, especially if it is also  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m to be used for routine follow-up assessment. Given these practical challenges, many national programmes use     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m HbA1c or FPG to identify high-risk individuals for interventions to reduce progression to T2DM. While the US    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m DPP includes testing with any of the three tests for identifying IH, the most used tests are HbA1c and FPG      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m rather than an OGTT. The UK DPP advocates blood testing with HbA1c or FPG. The Hong Kong Chronic Co-Care Pilot  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Scheme includes screening for IH based on an HbA1c of 6.0%â€“6.4% (42â€“47 mmol/mol) or FPG 6.1â€“6.9 mmol/L (110â€“125 \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m mg/dL).74 Advances in understanding the heterogenous nature of IH and in technology may increase the precision  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m with which the highest-risk individuals can be identified for a programme based on selective use of OGTT,       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m depending on available resources. Options include stratifying levels of risk and recommending OGTT testing in   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m the younger highest-risk category.75 Another option is the 1 h OGTT PG. Screening for diabetes prevention       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m programmes requires balancing the evidence, practicalities, potential impact, and cost. A comparison of a range \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m of screening scenarios, including OGTT, FPG, and HbA1c alone or following risk score assessment explored the    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m potential impact on reducing incident diabetes and cost. Compared with OGTT testing, costs of screening and     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m prevention were substantially lower with an initial assessment with a risk score, followed by a blood test, but \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m the potential for diabetes prevention was reduced by 35% to 75%. With all scenarios, there will be some         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m lower-risk individuals who will develop diabetes.76 IDF Global Clinical Practice Recommendations for Managing   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Type 2 Diabetes â€“ 2025 30 SCREENING AND PREVENTION into broader NCD prevention initiatives. Some programmes     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m offer financial incentives to encourage risk assessment and subsidise lifestyle educational interventions.      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Implementation If a decision is made to have a diabetes prevention programme for high-risk individuals, the     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m design will need to be decided according to local practice, local resources, feasibility, and cost. Data        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m systems and evaluation are important components of the programme to facilitate quality improvement. REFERENCES  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 1. International Diabetes Federation (IDF). IDF Diabetes Atlas. 11th edition. Brussels, Belgium: International  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Diabetes Federation, 2025. Available from: http://www.diabetesatlas.org. 2. World Health Organization.          \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Assessing national capacity for the prevention and control of noncommunicable diseases: report of the 2019      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m global survey [Internet]. Geneva: WHO; 2020]. Available from: https://iris.who.int/handle/10665/331452.         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m [Accessed February 2025]. 3. PAHO/NMH/NV/21-0041 Pan American Health Organization, 2021. Country snapshot of    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m diabetes prevention and control in the Americas. Available from: https://iris.\\npaho.org/handle/10665.2/55326.  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m [Accessed February 2025]. 4. Rahim NE, Flood D, Marcus ME, et al. Diabetes risk and provision of diabetes       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m prevention activities in 44 low-income and middle-income countries: a cross-sectional analysis of nationally    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m representative, individual-level survey data. Lancet Glob Health. 2023;11(10):e1576-e1586. 5. World Health      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Organization. Definition and diagnosis of diabetes mellitus and intermediate hyperglycaemia - report of a       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m WHO/IDF consultation. World Health Organization 2006. Available from: https://                                  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m www.who.int/publications/i/item/definition-and-diagnosis-of-diabetes-mellitus-and-intermediate-hyperglycaemia.  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m [Accessed February 2025]. 6. Bonora E, Tuomilehto J. The pros and cons of diagnosing diabetes with A1C.         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Diabetes Care. 2011;34 Suppl 2(Suppl 2):S184-190. 7. American Diabetes Association Professional Practice C. 2.  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Diagnosis and Classification of Diabetes: Standards of Care in Diabetes-2025. Diabetes Care.                    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 2025;48(Supplement_1):S27-S49. 8. World Health Organization. Use of Glycated Haemoglobin (HbA1c) in the         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Diagnosis of Diabetes Mellitus. 2011. WHO/NMH/CHP/ CPM/11.1 Available from:                                     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m https://apps.who.\\nint/iris/bitstream/handle/10665/70523/WHO_ NMH_CHP_CPM_11.1_eng.pdf. [Accessed February      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 2025]. 9. Cowie CC, Rust KF, Byrd-Holt DD, et al. Prevalence of diabetes and high risk for diabetes using A1C   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m criteria in the U.S. population in 1988-2006. Diabetes Care. 2010;33(3):562-568. 10. Sun H, Saeedi P, Karuranga \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m S, et al. IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m projections for 2045. Diabetes Res Clin Pract. 2022;183:109119. 11. NCD Risk Factor Collaboration. Worldwide    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m trends in diabetes prevalence and treatment from 1990 to 2022: a pooled analysis of 1108                        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m population-representative studies with 141 million participants. Lancet. 2024;404(10467):2077-2093. 12. NCD     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Risk Factor Collaboration. Global variation in diabetes diagnosis and prevalence based on fasting glucose and   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m hemoglobin A1c. Nat Med. 2023;29(11):2885-2901. 13. Ram Y, Xu Y, Cheng A, et al. Variation in the relationship  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m between fasting glucose and HbA1c: implications for the diagnosis of diabetes in different age and ethnic       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m groups. BMJ Open Diabetes Res Care. 2024;12(2):e003470. 14. National Diabetes Data Group. Classification and    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes. 1979;28(12):1039-1057.    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 15. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care. 1997;20(7):1183-1197. 16.    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Abdul-Ghani MA, Jenkinson CP, Richardson DK, et al. Insulin secretion and action in subjects with impaired      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m fasting glucose and impaired glucose tolerance: results from the Veterans Administration Genetic Epidemiology   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Study. Diabetes. 2006;55(5):1430-1435. 17. Richter B, Hemmingsen B, Metzendorf MI, et al. Development of type 2 \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m diabetes mellitus in people with intermediate hyperglycaemia. Cochrane Database Syst Rev. 2018;10(10):CD012661. \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 31 Chapter 1 18. International Expert Committee. International Expert Committee report on the role of the A1C   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m assay in the diagnosis of diabetes. Diabetes Care. 2009;32(7):1327-1334. 19. Zhang X, Gregg EW, Williamson DF,  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m et al. A1C level and future risk of diabetes: a systematic review. Diabetes Care. 2010;33(7):1665-1673. 20.     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m National Insititue for Health and Care Excellence (NICE). Type 2 diabetes: prevention in people at high risk.   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Guidance and guidelines. Available from: https:// www.nice.org.uk/guidance/ph38/chapter/                        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Recommendations#risk-assessment. [Accessed February 2025]. 21. James C, Bullard KM, Rolka DB, et al.            \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Implications of alternative definitions of prediabetes for prevalence in U.S. adults. Diabetes Care.            \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 2011;34(2):387-391. 22. Glumer C, Jorgensen T, Borch-Johnsen K, et al. Prevalences of diabetes and impaired     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m glucose regulation in a Danish population: the Inter99 study. Diabetes Care. 2003;26(8):2335-2340. 23.          \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Echouffo-Tcheugui JB, Selvin E. Prediabetes and what it means: The epidemiological evidence. Annu Rev Public    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Health. 2021;42:59-77. 24. Pan XR, Li GW, Hu YH, et al. Effects of diet and exercise in preventing NIDDM in     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care. 1997;20(4):537-544.  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 25. Tuomilehto J, Lindstrom J, Eriksson JG, et al. Prevention of type 2 diabetes mellitus by changes in         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001;344(18):1343-1350. 26.             \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Ramachandran A, Snehalatha C, Mary S, et al. The Indian Diabetes Prevention Programme shows that lifestyle      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m (IDPP-1). Diabetologia. 2006;49(2):289-297. 27. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346(6):393-403.   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 28. Nicolaisen SK, Pedersen L, Witte DR, et al. HbA1c-defined prediabetes and progression to type 2 diabetes in \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Denmark: A population-based study based on routine clinical care laboratory data. Diabetes Res Clin Pract.      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 2023;203:110829. 29. Rooney MR, Rawlings AM, Pankow JS, et al. Risk of progression to diabetes among older      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m adults with prediabetes. JAMA Intern Med. 2021;181(4):511-519. 30. Cai X, Zhang Y, Li M, et al. Association     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m between prediabetes and risk of all cause mortality and cardiovascular disease: updated meta-analysis. BMJ.     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 2020;370:m2297. 31. Gujral UP, Jagannathan R, He S, et al. Association between varying cut-points of            \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m intermediate hyperglycemia and risk of mortality, cardiovascular events and chronic kidney disease: a           \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m systematic review and meta-analysis. BMJ Open Diabetes Res Care. 2021;9(1):e001776. 32. Schmidt MI, Bracco PA,  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Yudkin JS, et al. Intermediate hyperglycaemia to predict progression to type 2 diabetes (ELSA-Brasil): an       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m occupational cohort study in Brazil. Lancet Diabetes Endocrinol. 2019;7(4):267-277. 33. Lee CMY, Colagiuri S,   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Woodward M, et al. Comparing different definitions of prediabetes with subsequent risk of diabetes: an          \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m individual participant data meta-analysis involving 76 513 individuals and 8208 cases of incident diabetes. BMJ \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Open Diabetes Res Care. 2019;7(1):e000794. 34. Chung WK, Erion K, Florez JC, et al. Precision medicine in       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m diabetes: a Consensus Report from the American Diabetes Association (ADA) and the European Association for the  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Study of Diabetes (EASD). Diabetologia. 2020;63(9):1671-1693. 35. Herman WH, Ye W. Precision prevention of      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m diabetes. Diabetes Care. 2023;46(11):1894-1896. 36. Kodama K, Tojjar D, Yamada S, et al. Ethnic differences in  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m the relationship between insulin sensitivity and insulin response: a systematic review and meta-analysis.       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Diabetes Care. 2013;36(6):1789-1796. 37. Kibirige D, Sekitoleko I, Lumu W, et al. Understanding the             \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m pathogenesis of lean non-autoimmune diabetes in an African population with newly diagnosed diabetes.            \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Diabetologia. 2022;65(4):675-683. 38. Chan JCN, Lim LL, Wareham NJ, et al. The Lancet Commission on diabetes:   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Using data to transform diabetes care and patient lives. Lancet. 2021;396(10267):2019-2082. 39. Lindstrom J,    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Tuomilehto J. The diabetes risk score: a practical tool to predict type 2 diabetes risk. Diabetes Care.         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 2003;26(3):725-731. 40. American Diabetes Association Professional Practice Committee. 3. Prevention or Delay   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m of Diabetes and Associated Comorbidities: Standards of Care in Diabetes-2024. Diabetes Care. 2024;47(Suppl      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 1):S43-S51. IDF Global Clinical Practice Recommendations for Managing Type 2 Diabetes â€“ 2025 32 SCREENING AND   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m PREVENTION 41. Davidson KW, Barry MJ, et al., US Preventive Services Task Force. Screening for prediabetes and  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m type 2 diabetes: US Preventive Services Task Force Recommendation Statement. JAMA. 2021;326(8):736-743. 42.     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Echouffo-Tcheugui JB, Perreault L, Ji L, et al. Diagnosis and management of prediabetes: A review. JAMA.        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 2023;329(14):1206-1216. 43. Bergman M, Manco M, Satman I, et al. International Diabetes Federation Position     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Statement on the 1-hour post-load plasma glucose for the diagnosis of intermediate hyperglycaemia and type 2    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m diabetes. Diabetes Res Clin Pract. 2024;209:111589. 44. Sathish T, Khunti K, Narayan KMV, et al. Effect of      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m conventional lifestyle interventions on type 2 diabetes incidence by glucose-defined prediabetes phenotype: An  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m individual participant data meta-analysis of randomized controlled trials. Diabetes Care.                       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 2023;46(11):1903-1907. 45. Gerstein HC, Yusuf S, et al. Effect of rosiglitazone on the frequency of diabetes in \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet.    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 2006;368(9541):1096-1105. 46. Rossing P, Inzucchi SE, Vart P, et al. Dapagliflozin and new-onset type 2         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m diabetes in patients with chronic kidney disease or heart failure: pooled analysis of the DAPA-CKD and DAPA-HF  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m trials. Lancet Diabetes Endocrinol. 2022;10(1):24-34. 47. Diabetes Prevention Program Research Group. HbA1c as  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m a predictor of diabetes and as an outcome in the diabetes prevention program: a randomized clinical trial.      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Diabetes Care. 2015;38(1):51-58. 48. Jenkins DJA, Willett WC, Yusuf S, et al. Association of glycaemic index    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m and glycaemic load with type 2 diabetes, cardiovascular disease, cancer, and all-cause mortality: a             \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m meta-analysis of mega cohorts of more than 100 000 participants. Lancet Diabetes Endocrinol.                    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 2024;12(2):107-118. 49. Neuenschwander M, Ballon A, Weber KS, et al. Role of diet in type 2 diabetes incidence: \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m umbrella review of meta-analyses of prospective observational studies. BMJ. 2019;366:l2368. 50. Neuenschwander  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m M, Barbaresko J, Pischke CR, et al. Intake of dietary fats and fatty acids and the incidence of type 2          \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m diabetes: A systematic review and dose-response meta-analysis of prospective observational studies. PLoS Med.   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 2020;17(12):e1003347. 51. Li J, Glenn AJ, Yang Q, et al. Dietary protein sources, mediating biomarkers, and     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m incidence of type 2 diabetes: Findings from the Womenâ€™s Health Initiative and the UK Biobank. Diabetes Care.    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 2022;45(8):1742-1753. 52. Lee Y, Park K. Adherence to a vegetarian diet and diabetes risk: A systematic review  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m and meta-analysis of observational studies. Nutrients. 2017;9(6):603. 53. Hemmingsen B, Gimenez-Perez G,        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Mauricio D, et al. Diet, physical activity or both for prevention or delay of type 2 diabetes mellitus and its  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m associated complications in people at increased risk of developing type 2 diabetes mellitus. Cochrane Database  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Syst Rev. 2017;12(12):CD003054. 54. Li G, Zhang P, Wang J, et al. The long-term effect of lifestyle             \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20-year follow-up study.    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Lancet. 2008;371(9626):1783-1789. 55. Lindstrom J, Peltonen M, Eriksson JG, et al. Improved lifestyle and       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m decreased diabetes risk over 13 years: long-term follow-up of the randomised Finnish Diabetes Prevention Study  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m (DPS). Diabetologia. 2013;56(2):284-293. 56. Diabetes Prevention Program Research Group. Long-term effects of   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m lifestyle intervention or metformin on diabetes development and microvascular complications over 15-year        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m follow-up: the Diabetes Prevention Program Outcomes Study. Lancet Diabetes Endocrinol. 2015;3(11):866-875. 57.  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Nathan DM, Bennett PH, Crandall JP, et al. Does diabetes prevention translate into reduced long-term vascular   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m complications of diabetes? Diabetologia. 2019;62(8):1319-1328. 58. Gong Q, Gregg EW, Wang J, et al. Long-term   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m effects of a randomised trial of a 6-year lifestyle intervention in impaired glucose tolerance on               \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m diabetes-related microvascular complications: the China Da Qing Diabetes Prevention Outcome Study.              \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Diabetologia. 2011;54(2):300-307. 59. Li G, Zhang P, Wang J, et al. Cardiovascular mortality, all-cause         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m the Da Qing Diabetes Prevention Study: a 23-year follow-up study. Lancet Diabetes Endocrinol.                   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 2014;2(6):474-480. 60. Madsen KS, Chi Y, Metzendorf MI, et al. Metformin for prevention or delay of type 2      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m diabetes mellitus and its associated complications in persons at increased risk 33 Chapter 1 for the            \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m development of type 2 diabetes mellitus. Cochrane Database Syst Rev. 2019;12(12):CD008558. 61. Zhang L, Zhang   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Y, Shen S, et al. Safety and effectiveness of metformin plus lifestyle intervention compared with lifestyle     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m intervention alone in preventing progression to diabetes in a Chinese population with impaired glucose          \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m regulation: a multicentre, open-label, randomised controlled trial. Lancet Diabetes Endocrinol.                 \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 2023;11(8):567-577. 62. Diabetes Prevention Program Research Group. Long-term effects of lifestyle intervention \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m or metformin on diabetes development and microvascular complications over 15-year follow-up: the Diabetes       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Prevention Program Outcomes Study. Lancet Diabetes Endocrinol. 2015;3(11):866-75. 63. Chiasson JL, Josse RG,    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Gomis R, et al. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet.   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 2002;359(9323):2072-2077. 64. le Roux CW, Astrup A, Fujioka K, et al. 3 years of liraglutide versus placebo for \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised,             \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m double-blind trial. Lancet. 2017;389(10077):1399-1409. 65. Ely EK, Gruss SM, Luman ET, et al. A national effort \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m to prevent type 2 diabetes: Participant-level evaluation of CDCâ€™s National Diabetes Prevention Program.         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Diabetes Care. 2017;40(10):1331-1341. 66. Saaristo T, Peltonen M, Keinanen-Kiukaanniemi S, et al. National type \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 2 diabetes prevention programme in Finland: FIN-D2D. Int J Circumpolar Health. 2007;66(2):101-112. 67.          \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Rintamaki R, Rautio N, Peltonen M, et al. Long-term outcomes of lifestyle intervention to prevent type 2        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m diabetes in people at high risk in primary health care. Prim Care Diabetes. 2021;15(3):444-450. 68. Valabhji J, \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Barron E, Bradley D, et al. Early outcomes from the English National Health Service Diabetes Prevention         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Programme. Diabetes Care. 2020;43(1):152-160. 69. Dunbar JA, Jayawardena A, Johnson G, et al. Scaling up        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m diabetes prevention in Victoria, Australia: policy development, implementation, and evaluation. Diabetes Care.  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 2014;37(4):934-942. 70. Shirinzadeh M, Afshin-Pour B, Angeles R, et al. The effect of community-based programs  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m on diabetes prevention in low- and middle-income countries: a systematic review and meta-analysis. Global       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Health. 2019;15(1):10. 71. Aekplakorn W, Tantayotai V, Numsangkul S, et al. Evaluation of a community-based     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Diabetes Prevention Program in Thailand: A cluster randomized controlled trial. J Prim Care Community Health.   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 2019;10:2150132719847374. 72. Catley D, Puoane T, Tsolekile L, et al. Evaluation of an adapted version of the   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Diabetes Prevention Program for low- and middle-income countries: A cluster randomized trial to evaluate        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m â€œLifestyle Africaâ€ in South Africa. PLoS Med. 2022;19(4):e1003964. 73. Magliano DJ, Chen L, Islam RM, et al.    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Trends in the incidence of diagnosed diabetes: a multicountry analysis of aggregate data from 22 million        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m diagnoses in high-income and middle-income settings. Lancet Diabetes Endocrinol. 2021;9(4):203-211. 74.         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Government-funded healthcare programme. Available from: https://www.qhms.com/en/                                \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m services/public-private-partnership/ccdc-pilot-scheme. [Accessed February 2025]. 75. Zhang Y, Luk AOY, Chow E,  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m et al. High risk of conversion to diabetes in first-degree relatives of individuals with young-onset type 2     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m diabetes: a 12-year follow-up analysis. Diabet Med. 2017;34(12):1701-1709. 76. Lee CMY, Versace VL, Malo JA, et \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m al. Screening for diabetes prevention with diabetes risk scores - A balancing act. Diabetes Res Clin Pract.     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 2018;135:120-127. 77. Wikstrom K, Lindstrom J, Tuomilehto J, et al. National diabetes prevention program        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m (DEHKO): awareness and self-reported lifestyle changes in Finnish middle-aged population. Public Health.        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 2015;129(3):210-217. 78. Ely EK, Ng BP, Cannon MJ. Delivering the National Diabetes Prevention Program:         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Assessment of outcomes in in-person and virtual organizations. J Diabetes Res. 2023;2023:8894593. 79. Catley D, \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Puoane T, Goggin K, et al. Adapting the Diabetes Prevention Program for low- and middle-income countries:       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m preliminary implementation findings from lifestyle Africa. Transl Behav Med. 2020;10(1):46-54. 34 Glycaemic     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Control Assessment and Targets In Type 2 Diabetes Chapter 2 GLYCAEMIC TARGETS 35 Chapter 2 Optimal Care Basic   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Care Glycated haemoglobin (HbA1c) â€¢\\tMeasure HbA1c at regular intervals â€¢\\tHbA1c general target 7.0% (53        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m mmol/mol) â€¢\\tPersonalise HbA1c - higher in the elderly - lower in the newly diagnosed â€¢\\tMeasure fructosamine   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m if HbA1c cannot be measured accurately â€¢\\tMeasure HbA1c at regular intervals â€¢\\tHbA1c general target 7.0% (53   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m mmol/mol) â€¢\\tPersonalise HbA1c (especially in the elderly) â€¢\\tIf HbA1c assay not available, use any available   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m glucose measure Self-monitoring of blood glucose (SMBG) â€¢\\tRoutinely recommend SMBG to all insulin-treated      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m people with type 2 diabetes mellitus (T2DM) â€¢\\tConsider SMBG in other people with T2DM â€¢\\tProvide education in  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m structured SMBG â€¢\\tRoutinely recommend SMBG to people with T2DM treated with multiple daily insulin regimens    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m â€¢\\tConsider SMBG in other people with T2DM treated with other insulin regimens â€¢\\tProvide education in          \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m structured SMBG â€¢\\tSMBG targets: Fasting and pre-prandial glucose - 4.0â€“8.0 mmol/L (70â€“144 mg/dL) Postprandial  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m glucoseâ€  - 4.0â€“8.0 mmol/L (70â€“144 mg/dL) (preferable) - 4.0â€“9.0 mmol/L (70â€“160 mg/dL) (acceptable) Continuous   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m glucose monitoring (CGM) â€¢\\tConsider CGM in all insulin-treated people with T2DM and in others on an individual \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m basis â€¢\\tConsider short-term CGM in select people with T2DM on intensive insulin regimens or insulin pump, if   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m available and affordable â€¢\\tCGM targets (refer to Table 2.1) â€ Measure postprandial glucose 1â€“2 h after          \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m beginning a meal.\\nRECOMMENDATIONS IDF Global Clinical Practice Recommendations for Managing Type 2 Diabetes â€“  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 2025 36 GLYCAEMIC TARGETS o Glycaemic control reduces the risk of both micro- and macrovascular complications   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m in type 2 diabetes mellitus (T2DM). o Assessing and monitoring glycaemia is an essential component of guiding   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m treatment decisions to achieve and maintain target glycaemic control. o Setting glycaemic targets is based on   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m established associations with adverse outcomes. o HbA1c is the established gold standard for assessing          \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m glycaemic control in T2DM. o The general HbA1c target of <7.0% (<53 mmol/mol) should be personalised, balancing \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m reducing complications, minimising hypoglycaemia and an individualâ€™s characteristics. o HbA1c measurement may   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m be affected by a variety of factors â€“ in these situations, fructosamine and glycated albumin are alternatives   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m for monitoring glycaemic control. o Improving HbA1c improves diabetes outcomes in the short- and longer-term. o \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m HbA1c variability may be important but has not been definitively confirmed as an independent risk factor for    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m diabetes complications. o The contribution of fasting plasma glucose (FPG) and postprandial glucose (PPG) to    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m overall glycaemia varies according to HbA1c levels, being greater for PPG at lower HbA1c levels and greater for \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m FPG at higher HbA1c levels. o In select individuals with T2DM, HbA1c measurement may be complemented with       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m self-monitoring of blood glucose (SMBG) or continuous glucose monitoring (CGM). o SMBG and CGM may provide      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m additional useful clinical information on glycaemic metrics relevant to diabetes management, including periods  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m of hyperglycaemia and hypoglycaemia. o SMBG is recommended in insulin-treated T2DM but may be useful in other   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m situations. o SMBG use (intensity and frequency) should be structured and individualised. o The proposed SMBG   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m targets are adapted to align with CGM metrics. o CGM is currently used mainly in people with type 1 diabetes    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m mellitus (T1DM) but use is increasing in insulin-treated T2DM in high-resource health settings. Data supporting \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m its use in non-insulin treated people with T2DM are limited. o Key CGM metrics include glycaemic variability    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m and time in defined glucose ranges. o Target CGM metrics are based on international consensus. o Most of the    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m global diabetes population lives in low-income and middle-income countries (LMICs) where access and             \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m affordability to HbA1c testing, SMBG, and CGM are limited.\\nKEY POINTS 37 Chapter 2 BACKGROUND Glycaemic        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m control is a treatment pillar for reducing the risk of both micro- and macrovascular complications in type 2    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m diabetes mellitus (T2DM),1 and early and intensive glycaemic control has a legacy effect in reducing            \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m cardiovascular and kidney disease events and all-cause mortality even after 24 years.2 Assessing and monitoring \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m glycaemia are essential components of guiding treatment decisions to achieve and maintain target glycaemic      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m control. Measurement of glycated haemoglobin (HbA1c) underpins the assessment of long-term glycaemic control in \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m people with T2DM. In select individuals with T2DM, this may be complemented with self-monitoring of blood       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m glucose (SMBG) by finger-stick capillary devices or continuous glucose monitoring (CGM) devices which measure   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m interstitial glucose. SMBG and CGM may provide additional useful clinical information on other dimensions of    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m glycaemia relevant to diabetes management, including periods of hyperglycaemia and hypoglycaemia. Determining   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m glycaemic targets is based on the established association of adverse diabetes outcomes derived from             \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m epidemiological studies or post-hoc analyses of intervention studies. Observational studies have shown a        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m relationship between HbA1c and macro- and microvascular complications, and death in people with T2DM.3          \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Interventional randomised controlled trials (RCTs) examining the effect of intensive glycaemic control have     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m achieved HbA1c levels ranging from 6.5%â€“7.1% (48â€“54 mmol/mol).4-8 Identifying actual â€œthresholdsâ€ in the HbA1c/ \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m complications relationship has given differing results. For example, post-hoc analyses of the ADVANCE trial     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m suggest an HbA1c â€œthresholdâ€ of below 7.0% (53 mmol/mol) for macrovascular events and death, and 6.5% (48       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m mmol/mol) for microvascular events.9 However other analyses of observational data suggest a continuous increase \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m in risk of major adverse cardiovascular disease (CVD) outcomes down to an HbA1c of 5.7% (39 mmol/mol).10        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Setting clinical target recommendations should consider both the individual and population-level impact. The    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m global prevalence of poor glycaemic control is high, ranging from between 45% and 93% in one systematic         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m review11 and another reporting that the proportion with adequate control was 22% since 2010.12 These estimates  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m are considerably lower than the World Health Organization (WHO) goal of 80% of people with diagnosed diabetes   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m achieving good control of glycaemia.13 The greatest population impact on complications will be achieved by      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m reducing HbA1c from very high to moderate glycaemic levels. Although lowering HbA1c from 7.0% to 6.0% (53       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m mmol/mol to 42 mmol/mol) is associated with a further reduction in the risk of microvascular complications, the \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m absolute risk reductions become much smaller and numbers needed to treat to benefit an individual increase.14   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Setting lower targets has implications for the impact on health services in different resource settings.        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m General glycaemic targets (e.g., HbA1c <7.0% [<53 mmol/mol]) are proposed as guides that are appropriate for    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m many people but need to be personalised, balancing reducing complications and minimising hypoglycaemia and      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m taking into account a range of factors relevant to the individual with T2DM, including comorbidities, age,      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m duration of diabetes, risk of hypoglycaemia, life expectancy, individual preferences, and available             \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m resources.14,15 Setting specific glycaemic (and other) goals during consultations are also helpful in improving \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m outcomes for individuals with diabetes.16 Advances in technology, such as continuous glucose monitoring (CGM),  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m have provided more detailed information on glycaemia in both healthy individuals without diabetes and people    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m with diabetes, and these data can be used to inform glycaemic targets in people with diabetes.17 To date, CGM   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m has largely been applied to people with type 1 diabetes mellitus (T1DM) but is increasingly being considered in \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m T2DM in high-resource health settings. GLOBAL CONSIDERATIONS Approximately 80% of the global diabetes           \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m population lives in low-income and middle-income countries (LMICs) where healthcare resources are often         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m limited, which impacts access, availability, and affordability to many established evidence-based diabetes      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m interventions.18 These considerations are relevant to formulating practical clinical recommendations and        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m implementation strategies for assessment of glycaemic control in resource-limited settings. Regular periodic    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m measurement of HbA1c is the gold standard for assessing longer-term glycaemic control, and health systems       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m should IDF Global Clinical Practice Recommendations for Managing Type 2 Diabetes â€“ 2025 38 GLYCAEMIC TARGETS    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m aim to ensure that it is available throughout their services. However, at present it is not available in many   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m health services. The 2019 periodic WHO country capacity survey on non-communicable diseases (NCDs) of 160       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m countries reported that overall HbA1c testing was generally available in only 53% of primary care facilities in \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m the public and private health sectors.19 The Pan American Health Organization separately reported that 18 of 35 \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m countries (51.4%) had HbA1c testing generally available in >50% primary healthcare facilities in the public     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m sector.20 In these situations, other less satisfactory methods of assessing glycaemia (e.g., fasting, random,   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m and postprandial glucose measurement) remain the only option for assessing glycaemic control. An additional     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m important consideration for HbA1c testing is that the assay is not currently well-enough standardised in many   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m countries.21 SMBG systems have been the standard method of self-assessment of glycaemia for many years in       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m well-resourced settings. However, access to SMBG in LMICs is often hindered by unavailability, high costs,      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m inadequate coverage by national health services, and even when available, usage is compromised by poor diabetes \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m education.22 Approximately 95% of SMBG expenses is attributable to testing strips. Consequently, SMBG is only   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m widely used if subsidised, but the availability of subsidised supplies varies considerably. One survey reported \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m that full provision by government of two or more blood glucose test strips per day for children with diabetes   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m aged less than 15 years occurred in 18 of 20 high-income countries (HIC), five of 15 upper MIC countries, and   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m none of 37 LMIC and LIC countries.23 Access in LMIC is further hindered because out-of-pocket prices to         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m individuals are often much higher than prices in HIC, making SMBG mostly unaffordable.24 An Indonesian study    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m reported that public sector facilities did not supply devices for self-testing and in the private sector, a     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m low-income worker required nine to 12 daysâ€™ wages to purchase a meter and a monthâ€™s supply of test strips.25    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m The 2023 WHOâ€™s Essential Diagnostics List recognised the role of blood glucose meters and test strips for SMBG  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m in home settings and added a new recommendation for glucose measurement for use in community settings â€œto       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m self-monitor type 1 and type 2 diabetes mellitus at homeâ€.26 This significant step should help increase access  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m to SMBG in LMICs. CGM has emerged as an option for self-monitoring which provides more detailed glycaemic       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m information but is considerably more expensive than SMBG systems. There are few data on the global use or       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m availability of CGM, which is at present largely restricted to well-resourced health settings. The Indonesian   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m study assessed the financial impact of CGM and reported that it would require spending 31 daysâ€™ salary of a     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m low-income worker to purchase a CGM reader, meaning no salary would remain for basic daily needs. Moreover,     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m buying a monthâ€™s supply of CGM sensors would require 61 daysâ€™ salary, effectively making access to CGM          \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m financially impossible for many individuals.25 EVIDENCE SUMMARY HbA1c (glycated haemoglobin) Measurement of     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m HbA1c is the established gold standard marker to assess glycaemic control in T2DM and has prognostic value for  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m the development of diabetes complications and is routinely used to measure glycaemia in outcome-related         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m clinical studies.27 HbA1c integrates the mean glycaemia from the past two to three months. It can be measured   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m in the laboratory or by point-of-care testing. Point-of-care technology can give HbA1c results of sufficient    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m quality to enable clinical decision-making and can be used in community and primary care settings.28 HbA1c      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m measurement may be affected by a variety of genetic, haematologic, and illness-related factors. The most common \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m worldwide important factors affecting HbA1c levels are haemoglobinopathies, certain anaemias, and disorders     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m associated with accelerated red cell turnover, such as malaria.21 Serum glycated proteins (fructosamine and     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m glycated albumin) are an alternative to monitor glycaemic control, especially in people with diabetes where     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m measurement or interpretation of HbA1c is problematic. Fructosamine reflects total glycated serum proteins and  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m glycated albumin, the proportion of total albumin that is glycated. These measures reflect glycaemia over the   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m past two to four weeks and are associated with long-term complications but lack definitive outcome data.14 39   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Chapter 2 HbA1c and diabetes complications Glycaemia measured by HbA1c is associated with increased risk of     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m microvascular and macrovascular complications in T2DM.29 Interventions to reduce HbA1c significantly reduce     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m macrovascular and microvascular complications in the short and longer-term.1,7 One meta-analysis suggested a    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 15% relative risk reduction in non-fatal myocardial infarction with every 1.0% (11 mmol/mol) reduction in       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m HbA1c30 and another that an absolute HbA1c reduction of 0.9% (10 mmol/mol) reduced the relative risk of kidney  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m events by 20% and eye events by 13%.31 HbA1c variability Serial measurements of HbA1c can be used to assess     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m long-term glycaemic variability.32,33 While HbA1c variability has not been definitively confirmed as an         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m independent risk factor for diabetes complications, observational studies34,35 and post-hoc analysis of         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m diabetes outcomes studies have reported an association between HbA1c variability and diabetes complications,    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m including macrovascular events in the ADVANCE study,36 CVD death in the EMPAREG study,37 and all-cause          \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m mortality in the ACCORD study.38 However in the VADT study, no HbA1c measures were associated with CVD.39 High  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m variability in HbA1c, even among individuals with T2DM whose average HbA1c was at target levels, has been       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m associated with an increased risk of CVD complications and other adverse outcomes.40,41 HbA1c target Setting    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m general HbA1c targets is based on observational studies and post-hoc analyses of interventional RCTs showing a  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m relationship between HbA1c levels and macrovascular and microvascular complications, and death in people with   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m T2DM. However, the nature of the relationship has varied. The UKPDS showed a curvilinear relationship between   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m HbA1c and microvascular complications.3 The ADVANCE trial showed a non-linear relationship between mean HbA1c   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m during follow-up and the risks of macrovascular events, microvascular events, and death with evidence of HbA1c  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m â€˜thresholdsâ€™ below 7.0% (53 mmol/mol) for macrovascular events and death, and 6.5% (48 mmol/mol) for            \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m microvascular events.9 An Italian registry-based study examined 251,339 newly diagnosed T2DM without CVD at     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m baseline and assessed major CVD outcomes-based mean HbA1c. After a mean follow-up of 4.6 years, compared with   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m mean HbA1c <5.7% (39 mmol/mol) during the first year after diagnosis, CVD risk increased progressively to 56%   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m for individuals with HbA1c >8.0% (>64 mmol/mol).10 Interventional RCTs examining the effect of intensive        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m glycaemic control have achieved HbA1c targets ranging from of 6.5%â€“7.1% (48â€“54 mmol/mol).4-8 These data are the \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m basis for the general target of HbA1c <7.0% (<53 mmol/mol) in people with T2DM recommended by most guidelines   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m for minimising risk of diabetes complications and hypoglycaemia. This target is proposed as a guide, which is   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m appropriate for many people, but it is important to consider personalising targets, based on a range of factors \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m relevant to the individual with T2DM. These factors include the presence of comorbidities, age, duration of     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m diabetes, risk of hypoglycaemia, life expectancy, individual preferences, and available resources.14,15         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Increasing age and declining functional and cognitive capacity are particularly relevant when setting less      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m stringent goals, as treatment burden and risk of harm outweigh potential benefits.42 It is also important to    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m adjust targets as required if circumstances change. Setting glycaemic targets should consider not only the      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m impact on the individual but also the broader population-level effects. Considering the high global levels of   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m poor glycaemic control,11,12 the greatest population impact on complications will be achieved by reducing HbA1c \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m from high to moderate glycaemic levels. Although further lowering of HbA1c is associated with an additional     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m reduction in the risk of complications, the absolute risk reductions become much smaller, and number needed to  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m treat to achieve a benefit for an individual increases.14 For example, if the annual incidence of a diabetes    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m complication is 5% at an HbA1c of 9.0% (75 mmol/mol) and lowering HbA1c by 1.0% (11 mmol/mol) is associated     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m with a 50% reduction in the annual incidence of that complication, 40 people would need to have their HbA1c     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m lowered from 9.0% (75 mmol/mol) to 8.0% (64 mmol/mol) to benefit one individual. The equivalent numbers for     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m lowering HbA1c from 8.0% (64 mmol/mol) to 7.0% (53 mmol/mol) is 80 individuals and from 7.0% (53 mmol/mol) to   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 6.5% (48 mmol/mol) is 270 individuals. Therefore, setting low HbA1c population targets has implications for the \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m impact on health services in different resource settings. IDF Global Clinical Practice Recommendations for      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Managing Type 2 Diabetes â€“ 2025 40 GLYCAEMIC TARGETS Postprandial and fasting glucose The contribution of       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m fasting plasma glucose (FPG) and postprandial glucose (PPG) to overall glycaemia in people with T2DM varies     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m according to HbA1c levels. The relative contribution of PPG decreased progressively from approximately 70% in   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m the lowest to approximately 30% in the highest quintile of HbA1c, whereas the opposite is observed for the      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m relative contribution of FPG â€“ approximately 30% in the lowest compared with approximately 70% in the highest   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m quintile.43,44 A short-term study assessed the relative contribution of controlling FPG and PPG in people with  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m T2DM with an HbA1c â‰¥7.5% (58 mmol/mol). Only 64% of people achieving an FPG <5.6 mmol/L (100 mg/dL) achieved an \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m HbA1c <7.0% (53 mmol/mol) compared with 94% who achieved a PPG of <7.8 mmol/L (140 mg/dL).45 However, the       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m contribution of FPG to HbA1c may also be influenced by the intervention to improve glycaemia with basal insulin \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m reducing the contribution of basal hyperglycaemia to approximately 35% with lowering mean FPG to 6.5 mmol/L     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m (117 mg/dL) and HbA1c to 7.0% (53 mmol/mol).46 Postprandial and fasting glucose and diabetes complications      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Atherosclerotic disease accounts for much of the increased mortality and morbidity associated with T2DM, and    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m PPG may have a direct toxic effect on the vascular endothelium, mediated by oxidative stress that is            \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m independent of other CVD risk factors.47 The HEART2D RCT in people with T2DM after acute myocardial infarction  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m compared controlling PPG with three premeal doses of insulin lispro (PRANDIAL strategy) versus a basal strategy \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m (BASAL) of twice daily NPH insulin or once daily insulin glargine. After 2.6 years, the trial was stopped due   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m to lack of efficacy.48 The Kumamoto study which used multiple daily insulin injections to control both fasting  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m and post-meal glycaemia in people with T2DM, reported a curvilinear relationship between retinopathy and        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m microalbuminuria with both FPG and two-hour PPG control with no development or progression of retinopathy or    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m nephropathy with FPG <6.1 mmol/L (110 mg/dL) and two-hour post-meal PG <10 mmol/L (180 mg/dL). This suggests    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m that both reduced PPG and reduced FPG are strongly associated with reductions in retinopathy and nephropathy.8  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m RCTs have examined CVD outcomes with glucose-lowering medications (GLMs) which target PPG. The NAVIGATOR trial  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m examined the effect of the short-acting insulin secretagogue, nateglinide, on risk of CVD events in 9,306       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m people with impaired glucose tolerance. CVD outcomes were not significantly reduced in the participants taking  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m nateglinide compared with placebo after a median of five years.49 Three studies have examined alpha glucosidase \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m inhibitors on CVD outcomes. The ACE (Acarbose Cardiovascular Evaluation) study examined the effect of acarbose  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m in people with coronary artery disease and impaired glucose tolerance and failed to show a difference in        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m outcomes between acarbose and placebo.50 The UKPDS randomised 1,946 people with T2DM to acarbose or placebo.    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m After three years, there was no difference in the primary aggregated outcome or microvascular disease.51 The    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m ABC study assessed the effect of voglibose on the recurrence of myocardial infarction in people with a previous \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m myocardial infarction and impaired glucose tolerance but was terminated early after an interim analysis         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m suggested a low probability of a positive outcome.52 Fasting plasma and postprandial glucose variability        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Long-term glycaemic variability can be assessed by serial measurements of HbA1c or other measures of glycaemia, \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m including FPG and PPG.32,33 Post-hoc analyses of diabetes outcomes studies have examined the relationship       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m between FPG variability and diabetes complications. In the ADVANCE study intensive treatment group, an increase \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m in visit-to-visit variation in FPG was associated with an increased risk of both macrovascular and              \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m microvascular events.36 In the DEVOTE study, higher day-to-day fasting glycaemic variability was associated     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m with increased risks of severe hypoglycaemia and all-cause mortality.53 In the VADT study, variability measures \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m of FPG were significantly associated with CVD events after adjusting for other risk factors. Considered         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m separately, this relationship was evident in the intensive treatment group but not in the standard group.39 In  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m the EMPAREG study, higher FPG variability was associated with an increased risk for CVD death in both treatment \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m arms.37 There are no equivalent in-depth data analyses examining PPG variability. 41 Chapter 2 Postprandial and \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m fasting glucose targets The Kumamoto study showed no development or progression of retinopathy or nephropathy   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m with FPG <6.1 mmol/L (110 mg/dL) and two-hour post-meal PG <10 mmol/L (180 mg/dL).8 Intervention RCTs on the    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m effects of glycaemic control used different glycaemic targets to intensify treatment in the intensive treatment \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m groups. The UKPDS aimed for an FPG <6.0 mmol/L (108 mg/dL);7 the ACCORD study intensified treatment in the      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m intensive glycaemic control group every month if required, if HbA1c levels were â‰¥6.0% (42 mmol/mol) or if >50%  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m of premeal or post-meal capillary glucose readings were >5.6 mmol/L (100 mg/dL) or >7.8 mmol/L (140 mg/dL),     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m respectively;54 and the VADT started or adjusted insulin based on achieving SMBG fasting glucose of 4.4 to 6.4  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m mmol/L (80 to 115 mg/dL).55 SMBG targets recommended by diabetes organisations have also differed but are       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m generally in the same range. The IDF recommended target levels for capillary plasma glucose levels of <6.0      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m mmol/L (<108 mg/dL) before meals, and <8.0 mmol/L (<144 mg/dL) one to two hours after meals;42 the ADA          \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m recommends a pre-prandial capillary plasma glucose level of 4.4â€“7.2 mmol/L (80â€“130 mg/dL) and a peak            \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m post-prandial capillary plasma glucose level of <10 mmol/L (180 mg/ dL);14 and the Research Society for the     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Study of Diabetes in India recommends an FPG â‰¤6.4 mmol/L (115 mg/dL) and a postprandial glucose â‰¤8.9 mmol/L     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m (160 mg/dL).56 CGM-derived glycaemic data are also useful in informing glycaemic targets. In 153 healthy        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m children and adults, all without diabetes and not overweight, CGM showed that 96% of glucose readings were      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m between 3.9 and 7.8 mmol/L (70 and 140 mg/dL during the day [6 am to 11:59 pm]) and 99% during the night (12 am \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m to 5:59 am). No glucose levels exceeded 10 mmol/L (180 mg/dL) and 1.4% and 0.4% of readings fell below this     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m level during the day and night, respectively.17 Taking into account available data and in particular aligning   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m with CGM data, Table 2.1 shows suggested general targets for SMBG glucose levels. Algorithms based on similar   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m targets have been used to safely and successfully adjust basal insulin in people with T2DM.57 Glycaemic         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m profiles / other measures of glycaemia While measurement of HbA1c is the established gold standard biomarker    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m for assessing glycaemic control, it does not provide information on short-term glycaemic variability or         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m hypoglycaemia. The advent of CGM has enabled a more comprehensive assessment and understanding of glycaemia.27  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m A number of glycaemic metrics are recommended for assessment of CGM-derived glycaemia. Short-term glycaemic     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m variability refers to how much glucose levels fluctuate between peaks and nadirs within or between the day and  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m is usually described as the percent coefficient of variation (%CV) of glucose within-day (%CV over 24 hours)    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m and between-day (%CV over several days).34 CGM-derived time in range (TIR), time above range (TAR), and time    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m below range (TBR) of defined glycaemic levels are useful measures of glycaemic status and in clinical           \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m management. Time in a defined range is assessed using a 14-day CGM assessment with a CGM wear of 70% or         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m higher.58 While there is a correlation with HbA1c, CGM metrics provide additional information on glycaemic      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m status. For example, a retrospective analysis examined the relationship between end-of-study HbA1c levels and   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m CGM data in 530 adults with T1DM or insulin-requiring T2DM from four randomised trials. HbA1c was strongly      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m correlated with mean glucose value, TIR in the * The mg/dL and mmol/L values are not strictly identical but     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m have been rounded for ease of use, noting that SMBG-generated values have an inbuilt accuracy error. **Measure  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m post-prandial glucose 1â€“2 h after beginning a meal. SMBG, self-monitoring of blood glucose. Measure Target*     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Fasting and pre-prandial glucose 4.0â€“8.0 mmol/L 70â€“144 mg/dL Post-prandial glucose** 4.0â€“8.0 mmol/L             \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m (preferable) 4.0â€“9.0 mmol/L (acceptable) 70â€“144 mg/dL (preferable) 70â€“160 mg/dL (acceptable) Table 2.1          \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Suggested general SMBG targets IDF Global Clinical Practice Recommendations for Managing Type 2 Diabetes â€“ 2025 \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 42 GLYCAEMIC TARGETS 3.9â€“10.0 mmol/L (70â€“180 mg/dL) range, and percentage of glucose values >13.9 mmol/L (250   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m mg/dL) but weakly correlated with the percentage of glucose values <3.9 mmol/L (70 mg/dL) or <3.0 mmol/L (54    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m mg/dL). The median percentage glucose <3.0 mmol/L (70 mg/dL) was 1.2% across all HbA1c ranges while the         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m percentage of glucose values >13.9 mmol/L (250 mg/dL) varied from 2.5% (0.6 h/day) to 27.8% (6.7 h/day) in the  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m lowest and highest HbA1c groups, respectively.59 CGM metrics and diabetes complications CGM-derived metrics are \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m associated with diabetes outcomes. A review of 34 publications, including 663 people with T1DM and 19,909 with  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m T2DM, reported an association of higher glycaemic variability and lower TIR with diabetes microvascular and     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m macrovascular complications. Higher TIR was associated with reduced risk of albuminuria, retinopathy,           \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m cardiovascular disease mortality, all-cause mortality, and abnormal carotid intima-media thickness. However,    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m the authors acknowledged several limitations, including 30 of the 34 papers being cross-sectional studies and   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m most studies using only a short period of CGM (48 to 72 hours).60 In prospective cohort studies in people with  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m T2DM, greater %CV was associated with increased risk for all-cause mortality even among people with seemingly   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m well-controlled diabetes (mean HbA1c of 7.3% [56 mmol/ mol]).61 Lower TIR was also associated with increased    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m risk of all-cause and CVD mortality in people with T2DM.62 A systematic review of 11 studies in 13,987 people   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m with T2DM examined the association between CGM-derived TIR and microvascular complications of diabetic          \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m retinopathy (DR) (n = 4 studies), diabetic nephropathy (DN) (n = 4 studies), and diabetic peripheral neuropathy \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m (DPN) (n = 7 studies). The majority of studies (10 of the 11) were conducted in Asia. A 10% increase in TIR was \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m associated with a reduction in albuminuria, severity of DR, and prevalence of DPN and cardiac autonomic         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m neuropathy.63 CGM metrics targets An international consensus has proposed targets for key glycaemic metrics as  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m summarised in Table 2.2.58 Table 2.2 Key metrics for assessing glycaemic status using continuous glucose        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m monitoring (CGM) in non-pregnant adults with diabetes58 Metric Interpretation Goal Number of days of CGM 14     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m days Percentage of time CGM device is active 70% data Coefficient of variation Percentage coefficient of        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m variation Intraday (i.e., within 24 h) and Interday (i.e., over multiple days) â‰¤36% Time in range 70â€“180 mg/dL  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m (3.9â€“10.0 mmol/L) Percentage readings and time in range >70% (most adults) >50% (older adults) Time below range \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m <70 mg/dL (<3.9 mmol/L) including readings <54 mg/dL (<3.0 mmol/L) Percentage readings and time below range <4% \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m (most adults) <1% (older adults) Time below range <54 mg/dL (<3.0 mmol/L) Percentage readings and time below    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m range <1% Time above range >180 mg/dL (>10.0 mmol/L) including readings >250 mg/dL (> 13.9 mmol/L) Percentage   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m readings and time above range <25% (most adults) <50% (older adults) Time above range >250 mg/dL (> 13.9        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m mmol/L) Percentage readings and time above range <5% (most adults) <10% (older adults) CGM, continuous glucose  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m monitoring. 43 Chapter 2 Methods for self-assessment of glycaemia Two approaches are available for              \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m self-assessment of glycaemia. Self-monitoring of blood glucose (SMBG) Self-monitoring of capillary              \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m (finger-stick) blood glucose (SMBG) is a common component of diabetes care and is commonly recommended in       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m people treated with a multiple-daily insulin regimen or insulin pump, including those with T2DM.64              \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Recommendations for SMBG use in less intensively insulin-treated people with T2DM (e.g., on basal insulin)      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m varies, although self-measurement of fasting glucose appears helpful in adjusting basal insulin dose and        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m improving glycaemic control.65 SMBG is generally not routinely recommended in people with non-insulin-treated   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m T2DM. A 2012 Cochrane review concluded that when diabetes duration is more than one year, the overall effect of \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m SMBG on glycaemic control in people with T2DM not using insulin is small up to six months after initiation and  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m subsides after 12 months while acknowledging that more research is needed to explore the impact of SMBG on      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m hypoglycaemia and diabetes complications.66 An IDF Guideline on SMBG use in non-insulin-treated T2DM suggested  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m that in RCTs, SMBG data are only likely to be an effective self-management tool when results are reviewed and   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m acted on by healthcare providers and/or people with T2DM to actively modify behaviour and/or adjust treatment.  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m The principal IDF recommendation was that SMBG should be used only when individuals with diabetes, their        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m caregivers, and/or their healthcare providers have the knowledge, skills, and willingness to incorporate SMBG   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m monitoring and therapy adjustment into their diabetes care plan in order to attain agreed treatment goals and   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m that its use should be individualised and structured.67 RCTs have examined the effects of structured SMBG in    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m people with non-insulin-treated T2DM. In a 12-month RCT, 483 poorly controlled (HbA1c â‰¥7.5% [58 mmol/mol])      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m insulin-naÃ¯ve people with T2DM were randomised to a control enhanced usual care group or enhanced usual care    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m group with structured SMBG. After 12-months, structured SMBG significantly improved glycaemic control (HbA1c    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m reduction 0.3% [3 mmol/mol]) and facilitated more timely and aggressive treatment changes.68 Another 12-month   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m RCT randomised 1,024 people with non-insulin-treated T2DM (median baseline HbA1c 7.3% [56 mmol/mol]) to         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m intensive structured SMBG and an active control group. A small but significantly greater reduction in HbA1c     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m (0.12% [1.3 mmol/mol]) was observed over 12 months in the structured SMBG group and more participants achieved  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m clinically meaningful reductions in HbA1c (>0.3% [3 mmol/mol]).69 A recent RCT examined the impact of           \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m structured SMBG, with or without TeleCare support, on glycaemic control in people with non-insulin-treated T2DM \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m that was suboptimally controlled (HbA1c â‰¥7.5% to â‰¤13% [â‰¥58 to â‰¤119 mmol/mol]) and a diabetes duration of more   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m than one year. After 12 months, HbA1c was significantly lower by 0.8% (8.9 mmol/mol) in both the structured     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m SMBG groups compared with the control group. No additional benefit to structured SMBG was observed with the     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m addition of once-monthly TeleCare support.70 SMBG protocols (intensity and frequency) should be individualised  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m to address each individualâ€™s specific educational, behavioural and clinical requirements, specific needs, and   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m goals and provider requirements for data on glycaemic patterns to monitor impact of therapeutic                 \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m decision-making. In addition to those with insulin-treated T2DM, SMBG may be considered for people using GLMs   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m who have an increased risk of hypoglycaemia, experience hypoglycaemia unawareness, have poor metabolic control  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m despite multiple medications, and/or temporarily as an aid to education in newly diagnosed people with          \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m T2DM.42,71 Continuous glucose monitoring (CGM) Personal CGM systems have evolved rapidly in recent years and    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m are increasingly used to manage diabetes. CGM systems continuously measure interstitial glucose concentrations  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m at intervals of one to five minutes, which correlate well with blood glucose levels. CGM provides the user with \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m immediate glucose information on asymptomatic hypoglycaemia or hyperglycaemia to make treatment decisions and   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m health professionals with more detailed information on glycaemia to guide therapeutic advice. CGM can also help \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m to educate and support healthier lifestyle choices. IDF Global Clinical Practice Recommendations for Managing   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Type 2 Diabetes â€“ 2025 44 GLYCAEMIC TARGETS There are currently limited data on CGM use in people with T2DM.    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m The IMMEDIATE study randomised 116 people with non-insulin-treated T2DM to isCGM with diabetes self-management  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m education (DSME) or DSME alone (which included SMBG). After 16 weeks, the isCGM and DSME group had              \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m significantly greater mean TIR, significantly less TAR, and a greater reduction in mean HbA1c by 0.3% (3        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m mmol/mol) compared with the DSME alone arm. TBR and hypoglycaemia were lower but not significantly different.   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Glucose monitoring satisfaction was higher among isCGM users.73 The RELIEF study was a retrospective analysis   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m of 74,011 people with T1DM or T2DM initiating flash glucose monitoring identified from the French national      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m claims database. After 12 months, hospitalisations for acute diabetes complications decreased by 39% in people  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m with T2DM following initiation of flash glucose monitoring, although the absolute change was small â€“ overall    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 2.67% versus 1.62%, hospitalisations for diabetic ketoacidosis 1.70% versus. 0.82%, severe hypoglycaemia 0.7%   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m versus 0.62%, and hyperglycaemia 0.12% versus 0.09%.74 These differences persisted after two years.75 CGM use   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m is currently not widely recommended or adopted as part of routine care for people with T2DM. Wider use of CGM   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m will require healthcare system adaptations, including training and education of both people with diabetes and   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m clinicians in guiding day-to-day management decisions. Further research is also needed to inform optimal CGM    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m usage guidelines and address cost-effectiveness challenges in people with T2DM. Although CGM technology offers  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m potential advantages, it is expensive and global availability and access are limited. Incorporating CGM use in  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m health systems where there are many challenges and barriers to achieving recommended standards of diabetes care \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m will test policy makers and it is likely their use will be limited to those who can privately afford them until \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m costs are substantially lower.\\nSMBG and CGM compared CGM has the potential to provide more detailed glycaemic  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m information than SMBG. However, to date, reported clinical differences in studies comparing CGM and SMBG have   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m been small. A systematic review of 12 RCTs compared SMBG and CGM in 1,248 people with T2DM. Compared with SMBG, \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m CGM use (rtCGM or isCGM) resulted in small but significantly lower HbA1c (mean difference 0.31% [3.4 mmol/mol]) \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m with the effect being similar in individuals using insulin with or without oral agents or oral agents only. A   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m larger effect was noted with rtCGM than isCGM. CGM was associated with a 6.4% increased TIR, a 0.7% decreased   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m TBR, a 5.9% decreased TAR, and a 1.5% decreased glycaemic variability. CGM was associated with a                \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m non-statistically significant difference in the incidence of severe hypoglycaemia and macrovascular             \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m complications. No trials reported data on microvascular complications.76 A systematic review of 26 RCTs         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m involving 2,783 people with T2DM compared CGM (real-time/ retrospective data analysis CGM or isCGM) versus      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m usual care (which may have included SMBG). Compared with usual care/SMBG, CGM reduced HbA1c by 0.19% (2         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m mmol/mol) and isCGM by 0.31% (3.4 mmol/mol) but increased risk of mainly device-related adverse events. Unlike  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m CGM, isCGM was associated with improved user satisfaction.77 More CGM data are expected to become available as  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m CGM is increasingly integrated into clinical trials. A recent consensus statement detailed how CGM might be     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m incorporated in diabetes RCTs, especially with new pharmaceutical agents, and could help identify treatment     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m differences related to hypoglycaemia and glycaemic metrics while minimising the potential confounding effect of \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m CGM use.78 Applying these consensus recommendations in LMICs presents challenges and may require different      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m approaches in resource-limited settings to ensure such technology does not widen the resource-driven digital    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m divide.79 There are two basic types of CGM systems: o Realtime CGM (rtCGM): automatically and continuously      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m transmits data to the user, provides alerts and active alarms and glucose data in real-time to a receiver       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m (e.g., smart watch or phone) o Intermittently scanned CGM (isCGM): provides the same type of glucose data but   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m requires the user to scan the sensor to obtain information and does not have alerts and alarms.72 45 Chapter 2  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m REFERENCES 1. Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m diabetes. N Engl J Med. 2008;359(15):1577-1589. 2. Adler AI, Coleman RL, Leal J, et al. Post-trial monitoring   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m of a randomised controlled trial of intensive glycaemic control in type 2 diabetes extended from 10 years to 24 \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m years (UKPDS 91). Lancet. 2024;404(10448):145-155. 3. Adler AI, Stratton IM, Neil HA, et al. Association of     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36):       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m prospective observational study. BMJ. 2000;321(7258):412-419. 4. Patel A, MacMahon S, Chalmers J, et al.        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med.           \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 2008;358(24):2560-2572. 5. Gerstein HC, Miller ME, Byington RP , et al. Effects of intensive glucose lowering   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m in type 2 diabetes. N Engl J Med. 2008;358(24):2545-2559. 6. Duckworth W, Abraira C, Moritz T, et al. Glucose   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360(2):129-139. 7. UK   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet.           \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 1998;352(9131):837-853. 8. Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m mellitus: A randomized prospective 6-year study. Diabetes Res Clin Pract. 1995;28(2):103-117. 9. Zoungas S,     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Chalmers J, Ninomiya T, et al. Association of HbA1c levels with vascular complications and death in patients    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m with type 2 diabetes: Evidence of glycaemic thresholds. Diabetologia. 2012;55(3):636-643. 10. Russo GT,         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Nicolucci A, Lucisano G, et al. When does metabolic memory start? Insights from the Association of Medical      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Diabetologists Annals Initiative on stringent HbA1c targets. Diabetes. 2025;74(1):75-81. 11. Bin Rakhis SA,     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Sr., AlDuwayhis NM, Aleid N, et al. Glycemic control for type 2 diabetes mellitus patients: A systematic        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m review. Cureus. 2022;14(6):e26180. 12. Shahrestanaki E, Mohammadian Khonsari N, Seif E, et al. The worldwide    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m trend in diabetes awareness, treatment, and control from 1985 to 2022: A systematic review and meta-analysis of \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 233 population-representative studies. Front Public Health. 2024;12:1305304. 13. World Health Organization.     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Guidance on global monitoring for diabetes prevention and control: Framework, indicators and application.       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Geneva: World Health Organization; 2024. Licence: CC BY-NC-SA 3.0 IGO. Available from: https://www.who.int/     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m publications/i/item/9789240102248 [Accessed November, 2024]. 14. American Diabetes Association Professional     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Practice Committee. 6. Glycemic Goals and Hypoglycemia: Standards of Care in Diabetes-2025. Diabetes Care.      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 2025;48(Suppl 1):S128-S145. 15. Cheung NW, Conn JJ, dâ€™Emden MC, et al. Position statement of the Australian     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Diabetes Society: Individualisation of glycated haemoglobin targets for adults with diabetes mellitus. Med J    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Aust. 2009;191(6):339-344. 16. Whitehead L, Glass C, Coppell K. The effectiveness of goal setting on glycaemic  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m control for people with type 2 diabetes and prediabetes: A systematic review and meta-analysis. J Adv Nurs.     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 2022;78(5):1212-1227. 17. Shah VN, DuBose SN, Li Z, et al. Continuous glucose monitoring profiles in healthy    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m nondiabetic participants: A multicenter prospective study. J Clin Endocrinol Metab. 2019;104(10):4356-4364.     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Erratum in: J Clin Endocrinol Metab. 2022;107(4):e1775-e1776. 18. International Diabetes Federation (IDF). IDF  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Diabetes Atlas, 11th edition. Brussels, Belgium: International Diabetes Federation, 2025. Available from:       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m https://diabetesatlas.org. 19. World Health Organization. Assessing national capacity for the prevention and    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m control of noncommunicable diseases: Report of the 2019 global survey. Geneva: World Health Organization; 2020. \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Licence: CC BY-NC-SA 3.0 IGO. Available from: https://www.who.int/ publications/i/item/9789240002319 [Accessed  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m November 2024]. 20. Pan American Health Organization (PAHO). Country snapshot of diabetes prevention and        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m control in the Americas. Information kit (folder, banner, brochure). PAHO; 2021. Available from:                \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m https://iris.paho.org/handle/10665.2/55326 [Accessed November 2024]. IDF Global Clinical Practice               \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Recommendations for Managing Type 2 Diabetes â€“ 2025 46 GLYCAEMIC TARGETS 21. World Health Organization. Use of  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Glycated Haemoglobin (HbA1c) in the Diagnosis of Diabetes Mellitus: Abbreviated Report of a WHO Consultation.   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Geneva: World Health Organization: 2011. Available from: https:// www.ncbi.nlm.nih.gov/books/NBK304267/         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m [Accessed November 2024]. 22. Klatman EL, Jenkins AJ, Ahmedani MY, et al. Blood glucose meters and test strips: \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Global market and challenges to access in low-resource settings. Lancet Diabetes Endocrinol. 2019;7(2):150-160. \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 23. Ogle GD, Middlehurst AC, Silink M. The IDF Life for a Child Program Index of diabetes care for children and \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m youth. Pediatr Diabetes. 2016;17(5):374-384. 24. Health Action International (HAI). Market report of diabetes   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m self-monitoring devices in LMICs - October 2021. Developed by the Clinton Health Access Initiative (CHAI).      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Available from:                                                                                                 \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m https://haiweb.org/wp-content/uploads/2021/09/Market-Report_Self-monitoring-Devices-in-LMICs.pdf [Accessed      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m November 2024]. 25. Ramadaniati HU, Anggriani Y, Lepeska M, et al. Availability, price and affordability of     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m insulin, delivery devices and self-monitoring blood glucose devices in Indonesia. PLoS One.                     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 2024;19(10):e0309350. 26. World Health Organization. The selection and use of essential in vitro diagnostics:   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Report of the fourth meeting of the WHO Strategic Advisory Group of Experts on In Vitro Diagnostics, 2022       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m (including the fourth WHO model list of essential in vitro diagnostics). Geneva: World Health Organization;     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 2023 (WHO Technical Report Series, No. 1053). Licence: CC BY-NC-SA 3.0.IGO. Available from:                     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m https://www.who.int/publications/i/ item/9789240081093 [Accessed January 2024]. 27. Ceriello A, Prattichizzo F, \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Phillip M, et al. Glycaemic management in diabetes: Old and new approaches. Lancet Diabetes Endocrinol.         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 2022;10(1):75-84. 28. Gourlay A, Sutherland C, Radley A. point-of-care testing of HbA(1)c levels in community   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m settings for people with established diabetes or people at risk of developing diabetes: A systematic review and \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m meta-analysis. Prim Care Diabetes. 2024;18(1):7-16. 29. Stratton IM, Adler AI, Neil HA, et al. Association of   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m observational study. BMJ. 2000;321(7258):405-412. 30. Turnbull FM, Abraira C, Anderson RJ, et al. Intensive     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia. 2009;52(11):2288-2298. 31. Zoungas \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m S, Arima H, Gerstein HC, et al. Effects of intensive glucose control on microvascular outcomes in patients with \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m type 2 diabetes: A meta-analysis of individual participant data from randomised controlled trials. Lancet       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Diabetes Endocrinol. 2017;5(6):431-437. 32. Monnier L, Colette C, Owens D. Glucose variability and diabetes     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m complications: Risk factor or biomarker? Can we disentangle the â€œGordian Knotâ€? Diabetes Metab.                 \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 2021;47(3):101225. 33. Monnier L, Colette C, Wojtusciszyn A, et al. Toward defining the threshold between low   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m and high glucose variability in diabetes. Diabetes Care. 2017;40(7):832-838. 34. Ceriello A, Monnier L, Owens   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m D. Glycaemic variability in diabetes: Clinical and therapeutic implications. Lancet Diabetes Endocrinol.        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 2019;7(3):221-230. 35. Li S, Nemeth I, Donnelly L, et al. Visit-to-visit HbA(1c) variability is associated with \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m cardiovascular disease and microvascular complications in patients with newly diagnosed type 2 diabetes.        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Diabetes Care. 2020;43(2):426-432. 36. Hirakawa Y, Arima H, Zoungas S, et al. Impact of visit-to-visit glycemic \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m variability on the risks of macrovascular and microvascular events and all-cause mortality in type 2 diabetes:  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m The ADVANCE trial. Diabetes Care. 2014;37(8):2359-2365. 37. Ceriello A, Ofstad AP, Zwiener I, et al.            \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Empagliflozin reduced long-term HbA1c variability and cardiovascular death: Insights from the EMPA-REG OUTCOME  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m trial. Cardiovasc Diabetol. 2020;19(1):176. 38. Sheng CS, Tian J, Miao Y, et al. Prognostic significance of     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m long-term HbA(1c) variability for all-cause mortality in the ACCORD trial. Diabetes Care. 2020;43(6):1185-1190. \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 39. Zhou JJ, Schwenke DC, Bahn G, et al. Glycemic variation and cardiovascular risk in the Veterans Affairs     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Diabetes Trial. Diabetes Care. 2018;41(10):2187-2194. 40. Sato M, Inaishi J, Saisho Y, et al. Association of    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m visit-to-visit glycemic variability with risk of cardiovascular diseases in high-risk Japanese patients with    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m type 2 diabetes: A subanalysis of the EMPATHY trial. J Diabetes Investig. 2021;12(12):2190-2196. 47 Chapter 2   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 41. Ceriello A, Lucisano G, Prattichizzo F, et al. HbA1c variability predicts cardiovascular complications in   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m type 2 diabetes regardless of being at glycemic target. Cardiovasc Diabetol. 2022;21(1):13. 42. International   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Diabetes Federation. Managing older people with type 2 diabetes - Global guideline. 2013. Available from:       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m https://idf.org/ media/uploads/2023/05/attachments-48.pdf [Accessed November 2024]. 43. Monnier L, Lapinski H,  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal           \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m hyperglycemia of type 2 diabetic patients: Variations with increasing levels of HbA(1c). Diabetes Care.         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 2003;26(3):881-885. 44. International Diabetes Federation. Guideline for management of postmeal glucose in      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m diabetes. Diabetes Res Clin Pract. 2014;103(2):256-268. 45. Woerle HJ, Neumann C, Zschau S, et al. Impact of    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m fasting and postprandial glycemia on overall glycemic control in type 2 diabetes. Importance of postprandial    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m glycemia to achieve target HbA1c levels. Diabetes Res Clin Pract. 2007;77(2):280-285. 46. Riddle M, Umpierrez   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m G, DiGenio A, et al. Contributions of basal and postprandial hyperglycemia over a wide range of A1C levels      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m before and after treatment intensification in type 2 diabetes. Diabetes Care. 2011;34(12):2508-2514. 47.        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Ceriello A, Hanefeld M, Leiter L, et al. Postprandial glucose regulation and diabetic complications. Arch       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Intern Med. 2004;164(19):2090-2095. 48. Raz I, Wilson PW, Strojek K, et al. Effects of prandial versus fasting  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m glycemia on cardiovascular outcomes in type 2 diabetes: The HEART2D trial. Diabetes Care. 2009;32(3):381-386.   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 49. Holman RR, Haffner SM, McMurray JJ, et al. Effect of nateglinide on the incidence of diabetes and           \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m cardiovascular events. N Engl J Med. 2010;362(16):1463-1476. 50. Holman RR, Coleman RL, Chan JCN, et al.        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m impaired glucose tolerance (ACE): A randomised, double-blind, placebo-controlled trial. Lancet Diabetes         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Endocrinol. 2017;5(11):877-886. 51. Holman RR, Cull CA, Turner RC. A randomized double-blind trial of acarbose  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m in type 2 diabetes shows improved glycemic control over 3 years (U.K. Prospective Diabetes Study 44). Diabetes  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Care. 1999;22(6):960-964. 52. Asakura M, Kim J, Asanuma H, et al. Does treatment of impaired glucose tolerance  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m improve cardiovascular outcomes in patients with previous myocardial infarction? Cardiovasc Drugs Ther.         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 2017;31(4):401-411. 53. Zinman B, Marso SP, Poulter NR, et al. Day-to-day fasting glycaemic variability in      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m DEVOTE: Associations with severe hypoglycaemia and cardiovascular outcomes (DEVOTE 2). Diabetologia.            \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 2018;61(1):48-57. 54. Gerstein HC, Riddle MC, Kendall DM, et al. Glycemia treatment strategies in the Action to \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol. 2007;99(12a):34i-43i. 55. Abraira C,      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Duckworth W, McCarren M, et al. Design of the cooperative study on glycemic control and complications in        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m diabetes mellitus type 2: Veterans Affairs Diabetes Trial. J Diabetes Complications. 2003;17(6):314-322. 56.    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Rao PV, Makkar BM, Kumar A, et al. RSSDI consensus on self-monitoring of blood glucose in types 1 and 2         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m diabetes mellitus in India. Int J Diabetes Dev Ctries. 2018;38(3):260-279. 57. Johnson ML, Bergenstal RM, Levy  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m BL, et al. A safe and simple algorithm for adding and adjusting mealtime insulin to basal-only therapy. Clin    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Diabetes. 2022;40(4):489-497. 58. Battelino T, Danne T, Bergenstal RM, et al. Clinical targets for continuous   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m glucose monitoring data interpretation: Recommendations from the International Consensus on Time in Range.      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Diabetes Care. 2019;42(8):1593-1603. 59. Hirsch IB, Welsh JB, Calhoun P, et al. Associations between HbA(1c)    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m and continuous glucose monitoring-derived glycaemic variables. Diabet Med. 2019;36(12):1637-1642. 60. Yapanis   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m M, James S, Craig ME, et aI. Complications of diabetes and metrics of glycemic management derived from          \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m continuous glucose monitoring. J Clin Endocrinol Metab. 2022;107(6):e2221-e2236. 61. Mo Y, Wang C, Lu J, et al. \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Impact of short-term glycemic variability on risk of all-cause mortality in type 2 diabetes patients with       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m well-controlled glucose profile by continuous glucose monitoring: A prospective cohort study. Diabetes Res Clin \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Pract. 2022;189:109940. 62. Lu J, Wang C, Shen Y, et al. Time in range IDF Global Clinical Practice             \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Recommendations for Managing Type 2 Diabetes â€“ 2025 48 GLYCAEMIC TARGETS in relation to all-cause and           \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m cardiovascular mortality in patients with type 2 diabetes: A prospective cohort study. Diabetes Care.           \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 2021;44(2):549-555. 63. Raj R, Mishra R, Jha N, et al. Time in range, as measured by continuous glucose         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m monitor, as a predictor of microvascular complications in type 2 diabetes: A systematic review. BMJ Open        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Diabetes Res Care. 2022;10(1):e002573. 64. American Diabetes Association Professional Practice Committee. 7.    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Diabetes technology: Standards of care in diabetes-2025. Diabetes Care. 2025;48(Suppl 1):S146-S166. 65. Garber  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m AJ. Treat-to-target trials: Uses, interpretation and review of concepts. Diabetes Obes Metab.                   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 2014;16(3):193-205. 66. Malanda UL, Welschen LM, Riphagen, II, et al. Self-monitoring of blood glucose in       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m patients with type 2 diabetes mellitus who are not using insulin. Cochrane Database Syst Rev. 2012;1:CD005060.  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 67. International Diabetes Federation. Guideline on self-monitoring of blood glucose in non-insulin treated     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m type 2 diabetes. 2013. Available from:                                                                          \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m https://d-net.idf.org/en/library/190-self-monitoring-of-blood-glucose-in-non-insulin-treated-type-2-diabetes.ht \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m ml [Accessed November 2024]. 68. Polonsky WH, Fisher L, Schikman CH, et al. Structured self-monitoring of blood \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m glucose significantly reduces A1C levels in poorly controlled, noninsulin-treated type 2 diabetes: Results from \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m the Structured Testing Program study. Diabetes Care. 2011;34(2):262-267. 69. Bosi E, Scavini M, Ceriello A, et  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m al. Intensive structured self-monitoring of blood glucose and glycemic control in noninsulin-treated type 2     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m diabetes: The PRISMA randomized trial. Diabetes Care. 2013;36(10):2887-2894. 70. Parsons SN, Luzio SD, Harvey   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m JN, et al. Effect of structured self-monitoring of blood glucose, with and without additional TeleCare support, \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m on overall glycaemic control in non-insulin treated Type 2 diabetes: The SMBG Study, a 12-month randomized      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m controlled trial. Diabet Med. 2019;36(5):578-590. 71. National Institute for Health and Care Excellence (NICE). \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Type 2 diabetes in adults: Management. NICE guideline [NG28]. Available from: https://www.nice.org.uk/          \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m guidance/ng28 [Accessed November 2024]. 72. Edelman SV, Argento NB, Pettus J, et al. Clinical implications of   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m real-time and intermittently scanned continuous glucose monitoring. Diabetes Care. 2018;41(11):2265-2274. 73.   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Aronson R, Brown RE, Chu L, et al. IMpact of flash glucose Monitoring in pEople with type 2 Diabetes            \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Inadequately controlled with non-insulin Antihyperglycaemic ThErapy (IMMEDIATE): A randomized controlled trial. \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Diabetes Obes Metab. 2023;25(4):1024-1031. 74. Roussel R, Riveline JP, Vicaut E, et al. Important drop in rate  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m of acute diabetes complications in people with type 1 or type 2 diabetes after initiation of flash glucose      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m monitoring in France: The RELIEF Study. Diabetes Care. 2021;44(6):1368-1376. 75. Riveline JP, Roussel R, Vicaut \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m E, et al. Reduced rate of acute diabetes events with flash glucose monitoring is sustained for 2 years after    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m initiation: Extended outcomes from the RELIEF Study. Diabetes Technol Ther. 2022;24(9):611-618. 76. Jancev M,   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Vissers T, Visseren FLJ, et al. Continuous glucose monitoring in adults with type 2 diabetes: A systematic      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m review and meta-analysis. Diabetologia. 2024;67(5):798-810. 77. Seidu S, Kunutsor SK, Ajjan RA, et al. Efficacy \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m and safety of continuous glucose monitoring and intermittently scanned continuous glucose monitoring in         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m patients with type 2 diabetes: A systematic review and meta-analysis of interventional evidence. Diabetes Care. \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 2024;47(1):169-179. 78. Battelino T, Alexander CM, Amiel SA, et al. Continuous glucose monitoring and metrics   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m for clinical trials: An international consensus statement. Lancet Diabetes Endocrinol. 2023;11(1):42-57. 79.    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Gupta Y, Goyal A, Tandon N. Implications of technology guidelines for low-income and middle-income countries.   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Lancet Diabetes Endocrinol. 2023;11(3):155. 49 Chapter 2 50 Blood Glucose-Lowering Therapies â€“ Non-Insulin      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Options for Type 2 Diabetes Chapter 3 BLOOD GLUCOSE-LOWERING THERAPIES â€“ NON-INSULIN 51 Chapter 3               \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m RECOMMENDATIONS Optimal Care Basic Care At diagnosis No complications or low cardio-renal risk In obese persons \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m â€¢\\tLifestyle modification â€¢\\tMetformin â€¢\\tCombination therapy is an option â€¢\\tConsider metformin and GLP-1RA    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m â€¢\\tLifestyle modification â€¢\\tMetformin â€¢\\tConsider metformin and SGLT2i* Risk of or with cardio-renal           \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m complications â€¢\\tLifestyle modification â€¢\\tMetformin and SGLT2i or GLP-1RA (SGLT2i preferred in HF)             \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m â€¢\\tLifestyle modification â€¢\\tMetformin and SGLT2i* On therapy and not at glycaemic target No complications or   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m low cardio-renal risk â€¢\\tReinforce lifestyle modification If only on metformin â€¢\\tAdd SGLT2i In obese persons   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m â€¢\\tAdd GLP-1RA If on combination therapy â€¢\\tAdd an SGLT2i or GLP-1RA â€¢\\tIf already taking an SGLT2i or GLP-1RA, \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m add an agent from another BGL therapy â€¢\\tReinforce lifestyle modification If only on metformin â€¢\\tAdd SGLT2i*   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m or any available BGL therapy If on combination therapy â€¢\\tAdd SGLT2i* or any available BGL therapy Risk of or   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m with cardio-renal complications â€¢\\tReinforce lifestyle modification If only on metformin: â€¢\\tAdd SGLT2i or      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m GLP-1RA In obese persons â€¢\\tAdd GLP-1RA If on combination therapy â€¢\\tAdd an SGLT2i or GLP-1RA â€¢\\tIf already     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m taking an SGLT2i or GLP-1RA, add an agent from another BGL therapy â€¢\\tReinforce lifestyle modification If only  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m on metformin: â€¢\\tAdd SGLT2i* or any available BGL therapy If on combination therapy â€¢\\tAdd SGLT2i* or any       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m available BGL therapy * SGLT2 inhibitors are increasingly available in several low- and middle-income countries \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m at generally affordable cost.\\nBGL, blood glucose- lowering; GLP-1RA, glucagon-like peptide-1 receptor agonist; \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m HF, heart failure; SGLT2i, sodium-glucose cotransporter-2 inhibitor.\\nIDF Global Clinical Practice              \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Recommendations for Managing Type 2 Diabetes â€“ 2025 52 BLOOD GLUCOSE-LOWERING THERAPIES â€“ NON-INSULIN o         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Globally, poor glycaemic control is common in people with type 2 diabetes mellitus (T2DM) and improving         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m glycaemic control remains an unmet need and a key diabetes care priority. o Early and intensive glycaemic       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m control in T2DM not only reduces micro- and macrovascular complications but also has a legacy effect that lower \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m risk for decades. o Intensive multifactorial risk management, including blood glucose, blood pressure, and      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m lipids, decreases long-term cardio-renal events and overall mortality. o Recent cardiovascular outcome trials   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m with sodium-glucose cotransporter-2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m have demonstrated significant cardio-renal protection, prompting debate about balancing the focus on glycaemic  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m control and organ protection, particularly for individuals at low risk of cardio-renal complications. o Global  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m availability, access, and affordability of blood glucose-lowering therapies (BGL) vary widely and impact        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m treatment options in lower resource settings. o The majority of cardio-renal outcome studies have added trial   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m therapies to usual care with placebo as the comparator and outcome data from head-to-head studies comparing     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m blood glucose-lowering therapies are limited. o Initiating therapy should be personalised based on individual   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m characteristics, comorbidities, and shared decision-making, with lifestyle interventions (e.g., self-management \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m education, nutrition, and exercise) as essential components. o Metformin remains the recommended first-line     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m monotherapy due to its global availability, efficacy, safety profile, low hypoglycaemia risk, and               \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m cost-effectiveness, along with demonstrated long-term cardiovascular benefits. o Emerging data support the      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m early use of SGLT2 inhibitors and GLP-1 receptor agonists, usually added to metformin, to mitigate the adverse  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m consequences of poor glycaemic control and improve cardio-renal outcomes, although evidence supporting their    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m role as first-line monotherapy is limited. o Initial combination therapy may increase durability of glycaemic   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m control compared with stepwise addition of BGL therapies. o Timely treatment intensification is crucial to      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m overcome clinical inertia, while deintensification should be considered in individuals at or near glycaemic     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m targets, especially in the elderly and those prone to hypoglycaemia. o Therapy choices should factor in         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m management of coexisting conditions such as cardio-renal complications, metabolic dysfunction-associated        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m steatotic liver disease, and weight control.\\nKEY POINTS 53 Chapter 3 BACKGROUND Early and intensive glycaemic  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m control Evidence strongly suggests that good glycaemic control is the key to decreasing the risk of both micro- \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m and macrovascular complications in type 2 diabetes mellitus (T2DM).1 Furthermore, early and intensive glycaemic \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m control has a legacy effect in decreasing the risk of developing complications even after 24 years, compared to \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m non-intensive glycaemic control.2 This legacy effect underscores the long-term benefits of early and intensive  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m glycaemic control in reducing cardiovascular and kidney disease events and all-cause mortality. Globally, poor  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m glycaemic control in people with T2DM is common, being observed in 45%â€“93% of individuals, with considerable    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m inter- and within-country variations.3 Consequently, improving glycaemic control remains an unmet need and a    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m key diabetes care priority. In addition, intensive multifactorial risk factor management (blood glucose, blood  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m pressure, lipids) reduces microvascular complications and long-term cardio-renal events and mortality.4,5       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Cardio-renal protection Several sodium-glucose cotransporter-2 (SGLT2) inhibitor and glucagon-like peptide-1    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m (GLP-1) receptor agonist cardiovascular outcome trial (CVOT) randomised controlled trials (RCTs) have           \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m demonstrated cardio-renal protection with benefits in cardiovascular disease (CVD), heart failure, and renal    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m outcomes. These findings have stimulated a paradigm shift to focusing on organ protection with less emphasis on \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m glycaemic control. As a result, there is debate about the relative importance of glycaemic control in the       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m management of T2DM and potential unintended consequences for the many individuals with poor glycaemic control   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m without or at low risk of cardio-renal complications.6 Separating an effect of intensive glucose control and    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m the cardio-renal protection of newer blood glucose-lowering (BGL) medications is limited by a lack of dedicated \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m RCTs. CVOT RCTs have been mainly performed in people with T2DM with prior cardiovascular and/or kidney disease  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m or multiple risk factors, and the majority of participants in the CVOTs of SGLT2 inhibitors and GLP-1 receptor  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m agonists were treated with conventional BGL medications and reninâ€“ angiotensinâ€“aldosterone system inhibitors,   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m statins, and antiplatelet therapy. Of note, these newer agents have no demonstrated benefits on diabetes        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m microvascular complications of retinopathy and neuropathy, which are known to be influenced by improved         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m glycaemic control. Achieving glycaemic control is a universally accepted goal. Complimenting this with specific \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m cardio-renal protection interventions in a low-resource health environment will be determined by availability,  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m accessibility, and affordability of newer BGL medications. GLOBAL CONSIDERATIONS A number of classes of         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m non-insulin BGL therapies are available and their attributes have been reviewed and summarised elsewhere.7,8    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m The global availability, access to, and affordability of BGL therapies vary widely. The World Health            \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Organization (WHO) periodically publishes an Essential Medicines List (EML).9 This includes a core list of      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m minimum medicine needs for a basic healthcare system of the most efficacious, safe, and cost-effective          \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m medicines for priority conditions, including diabetes, selected on the basis of current and estimated future    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m public health relevance, and potential for safe and cost-effective treatment. The current list for diabetes is  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m shown in Table 3.1. IDF Global Clinical Practice Recommendations for Managing Type 2 Diabetes â€“ 2025 54 BLOOD   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m GLUCOSE-LOWERING THERAPIES â€“ NON-INSULIN The WHO EML is reviewed and updated every two years, and in 2023,      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m SGLT2 inhibitors were included. In some low- and middle-income countries (LMICs), generic SGLT2 inhibitors are  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m becoming available at affordable prices. The WHO EML serves as a basis for National EMLs (NEML) with            \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m approximately 70% of the 194 WHO member states having NEMLs. The congruence of NEMLs with the WHO EML varies    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m considerably across conditions, with the median of listed diabetes drugs being 0.60.10 In another study, the    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m total number of diabetes medicines listed on NEMLs ranged from 0 to 16 across 127 countries (median: 4;         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m interquartile range: 3â€“6) and diabetes health outcome scores were associated with the number of diabetes        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m medicines on NEMLs.11 As reviewed in Chapter 2, assessment of glycaemic control is important in monitoring the  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m effectiveness of BGL medications. Global consensus is that measurement of glycated haemoglobin (HbA1c) should   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m be used to initiate and modify BGL therapy. Other tests, such as fasting and postprandial self-blood glucose,   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m glucose variability, and time in range measurements, provide additional information about glycaemic status and  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m underlying pathophysiology, and influence therapeutic choice.12 Unfortunately, HbA1c measurement and other      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m technologies are not available in many health facilities throughout the world and therefore healthcare          \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m providers should remain flexible in using alternative methods for glucose monitoring and treatment planning as  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m per local resources and capabilities. EVIDENCE SUMMARY Initiating therapy Determining the optimal timing for    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m initiating and choosing BGL therapy in drug-naÃ¯ve individuals with unsatisfactory diabetes control requires     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m assessment of individual characteristics (advanced age), personal circumstances (financial constraints, living  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m alone or in a care facility), glycaemic targets, and the presence of comorbidities and cardio-renal disease or  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m risk. Shared decision-making should include an evaluation of benefits and risks such as hypoglycaemia and is a  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m continuous process.13 Lifestyle intervention Lifestyle interventions, including diabetes self-management        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m education, medical nutrition therapy, and regular physical activity, play a pivotal role in managing T2DM       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m regardless of BGL medication,14 and contribute to improved outcomes, including quality of life,15 reduced       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m all-cause mortality,16 hospitalisation, and lower healthcare costs,17,18 emphasising their importance in        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m initial management. Individuals should be encouraged to aim for specific lifestyle goals, such as at least 150  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m minutes of moderate exercise per week and a reduction in excess body weight of 5%â€“10%. Weight loss can improve  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Table 3.1 World Health Organization Model List of Essential Medicines â€“ 23rd List (2023) Medicines for Diabetes \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Oral hypoglycaemic agents Empagliflozin Therapeutic alternatives: â€¢ canagliflozin â€¢ dapagliflozin Tablet: 10    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m mg; 25 mg.\\nGliclazide* Therapeutic alternatives: â€¢ 4th level ATC chemical subgroup (A10BB Sulfonylureas) Solid \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m oral dosage form: (controlled-release tablets) 30 mg; 60 mg; 80 mg.\\n*glibenclamide not suitable above 60       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m years.\\nMetformin Tablet: 500 mg (hydrochloride). ATC, Anatomical Therapeutic Chemical. Adapted from World      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Health Organization, 20239 55 Chapter 3 glycaemic control, induce diabetes remission, and lead to improvements  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m in various metabolic and cardiovascular risk factors (see Chapter 5). Globally, there is considerable variation \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m in local diets, influenced by tradition, local customs, religion, and the availability and affordability of     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m food. Consequently, the applicability of nutrition-related studies to a particular environment will vary,       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m although some overarching observations are relevant. Most intervention studies of different diets and dietary   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m components associated with benefits in diabetes control have been short-term. Beneficial effects diminish over  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m time and are not consistently maintained in studies with follow-up periods longer than 12 months. Carbohydrate  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m in foods comprises the major nutrient component in most diets worldwide. Many less economically secure          \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m communities rely on carbohydrate foods for their sustenance. Wealthier nations have selected types of           \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m carbohydrate foods that have contributed to obesity, diabetes, and ill health. A systematic review and          \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m meta-analysis of RCTs on varying carbohydrate quantity reported a dose-dependent effect. Each 10% decrease in   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m carbohydrate intake reduced HbA1c by 0.2% (3 mmol/mol) after six months, compared to a carbohydrate intake      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m between 55%â€“65%.19 A recent RCT compared a healthy low-carbohydrate diet with a usual diet in adults with HbA1c \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m between 6.0%â€“6.9% (42â€“52 mmol/mol) who were not taking BGL medications. After six months, the low-carbohydrate  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m diet group had a significantly lower HbA1c (0.23% [3 mmol/mol]) compared to the usual diet group.20 Diets that  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m improve carbohydrate quality by using low glycaemic index foods may help improve glycaemic control, with a      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m systematic review reporting a statistically significant reduction of HbA1c of 0.19% (2 mmol/mol) compared with  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m a range of other diets.21 The more restrictive vegan diet (low-fat, excluding all animal-based products)        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m demonstrated an HbA1c reduction of 0.41% (4 mol/mol) compared with a conventional diet.22 The diets to be       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m advised for the management of T2DM must be culturally and economically appropriate. Dietitians with local       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m experience must be part of the team. Foods such as legumes, fresh fruit and non-starchy vegetables, nuts and    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m seeds in acceptable form should be encouraged, and advice against consumption of soft drinks and sugars should  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m be given, together with reducing amounts of starchy foods, especially those that are highly processed. Such     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m diets will not only benefit people with T2DM but human health globally and reduce the environmental impact of   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m human food production. Understanding how nutrition therapy and pharmacotherapy interact in real-world diabetes  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m management remains a challenge. The lack of clear evidence of complementarity between diet quality and the      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m intensity of BGL medications highlights the challenge and need for better integration between diet and          \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m pharmacologic approaches.23 First-line monotherapy Metformin When pharmacologic intervention is necessary,      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m metformin is traditionally recommended as first-line monotherapy based on its blood glucose-lowering efficacy,  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m low hypoglycaemia risk, weight neutrality with the potential for modest weight loss, good safety profile,       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m general availability, and low cost.8,13 In addition, there is a long experience with its use, and long-term CVD \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m benefits were observed in the UKDPS.24 Metforminâ€™s safety profile extends to individuals with reduced estimated \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m glomerular filtration rates (eGFR), supporting its use in those with an eGFR â‰¥30 mL/min/1.73 mÂ². Other          \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m therapies Other therapies are also effective as first-line treatments, with some well-recognised class effect   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m differences. Reductions in HbA1c were similar across monotherapies except that dipeptidyl peptidase 4 (DPP4)    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m inhibitors had smaller effects. Body weight was reduced or maintained with metformin, DPP4 inhibitors, GLP-1    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m receptor agonists, and SGLT2 inhibitors and increased with sulfonylureas and thiazolidinediones. Hypoglycaemia  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m was more frequent with sulfonylureas. Gastrointestinal adverse events were highest with metformin and GLP-1     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m receptor agonists. Genital mycotic infections were increased with SGLT2 inhibitors.25 Within each class, there  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m are also differences between individual agents. Of particular relevance to Basic Care Recommendations where the \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m range and choice of therapeutic options are limited due to access, availability, and affordability, there are   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m well-documented differences in sulfonylureas with regard to hypoglycaemia risk and impact on weight.26 IDF      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Global Clinical Practice Recommendations for Managing Type 2 Diabetes â€“ 2025 56 BLOOD GLUCOSE-LOWERING          \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m THERAPIES â€“ NON-INSULIN SGLT2 inhibitors and GLP-1 receptor agonists T2DM significantly increases the risk of   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m cardio-renal complications. The findings of cardio-renal protection in recent RCTs with SGLT2 inhibitors and    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m GLP-1 receptor agonists have led to guidelines and consensus statements proposing the use of these agents as    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m first-line therapy in individuals with or at high risk of cardio-renal disease, either in combination with      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m metformin13 or as monotherapy.27 At present, the evidence supporting these agents as first-line monotherapy is  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m inconclusive.28 All CVOT RCTs demonstrating cardio-renal protection have added the study medication to existing \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m therapy of study participants, with the majority taking metformin. Post-hoc analyses have shown no evidence of  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m heterogeneity in the CV efficacy of the GLP-1 receptor agonist liraglutide based on background metformin29 or   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m with SGLT2 inhibitors for reductions in cardiovascular, kidney, and mortality outcomes regardless of whether    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m individuals were receiving or not receiving metformin. However, it should be noted that baseline metformin      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m users had an approximately 30% lower risk of the primary outcome than metformin non-users.30 A meta-analysis of \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m newer BGL medications in metformin-naÃ¯ve people with T2DM reported beneficial effect of GLP-1 receptor agonists \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m and SGLT2 inhibitors.31 A recent observational registry-based study using the AMD Annals Initiative assessed    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m the association between the early introduction of SGLT2 inhibitors and consequences of poor glycaemic control   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m in newly diagnosed individuals with T2DM without CVD.32 The early introduction of SGLT2 inhibitors in people    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m with T2DM, 90% of whom were also taking metformin, eliminated the association between poor glycaemic control in \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m the first two years after T2DM diagnosis and later CVD events, suggesting that SGLT2 inhibitors may attenuate   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m the consequences of poor glycaemic control after T2DM diagnosis. To date, there have not been any direct        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m comparisons of metformin versus newer agents on diabetes-related outcomes as first-line monotherapy. A          \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m registry-based randomised trial (SMARTEST) is underway to directly assess dapagliflozin versus metformin on a   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m primary composite endpoint of macro- or microvascular events in approximately 4,300 participants with early     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m T2DM.33 Combination therapy There are numerous combinations of non-insulin BGL therapies, and it is beyond the  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m scope of this document to review all potential combinations. This section highlights some aspects of            \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m combination therapy. Combination first-line therapy Metformin serves as the cornerstone for combination         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m therapy. While conventional approaches have favoured stepwise addition of therapy, some individuals may require \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m combination therapy (two BGL medications) to achieve glycaemic control early in the course of their diabetes.   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Dual initial oral therapy can be considered in those with HbA1c levels exceeding 9%â€“10% (75â€“86 mmol/mol)        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m without symptoms. In some cases, insulin may be required as part of initial pharmacotherapy, particularly in    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m those with clear symptoms and/ or signs of significant hyperglycaemia.7,34 In these situations, combination     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m therapy may be temporary. A decision to reduce hyperglycaemia quickly through combination therapy should also   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m consider potential detrimental effects such as the risk of retinopathy progression.35 The primary focus should  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m not be rapid reduction but rather reaching glycaemic goals and maintaining them over time. Initial combination  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m therapy may increase durability of glycaemic control compared with stepwise addition of BGL therapies. The      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m VERIFY trial demonstrated the superiority of initial combination therapy over sequential addition in slowing    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m the decline of glycaemic control. Participants with T2DM diagnosed within two years prior to enrolment with     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m HbA1c of 6.5%â€“7.5% (48â€“58 mmol/mol) received either combination treatment with metformin and vildagliptin or    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m initial metformin monotherapy with the subsequent addition of vildagliptin if required to improve diabetes      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m control. The endpoint, time from randomisation to initial treatment failure (HbA1c â‰¥7.0% [53 mmol/mol]),        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m occurred in 43.6% in the combination treatment group and 62.1% in the monotherapy group.36 The VERIFY study was \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m not designed or powered to assess the effect of combination treatment on cardiovascular outcomes. The effect of \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m initial triple therapy on long-term glycaemic control has also been studied. In the EDICT study, drug-naÃ¯ve     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m individuals with new-onset T2DM were randomly assigned to receive either 1) combination therapy with 57 Chapter \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 3 metformin, pioglitazone, and exenatide (triple therapy) or 2) sequential addition of metformin followed by    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m glipizide and insulin (conventional therapy) aiming to maintain HbA1c below 6.5% (48 mmol/mol). After three     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m years, HbA1c was significantly lower with initial triple therapy compared with conventional therapy (6.4% [47   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m mmol/mol] versus 6.9% [52 mmol/mol]).37 The TRIPLE-AXEL study randomised individuals with drug-naÃ¯ve T2DM to    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m triple combination therapy with metformin, dapagliflozin, and saxagliptin or conventional stepwise add-on       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m therapy (initiated with metformin, followed by glimepiride and sitagliptin). The primary outcome, the           \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m proportion who achieved an HbA1c <6.5% (48 mmol/mol) without hypoglycaemia, weight gain of 5% or higher, or     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m discontinuation of drugs because of adverse events at 104 weeks, was achieved in 39.0% and 17.1%, respectively, \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m although HbA1c reduction from baseline was similar in both groups.38 However, in both triple therapy studies,   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m the treatment regimens differed between the two groups. There are no dedicated outcome studies comparing        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m treatment initiation with combinations of BGL therapies. Combination SGLT2 inhibitors and GLP-1 receptor        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m agonists Some guidance suggests combining SGLT2 inhibitor and GLP-1 receptor agonist therapies. However, this   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m combination has not been evaluated in an outcome RCT and the results of analyses of administrative datasets are \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m not convincing. Nested case-control studies of individuals with T2DM in England and Wales of primary care data  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m from the Clinical Practice Research Datalink and Secure Anonymised Information Linkage Databank reported on the \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m association of SGLT2 inhibitors, GLP-1 receptor agonists, or their combination regimens on major adverse        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m cardiac and cerebrovascular events (MACCE) and heart failure (HF) compared to other BGL regimens. Use of SGLT2  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m inhibitor was associated with an 18% lower odds of MACCE, and the odds of HF were 51% lower with SGLT2          \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m inhibitors and 18% lower with GLP-1 receptor agonists, but the combination was not superior to either agent     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m used alone.39 The addition of either SGLT2 inhibitors or sulfonylureas to baseline GLP-1 receptor agonists on   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m CVD outcomes was explored in an analysis of three US claims datasets in 12,584 people with T2DM and showed      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m significant reductions in the risk of MACCE and HF hospitalisations in the SGLT2 inhibitor/GLP-1 receptor       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m agonist combination compared to the sulfonylureas/GLP-1 receptor agonist combination.40 However, the magnitude  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m of the CVD risk reduction was comparable to the benefit seen in CVOTs of SGLT2 inhibitors versus placebo, where \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m baseline GLP-1 receptor agonist use was minimal. Treatment intensification, deintensification, or modification  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Early intervention is required in people with T2DM not reaching or maintaining their individualised glycaemia   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m targets. Clinical inertia is one of the most difficult barriers to overcome in clinical practice and has a      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m dramatic impact on the prognosis of complications and quality of life.41,42 Timely treatment intensification    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m with additional BGL therapy when required is crucial to avoid clinical inertia. Failure to reach or maintain    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m glycaemic targets should be a trigger to consider a change in therapy. The presence or emergence of             \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m comorbidities also influence this decision. Any change or intensification of therapy should be reassessed       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m within three months. Meta-analyses suggest that any drug added to an initial therapy, particularly with         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m metformin, can improve glycaemic control.43,44 Conversely, deintensification of therapy should be considered in \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m people at or near glycaemic target who are prone to hypoglycaemia, especially the elderly.45 The use of         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m sulfonylureas (and glinides) should be minimised where alternatives are available and affordable, or dose       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m should be reduced.46 Achieving glycaemic targets does not mandate treatment deintensification, especially with  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m newer agents such as GLP-1 receptor agonists and SGLT2 inhibitors, which not only manage hyperglycaemia but     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m also provide additional cardio-renal benefits in high-risk individuals without increasing hypoglycaemia, as     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m well as supporting weight control. Managing coexisting cardio-renal complications, metabolic                    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m dysfunction-associated steatotic liver disease (MASLD), and weight control are addressed in specific chapters.  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m In brief, therapies with demonstrated benefits in managing these comorbidities should be preferred considering  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m that they are also efficacious in controlling hyperglycaemia, if they are available, affordable, and            \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m accessible. IDF Global Clinical Practice Recommendations for Managing Type 2 Diabetes â€“ 2025 58 BLOOD           \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m GLUCOSE-LOWERING THERAPIES â€“ NON-INSULIN REFERENCES 1. Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359(15):1577-1589. 2. Adler AI, Coleman RL, \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Leal J, et al. Post-trial monitoring of a randomised controlled trial of intensive glycaemic control in type 2  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m diabetes extended from 10 years to 24 years (UKPDS 91). Lancet. 2024;404(10448):145-155. 3. Bin Rakhis SA, Sr., \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m AlDuwayhis NM, Aleid N, et al. Glycemic control for type 2 diabetes mellitus patients: A systematic review.     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Cureus. 2022;14(6):e26180. 4. Gaede P, Vedel P, Parving HH, et al. Intensified multifactorial intervention in   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m patients with type 2 diabetes mellitus and microalbuminuria: The Steno type 2 randomised study. Lancet.         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 1999;353(9153):617-622. 5. Gaede P, Vedel P, Larsen N, et al. Multifactorial intervention and cardiovascular    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m disease in patients with type 2 diabetes. N Engl J Med. 2003;348(5):383-393. 6. Khunti K, Zaccardi F, Amod A,   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m et al. Glycaemic control is still central in the hierarchy of priorities in type 2 diabetes management.         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Diabetologia. 2024 [Epub ahead of print]. DOI: 10.1007/s00125-024-06254-w. 7. American Diabetes Association     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Professional Practice Committee. 9. Pharmacologic approaches to glycemic treatment: Standards of care in        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m diabetes-2024. Diabetes Care. 2024;47(Suppl 1):S158-S178. 8. National Institute for Health and Care Excellence  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m (NICE). NICE guideline [NG28] Type 2 diabetes in adults: Management. Available from:                            \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m https://www.nice.org.uk/guidance/ng28 [Accessed August 2024]. 9. World Health Organization. Web Annex A. World  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Health Organization Model List of Essential Medicines - 23rd List. In: The selection and use of essential       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m medicines 2023: Executive summary of the report of the 24th WHO Expert Committee on the Selection and Use of    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Essential Medicines, 24 - 28 April 2023. Geneva: World Health Organization; 2023 (WHO/MHP/HPS/EML/2023.02).     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Licence: CC BY-NC-SA3.0 IGO. 10. Piggott T, Nowak A, Brignardello-Petersen R, et al. Global status of essential \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m medicine selection: a systematic comparison of national essential medicine lists with recommendations by WHO.   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m BMJ Open. 2022;12(2):e053349. 11. Budhram D, Benipal S, Bilimoria K, et al. Essential diabetes medicines and    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m health outcomes in 127 countries. Diabetes Obes Metab. 2021;23(5):1121-1128. 12. Ceriello A, Prattichizzo F,    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Phillip M, et al. Glycaemic management in diabetes: Old and new approaches. Lancet Diabetes Endocrinol.         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 2022;10(1):75-84. 13. Davies MJ, Aroda VR, Collins BS, et al. Management of hyperglycemia in type 2 diabetes,   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m of Diabetes (EASD). Diabetes Care. 2022;45(11):2753-2786. 14. American Diabetes Association Professional        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Practice Committee. 5. Facilitating positive health behaviors and well-being to improve health outcomes:        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Standards of care in diabetes-2024. Diabetes Care. 2024;47(Suppl 1):S77-S110. Erratum in: Diabetes Care.        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 2024;47(4):761-762. 15. Cochran J, Conn VS. Meta-analysis of quality of life outcomes following diabetes        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m self-management training. Diabetes Educ. 2008;34(5):815-823. 16. He X, Li J, Wang B, et al. Diabetes            \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m self-management education reduces risk of all-cause mortality in type 2 diabetes patients: A systematic review  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m and meta-analysis. Endocrine. 2017;55(3):712-731. 17. Robbins JM, Thatcher GE, Webb DA, et al. Nutritionist     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m visits, diabetes classes, and hospitalization rates and charges: the Urban Diabetes Study. Diabetes Care.       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 2008;31(4):655-660. 18. Strawbridge LM, Lloyd JT, Meadow A, et al. One-year outcomes of diabetes                \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m self-management training among medicare beneficiaries newly diagnosed with diabetes. Med Care.                  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 2017;55(4):391-397. 19. Jayedi A, Zeraattalab-Motlagh S, Jabbarzadeh B, et al. Dose-dependent effect of         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m carbohydrate restriction for type 2 diabetes management: A systematic review and dose-response meta-analysis of \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m randomized controlled trials. Am J Clin Nutr. 2022;116(1):40-56. 20. Dorans KS, Bazzano LA, Qi L, et al.        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Effects of a low-carbohydrate dietary intervention on hemoglobin A1c: A randomized clinical trial. JAMA Netw    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Open. 2022;5(10):e2238645. 21. Zafar MI, Mills KE, Zheng J, et al. Low-glycemic index diets as an intervention  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m for diabetes: a systematic review and meta-analysis. Am J Clin Nutr. 2019;110(4):891-902. 59 Chapter 3 22.      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Barnard ND, Cohen J, Jenkins DJ, et al. A low-fat vegan diet and a conventional diabetes diet in the treatment  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m of type 2 diabetes: A randomized, controlled, 74-wk clinical trial. Am J Clin Nutr. 2009;89(5):1588S-1596S. 23. \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Desjardins C, Leblay L, BÃ©langer A, et al. Relationship between diet quality and glucose-lowering medication    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m intensity among adults with type 2 diabetes: Results from the CARTaGENE cohort. CJC Open. 2024;6(1):20-29. 24.  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352(9131):854-865. 25.       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Maruthur NM, Tseng E, Hutfless S, et al. Diabetes medications as monotherapy or metformin-based combination     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m therapy for type 2 diabetes: A systematic review and meta-analysis. Ann Intern Med. 2016;164(11):740-751. 26.   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Kalra S, Bahendeka S, Sahay R, et al. Consensus recommendations on sulfonylurea and sulfonylurea combinations   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m in the management of type 2 diabetes mellitus - International Task Force. Indian J Endocrinol Metab.            \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 2018;22(1):132-157. 27. Marx N, Federici M, SchÃ¼tt K, et al. 2023 ESC Guidelines for the management of          \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m cardiovascular disease in patients with diabetes. Eur Heart J. 2023;44(39):4043-4140. 28. Prattichizzo F,       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Ceriello A. Is time ready for combination therapy at diagnosis of type 2â€¯diabetes? Diabetes Metab Res Rev.      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 2021;37(5):e3460. 29. Crowley MJ, McGuire DK, Alexopoulos AS, et al. Effects of liraglutide on cardiovascular   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m outcomes in type 2 diabetes patients with and without baseline metformin use: Post hoc analyses of the LEADER   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m trial. Diabetes Care. 2020;43(9):e108-e110. 30. Neuen BL, Arnott C, Perkovic V, et al. Sodium-glucose           \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m co-transporter-2 inhibitors with and without metformin: A meta-analysis of cardiovascular, kidney and mortality \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m outcomes. Diabetes Obes Metab. 2021;23(2):382-390. 31. Masson W, Lavalle-Cobo A, Lobo M, et al. Novel           \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m antidiabetic drugs and risk of cardiovascular events in patients without baseline metformin use: A              \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m meta-analysis. Eur J Prev Cardiol. 2021;28(1):69-75. 32. Ceriello A, Lucisano G, Prattichizzo F, et al. The     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m legacy effect of hyperglycemia and early use of SGLT-2 inhibitors: A cohort study with newly-diagnosed people   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m with type 2 diabetes. Lancet Reg Health Eur. 2023;31:100666. 33. SundstrÃ¶m J, KristÃ³fi R, Ã–stlund O, et al. A   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m registry-based randomised trial comparing an SGLT2 inhibitor and metformin as standard treatment of early stage \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m type 2 diabetes (SMARTEST): Rationale, design and protocol. J Diabetes Complications. 2021;35(10):107996. 34.   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Samson SL, Vellanki P, Blonde L, et al. American Association of Clinical Endocrinology Consensus Statement:     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Comprehensive Type 2 Diabetes Management Algorithm - 2023 Update. Endocr Pract. 2023;29(5):305-340. 35. Bain    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m SC, Klufas MA, Ho A, et al. Worsening of diabetic retinopathy with rapid improvement in systemic glucose        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m control: A review. Diabetes Obes Metab. 2019;21(3):454-466. 36. Matthews DR, PaldÃ¡nius PM, Proot P, et al.      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential          \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): A 5-year, multicentre, randomised,           \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m double-blind trial. Lancet. 2019;394(10208):1519-1529. 37. Abdul-Ghani M, Puckett C, Adams J, et al. Durability \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m of triple combination therapy versus stepwise addition therapy in patients with new-onset T2DM: 3-year          \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m follow-up of EDICT. Diabetes Care. 2021;44(2):433-439. 38. Kim NH, Moon JS, Lee YH, et al. Efficacy and         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m tolerability of initial triple combination therapy with metformin, dapagliflozin and saxagliptin compared with  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m stepwise add-on therapy in drug-naÃ¯ve patients with type 2 diabetes (TRIPLE-AXEL study): A multicentre,         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m randomized, 104-week, open-label, active-controlled trial. Diabetes Obes Metab. 2024;26(9):3642-3652. 39.       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Wright AK, Carr MJ, Kontopantelis E, et al. Primary prevention of cardiovascular and heart failure events with  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m SGLT2 inhibitors, GLP-1 receptor agonists, and their combination in type 2 diabetes. Diabetes Care.             \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 2022;45(4):909-918. 40. Dave CV, Kim SC, Goldfine AB, et al. Risk of cardiovascular outcomes in patients with   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m type 2 diabetes after addition of SGLT2 inhibitors versus sulfonylureas to baseline GLP-1RA therapy.            \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Circulation. 2021;143(8):770-779. 41. Chew BH, Mohd-Yusof BN, Lai PSM, Khunti K. Overcoming therapeutic inertia \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m as the Achillesâ€™ heel for improving suboptimal diabetes care: An integrative review. Endocrinol Metab (Seoul).  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 2023;38(1):34-42. IDF Global Clinical Practice Recommendations for Managing Type 2 Diabetes â€“ 2025 60 BLOOD     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m GLUCOSE-LOWERING THERAPIES â€“ NON-INSULIN 42. Reach G, Pechtner V, Gentilella R, et al. Clinical inertia and its \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m impact on treatment intensification in people with type 2 diabetes mellitus. Diabetes Metab.                    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 2017;43(6):501-511. 43. Bennett WL, Maruthur NM, Singh S, et al. Comparative effectiveness and safety of        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m medications for type 2 diabetes: an update including new drugs and 2-drug combinations. Ann Intern Med.         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 2011;154(9):602-613. 44. Maloney A, Rosenstock J, Fonseca V. A model-based meta-analysis of 24                  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m antihyperglycemic drugs for type 2 diabetes: Comparison of treatment effects at therapeutic doses. Clin         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Pharmacol Ther. 2019;105(5):1213-1223. 45. Oâ€™Neil H, Todd A, Pearce M, et al. What are the consequences of over \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m and undertreatment of type 2 diabetes mellitus in a frail population? A systematic review. Endocrinol Diabetes  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Metab. 2024;7(2):e00470. 46. Lipska KJ, Ross JS, Miao Y, et al. Potential overtreatment of diabetes mellitus in \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m older adults with tight glycemic control. JAMA Intern Med. 2015;175(3):356-362. 61 Chapter 3 62 Blood           \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Glucose-Lowering Therapies â€“ Insulin Options for Type 2 Diabetes Chapter 4 BLOOD GLUCOSE-LOWERING THERAPIES â€“   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m INSULIN 63 Chapter 4 RECOMMENDATIONS Optimal Care Basic Care Insulin initiation â€¢\\tBegin insulin therapy when   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m optimised glucose-lowering medications and lifestyle interventions do not maintain target blood glucose control \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m â€¢\\tBegin insulin therapy when optimised available glucose-lowering medications and lifestyle interventions do   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m not maintain target blood glucose control Support â€¢\\tProvide education, continuing lifestyle management, and    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m regular review, including telehealth â€¢\\tProvide education, continuing lifestyle management, and regular review  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Monitoring â€¢\\tSelf-monitoring of blood glucose â€¢\\tConsider CGM with complex insulin regimens and insulin pump   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m therapy â€¢\\tRegular HbA1c measurement â€¢\\tSelf-monitoring of blood glucose â€¢\\tRegular HbA1c measurement Insulin   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m regimen â€¢\\tSelect from a broad range of affordable insulins and insulin delivery devices â€¢\\tAccess to insulin   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m pump therapy available â€¢\\tSelect from a limited range of affordable and continuously available insulin Insulin  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m initiation â€¢\\tCommence with single daily injection of basal analogue insulin â€¢\\tContinue metformin (if          \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m tolerated and not contraindicated) â€¢\\tContinue with other blood glucose- lowering therapies if appropriate      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m â€¢\\tCommence with single daily injection of affordable human, analogue, or biosimilar insulin â€¢\\tContinue        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m metformin (if tolerated and not contraindicated) â€¢\\tContinue with other affordable and available blood          \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m glucose-lowering therapies if appropriate Insulin intensification â€¢\\tOptions include: - Basal bolus - Premixed  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m insulin - Add GLP-1RA (either separately or switch to FDC) - Insulin pump â€¢\\tOptions include: - Basal bolus -   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Premixed human insulin - Other affordable and available blood glucose-lowering therapies Insulin                \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m deintensification â€¢\\tRegularly review insulin dose, need for insulin, and complex insulin regimens, especially  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m in the elderly and individuals at target glycaemia or experiencing hypoglycaemia â€¢\\tDeintensify and simplify    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m treatment as required CGM, continuous glucose monitor; FDC, fixed-dose combination; GLP-1RA, glucagon-like      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m peptide-1 receptor agonist; HbA1c, glycated haemoglobin.\\nIDF Global Clinical Practice Recommendations for      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Managing Type 2 Diabetes â€“ 2025 64 BLOOD GLUCOSE-LOWERING THERAPIES - INSULIN o Insulin therapy is a key option \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m for type 2 diabetes mellitus (T2DM) when nonâ€insulin treatments fail to achieve glycaemic targets. o Long term  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m outcome studies confirm insulinâ€™s efficacy in improving glycaemic control and its legacy effect on reducing     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m micro- and macrovascular complications in T2DM. o The decision to use insulin should consider the individualâ€™s  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m views on safety, cultural values, social and religious influences, health literacy and language barriers. o A   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m diverse range of insulin types (human, analogue, and biosimilar) is available. o The clinical effects of these  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m insulin types in T2DM are similar except for small differences in hypoglycaemia between intermediate human and  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m long-acting analogue insulins. o Global access to insulin remains a significant challenge and only about half   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m of those with T2DM who could benefit have access to appropriate insulin therapy due to regulatory, supply       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m chain, cost, and device access barriers. o Biosimilar insulins offer the potential for cost reduction and       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m improved accessibility. o The different insulin pharmacokinetic profiles, ultra rapid-acting, rapid-acting,     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m short-acting, intermediate-acting, and long-acting, facilitate personalised and tailored treatment. o Premixed  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m insulins offer a range of fixed-dose combinations of rapid- or short-acting with intermediate- or long-acting   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m insulins aiming to control fasting and postprandial glucose. o Combining insulin with other agents such as      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m glucagon-like peptide-1 (GLP-1) receptor agonists (including fixed dose combinations) or sodium-glucose         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m cotransporter-2 (SGLT2) inhibitors has the potential to enhance glycaemic control, promote weight loss, reduce  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m insulin dosage, and lower hypoglycaemia risk. o Insulin initiation typically begins by adding once daily basal  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m insulin and continuing some oral blood glucose lowering medication(s), with treatment intensification options   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m including adding prandial insulin, switching to premixed regimens, adding a GLP-1 receptor agonist or an SGLT2  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m inhibitor, tailored to the individual glycaemic responses and preferences, and resource considerations. o       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Regular reassessment of insulin therapy is essential and insulin deintensification or simplification should be  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m regularly considered, especially in older or frail individuals, to minimise hypoglycaemia risk, reduce          \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m treatment burden, and improve quality of life. KEY POINTS 65 Chapter 4 BACKGROUND Insulin therapy is an         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m often-used therapeutic option in people with type 2 diabetes mellitus (T2DM) when glycaemic control is not      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m achieved with non-insulin blood glucose-lowering therapies. The decision to use insulin therapy should not only \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m consider glycaemic control but also take into account the individualâ€™s views on insulin safety, cultural values \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m and beliefs, social influences, religious considerations, health literacy, and language barriers. The diverse   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m landscape of insulin types allows for customisation to address specific requirements of the individual.         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Advances in the manufacture and design of commercial insulin have guaranteed supplies and led to insulins with  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m different pharmacokinetics as well as the potential for more flexible and personalised treatment regimens. The  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m emergence of biosimilar insulins provides an opportunity to decrease cost and increase global insulin access.   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m The development of fixed-dose combinations (FDCs) of basal insulin and glucagon-like peptide-1 (GLP-1) receptor \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m agonists adds to the range of insulin-related treatments. GLOBAL CONSIDERATIONS Global access to insulin        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m remains a challenge. The World Health Organization (WHO) estimated that 15% of people with T2DM require         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m insulin, but only half are appropriately treated because of barriers to insulin availability such as regulatory \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m challenges and issues with supply chains and cost.1 A range of insulins are listed in the WHO Model List of     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Essential Medicines (Table 4.1). Insulin (soluble and intermediate) has been listed since the first WHO         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Essential Medicine List in 1977. In 2021, long-acting insulin analogues (insulin glargine, detemir, degludec,   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m and their quality-assured biosimilars, as therapeutic alternatives) were added, with the WHO Expert Committee   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m on the Selection and Use of Essential Medicines noting that access to affordable human insulin remained a       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m critical global priority.1 In addition, appropriate use of insulin is hampered by a lack of access to           \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m affordable medical devices for safe administration and optimal glucose monitoring to guide insulin use.1 The    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m challenges of global access to insulin are experienced in most regions of the world.3 EVIDENCE SUMMARY Insulins \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m can be described by the method of manufacture and their pharmacokinetic characteristics. Methods of modern-day  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m insulin manufacture Human insulin In the past, insulin was obtained from pig and beef pancreas. These were      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m replaced in the 1980s Medicines for Diabetes Insulins Insulin injection (soluble)* *including quality-assured   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m biosimilars Injection: 40 IU/mL in 10 mL vial; 100 IU/mL in 10 mL vial; 100 IU/mL in 3 mL cartridge or          \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m pre-filled pen. Intermediate-acting insulin* *including quality-assured biosimilars Injection: 40 IU/mL in 10   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m mL vial; 100 IU/mL in 10 mL vial; 100 IU/mL in 3 mL cartridge or pre-filled pen (as compound insulin zinc       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m suspension or isophane insulin).\\nLong-acting insulin analogues* Therapeutic alternatives: â€¢ insulin degludec â€¢ \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m insulin detemir â€¢ insulin glargine *including quality-assured biosimilars Injection: 100 IU/mL in 3 mL          \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m cartridge or pre-filled pen.\\nTable 4.1 World Health Organization Model List of Essential Medicines â€“ 23rd List \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m (2023) Adapted from World Health Organization, 2023.2 IDF Global Clinical Practice Recommendations for Managing \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Type 2 Diabetes â€“ 2025 66 BLOOD GLUCOSE-LOWERING THERAPIES - INSULIN by genetically engineered human insulin    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m made by recombinant DNA technology using fermentation in micro-organisms (bacteria or yeast). Consequently,     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m human insulin can be produced in large quantities with a high level of purity and consistent quality at         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m relatively low cost.4 Analogue insulin The first insulin analogue (insulin Lispro rDNA) was approved for human  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m therapy in 1996. Analogue insulins are genetic modifications of human insulin, produced using recombinant DNA   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m technology, and designed to alter the absorption of subcutaneously injected insulin. Following subcutaneous     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m injection, insulin molecules form a depot from which absorption into the systemic circulation occurs. All       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m insulin molecules have a tendency to self-aggregate into hexameric complexes, and these clusters must           \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m dissociate into dimers and monomers to enter the bloodstream. The pharmacologic features of individual insulin  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m analogue preparations largely alter the rate of hexamer dissociation and insulin movement into the circulation. \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Fast-acting analogues either have less tendency to aggregate after injection or dissociate quickly and enter    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m the bloodstream faster; long-acting analogues aggregate more, remain aggregated for longer, and enter the       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m bloodstream slowly. Biosimilar insulin Biosimilar insulin is also developed through recombinant DNA technology  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m and is highly similar to an already approved reference insulin.5 Criteria for approval of a biosimilar require  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m a quality assessment; demonstration of similarity in physicochemical and biological characterisation, including \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m receptor binding, metabolic potency, and mitogenicity; pharmacokinetic/pharmacodynamic profiles in phase 1      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m studies; and assessment of safety endpoints in phase 3 clinical trials, with an emphasis on immunogenicity.6    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m The first biosimilar insulin, Abasaglar, was approved in the European Union in 2014 and in the US, the first    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m biosimilar insulin (Basaglar) was approved in 2016.6 Semglee (insulin glargine-yfgn) received FDA approval in   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m July 2021 as the first interchangeable insulin glargine biosimilar.7 Studies consistently demonstrate the       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m efficacy and safety of biosimilar insulin analogues in glycaemic control, with no notable differences in        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m insulin antibody formation compared to reference.8 Biosimilar insulins present an option for lower-priced and   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m efficacious insulin alternatives.9 Categorisation of insulin by pharmacokinetic characteristics Insulin can be  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m categorised into five groups: ultra rapid-acting analogue (URAA) insulins, rapid-acting analogue insulins       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m (RAAI), short-acting human insulins, intermediate-acting human insulins, and long-acting analogue insulins.     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Notable examples are shown in Table 4.2. The pharmacokinetic profiles of insulin analogues are significantly    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m altered by changing the amino acid sequence compared with native human insulin. Increasing the onset of action  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m is designed to better control postprandial glucose excursions, whereas the long-acting insulins are designed to \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m control fasting plasma glucose levels. The main anticipated beneficial consequences include improved glycaemic  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m control and reduced hypoglycaemia compared with human insulin. However, this has not been clearly established   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m in T2DM. A Cochrane systematic review concluded that overall, there were no clear benefits of rapid-acting      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m analogue insulin over regular short-acting human insulin in people with T2DM in change in glycated haemoglobin  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m (HbA1c) or number of non-severe hypoglycaemic episodes.10 There is limited evidence on ultra rapid-acting       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m analogue (URAA) insulins in T2DM. A recent Ultra rapid-acting analogue insulins (URAA) Rapid-acting analogue    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m insulins (RAAI) Short-acting human insulins Intermediate-acting human insulins Long-acting analogue insulins    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Faster aspart (URAsp) Insulin lispro-aabc (URLi) Insulin lispro Insulin aspart Insulin glulisine Regular human  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m insulin NPH human insulin Insulin glargine Insulin detemir Insulin degludec Insulin glargine-yfgn (Semglee)     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m NPH, neutral protamine Hagedorn.\\nTable 4.2 Types of insulins 67 Chapter 4 meta-analysis showed no difference   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m in HbA1c compared with RAAI but a small reduction in 1-hour (but not 2-hour) postprandial glucose in people     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m with T2DM, and consequently concluded that they are not routinely recommended.11 Another Cochrane systematic    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m review in people with T2DM compared long-acting analogue insulins (insulin glargine and insulin detemir) with   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m intermediate-acting human insulin (NPH insulin) and showed that while the effect on HbA1c was comparable,       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m treatment with insulin glargine and insulin detemir was associated with fewer participants experiencing         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m hypoglycaemia compared with NPH insulin. Treatment with insulin detemir also reduced the incidence of serious   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m hypoglycaemia; however, serious hypoglycaemic events were rare.12 Premixed insulins Premixed insulins (Table    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 4.3) offer a diverse array of fixed component formulations designed to address both fasting and postprandial    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m glycaemia.13,14 These formulations combine rapid or short-acting insulin with intermediate- or long-acting      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m insulin and their pharmacokinetic profile is designed to strike a balance between 24-hour efficacy and          \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m convenience for the person with T2DM.14 The efficacy of premixed insulins in improving glycaemic control is     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m well-established. Premixed analogues were found to be similar to premixed human insulin in lowering fasting     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m glucose, HbA1c, and the incidence of hypoglycaemia, but more effective in lowering postprandial glucose.        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Compared to long-acting insulin analogues, premixed analogues were superior in lowering postprandial glucose    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m and HbA1c (mean difference â€“0.39% [-4 mmol/mol]) but inferior in lowering fasting glucose, and had higher       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m incidence of hypoglycaemia.16 Premixed and basal bolus regimens (defined as any basal injection with at least a \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m single bolus injection per day) have been compared in randomised controlled trials (RCTs) and real-world        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m settings. There were no significant differences between the insulin regimens but there was a discordance        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m between real-world and RCT data. Both insulin regimens were associated with HbA1c reductions (real-world data   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m â€“0.28% [-3 mmol/mol]; RCT data, â€“1.4% [-15 mmol/mol]) and weight gain (real-world data, +0.27 kg; RCT data,     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m +2.96 kg), demonstrating greater changes in RCTs compared with real-world conditions.17 Combining insulin and a \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m GLP-1 receptor agonist Treatment can be intensified in a person with insulin-treated T2DM by adding a GLP-1     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m receptor agonist. A systematic review comparing basal plus/basal bolus and adding a GLP-1 receptor agonist to   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m insulin combinations was associated with a similar HbA1c reduction (-0.06% [-0.7 mmol/mol]) but greater weight  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m loss (-3.72 kg), a lower incidence of hypoglycaemic events (relative risk [RR] -0.46), and a reduction in       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m insulin dosage of 30.3 units/day.18 Fixed-dose combinations (FDC) of insulin and a GLP-1 receptor agonist are   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m available. IDegLira is a combination of insulin degludec (IDeg) and liraglutide with one unit of IDeg combined  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m with 0.036 mg of liraglutide. IGlarLixi is a combination of insulin glargine and lixisenatide with one unit of  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m insulin glargine combined with 0.33-to-1 Î¼g of lixisenatide. These products are administered once daily and aim \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m to optimise efficacy and minimise drawbacks associated with individual components.19 Compared with a control    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m group (mostly the individual components or another Type of premixed insulin Low-mixed formulations Mid-mixed    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m formulations High-mixed formulations Premixed human regular insulin-NPH insulin 30% regular insulin/70% NPH     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m insulin 50% regular insulin/50% NPH insulin 75% regular insulin/25% NPH insulin Premixed insulin analogues 30%  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m insulin aspart/70% insulin aspart protamine 25% insulin lispro/75% insulin lispro protamine 50% insulin         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m aspart/50% insulin aspart protamine 50% insulin lispro/50% insulin lispro protamine 75% insulin lispro/25%      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m insulin lispro protamine Coformulation 70% insulin degludec/30% insulin aspart NPH, neutral protamine Hagedorn. \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Adapted from Kalra et al. 201815 Table 4.3 Formulations of premixed insulin IDF Global Clinical Practice        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Recommendations for Managing Type 2 Diabetes â€“ 2025 68 BLOOD GLUCOSE-LOWERING THERAPIES - INSULIN insulin       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m regimen), IDegLira significantly lowered HbA1c by 0.63% (7 mmol/mol) but there was no difference in body weight \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m change. The percentage of those achieving HbA1c <6.5% or <7.0% (<48 mmol/mol or <53 mmol/mol) without weight    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m gain and hypoglycaemia episodes was higher with IDegLira.20 Similar results were reported for iGlarLixi, which  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m achieved an HbA1c reduction of 0.56% (6 mmol/mol).21 A meta-analysis of RCTs compared free or FDC combinations  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m of a GLP-1 receptor agonist plus basal insulin versus insulin intensification on glycaemic control in people    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m with T2DM. Compared with insulin uptitration, insulin and GLP-1 receptor agonist combined therapy resulted in a \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m significantly greater decrease in HbA1c (-0.53% [-6 mmol/mol]), more individuals at HbA1c target, greater       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m reduction in body weight (-1.9 kg) but similar hypoglycaemic events. Results did not differ in either the free  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m or FDC subgroups.22 Use of FDC has been associated with increased treatment persistence and improved            \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m adherence.23 Combining insulin and sodium-glucose cotransporter-2 inhibitors Insulin can also be effectively    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m combined with sodium-glucose cotransporter-2 (SGLT2) inhibitors as reported in a systematic review and          \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m meta-analysis. Compared with the control group of insulin plus placebo or insulin alone, SGLT2 inhibitor        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m reduced HbA1c by 1.4% (15 mmol/mol), body weight by 2.3 kg, and decreased the dose of insulin without           \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m increasing the risk of hypoglycaemia.24 Insulin outcome studies Numerous studies have examined the impact of    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m insulin therapy on glycaemic control in people with T2DM. However, there are limited data on clinical outcomes  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m focused specifically on insulin treatment, rather than its use as a component of an intensified glycaemic       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m control strategy in RCTs. The UKPDS is the main long-term study which assessed insulin treatment and randomised \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m people with newly diagnosed T2DM to intensive glycaemic control (with sulfonylurea or insulin, or metformin if  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m overweight) or conventional glycaemic control (primarily diet). Over 10 years, mean HbA1c was 7.0% (53          \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m mmol/mol) in the intensive group compared with 7.9% (63 mmol/mol) in the conventional group, with no            \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m differences in agents in the intensive group. Compared with the conventional group, the risk in the intensive   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m group was 12% significantly lower for any diabetes-related endpoint, driven by a significant 25% risk reduction \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m in microvascular endpoints. There was no difference in endpoints between sulfonylureas and insulin.25 In the    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 10-year post-trial follow-up study, participants randomised to the intensive group with sulfonylurea or insulin \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m showed a continued 9% risk reduction for any diabetes-related endpoint and 24% reduction in microvascular       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m disease. Risk reductions of 15% for myocardial infarction and 13% in death from any cause emerged over time,    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m despite an early loss of glycaemic differences. Outcome results for insulin and sulfonylureas were not reported \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m separately.26 The UKPDS results have recently been reported for another 14 years of follow up. The beneficial   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m effects of early intensive glycaemic control with sulfonylurea or insulin therapy, compared with conventional   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m glycaemic control, persisted with risk reductions of 10% for death from any cause, 17% for myocardial           \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m infarction, and 26% for microvascular disease.27 The ORIGIN study randomised individuals to insulin glargine to \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m normalise fasting glucose (targeting a fasting blood glucose level of â‰¤5.3 mmol/L [â‰¤95 mg/dL]) or standard care \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m to assess the impact on cardiovascular events. After a median follow up of 6.2 years, incident cardiovascular   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m outcomes were similar in the insulin glargine and standard care groups.28 The GRADE study assessed the          \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m comparative effectiveness of insulin glargine U-100, glimepiride, liraglutide, and sitagliptin added to         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m metformin in achieving and maintaining an HbA1c <7.0% (<53 mmol/mol) in people with T2DM. During a mean 5.0     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m years of follow up, the incidences of microvascular complications and death were not materially different among \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m the four treatment groups. There was a possible non-significant difference among the groups in the incidence of \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m any cardiovascular disease, favouring the GLP-1 receptor agonist.29 Overall, insulin is an established and safe \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m long-term treatment for improving glycaemic control in people with T2DM and is associated with a legacy effect  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m of improved micro- and macrovascular outcomes in newly diagnosed people with T2DM. Initiating and optimising    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m insulin therapy in individuals with T2DM Although insulin therapy is a treatment option at any stage of T2DM,   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m it is usually initiated after other treatments have failed to achieve 69 Chapter 4 personalised glycaemic       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m targets. It may be introduced earlier if diabetes control is poor (e.g., HbA1c >10% [>86 mmol/mol], blood       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m glucose consistently >16.7 mmol/L [>300 mg/dL]) and the person has symptomatic hyperglycaemia. For most people  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m with T2DM, insulin is usually used as a third or fourth blood glucose-lowering therapy in combination with      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m metformin and/or other blood glucose-lowering therapies, taking into account level of diabetes control,         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m diabetes duration, obesity, age, comorbidities, personal preferences, and medication attributes such as         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m efficacy, hypoglycaemia risk, adverse events, availability, and cost. An overview of insulin initiation and     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m intensification options is shown in Figure 4.1. Choice will depend on availability and affordability of         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m options, especially in resource-limited settings. The most frequently used options are basal insulin (with or   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m without prandial insulin) or premixed insulin. Insulin initiation and treatment intensification Insulin         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m treatment is usually initiated with once daily basal insulin. An alternate approach is to commence with once or \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m twice daily premixed insulin. The commencing dose for basal insulin is 10 units/day or 0.1â€“0.2 units/kg/ day    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m and increasing 2â€“4 units or by 10%â€“15% units at agreed intervals (often once weekly) to achieve target fasting  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m plasma glucose, unless hypoglycaemia occurs. Care should be taken to avoid excessive increases in the dose of   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m basal insulin (â€œoverbasalisationâ€). There is a ceiling effect of basal insulin, where increasing doses result   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m in proportionally smaller reductions in fasting blood glucose.30 The plateau effect is observed at doses around \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 0.5 units/kg/ day, with variations noted in different patient populations. Exceeding this threshold offers      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m modest glycaemic benefits and may lead to weight gain and increased hypoglycaemia.31,32 There is usually a      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m linear response to increasing basal insulin doses up to 0.3 units/kg/day, but between 0.3 and 0.5 units/kg/day, \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m the response diminishes non-linearly. Therefore, treatment intensification should be considered when basal      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m insulin doses surpass 0.3 units/kg/day.32 Basal insulin treatment should be intensified in people who are       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m taking a basal insulin dose of 0.3â€“0.5 units/kg/day or who have not attained their personalised HbA1c target    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m and fasting blood glucose is below 7.0 mmol/L (126 mg/dL). Assessment of the difference between bedtime and     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m morning blood glucose values (BeAM value) may assist in identifying individuals on basal insulin who need       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m treatment intensification, with large positive BeAM values with fasting glucose at goal suggestive of poor      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m control of postprandial glucose.33 Figure 4.1 Insulin initiation and intensification â€ either separately or as a \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m fixed dose combination GLP-1RA, glucagon-like peptide-1 receptor agonist.\\nIDF Global Clinical Practice         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Recommendations for Managing Type 2 Diabetes â€“ 2025 70 BLOOD GLUCOSE-LOWERING THERAPIES - INSULIN Adding        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m prandial insulin allows for greater flexibility for individuals with variable daily routines but requires a     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m higher level of cognitive and dexterity abilities, necessitates more frequent blood glucose monitoring, and may \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m involve more frequent injections compared to premixed insulin regimens. An alternate approach to escalating     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m basal insulin doses and avoiding additional injections is to add a blood glucose-lowering oral agent with       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m reduced hypoglycaemia and weight gain potential such as a SGLT2 inhibitor. Treatment intensification by         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m switching from a basal to a premixed insulin is a simple, safe, and effective approach, especially in           \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m resource-limited settings. For individuals on basal bolus insulin who do not achieve glycaemic targets, further \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m intensification of insulin therapy involves increasing the number of bolus injections (multiple daily           \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m injections). This typically involves a basal insulin and a prandial insulin injection before each of the main   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m meals. Other glucose-lowering medications can be continued but sulfonylurea should be discontinued. Access to   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m blood glucose monitoring is essential to guide bolus prandial insulin adjustments. Finally, insulin pump        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m therapy may be considered. This is not common in T2DM and requires access to and affordability of blood glucose \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m monitoring, preferably continuous glucose monitoring. However, the lack and cost of the required technology     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m mean that these options are usually not available in resource-limited settings. Insulin and treatment           \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m deintensification As with all therapies, the dose and the continuing need for insulin should be periodically    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m reassessed. This is particularly important in older individuals with T2DM. Deintensifying insulin treatment may \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m include insulin discontinuation, dose reduction, or changing to an alternate medication when benefits outweigh  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m harm, particularly in older people.34 Real-world single-arm clinical trials in older individuals support the    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m findings of improved quality of life, reduced stress, and fewer complications arising from hypoglycaemia.35 A   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m particularly concerning trend of overtreatment relates to individuals with HbA1c below 6.5% (48 mmol/mol) not   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m being considered or offered therapy simplification. A population-based retrospective cohort study using claims  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m database data reported that over three-quarters of frail individuals or those with multiple comorbidities did   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m not undergo therapy simplification, posing potential risks associated with polypharmacy.36 Treatment            \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m simplification should be considered for all individuals with T2DM on complex insulin regimens. Triggers for     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m simplification include poor glycaemic control, adherence difficulties, hypoglycaemic episodes, substantial      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m weight gain, comorbidities, cognitive impairments, frailty, limited life expectancy, a history of falls, and    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m negative impacts on quality of life.37 Deintensification of complex insulin regimens can be done by simplifying \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m the regimen from a basal bolus regimen or with two premixed insulins to a basal regimen with or without         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m non-insulin medications. The decision should be personalised, involving shared decision-making and continuous   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m assessments. The BEYOND trial demonstrated the feasibility of switching individuals on basal bolus insulin with \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m inadequate glycaemic control to basal insulin plus either a SGLT2 inhibitor or GLP-1 receptor agonist, which    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m resulted in fewer injections, lower insulin dose, less hypoglycaemia, and improved glycaemic control.38 In      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m individuals with proven insulinopaenia (undetectable C-peptide or history of ketoacidosis or severe             \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m decompensation after insulin reduction or withdrawal), and in those with long-standing diabetes and treatment   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m with complex insulin regimens due to proven ineffectiveness of other regimens, deintensification by reducing    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m insulin dose should be performed gradually and cautiously with regular monitoring. There are three main options \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m for intensifying treatment, with the choice depending on the personâ€™s preference, blood glucose monitoring      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m requirement, and medication availability and cost: 1. Add prandial insulin: administer one rapid-acting insulin \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m injection before the meal with the highest carbohydrate content. 2. Switch to premixed insulin: replace basal   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m insulin with a premixed insulin, usually twice daily â€“ before breakfast and before evening meal.\\n3. Add a      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m GLP-1 receptor agonist. 71 Chapter 4 REFERENCES 1. World Health Organization (WHO). Keeping the 100-year-old    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m promise: Making insulin access universal. Available from:                                                       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m https://www.\\nwho.int/publications/i/item/9789240039100 [Accessed August 2024]. 2. World Health Organization.   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Web Annex A. World Health Organization Model List of Essential Medicines â€“ 23rd List, 2023. In: The selection   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m and use of essential medicines 2023: Executive summary of the report of the 24th WHO Expert Committee on the    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Selection and Use of Essential Medicines, 24 - 28 April 2023.\\nGeneva: World Health Organization; 2023          \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m (WHO/MHP/HPS/EML/2023.02) Licence: CC BY-NC-SA 3.0 IGO. 3. Fralick M, Jenkins AJ, Khunti K, et al. Global       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m accessibility of therapeutics for diabetes mellitus. Nat Rev Endocrinol. 2022;18(4):199-204. 4. Beran D, Gale   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m EAM, Yudkin JS. The insulin market reaches 100. Diabetologia. 2022;65(6):931-935. 5. Heller S, Raposo JF, TofÃ©  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m S, et al. Breaking barriers with basal insulin biosimilars in type 2 diabetes. Clin Diabetes.                   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 2023;41(2):154-162. 6. Davies M, Dahl D, Heise T, et al. Introduction of biosimilar insulins in Europe. Diabet  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Med. 2017;34(10):1340-1353. 7. U.S. Food and Drug Administration. FDA approves first interchangeable biosimilar \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m insulin product for treatment of diabetes. Available from: https://www.fda.gov/                                 \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m news-events/press-announcements/                                                                                \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m fda-approves-first-interchangeable-biosimilar-insulin-product-treatment-diabetes#:~:text=Semglee%20(insulin%20  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m glargine%2Dyfgn)%20is%20the%20first%20 interchangeable%20biosimilar,effective%20                                \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m options%20for%20treating%20diabetes.. [Accessed August 2024]. 8. Yang LJ, Wu TW, Tang CH, et al. Efficacy and   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m immunogenicity of insulin biosimilar compared to their reference products: a systematic review and              \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m meta-analysis. BMC Endocr Disord. 2022;22(1):35. 9. Heinemann L, Fritz I, Khatami H, et al. Administration of   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m biosimilar insulin analogs: Role of devices. Diabetes Technol Ther. 2017;19(2):79-84. 10. Fullerton B,          \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Siebenhofer A, Jeitler K, et al. Short-acting insulin analogues versus regular human insulin for adult,         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m non-pregnant persons with type 2 diabetes mellitus. Cochrane Database Syst Rev. 2018;12(12):CD013228. 11.       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Villar-Taibo R, GaldÃ³n Sanz-Pastor A, FernÃ¡ndez-Rubio E, et al. Are new ultra-rapid-acting insulins associated  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m with improved glycemic control and reduced hypoglycemia in comparison to conventional rapid-acting insulins for \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m individuals with type 1 and type 2 diabetes? A systematic review and meta-analysis. Diabetes Technol Ther.      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 2024;26(8):575-586. 12. Semlitsch T, Engler J, Siebenhofer A, et al. (Ultra-)long-acting insulin analogues      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus. Cochrane Database Syst    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Rev. 2020;11(11):CD005613. 13. Mohan V, Kalra S, Kesavadev J, et al. Consensus on initiation and                \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m intensification of premix insulin in type 2 diabetes management. J Assoc Physicians India. 2017;65(4):59-73.    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 14. Silver B, Ramaiya K, Andrew SB, et al. EADSG Guidelines: Insulin therapy in diabetes. Diabetes Ther.        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 2018;9(2):449-492. 15. Kalra S, Czupryniak L, Kilov G, et al. Expert opinion: Patient selection for premixed    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m insulin formulations in diabetes care. Diabetes Ther. 2018;9(6):2185-2199. 16. Qayyum R, Bolen S, Maruthur N,   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m et al. Systematic review: Comparative effectiveness and safety of premixed insulin analogues in type 2          \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m diabetes. Ann Intern Med. 2008;149(8):549-559. 17. Anyanwagu U, Mamza J, Gordon J, et al. Premixed vs           \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m basal-bolus insulin regimen in type 2 diabetes: Comparison of clinical outcomes from randomized controlled      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m trials and real-world data. Diabet Med. 2017;34(12):1728-1736. 18. Castellana M, Cignarelli A, Brescia F, et    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m al. GLP-1 receptor agonist added to insulin versus basal-plus or basal-bolus insulin therapy in type 2          \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m diabetes: A systematic review and meta-analysis. Diabetes Metab Res Rev. 2019;35(1):e3082. 19. Nomoto H.        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Fixed-ratio combinations of basal insulin and glucagon-like peptide-1 receptor agonists as a promising strategy \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m for treating diabetes. World J Diabetes. 2023;14(3):188-197. 20. Liu Y, Li X, Zheng Y, et al. IDegLira for type \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 2 diabetes: A systematic review and meta-analysis. Endocrine. 2024;83(3):648-658. IDF Global Clinical Practice  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Recommendations for Managing Type 2 Diabetes â€“ 2025 72 BLOOD GLUCOSE-LOWERING THERAPIES - INSULIN 21. Liu Y, Li \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m C, Li X, et al. iGlarLixi for type 2 diabetes: A systematic review and meta-analysis. Endocrine. 2024. [Epub    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m ahead of print]. DOI: 10.1007/s12020-024-03868-3. 22. Maiorino MI, Chiodini P, Bellastella G, et al. Free and   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m fixed-ratio combinations of basal insulin and GLP-1 receptor agonists versus basal insulin intensification in   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials. Diabetes Obes Metab.    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 2018;20(9):2309-2313. 23. Edelman S, Cassarino D, Kayne D, et al. Treatment persistence and adherence in people \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m with type 2 diabetes switching to iGlarLixi vs free-dose combinations of basal insulin and glucagon-like        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m peptide 1 receptor agonist. J Manag Care Spec Pharm. 2022;28(9):958-968. 24. Yang Y, Chen S, Pan H, et al.      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Safety and efficiency of SGLT2 inhibitor combining with insulin in subjects with diabetes: Systematic review    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m and meta-analysis of randomized controlled trials. Medicine (Baltimore). 2017;96(21):e6944. Erratum in:         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Medicine (Baltimore). 2017;96(26):e7458. 25. UK Prospective Diabetes Study (UKPDS) Group. Intensive             \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of           \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352(9131):837-853. 26. Holman RR, Paul  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med.          \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 2008;359(15):1577-1589. 27. Adler AI, Coleman RL, Leal J, et al. Post-trial monitoring of a randomised          \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m controlled trial of intensive glycaemic control in type 2 diabetes extended from 10 years to 24 years (UKPDS    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 91). Lancet. 2024;404(10448):145-155. 28. Gerstein HC, Bosch J, Dagenais GR, et al. Basal insulin and           \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m cardiovascular and other outcomes in dysglycemia. N Engl J Med. 2012;367(4):319-328. 29. Nathan DM, Lachin JM,  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Bebu I, et al. Glycemia reduction in type 2 diabetes - microvascular and cardiovascular outcomes. N Engl J Med. \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 2022;387(12):1075-1088. 30. Cowart K. Overbasalization: Addressing hesitancy in treatment intensification       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m beyond basal insulin. Clin Diabetes. 2020;38(3):304-310. 31. Meece J. Basal insulin intensification in patients \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m with type 2 diabetes: A review. Diabetes Ther. 2018;9(3):877-890. 32. Umpierrez GE, Skolnik N, Dex T, et al.    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m When basal insulin is not enough: A dose-response relationship between insulin glargine 100 units/mL and        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m glycaemic control. Diabetes Obes Metab. 2019;21(6):1305-1310. 33. Zisman A, Morales F, Stewart J, et al. BeAM   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m value: An indicator of the need to initiate and intensify prandial therapy in patients with type 2 diabetes     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m mellitus receiving basal insulin. BMJ Open Diabetes Res Care. 2016;4(1):e000171. 34. Seidu S, Kunutsor SK,      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Topsever P, et al. Deintensification in older patients with type 2 diabetes: A systematic review of approaches, \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m rates and outcomes. Diabetes Obes Metab. 2019;21(7):1668-1679. 35. Munshi MN, Slyne C, Segal AR, et al.         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Simplification of insulin regimen in older adults and risk of hypoglycemia. JAMA Intern Med.                    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 2016;176(7):1023-1025. 36. McAlister FA, Youngson E, Eurich DT. Treatment deintensification is uncommon in      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m adults with type 2 diabetes mellitus: A retrospective cohort study. Circ Cardiovasc Qual Outcomes.              \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 2017;10(4):e003514. 37. Jude EB, Malecki MT, Gomez Huelgas R, et al. Expert panel guidance and narrative review \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m of treatment simplification of complex insulin regimens to improve outcomes in typeâ€¯2 diabetes. Diabetes Ther.  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 2022;13(4):619-634. 38. Giugliano D, Longo M, Caruso P, et al. Feasibility of simplification from a basal-bolus \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m insulin regimen to a fixed-ratio formulation of basal insulin plus a GLP-1RA or to basal insulin plus an SGLT2  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m inhibitor: BEYOND, a randomized, pragmatic trial. Diabetes Care. 2021;44(6):1353-1360.\\n73 Chapter 4 74 Weight  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Control in Type 2 Diabetes Management Chapter 5 WEIGHT CONTROL 75 Chapter 5 Optimal Care Basic Care Weight      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m reduction â€¢\\tLifestyle change â€¢\\tVLCD â€¢\\tIncretin-based therapy â€¢\\tMetabolic bariatric surgery â€¢\\tLifestyle     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m change â€¢\\tLow-calorie diet â€¢\\tUse weight-sparing BGL therapy â€¢\\tSGLT2i if available Improving diabetes control  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m â€¢\\tLifestyle change â€¢\\tIncretin-based therapy â€¢\\tMetabolic bariatric surgery â€¢\\tLifestyle change â€¢\\tMetformin   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m â€¢\\tAdd weight-sparing BGL therapy when indicated â€¢\\tSGLT2i if available Diabetes prevention â€¢\\tLifestyle change \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m â€¢\\tConsider: - Metformin - SGLT2i/incretin-based therapy - Metabolic bariatric surgery â€¢\\tLifestyle change      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m â€¢\\tConsider metformin Diabetes remission â€¢\\tLifestyle change â€¢\\tVLCD â€¢\\tMetabolic bariatric surgery             \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m â€¢\\tLifestyle change â€¢\\tLow-calorie diet â€¢\\tVLCD BGL, blood glucose-lowering; SGLT2i, sodium-glucose             \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m cotransporter-2 inhibitor; VLCD, very low-calorie diet.\\nRECOMMENDATIONS IDF Global Clinical Practice           \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Recommendations for Managing Type 2 Diabetes â€“ 2025 76 WEIGHT CONTROL o Obesity is a major driver of type 2     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m diabetes mellitus (T2DM) accounting for an estimated 43% of cases globally and a major factor in the increase   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m in childhood T2DM. o People in many Asian countries develop T2DM at a lower body weight and a high proportion   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m have an ideal body weight at diagnosis. o A complex interplay of biological, genetic, socioeconomic,            \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m educational, environmental, and commercial factors underlies both obesity and T2DM. o The health and economic   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m burden of diabetes is immense accounting for around 12% of global health expenditure (nearly US $1.015 trillion \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m annually); lower- and middle-income countries (LMICs) face the double burden of malnutrition and rising obesity \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m rates. o There is compelling evidence that strategies to reduce weight can prevent and reverse T2DM and other   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m obesity-associated comorbidities. o While several factors influence the relationship of weight and T2DM         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m control, in general a 1 kg weight loss results in a 0.1% (1.1 mmol/mol) reduction in glycated haemoglobin       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m (HbA1c). o Ethnic-specific cut-offs for BMI and waist circumference should be used. o A stratified,             \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m personalised approach to weight management, ranging from lifestyle interventions (nutrition, physical activity, \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m behavioural counselling) to pharmacotherapy and metabolic bariatric surgery, is recommended based on the        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m severity of overweight/obesity, associated comorbidities and available resources. o Intensive lifestyle         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m interventions, very low-calorie diets and metabolic bariatric surgery can result in T2DM remission but          \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m maintaining long term remission is challenging. o Incretin-based therapies (such as semaglutide, tirzepatide,   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m and retatrutide) show robust efficacy for weight loss and improved glycaemic control but their high cost and    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m limited availability restrict their use in resource-limited settings. o The choice of blood glucose-lowering    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m therapies should consider their impact on body weight - agents like sodium-glucose cotransporter-2 (SGLT2)      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m inhibitors, glucagon-like peptide-1 (GLP-1) receptor agonist and metformin promote weight loss, whereas         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m sulfonylureas and glitazones tend to increase weight. o Metabolic bariatric surgery is associated with longer   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m term diabetes remission, improved glycaemic control and benefits on microvascular and macrovascular outcomes    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m but availability and access are often restricted, especially in resource-limited settings.\\nKEY POINTS 77       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Chapter 5 BACKGROUND There is a close relationship between diabetes and obesity. Obesity is estimated to be     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m responsible for around 218 million cases of type 2 diabetes mellitus (T2DM) and is associated with a seven-fold \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m increased risk of developing T2DM compared with a healthy weight. Globally, obesity is responsible for around   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 43% of T2DM cases. However, this relationship varies across countries. In the US and UK, obesity contributes to \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m an estimated 80%â€“90% of T2DM while in many Asian countries people develop T2DM at a lower body weight, with one \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m study showing that 63% of people with T2DM diabetes in India had an ideal body weight at diagnosis. The         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m increasing rates of childhood obesity are a major factor in the increase of childhood T2DM.1 A complex          \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m interplay of common factors contributes to obesity and T2DM, including biology, genetics, food, education,      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m social deprivation, social economic status, healthcare access, stigma, and commercial determinants of health.1  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m The health and economic burden of diabetes has profound repercussions, particularly in lower- and middle-income \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m countries (LMICs),2,3 where there is the paradoxical double burden of malnutrition and soaring obesity.3        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Diabetes consumes approximately 12% of global health expenditure, translating to US $1.015 trillion annually.4  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m This cost has surged by 338% in the last 17 years and is projected to reach US $1.043 trillion by 2050.4 There  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m is now compelling evidence that strategies to reduce weight can prevent and reverse T2DM and other              \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m obesity-associated conditions and comorbidities. Overweight and obesity are commonly defined by body mass index \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m (BMI). Since this measure alone may not provide information about the health of an individual, there has been a \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m recent call to identify increased adiposity as an indicator of clinical obesity to guide management decisions.  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m T2DM is an established obesity-related disorder and an indicator of clinical obesity and consequently           \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m management of overweight and obesity is an important aspect of diabetes care.5 Since Asians manifest T2DM at    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m lower body weights, lower cut-offs are proposed for defining overweight and obesity in these populations (Table \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 5.1). Unhealthy weight can also be characterised by measurement of waist circumference and should be            \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m interpreted using published ethnic-specific cut-points.7 The routine measurement of waist circumference can     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m also be used to guide management and determine the efficacy of weight reduction interventions.7 Weight          \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m management treatment options are usually guided by the severity of overweight/ obesity assessed by weight       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m anthropometry (BMI/waist circumference) and tailored to improve person-specific cardiovascular, renal, and      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m metabolic outcomes using a personalised Table 5.1 Classification of weight category by race/ethnic-appropriate  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m body mass index (BMI)6 BMI, body mass index. General population Asian populations Obesity BMI â‰¥30 BMI â‰¥27.5     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Obesity class I BMI 30â€“34.9 BMI 27.5â€“32.4 Obesity class II BMI 35â€“39.9 BMI 32.5â€“37.4 Obesity class III BMI â‰¥40  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m BMI â‰¥37.5 Overweight BMI 25â€“29.9 BMI 23â€“27.4 Normal BMI 18.5â€“25 BMI 18.5â€“22.9 IDF Global Clinical Practice      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Recommendations for Managing Type 2 Diabetes â€“ 2025 78 WEIGHT CONTROL treatment plan (Table 5.2). Success       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m requires a combination of caring and supportive health professionals, a motivated person, and a flexible        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m programme which uses the range of available options. Treatment should always include supervised lifestyle       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m interventions, which can be intensified with reduced or low energy diet, very low-calorie diet (VLCD),          \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m pharmacotherapy, or metabolic bariatric surgery (MBS). Unfortunately, the availability and affordability of     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m weight control treatment options is limited globally. GLOBAL CONSIDERATIONS Weight control is complex and       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m requires significant health resources. The relationship between weight and T2DM varies considerably across      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m countries and many weight control recommendations have limited relevance where a significant proportion of the  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m diabetes population is not overweight or obese. Large-scale weight control programmes are particularly          \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m challenging in countries faced with the double burden of malnutrition and increasing rates of                   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m overweight/obesity. The emerging incretin-based anti-obesity medications are costly and not generally           \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m affordable or reimbursed in most countries and especially in resource-limited settings. Access is also an issue \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m with metabolic bariatric surgery. With limited availability and affordability of BGL medications with           \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m established weight loss potential in many countries throughout the world, alternate weight mitigating           \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m strategies become increasingly important including nutrition education and use of BGL medications with minimal  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m negative impact on weight. EVIDENCE SUMMARY Weight loss results in improvement of a range of parameters         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m relevant to improving outcomes in people with T2DM linked to the degree of weight loss.8 Weight loss and        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m diabetes control A number of factors influence the relationship of weight and diabetes control (glycated        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m haemoglobin [HbA1c] change) in people with T2DM, including choice of blood glucose-lowering (BGL) therapy and   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m baseline HbA1c. However, as a general guide, a 1 kg weight loss is estimated to result in a 0.1% reduction in   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m HbA1c (approximately 1.1 mmol/mol), although a higher baseline HbA1c is associated with a greater reduction in  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m HbA1c for the same degree of weight loss.9 Impact of weight loss in type 2 diabetes Preventing type 2 diabetes  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m As reviewed in Chapter 1, lifestyle interventions and pharmacotherapy can prevent progression from intermediate \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m hyperglycaemia, in particular impaired glucose tolerance (IGT), to T2DM and can also reverse intermediate       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m hyperglycaemia to normoglycaemia. * Refer to Table 5.1. T2DM, type 2 diabetes mellitus. Intervention 25.0â€“26.9  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m (or 23.0â€“24.9*) 27.0â€“29.9 (or 25.0â€“27.4*) â‰¥30.0 (or â‰¥27.5*) Nutrition, physical activity, and behavioural       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m counselling Indicated in all individuals Indicated in all individuals as an adjunct to intensifying treatment   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Indicated in all individuals as an adjunct to intensifying treatment Pharmacotherapy Preferred treatment        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m intensification option if available Initial treatment intensification option if available Metabolic bariatric   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m surgery (MBS) Consider in individuals with comorbidities Table 5.2 A stratified approach to weight management   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m in people with T2DM 79 Chapter 5 In the US Diabetes Prevention Program (DPP), an average weight loss of 6.7%    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m was associated with a 58% reduced incidence of T2DM in people with IGT.10 A subsequent analysis showed that for \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m every kilogram of weight lost there was a 16% reduction in risk for progression to diabetes, but after 10 kg    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m weight loss, there was negligible benefit of further weight loss on diabetes risk reduction.11 These data       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m illustrate that even 1â€“2 kg of weight loss in people at risk for developing T2DM can have health benefits,      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m although it is generally accepted that a weight loss of at least 2.5% or more is required, with maximal impact  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m on T2DM prevention occurring at 10% weight loss.12 Type 2 diabetes remission It has long been recognised that   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m in some people with T2DM, glucose levels can improve into the normal range either spontaneously or after        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m medical or surgical interventions, which can persist, at least temporarily, after glucose-lowering              \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m pharmacotherapy is withdrawn. This occurrence is now referred to as â€œremissionâ€ and is generally defined as an  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m HbA1c <6.5% (48 mmol/mol) without blood glucose medications for a period of three months or more.13 However, it \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m should be noted that publications on diabetes remission have used various definitions and are therefore not     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m always directly comparable. Furthermore, current definitions exclude those achieving remission while taking     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m newer diabetes and weight loss glucagon-like peptide-1 (GLP-1) receptor agonists based therapies.14 Since       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m weight loss is strongly associated with diabetes remission, the introduction of these newer BGL medications     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m with significant weight-lowering potential has raised the question of revisiting the diabetes remission         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m definition to include a provision for continuing these medications, analogous to the situation of metabolic     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m bariatric surgery where remission is defined in the presence of the intervention which induced weight loss.     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Data from the National Diabetes Audit in England reported that 1.7% of 2,297,700 people underwent T2DM          \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m remission without specific intervention. The odds of remission was 2.87-fold greater in people diagnosed with   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m T2DM within one year compared to three to five years, and a BMI reduction of â‰¥10%, as compared to <5%, was      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m associated with 3.57 greater odds of remission.15 A younger age, shorter duration of diabetes, lower baseline   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m weight, and detectable C-peptide levels without insulin treatment are associated with the highest diabetes      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m remission rates.16 Intensive lifestyle intervention (ILI), very low-calorie diet (VLCD), and MBS not only       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m substantially enhance glycaemic control but may also induce T2DM remission. Intensive lifestyle intervention In \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m the Look AHEAD (Action for Health in Diabetes) trial in 5,145 overweight or obese individuals with T2DM,        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m greater weight loss was achieved in the group randomised to ILI compared to diabetes education at one year      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m (-7.9%), which decreased to -3.9% at four years.17 This translated into diabetes remission in 2% in the control \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m group and 11.5% and 7.3% in ILI participants at one and four years, respectively. Very low-calorie diet VLCDs   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m are effective interventions to induce rapid weight loss and improving glycaemia. Two randomised controlled      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m trials (RCTs) of VLCD interventions in the UK (DiRECT-predominantly White European) and Qatar                   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m (DIADEM-1-predominantly Arab) reported significant reductions in body weight of 11.2%, with T2DM remission in   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 45%â€“60% at 12 months18,19 and 35% in the DiRECT study at 24 months.16 A small RCT, the South Asian Diabetes     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Remission Feasibility Trial (STANDby), of 25 South Asians in the UK, reported weight loss of 7.2% and T2DM      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m remission in 38% at four months.20 In a non-randomised, open-label primary care study from Australia            \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m (DiRECT-Aus), VLCD achieved a weight loss of 11.2% and T2DM remission in 55% of 155 participants at one year.21 \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Maintaining these remission rates for a longer period is challenging, as reported by the five-year DiRECT       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m extension study, with 13% overall remaining in remission at five years.22 In relation to weight loss required   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m for T2DM remission, the DiRECT study showed that weight loss of 5â€“10 kg (baseline weight approximately 100 kg)  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m resulted in remission rates of 34% at one year and 29% at two years. With weight losses of 10â€“15 kg, remission  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m rates were 57% and 60% and with weight loss more than 15 kg, remission rates were 86% and 70%, respectively, at \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m one and two years. After five years, remission rate was 19% for individuals maintaining a weight loss of more   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m than 10 kg.16 Metabolic bariatric surgery (MBS) MBS offers superior diabetes remission and blood glucose        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m control compared to non-surgical interventions for people with T2DM.23,24 In the IDF Global Clinical Practice   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Recommendations for Managing Type 2 Diabetes â€“ 2025 80 WEIGHT CONTROL Alliance of Randomized Trials of Medicine \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Versus Metabolic Surgery in Type 2 Diabetes (ARMMS-T2D), people with T2DM aged 20â€“65 years and BMI 27â€“45 kg/m2  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m reported diabetes remission at three years of 37.5% of participants after MBS compared with 2.6% with           \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m medical/lifestyle intervention.25 A recent systematic review included 85,473 people with T2DM, of whom 24,451   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m were in the surgical group, with followâ€up durations between five and 15 years. Data on 972 people from seven   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m studies (three cohort studies and four RCTs) were available for long-term assessment of diabetes remission.     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m There was a significant increase in diabetes remission with MBS compared with conventional medical therapy with \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m remission rates of 32% versus 6% over five to 15 years.26 The wide range of remission rates reported with MBS   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m may be due to the diversity of surgical procedures, limited numbers in the RCTs, different lengths of           \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m follow-up, different definitions of diabetes remission, and difference in reporting of remission â€“ cumulative   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m remission (counted as any individual who ever achieved remission) and/or prevalent remission (counted as only   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m individuals who were in remission at the time of measurement).27 MBS improves control of diabetes through both  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m weight-dependent and weight-independent actions. Some degree of glycaemic improvement is associated with weight \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m loss as reported in a meta-analysis of eight studies involving 1,247 participants who underwent MBS, which      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m demonstrated that percentage excess weight loss was positively associated with remission rate.28 Furthermore,   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 75% of participants who do not achieve diabetes remission had weight regain.29 Improvement in insulin           \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m sensitivity following weight loss with MBS is a likely mechanism and changes in gut microbiome may also be a    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m factor. A striking feature of MBS is the rapid improvement in glycaemic control that precedes weight loss with  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m reports of individuals being insulin-free at the time of discharge. Mechanisms driving these rapid,             \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m weight-independent improvements in glucose homeostasis may be related to alterations in gut hormones.27         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Mortality and diabetes-related complications Accumulating data demonstrate that interventions leading to weight \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m loss in people with T2DM are associated with reduced risk of premature mortality and diabetes-related           \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m microvascular and macrovascular complications. This may be the direct result of improved control of glycaemic   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m and other risk factors (hypertension, lipids), or due to periods of diabetes remission, or a direct effect of   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m pharmacotherapy used to induce weight loss. Intensive lifestyle intervention The primary aim of the LOOK AHEAD  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m study was to examine whether an intensive lifestyle weight loss intervention would decrease cardiovascular      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m morbidity and mortality in 5,145 overweight or obese people with T2DM. Despite greater weight loss in the       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m intervention group than in the control group throughout the study (6.0% versus 3.5% at study end), after a      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m median follow-up of 9.6 years, rates of cardiovascular disease (CVD) events were similar in both groups.30      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Secondary analyses showed a benefit on diabetic nephropathy31 and symptoms of neuropathy.32 Additionally, a     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m recent analysis of study participants who achieved diabetes remission at any stage during the study had a 40%   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m lower rate of CVD and 33% lower rate of chronic kidney disease after adjusting for HbA1c, lipids, blood         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m pressure, and CVD history.33 In a similar post-hoc analysis, weight loss >10% was also associated with a        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m reduction in CVD by 20%.30,34 Metabolic bariatric surgery A systematic review assessed long-term outcomes in    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 84,890 people with T2DM, of whom 24,247 underwent MBS (11 studies â€“ nine retrospective cohort, one prospective  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m cohort, one small RCT [n = 150]) with follow-up durations between five and 15 years. Significant decreases were \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m observed in microvascular complications incidence (hazard ratio [HR]=0.57), macrovascular complications         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m incidence (HR=0.59), and mortality (HR=0.53).26 A recently published network meta-analysis has undertaken an    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m indirect comparison between MBS and blood glucose-lowering therapies and reported an advantage in glycaemic     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m control and weight management for MBS. However, the lack of direct head-to-head comparative trials between MBS  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m and the incretin-based therapies is a critical research gap.35 Anti-obesity pharmacotherapy Pharmacotherapeutic \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m options for the management of obesity were limited in the pre-incretin-based era. The increasing range of novel \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 81 Chapter 5 anti-obesity medications include GLP-1 receptor agonists (such as higher strength liraglutide 3.0  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m mg and semaglutide 2.4 mg), dual GLP-1 and GIP receptor agonists (such as tirzepatide), and triple GLP-1, GIP,  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m and glucagon receptor agonists (such as retatrutide). However, they are expensive and not generally available,  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m especially in resource-limited settings. Incretin-based therapies have demonstrated benefits in the management  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m of people with T2DM, as reviewed in Chapter 3. This section reviews the incretin-based therapies targeting      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m weight management and their use in people with T2DM. Semaglutide Semaglutide has been shown to effectively      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m reduce weight and improve CVD, renal, and heart failure outcomes in overweight and obese people with T2DM. The  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m weight loss efficacy of higher doses of once-weekly subcutaneous GLP-1 receptor agonist, semaglutide 2.4 mg,    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m has been established in the STEP-1 trial in people without diabetes with a BMI â‰¥30 or â‰¥27 kg/m2 with one or     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m more weight-related coexisting condition where placebo-subtracted weight loss of 12.4% was observed over 68     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m weeks.36 The STEP-2 trial assessed once-weekly subcutaneous semaglutide 2.4 mg versus 1.0 mg (approved dose for \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m diabetes management) and placebo in adults with overweight or obesity and T2DM. Semaglutide 2.4 mg achieved a   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m placebo-subtracted weight loss of 6.2% and a placebo-subtracted improvement in HbA1c of 1.4% (15 mmol/mol) over \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 68 weeks while semaglutide 1.0 mg achieved a placebo-subtracted weight loss of 3.8% and a placebo-subtracted    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m improvement in HbA1c of 1.1% (12 mmol/mol) over 68 weeks.37 The PIONEER 6 trial randomised 3,183 individuals    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m with T2DM to once-daily oral semaglutide (14 mg) or placebo for a median of 15.9 months. There was a            \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m significant reduction in body weight (â€“4.2 kg versus â€“0.8 kg) and HbA1c (â€“1.0% versus â€“0.3% [-11 mmol/mol       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m versus -3 mmol/mol]) in the oral semaglutide compared to placebo group. The primary outcome (cardiovascular     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m death, non-fatal myocardial infarction, or non-fatal stroke) was not significantly different in the oral        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m semaglutide group versus the placebo group, demonstrating non-inferiority but not superiority to placebo.38     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Among people with T2DM and obesity-related heart failure with preserved ejection fraction, semaglutide 2.4 mg   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m once-weekly resulted in a 6.4% greater placebo-subtracted weight loss at one year and was associated with       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m significantly larger reductions in heart failure-related symptoms and physical limitations.39 Tirzepatide In    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m SURPASS-2, 1,879 adults with T2DM (HbA1c 8.3% [67 mmol/mol], weight 93.7 kg) were randomised to receive         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m tirzepatide (GLP-1/ GIP dual agonist) 5 mg, 10 mg, 15 mg, or semaglutide 1.0 mg subcutaneously weekly over 40   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m weeks. The change from baseline in HbA1c was -2.01% (-17 mmol/mol), -2.24% (24.5 mmol/ mol), -2.30% (25.1       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m mmol/mol), and -1.86% (20.3 mmol/mol) and body weight loss was -7.6 kg, -9.3 kg, -11.2 kg, and -5.7 kg,         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m respectively. An HbA1c <6.5% (48 mmol/mol) was achieved in 69%, 77%, 80%, and 64% and diabetes remission (HbA1c \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m <5.7% [<39 mmol/mol]) was achieved in 27%, 40%, 46%, and 19%, respectively.40 The SURMOUNT-2, a 72-week phase 3 \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m trial of tirzepatide in adults with obesity and T2DM, demonstrated significant weight reductions with           \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m tirzepatide 10 mg and 15 mg, with mean body weight decreases of 12.8% and 14.7%, respectively, compared to a    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 3.2% reduction in the placebo group. This study confirmed the robust effect of tirzepatide on weight loss in a  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m population with diabetes, with 79%â€“83% of tirzepatide-treated participants achieving a body weight reduction of \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 5% or higher.41 Similar to semaglutide studies, in the SURMONT-4 trial, in participants with obesity/           \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m overweight, withdrawing tirzepatide led to substantial regain of lost weight while those who continued          \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m treatment maintained and augmented the initial weight reduction.42 The SURPASS-CVOT study is currently          \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m examining the cardiovascular safety and efficacy of tirzepatide compared with the GLP-1 receptor agonist        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m dulaglutide in T2D.43 Retatrutide Retatrutide is a novel GLP-1/GIP/glucagon receptor triple agonist which is in \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m the early stages of clinical trials. In a phase 2, double-blind, randomised, placebo-controlled trial, 338      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m adults with a BMI â‰¥30 or â‰¥27 with at least one weight-related complication, excluding diabetes, were randomised \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m to retatrutide 1 mg, IDF Global Clinical Practice Recommendations for Managing Type 2 Diabetes â€“ 2025 82 WEIGHT \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m CONTROL 2 mg, 4 mg, 12 mg, or placebo administered subcutaneously once-weekly for 48 weeks. There was a         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m dose-dependent weight reduction of 8.7%, 16.3%, 21.7% and 24.2% respectively with increasing dose compared with \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 2.1% weight loss in the placebo group. At week 48, 72% of the participants with intermediate hyperglycaemia at  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m baseline had a HbA1c <5.7% (<39 mmol/mol) in the retatrutide groups compared to 22% in the placebo group.44 In  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m a subsequent study, adults with T2DM received once-weekly doses of retatrutide, dulaglutide, or placebo over 24 \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m weeks, with a 36-week follow-up. Retatrutide 12 mg significantly improved HbA1c levels by 2% (17 mmol/mol) and  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m achieved a 16.9% decrease in body weight compared with a 0.01% (~0.1 mmol/ mol) reduction in HbA1c and a 3%     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m reduction in body weight in the placebo group.45 Effects of other blood glucose-lowering therapies on weight    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m With the limited availability and affordability of BGL medications with established weight loss potential in    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m many countries throughout the world, particularly incretin-based therapies, a key strategy for Basic Care is to \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m preferentially use BGL therapies with minimal negative impact on weight. In these settings, nutrition education \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m at diagnosis and throughout the care process is particularly important for mitigating weight gain. The effects  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m of BGL therapies on body weight vary both between and within drug classes. Sodium-glucose cotransporter-2       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m (SGLT2) inhibitors are associated with weight loss and their global availability is improving. Metformin        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m results in a small weight loss; dipeptidyl peptidase 4 (DPP4) inhibitors and Î±-glucosidase inhibitors are       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m considered weight-neutral; and glitazones are associated with weight gain.46 As a class, sulfonylurea           \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m monotherapy is associated with a weight gain of approximately 2.0 kg.46 However, weight change has been         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m reported to be limited in other longer-term studies. In the ADVANCE study, mean body weight with gliclazide     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m during the RCT follow-up period was 0.7 kg greater in the intensive control group than in the standard control  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m group,47 but only 0.1 kg over five years in the post-trial.48 The RECORD trial showed that weight was not       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m increased in those randomised to dual therapy with metformin and a sulfonylurea.49 The TOSCA study showed that  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m dual metformin and sulfonylurea therapy was associated with an initial small weight gain in the first year,     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m returning to baseline weight over five years.50 Globally, sulfonylureas remain an important option, either as   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m monotherapy or more commonly as combination therapy. While concerns remain about the risk of hypoglycaemia and  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m weight gain with some sulfonylureas, newer agents (such as glimepiride and gliclazide) are associated with      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m better safety profiles and continue to be promoted in guidelines, especially in combination with other BGL      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m therapies.51,52 REFERENCES 1. Obesity and type 2 diabetes: a joint approach to halt the rise. A policy brief by \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m the International Diabetes Federation and the World Obesity Federation. Available from:                         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m https://www.idf.org/media/uploads/2022/11/                                                                      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m IDF-WOF-Obesity-and-type-2-diabetes_A-joint-approach-to-halt-the-rise-WEB-2.pdf [Accessed September 2024]. 2.   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m World Obesity Federation. Missing the 2025 Global Targets. Available from: https://www.\\nworldobesity.org       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m [Accessed September 2024]. 3. World Obesity Federation. World Obesity Atlas 2022. Available from:               \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m http://s3-eu-west-1.\\namazonaws.com/wof-files/World_Obesity_ Atlas_2022.pdf [Accessed September 2024]. 4.       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m International Diabetes Federation (IDF). IDF Diabetes Atlas. 11th edition. Brussels, Belgium: International     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Diabetes Federation, 2025. Available from: http://www.diabetesatlas.org. 5. Rubino F, Cummings DE, Eckel RH, et \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m al. Definition and diagnostic criteria of clinical obesity. Lancet Diabetes Endocrinol. 2025;13(3):221-262. 6.  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m World Health Organization (WHO) Expert Consultation. Appropriate body-mass index for Asian populations and its  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m implications for policy and intervention strategies. Lancet. 2004;363(9403):157-163. Erratum in: Lancet.        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 2004;363(9412):902. 7. Ross R, Neeland IJ, Yamashita S, et al. Waist circumference as a vital sign in clinical  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m practice: a Consensus Statement from the IAS and ICCR Working Group on Visceral Obesity. Nat Rev Endocrinol.    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 2020;16(3):177-189. 8. Horn DB, Almandoz JP, Look M. What is clinically relevant weight loss for your patients  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m and how can it be achieved? A narrative review. Postgrad Med. 2022;134(4):359-375. 83 Chapter 5 9. Gummesson A, \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Nyman E, Knutsson M, et al. Effect of weight reduction on glycated haemoglobin in weight loss trials in         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m patients with type 2 diabetes. Diabetes Obes Metab. 2017;19(9):1295-1305. 10. Knowler WC, Barrett-Connor E,     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Engl J Med. 2002;346(6):393-403. 11. Hamman RF, Wing RR, Edelstein SL, et al. Effect of weight loss with        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m lifestyle intervention on risk of diabetes. Diabetes Care. 2006;29(9):2102-2107. 12. Ryan DH, Yockey SR. Weight \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m loss and improvement in comorbidity: Differences at 5%, 10%, 15%, and over. Curr Obes Rep. 2017;6(2):187-194.   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 13. Riddle MC, Cefalu WT, Evans PH, et al. Consensus report: Definition and interpretation of remission in type \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 2 diabetes. Diabetes Care. 2021;44(10):2438-2444. 14. Taheri S. Type 2 diabetes remission: A new mission in     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m diabetes care. Diabetes Care. 2024;47(1):47-49. 15. Holman N, Wild SH, Khunti K, et al. Incidence and           \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m characteristics of remission of type 2 diabetes in England: A cohort study using the National Diabetes Audit.   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Diabetes Care. 2022;45(5):1151-1161. 16. Lean MEJ, Leslie WS, Barnes AC, et al. Durability of a primary         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m care-led weight-management intervention for remission of type 2 diabetes: 2-Year results of the DiRECT          \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m open-label, cluster-randomised trial. Lancet Diabetes Endocrinol. 2019;7(5):344-355. 17. Gregg EW, Chen H,      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Wagenknecht LE, et al. Association of an intensive lifestyle intervention with remission of type 2 diabetes.    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m JAMA. 2012;308(23):2489-2496. 18. Lean ME, Leslie WS, Barnes AC, et al. Primary care-led weight management for  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m remission of type 2 diabetes (DiRECT): An open-label, cluster-randomised trial. Lancet.                         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 2018;391(10120):541-551. 19. Taheri S, Zaghloul H, Chagoury O, et al. Effect of intensive lifestyle             \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m intervention on bodyweight and glycaemia in early type 2 diabetes (DIADEM-I): An open-label, parallel-group,    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m randomised controlled trial. Lancet Diabetes Endocrinol. 2020;8(6):477-489. 20. Sattar N, Welsh P, Leslie WS,   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m et al. Dietary weight-management for type 2 diabetes remissions in South Asians: The South Asian diabetes       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m remission randomised trial for proof-of-concept and feasibility (STANDby). Lancet Reg Health Southeast Asia.    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 2023;9:100111. 21. Hocking SL, Markovic TP, Lee CMY, et al. Intensive lifestyle intervention for remission of   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m early type 2 diabetes in primary care in Australia: DiRECT-Aus. Diabetes Care. 2024;47(1):66-70. 22. Lean ME,   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Leslie WS, Barnes AC, et al. 5-year follow-up of the randomised Diabetes Remission Clinical Trial (DiRECT) of   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m continued support for weight loss maintenance in the UK: an extension study. Lancet Diabetes Endocrinol.        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 2024;12(4):233-246. 23. Mingrone G, Panunzi S, De Gaetano A, et al. Bariatric surgery versus conventional       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m medical therapy for type 2 diabetes. N Engl J Med. 2012;366(17):1577-1585. 24. Schauer PR, Kashyap SR, Wolski   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m K, et al. Bariatric surgery versus intensive medical therapy in obese patients with diabetes. N Engl J Med.     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 2012;366(17):1567-1576. 25. Kirwan JP, Courcoulas AP, Cummings DE, et al. Diabetes remission in the Alliance of \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Randomized Trials of Medicine versus Metabolic Surgery in Type 2 Diabetes (ARMMS-T2D). Diabetes Care.           \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 2022;45(7):1574-1583. 26. Yang Y, Miao C, Wang Y, et al. The long-term effect of bariatric/metabolic surgery    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m versus pharmacologic therapy in type 2 diabetes mellitus patients: A systematic review and meta-analysis.       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Diabetes Metab Res Rev. 2024;40(5):e3830. 27. Affinati AH, Esfandiari NH, Oral EA, et al. Bariatric surgery in  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m the treatment of type 2 diabetes. Curr Diab Rep. 2019;19(12):156. 28. Yan YX, Wang GF, Xu N, et al. Correlation \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m between postoperative weight loss and diabetes mellitus remission: A meta-analysis. Obes Surg.                  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 2014;24(11):1862-1869. 29. Mingrone G, Panunzi S, De Gaetano A, et al. Bariatric-metabolic surgery versus       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m conventional medical treatment in obese patients with type 2 diabetes: 5 Year follow-up of an open-label,       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m single-centre, randomised controlled trial. Lancet. 2015;386(9997):964-973. 30. Wing RR, Bolin P, Brancati FL,  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m et al. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med.             \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 2013;369(2):145-154. 31. Knowler WC, Bahnson JL, Bantle JP, et al. Effect of a long-term behavioural weight     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m loss intervention on nephropathy in overweight or obese adults with type 2 diabetes: A secondary analysis of    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m the Look AHEAD IDF Global Clinical Practice Recommendations for Managing Type 2 Diabetes â€“ 2025 84 WEIGHT       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m CONTROL randomised clinical trial. Lancet Diabetes Endocrinol. 2014;2(10):801-809. 32. Look AHEAD Research      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Group. Effects of a long-term lifestyle modification programme on peripheral neuropathy in overweight or obese  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m adults with type 2 diabetes: The Look AHEAD study. Diabetologia. 2017;60(6):980-988. 33. Gregg EW, Chen H,      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Bancks MP , et al. Impact of remission from type 2 diabetes on long-term health outcomes: Findings from the     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Look AHEAD study. Diabetologia. 2024;67(3):459-469. 34. Gregg EW, Jakicic JM, Blackburn G, et al. Association   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m of the magnitude of weight loss and changes in physical fitness with long-term cardiovascular disease outcomes  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m in overweight or obese people with type 2 diabetes: A post-hoc analysis of the Look AHEAD randomised clinical   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m trial. Lancet Diabetes Endocrinol. 2016;4(11):913-921. 35. Wu T, Wong CKH, Lui DTW, et al. Bariatric surgery,   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m novel glucose-lowering agents, and insulin for type 2 diabetes and obesity: Bayesian network meta-analysis of   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m randomized controlled trials. BJS Open. 2023;7(4):zrad077. 36. Wilding JPH, Batterham RL, Calanna S, et al.     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989-1002. 37. Davies   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m M, FÃ¦rch L, Jeppesen OK, et al. Semaglutide 2Â·4 mg once a week in adults with overweight or obesity, and type 2 \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m diabetes (STEP 2): A randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet.         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 2021;397(10278):971-984. 38. Husain M, Birkenfeld AL, Donsmark M, et al. Oral semaglutide and cardiovascular    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m outcomes in patients with type 2 diabetes. N Engl J Med. 2019;381(9):841-851. 39. Kosiborod MN, Petrie MC,      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Borlaug BA, et al. Semaglutide in patients with obesity-related heart failure and type 2 diabetes. N Engl J     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Med. 2024;390(15):1394-1407. 40. FrÃ­as JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus semaglutide once  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m weekly in patients with type 2 diabetes. N Engl J Med. 2021;385(6):503-515. 41. Garvey WT, Frias JP, Jastreboff \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m AM, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): A  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2023;402(10402):613-626. 42.  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Aronne LJ, Sattar N, Horn DB, et al. Continued treatment With tirzepatide for maintenance of weight reduction   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m in adults with obesity: The SURMOUNT-4 randomized clinical trial. JAMA. 2024;331(1):38-48. 43. Nicholls SJ,     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Bhatt DL, Buse JB, et al. Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS-CVOT design and baseline  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m characteristics. Am Heart J. 2024;267:1-11. 44. Jastreboff AM, Kaplan LM, FrÃ­as JP, et al.                      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Triple-hormone-receptor agonist retatrutide for obesity - a phase 2 trial. N Engl J Med. 2023;389(6):514-526.   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 45. Rosenstock J, Frias J, Jastreboff AM, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m people with type 2 diabetes: A randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m trial conducted in the USA. Lancet. 2023;402(10401):529-544. 46. Apovian CM, Okemah J, Oâ€™Neil PM. Body weight   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m considerations in the management of type 2 diabetes. Adv Ther. 2019;36(1):44-58. 47. Patel A, MacMahon S,       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Chalmers J, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Engl J Med. 2008;358(24):2560-2572. 48. Zoungas S, Chalmers J, Kengne AP, et al. The efficacy of lowering       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m glycated haemoglobin with a gliclazide modified release-based intensive glucose lowering regimen in the ADVANCE \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m trial. Diabetes Res Clin Pract. 2010;89(2):126-133. 49. Home PD, Pocock SJ, Beck-Nielsen H, et al.              \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m (RECORD): a multicentre, randomised, open-label trial. Lancet. 2009;373(9681):2125-2135. 50. Vaccaro O, Masulli \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m M, Nicolucci A, et al. Effects on the incidence of cardiovascular events of the addition of pioglitazone versus \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): A randomised, \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m multicentre trial. Lancet Diabetes Endocrinol. 2017;5(11):887-897. 51. Kalra S, Bahendeka S, Sahay R, et al.    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Consensus recommendations on sulfonylurea and sulfonylurea combinations in the management of type 2 diabetes    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m mellitus - International Task Force. Indian J Endocrinol 85 Chapter 5 Metab. 2018;22(1):132-157. 52. Al-Saleh   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Y, Sabico S, Al-Furqani A, et al. Sulfonylureas in the current practice of type 2 diabetes management: Are they \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m all the same? Consensus from the Gulf Cooperation Council (GCC) countries advisory board on sulfonylureas.      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Diabetes Ther. 2021;12(8):2115-2132. Erratum in: Diabetes Ther. 2021;12(8):2265-2266. 86 Cardio-Renal           \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Protection in Type 2 Diabetes Chapter 6 CARDIO-RENAL PROTECTION 87 Chapter 6 RECOMMENDATIONS Optimal Care Basic \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Care Atherosclerotic Cardiovascular Disease (ASCVD) Screening/risk assessment â€¢\\tHistory of ASCVD â€¢\\tHigh-risk  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m assessment - Age plus 2 risk factors - CVD risk score Management â€¢\\tGlycaemic control â€¢\\tRisk factor control    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m â€¢\\tBlood pressure/lipid control â€¢\\tConsider aspirin â€¢\\tSGLT2i or GLP-1RA â€¢\\tConsider SGLT2i and GLP-1RA         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m â€¢\\tGlycaemic control â€¢\\tRisk factor control â€¢\\tBlood pressure/lipid control â€¢\\tConsider aspirin â€¢\\tSGLT2i*      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Heart Failure (HF) Screening/risk assessment â€¢\\tSymptoms â€¢\\tHospitalisation for HF â€¢\\tECG â€¢\\tEchocardiography   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m â€¢\\tRisk score â€¢\\tBiomarkers - BNP / NT-proBNP â€¢\\tSymptoms â€¢\\tHospitalisation for HF â€¢\\tECG â€¢\\tRisk score        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Management â€¢\\tGlycaemic control â€¢\\tRisk factor control â€¢\\tBlood pressure/lipid control â€¢\\tACEi or ARB           \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m â€¢\\tBeta-blockers â€¢\\tMetformin+SGLT2i â€¢\\tConsider adding a non-steroidal MRA â€¢\\tConsider adding                  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m GLP-1RA/tirzepatide in obese individuals â€¢\\tGlycaemic control â€¢\\tRisk factor control â€¢\\tBlood pressure/lipid    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m control â€¢\\tACEi or ARB â€¢\\tBeta-blockers â€¢\\tMetformin+SGLT2i* â€¢\\tConsider adding a steroidal MRA Chronic Kidney  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Disease (CKD) Screening/risk assessment â€¢\\teGFR â€¢\\tUACR Management â€¢\\tGlycaemic control â€¢\\tRisk factor control  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m â€¢\\tBlood pressure/lipid control â€¢\\tACEi or ARB â€¢\\tSGLT2i â€¢\\tConsider adding semaglutide â€¢\\tGlycaemic control    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m â€¢\\tRisk factor control â€¢\\tBlood pressure/lipid control â€¢\\tACEi or ARB â€¢\\tSGLT2i* * SGLT2 inhibitors are         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m increasingly available in several low- and middle-income countries at generally affordable cost.\\nACEi,         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; BNP/NT-proBNP, b-type            \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m natriuretic peptide/N- terminal pro-b-type natriuretic peptide; CVD, cardiovascular disease; ECG,               \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m electrocardiogram; eGFR, estimated glomerular filtration rate; GLP-1RA, glucagon-like peptide-1 receptor        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m agonist; HF, heart failure; MRA, mineralocorticoid receptor antagonist; SGLT2i, sodium-glucose cotransporter-2  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m inhibitor; UACR, urine albumin-to-creatinine ratio.\\nIDF Global Clinical Practice Recommendations for Managing  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Type 2 Diabetes â€“ 2025 88 CARDIO-RENAL PROTECTION o Diabetes complications result from a complex interplay of   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m hyperglycaemia, cardiometabolic risk factors (e.g., elevated blood pressure and lipids), obesity, and unhealthy \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m lifestyle behaviours. o Cardio-renal complications, including atherosclerotic cardiovascular disease (ASCVD),   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m heart failure (HF), and chronic kidney disease (CKD), are major drivers of premature mortality and morbidity in \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m type 2 diabetes mellitus (T2DM). o Cardiovascular disease (CVD) is highly prevalent in T2DM, around 30%         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m overall, with significant rates of coronary artery disease, silent myocardial infarctions, and HF; CKD affects  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m around 40% of individuals, with marked ethnic differences. o Early and regular screening for CVD (using risk    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m scores, symptom assessment, electrocardiogram, echocardiography, and biomarkers) and CKD (estimated glomerular  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m filtration rate [eGFR] and urine albumin-to-creatinine ratio) is critical for timely intervention. o A          \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m multi-pillar management approach is essential, focusing on glycaemic control, risk factor modification (blood   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m pressure and lipid management, smoking cessation, weight control), and use of proven cardio-renal protective    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m therapies. o Newer blood glucose lowering agents, especially SGLT2 inhibitors and GLP-1 receptor agonists, have \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m demonstrated robust benefits in reducing adverse cardio-renal outcomes. o SGLT2 inhibitors consistently reduce  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m risks of kidney disease progression, HF hospitalisations, and cardiovascular death across diverse groups with   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m T2DM. o GLP-1 receptor agonists reduce major adverse cardiovascular events, all-cause mortality, and composite  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m kidney outcomes. o Other glucose lowering therapies (metformin, sulfonylureas, DPP4 inhibitors, insulin)        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m generally have neutral cardio-renal effects while thiazolidinediones increase HF risk. o Non-steroidal          \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m mineralocorticoid receptor antagonists (e.g., finerenone) further expand options for reducing cardio-renal risk \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m in T2DM. o Global challenges, especially in low resource settings, limit availability and access to             \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m comprehensive screening and optimal medications to reduce cardio-renal risk. o A structured, multi-pillar       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m treatment approach that integrates both traditional and novel therapies is recommended to improve cardio-renal  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m outcomes in people with T2DM. KEY POINTS 89 Chapter 6 BACKGROUND Diabetes complications are the result of a     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m complex interplay of hyperglycaemia, cardiometabolic risk factors such as elevated blood pressure and lipids,   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m obesity, and an unhealthy lifestyle (diet, physical inactivity, smoking). In addition, some complications       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m increase the risk of other complications, with chronic kidney disease (CKD) associated with an increased risk   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m of all-cause and cardiovascular (CVD) mortality, CVD events, and hospitalisation with heart failure (HF).1 This \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Chapter focuses on cardio-renal protection, a major driver of premature mortality and significant morbidity in  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m people with type 2 diabetes mellitus (T2DM) (Figure 6.1). Minimising cardio-renal complications requires        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m effective and regular screening to detect CVD and CKD, and early comprehensive intervention, including          \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m consideration of newer blood glucose-lowering (BGL) medications with established cardio-renal protection        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m (sodium-glucose cotransporter-2 [SGLT2] inhibitors and glucagon-like peptide-1 [GLP-1] receptor agonists)1 in   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m the context of the key pillars in diabetes management (Figure 6.2). GLOBAL CONSIDERATIONS In low resource       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m settings, particularly in low- and middle-income countries, access, availability, and affordability of          \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m comprehensive Optimal Care for screening and management of cardio-renal risk is often limited. This includes    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m healthcare services, qualified healthcare professionals, diagnostic tests, and availability and affordability   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m of medications. For example, in 125 surveyed countries, fewer than one in four had facilities available for     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m routine measurements of serum creatinine or proteinuria and there was considerable interregional and            \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m intraregional variability.2 A broad range of medications is available on the World Health Organization (WHO)    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Essential Medicines List (EML) for managing cardio-renal risk, including angiotensin-converting enzyme (ACE)    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m inhibitors, angiotensin receptor blockers (ARBs), beta-blockers, diuretics, and spironolactone.3 While this     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m does not guarantee local availability, the WHO EML serves as a platform for lobbying local policy makers to     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m have these medications on the countryâ€™s national EML. As described in Chapter 3 on non-insulin glucose-lowering \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m medications, while access to these medications is limited globally, MASLD, Metabolic dysfunction-associated     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m steatotic liver disease; MASH, Metabolic dysfunction-associated steatohepatitis; PVD, peripheral vascular       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m disease.\\nFigure 6.1 Diabetes-associated complications IDF Global Clinical Practice Recommendations for         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Managing Type 2 Diabetes â€“ 2025 90 CARDIO-RENAL PROTECTION the range is increasing in many countries, including \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m generic and affordable SGLT2 inhibitors. However, if Optimal Care cannot be achieved, implementing programmes   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m to achieve Basic Care standards have the potential to significantly reduce cardio-renal risk and improve        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m outcomes for people with T2DM. EVIDENCE SUMMARY Prevalence of CVD and CKD in people with T2DM T2DM increases    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m the risk of developing atherosclerotic cardiovascular disease (ASCVD), HF, CKD, and risk of premature death     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m compared with those without T2DM.4 A recent systematic review of over four million individuals with T2DM        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m reported an overall CVD prevalence of 32.2%; 29.1% with coronary artery disease (CAD), 14.9% HF, 14.6% angina,  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 10.0% myocardial infarction (MI), and 7.6% stroke.5 CVD was the cause of death in 9.9%, representing 50.3% of   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m all deaths.5 In a real-world study in primary care of 123,261 individuals (9,616 with T2DM), 43.7% presented    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m with ASCVD and/or CKD and/or HF: 34.8% ASCVD, 4.0% HF, and 14.6% CKD.6 Asymptomatic CVD is common in T2DM with  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m approximately one in three individuals experiencing undetected ischaemic episodes.7 The UKPDS study reported a  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m prevalence of around 20% of â€œsilentâ€ MI in people with T2DM.8 Heart failure is an important but                 \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m under-recognised risk factor for adverse outcomes in people with T2DM and has often been overlooked compared    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m with prevention of ASCVD. HF represents a substantial global burden with significant unmet needs in terms of    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m morbidity and mortality. A meta-analysis of 43 studies established diabetes as a significant adverse factor     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m linked to long-term survival and hospitalisation risk in both acute and chronic HF.9 In a 2016 cross-sectional  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m study, 26.4% of US nursing home residents aged 65 or older with T2DM had HF.10 HF is not only common in T2DM    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m but is preventable and treatable. CKD affects approximately 40% of individuals with T2DM overall but prevalence \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m varies with age, ethnic background, duration of diabetes, and presence of cardiometabolic risk factors.11 CKD   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m in individuals with T2DM has remained consistently high at approximately 40% from 2007 to 2012.12 There are     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m significant ethnic disparities with higher rates among Black and Mexican-American populations. Alarmingly, one  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m in four persons under age 65 with T2DM has CKD, underscoring the need to improve early detection and            \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m management.12 The intricate relationship between T2DM, CVD, and CKD is highlighted in a cross-sectional         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m multicentre study of individuals with T2DM from the United Arab Emirates and Kuwait, in whom CKD prevalence was \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 44.3%, followed by CVD (17.3%) and CAD (15%), with a discernible male predilection. Co-prevalence of CVD and    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m CKD was common (11.7%), and a longer duration of T2DM correlated with heightened risks of CVD, CAD, and         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m peripheral artery disease.13 Individuals with T2DM without known cardio-renal disease have an 80% lifetime risk \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m of developing CVD or renal events: a 54% risk of CKD; 41% risk of CVD death; 29% risk of HF; 20% risk of        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m stroke; 19% risk of MI; and 9% risk of peripheral vascular disease (PVD). Achieving ideal CVD health could      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m potentially reduce risks by 37% if evidence-based interventions for reducing CVD associated with T2DM were more \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m widely used.14 Figure 6.2 Key pillars of diabetes management 91 Chapter 6 Screening for CVD and CKD in people   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m with T2DM The availability of effective therapeutic options to prevent and reduce adverse cardio-renal outcomes \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m underscores the importance of screening and early detection for both CVD and CKD in people with T2DM. The       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m following is an overview of approaches for assessing cardio-renal risk. While access will vary across countries \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m and health systems, it is important for each health service to develop local criteria for assessing and         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m defining cardio-renal risk and to implement management strategies. CVD screening and risk assessment (i) ASCVD  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m â€“ established event and/or high-risk a. Established ASCVD traditionally includes those who have had an MI,      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m stroke, or a revascularisation procedure. Some definitions also include a transient ischaemic attack, angina,   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m amputation, PVD. b. High CVD risk can be assessed using a formal CVD risk score or by clinical characteristics  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m (e.g., age plus 2 additional risk factors such as smoking, elevated blood pressure, dyslipidaemia).15 Screening \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m should include routine questions for symptoms of ASCVD. Risk assessment in people with T2DM should be           \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m considered from age 40 years. (ii) Heart failure a. Symptoms of HF, hospitalisation for HF b. Electrocardiogram \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m (ECG / EKG) c. Echocardiography with measurement of ejection fraction d. Biomarkers â€“ natriuretic peptides      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m (b-type natriuretic peptide [BNP] and N-terminal pro-b-type natriuretic peptide [NT-proBNP]). BNP or NT-proBNP  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m are biomarkers which are surrogates for intracardiac volumes and filling pressures. Screening protocols using   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m these biomarkers and cut-off values are not universally agreed, require further validation, and are currently   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m not widely available in routine clinical practice.16-20 Screening should include routine questions for symptoms \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m of HF. There is no consensus on routine screening for HF but some suggest formal assessment for HF should       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m commence at least from five years post-T2DM diagnosis.21 CKD screening and risk assessment Renal function       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m should be assessed by measuring the following: 1. Estimated glomerular filtration rate (eGFR) 2. Urine          \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m albumin-to-creatinine ratio (UACR) The primary biomarkers for CKD are eGFR and UACR.22 Normal albuminuria is    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m defined as less than 30 mg/g of creatinine (3 mg/mmol), 30â€“300 mg/g (3â€“30 mg/mmol) as moderately increased      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m albuminuria, and greater than 300 mg/g (30 mg/mmol) as severely increased albuminuria. An eGFR <60 mL/min/1.73  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m m2 signifies impaired renal function. Figure 6.3, shown on the next page, illustrates the Kidney Disease â€“      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Improving Global Outcomes (KDIGO) classification of CKD based on eGFR and UACR and the associated level of      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m risk. Higher categories of CKD, characterised by lower GFR and greater albuminuria, independently increase risk \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m for adverse outcomes which include CKD progression, CVD, all-cause and CVD mortality, HF, kidney failure, and   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m acute kidney injury.23 Annual screening is recommended for CKD starting at diagnosis of T2DM because evidence   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m of CKD is often present already at diagnosis. Management of CVD and CKD in people with T2DM The key pillars for \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m reducing cardio-renal risk follow the same principles for diabetes complications in general (Figure 6.2),       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m adapted according to local availability and affordability of specific therapies in developing and implementing  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m a personalised treatment plan. Pillars of management to improve cardio-renal outcomes in people with T2DM 1.    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Glycaemic control The importance of early and intensive glycaemic control is considered in Chapter 3 on         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m non-insulin glucose-lowering medications; meta-analyses of randomised controlled trials (RCTs) have confirmed   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m that intensive glucose control reduces the risk of CVD, retinopathy, and nephropathy.24,25 2. Risk factor       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m control This is an essential and routine pillar of diabetes care and cardio-renal risk protection irrespective  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m of other interventions and is of IDF Global Clinical Practice Recommendations for Managing Type 2 Diabetes â€“    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 2025 92 CARDIO-RENAL PROTECTION added relevance when access and availability to newer therapies are limited.    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Modifiable risk factors include blood pressure control, lipid control, smoking cessation, and management of     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m obesity or overweight. A comprehensive review of the complete spectrum of risk factor control is outside the    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m scope of these clinical recommendations but can be found elsewhere.15,23,26 The following is a summary of key   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m points relevant to blood pressure and lipid control. (i) Blood pressure control26 â€¢ Hypertension is common      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m among people with T2DM, is a major risk factor for ASCVD, HF, and CKD, and its treatment reduces cardio-renal   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m complications. â€¢ An elevated blood pressure is defined as a systolic blood pressure (SBP) 120â€“129 mmHg and a    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m diastolic blood pressure (DBP) <80 mmHg and hypertension as a SBP â‰¥130 mmHg or a DBP â‰¥80 mmHg. â€¢ Blood pressure \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m should be measured at every routine clinical visit. â€¢ The treatment goal is a blood pressure <130/80 mmHg, if   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m it can be safely attained. â€¢ ACE inhibitors or ARBs are recommended first-line therapy for hypertension in      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m people with T2DM with or at risk of cardio-renal complications. â€¢ Multiple-drug therapy is often required to    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m achieve blood pressure targets. â€¢ Combinations of ACE inhibitors and ARBs and combinations of ACE inhibitors or \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m ARBs with direct renin inhibitors should not be used. â€¢ An ACE inhibitor or ARB is recommended first-line       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m treatment for hypertension in people with diabetes and elevated UACR. The benefits of tighter blood pressure    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m control were confirmed in a recent study in people with T2DM which reported a significantly lower incidence of  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m major CVD events (composite of non-fatal stroke, non-fatal MI, treatment or hospitalisation for HF, or death    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m from CVD) with intensive treatment targeting a SBP of <120 mmHg compared with standard treatment targeting a    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m SBP of <140 mmHg.27 (ii) Lipids26 â€¢ Lipid should be measured at T2DM diagnosis and annually. â€¢ Target           \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m low-density lipoprotein (LDL) cholesterol goals are <1.8 mmol/L (70 mg/dL) for primary prevention and           \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m <1.4mmol/L (55 mg/dL) for secondary prevention. â€¢ Statins are first-choice pharmacotherapy Figure 6.3 KDIGO     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m nomenclature for chronic kidney disease23 CKD, chronic kidney disease; GFR, glomerular filtration rate; KDIGO,  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Kidney Disease â€“ Improving Global Outcomes.\\n93 Chapter 6 for primary and secondary prevention with other       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m therapies considered if LDL cholesterol goal is not met on statins or if intolerant to statins. â€¢ KDIGO         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m recommends statins in adults with T2DM aged 18â€“49 years with CKD if not treated with chronic dialysis or kidney \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m transplantation.23 â€¢ Hypertriglyceridemia should be addressed as required. 3. Other standard therapies (i) ACE  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m inhibitors or ARBs KDIGO recommends starting an ACE inhibitor or ARB for people with CKD and T2DM and           \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m moderately-to-severely increased albuminuria (G1â€“G4, A2 and A3 â€“ Figure 6.3) but avoiding any combination of    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m ACE inhibitors, ARB, and direct renin inhibitor therapy.23 (ii) Beta-blockers Beta-blockers are effective in    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m reducing all-cause death and hospitalisation for HF in people with HF with reduced ejection fraction (HFrEF)    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m with diabetes.15 4. Blood glucose-lowering therapies (i) SGLT2 inhibitors and GLP-1 receptor agonists There is  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m now compelling evidence of specific cardio-renal protection with SGLT2 inhibitors and GLP-1 receptor agonists.  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Consequently, these agents should be considered as mainstream therapies for people with T2DM with or at         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m increased cardio-renal risk and their use has become a key pillar of managing cardio-renal risk.28 SGLT2        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m inhibitors SGLT2 inhibitors have clearly demonstrated benefits across the spectrum of cardio-renal outcomes.    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m The weight of current evidence favours these agents in people with T2DM at high risk or with established HF or  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m CKD. In a meta-analysis of six studies of 46,969 individuals with T2DM, including 66% with ASCVD, SGLT2         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m inhibitors were associated with a 10% reduced risk of major adverse CVD events, 32% reduced risk of             \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m hospitalisation for HF, and 38% reduction in adverse kidney outcomes. The largest benefit across the SGLT2      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m inhibitor class was risk reduction for hospitalisation for HF and adverse kidney outcomes.29 A meta-analysis of \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 13 studies with 90,409 participants (82.7% with T2DM) compared SGLT2 inhibitors with placebo. SGLT2 inhibitors  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m reduced the risk of kidney disease progression by 37% and reduced the risk of CVD death or hospitalisation for  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m HF by 23%. The risk reduction was similar in individuals with and without diabetes and irrespective of mean     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m baseline eGFR.30 A meta-analysis of 48 studies involving 58,165 people with T2DM demonstrated that SGLT2        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m inhibitors were associated with significant reductions in UACR and reduced the risk of microalbuminuria by 31%  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m and macroalbuminuria by 51% compared with placebo or active comparators.31 The EMPA KIDNEY study showed that    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m empagliflozin slowed the progression of impaired glomerular filtration in people with or without T2DM, and with \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m or without albuminuria.32 A meta-analysis of four heart failure studies (n = 15,684 participants, 42%â€“100% with \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m T2DM), four trials in people with T2DM at high ASCVD (n = 42,568), and three trials in CKD (n = 19,289          \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m participants, 68%â€“100% T2DM) reported significantly better outcomes with SGLT2 inhibitors compared with         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m placebo: 23% reduced risk of hospitalisation for HF or CVD death, 14% reduced CVD death, 36% less kidney        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m disease progression, and a 12% reduction in all-cause mortality.33 In five trials of 21,947 people with HF,     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m SGLT2 inhibitors reduced the risk of composite CVD death or hospitalisation for HF by 23%, CVD death by 13%,    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m first hospitalisation for HF by 28%, and all-cause mortality by 8%. These outcomes for each endpoint were       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m consistently observed in HF with mildly reduced or preserved ejection fraction and results were similar in      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m those with and without diabetes.34 GLP-1 receptor agonists A recent meta-analysis of 11 trials involving 67,769 \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m people with T2DM examined the cardio-renal effects of GLP-1 receptor agonists versus placebo. Composite renal   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m outcome was reduced by 18%, kidney failure by 16%, major adverse cardiovascular events (MACE) by 13%, and       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m all-cause mortality by 12%. Overall hospitalisation for HF was reduced by 13% but no baseline information was   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m available on HF status or ejection fraction. Risk of serious adverse events was similar but treatment           \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m discontinuation due to adverse events was 51% higher with GLP-1 receptor agonists.35 A meta-analysis of 13      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m cardiovascular outcome trials (CVOTs; 83,258 people with and without diabetes) examined the effects of GLP-1    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m IDF Global Clinical Practice Recommendations for Managing Type 2 Diabetes â€“ 2025 94 CARDIO-RENAL PROTECTION     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m receptor agonists versus placebo. GLP-1 receptor agonists significantly reduced MACE by 14%, all-cause          \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m mortality by 13%, CV mortality by 13%, fatal stroke by 26%, non-fatal stroke by 13%, coronary revascularisation \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m by 14%, and composite kidney outcome by 24%. These effects were independent of sex, CVD history, body mass      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m index (BMI), and eGFR. GLP-1 receptor agonists did not significantly reduce fatal or non-fatal MI,              \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m hospitalisation for unstable angina, or HF hospitalisation.36 Until recently, the renal effects of GLP-1        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m receptor agonists have been derived from secondary and post-hoc kidney outcomes analysis in clinical trials of  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m GLP-1 receptor agonists for CVD and glycaemic control studies. The FLOW study is the first dedicated study      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m comparing a GLP-1 receptor agonist (semaglutide 1.0 mg once weekly) and placebo in people with T2DM and CKD.    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m The study was ceased early after a prespecified interim analysis demonstrated a 24% reduction in the composite  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m primary outcome with semaglutide. Benefits were observed in the composite of the kidney-specific components of  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m the primary outcome (21% reduction) and CVD death (29% reduction). The results of all confirmatory secondary    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m outcomes also favoured semaglutide.37 To date, no clinical trial has specifically evaluated the efficacy of     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m GLP-1 receptor agonists on CVD outcomes in people with T2DM and heart failure. The STEP-HFpEF DM Trial          \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m randomised people with T2DM and HF with preserved ejection fraction and a BMI â‰¥30 to receive once-weekly        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m semaglutide (2.4 mg) or placebo for 52 weeks. The primary HF endpoint was change from baseline in the Kansas    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m City Cardiomyopathy Questionnaire clinical summary score. Semaglutide resulted in larger reductions in heart    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m failure-related symptoms and physical limitations.38 The cardiovascular outcome SUSTAIN-6 study noted an        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m increase in retinopathy.39 A dedicated RCT of semaglutide versus placebo (FOCUS-NCT03811561) to assess the      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m impact on retinopathy in people with T2DM is due to report in 2026.40 Combination SGLT2 inhibitors and GLP-1    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m receptor agonists No clinical trial has studied combinations of SGLT2 inhibitors and GLP-1 receptor agonists on \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m cardio-renal outcomes in people with T2DM and CKD. However, some indirect data are available. A meta-analysis   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m of 13 real-world observational studies examined combinations of SGLT2 inhibitors and GLP-1 receptor agonists in \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m people with T2DM. The combination was associated with a 51% significantly lower all-cause mortality compared    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m with individual therapies and significant reductions in weight, SBP, and HbA1c. However, the study had a number \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m of limitations, with the authors concluding that the certainty of evidence was deemed to be low-to-very low by  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m the GRADE criteria.41 In a prespecified analysis, the FLOW trial examined the overall benefits of semaglutide   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m on kidney and CVD outcomes in people with T2DM and CKD in relation to baseline users (n = 550) and non-users (n \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m = 2,983) of SGLT2 inhibitors and reported that outcomes were not influenced by the concomitant use of SGLT2     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m inhibitors. However, the power of the analysis was limited by the low use of SGLT2 inhibitors at trial entry    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m and that more participants initiated SGLT2 inhibitors in the placebo group during the trial.42 (ii) Tirzepatide \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Tirzepatide is a long-acting agonist of glucose-dependent insulinotropic polypeptide and glucagon-like          \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m peptide-1 receptors, which results in considerable weight loss. To date, clinical trial data are lacking with   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m respect to its effects on cardio-renal outcomes. The SURPASS-CVOT study is currently examining the              \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m cardiovascular safety and efficacy of tirzepatide compared with the GLP-1 receptor agonist dulaglutide in with  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m T2DM43 The SUMMIT trial randomised people with HF and preserved ejection fraction (48% with T2DM) and BMI â‰¥ 30  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m to receive tirzepatide (up to 15 mg subcutaneously once per week) or placebo. After a median follow-up 104      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m weeks, CVD death or a worsening HF event was reduced by 38% (worsening HF events by 46%) and health status was  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m improved in the tirzepatide group compared with placebo group.44 (iii) Effects of other blood glucose-lowering  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m therapies on cardio-renal outcomes The following is a brief summary of the cardio-renal effects of other BGL    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m therapies. Overall cardio-renal effects have been neutral (except for increased risk of HF with                 \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m thiazolidinediones), suggesting that these agents can be used when required to improve glycaemic control.       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Metformin The cardio-renal effects of metformin have not been studied in a dedicated CVOT. While the UKPDS      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m showed beneficial effects of metformin on long-term diabetes outcomes, the primary focus of the RCT component   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m of the UKPDS was 95 Chapter 6 on comparing intensive with less intensive diabetes control. The UKPDS included a \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m nested RCT of 753 overweight or obese people with T2DM, comparing conventional glucose targets with a policy of \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m intensive glucose lowering with metformin.45 Metformin reduced MI by 39%, coronary death by 50%, and stroke by  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 41% over a median period of 10.7 years. Post-trial follow-up after 24 years showed that early intensive         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m glycaemic control with metformin therapy compared with conventional glycaemic control resulted in 20% risk      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m reduction in all-cause mortality and a 31% reduction in MI.46 Sulfonylureas CVD outcomes with sulfonylureas has \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m been studied in two RCTs. The ADVANCE study examined gliclazide in the context of intensified glycaemic control \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m and did not show any CVD benefits or harms.47 Similarly, the post-trial follow-up ADVANCE-ON study observed no  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m differences in risk of death from any cause or major macrovascular events.48 The dedicated CAROLINA CVOT        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m compared CVD outcomes in people with T2DM randomised to the DPP4 inhibitor, linagliptin, and the sulfonylurea,  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m glimepiride, in addition to usual care. The primary outcome of time to first occurrence of CVD death, non-fatal \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m MI, or non-fatal stroke over a follow-up period of 6.3 years was not different between the two groups but       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m hypoglycaemia was more common in the sulfonylurea group.49 In the UKPDS in individuals with newly diagnosed     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m T2DM, the sulfonylureas chlorpropamide and glibenclamide/glyburide had no statistically significant effects on  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m CV outcomes and equally did not suggest adverse CVD effects of sulfonylureas.50 Alpha glucosidase inhibitors    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m There is no dedicated CVOT with an alpha glucosidase inhibitor (AGI) in people with T2DM. The ACE study         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m examined the effect of the AGI acarbose on CVD outcomes in people with CAD and impaired glucose tolerance and   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m failed to show a difference in outcomes between acarbose and placebo.51 Thiazolidinediones The RECORD study     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m assessed CV outcomes in people with T2DM after addition of rosiglitazone to either metformin or sulfonylurea    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m compared with the combination of the two. Rosiglitazone did not increase the risk of overall CVD morbidity or   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m mortality although there was a possible increase in MI compared with standard glucose-lowering therapies.52 The \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m PROACTIVE CVOT assessed the CVD effects of pioglitazone versus placebo in individuals with T2DM and ASCVD and   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m failed to show a statistically significant effect on the primary composite outcome.53 The thiazolidinediones    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m pioglitazone and rosiglitazone are associated with increased risk of HF. DPP4 inhibitors Four CVOTs in people   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m with T2DM with or at high risk of ASCVD have assessed the CVD effects of DPP4 inhibitors versus placebo and     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m demonstrated non-inferiority but not superiority of DPP4 inhibition in the primary CVD endpoint.54-57 The       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m SAVOR-TIMI 53 study showed that saxagliptin significantly increased the risk of hospitalisation for HF versus   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m placebo.58 Insulin Two basal insulins have been formally evaluated in dedicated CVOTs and did not show a        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m difference in CVD outcomes. The ORIGIN study of insulin glargine included individuals at high CVD risk with     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m impaired fasting glucose, impaired glucose tolerance, or T2DM. After a median follow-up of 6.2 years, the       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m incidence of CV outcomes did not differ between the insulin glargine and standard care groups.59 The DEVOTE     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m trial randomised individuals with T2DM with ASCVD or with a high CVD risk to once daily insulin degludec versus \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m insulin glargine. There was no significant difference in the primary composite of CVD death, non-fatal MI, or   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m non-fatal stroke between the two groups after a median 1.8 years follow-up.60 Mineralocorticoid receptor        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m antagonists a. Steroidal mineralocorticoid receptor antagonists (MRAs) spironolactone or eplerenone reduce      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m death and HF hospitalisation in people with HFrEF, with consistent results in people with or without diabetes.  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Caution is required when using MRAs in people with impaired renal function and in those with serum potassium    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m concentration >5.0 mmol/L.15 The efficacy of these agents in people with HF and mildly reduced or preserved     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m ejection fraction has not been established. b. Non-steroidal MRA â€“ finerenone The placebo-controlled            \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m FIDELIO-DKD61 and IDF Global Clinical Practice Recommendations for Managing Type 2 Diabetes â€“ 2025 96           \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m CARDIO-RENAL PROTECTION FIGARO-DKD62 trials demonstrated that finerenone reduced risk of kidney failure and CVD \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m outcomes (CVD death, non-fatal MI, non-fatal stroke, or hospitalisation for HF) in people with CKD and T2DM who \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m were on maximum doses of ACE inhibitors or ARBs.63 Finerenone has also been shown to further improve renal      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m function in people with CKD and T2DM already receiving SGLT2 inhibitors at baseline64 and cardio-renal outcomes \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m in people with CKD and T2DM irrespective of SGLT2 inhibitor use.65 A recent outcome study reported that in      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m people with HF and mildly reduced or preserved ejection fraction (41% of whom had T2DM), finerenone resulted in \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m a significantly lower rate of a composite of total worsening HF events and death from CVD compared with         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m placebo.66 Summary The emergence of newer therapies has resulted in a significant paradigm shift in the         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m management of cardio-renal risk through a structured, multi-pillar treatment approach to improve outcomes. In   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m addition to the traditional pillars of improving glycaemic control and interventions for established risk       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m factors, the cardio-renal benefits of SGLT2 inhibitors, GLP-1 receptor agonists, and non-steroidal              \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m mineralocorticoid receptor antagonists are supported by robust clinical trial evidence.67 These therapies have  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m expanded standard CKD treatment with renin-angiotensin system (RAS) blockers.68 Current guidelines15,26 include \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m decision algorithms which highlight established and new pillars for managing cardio-renal risk and enhance risk \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m reduction for people with T2DM with at least one of ASCVD, HF, CKD, or those at high risk for ASCVD.26,69       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m REFERENCES 1. Ibrahim M, Ba-Essa EM, Baker J, et al. Cardio-renal-metabolic disease in primary care setting.    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Diabetes Metab Res Rev. 2024;40(3):e3755. 2. Bello AK, Levin A, Tonelli M, et al. Assessment of global kidney   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m health care status. JAMA. 2017;317(18):1864-1881. 3. World Health Organization. Web Annex A. World Health       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Organization Model List of Essential Medicines â€“ 23rd List, 2023. In: The selection and use of essential        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m medicines 2023: Executive summary of the report of the 24th WHO Expert Committee on the Selection and Use of    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Essential Medicines, 24 - 28 April 2023.\\nGeneva: World Health Organization; 2023 (WHO/MHP/HPS/EML/2023.02). 4. \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Castro Conde A, Marzal MartÃ­n D, Campuzano Ruiz R, et al. Comprehensive cardiovascular and renal protection in  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m patients with type 2 diabetes. J Clin Med. 2023;12(12):3925. 5. Einarson TR, Acs A, Ludwig C, et al. Prevalence \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m of cardiovascular disease in type 2 diabetes: A systematic literature review of scientific evidence from across \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m the world in 2007-2017. Cardiovasc Diabetol. 2018;17(1):83. 6. Goderis G, Vaes B, Mamouris P, et al. Prevalence \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m of atherosclerotic cardiovascular disease, heart failure, and chronic kidney disease in patients with type 2    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m diabetes mellitus: A primary care research network-based study. Exp Clin Endocrinol Diabetes.                   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 2022;130(7):447-453. 7. Cohn PF, Fox KM, Daly C. Silent myocardial ischemia. Circulation.                       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 2003;108(10):1263-1277. 8. Davis TM, Coleman RL, Holman RR. Prognostic significance of silent myocardial        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m infarction in newly diagnosed type 2 diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS) 79.   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Circulation. 2013;127(9):980-987. 9. Dauriz M, Mantovani A, Bonapace S, et al. Prognostic impact of diabetes on \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m long-term survival outcomes in patients with heart failure: A meta-analysis. Diabetes Care.                     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 2017;40(11):1597-1605. 10. Osundolire S, Naqvi S, Nunes AP, et al. Heart failure among US nursing home          \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m residents with diabetes mellitus. Int J Cardiol. 2022;349:138-143. 11. Skolnik NS, Style AJ. Importance of      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m early screening and diagnosis of chronic kidney disease in patients with type 2 diabetes. Diabetes Ther.        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 2021;12(6):1613-1630. 12. Wu B, Bell K, Stanford A, et al. Understanding CKD among patients with T2DM:          \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Prevalence, temporal trends, and treatment patterns-NHANES 2007-2012. BMJ Open Diabetes Res Care.               \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 2016;4(1):e000154. 13. Al-Ozairi E, Jallo MK, Hafidh K, et al. Prevalence of cardiovascular and renal           \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m co-morbidities in patients with type 2 diabetes in the Gulf, a cross-sectional observational study. Diabetes    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Ther. 2021;12(4):1193-1207. 14. Zhang R, Mamza JB, Morris T, et al. Lifetime 97 Chapter 6 risk of               \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m cardiovascular-renal disease in type 2 diabetes: A population-based study in 473,399 individuals. BMC Med.      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 2022;20(1):63. 15. Marx N, Federici M, SchÃ¼tt K, et al. 2023 ESC Guidelines for the management of               \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m cardiovascular disease in patients with diabetes. Eur Heart J. 2023;44(39):4043-4140. 16. SeferoviÄ‡ P, Farmakis \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m D, Bayes-Genis A, et al. Biomarkers for the prediction of heart failure and cardiovascular events in patients   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m with type 2 diabetes: A position statement from the Heart Failure Association of the European Society of        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Cardiology. Eur J Heart Fail. 2022;24(7):1162-1170. 17. Mueller C, McDonald K, de Boer RA, et al. Heart Failure \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Association of the European Society of Cardiology practical guidance on the use of natriuretic peptide          \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m concentrations. Eur J Heart Fail. 2019;21(6):715-731. 18. Ceriello A, Catrinoiu D, Chandramouli C, et al. Heart \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m failure in type 2 diabetes: current perspectives on screening, diagnosis and management. Cardiovasc Diabetol.   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 2021;20(1):218. 19. Pop-Busui R, Januzzi JL, Bruemmer D, et al. Heart failure: An underappreciated complication \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m of diabetes. A consensus report of the American Diabetes Association. Diabetes Care. 2022;45(7):1670-1690. 20.  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Bayes-Genis A, Docherty KF, Petrie MC, et al. Practical algorithms for early diagnosis of heart failure and     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m heart stress using NT-proBNP: A clinical consensus statement from the Heart Failure Association of the ESC. Eur \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m J Heart Fail. 2023;25(11):1891-1898. 21. Packer M. Heart failure: The most important, preventable, and          \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m treatable cardiovascular complication of type 2 diabetes. Diabetes Care. 2018;41(1):11-13. 22. ElSayed NA,      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Aleppo G, Aroda VR, et al. 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes-2023.  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Diabetes Care. 2023;46(Suppl 1):S191-S202. 23. Stevens PE, Ahmed SB, Carrero JJ, et al. KDIGO 2024 Clinical     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Practice Guideline for the evaluation and management of chronic kidney disease. Kidney Int.                     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 2024;105(4):S117-S314. 24. Turnbull FM, Abraira C, Anderson RJ, et al. Intensive glucose control and            \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m macrovascular outcomes in type 2 diabetes. Diabetologia. 2009;52(11):2288-2298. 25. Zoungas S, Arima H,         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Gerstein HC, et al. Effects of intensive glucose control on microvascular outcomes in patients with type 2      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m diabetes: A meta-analysis of individual participant data from randomised controlled trials. Lancet Diabetes     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Endocrinol. 2017;5(6):431-437. 26. ElSayed NA, Aleppo G, Bannuru RR, et al. 10. Cardiovascular Disease and Risk \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Management: Standards of Care in Diabetes-2024. Diabetes Care. 2024;47(Suppl 1):S179-S218. 27. Bi Y, Li M, Liu  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Y, et al. Intensive blood-pressure control in patients with type 2 diabetes. N Engl J Med. 2024. [Epub ahead of \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m print]. DOI: 10.1056/NEJMoa2412006. 28. Prattichizzo F, Ceriello A. Positioning newer drugs in the management   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m of type 2 diabetes. Lancet Diabetes Endocrinol. 2021;9(3):138-139. 29. McGuire DK, Shih WJ, Cosentino F, et al. \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: A     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m meta-analysis. JAMA Cardiol. 2021;6(2):148-158. 30. Nuffield Department of Population Health Renal Studies      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Group; SGLT2 inhibitor Meta-Analysis Cardio-Renal Trialistsâ€™ Consortium. Impact of diabetes on the effects of   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m sodium glucose co-transporter-2 inhibitors on kidney outcomes: Collaborative meta-analysis of large             \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m placebo-controlled trials. Lancet. 2022;400(10365):1788-1801. 31. Bae JH, Park EG, Kim S, et al. Effects of     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m sodium-glucose cotransporter 2 inhibitors on renal outcomes in patients with type 2 diabetes: A systematic      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m review and meta-analysis of randomized controlled trials. Sci Rep. 2019;9(1):13009. 32. Herrington WG, Staplin  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m N, Wanner C, et al. Empagliflozin in patients with chronic kidney disease. N Engl J Med. 2023;388(2):117-127.   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 33. Staplin N, Roddick AJ, Emberson J, et al. Net effects of sodium-glucose co-transporter-2 inhibition in      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m different patient groups: A meta-analysis of large placebo-controlled randomized trials. EClinicalMedicine.     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 2021;41:101163. 34. Vaduganathan M, Docherty KF, Claggett BL, et al. SGLT-2 inhibitors in patients with heart   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m failure: A comprehensive meta-analysis of five randomised controlled trials. Lancet. 2022;400(10354):757-767.   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 35. Badve SV, Bilal A, Lee MMY, et al. Effects of GLP-1 receptor agonists on kidney and cardiovascular disease  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m outcomes: A meta-analysis of randomised controlled trials. Lancet Diabetes Endocrinol. 2024. [Epub ahead of IDF \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Global Clinical Practice Recommendations for Managing Type 2 Diabetes â€“ 2025 98 CARDIO-RENAL PROTECTION print]. \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m DOI: 10.1016/s2213-8587(24)00271-7. 36. Rivera FB, Cruz LLA, Magalong JV, et al. Cardiovascular and renal       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m outcomes of glucagon-like peptide 1 receptor agonists among patients with and without type 2 diabetes mellitus: \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m A meta-analysis of randomized placebo-controlled trials. Am J Prev Cardiol. 2024;18:100679. 37. Perkovic V,     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Tuttle KR, Rossing P, et al. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m N Engl J Med. 2024;391(2):109-121. 38. Kosiborod MN, Petrie MC, Borlaug BA, et al. Semaglutide in patients with \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m obesity-related heart failure and type 2 diabetes. N Engl J Med. 2024;390(15):1394-1407. 39. Marso SP, Bain SC, \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med.       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 2016;375(19):1834-1844. 40. A research study to look at how semaglutide compared to placebo affects diabetic    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m eye disease in people with type 2 diabetes (FOCUS). ClinicalTrials.gov Identifier: NCT03811561. Available from: \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m https:// clinicaltrials.gov/study/NCT03811561[Accessed September 2024]. 41. Ahmad A, Sabbour H. Effectiveness   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m and safety of the combination of sodium-glucose transport protein 2 inhibitors and glucagon-like peptide-1      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m receptor agonists in patients with type 2 diabetes mellitus: A systematic review and meta-analysis of           \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m observational studies. Cardiovasc Diabetol. 2024;23(1):99. 42. Mann JFE, Rossing P, Bakris G, et al. Effects of \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m kidney disease in the FLOW trial. Nat Med. 2024;30(10):2849-2856. 43. Nicholls SJ, Bhatt DL, Buse JB, et al.    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m diabetes and atherosclerotic cardiovascular disease: SURPASS-CVOT design and baseline characteristics. Am Heart \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m J. 2024;267:1-11. 44. Packer M, Zile MR, Kramer CM, et al. Tirzepatide for heart failure with preserved         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m ejection fraction and obesity. N Engl J Med. 2024. [Epub ahead of print]. DOI: 10.1056/ NEJMoa2410027. 45. UK   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on           \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet.1998;352(9131):854-865. 46. Adler  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m AI, Coleman RL, Leal J, et al. Post-trial monitoring of a randomised controlled trial of intensive glycaemic    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m control in type 2 diabetes extended from 10 years to 24 years (UKPDS 91). Lancet. 2024;404(10448):145-155. 47.  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Patel A, MacMahon S, Chalmers J, et al. Intensive blood glucose control and vascular outcomes in patients with  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m type 2 diabetes. N Engl J Med. 2008;358(24):2560-2572. 48. Zoungas S, Chalmers J, Neal B, et al. Follow-up of   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m blood-pressure lowering and glucose control in type 2 diabetes. N Engl J Med. 2014;371(15):1392-1406. 49.       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Rosenstock J, Kahn SE, Johansen OE, et al. Effect of linagliptin vs glimepiride on major adverse cardiovascular \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m outcomes in patients with type 2 diabetes: The CAROLINA randomized clinical trial. JAMA.                        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 2019;322(12):1155-1166. 50. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 2 diabetes (UKPDS 33). Lancet. 1998;352(9131):837-853. 51. Holman RR, Coleman RL, Chan JCN, et al. Effects of   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m tolerance (ACE): A randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol.              \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 2017;5(11):877-886. 52. Home PD, Pocock SJ, Beck-Nielsen H, et al. Rosiglitazone evaluated for cardiovascular   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m outcomes in oral agent combination therapy for type 2 diabetes (RECORD): A multicentre, randomised, open-label  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m trial. Lancet. 2009;373(9681):2125-2135. 53. Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m of macrovascular events in patients with type 2 diabetes in the PROactive study (PROspective pioglitAzone       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Clinical Trial In macroVascular Events): A randomised controlled trial. Lancet. 2005;366(9493):1279-1289. 54.   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m diabetes mellitus. N Engl J Med. 2013;369(14):1317-1326. 55. White WB, Cannon CP, Heller SR, et al. Alogliptin  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m after acute coronary syndrome in 99 Chapter 6 patients with type 2 diabetes. N Engl J Med.                      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 2013;369(14):1327-1335. 56. Green JB, Bethel MA, Armstrong PW, et al. Effect of sitagliptin on cardiovascular   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m outcomes in type 2 diabetes. N Engl J Med. 2015;373(3):232-242. 57. Rosenstock J, Perkovic V, Johansen OE, et   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m al. Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m cardiovascular and renal risk: The CARMELINA randomized clinical trial. JAMA. 2019;321(1):69-79. 58. Scirica    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m BM, Braunwald E, Raz I, et al. Heart failure, saxagliptin, and diabetes mellitus: Observations from the         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m SAVOR-TIMI 53 randomized trial. Circulation. 2014;130(18):1579-1588. 59. Gerstein HC, Bosch J, Dagenais GR, et  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m al. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med. 2012;367(4):319-328. 60.  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Pratley RE, Husain M, Lingvay I, et al. Heart failure with insulin degludec versus glargine U100 in patients    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m with type 2 diabetes at high risk of cardiovascular disease: DEVOTE 14. Cardiovasc Diabetol. 2019;18(1):156.    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 61. Bakris GL, Agarwal R, Anker SD, et al. Effect of finerenone on chronic kidney disease outcomes in type 2    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m diabetes. N Engl J Med. 2020;383(23):2219-2229. 62. Pitt B, Filippatos G, Agarwal R, et al. Cardiovascular      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m events with finerenone in kidney disease and type 2 diabetes. N Engl J Med. 2021;385(24):2252-2263. 63. Agarwal \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m R, Filippatos G, Pitt B, et al. Cardiovascular and kidney outcomes with finerenone in patients with type 2      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m diabetes and chronic kidney disease: The FIDELITY pooled analysis. Eur Heart J. 2022;43(6):474-484. 64. Rossing \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m P, Filippatos G, Agarwal R, et al. Finerenone in predominantly advanced CKD and type 2 diabetes with or without \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m sodium-glucose cotransporter-2 inhibitor therapy. Kidney Int Rep. 2022;7(1):36-45. 65. Rossing P, Anker SD,     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Filippatos G, et al. Finerenone in patients with chronic kidney disease and type 2 diabetes by sodium-glucose   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m cotransporter 2 inhibitor treatment: The FIDELITY analysis. Diabetes Care. 2022;45(12):2991-2998. 66. Solomon   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m SD, McMurray JJV, Vaduganathan M, et al. Finerenone in heart failure with mildly reduced or preserved ejection  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m fraction. N Engl J Med. 2024;391(16):1475-1485. 67. Naaman SC, Bakris GL. Diabetic nephropathy: Update on       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m pillars of therapy slowing progression. Diabetes Care. 2023;46(9):1574-1586. 68. Blazek O, Bakris GL. The       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m evolution of â€œpillars of therapyâ€ to reduce heart failure risk and slow diabetic kidney disease progression. Am \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Heart J Plus. 2022;19:100187. 69. Bae J, Liu D, Chinthammit C, et al. Type 2 diabetes pharmacotherapy trends in \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m high-risk subgroups. Diabetes Obes Metab. 2022;24(6):1166-1171.\\n100 Management of Metabolic                    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Dysfunction-Associated Steatotic Liver Disease (MASLD) in Type 2 Diabetes Chapter 7 MANAGEMENT OF MASLD 101     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Chapter 7 RECOMMENDATIONS Optimal Care Basic Care Screening and risk assessment â€¢\\tSuspect MASLD in all people  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m with T2DM, especially if overweight or obese; LFTs are abnormal â€¢\\tScreen for MASLD-related fibrosis - FIB-4    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m score - Imaging if FIB-4 result elevated - VCTE - MRE â€¢\\tSuspect MASLD in all people with T2DM, especially if   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m overweight or obese; LFTs are abnormal â€¢\\tScreen for MASLD-related fibrosis - FIB-4 score - Imaging if FIB-4    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m result elevated (if available) Management of people with T2DM and at-risk MASLD â€¢\\tImplement Pillars of         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Diabetes Care (Chapter 6) â€¢\\tAt-risk MASLD determined by FIB-4 and imaging â€¢\\tPromote healthy lifestyle change  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m and at least 5% weight loss if overweight or obese â€¢\\tSpecific MASLD therapy - Resmetirom (where approved) -    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m GLP-1RAs (including semaglutide, liraglutide, and tirzepatide) â€¢\\tConsider metabolic bariatric surgery          \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m â€¢\\tImplement Pillars of Diabetes Care (Chapter 6) â€¢\\tAt-risk MASLD determined by FIB-4 alone or with imaging if \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m available â€¢\\tPromote healthy lifestyle change and at least 5% weight loss if overweight or obese â€¢\\tSpecific    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m MASLD therapy - Pioglitazone (if available and not contraindicated) - SGLT2i for weight loss and cardio-renal   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m protection Note: These recommendations also apply to people with intermediate hyperglycaemia.\\nFIB-4,           \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m fibrosis-4 index; GLP-1RA, glucagon-like peptide-1 receptor agonist; LFT, liver function test(s); MASLD,        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m metabolic dysfunction-associated steatotic liver disease; MRE, magnetic resonance elastography; SGLT2i,         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m sodium-glucose cotransporter-2 inhibitor; T2DM, type 2 diabetes mellitus; VCTE, vibration-controlled transient  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m elastography.\\nIDF Global Clinical Practice Recommendations for Managing Type 2 Diabetes â€“ 2025 102 MANAGEMENT  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m OF MASLD o Metabolic dysfunction-associated steatotic liver disease (MASLD), previously termed non-alcoholic    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m fatty liver disease (NAFLD), is steatotic liver disease without harmful alcohol intake. o MASLD is the most     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m common chronic liver disease and is closely linked with type 2 diabetes mellitus (T2DM), intermediate           \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m hyperglycaemia, and obesity. o MASLD increases risk of adverse liver and cardio-renal outcomes. o All people    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m with T2DM are at-risk of MASLD. The main objective is to identify and manage those with â€œat-risk MASLDâ€ to      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m prevent progression to cirrhosis and its complications. o Identifying and managing MASLD in resource-poor       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m settings is challenging due to the limited availability of required blood and imaging tests, access to          \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m preferred glucose-lowering medications, and the scarcity of specialised services. o The global prevalence of    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m MASLD in people with T2DM is 65% and metabolic dysfunction-associated steatohepatitis (MASH) is 32%. Thirty-six \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m per cent of people have fibrosis and 15% advanced fibrosis. MASLD is common in obesity. o Individuals with T2DM \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m and suspected MASLD should be assessed for risk of developing advanced liver disease with a blood-based risk    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m score (Fibrosis-4 index [FIB-4]) and followed up with vibration-controlled transient elastography (VCTE) or     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m magnetic resonance elastography (MRE) imaging to detect fibrosis, if available. o Liver biopsy is not required  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m for managing most people with MASLD. o MASLD-specific interventions include lifestyle modification and weight   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m loss (â‰¥5%â€“10%). o Resmetirom is the only approved (in the USA) MASH-targeted therapy. It is an oral,            \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m liver-directed, thyroid hormone beta-1 receptor agonist and is indicated for non-cirrhotic MASH and             \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m moderate-to-advanced liver fibrosis. o No blood glucose-lowering (BGL) medication for T2DM has an indication as \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m a MASLD-targeted therapy. o Some glucagon-like peptide-1 (GLP-1) receptor agonists (semaglutide, liraglutide,   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m tirzepatide) and pioglitazone improve histological features of MASH. Semaglutide has recently been demonstrated \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m to improve liver fibrosis. o Pioglitazone is not available in many countries and its side effect profile should \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m be considered in deciding whether or not to prescribe it. o Sodium-glucose cotransporter-2 (SGLT2) inhibitors   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m improve liver steatosis without affecting liver fibrosis linked to weight loss. o Insulin is the preferred      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m treatment of hyperglycaemia in T2DM with decompensated cirrhosis. o Statin therapy is safe in T2DM and MASLD,   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m including compensated cirrhosis. o Metabolic bariatric surgery is an option to treat MASLD/MASH in those with   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m severe obesity and has been associated with resolution of MASLD and MASH but not advanced fibrosis.\\nKEY POINTS \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 103 Chapter 7 BACKGROUND Metabolic dysfunction-associated steatotic liver disease (MASLD), previously termed    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m non-alcoholic fatty liver disease (NAFLD), is defined as steatotic liver disease (SLD) in the presence of one   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m or more cardiometabolic risk factors (including type 2 diabetes mellitus [T2DM] and intermediate                \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m hyperglycaemia) and the absence of harmful alcohol intake. The change in nomenclature from â€œnon-alcoholicâ€ to   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m â€œmetabolic dysfunctionâ€ reflects an evolving understanding of these conditions and their metabolic links.1      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m MASLD is the most common chronic liver disease and is closely linked with T2DM, intermediate hyperglycaemia,    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m and obesity. In addition to adverse liver outcomes, MASLD is associated with an increased risk of adverse       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m cardio-renal outcomes. Other forms of SLD include alcohol-related liver disease (ALD) (alcohol intake >50 g/day \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m for females and >60 g/day for males) and MASLD with moderate increased alcohol intake (MetALD) (alcohol intake  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 20â€“50 g/day for females and 30â€“60 g/day for males).1 have a high index of suspicion for MASLD in all people     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m with T2DM and to specifically identify and intervene in those with â€œat-risk MASLDâ€ to prevent progression to    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m cirrhosis and its complications. GLOBAL CONSIDERATIONS MASLD is an important, common, and increasingly          \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m recognised serious comorbidity in people with T2DM and intermediate hyperglycaemia. Identifying and managing    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m MASLD in resource-poor settings present several challenges. The blood and imaging tests required for screening  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m for at-risk individuals with MASLD may not be available. Preferred glucose-lowering medications for managing    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m people with MASLD may not be available, accessible, and affordable. The only MASLD-targeted treatment is only   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m currently approved in the United States. Specialised services are scarce. Despite these limitations, much can   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m still be done through primary care and diabetes services in resource-limited settings to improve the management \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m and outcomes for people with T2DM and MASLD. EVIDENCE SUMMARY The prevalence of MASLD, MASH, and fibrosis in    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m T2DM An estimated 30% of the global general population has MASLD with regional differences ranging from 25% in  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Western Europe to 44% in Latin America.2 The global prevalence of MASLD in people with T2DM is 56%, two-fold    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m higher than in the general population, with studies from Europe reporting the highest prevalence at 68%. The    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m reported prevalence of MASH is 37%, and 17% who had a liver biopsy had advanced fibrosis. Individuals with T2DM \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m not only have a greater prevalence of MASLD but also an increased risk of developing MASH and advanced fibrosis \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m compared with the general population.2 A more recent analysis of nearly two million individuals with T2DM       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m reported prevalence rates of MASLD of 65% and MASH of 32%, with 36% of those with MASLD having fibrosis (stage  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m F2â€“ F4) and 15% advanced fibrosis (stage F3â€“F4).3 However, it should be noted that many of the included studies \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m were from clinics and hospital settings and were not random samples. The spectrum of MASLD includes: o          \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Metabolic dysfunction-associated steatotic (fatty) liver (MASL) o Metabolic dysfunction-associated              \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m steatohepatitis (MASH) o Fibrosis o Cirrhosis o MASH-related hepatocellular carcinoma (HCC) The intricate       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m association between MASLD/MASH in individuals with T2DM and intermediate hyperglycaemia and adverse liver and   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m systematic impacts emphasises the need for proactive intervention and tailored personalised management          \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m strategies. A definitive diagnosis of hepatic steatosis requires either imaging or histology and is not         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m practical or necessary in a routine clinical setting. Adverse outcomes of MASLD relate to MASH and fibrosis.    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Consequently, the objective is to IDF Global Clinical Practice Recommendations for Managing Type 2 Diabetes â€“   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 2025 104 MANAGEMENT OF MASLD In a study involving 360 people with T2DM who underwent liver biopsies when        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m alanine aminotransferase (ALT) levels were persistently >20 IU/L in females or >30 IU/L in males in the absence \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m of other liver disease, the prevalence of MASH, advanced fibrosis, and cirrhosis was 58%, 38%, and 10%,         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m respectively.4 Of note and relevance to diabetes, in overweight populations the prevalence of MASLD was 70%,    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m MASL 42%, MASH 34%, fibrosis stages 2â€“4 20%, and 7% had advanced fibrosis stages 3â€“4. Prevalences were similar  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m in the obese population.5 Fibrosis progression is subject to a myriad of influences, including comorbidities,   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m genetic factors, and environmental conditions. The increased risk of major adverse liver outcomes is linked to  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m the particular manifestation of MASLD. A Swedish registry-based cohort study of 230,992 people with T2DM        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m without a history of liver disease reported a low incidence of adverse outcomes, with 3,215 (1.4%) developing   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m major adverse liver outcomes over 10 years.6 In a national matched prospective cohort study of 10,568           \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m individuals with biopsy-confirmed MASLD with a median follow-up of 14.2 years, 4,338 with MASLD died. Compared  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m with controls, individuals with MASLD had significantly increased overall mortality (16.9 versus 28.6/1000      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m person-years). Significant excess mortality risk was 8.3/1000 person-years for simple steatosis, 13.4/1000      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m person-years for non-fibrotic MASH, 18.4/1000 person-years for non-cirrhotic fibrosis, and 53.6/1000            \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m person-years for cirrhosis.7 T2DM is associated with poorer outcomes in individuals with biopsy-proven MASH and \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m compensated cirrhosis, including an increased risk of death and HCC. Compared with metabolically healthy        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m individuals, people with T2DM had the highest risk of having MASLD (odds ratio [OR] = 10.88) followed by        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m intermediate hyperglycaemia (OR = 4.19). During a median follow-up of 26.7 years, people with MASLD had         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m significantly higher age-adjusted mortality than non-MASLD (32.7% versus 28.7%) with the highest                \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m age-standardised cumulative mortality in those with T2DM (41.3%), followed by intermediate hyperglycaemia       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m (35.1%), compared with metabolically healthy individuals (21.9%).8 While the natural history of MASLD is        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m relatively well-defined, there is substantial individual variability in disease trajectories. The risk of       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m future liver-related events starts to increase at the fibrosis stage. However, it takes decades for MASLD to    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m progress to cirrhosis and hepatic decompensation.1 Screening and diagnosis of MASLD at-risk of advanced liver   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m disease in people with T2DM The association between MASLD stage and adverse outcomes underlines the need for    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m nuanced clinical approaches.1 The primary goal in the management of MASLD in people with T2DM is to identify    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m individuals at-risk of MASLD-related fibrosis, particularly those with abdominal obesity and additional         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m metabolic risk factors or abnormal liver function tests. This has become an important aspect of comprehensive   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m care for T2DM but remains challenging in resource-limited health systems. Screening and diagnosis of            \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m individuals with MASLD who are at-risk of developing advanced liver disease usually involves a two-step         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m approach of an initial blood-based score followed by imaging. Blood-based score The Fibrosis-4 index (FIB-4) is \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m the most widely used available tool. It uses a combination of blood test values and anthropometric information  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m to screen for risk of liver fibrosis. FIB-4 is calculated as age x aspartate transaminase (AST)/(platelet count \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m x âˆš ALT) (age in years, ALT and AST in U/L, and platelet count in 109/L).9 A FIB-4 score <1.3 identifies        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m individuals who are not likely to have advanced fibrosis and who require ongoing periodic re-evaluation (one to \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m three years) while a FIB-4 value >2.67 is associated with high-risk and ideally should be referred to a         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m hepatologist.10 The ability of FIB-4 to detect fibrosis is limited in the intermediate score range (1.30â€“2.67). \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m A lower cut-off value of 2.0 is recommended in people aged over 65 years and the test does not perform well in  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m individuals younger than 35 years, and also less well in people with diabetes.11 Automated FIB-4 score          \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m calculation followed by reminder messages in the electronic health system has been shown to increase referral   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m of individuals with increased fibrosis scores to hepatologists from 3% to 33%.12 Persistently or intermittently \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m elevated ALT levels >30 U/L may indicate chronic liver injury, whereas AST levels lack sensitivity and          \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m specificity in identifying MASLD with advanced fibrosis. 105 Chapter 7 Imaging Individuals assessed as moderate \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m or high-risk of advanced disease on FIB-4 should undergo further assessment with imaging. Vibration-controlled  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m transient elastography (VCTE) is commonly used to estimate liver stiffness measurement (LSM) as an assessment   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m of degree of fibrosis and controlled attenuation parameter (CAP) as an assessment of steatosis.13 Other         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m ultrasound-based methods like acoustic radio force impulse (if available) may be preferred due to cost          \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m considerations. Some ultrasound techniques may not be reliably used to examine adults with class 2 obesity.1    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Magnetic resonance elastography (MRE) can also be used to assess liver stiffness and is more sensitive than     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m VCTE in detecting fibrosis stage â‰¥2 but requires specialised equipment to generate mechanical waves and         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m dedicated acquisition techniques, which are only available at a few sites.10 Tests of specific collagen-related \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m blood constituents (e.g., the Enhanced Liver Fibrosis test, ELF) may be an alternative to imaging to identify   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m advanced liver fibrosis in the future.1 Liver biopsy is not required for clinical management in most cases of   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m people with MASLD. Management The evolving landscape of MASLD management in T2DM requires personalised          \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m approaches based on the Key Pillars of Diabetes Management (See Chapter 6) and considering MASH-targeted        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m therapy if available, accessible, and affordable. MASLD-specific interventions Lifestyle modification and       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m weight loss Overweight and obese MASLD people with T2DM and intermediate hyperglycaemia should be recommended   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m dietary and physical activity lifestyle changes that promote weight loss to reduce liver steatosis and improve  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m cardiometabolic profile, while discouraging alcohol consumption.1 The degree of weight loss has a significant   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m impact on different MASLD manifestations. Sustained diet-induced weight loss of â‰¥5% reduces liver fat, 7%â€“10%   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m weight loss improves liver inflammation, and â‰¥10% weight loss improves fibrosis.1, 14 For example, weight loss  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m of at least 7% by lifestyle modification with a Mediterranean diet was associated with MASH resolution after 52 \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m weeks, and weight loss of more than 10% with improvement in liver fibrosis. However, histological changes with  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m lifestyle intervention are achieved in less than 20% of people.15 Pharmacotherapy 1. MASH-targeted therapy â€“    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m resmetirom Resmetirom is the first specific medication for the treatment of MASLD and received accelerated FDA  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m approval in March 2024. It is an orally active, liver-directed, thyroid hormone beta-1 receptor agonist and is  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m indicated for adults with non-cirrhotic MASH and moderate-to-advanced liver fibrosis in conjunction with diet   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m and exercise. In a phase 3 randomised controlled trial (RCT), resmetirom 80 mg resulted in resolution of MASH   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m without worsening of fibrosis in 25.9% of individuals compared with 9.7% in the placebo group, and fibrosis     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m improvement by at least one stage with no worsening of MASLD activity score in 24.2% compared with 14.2% in the \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m placebo group. Low-density lipoprotein concentrations were also significantly decreased.16 The usual daily dose \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m is 80 mg in individuals with a body weight <100 kg and 100 mg with body weight â‰¥100 kg. Dose reduction should   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m be considered with moderate CYP2C8 inhibitors such as clopidogrel. Resmetirom is generally well-tolerated with  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m the most common side effects being gastrointestinal (diarrhoea, nausea, and vomiting) and pruritus.1, 14        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m However, it is not widely available. There is currently no effective MASH-targeted pharmacotherapy available    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m for people with MASH and cirrhosis. 2. Blood glucose-lowering medications Blood glucose-lowering (BGL)          \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m medications for T2DM have been reviewed in Chapters 3 and 4. BGL medications may impact MASLD directly or       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m through improved glycaemic control and/or weight loss. No currently available BGL or weight management          \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m medication is approved as a MASLD-targeted therapy. The following is a brief review of the specific effects of  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m BGL medications on MASLD. IDF Global Clinical Practice Recommendations for Managing Type 2 Diabetes â€“ 2025 106  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m MANAGEMENT OF MASLD Metformin Metformin has not been shown to improve steatohepatitis in paired-biopsy studies. \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m However, it is safe and should be continued in individuals with cirrhosis unless discontinuation is required    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m due to hepatic decompensation or renal failure. Sulfonylureas There are no RCTs with liver histological         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m endpoints which have examined the effects of sulfonylureas as a MASLD-targeted therapy. There is an increased   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m risk of hypoglycaemia in cirrhotic liver disease. Insulin Insulin reduces hepatic steatosis but its effect on   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m steatohepatitis remains unknown.17 Insulin treatment for uncontrolled T2DM in the presence of MASLD can         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m decrease liver steatosis by addressing lipotoxicity and glucotoxicity. However, it may potentially increase     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m hepatic triacylglycerol content and contribute to hepatic fat accumulation.18 Insulin is the preferred          \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m treatment of hyperglycaemia in adults with T2DM with decompensated cirrhosis. Thiazolidinediones (pioglitazone) \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Pioglitazone has been demonstrated in several phase 2 RCTs to improve histological features of MASH but has no  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m clear effect on fibrosis regression.19-21 However, there has not been a large phase 3 multicentre trial with    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m pioglitazone which has further assessed these findings. Pioglitazone is not available in many countries and its \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m side effect profile should be considered in deciding whether or not to prescribe it. SGLT2 inhibitors           \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Short-term SGLT2 inhibitor RCTs have shown reversal of liver steatosis and a reduction in plasma                \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m aminotransferase levels but no improvement in markers of liver fibrosis.22, 23 These changes seem to be         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m primarily linked to weight loss rather than specific targeted MASLD effects. SGLT2 inhibitors are safe in       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m people with T2DM and MASLD and have other well-documented cardio-renal benefits. GLP-1 receptor agonists Single \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m GLP-1 receptor agonists (liraglutide and semaglutide),18 dual GLP-1 receptor agonists (tirzepatide24, 25 and    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m survodutide26), and triple GLP-1 receptor agonists (retatrutide)27 have shown positive effects not only on      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m weight loss and hyperglycaemia but also on the reduction of liver steatosis, with some showing benefits on      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m histological parameters in people with biopsy-proven non-cirrhotic MASH.25, 27 Recently, the positive results   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m of the ESSENCE study were released. The ESSENCE study is a phase 3 RCT evaluating the effect of subcutaneous    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m semaglutide 2.4 mg in people with biopsy-proven MASH and fibrosis stage 2 or 3, which included 56% of           \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m participants with T2DM.28 After 72 weeks in the first 800 individuals (56% T2DM), endpoints were significantly  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m better with semaglutide compared with placebo. Primary endpoints showed 62.9% of people treated with            \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m semaglutide 2.4 mg achieved resolution of steatohepatitis with no worsening of liver fibrosis compared to 34.1% \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m taking placebo, and 37.0% treated with semaglutide achieved improvements in liver fibrosis with no worsening of \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m steatohepatitis compared to 22.5% taking placebo. Secondary endpoints showed 32.8% of participants treated with \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m semaglutide achieved both resolution of steatohepatitis and improvements in liver fibrosis (compared to 16.2%   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m taking placebo).29 This is the first phase 3 GLP-1 receptor agonist-related study to show significant           \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m definitive improvement in liver fibrosis in MASLD. GLP-1 receptor agonists have not been shown to be beneficial \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m in cirrhosis, with a placebo-controlled RCT in adults with biopsy-confirmed MASH-related compensated cirrhosis  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m and body mass index â‰¥27 kg/mÂ² failing to show an improvement with semaglutide 2.4 mg weekly in fibrosis or      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m achievement of MASH resolution, but there were no safety concerns.30 Cohort studies have reported that GLP-1    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m receptor agonist use in people with T2DM are associated with lower risk of progression to cirrhosis and lower   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m mortality compared with using DPP4 inhibitors but the protective association was not seen in people with        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m existing cirrhosis.31 Another cohort study which matched people with T2DM with and without cirrhosis reported   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m that GLP-1 receptor agonist use was associated with lower risk of death and major liver outcomes.32 Overall,    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m given the established cardio-renal benefits of SGLT2 inhibitors and GLP-1 receptor agonists and the weight      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m reduction effects, especially of GLP-1 receptor agonists, these agents are preferred in people with T2DM and    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m MASLD, if available, accessible, and affordable, and taking into account each individualâ€™s characteristics and  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m comorbidities. 107 Chapter 7 3. Statins Statin therapy is safe in adults with T2DM and MASLD, including in      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m those with compensated cirrhosis. Statins should be initiated or continued for cardiovascular risk reduction as \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m clinically indicated. Recent data have reported that regular use of statins was associated with a 15% lower     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m hazard ratio of new-onset liver disease and a 28% lower hazard ratio for liver-related deaths (cirrhosis and    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m HCC) compared with no statin use.33 Data on statin safety and efficacy in individuals with decompensated        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m cirrhosis are limited and therefore statin therapy should be used with caution and closely monitored. 4.        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Metabolic bariatric surgery Metabolic bariatric surgery (MBS) is an option to treat MASLD/MASH in those with    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m severe obesity given the positive effect on T2DM and cardiovascular disease and has been associated with        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m resolution of MASLD and MASH.34, 35 However, advanced fibrosis can persist for many years and is associated     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m with lesser weight loss and metabolic improvement.36 In adults with T2DM and compensated cirrhosis from MASLD,  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m MBS should be used with caution and is currently not recommended in decompensated cirrhosis. REFERENCES 1.      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m European Association for the Study of the Liver, European Association for the Study of Diabetes, European       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Association for the Study of Obesity. EASL-EASD-EASO Clinical Practice Guidelines on the management of          \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m metabolic dysfunction-associated steatotic liver disease (MASLD). J Hepatol. 2024;81(3):492-542. 2. Younossi    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m ZM, Golabi P, Paik JM, et al. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and           \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology. 2023;77(4):1335-1347. 3. En Li Cho E, Ang \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m CZ, Quek J, et al. Global prevalence of non-alcoholic fatty liver disease in type 2 diabetes mellitus: an       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m updated systematic review and meta-analysis. Gut. 2023;72(11):2138-2148. 4. Castera L, Laouenan C,              \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Vallet-Pichard A, et al. High prevalence of NASH and advanced fibrosis in type 2 diabetes: A prospective study  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m of 330 outpatients undergoing liver biopsies for elevated ALT, using a low threshold. Diabetes Care.            \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 2023;46(7):1354-1362. 5. Quek J, Chan KE, Wong ZY, et al. Global prevalence of non-alcoholic fatty liver        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m disease and non-alcoholic steatohepatitis in the overweight and obese population: a systematic review and       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m meta-analysis. Lancet Gastroenterol Hepatol. 2023;8(1):20-30. 6. Shang Y, Grip ET, Modica A, et al. Metabolic   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m syndrome traits increase the risk of major adverse liver outcomes in type 2 diabetes. Diabetes Care.            \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 2024;47(6):978-985. 7. Simon TG, Roelstraete B, Khalili H, et al. Mortality in biopsy-confirmed nonalcoholic    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m fatty liver disease: results from a nationwide cohort. Gut. 2021;70(7):1375-1382. 8. Golabi P, Paik JM, Kumar   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m A, et al. Nonalcoholic fatty liver disease (NAFLD) and associated mortality in individuals with type 2          \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m diabetes, pre-diabetes, metabolically unhealthy, and metabolically healthy individuals in the United States.    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Metabolism. 2023;146:155642. 9. Vallet-Pichard A, Mallet V, Nalpas B, et al. FIB-4: An inexpensive and accurate \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest. Hepatology. 2007;46(1):32-36.  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 10. Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, et al. AASLD Practice Guidance on the clinical assessment   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m and management of nonalcoholic fatty liver disease. Hepatology. 2023;77(5):1797-1835. 11. European Association  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m for the Study of the L. EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m severity and prognosis - 2021 update. J Hepatol. 2021;75(3):659-689. 12. Zhang X, Yip TC, Wong GL, et al.       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Clinical care pathway to detect advanced liver disease in patients with type 2 diabetes through automated       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m fibrosis score calculation and electronic reminder messages: A randomised controlled trial. Gut.                \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 2023;72(12):2364-2371. 13. Mikolasevic I, Orlic L, Franjic N, et al. Transient elastography (FibroScan(Â®)) with \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m controlled attenuation parameter in the assessment of liver steatosis and fibrosis in patients with             \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m nonalcoholic fatty liver disease - Where do we stand? World J Gastroenterol. 2016;22(32):7236-7251. 14.         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Koutoukidis DA, Koshiaris C, Henry JA, et al. The effect of the magnitude of weight loss on non-alcoholic fatty \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m liver disease: A systematic review and meta-analysis. Metabolism. 2021;115:154455. IDF Global Clinical Practice \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Recommendations for Managing Type 2 Diabetes â€“ 2025 108 MANAGEMENT OF MASLD 15. Vilar-Gomez E, Martinez-Perez   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Y, Calzadilla-Bertot L, et al. Weight loss through lifestyle modification significantly reduces features of     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m nonalcoholic steatohepatitis. Gastroenterology. 2015;149(2):367-378 e365; quiz e314-365. 16. Harrison SA,       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Bedossa P, Guy CD, et al. A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis. N  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Engl J Med. 2024;390(6):497-509. 17. Budd J, Cusi K. Role of agents for the treatment of diabetes in the        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m management of nonalcoholic fatty liver disease. Curr Diab Rep. 2020;20(11):59. 18. Gastaldelli A, Stefan N,     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Haring HU. Liver-targeting drugs and their effect on blood glucose and hepatic lipids. Diabetologia.            \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 2021;64(7):1461-1479. 19. Cusi K, Orsak B, Bril F, et al. Long-term pioglitazone treatment for patients with    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: A randomized trial. Ann Intern Med.   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 2016;165(5):305-315. 20. Aithal GP, Thomas JA, Kaye PV, et al. Randomized, placebo-controlled trial of          \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. Gastroenterology.                       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 2008;135(4):1176-1184. 21. Sanyal AJ, Chalasani N, Kowdley KV, et al. Pioglitazone, vitamin E, or placebo for   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m nonalcoholic steatohepatitis. N Engl J Med. 2010;362(18):1675-1685. 22. Abdelgani S, Khattab A, Adams J, et al. \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Empagliflozin reduces liver fat in individuals with and without diabetes. Diabetes Care. 2024;47(4):668-675.    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 23. Kahl S, Gancheva S, Strassburger K, et al. Empagliflozin effectively lowers liver fat content in            \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m well-controlled type 2 diabetes: A randomized, double-blind, phase 4, placebo-controlled trial. Diabetes Care.  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 2020;43(2):298-305. 24. Gastaldelli A, Cusi K, Fernandez Lando L, et al. Effect of tirzepatide versus insulin   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): A    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial. Lancet Diabetes Endocrinol.    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 2022;10(6):393-406. 25. Loomba R, Hartman ML, Lawitz EJ, et al. Tirzepatide for metabolic                       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m dysfunction-associated steatohepatitis with liver fibrosis. N Engl J Med. 2024;391(4):299-310. 26. Sanyal AJ,   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Bedossa P, Fraessdorf M, et al. A phase 2 randomized trial of survodutide in MASH and fibrosis. N Engl J Med.   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 2024;391(4):311-319. 27. Sanyal AJ, Kaplan LM, Frias JP, et al. Triple hormone receptor agonist retatrutide for \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m metabolic dysfunction-associated steatotic liver disease: A randomized phase 2a trial. Nat Med.                 \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 2024;30(7):2037-2048. 28. Newsome PN, Sanyal AJ, Engebretsen KA, et al. Semaglutide 2.4 mg in participants with \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m metabolic dysfunction-associated steatohepatitis: Baseline characteristics and design of the phase 3 ESSENCE    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m trial. Aliment Pharmacol Ther. 2024;60(11-12):1525-1533. 29. Newsome PN, Sanyal AJ, Kliers I. Phase 3 ESSENCE   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m trial: Semaglutide in metabolic dysfunction-associated steatohepatitis. Gastroenterol Hepatol (N Y). 2024;20(12 \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Suppl 11):6-7. 30. Loomba R, Abdelmalek MF, Armstrong MJ, et al. Semaglutide 2.4 mg once weekly in patients     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m with non-alcoholic steatohepatitis-related cirrhosis: A randomised, placebo-controlled phase 2 trial. Lancet    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Gastroenterol Hepatol. 2023;8(6):511-522. 31. Kanwal F, Kramer JR, Li L, et al. GLP-1 receptor agonists and     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m risk for cirrhosis and related complications in patients with metabolic dysfunction-associated steatotic liver  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m disease. JAMA Intern Med. 2024;184(11):1314-1323. 32. Yen FS, Hou MC, Cheng-Chung Wei J, et al. Glucagon-like   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m peptide-1 receptor agonist use in patients with liver cirrhosis and type 2 diabetes. Clin Gastroenterol         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Hepatol. 2024;22(6):1255-1264 e1218. 33. Vell MS, Loomba R, Krishnan A, et al. Association of statin use with   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m risk of liver disease, hepatocellular carcinoma, and liver-related mortality. JAMA Netw Open.                   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 2023;6(6):e2320222. 34. Verrastro O, Panunzi S, Castagneto-Gissey L, et al. Bariatric-metabolic surgery versus  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m lifestyle intervention plus best medical care in non-alcoholic steatohepatitis (BRAVES): A multicentre,         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m open-label, randomised trial. Lancet. 2023;401(10390):1786-1797. 35. Lee Y, Doumouras AG, Yu J, et al. Complete \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m resolution of nonalcoholic fatty liver disease after bariatric surgery: A systematic review and meta-analysis.  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Clin Gastroenterol Hepatol. 2019;17(6):1040-1060 e1011. 36. Pais R, Aron-Wisnewsky J, Bedossa P, et al.         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Persistence of severe liver fibrosis despite substantial weight loss with bariatric surgery. Hepatology.        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 2022;76(2):456-468.\\n109 Chapter 7 International Diabetes Federation Avenue Herrmann-Debroux 54 B-1160          \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Brussels, Belgium info@idf.org idf.org\\n\\n##Source\\nhttps://idf.org/media/uploads/2025/04/IDF_Rec_2025.pdf\",    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m \"## Title\\nThe American Diabetes Association Releases Standards of Care in ...\\n\\n## Content\\n![ADA             \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Logo](https://diabetes.org/sites/default/files/ADA85_logo_full_RGB_0.svg)\\n![prediabetes medical                \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m chart](/sites/default/files/2023-08/prediabetes-icon.svg)\\n\\nLearn your risk for type 2 and take steps to       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m prevent it\\n\\n![Diabetes Prevention](/sites/default/files/2023-08/diabetes-prevention-icon.svg)\\n\\nLearn the    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m ins and outs of diabetes and steps for better care\\n\\n![weight                                                  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m scale](/sites/default/files/2024-07/ADA_Icon_Library_scale-full.svg)\\n\\nObesity care is as unique as you are.   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Discover the different treatment and prevention                                                                 \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m options.\\n\\n![Education](/sites/default/files/2023-09/Education.svg)\\n\\nLearn what you can do to keep your      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m child with diabetes safe at school\\n\\n![Gestational](/sites/default/files/2023-09/Gestational.svg)\\n\\nWhat you  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m need to know about gestational diabetes\\n\\n![Diabetes                                                           \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Prevention](/sites/default/files/2023-08/diabetes-prevention-icon.svg)\\n\\nMake a plan to be prepared when       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m illness                                                                                                         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m strikes\\n\\n![Calculator](/sites/default/files/2023-09/Calculator.svg)\\n![Paper](/sites/default/files/2023-09/Pa \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m per.svg)\\n\\nSign up to receive timely information on topics to help you and your family live a healthy          \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m life\\n\\n![Better Choices for Life logo](/sites/default/files/2023-09/bcfl.svg)\\n\\nBringing ADA's evidence-based \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m guidelines and perspective directly to you in the store so you can make informed choices.\\n\\n![Food             \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Bowl](/sites/default/files/2023-09/Food_Bowl.svg)\\n![Milk carrot                                                \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m apple](/sites/default/files/2024-06/meal-patterns-side-nav.svg)\\n![Utensils](/sites/default/files/2023-09/Utens \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m ils.svg)\\n![checklist](/sites/default/files/2023-09/NewlyDiagnosed_checklist.svg)\\n\\nTake the 60-second test to \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m find out your                                                                                                   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m risk\\n\\n![Book](/sites/default/files/2023-09/two%20tone.svg)\\n![Location](/sites/default/files/2023-09/Location \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m .svg)\\n\\nFind help and resources in your zip code\\n\\n![Money                                                    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m hand](/sites/default/files/2023-09/Money_Hand.svg)\\n\\nChoose between a one-time donation or recurring monthly   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m gifts.\\n\\n![Handshake](/sites/default/files/2023-09/handshake.svg)\\n\\nReach out and get involved in programs    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m and events near you.\\n\\n![Transportation](/sites/default/files/2023-09/Transportation.svg)\\n\\nWe make vehicle   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m donations easy so you can help fuel our fight,                                                                  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m hassle-free.\\n\\n![People](/sites/default/files/2023-09/people.svg)\\n![Recipients](/sites/default/files/2023-09/ \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Recipients.svg)\\n![Book](/sites/default/files/2023-09/two%20tone.svg)\\n![capitol                                \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m icon](/sites/default/files/2023-10/capitol.svg)\\n\\n## Breadcrumb\\n\\n# The American Diabetes Association         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Releases Standards of Care in Diabetesâ€”2025\\n\\n![American Diabetes Association logo reversed out white on red   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m background](/sites/default/files/styles/large/public/2024-06/ada-a_comms_logo-full-crops-clean.jpg?itok=HH6Loyi \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m L)\\n\\n*New recommendations on nutrition, weight-loss medications and technology*\\n\\nToday, the American         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Diabetes AssociationÂ® released the [*Standards of Care in                                                       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Diabetesâ€”2025*](https://diabetesjournals.org/care/issue/48/Supplement_1) (*Standards of Care*) the gold         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m standard in evidence-based guidelines for diagnosing and managing diabetes and prediabetes. Based on the latest \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m scientific research and clinical trials, the *Standards of Care* includes strategies for diagnosing and         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m treating diabetes in both youth and adults, methods to prevent or delay type 2 diabetes and its associated      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m comorbidities like obesity, and care recommendations to enhance health outcomes.\\n\\nâ€œThe latest ADA guidelines  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m combine comprehensive, evidence-based recommendations for diabetes care with actionable guidance to enable      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m health care professionals provide the best care possible for those living with diabetes,â€ said Nuha El Sayed,   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m MD, MMSc, the ADAâ€™s senior vice president of health care improvement.\\n\\nNotable updates to the [*Standards of  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Care in Diabetesâ€”2025*](https://diabetesjournals.org/care/issue/48/Supplement_1) include*:*\\n\\nThe ADA annually \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m updates its *Standards of Care* through the efforts of its Professional Practice Committee (PPC). Comprising    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m global experts from diverse professional backgrounds, the PPC includes physicians, nurse practitioners,         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m certified diabetes care and education specialists, registered dietitian nutritionists, pharmacists, and         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m methodologists. Its members hold expertise in a range of related fields. The 2025 *Standards of Care* has       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m garnered endorsements from the American College of Cariology (Section 10), the American Geriatrics Society      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m (Section 13), the American Society of Bone and Mineral Research (Bone Health, Section 4), and the Obesity       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Society (Section 8).\\n\\nOther noteworthy changes include:\\n\\nâ€œImproving the lives of people affected by         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m diabetes is a key part of the ADAâ€™s mission. The *Standards of Care* offers the trusted support needed for      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m people living with diabetes and those caring for them to manage the disease and thrive until we find a cure,â€   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m said Charles â€œChuckâ€ Henderson, the ADAâ€™s chief executive officer.\\n\\n*The* [*Standards of Care in              \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Diabetesâ€”2025*](https://diabetesjournals.org/care/issue/48/Supplement_1) is now available online as a           \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m supplement to the January 2025 issue of *Diabetes CareÂ®.* In addition, a convenient [Standards of Care          \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m app](https://professional.diabetes.org/content-page/standards-care-app-1), available for iOS and Android        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m systems, offers the latest guidelines with interactive tables and algorithms for easy reference. Additional     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m resources, including a comprehensive slide deck and a webcast offering continuing education (CE) credit, are    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m available on the ADAâ€™s professional website [DiabetesPro](https://professional.diabetes.org/)Â®. A               \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m quick-reference pocket chart will soon be available for purchase on ShopDiabetes.org. For primary care          \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m providers, the Abridged Standards of Care, developed by the ADAâ€™s Primary Care Advisory Group, is planned for   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m release in Spring 2025 in *Clinical DiabetesÂ®*. Through the [â€œlivingâ€ Standards of Care                         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m process](https://professional.diabetes.org/standards-of-care/living-standards-update), the online version,      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m abridged guidelines, and all related materials will be updated in real time throughout the year to reflect the  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m latest evidence and regulatory changes.\\n\\n# # #\\n\\n**About the American Diabetes Association**Â   \\nThe         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m American Diabetes Association (ADA) is the nationâ€™s leading voluntary health organization fighting to end       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m diabetes and helping people thrive. For 84 years, the ADA has driven discovery and research to prevent, manage, \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m treat, and ultimately cure diabetes. There are 136 million Americans living with diabetes or prediabetes.       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Through advocacy, program development, and education, weâ€™re fighting for them all. To learn more or to get      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m involved, visit us at [diabetes.org](https://diabetes.org/) or call 1-800-DIABETES (800-342-2383). Join the     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m fight with us on Facebook ([American Diabetes                                                                   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Association](https://www.facebook.com/AmericanDiabetesAssociation?loc=superfooter)), Spanish Facebook           \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m ([AsociaciÃ³n Americana de la Diabetes](https://www.facebook.com/AsocAmericanaDiabetes)), LinkedIn ([American    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Diabetes Association](https://www.linkedin.com/company/american-diabetes-association/)), and Instagram          \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m ([@AmDiabetesAssn](https://www.instagram.com/AmDiabetesAssn/)). To learn more about how we are advocating for   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m everyone affected by diabetes, visit us on X ([@AmDiabetesAssn](https://x.com/AmDiabetesAssn)).\\n\\n## Contact   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Virginia Cramer for press-related                                                                               \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m questions.\\n\\n![ADA](https://diabetes.org/sites/default/files/2024-05/JoinTheFight_PopUp_1032x578.jpg)\\n\\n###   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Give Today and Change lives!\\n\\nWith your support, the American Diabetes AssociationÂ® can continue our          \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m lifesaving work to make breakthroughs in research and provide people with the resources they need to fight      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m diabetes.\\n\\n![ADA Logo](/sites/default/files/ADA85_logo_full_RGB_0.svg)\\n\\n2451 Crystal Drive, Suite           \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 900\\n\\nArlington, VA 22202\\n\\nP.O. Box 7023\\n\\nMerrifield, VA 22116-7023\\n\\n[Center for                         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Information](/about-us/center-information \\\"Center for Information\\\")\\n\\nMonday to Friday\\n\\n9:00 AMâ€“5:30 PM    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m ET\\n\\n![National Health council                                                                                 \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m logo](/sites/default/files/styles/sponsor_logo_288_180_no_crop/public/2023-09/National-Health-Council.png.png?i \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m tok=WPKlFArr)\\n![Charity navigator                                                                              \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m logo](/sites/default/files/styles/sponsor_logo_288_180_no_crop/public/2023-09/charity-navigator-g.png.png?itok= \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m pJ3CJ7R2)\\n![Accredited charity                                                                                 \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m seal](/sites/default/files/styles/sponsor_logo_288_180_no_crop/public/2023-09/accredited-charity-seal.png.png?i \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m tok=v8BJGkOD)\\n\\nCopyright 1995â€“2025. American Diabetes AssociationÂ®. All rights                                \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m reserved.\\n\\n##Source\\nhttps://diabetes.org/newsroom/press-releases/american-diabetes-association-releases-stan \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m dards-care-diabetes-2025\", \"## Title\\nSummary of Revisions: Standards of Care in Diabetesâ€”2025\\n\\n##            \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Content\\nSummary of Revisions: Standards of Care in Diabetesâ€”2025 | Diabetes Care | American Diabetes           \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Association\\n\\n===============\\n[Skip to Main                                                                   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Content](https://diabetesjournals.org/care/article/48/Supplement_1/S6/157564/Summary-of-Revisions-Standards-of- \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Care-in-Diabetes#skipNav)\\n\\n[![Image 1: American Diabetes Association                                          \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Logo](https://ada.silverchair-cdn.com/data/SiteBuilderAssetsOriginals/Live/Images/umbrella/logo-umbrella.svg)_O \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m pen Menu_](javascript:;)\\n\\n[![Image 2: American Diabetes Association                                           \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Logo](https://ada.silverchair-cdn.com/data/SiteBuilderAssetsOriginals/Live/Images/umbrella/logo-umbrella.svg)]( \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m https://diabetesjournals.org/)[Close](javascript:;)\\n\\n*   [Professional                                        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Books](https://diabetesjournals.org/books)\\n*   [Clinical Compendia](https://diabetesjournals.org/compendia)\\n* \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m [Journals _Open Menu_](javascript:;)\\n    *   [Journals Home](https://diabetesjournals.org/journals)\\n    *     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m [Diabetes](https://diabetesjournals.org/diabetes)\\n    *   [Diabetes Care](https://diabetesjournals.org/care)\\n \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m *   [Clinical Diabetes](https://diabetesjournals.org/clinical)\\n    *   [Diabetes                               \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Spectrum](https://diabetesjournals.org/spectrum)\\n    *   [Diabetes, Obesity, and Cardiometabolic               \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m CARE](https://diabetesjournals.org/docm-care)\\n    *   [BMJ Open Diabetes Research & Care Open External         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Link](https://drc.bmj.com/)\\n    *   [Journal Article                                                           \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Collections](https://diabetesjournals.org/journals/pages/journals_special_collections)\\n\\n*   [ADA Standards of \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Care](https://diabetesjournals.org/care/issue/48/Supplement_1)\\n*   [ADA Meeting                                \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Abstracts](https://diabetesjournals.org/journals/pages/scientific-sessions-abstracts)\\n*   [Podcasts _Open      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Menu_](javascript:;)\\n    *   [All ADA Podcasts](https://diabetesjournals.org/journals/pages/podcasts)\\n    *   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m [DiabetesBio Open External Link](https://diabetesbio.libsyn.com/)\\n    *   [Diabetes Care On Air Open External  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Link](https://diabetescareonair.libsyn.com/site)\\n    *   [Diabetes Core Update Open External                   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Link](https://docupdate.libsyn.com/site)\\n    *   [Diabetes Core Update Special                                 \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Editions](https://diabetesjournals.org/journals/pages/diabetes-core-update-special-editions)\\n    *   [Diabetes \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Day by Day Open External Link](https://diabetesdaybyday.libsyn.com/site)\\n\\n*   [Professional News Open         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m External Link](https://professional.diabetes.org/)\\n\\n[_Search Dropdown Menu_](javascript:;)\\n\\nheader          \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m search\\n\\nsearch input Search input auto suggest \\n\\nfilter your search \\n\\n[Search](javascript:;)\\n\\n[Advanced \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Search](https://diabetesjournals.org/advanced-search)\\n\\n[_User Tools Dropdown_](javascript:;)\\n\\n[Sign In      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m _Open Menu_](javascript:;)\\n\\n[![Image 3: Diabetes                                                              \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Care](https://ada.silverchair-cdn.com/data/SiteBuilderAssets/Live/Images/care/care-header-97500660.svg)](https: \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m //diabetesjournals.org/care)\\n\\n[_Toggle Menu_ Menu](javascript:;)\\n*   [Articles & Issues _Open                \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Menu_](javascript:;)\\n    *   [Current Issue](https://diabetesjournals.org/care/issue)\\n    *   [Online Ahead   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m of Print](https://diabetesjournals.org/care/online-ahead-of-print)\\n    *   [ADA Standards of                   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Care](https://diabetesjournals.org/care/issue/48/Supplement_1)\\n    *   [Issue                                  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Archive](https://diabetesjournals.org/care/issue-covers)\\n    *   [Featured Article                             \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Collections](https://diabetesjournals.org/journals/pages/diabetes_care_featured_collection)\\n    *   [All       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Article Collections](https://diabetesjournals.org/journals/collections)\\n    *   [Saved                         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Searches](https://diabetesjournals.org/my-account/saved-searches)\\n\\n*   [Review                                \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Articles](https://diabetesjournals.org/collection/2178/Review-Articles)\\n*   [Info & About _Open                \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Menu_](javascript:;)\\n    *   [About the Journal](https://diabetesjournals.org/care/pages/about-the-journal)\\n  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m *   [About the Editors](https://diabetesjournals.org/care/pages/Editorial_Board)\\n    *   [ADA Journal          \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Policies](https://diabetesjournals.org/journals/pages/ada-journal-policies)\\n    *   [Reuse, Licensing, and     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Public Access](https://diabetesjournals.org/journals/pages/license)\\n    *   [Reprints and                      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Permissions](https://diabetesjournals.org/journals/pages/reprints-and-permissions)\\n    *                       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m [Advertising](https://diabetesjournals.org/journals/pages/advertising)\\n\\n*   [Podcasts _Open                   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Menu_](javascript:;)\\n    *   [All ADA Podcasts](https://diabetesjournals.org/journals/pages/podcasts)\\n    *   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m [DiabetesBio Open External Link](https://diabetesbio.libsyn.com/)\\n    *   [Diabetes Care On Air Open External  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Link](https://diabetescareonair.libsyn.com/site)\\n    *   [Diabetes Core Update Open External                   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Link](https://docupdate.libsyn.com/site)\\n    *   [Diabetes Core Update Special                                 \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Editions](https://diabetesjournals.org/journals/pages/diabetes-core-update-special-editions)\\n    *   [Diabetes \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Day by Day Open External Link](https://diabetesdaybyday.libsyn.com/site)\\n\\n*   [Submit & Review _Open          \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Menu_](javascript:;)\\n    *   [Instructions for                                                                 \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Authors](https://diabetesjournals.org/care/pages/instructions-for-authors)\\n    *   [Submit a Manuscript Open   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m External Link](http://mc.manuscriptcentral.com/diabetescare)\\n    *   [Submit Cover                             \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Artwork](https://diabetesjournals.org/care/pages/submit_a_cover_image)\\n    *   [Guidance for                   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Reviewers](https://diabetesjournals.org/journals/pages/reviewers)\\n\\n*   [Subscribe _Open                       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Menu_](javascript:;)\\n    *   [Subscriptions                                                                    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Home](https://diabetesjournals.org/journals/pages/journal_subscriptions)\\n    *   [Individual                   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Subscriptions](https://diabetesjournals.org/journals/pages/individual_subscriptions)\\n    *   [Institutional    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Subscriptions](https://diabetesjournals.org/journals/pages/institutional_journal_subscriptions)\\n    *   [Site  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Licensing](https://diabetesjournals.org/journals/pages/site_licensing)\\n    *   [Access Institutional Usage     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Reports](https://diabetesjournals.org/journals/pages/access-institutional-usage-reports)\\n    *   [Sign Up for  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Email Alerts](https://diabetesjournals.org/my-account/alerts)\\n\\n[Skip Nav                                      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Destination](https://diabetesjournals.org/care/article/48/Supplement_1/S6/157564/Summary-of-Revisions-Standards \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m -of-Care-in-Diabetes#)\\n\\nClose navigation menu\\n\\nArticle navigation\\n\\n[Volume 48, Issue                      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Supplement_1](https://diabetesjournals.org/care/issue/48/Supplement_1)\\n\\n January 2025 \\n\\n[![Image 4:         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Diabetes Care Cover Image for Volume 48, Issue                                                                  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Supplement_1](https://ada.silverchair-cdn.com/ada/content_public/journal/care/issue/48/supplement_1/7/m_diacare \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m _48_supplement_1_cover.png?Expires=1765621439&Signature=kpBXHYiNj~-5SAPfzmcft5iXOlw2MQsyxjf8g2DRlDFgeuWxA9yeTll \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m zjgPTvuAf0XVVktjE4PCG8761SHu-5P3DffgyJDroTJs6Ac-9gyzwTyU0ffeZukjU3eGr41DbJggTN6XfkbYKnrtQ89Txb8pZm2PSVYGqL06GEV \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 8TlyVg2VWEu1zeNlbLxIk-ZNFgaFZ4QY8-qdNJb~OU0TflpiZZaDrMHyVD4~6xeshPECZEdFMwPu1u-aY5~S~uj-o7q3nRmIA8C3yr5QHsIC86M \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Z6WuIhYQ7OWbMkpcJmYD5c0k~kRe9kzDm~06Bww6fw9EJy9SuBloNnyPbEP2BxwyA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)](https:// \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m diabetesjournals.org/care/issue/48/Supplement_1)\\n\\n*   [Previous                                               \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Article](https://diabetesjournals.org/care/article/48/Supplement_1/S1/157562/Introduction-and-Methodology-Stand \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m ards-of-Care-in)\\n*   [Next                                                                                     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Article](https://diabetesjournals.org/care/article/48/Supplement_1/S14/157553/1-Improving-Care-and-Promoting-He \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m alth-in)\\n\\nArticle Contents\\n\\n*   [General                                                                    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Changes](https://diabetesjournals.org/care/article/48/Supplement_1/S6/157564/Summary-of-Revisions-Standards-of- \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Care-in-Diabetes#5310725) \\n*   [Section                                                                        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Changes](https://diabetesjournals.org/care/article/48/Supplement_1/S6/157564/Summary-of-Revisions-Standards-of- \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Care-in-Diabetes#5310729) \\n\\nArticle Navigation\\n\\nSummary of Revisions|December 09 2024\\n\\nSummary of         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Revisions: Standards of Care in Diabetesâ€”2025                                                                   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m _Free_\\n===============================================================\\n\\n[American Diabetes Association       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Professional Practice Committee](javascript:;)\\n\\n American Diabetes Association Professional Practice          \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Committee \\n\\n Search for other works by this author on: \\n\\n[This                                              \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Site](https://diabetesjournals.org/care/search-results?f_AllAuthors=American+Diabetes+Association+Professional+ \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Practice+Committee+)\\n\\n[PubMed](http://www.ncbi.nlm.nih.gov/pubmed?cmd=search&term=American%20Diabetes%20Assoc \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m iation%20Professional%20Practice%20Committee)\\n\\n[Google                                                        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Scholar](http://scholar.google.com/scholar?q=author:%22%20%22)\\n\\n[![Image 5: Crossmark: Check for              \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Updates](https://crossmark-cdn.crossref.org/widget/v2.0/logos/CROSSMARK_Color_horizontal.svg)](javascript:;)\\n\\ \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m n_Diabetes Care_                                                                                                \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 2025;48(Supplement_1):S6â€“S13\\n\\n[https://doi.org/10.2337/dc25-SREV](https://doi.org/10.2337/dc25-SREV)\\n\\nPubMe \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m d:\\n\\n[39651984](https://pubmed.ncbi.nlm.nih.gov/39651984)\\n\\n*                                                 \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m [Split-Screen](https://diabetesjournals.org/care/article-split/48/Supplement_1/S6/157564/Summary-of-Revisions-S \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m tandards-of-Care-in-Diabetes)\\n*   [_Views Icon_ Views _Open Menu_](javascript:;)\\n    *   [Article             \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m contents](javascript:;)\\n\\n*   [Open the PDF for in another                                                     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m window](https://diabetesjournals.org/care/article-pdf/48/Supplement_1/S6/791587/dc25srev.pdf)\\n*   [_Share      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Icon_ Share](javascript:;)\\n    *   [Facebook](javascript:;)\\n    *   [X](javascript:;)\\n    *                  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m [LinkedIn](javascript:;)\\n    *   [Email](javascript:;)\\n\\n*   [_Cite Icon_ Cite](javascript:;) \\n*   [Get      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Permissions](http://s100.copyright.com/AppDispatchServlet?publisherName=Wiley&publication=0149-5992&title=Summa \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m ry%20of%20Revisions%3A%20Standards%20of%20Care%20in%20Diabetes%E2%80%942025&publicationDate=2024-12-09&volumeNu \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m m=48&issueNum=Supplement_1&author=American%20Diabetes%20Association%20Professional%20Practice%20Committee%3B%20 \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m ElSayed%2C%20Nuha%20A.&startPage=S6&endPage=S13&contentId=10.2337%2Fdc25-SREV&oa=&orderBeanReset=True)          \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m \\n\\nCitation\\n\\nAmerican Diabetes Association Professional Practice Committee; Summary of Revisions: Standards  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m of Care in Diabetesâ€”2025. _\\\\_Diabetes Care\\\\__ 1 January 2025; 48 (Supplement_1): S6â€“S13.                      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m [https://doi.org/10.2337/dc25-SREV](https://doi.org/10.2337/dc25-SREV)\\n\\nDownload citation file:\\n\\n*   [Ris   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m (Zotero)](https://diabetesjournals.org/Citation/Download?resourceId=157564&resourceType=3&citationFormat=0)\\n*  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m [Reference                                                                                                      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Manager](https://diabetesjournals.org/Citation/Download?resourceId=157564&resourceType=3&citationFormat=0)\\n*   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m [EasyBib](https://diabetesjournals.org/Citation/Download?resourceId=157564&resourceType=3&citationFormat=0)\\n*  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m [Bookends](https://diabetesjournals.org/Citation/Download?resourceId=157564&resourceType=3&citationFormat=0)\\n* \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m [Mendeley](https://diabetesjournals.org/Citation/Download?resourceId=157564&resourceType=3&citationFormat=0)\\n* \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m [Papers](https://diabetesjournals.org/Citation/Download?resourceId=157564&resourceType=3&citationFormat=0)\\n*   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m [EndNote](https://diabetesjournals.org/Citation/Download?resourceId=157564&resourceType=3&citationFormat=1)\\n*  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m [RefWorks](https://diabetesjournals.org/Citation/Download?resourceId=157564&resourceType=3&citationFormat=3)\\n* \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m [BibTex](https://diabetesjournals.org/Citation/Download?resourceId=157564&resourceType=3&citationFormat=2)\\n\\nt \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m oolbar search\\n\\n[_Search Dropdown Menu_](javascript:;)\\n\\ntoolbar search\\n\\nsearch input Search input auto     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m suggest \\n\\nfilter your search \\n\\n[Search](javascript:;)\\n\\n[Advanced                                          \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Search](https://diabetesjournals.org/advanced-search)\\n\\nGeneral Changes\\n---------------\\n\\nThe field of       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m diabetes care is rapidly changing as new research, technology, and treatments that can improve the health and   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m well-being of people with diabetes continue to emerge. With annual updates since 1989, the American Diabetes    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Association has long been a leader in producing guidelines that capture the most current state of the           \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m field.\\n\\nThe 2025 â€œStandards of Care in Diabetesâ€ has continued to incorporate person-first and inclusive      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m language. Efforts were made to consistently apply terminology that empowers people with diabetes and recognizes \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m the individual at the center of diabetes care.\\n\\nAlthough levels of evidence for several recommendations have  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m been updated, these changes are not outlined below where the clinical recommendation has remained the same.     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m That is, changes in evidence level from, for example, **E** to **C**, are not noted below. The 2025 Standards   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m of Care contains, in addition to many minor changes that clarify recommendations or reflect new evidence, more  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m substantive revisions detailed below.\\n\\nSection Changes\\n---------------\\n\\n### Endorsements\\n\\nFor the second \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m consecutive year, the â€œBone Heathâ€ subsection in Section 4, â€œComprehensive Medical Evaluation and Assessment of \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Comorbidities,â€ received endorsement from the American Society for Bone and Mineral Research and Section 8,     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m â€œObesity and Weight Management for the Prevention of Type 2 Diabetes,â€ received endorsement from The Obesity    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Society. For the seventh consecutive year, Section 10, â€œCardiovascular Disease and Risk Management,â€ received   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m endorsement from the American College of Cardiology. For the first time, Section 13, â€œOlder Adults,â€ received   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m endorsement from the American Geriatrics Society.\\n\\n### Section 1. Improving Care and Promoting Health in      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Populations\\n\\n([https://doi.org/10.2337/dc25-S001](https://doi.org/10.2337/dc25-S001))\\n\\nRecommendation 1.1   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m was expanded to include people at risk for diabetes in addition to those with diabetes.\\n\\nRecommendation 1.2   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m was revised to include, in addition to the Chronic Care Model, other evidence-based care delivery models and    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m frameworks that have been demonstrated to improve diabetes care delivery and health outcomes. These include the \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Patient-Centered Medical Home model, Accountable Care Organizations, and value-based payment models and are     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m discussed in the text.\\n\\nRecommendation 1.5 was added to emphasize the importance of quality improvement       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m initiatives and interprofessional teams for supporting sustainable and scalable process changes that improve    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m quality of care and health outcomes. Implementation concepts were added throughout the section to provide       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m actionable guidance on how to implement and sustain interventions that improve care delivery and population     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m health.\\n\\nRecommendation 1.6 was added to emphasize the importance of assessing and addressing disparities in  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m diabetes care and health outcomes. The text includes actionable guidance on measuring health disparities and    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m engaging interprofessional teams and community partners to address them.\\n\\nRecommendation 1.7 was revised to   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m emphasize the importance of screening for and addressing multiple social determinants of health that impact     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m diabetes management, health outcomes, and quality of life.\\n\\nThe narrative text now includes an expanded       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m discussion of cost and affordability considerations as well as health disparities and social determinants of    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m health.\\n\\n[**Table 1.1**](https://doi.org/10.2337/dc25-S001) was added to highlight the importance of engaging \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m an interprofessional team approach to person-centered care for people with diabetes across the life             \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m span.\\n\\n### Section 2. Diagnosis and Classification of                                                         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Diabetes\\n\\n([https://doi.org/10.2337/dc25-S002](https://doi.org/10.2337/dc25-S002))\\n\\n[**Table                \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 2.3**](https://doi.org/10.2337/dc25-S002) was added to provide considerations related to the use and            \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m interpretation of laboratory measurement of glucose and A1C.\\n\\nThe â€œClassificationâ€ subsection has been        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m updated to provide a pragmatic approach to management of individuals who have features of both type 1 and type  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 2 diabetes.\\n\\nIn the â€œType 1 Diabetesâ€ subsection, Recommendation 2.7 was added to emphasize the importance of \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m antibody-based screening for presymptomatic type 1 diabetes in individuals with a family history of type 1      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m diabetes or otherwise known elevated genetic risk. The associated text was also updated and expanded to reflect \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m these changes.\\n\\nThe â€œGestational Diabetes Mellitusâ€ subsection was completely updated to facilitate           \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m understanding and implementation of the current various approaches to screening for and diagnosis of            \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m gestational diabetes mellitus (GDM).\\n\\nThe text in various other subsections, including those that discuss     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m diabetes and immune checkpoint inhibitors, the role of the gut microbiome in diabetes risk, and monogenic       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m diabetes, was updated.\\n\\n### Section 3. Prevention or Delay of Diabetes and Associated                         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Comorbidities\\n\\n([https://doi.org/10.2337/dc25-S003](https://doi.org/10.2337/dc25-S003))\\n\\nIn the â€œLifestyle  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Behavior Change for Type 2 Diabetes Preventionâ€ subsection, text pertaining to sleep health in relation to risk \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m of type 2 diabetes was added. This addition highlights sleep as a central component in the management of        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m prediabetes and type 2 diabetes, placing it on a level playing field with other lifestyle behaviors (e.g.,      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m physical activity and eating patterns).\\n\\nIn the â€œPharmacologic Interventions to Delay Type 2 Diabetesâ€        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m subsection, the text on the proposed use of vitamin D therapy to prevent type 2 diabetes was extensively        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m updated. The text related to long-term metformin therapy and associated vitamin B12 deficiency was also         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m updated.\\n\\nThe language in Recommendation 3.15 was strengthened to facilitate discussion with selected         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m individuals aged â‰¥8 years with stage 2 type 1 diabetes about the role of teplizumab-mzwv infusion to delay the  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m onset of symptomatic type 1 diabetes (stage 3).\\n\\n### Section 4. Comprehensive Medical Evaluation and          \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Assessment of                                                                                                   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Comorbidities\\n\\n([https://doi.org/10.2337/dc25-S004](https://doi.org/10.2337/dc25-S004))\\n\\nLanguage in        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m [**Fig. 4.1**](https://doi.org/10.2337/dc25-S004) was updated, and [**Table                                     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 4.1**](https://doi.org/10.2337/dc25-S004) was modified to include changes made throughout Section               \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 4.\\n\\nRecommendation 4.3 was changed to include assessment for glycemic status and previous treatment at the    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m initial visit and follow-up visits as appropriate.\\n\\n[**Table 4.2**](https://doi.org/10.2337/dc25-S004) was    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m amended to include essential components for assessment, planning, and referral as appropriate.\\n\\nChanges were  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m made in the â€œImmunizationsâ€ subsection to reflect updates for COVID-19, pneumococcal pneumonia, influenza, and  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m respiratory syncytial virus. [**Table 4.3**](https://doi.org/10.2337/dc25-S004) was revised to include          \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m important vaccination updates.\\n\\nRecommendation 4.6 was modified to specify initial and repeat screening for   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m autoimmune thyroid disease.\\n\\nRecommendation 4.10 was updated to specify avoiding medications with known       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m association with higher fracture risk.\\n\\nRecommendation 4.12 was revised to include the recommended intake of  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m calcium for people with diabetes.\\n\\nRecommendation 4.13 was updated to specify when antiresorptive medications \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m and osteoanabolic agents should be considered.\\n\\n[**Table 4.4**](https://doi.org/10.2337/dc25-S004) was        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m updated to specify when bone mineral density testing should be performed.\\n\\nA new subsection, â€œDental Care,â€   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m was added and includes two new recommendations. Recommendation 4.15 was added to state people with diabetes     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m should be referred for a dental exam at least once per year. Recommendation 4.16 was added to state that        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m efforts between medical and dental teams should be coordinated so that glucose-lowering medications can be      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m appropriately adjusted prior to and in the postâ€“dental procedure period as needed.\\n\\nRecommendation 4.17 was   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m updated to reflect that an assessment for disability should be performed at the initial visit and an assessment \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m for decline in function should be performed at each subsequent visit.\\n\\nRecommendation 4.18 was modified to    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m include inquiring about sexual health in men and to screen with a morning serum total testosterone if symptoms  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m and/or signs of hypogonadism are present.\\n\\nRecommendation 4.19 was added to specifically state that men with  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m diabetes or prediabetes should be screened for erectile dysfunction, and new text was added on erectile         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m dysfunction.\\n\\nA new subsection, â€œFemale Sexual Dysfunction,â€ was added and includes two new recommendations.  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Recommendation 4.20 states that health care professionals should inquire about sexual health, particularly in   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m women who experience depression and/or anxiety and those with recurrent urinary tract infections.               \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Recommendation 4.21 was added to state that health care professionals should screen for symptoms and/or signs   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m of genitourinary syndrome of menopause.\\n\\nThe terminology for nonalcoholic fatty liver disease (NAFLD) and     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m nonalcoholic steatohepatitis (NASH) was updated to metabolic dysfunctionâ€“associated steatotic liver disease     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m (MASLD) and metabolic dysfunctionâ€“associated steatohepatitis (MASH), respectively. This updated nomenclature    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m was incorporated throughout the section.\\n\\nRecommendation 4.22a was revised to specify when to screen for the  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m risk of having or developing cirrhosis related to MASH using the calculated fibrosis-4 index                    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m (FIB-4).\\n\\nRecommendation 4.23 was amended to state that adults with type 2 diabetes or prediabetes and a      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m FIB-4 >1.3 should have additional risk stratification performed.\\n\\nRecommendation 4.24 was revised to state    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m that individuals with a higher risk for significant liver fibrosis should be referred to a gastroenterologist   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m or hepatologist.\\n\\nRecommendation 4.25 was revised to include an interprofessional team approach when          \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m promoting weight loss, particularly with a structured nutrition plan and physical activity program for          \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m cardiometabolic benefits and histological improvement.\\n\\nRecommendation 4.26 was revised to include a dual     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m glucose-dependent insulinotropic polypeptide (GIP) and glucagon like peptide 1 (GLP-1) receptor agonist (RA)    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m with potential benefits in MASH as an adjunctive therapy to lifestyle interventions for weight loss in adults   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m with type 2 diabetes, MASLD, and overweight or obesity.\\n\\nRecommendation 4.27a was revised to state that in    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m adults with type 2 diabetes and biopsy-proven MASH or those at high risk for liver fibrosis, use of             \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m pioglitazone or a GLP-1 RA or a dual GIP and GLP-1 RA is preferred for glycemic management due to potential     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m beneficial effects on MASH.\\n\\nRecommendation 4.27b was added to state that combination therapy with            \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m pioglitazone and a GLP-1 RA can be considered for treatment of hyperglycemia in adults with type 2 diabetes     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m with biopsy-proven MASH or those at high risk of liver fibrosis because of potential beneficial effects of such \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m a combination on MASH.\\n\\nRecommendation 4.28 was added to state that treatment with a thyroid hormone          \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m receptor-Î² agonist in adults with type 2 diabetes or prediabetes with MASLD with moderate (F2) or advanced (F3) \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m liver fibrosis may be considered and that the individual should be referred to a gastroenterologist or          \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m hepatologist with expertise in MASLD management for the initiation and monitoring of this                       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m therapy.\\n\\nRecommendation 4.29 was added to emphasize that treatment initiation and monitoring should be       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m individualized and within the context of an interprofessional team for MASLD and MASH management.\\n\\n[**Figure  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 4.2**](https://doi.org/10.2337/dc25-S004) was revised to reflect important updates to the diagnostic algorithm  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m for risk stratification and the prevention of cirrhosis in individuals MASLD, and new [**Fig.                   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 4.3**](https://doi.org/10.2337/dc25-S004) includes the MASLD treatment algorithm.\\n\\n### Section 5.             \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Facilitating Positive Health Behaviors and Well-being to Improve Health                                         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Outcomes\\n\\n([https://doi.org/10.2337/dc25-S005](https://doi.org/10.2337/dc25-S005))\\n\\nIn the â€œDiabetes        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Self-Management Education and Supportâ€ subsection, Recommendation 5.1 was updated to emphasize that all people  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m with diabetes should be advised to participate in diabetes self-management education and support (DSMES) rather \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m than being just encouraged to participate.\\n\\nRecommendation 5.2 was updated to clarify when to provide         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m DSMES.\\n\\nRecommendation 5.3 was revised to be more succinct and action-oriented, placing emphasis on routine   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m assessment of key goals of DSMES.\\n\\nRecommendation 5.4 was added to emphasize the importance of screening for  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m behavioral health concerns at the same time points as evaluating the need for DSMES.\\n\\nLanguage in             \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Recommendation 5.5 was updated to state that DSMES should be culturally appropriate and responsive to           \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m individual preferences, needs, and values.\\n\\nRecommendation 5.6 was updated to reflect the now-common practice \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m of remote-delivery of DSMES and reimbursement for remotely delivered modalities.\\n\\nRecommendation 5.9 was      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m updated to reinforce the importance of screening for and including social determinants of health in guiding the \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m design and delivery of DSMES.\\n\\nIn the â€œMedical Nutrition Therapyâ€ subsection, Recommendation 5.12 was updated \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m to emphasize the importance of providing treatment based on nutrition, physical activity, and behavioral        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m therapy for individuals with overweight or obesity, aiming for at least 3â€“7% weight loss.\\n\\nRecommendation     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 5.14 on eating patterns now has revised verbiage to include processed foods, lean proteins, and nondairy        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m alternatives.\\n\\nRecommendation 5.16 was updated to include actionable language and clarity regarding the use   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m of dietary supplements for glycemic benefits.\\n\\nRecommendations 5.17 and 5.18 were updated to have revised and \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m actionable language, respectively.\\n\\nRecommendation 5.19 was updated to use actionable                         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m language.\\n\\nRecommendation 5.20 was revised to recommend limiting sodium as clinically appropriate, which can  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m be done, in part, by limiting consumption of processed foods.\\n\\nRecommendation 5.21 was modified to recommend  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m water over nutritive and nonnutritive sweetened beverages, and Recommendation 5.22 was added to state that      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m nonnutritive sweeteners can be used instead of sugar-sweetened products in moderation and for short term to     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m reduce overall calorie and carbohydrate intake.\\n\\nRecommendation 5.23 was added to emphasize the screening for \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m malnutrition, especially for those who have undergone metabolic surgery and for those being treated with weight \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m management pharmacological therapies.\\n\\nRecommendation 5.25 was revised to use actionable                      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m language.\\n\\nRecommendation 5.26 was added to address the issue of sodiumâ€“glucose cotransporter (SGLT)          \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m inhibition being associated with ketoacidosis under certain conditions. It provides guidance on awareness,      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m prevention, risk mitigation, and dietary adjustments.\\n\\nRecommendation 5.29 was added to encourage intake of   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m plant-based proteins and fiber, and Recommendation 5.31 was added to encourage limiting foods high in saturated \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m fats to reduce cardiovascular disease risk.\\n\\nTwo new recommendations were added for religious fasting.        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Recommendation 5.32 states to use the Diabetes and Ramadan International Alliance comprehensive prefasting risk \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m assessment for risk stratification of people with diabetes prior to engaging in religious fasting.              \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Recommendation 5.33 was created to provide guidance to health care professionals caring for people with         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m diabetes who participate in religious fasting.\\n\\nAdditionally, newly added [**Fig.                             \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 5.1**](https://doi.org/10.2337/dc25-S005) illustrates differences and similarities between religious and        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m intermittent fasting for people with diabetes. [**Table 5.4**](https://doi.org/10.2337/dc25-S005) includes a    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m risk calculation and suggested risk score for people with diabetes who seek to fast during Ramadan, and         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m [**Table 5.5**](https://doi.org/10.2337/dc25-S005) includes information about medication changes during         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m fasting.\\n\\nIn the â€œPhysical Activityâ€ subsection, Recommendation 5.34 was updated to include a statement about \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m limiting the amount of time spent sedentary, which includes recreational screen time.\\n\\nRecommendation 5.38    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m was modified to state that prolonged sitting should be interrupted at least every 30 min for glycemic           \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m benefits.\\n\\nRecommendation 5.39 was added to counsel adults and youth receiving weight management              \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m pharmacotherapy or metabolic surgery to meet physical activity recommendations. The accompanying text addresses \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m the concern of sarcopenic obesity with use of incretin therapies and metabolic surgery.\\n\\nIn the â€œSmoking      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Cessation: Tobacco, E-cigarettes, and Cannabisâ€ subsection, Recommendation 5.42 was added to advise people with \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m type 1 diabetes and those with other forms of diabetes at risk for diabetic ketoacidosis (DKA) to not use       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m recreational cannabis in any form due to the risk of cannabis hyperemesis syndrome. The accompanying text       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m describes cannabis hyperemesis syndrome and its diagnostic criteria.\\n\\nRecommendation 5.43 in â€œSupporting      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Positive Health Behaviorsâ€ was updated to include health-related quality of life as an outcome when using       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m behavioral health strategies to support self-management and healthy behaviors.\\n\\nRecommendation 5.45 in        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m â€œPsychosocial Careâ€ was revised to state the specific psychosocial concerns health care professionals should    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m screen for including diabetes distress, depression, anxiety, fear of hypoglycemia, and disordered eating        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m behaviors.\\n\\nRecommendation 5.48 in â€œDiabetes Distressâ€ was updated to recommend the frequency of at least     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m annual screening for diabetes distress in people with diabetes, caregivers, and family                          \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m members.\\n\\nRecommendation 5.49 in â€œAnxietyâ€ was updated to recommend screening for anxiety, which is in        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m accordance with the U.S. Preventive Services Task Force recommendation for screening for                        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m anxiety.\\n\\nRecommendation 5.50 in â€œAnxietyâ€ was added to include a recommendation for screening for fear of    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m hypoglycemia in people with diabetes at risk for hypoglycemia or fear of hypoglycemia.\\n\\nRecommendation 5.51   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m in â€œDepressionâ€ was modified to have more actionable language for the importance of depression                  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m rescreening.\\n\\nRecommendation 5.54 in â€œDisordered Eating Behaviorâ€ was updated to recommend screening for      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m disordered or disrupted eating using validated screening measures. The accompanying text describes the          \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m disordered or disrupted eating behaviors commonly reported in people with diabetes.\\n\\n[**Tables                \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 5.7**](https://doi.org/10.2337/dc25-S005) and [**5.8**](https://doi.org/10.2337/dc25-S005) were added to        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m illustrate psychosocial concerns and their association with diabetes-related outcomes in adults with type 1 and \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m type 2 diabetes, respectively.\\n\\n### Section 6. Glycemic Goals and                                             \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Hypoglycemia\\n\\n([https://doi.org/10.2337/dc25-S006](https://doi.org/10.2337/dc25-S006))\\n\\nRecommendation 6.12 \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m was added to promote routine screening for fear of hypoglycemia in individuals at risk for hypoglycemia.\\n\\nA   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m new subsection entitled â€œHyperglycemic Crises: Diagnosis, Management, and Preventionâ€ was added to cover the    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m epidemiology, diagnostic criteria, and outpatient prevention of DKA and the hyperglycemic hyperosmolar state    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m (HHS).\\n\\nNew recommendations on routine assessment of history of DKA and HHS (recommendation 6.20) and         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m providing structured prevention education (Recommendation 6.21) in the outpatient setting were                  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m added.\\n\\n[**Tables 6.9**](https://doi.org/10.2337/dc25-S006) and [**6.10**](https://doi.org/10.2337/dc25-S006) \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m were added and include risk factors for hyperglycemic crises as well as clinical presentation of DKA and HHS in \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m people with diabetes, respectively.\\n\\n[**Figure 6.2**](https://doi.org/10.2337/dc25-S006) was revised to       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m provide a specific and actionable approach to selecting individual glycemic goals, accounting for health status \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m and other person- and treatment-specific factors favoring more or less stringent goals.\\n\\n### Section 7.       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Diabetes                                                                                                        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Technology\\n\\n([https://doi.org/10.2337/dc25-S007](https://doi.org/10.2337/dc25-S007))\\n\\nRecommendation 7.8    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m was modified to emphasize consideration for starting diabetes technology early, even at                         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m diagnosis.\\n\\nRecommendation 7.9 was added to emphasize that reports for all continuous glucose monitoring      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m (CGM) devices, connected insulin devices, and continuous subcutaneous insulin infusion and automated insulin    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m delivery (AID) systems should be standardized with at a minimum the ambulatory glucose profile and weekly       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m summary. In addition, there should be options for raw data or daily and weekly reports available to the health  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m care professionals.\\n\\nRecommendation 7.14 was modified to make the clinician aware of potential interference   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m of medications and other substances on glucose levels measured by blood glucose meters.\\n\\n[**Table             \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 7.2**](https://doi.org/10.2337/dc25-S007) was modified to include the various potential substances or medical   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m conditions that may affect glucose levels when measured by blood glucose meters.\\n\\n[**Table                    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 7.3**](https://doi.org/10.2337/dc25-S007) was modified to include the description of over-the-counter CGM       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m devices.\\n\\nRecommendation 7.15 was modified to support the use of real-time CGM (rtCGM) and intermittently     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m scanned CGM (isCGM) for youth and adults with diabetes (type 1 or type 2) on any type of insulin therapy based  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m on the most recent literature.\\n\\nRecommendation 7.16 was added to consider the use of rtCGM or isCGM in adults \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m with type 2 diabetes on glucose-lowering agents other than insulin to achieve and maintain individualized       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m glycemic goals.\\n\\nRecommendation 7.18 was modified to align with Section 15, â€œManagement of Diabetes in        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Pregnancy,â€ and reflect the update of CGM benefits in type 1 diabetes and pregnancy and other types of diabetes \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m in pregnancy.\\n\\nThe text on CGM was expanded to include the updated sensors integrated with AID systems and to \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m update the most recent literature evidence supporting the benefits of CGM in individuals with type 2 diabetes   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m on glucose-lowering agents other than insulin from clinical trials and real-world studies. Furthermore, the CGM \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m section was expanded to include the need to standardize any diabetes technology device reports and to provide   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m clinicians not only with single page summaries but also with access to detailed reports and even raw data from  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m devices, especially those reporting insulin dose modifications, such as AID systems.\\n\\nThe text on insulin     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m pumps and AID systems was greatly expanded to discuss the features of the various AID systems and their data    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m from pivotal trials and real-world studies in type 1 and type 2 diabetes.\\n\\nRecommendation 7.29 was modified   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m to include provision of support and diabetes management advice in people with diabetes using open-source        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m closed-loop systems.\\n\\nThe text for open-source closed-loop systems was also expanded to include the most      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m recent published evidence on the safety and effectiveness of these systems in people with type 1                \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m diabetes.\\n\\nRecommendation 7.30 was expanded to include the benefits of combining technology with online or    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m virtual coaching to improve glycemic outcomes in individuals with diabetes and prediabetes.\\n\\nRecommendation   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 7.32 was refined to emphasize the importance of continuing the use of insulin pumps or AID in people with       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m diabetes while hospitalized when clinically appropriate and with confirmatory point-of-care blood glucose       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m measurements for insulin dose adjustments and hypoglycemia assessment and treatment. The use of these devices   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m in the inpatient setting should be contingent on the availability of infrastructure support and institutional   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m diabetes technology protocols.\\n\\n### Section 8. Obesity and Weight Management for the Prevention and Treatment \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m of Type 2                                                                                                       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Diabetes\\n\\n([https://doi.org/10.2337/dc25-S008](https://doi.org/10.2337/dc25-S008))\\n\\nRecommendation 8.2a was \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m updated to clarify that additional measurements of body fat distribution are warranted if BMI is                \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m indeterminant.\\n\\nRecommendation 8.2b was revised to recommend monitoring of obesity-related anthropometric     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m measurements at least every 3 months during active weight management treatment.\\n\\nDiscussion of weight stigma  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m and bias toward people living in larger bodies was added to the text.\\n\\nRecommendation 8.11 was enhanced to    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m reflect the importance of continued monitoring, support, and interventions for individuals who have achieved    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m weight loss goals to support the maintenance of these goals long term.\\n\\nRecommendation 8.18 was added to      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m recommend screening for malnutrition for people with diabetes and obesity who have lost significant             \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m weight.\\n\\nRecommendation 8.19 was added to recommend continuing weight management pharmacotherapy, as          \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m indicated, beyond reaching weight loss goals to maintain health benefits and avoid weight regain and worsening  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m of cardiometabolic abnormalities that often result from sudden discontinuation of weight management             \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m pharmacotherapy.\\n\\nRecommendation 8.25 was revised to emphasize use of a CGM device to improve safety in       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m individuals with postâ€“metabolic surgery hypoglycemia.\\n\\nUpdated [**Tables                                      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 8.1**](https://doi.org/10.2337/dc25-S008) and [**8.2**](https://doi.org/10.2337/dc25-S008) provide detailed     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m information on the efficacy, common side effects, safety considerations, and costs of approved weight           \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m management pharmacotherapy options.\\n\\nDiscussion of medication cost and access barriers was added to the text, \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m including suggestions to members of the interprofessional diabetes care team on mitigating financial            \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m barriers.\\n\\n### Section 9. Pharmacologic Approaches to Glycemic                                                \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Treatment\\n\\n([https://doi.org/10.2337/dc25-S009](https://doi.org/10.2337/dc25-S009))\\n\\nThis section was       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m reorganized and expanded with two new subsections: _1_) a subsection titled â€œAdditional Recommendations for All \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Individuals With Diabetesâ€ that includes new recommendations as well as recommendations previously listed with  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m those for individuals with type 1 or type 2 diabetes if pertinent to individuals regardless of their type of    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m diabetes, and _2_) a subsection titled â€œSpecial Circumstances and Populations.â€\\n\\n[**Figure                    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 9.1**](https://doi.org/10.2337/dc25-S009) was revised for clarity, and a general statement was added to         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m [**Table 9.1**](https://doi.org/10.2337/dc25-S009) on dose adjustments when using AID systems.\\n\\nThe           \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m subsection on insulin administration technique was expanded to address inhaled insulin and use of insulin bolus \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m patches.\\n\\nRecommendation 9.8 was revised to emphasize the importance of selecting glucose-lowering            \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m medications that provide sufficient effectiveness and achieve and maintain multiple treatment goals             \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m simultaneously, including improving cardiovascular, kidney, weight, and other relevant outcomes, reducing       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m hypoglycemia risk, and considering cost, access, risk for adverse reactions, and individual                     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m preferences.\\n\\nRecommendations were revised to explicitly advise on choice of pharmacotherapy for individuals  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m with type 2 diabetes and established or high risk of atherosclerotic cardiovascular disease (ASCVD)             \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m (Recommendation 9.10), heart failure (Recommendation 9.11), and chronic kidney disease (CKD) (Recommendation    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 9.12) to improve health outcomes for individuals with these conditions irrespective of A1C.\\n\\nRecommendation   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 9.12 was added to recommend use of GLP-1 RA with demonstrated benefits in individuals with type 2 diabetes,     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m symptomatic heart failure with preserved ejection fraction, and obesity.\\n\\nRecommendation 9.13 was revised to  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m recommend use of either SGLT2 inhibitor or GLP-1 RA with demonstrated benefits in individuals with type 2       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m diabetes and CKD.\\n\\nRecommendations 9.15 and 9.16 were added to recommend treatment of individuals with type 2 \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m diabetes and MASLD or MASH with GLP-1 RA, dual GIP and GLP-1 RA, pioglitazone, or a combination of GLP-1 RA and \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m pioglitazone based on the staging of liver disease risk and need for weight management.\\n\\n[**Figure            \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 9.3**](https://doi.org/10.2337/dc25-S009) and the text discussing choice of glucose-lowering therapy in adults  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m with type 2 diabetes were extensively revised to facilitate evidence-based selection of glucose-lowering        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m therapies based on individualized treatment goals. Considerations of glucose-lowering medication effects on     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m MASLD and MASH were added to [**Fig. 9.3**](https://doi.org/10.2337/dc25-S009).\\n\\n[**Table                     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 9.2**](https://doi.org/10.2337/dc25-S009) was simplified and revised to better highlight important              \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m considerations when choosing medications for lowering glucose in type 2 diabetes.\\n\\nRecommendation 9.20 was    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m clarified to recommend reassessing the need for and/or dose of medications with higher hypoglycemia risk (i.e., \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m sulfonylureas, meglitinides, and insulin) when initiating a new glucose-lowering medication to minimize the     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m risk of hypoglycemia and treatment burden.\\n\\nRecommendation 9.21 was added to advise against concurrent use of \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m a dipeptidyl peptidase 4 inhibitor with a GLP-1 RA due to lack of additional glucose lowering beyond that of a  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m GLP-1 RA alone.\\n\\nRecommendation 9.24 was clarified by specifying that a GLP-1 RA or a dual GIP and GLP-1 RA   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m is preferred to insulin in adults with type 2 diabetes only in the absence of evidence of insulin               \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m deficiency.\\n\\nText in the â€œBasal Insulinâ€ section was revised to provide guidance on switching between         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m different basal insulin formulations.\\n\\n[**Figure 9.4**](https://doi.org/10.2337/dc25-S009) was revised for    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m clarity, and the list of options for prandial insulin was expanded.\\n\\nRecommendation 9.27 was revised to       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m remove consideration of basal insulin doses exceeding 0.5 units/kg/day as evidence of overbasalization.         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Instead, signs of overbasalization including significant bedtime-to-morning or postprandial-to-preprandial      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m glucose differential, occurrences of hypoglycemia (aware or unaware), and high glycemic variability should be   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m used.\\n\\n[**Tables 9.3**](https://doi.org/10.2337/dc25-S009) and [**9.4**](https://doi.org/10.2337/dc25-S009)   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m were updated with glucose-lowering medication and insulin costs as of 1 July 2024, and an expanded discussion   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m on medication costs and affordability was added to the text.\\n\\nIn the new subsection â€œSpecial Circumstances    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m and Populations,â€ Recommendations 9.31a, 9.31b, and 9.31c were added to advise on actions to take when          \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m medications are not available (such as medication shortages); Recommendations 9.32a and 9.32b were added to     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m address care considerations for individuals of childbearing potential; and Recommendation 9.33 was added to     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m provide guidance on mitigating risk of ketoacidosis when individuals at risk for ketoacidosis or who follow a   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m ketogenic eating pattern are treated with SGLT inhibition. Additional text in this subsection discusses         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m considerations for glucose-lowering pharmacotherapy for individuals with diabetes secondary to chemotherapy and \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m with other types of diabetes (i.e., pancreatogenic diabetes, cystic fibrosisâ€“related diabetes, posttransplant   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m diabetes, maturity-onset diabetes of the young, and neonatal diabetes).\\n\\n### Section 10. Cardiovascular       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Disease and Risk                                                                                                \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Management\\n\\n([https://doi.org/10.2337/dc25-S010](https://doi.org/10.2337/dc25-S010))\\n\\nRecommendation 10.1   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m was updated with details on the frequency of recommended blood pressure monitoring.\\n\\n[**Figure                \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 10.2**](https://doi.org/10.2337/dc25-S010) was updated to provide clarity on medication classes for the         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m treatment of confirmed hypertension in nonpregnant people with diabetes.\\n\\nRecommendation 10.12 was modified   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m to specify appropriate monitoring for increased serum creatinine levels, serum potassium levels, and            \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m hypokalemia when ACE inhibitors, angiotensin receptor blockers (ARBs), or mineralocorticoid receptor            \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m antagonists are used.\\n\\nRecommendation 10.13 was added to specify hypertension treatment options that should   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m be avoided during pregnancy and in sexually active individuals of childbearing potential not using reliable     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m contraception.\\n\\nRecommendation 10.26 was added to recommend that in most cases lipid-lowering agents should   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m be discontinued prior to conception and avoided in sexually active individuals of childbearing potential not    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m using reliable contraception, unless the benefits may outweigh the risk.\\n\\n[**Figures                          \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 10.3**](https://doi.org/10.2337/dc25-S010) and [**10.4**](https://doi.org/10.2337/dc25-S010) were added to      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m illustrate recommendations for primary prevention and secondary prevention of ASCVD, respectively, in people    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m with diabetes using cholesterol-lowering therapy.\\n\\nTriglyceride thresholds were updated in Recommendations    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 10.31 and 10.32.\\n\\nThe criteria for coronary artery disease investigations in Recommendation 10.39b were       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m revised to include signs or symptoms of cardiac or associated vascular disease or electrocardiogram             \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m abnormalities.\\n\\nRecommendation 10.41 was modified to include screening for peripheral artery disease (PAD)    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m with ankle-brachial index testing in asymptomatic people with diabetes aged â‰¥65 years, microvascular disease in \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m any location, or foot complications or any end-organ damage from diabetes if a PAD diagnosis would change       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m management. PAD screening should also be considered in individuals with diabetes duration â‰¥10 years and high    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m cardiovascular risk.\\n\\nFor individuals with type 2 diabetes, obesity, and symptomatic heart failure with       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m preserved ejection fraction, Recommendation 10.46d was added to recommend treatment with a GLP-1 RA with        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m demonstrated benefit in this population to reduce heart failureâ€“related symptoms, reduce physical limitations,  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m and improve exercise function.\\n\\n[**Figure 10.5**](https://doi.org/10.2337/dc25-S010) was added to illustrate  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m recommendations for screening for asymptomatic and undiagnosed cardiovascular disease, and [**Fig.              \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 10.6**](https://doi.org/10.2337/dc25-S010) was added to provide an overview of recommendations for the          \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m prevention of the development of symptomatic heart failure in people with diabetes.\\n\\n### Section 11. Chronic  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Kidney Disease and Risk                                                                                         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Management\\n\\n([https://doi.org/10.2337/dc25-S011](https://doi.org/10.2337/dc25-S011))\\n\\nRecommendation 11.3   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m was amended for clarity about optimizing blood pressure management goals.\\n\\nRecommendation 11.4a was revised   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m to clarify that ACE inhibitors or ARBs should be titrated to the maximally tolerated dose to prevent the        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m progression of CKD and reduce cardiovascular events in nonpregnant individuals with diabetes and                \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m hypertension.\\n\\nRecommendation 11.4b was modified to specify appropriate monitoring for increased serum        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m creatinine levels, serum potassium levels, and hypokalemia when ACE inhibitors, ARBs, or mineralocorticoid      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m receptor antagonists are used.\\n\\nRecommendation 11.5b was updated to state that for people with type 2         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m diabetes and CKD, a GLP-1 RA with demonstrated benefit in this population should be used to reduce              \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m cardiovascular risk and kidney disease progression.\\n\\nRecommendation 11.6 was added to state that potentially  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m harmful antihypertensive medications in pregnancy should be avoided in sexually active individuals of           \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m childbearing potential not using reliable contraception and to switch to options considered safer prior to      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m conception and during pregnancy.\\n\\nRecommendation 11.7 was updated to specify reducing urinary albumin by â‰¥30% \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m to slow progression of CKD.\\n\\nRecommendation 11.8 was updated to specify protein goals for individuals with    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m stage 3 or higher CKD and those who are treated with dialysis.\\n\\n[**Table                                      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 11.1**](https://doi.org/10.2337/dc25-S011) was added to include reasons to consider nonâ€“diabetes-related kidney \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m diseases in a person with CKD and diabetes, and [**Table 11.3**](https://doi.org/10.2337/dc25-S011) was added   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m to include suggestions for interventions that lower albuminuria.\\n\\n### Section 12. Retinopathy, Neuropathy,    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m and Foot Care\\n\\n([https://doi.org/10.2337/dc25-S012](https://doi.org/10.2337/dc25-S012))\\n\\nRecommendation     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 12.5 was updated to specify involvement of an ophthalmologist for more frequent examinations if retinopathy is  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m progressing or sight threatening.\\n\\nRecommendation 12.8 wording was changed to reflect that a dilated eye exam \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m should be performed before and in the first trimester, rather than one or the other.\\n\\nRecommendation 12.19    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m was modified to include additional screening criteria for symptoms and signs of autonomic                       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m neuropathy.\\n\\nRecommendation 12.22 was updated to recommend against opioid use for neuropathic pain treatment  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m due to the potential for adverse events, and the narrative text was updated to expand on this.\\n\\nA short       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m discussion on the role of weight management and neuropathy was added to the narrative text.\\n\\nRecommendation   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 12.24 was updated to include the Ipswich touch test as an option for neurological assessment.\\n\\nRecommendation \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 12.29 was expanded to include the importance of smoke cessation and referral for counseling for individuals who \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m smoke and have a prior history of lower-extremity complications, loss of protective sensation, structural       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m abnormalities, or PAD.\\n\\nIncreasing role of surgery in diabetic foot management was added to the narrative     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m text of foot care section.\\n\\n### Section 13. Older                                                             \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Adults\\n\\n([https://doi.org/10.2337/dc25-S013](https://doi.org/10.2337/dc25-S013))\\n\\nThe 4Ms framework of      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m age-friendly health systems (Mentation, Medications, Mobility, and What Matters Most) as it applies to diabetes \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m management in older adults was introduced and illustrated in the new [**Fig.                                    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 13.1**](https://doi.org/10.2337/dc25-S013).\\n\\nRecommendation 13.8a was modified to include time in range and   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m time below range in addition to A1C treatment goals for older adults who are otherwise healthy with few and     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m stable chronic conditions and intact cognitive functional status.\\n\\nRecommendation 13.8b was modified to       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m include time in range and time below range in addition to A1C treatment goals for older adults who have         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m intermediate or complex health who are clinically heterogeneous with variable life expectancy.\\n\\n[**Table      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 13.1**](https://doi.org/10.2337/dc25-S013) was modified to include a column on reasonable CGM goals for each    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m health status category.\\n\\nIn the â€œTreatmentâ€ section, the appropriate selection and use of SGLT2 inhibitors in \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m older adults was expanded.\\n\\n### Section 14. Children and                                                      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Adolescents\\n\\n([https://doi.org/10.2337/dc25-S014](https://doi.org/10.2337/dc25-S014))\\n\\nRecommendation 14.4  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m in the â€œType 1 Diabetesâ€ section was added to emphasize key nutrition principles.\\n\\nRecommendation 14.10 was   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m altered to emphasize limits on sedentary activity.\\n\\nRecommendation 14.21 was changed to state that insulin    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m pumps should be offered to anyone with type 1 diabetes who can use the devices safely.\\n\\nRecommendation 14.24  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m was modified to remove lack of access as a reason for less stringent A1C goals.\\n\\nRecommendation 14.26 was     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m altered to include weight gain as a balancing measure for more stringent A1C goals.\\n\\nRecommendation 14.36 was \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m changed to exclude secondary causes of hypertension.\\n\\nRecommendation 14.41 was updated to include the use of  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m age-approved statins.\\n\\nRecommendation 14.50 was modified to state that screening should be repeated at a      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m minimum of 2-year intervals or more frequently if screening is normal and BMI is increasing.\\n\\nRecommendation  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 14.57 was revised to include the key nutritional principles and provide specific examples of healthy food       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m choices and what foods should be avoided.\\n\\nRecommendation 14.60 was changed to recommend an A1C goal of <6.5% \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m (<48 mmol/mol) for most children and adolescents with type 2 diabetes who have a low risk of hypoglycemia and a \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m higher risk of complications.\\n\\nRecommendation 14.65 was revised to change the terminology from â€œhyperglycemic \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m hyperosmolar nonketotic syndromeâ€ to â€œhyperglycemic hyperosmolar stateâ€ and include intravenous fluid as the    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m initial step to treat severe hyperglycemia (blood glucose â‰¥600 mg/dL) once the diagnosis is confirmed.\\n\\nThe   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m narrative was updated to reinforce the benefits and safety of GLP-1 RAs in decreasing A1C, weight, blood        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m pressure, and insulin dose reduction. [**Figure 14.1**](https://doi.org/10.2337/dc25-S014) was updated to       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m reflect the revision in this recommendation.\\n\\nRecommendation 14.73 was modified to reflect that excluding     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m secondary hypertension is an essential step in hypertension management.\\n\\nRecommendation 14.104 was revised to \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m state that vaping and electronic cigarettes are both discouraged.\\n\\nRecommendation 14.105 in the â€œSubstance    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Use in Pediatric Diabetesâ€ section was added to state that all youth with diabetes should be advised not to use \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m cannabis recreationally in any form.\\n\\nRecommendation 14.108 was modified to encourage pediatric diabetes      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m specialists to partner with youth with diabetes and their caregivers to engage in shared                        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m decision-making.\\n\\n[**Tables 14.1 _A_**](https://doi.org/10.2337/dc25-S014) and [**14.1                        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m _B_**](https://doi.org/10.2337/dc25-S014) were modified to include changes made throughout Section 14.\\n\\n###   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Section 15. Management of Diabetes in                                                                           \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Pregnancy\\n\\n([https://doi.org/10.2337/dc25-S015](https://doi.org/10.2337/dc25-S015))\\n\\nSection 15 was         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m restructured to discuss the care of pregnant individuals with type 1 diabetes, type 2 diabetes, and GDM in all  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m sections and to discuss aspects of management in each relevant subsection (e.g., preconception care and         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m pharmacotherapy); consequently, the order of appearance of some of the recommendations                          \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m changed.\\n\\nRecommendation 15.7 wording was changed to reflect that a dilated eye exam should be performed      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m before and in the first trimester, rather than one or the other.\\n\\n[**Table                                    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 15.1**](https://doi.org/10.2337/dc25-S015) was updated with a folic acid supplement recommendation of 400â€“800   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Î¼g/day and clarification for which checklist items are only for individuals with preexisting diabetes and not   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m for individuals with prediabetes or a history of GDM, and specific immunizations were omitted and               \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m referenced.\\n\\nIn Recommendation 15.10, the benefits of CGM use in type 1 diabetes and pregnancy were           \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m clarified, and an addition of its potential to be beneficial in other types of diabetes in pregnancy was        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m added.\\n\\nRecommendation 15.12 no longer states that CGM metrics should not be used as a substitute for blood   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m glucose monitoring; the recommendation now states that CGM may be used in conjunction with blood glucose        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m monitoring to achieve glycemic goals.\\n\\nGlucose goals for preexisting diabetes, GDM treated with insulin, and  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m GDM not treated with insulin are consolidated into a new [**Table                                               \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 15.2**](https://doi.org/10.2337/dc25-S015).\\n\\nâ€œManagement of Gestational Diabetes Mellitusâ€ and â€œManagement of \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Preexisting Type 1 Diabetes and Type 2 Diabetes Pregnancyâ€ were merged into one subsection, titled â€œManagement  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m of Diabetes in Pregnancy,â€ which includes all aspects of management for all types of diabetes (e.g., nutrition, \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m physical activity, and pharmacotherapy).\\n\\nRecommendation 15.14 provides more clarification on the recommended \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m eating pattern in pregnancy.\\n\\nInsulin recommendations that were previously split into separate                \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m recommendations for preexisting diabetes and GDM were merged.\\n\\nThere are two new recommendations regarding    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m AID use in type 1 diabetes and pregnancy. Recommendation 15.19 states that AID systems are recommended if the   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m system has a pregnancy-specific glucose goal. Recommendation 15.20 states that AID systems may be considered    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m for select individuals with an experienced health care team if the system does not have a pregnancy-specific    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m glucose goal or algorithm.\\n\\nRecommendation 15.21 provides more clarification for why metformin and glyburide  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m should not be first-line agents for management of diabetes in pregnancy.\\n\\nThe narrative for subsection        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m â€œPhysical Activityâ€ includes recommended activity levels for pregnancy, as these pertain to individuals with    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m any type of diabetes in pregnancy.\\n\\nThe â€œInsulinâ€ subsection includes information on different insulin        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m delivery modalities used during labor and delivery or postpartum.\\n\\nThe recommendation to explicitly measure   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m blood pressure during pregnancy is now mentioned in the narrative of the â€œPreeclampsia and Aspirinâ€ subsection  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m per the recent guidelines of the U.S. Preventive Services Task Force.\\n\\nRecommendation 15.25 was split into    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m two recommendations. Recommendation 15.25a provides more examples of potentially harmful medications in         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m pregnancy. Recommendation 15.25b recommends that lipid-lowering medications be avoided in most circumstances in \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m pregnancy but that statins may be considered for use in high-risk individuals (such as those with prior ASCVD   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m and familial hypercholesterolemia) when benefits outweigh risks. The narrative discusses Recommendation 15.25b  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m in more detail and includes discussion of studies of pravastatin use in pregnancy.\\n\\n### Section 16. Diabetes  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Care in the Hospital\\n\\n([https://doi.org/10.2337/dc25-S016](https://doi.org/10.2337/dc25-S016))\\n\\nDiabetes    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m care in the hospital stresses identification and treatment of dysglycemia and provides glycemic goals. For the  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m treatment of persistent hyperglycemia starting at a threshold of â‰¥180 mg/dL (â‰¥10.0 mmol/L), Recommendation      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 16.4a was amended to reflect that insulin should be initiated or intensified for the majority of critically ill \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m individuals, and Recommendation 16.4b was added to state that insulin and/or other glucose-lowering therapies   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m should be initiated or intensified for the majority of noncritically ill individuals.\\n\\nRecommendation 16.5a   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m was updated to state that a glycemic goal of 140â€“180 mg/dL (7.8â€“10.0 mmol/L) is recommended for most critically \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m ill individuals, but more stringent individualized glycemic goals may be appropriate if they can be achieved    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m without significant hypoglycemia. Recommendation 16.5b was updated to recommend a glycemic goal of 100â€“180      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m mg/dL (5.6â€“10.0 mmol/L) for most noncritically ill individuals if it can be achieved without significant        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m hypoglycemia.\\n\\nRecommendation 16.7 was amended for clarity on the use of insulin pump or AID continuation and \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m their use in people with diabetes who are hospitalized, when clinically appropriate.\\n\\nRecommendation 16.8a    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m was added to state that continuous intravenous insulin infusion is recommended for achieving glycemic goals and \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m avoiding hypoglycemia in critically ill individuals.\\n\\nThe language regarding a hypoglycemia management        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m surveillance protocol for health systems was updated for clarity in Recommendation 16.12.\\n\\nGuidance regarding \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m use of GLP-1 RA and dual GIP and GLP-1 RA medications in the perioperative setting and regarding instructions   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m in preparation for procedures or surgery has been added to the narrative text.\\n\\nRecommendations 16.14 and     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 16.15 were added for DKA and HHS management; transition to maintenance subcutaneous insulin administration and  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m discharge planning were added. Additionally, the newly added [**Fig. 16.1**](https://doi.org/10.2337/dc25-S016) \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m includes treatment pathways for DKA and HHS.\\n\\n### Section 17. Diabetes                                        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Advocacy\\n\\n([https://doi.org/10.2337/dc25-S017](https://doi.org/10.2337/dc25-S017))\\n\\nThe subsections         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m â€œDiabetes Care in the School Settingâ€ and â€œDiabetes and Drivingâ€ were updated with information from recently    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m published advocacy statements. The subsection â€œDiabetes Management in Detention Facilitiesâ€ was added with      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m information from a recently published advocacy statement.\\n\\n*A complete list of members of the American        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Diabetes Association Professional Practice Committee can be found at                                            \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m [https://doi.org/10.2337/dc25-SINT](https://doi.org/10.2337/dc25-SINT).\\n\\nDuality of interest information for  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m each author is available at [10.2337/dc25-SDIS](https://doi.org/10.2337/dc25-SDIS).\\n\\nSuggested citation:      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m American Diabetes Association Professional Practice Committee. Summary of revisions: Standards of Care in       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Diabetesâ€”2025. Diabetes Care 2025;48(Suppl. 1):S6â€“S13\\n\\nÂ© 2024 by the American Diabetes                        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Association\\n\\n2024\\n\\nReaders may use this article as long as the work is properly cited, the use is           \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m educational and not for profit, and the work is not altered. More information is available at                   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m [https://www.diabetesjournals.org/journals/pages/license](https://www.diabetesjournals.org/journals/pages/licen \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m se).\\n\\n[](https://diabetesjournals.org/care/article/48/Supplement_1/S6/157564/Summary-of-Revisions-Standards-o \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m f-Care-in-Diabetes)\\n\\n417,299                                                                                  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Views\\n\\n[29](https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=silverchair&SrcAuth=WosAPI&KeyUT=WOS: \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 001378283000018&DestLinkType=CitingArticles&DestApp=WOS_CPL)Web of Science\\n\\n[![Image 6: Article has an        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m altmetric score of                                                                                              \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 32](https://badges.altmetric.com/?size=128&score=32&types=mttttttu)](https://www.altmetric.com/details.php?doma \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m in=diabetesjournals.org&citation_id=171817539)\\n\\n[View Metrics](javascript:;)\\n\\n[Ã—Close                       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Modal](javascript:;)\\n\\n### Email alerts\\n\\n[Article Activity Alert](javascript:;)\\n\\n[Online Ahead of Print    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Alert](javascript:;)\\n\\n[Latest Issue Alert](javascript:;)\\n\\n[Close Modal](javascript:;)\\n\\n*   Online ISSN    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 1935-5548\\n*   Print ISSN 0149-5992\\n\\n### Journals\\n\\n*   [Diabetes](https://diabetesjournals.org/diabetes)\\n* \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m [Diabetes Care](https://diabetesjournals.org/care)\\n*   [Diabetes, Obesity, and Cardiometabolic                 \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m CARE](https://diabetesjournals.org/docm-care)\\n*   [Clinical                                                    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Diabetes](https://diabetesjournals.org/clinical)\\n*   [Diabetes                                                 \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Spectrum](https://diabetesjournals.org/spectrum)\\n*   [Standards of Medical Care in                             \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Diabetes](https://diabetesjournals.org/care/issue/48/Supplement_1)\\n*   [Scientific Sessions                    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Abstracts](https://diabetesjournals.org/journals/pages/scientific-sessions-abstracts)\\n*   [BMJ Open Diabetes   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Research & Care](https://drc.bmj.com/)\\n\\n### Books\\n\\n*                                                        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m [ShopDiabetes.org](https://shopdiabetes.org/collections/professional-books)\\n*   [ADA Professional              \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Books](https://diabetesjournals.org/books)\\n\\n### Clinical Compendia\\n\\n*   [Clinical Compendia                 \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Home](https://diabetesjournals.org/compendia)\\n\\n### News\\n\\n*   [Latest                                        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m News](https://www.diabetes.org/newsroom)\\n*   [DiabetesPro                                                      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m SmartBrief](https://www2.smartbrief.com/signupSystem/subscribe.action?pageSequence=1&briefName=diabetespro)\\n\\n \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m ### Podcasts\\n\\n*   [Diabetes Core                                                                              \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Update](https://diabetesjournals.org/journals/pages/diabetes-core-update-podcasts)\\n*   [Diabetes Care \\\"On     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Air\\\"](https://sites.libsyn.com/453336/site)\\n*   [DiabetesBio](https://sites.libsyn.com/499063/site)\\n*        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m [Diabetes Day by Day](https://sites.libsyn.com/435096/site)\\n*   [Diabetes Core Update: Special                 \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Editions](https://diabetesjournals.org/journals/pages/diabetes-core-update-special-editions)\\n\\n### Other\\n\\n*  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m [Special Collections](https://diabetesjournals.org/journals/pages/journals_special_collections)\\n*              \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m [DiabetesProÂ®](https://professional.diabetes.org/)\\n*   [Diabetes Food                                          \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Hubâ„¢](https://www.diabetesfoodhub.org/)\\n*   [Insulin Affordability](https://doi.org/10.2337/dci18-0019)\\n*     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m [Know Diabetes By Heartâ„¢](https://www.knowdiabetesbyheart.org/)\\n\\n### About\\n\\n*   [About the                  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m ADA](https://www.diabetes.org/about-us)\\n*   [Journal                                                           \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Policies](https://diabetesjournals.org/journals/pages/ada-journal-policies)\\n*   [For                           \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Reviewers](https://diabetesjournals.org/journals/pages/reviewers)\\n*   [Advertising in ADA                      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Journals](https://diabetesjournals.org/journals/pages/advertising)\\n*   [Reprints and Permission for            \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Reuse](https://diabetesjournals.org/journals/pages/reprints-and-permissions)\\n*   [Copyright Notice/Public      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Access Policy](https://diabetesjournals.org/journals/pages/license)\\n*   [Privacy                               \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Policy](https://diabetes.org/about-us/policies/privacy-policy)\\n\\n### Resources\\n\\n*   [ADA Professional        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Membership](https://professional.diabetes.org/membership)\\n*   [ADA Member                                      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Directory](http://professional.diabetes.org/directory)\\n*                                                       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m [Diabetes.org](http://www.diabetes.org/)\\n\\n[![Image                                                            \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 7](https://ada.silverchair-cdn.com/data/SiteBuilderAssetsOriginals/Live/images/umbrella/logo-umbrella-footer.sv \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m g?versionId=6439)](https://diabetes.org/)\\n\\n*   [Bluesky](https://bsky.app/profile/adapubs.bsky.social)\\n*     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m [X (Twitter)](https://twitter.com/ADA_Pubs)\\n*   [Facebook](https://www.facebook.com/adaPublications)\\n*        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m [LinkedIn](https://www.linkedin.com/company/american-diabetes-association/)\\n\\n*   [Contact                     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Us](https://diabetesjournals.org/contact-us)\\n*   [Cookie                                                       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Policy](https://diabetesjournals.org/journals/pages/Policies)\\n*                                                \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m [Accessibility](https://diabetesjournals.org/pages/Accessibility)\\n*   [Terms &                                 \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Conditions](https://diabetes.org/about-us/policies/terms-of-use)\\n*   [Get Adobe Acrobat                        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Reader](https://get.adobe.com/reader/)\\n*   Â© Copyright American Diabetes Association\\n\\n[_Close                \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Modal_](javascript:;)\\n\\n[Close Modal](javascript:;)\\n\\n##### This Feature Is Available To Subscribers          \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Only\\n\\n[Sign                                                                                                   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m In](https://diabetesjournals.org/sign-in?returnUrl=%2fcare%2farticle%2f48%2fSupplement_1%2fS6%2f157564%2fSummar \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m y-of-Revisions-Standards-of-Care-in-Diabetes) or [Create an                                                     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Account](https://diabetesjournals.org/my-account/register?siteId=1000003&returnUrl=%2fcare%2farticle%2f48%2fSup \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m plement_1%2fS6%2f157564%2fSummary-of-Revisions-Standards-of-Care-in-Diabetes)\\n\\n[_Close                        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Modal_](javascript:;)\\n\\n[_Close Modal_](javascript:;)\\n\\n This site uses cookies. By continuing to use our     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m website, you are agreeing to [our privacy                                                                       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m policy.](https://www.diabetesjournals.org/content/privacy-policy-american-diabetes-association-journals)\\n\\n[Ac \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m cept](javascript:;)\\n\\nclose                                                                                    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m advertisement\\n\\n##Source\\nhttps://diabetesjournals.org/care/article/48/Supplement_1/S6/157564/Summary-of-Revis \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m ions-Standards-of-Care-in-Diabetes\"]                                                                            \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ•°â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â•¯\u001b[0m\n"
            ],
            "text/html": [
              "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #808000; text-decoration-color: #808000\">â•­â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€ ðŸ”§ Tool Output â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â•®</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> [\"## Title\\n[PDF] IDF Global Clinical Practice Recommendations for Managing Type 2 ...\\n\\n## Content\\nIDF       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Global Clinical Practice Recommendations for Managing Type 2 Diabetes 2025 IDF Global Clinical Practice         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Recommendations for Managing Type 2 Diabetes 2025 In Memoriam We are deeply saddened by the passing of          <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Professor Akhtar Hussain (IDF President 2022-2024), who served as Chair of this initiative and led its          <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> development. His leadership, dedication, and expertise significantly shaped this publication. We respectfully   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> dedicate this work to his memory.\\nCorrespondence Prof. Stephen Colagiuri (co-chair), University of Sydney,     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Sydney, Australia. stephen.colagiuri@sydney.edu.au; Prof. Antonio Ceriello (co-chair), IRCCS MultiMedica,       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Milan, Italy. antonio.ceriello@hotmail.it Acknowledgements International Centre for Professional Development in <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Health and Medicine (ICPDHM), Team â€“ Canada Bhavadharini Balaji, PhD - Lead medical writer, Alanna Grant, PhD - <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Senior medical writer and editorial support, Jenny Anawati, Vice President, Anatoly Langer, MD, MSc, FRCPS(C),  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> FACC, Chair, Vivianne Vinet, Chief Executive Officer, IDF Executive Office Lorenzo Piemonte (Belgium) Lucy      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Michaeloudis (France) Paraskevi Salpea (United States) Phil Riley (Belgium) Sameer Pathan (United Kingdom)      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Xango Bimont (France) Sponsorsâ€™ duality of interest This update of the 2005 International Diabetes Federation   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> (IDF) Global Guideline on type 2 diabetes was supported by educational grants from Sanofi and Servier.\\nThese   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> companies did not take part in any aspect of the development of these clinical practice recommendations.        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Copyright No part of this publication may be reproduced or transmitted in any form or by any means without the  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> written prior permission of the International Diabetes Federation. Requests to reproduce or translate this      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> publication should be e-mail at communications@idf.org.\\nÂ© International Diabetes Federation, 2025 ISBN         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 978-2-930229-97-3 Please cite this report as International Diabetes Federation. IDF Global Clinical Practice    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Recommendations for Managing Type 2 Diabetes â€“ 2025. https://idf.org/t2d-cpr-2025 Co-chairs: Antonio Ceriello   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> (Italy) Contributors: Tadej Battelino (Slovenia) A Enrique Caballero (USA) Juliana CN Chan (Hong Kong, China)   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Francesco Cosentino (Sweden) Amalia Gastadelli (Italy) Per-Henrik Groop (Finland) Akhtar Hussain (Norway) â€“ in  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> memoriam David Jenkins (Canada) Linong Ji (China) Stephen Colagiuri (Australia) IDF TECHNICAL WORKING GROUP     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Nebojsa Lalic (Serbia) Carolyn SP Lam (Singapore) Rayaz A Malik (Qatar) Roopa Mehta (Mexico) Viswanathan Mohan  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> (India) Renan MagalhÃ£es Montenegro Junior (Brazil) Ayesha A Motala (South Africa) Peter E.H. Schwarz (Germany)  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Luc Van Gaal (Belgium) Antonio PÃ©rez (Spain) Gojka Roglic (Switzerland) Banshi Saboo (India) Petar M SeferoviÄ‡  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> (Serbia) Jonathan Shaw (Australia) Wayne H-H Sheu (Taiwan, China) Nigel Unwin (UK) Daisuke Yabe (Japan) Jian    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Zhou (China) Project Development, Coordination, and Dissemination Sameer Pathan, Senior Manager at the          <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> International Diabetes Federation, served as project lead and coordinator for this publication, overseeing its  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> development, expert engagement, finalisation, and global dissemination.\\nExternal Reviewers: Adel El Sayed      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> (Egypt) Mohammed Eslam (Australia) Massimo Federici (Italy) Edward W Gregg (UK) James L Januzzi, Jr (USA)       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Alicia Jenkins (Australia) Anatoly Langer (Canada) Maddalena Lettino (Italy) Geltrude Mingrone (Italy) Bernard  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Omech (Uganda) Foreward Introduction Antonio Ceriello, MD &amp; Stephen Colagiuri, MD Chapter 1 Detection of        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> diabetes and intermediate hyperglycaemia, and prevention of type 2 diabetes Chapter 2 Glycaemic control         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> assessment and targets in type 2 diabetes Chapter 3 Blood glucose-lowering therapies â€“ non-insulin options for  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> type 2 diabetes Chapter 4 Blood glucose-lowering therapies â€“ insulin options for type 2 diabetes Chapter 5      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Weight control in type 2 diabetes mellitus management Chapter 6 Cardio-renal protection in type 2 diabetes      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Chapter 7 Management of metabolic dysfunction-associated steatotic liver disease (MASLD) in type 2 diabetes Pg. <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 13 Pg. 9 Pg. 18 Pg. 34 Pg. 50 Pg. 62 Pg. 74 Pg. 86 Pg. 100 TABLE OF CONTENTS 9 Foreward IDF Global Clinical     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Practice Recommendations for Managing Type 2 Diabetes â€“ 2025 FOREWARD IDF Global Clinical Practice              <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Recommendations for Managing Type 2 Diabetes â€“ 2025 10 On behalf of the International Diabetes Federation       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> (IDF), it is my great pleasure to present this 2025 edition of the IDF Global Clinical Practice Recommendations <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> for Managing Type 2 Diabetes. These recommendations reflect our ongoing commitment to improving the lives of    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> people living with diabetes worldwide by equipping healthcare providers with the tools to help them deliver     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> high-quality, evidence-based care. Diabetes remains a serious and fast-growing public health challenge. The IDF <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Diabetes Atlas estimated that 589 million adults aged 20â€“79 years were living with diabetes in 2024 and that    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> this number is projected to reach 853 million by 2050. Type 2 diabetes mellitus (T2DM), which accounts for      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> between 90% and 95% of all diabetes cases, places a substantial burden on individuals, families, and healthcare <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> systems. Around half of all T2DM cases remain undiagnosed. If not managed, T2DM can lead to severe              <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> complications, including cardiovascular disease, chronic kidney disease, retinopathy, neuropathy, and liver     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> disease. With an early diagnosis and access to appropriate treatment and support, T2DM can be controlled and    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> its associated complications prevented or delayed. Furthermore, there is increasing evidence that remission of  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> T2DM may be possible in the early stages of the condition. Therefore, early detection, effective management,    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> and preventive strategies are imperative to address the burden T2DM places on individuals and their families.   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> The 2025 IDF global clinical practice recommendations have been updated to incorporate the latest evidence and  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> advancements in diabetes care. These recommendations provide a structured yet adaptable framework for           <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> healthcare professionals, ensuring they are equipped with practical guidance tailored to diverse clinical       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> settings. A key feature of these recommendations is their unique approach to distinguishing between optimal and <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> basic care strategies, allowing for context-specific adaptation while maintaining high standards of diabetes    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> management. This edition covers a broad range of critical topics, including epidemiology, glycaemic targets,    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> blood glucose management (both non-insulin and insulin therapies), weight control, cardio-renal health, and the <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> impact FOREWARD 11 Foreward of metabolic dysfunction-associated steatotic liver disease (MASLD) on diabetes     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> outcomes. These recommendations prioritise a person-centred approach, ensuring that care is aligned with the    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> individual needs, preferences, and circumstances of people living with diabetes. The development of these       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> recommendations has been a collaborative effort, bringing together leading experts from around the world. I     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> extend my heartfelt gratitude to the co-chairs of the Technical Working Group, Professor Stephen Colagiuri and  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Professor Antonio Ceriello, and to all the contributors, reviewers, and editors who have dedicated their time   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> and expertise to this initiative. I acknowledge the essential contribution of our past president, the late      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Professor Akhtar Hussain, whose vision and dedication were instrumental in shaping this project from the        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> outset. He would be extremely proud that this document has been produced and launched in time for our congress, <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> in keeping with his wishes. His contributions will remain a legacy in the field of diabetes care and education. <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Additionally, I extend my appreciation to the IDF Executive Office for their unwavering support in delivering   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> this document. The impact of these recommendations will be determined by their implementation. We urge          <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> healthcare providers, policymakers, and other key diabetes stakeholders to adopt and adapt these guidelines     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> within their local contexts, ensuring they lead to meaningful improvements in diabetes care. By working         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> together, we can alleviate the global burden of diabetes, prevent its complications, and move closer to         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> achieving universal health coverage and health equity for all those living with or at risk of diabetes. The     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> International Diabetes Federation remains steadfast in its goal to support healthcare professionals, empower    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> people living with diabetes, and drive innovation in diabetes care. We hope these recommendations will serve as <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> a valuable resource for all those working to improve diabetes management in primary care settings. Thank you    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> for joining us in this vital effort. Together, we can create a world where everyone has access to the care they <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> need to lead healthy, fulfilling lives. Professor Peter Schwarz IDF President, 2024â€“2027 13 Introduction        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Antonio Ceriello &amp; Stephen Colagiuri IDF Global Clinical Practice Recommendations for Managing Type 2 Diabetes  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> â€“ 2025 STANDARDS OF CARE IDF Global Clinical Practice Recommendations for Managing Type 2 Diabetes â€“ 2025 14    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> The principles of T2DM care are as follows: o An holistic approach to delivering evidence-based care centred    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> around the person with diabetes, empowered through self-management education and support o A well-trained       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> multidisciplinary health professional team o Decision support systems (registries, reminders, audits, and       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> feedback) Diabetes is a major global health challenge, with an estimated 589 million adults in 2024 living with <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> diabetes, of whom almost one-in-two were undiagnosed. In addition, another 1.1 billion adults worldwide had     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> impaired glucose tolerance or impaired fasting glycaemia predisposing them to an increased risk of developing   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> type 2 diabetes mellitus (T2DM). These numbers are projected to increase significantly over the next two        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> decades.1 T2DM is the most common type of diabetes, accounting for over 90% of all diabetes worldwide, and is   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> associated with increased all-cause mortality and macrovascular and microvascular complications. There is       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> strong evidence that the T2DM burden can be reduced by controlling hyperglycaemia and associated risk factors,  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> diagnosing earlier, and preventing high-risk individuals from progressing to T2DM. The global burden of T2DM    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> continues to increase despite the wealth of existing evidence on diabetes care and prevention. Optimal diabetes <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> management is not reaching the majority of individuals who could benefit. Poor glycaemic control is common in   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> T2DM and does not meet the World Health Organization (WHO) goal of 80% of people with diagnosed diabetes        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> achieving good glycaemic control.2 INTEGRATED DIABETES CARE deliver care in the context of a chronic care model <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> which addresses the multifaceted challenges inherent to this complex condition. Structured diabetes care is an  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> essential aspect of integrated care and underscores the significance of systematic and organised processes,     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> including assessment as a crucial component of quality assurance. Regular evaluation of the person with T2DMâ€™s  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> progress and adherence to agreed care plans creates a foundation for data-driven decision-making. International <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Diabetes Federation guidelines The first International Diabetes Federation (IDF) Global Guideline for Type 2    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Diabetes was published in 20053,4 and an update for primary care physicians was published in 2017.5 Since then, <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> T2DM management has undergone considerable transformation marked by noteworthy developments. New medications    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> have emerged, offering a broader range of therapeutic options and a more personalised approach to care aligning <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> interventions with individual needs. Concurrently, tests for assessing and monitoring diabetes have evolved.    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> The integration of technology into diabetes care has transformed the interaction between individuals with T2DM  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> and their providers. Wearable devices, continuous glucose monitoring systems, and mobile applications are       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> available for the daily management of T2DM in well-resourced healthcare systems. Coupled with the adoption of   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> virtual care, including telemedicine and digital health platforms, these technological advancements have        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> expanded access to care, fostering engagement and facilitating ongoing monitoring and support. The IDF Global   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Clinical Practice Recommendations for Managing Type 2 Diabetes - 2025 IDF is a global umbrella organisation of  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> more than 240 national diabetes associations from 161 countries and territories, representing a diverse range   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> of health systems and populations. Developing global clinical practice recommendations which are relevant,      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> applicable, and equitable across these various healthcare settings presents a unique challenge. Clinical        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> guidance recommendations of national and international learned societies are formulated on the highest level of <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> available evidence in relatively well-resourced health STANDARDS OF CARE Providing this care requires a         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> comprehensive, integrated, individual-centred strategy supported by a health system structured to 15            <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Introduction systems with universal health coverage or at least coverage of essential health services. This     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> does not reflect global reality, with an estimated 4.5 billion people not covered by essential health services  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> and exposed to out-of-pocket health expenses and impoverishing financial hardship. Regrettably, the recent      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> global pattern is one of stagnating progress in service coverage with catastrophic health spending increasing   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> across all regions and most countries.6 In this context, current clinical guidance may be of limited practical  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> use in countries with resource-challenged health systems. This new IDF Global Clinical Practice Recommendations <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> for Managing Type 2 Diabetes - 2025 attempts to strike a balance, embracing the latest therapeutic and          <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> technological evidence while acknowledging the realities of providing diabetes care in a diverse global         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> healthcare environment. These guidelines aspire to provide healthcare professionals and policy makers with an   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> effective and contemporary framework for navigating the complexities of diabetes management that is sensitive   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> to resource, affordability, access, and equity. Levels of diabetes care and prevention approach All people with <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> or at risk of diabetes should have equitable and affordable access to the best available evidence-based,        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> cost-effective integrated diabetes care and prevention. However, it is widely recognised that many countries    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> and health systems around the world do not currently have the workforce or financial resources to provide this  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> level of diabetes care. An imperative in formulating IDF guidance is recognising the limitations and            <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> opportunities presented in the context of varying healthcare systems globally. This is pivotal in guiding       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> recommendations that cater to diverse settings, and which can evolve and be adapted to encourage and facilitate <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> healthcare system reform. The 2005 IDF guideline adopted a Levels of Care approach to formulate recommendations <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> for diabetes care and prevention to address the challenges of global variations in available healthcare         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> resources, expertise, and funding across different countries and localities.3,4 Unlike national guidelines      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> formulated for a particular healthcare system, this perspective is necessary to increase the global relevance   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> and applicability of IDF recommendations. To serve its global membership, the IDF has developed this global     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> guidance that is resource-, capacity-, and cost-sensitive while ensuring an appropriate level of care which     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> will improve outcomes relative to the current situation. Standards of diabetes care and prevention IDF clinical <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> and prevention recommendation advice is now based on two levels of standards of diabetes care and prevention    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> which recognise the diversity of global healthcare systems and inherent resource constraints. Optimal Careâ€¯sets <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> the standard for evidence-based care which would ideally be universally available and represents the most       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> desirable care to achieve best outcomes. This care requires well-resourced health systems which would usually   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> include some form of universal health coverage. It may be available to subgroups of the population in less      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> well-resourced health systems but is not generally available. It should be the aim of all healthcare systems to <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> achieve this standard of care. Basic Careâ€¯aims to achieve the main objectives of \\\"Optimal Care\\\" but is        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> provided in a healthcare setting with limited resources. It serves as a foundational level or starting point to <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> ensure that, even with limited resources, individuals receive essential care and establishes a pathway towards  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Optimal Care. IDF Global Clinical Practice Recommendations for Managing Type 2 Diabetes â€“ 2025 16 The intended  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> users of these guidelines are all healthcare professionals involved in the management of people with T2DM (and  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> those at risk of developing T2DM) and policy makers who are responsible for healthcare services to improve      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> individual and population health. The focus on policy makers is particularly important to ensure that           <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> healthcare and health system reform is implemented to provide universal optimal care. Methodology This guidance <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> focuses on recent advances in diabetes care and prevention. An IDF expert panel was appointed to guide the      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> development of these recommendations, which were formulated using an evidence-based consensus approach. The     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> process included proposing pertinent questions deemed most relevant for the effective management of individuals <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> with, or at risk of, T2DM. These questions were systematically categorised into various topics. Experts in      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> their respective field compiled evidence summaries for each section. The entire group convened to discuss the   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> synthesised evidence on the various topics and draft recommendations. A preliminary document was shared with    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> external reviewers for broader input. Feedback received was carefully reviewed, and revisions made to address   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> duplications and consolidate the evidence and recommendations. The International Centre for Professional        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Development in Health and Medicine (ICPDHM.com), a not-for-profit physician organisation based in Canada,       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> provided medical writing, editorial, and logistical support throughout the development. Acknowledgements The    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> IDF Global Clinical Practice Recommendations for Managing Type 2 Diabetes - 2025 was supported by educational   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> grants from Sanofi and Servier. These companies did not take part in any aspect of the development of these     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> clinical practice recommendations. Medical writing support was provided by, Bhavadharini Balaji, PhD and Alanna <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Grant, PhD of the International Centre for Professional Development in Health and Medicine (ICPDHM), Quebec,    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Canada. REFERENCES 1. International Diabetes Federation (IDF). IDF Diabetes Atlas, 11th edition. Brussels,      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Belgium: International Diabetes Federation, 2025. Available from: http://www.diabetesatlas.org. 2. World Health <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Organization. First-ever global coverage targets for diabetes adopted at the 75th World Health Assembly.        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Available from: https://www.who.int/news-room/                                                                  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> feature-stories/detail/first-ever-global-coverage-targets-for-diabetes-adopted-at-the-75-th-world-health-assemb <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> ly [Accessed February 2025]. Optimal Care Basic Care Definition Evidence-based care and prevention provided in  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> well-resourced settings Evidence-based care and prevention adapted for resource-constrained settings. Serves as <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> a starting point towards Optimal Care Target audience Healthcare professionals and policy makers in             <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> well-resourced settings Healthcare professionals and policy makers in resource-constrained settings             <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Accessibility All individuals with or at risk of diabetes Essential care for all individuals regardless of      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> resource limitations Scope â€¢\\tComprehensive â€¢\\tIndividual-centred â€¢\\tMultidisciplinary care â€¢\\tDecision support <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> systems â€¢\\tFocus on essential services and prioritised programmes â€¢\\tAdapted to challenges of local healthcare  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> settings â€¢\\tIndividual-centred â€¢\\tBest available multidisciplinary care approach Table 1. Standards of diabetes <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> care and prevention STANDARDS OF CARE 17 Introduction 3. IDF Clinical Guidelines Task Force. Global guideline   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> for type 2 diabetese. Brussels: International Diabetes Federation, 2005. IDF Clinical Guidelines Task Force.    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Global guideline for type 2 diabetes: Recommendations for standard, comprehensive, and minimal care. Diabet     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Med. 2006;23(6):579-93. 4. IDF Clinical Guidelines Task Force. Global guideline for type 2 diabetes:            <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Recommendations for standard, comprehensive, and minimal care. Diabet Med. 2006;23(6):579-93. 5. IDF Working    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Group. IDF clinical practice recommendations for managing type 2 diabetes in primary care. Available from:      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> https://idf.org/media/uploads/2023/05/ attachments-63.pdf [Accessed May 2024]. 6. World Health Organization.    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Tracking universal health coverage: 2023 global monitory report. Available from: https://www.who.int/           <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> publications/i/item/9789240080379 [Accessed February 2025]. 18 Detection of Diabetes and Intermediate           <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Hyperglycaemia, and Prevention of Type 2 Diabetes Chapter 1 SCREENING AND PREVENTION 19 Chapter 1               <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> RECOMMENDATIONS Optimal Care Basic Care Criteria for defining diabetes and intermediate hyperglycaemia WHO      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> criteria ADA criteria Diabetes Fasting plasma glucose (FPG) â‰¥7.0 mmol/L (126 mg/dL) â‰¥7.0 mmol/L (126 mg/dL) 2 h <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> plasma glucose* â‰¥11.1 mmol/L (200 mg/dL) â‰¥11.1 mmol/L (200 mg/dL) HbA1c â‰¥6.5% (48 mmol/mol) â‰¥6.5% (48 mmol/mol) <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Intermediate hyperglycaemia Impaired fasting glucose (IFG) Fasting plasma glucose 6.1â€“6.9â€¯mmol/L (110â€“125       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> mg/dL) 5.6â€“6.9 mmol/L (100â€“125 mg/dL) Impaired glucose tolerance (IGT) 2 h plasma glucose* 7.8â€“11.0 mmol/L      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> (140â€“199 mg/dL) 7.8â€“11.0 mmol/L (140â€“199 mg/dL) HbA1c â€“ 5.7%â€“6.4% (39â€“47 mmol/mol) Options for screening for    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> diabetes and intermediate hyperglycaemia Target group: determine locally Risk assessment: â€¢\\tRisk scores â€“      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> developed locally or adapted to local factors â€¢ Risk factors â€“ excessive weight, family history, gestational    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> diabetes history, etc.\\nBiochemical testing options: â€¢\\tFPG â€¢\\t2 h OGTT â€¢\\tHbA1c 1 h PG during 75 g OGTT is an  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> emerging option Select the screening protocol based on available resources and capacity to intervene (in those  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> identified as high-risk) with a diabetes prevention programme Diabetes prevention programmes for high-risk      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> individuals â€¢ Offer a locally developed or adapted 6â€“12-month structured lifestyle modification diabetes        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> prevention programme aiming for 5% weight loss if overweight/obese. â€¢ Consider metformin as additional          <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> intervention â€¢ Provide regular reassessment of individuals â€¢ Support the programme with data systems â€¢          <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Regularly monitor and evaluate the programme Consider the feasibility of implementing a community-based         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> lifestyle modification diabetes prevention programme Diabetes prevention population strategies Implement        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> population programmes to encourage healthier eating, increased physical activity, and healthy weight Consider   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> population programme to encourage healthier eating, increased physical activity, and healthy weight *Following  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> a 75 g oral glucose tolerance test.\\nADA, American Diabetes Association; FPG, fasting plasma glucose; HbA1c,    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> glycated haemoglobin; OGTT, oral glucose tolerance test; WHO, World Health Organization.\\nIDF Global Clinical   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Practice Recommendations for Managing Type 2 Diabetes â€“ 2025 20 SCREENING AND PREVENTION o Globally, there is a <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> high number of people with diabetes, which is predicted to continue to increase; almost one in two people       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> living with diabetes are undiagnosed. o Diabetes can be diagnosed by fasting plasma glucose, 2 h oral glucose   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> tolerance test (OGTT), and glycated haemoglobin (HbA1c) with universally agreed diagnostic criteria. However,   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> there is a lack of congruence between these measures. o Screening for undiagnosed diabetes will identify        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> individuals who will benefit from early treatment. o Intermediate hyperglycaemia (IH) (also referred to as      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> â€œprediabetesâ€) includes impaired glucose tolerance (IGT), impaired fasting glucose (IFG), and intermediate      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> HbA1c. The WHO and ADA criteria for defining IH differ for IFG and WHO does not have an HbA1c criterion. o The  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> prevalence of IH is higher than diabetes but varies with the screening test â€“ these tests lack congruence. IGT  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> can only currently be detected by a 2 h OGTT. o The 1 h OGTT test has recently been advocated as another        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> option. o Screening for IH identifies individuals who can benefit from interventions to prevent type 2 diabetes <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> mellitus (T2DM). o Strategies for diabetes prevention include the individual-based high-risk approach and the   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> population approach. o Structured lifestyle modification programmes are effective in preventing or delaying     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> T2DM in people with IGT but not isolated IFG. Data for HbA1c-detected IH are limited. Some medications can      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> prevent or delay T2DM. o Prevention strategies have been successfully translated in community or national       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> programmes in a number of countries. o The design of programmes has differed in relation to target group,       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> screening process and test, and intensity and method of delivery of the lifestyle intervention. Little data are <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> available on the impact on diabetes prevention, but weight reduction and increased physical activity are        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> encouraging. o A decision to implement a high-risk individual diabetes prevention programme should be guided by <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> local resources, health system capacity, and cost. Local design and adaptation are important. o Population      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> approaches aiming to reduce modifiable diabetes risk factors in the whole population include healthier eating,  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> regular physical activity, and preventing and managing overweight and obesity. o Encouragingly, there appears   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> to be a stabilisation or decline in diabetes incidence in many higher-income countries. KEY POINTS 21 Chapter 1 <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> BACKGROUND In 2024, an estimated 589 million adults aged 20 to 79 were living with diabetes, giving a           <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> prevalence of 11.1%. Almost one-in-two (42.8%; 251.7million) adults with diabetes were undiagnosed, with        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> considerable regional differences.1 In addition, the global prevalence of impaired glucose tolerance (IGT) was  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 12.0% and that of impaired fasting glucose (IFG) was 9.2%.1 Individuals with undiagnosed type 2 diabetes        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> mellitus (T2DM) and intermediate hyperglycaemia (IH) are at increased risk of adverse outcomes and premature    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> mortality. Type 2 diabetes is a silent, progressive disease with chronic hyperglycaemia often preceded by IH.   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Earlier detection of T2DM provides an opportunity to intervene with evidence-based care and studies over the    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> last three decades confirm that progression from IH to T2DM can be prevented or delayed. Tests used for the     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> early detection of diabetes and IH include fasting plasma glucose (FPG), 2 h PG during a 75 g oral glucose      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> tolerance test (OGTT), or glycated haemoglobin (HbA1c). Programmes for the detection of undiagnosed T2DM and    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> the prevention of progression to T2DM in high-risk individuals are well-accepted strategies to reduce the       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> burden of diabetes. GLOBAL CONSIDERATIONS The capacity to detect individuals with undiagnosed T2DM and IH and   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> implement diabetes prevention programmes varies considerably between countries and health services and systems, <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> especially in low- and middle-income countries (LMIC). The World Health Organization (WHO) periodically         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> conducts a country capacity survey on non-communicable diseases (NCDs) to assess the national-level response to <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> the NCD burden, which includes information on health system capacity for diabetes detection, treatment, and     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> care. The most recent survey in 2019 collected data from 160 countries; 75% reported having an operational      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> policy, strategy, or action plan for diabetes. Specific details on diabetes screening and prevention were not   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> reported. The percent of countries with guidelines utilised in at least 50% of healthcare facilities was 22%    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> for overweight/obesity and 33% for physical activity. Fifty-two percent of countries had an OGTT generally      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> available in 50% of their primary care facilities in the public and private health sector; 53% of countries had <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> HbA1c tests.2 The Pan American Health Organization separately reported its survey results and found that 33 of  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 35 countries (94%) had blood glucose measurement equipment, 22 of 35 countries (63%) had OGTT testing, and 18   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> of 35 countries (51%) had HbA1c testing generally available in 50% of public primary healthcare facilities.3 A  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> survey of individuals from LMICs showed that the reach of any diabetes prevention-related activities was low:   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 40% for physical activity counselling, 37% for weight loss counselling, 43% for dietary counselling, and 37%    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> for blood glucose screening. The lowest receipt of these activities was among people in low-income countries    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> and people with no formal education.4 EVIDENCE SUMMARY Criteria for diabetes and intermediate hyperglycaemia    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Criteria for diabetes and IH have evolved since the first WHO guidelines were published in 1965, with           <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> significant changes made by expert panels of WHO and the American Diabetes Association (ADA) to reflect         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> evolving evidence and its interpretation.5 Since there is no specific marker which unequivocally defines        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> diabetes, the diagnosis is based on cut-points derived from the relationship between various measures of        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> glycaemia associated with risk of diabetes microvascular complications, particularly retinopathy.5 Without a    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> true gold standard among the biochemical tests for diagnosing diabetes (FPG, 2 h OGTT PG, HbA1c), comparisons   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> of these tests are questionable. It has been suggested that the closest to a gold standard would be a           <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> combination of FPG, 2 h PG, and HbA1c assessments with confirmatory testing for all parameters, but this is not <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> feasible.6 This also applies to tests and comparisons of tests for IH. There are significant differences in the <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> attributes of tests used to diagnose diabetes and IH which influence the testing method adopted in different    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> health settings and services.7,8 These include requirement for fasting, global access and affordability,        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> analytic stability, biologic variation, and factors affecting the assay (Table 1.1). IDF Global Clinical        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Practice Recommendations for Managing Type 2 Diabetes â€“ 2025 22 SCREENING AND PREVENTION FPG OGTT HbA1c Fasting <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> required Yes Yes No Test preparation Fasting Pretest CHO intake Nil Convenience Reasonable Low Good Global      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> access and affordability Highest Intermediate Intermediate Pre-analytic stability Poor â€“ influenced by sample   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> handling Good Assay standardisation Not standardised Standardised but varies globally Biological variation      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Intermediate High Low Within-person variation High Low Acute factors affecting result Food intake, stress,      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> activity Not affected Other factors affecting results Diurnal variation Older age Medications                   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Haemoglobinopathies Altered red cell turnover, uraemia Ethnicity Diagnostic sensitivity (compared to OGTT)      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Lower Highest Lower Identifies IGT No Yes No Lifestyle prevention intervention effect Negative (for isolated    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> IFG) Positive (for IGT +/â€“ IFG) Limited data Table 1.1 Comparison of tests to diagnose diabetes and define      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> intermediate hyperglycaemia CHO, carbohydrate; FPG, fasting plasma glucose; IFG, impaired fasting glucose;      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> HbA1c, glycated haemoglobin; IGT, impaired glucose tolerance; OGTT, oral glucose tolerance test. Diabetes       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Criteria Definitions of diabetes are universally agreed, with both WHO and ADA adopting the same FPG, 2 h PG,   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> and HbA1c diagnostic values (Table 1.2). WHO criteria ADA criteria Diabetes Fasting plasma glucose (FPG) â‰¥7.0   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> mmol/L (126 mg/dL) â‰¥7.0 mmol/L (126 mg/dL) 2 h plasma glucose* â‰¥11.1 mmol/L (200 mg/dL) â‰¥11.1 mmol/L (200       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> mg/dL) HbA1c â‰¥6.5% (48 mmol/mol) â‰¥6.5% (48 mmol/mol) Intermediate hyperglycaemia Impaired fasting glucose (IFG) <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Fasting plasma glucose 6.1â€“6.9â€¯mmol/L (110â€“125 mg/dL) 5.6â€“6.9 mmol/L (100â€“125 mg/dL) Impaired glucose tolerance <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> (IGT) 2 h plasma glucose* 7.8â€“11.0 mmol/L (140â€“199 mg/dL) 7.8â€“11.0 mmol/L (140â€“199 mg/dL) HbA1c â€“ 5.7%â€“6.4%     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> (39â€“47 mmol/mol) *Following a 75 g oral glucose tolerance test. ADA, American Diabetes Association; HbA1c,      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> glycated haemoglobin; WHO, World Health Organization.\\nIn asymptomatic individuals, two abnormal values either  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> in the same setting or on separate occasions are recommended for clinical management.5 Table 1.2 Criteria for   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> defining diabetes and intermediate hyperglycaemia 23 Chapter 1 Prevalence Prevalence data for diabetes vary and <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> are influenced by the method used to identify individuals with diabetes, which may include diabetes based on    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> self-report, and/or taking diabetes-specific medication, and/or testing of people without known diabetes,       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> and/or testing people with self-report diabetes but not taking medication. Furthermore, there is a              <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> well-recognised lack of congruence between FPG, 2 h PG, and HbA1c tests in identifying individuals as having    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> diabetes.9 In 2024, the International Diabetes Federation (IDF) reported a global diabetes prevalence in        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 20â€“79-year-olds of 11.1% (589 million people), which was predicted to increase to 853 million by 2050. Diabetes <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> prevalence was similar in men and women, highest in those aged 75â€“79 years, higher in urban (12.7%) than rural  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> (8.8%) areas, and in high-income (12.4%) compared to low-income countries (6.1%). Regional differences were     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> also noted, with the highest prevalence in the Middle East and North Africa IDF region (19.9%) and the lowest   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> in the Africa IDF region (5.0%), and the largest numbers of people with diabetes in China (148 million) and     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> India (90 million).1 Methods for diabetes diagnosis included any of the three glucose measures, self-report,    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> medical record or clinic diagnosis, and extrapolations for countries without data.10 In 2022, the NCD Risk      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Factor Collaboration estimated that 828 million adults aged 18 years and older had diabetes, an increase of 630 <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> million from 1990, with the largest increases in low- and middle-income countries. The global age-standardised  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> diabetes prevalence was 13.9% for women and 14.3% for men. These estimates were based on defining diabetes as   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> an FPG â‰¥7.0 mmol/L (126 mg/dL) or an HbA1c â‰¥6.5% (48 mmol/mol), or taking medication for diabetes.11 Previously <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> undiagnosed diabetes In 2024, almost one in two (42.8%; 251.7 million) adults aged 20â€“79 years old living with  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> diabetes were undiagnosed. There were significant regional disparities in undiagnosed diabetes, and 86.9% of    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> all undiagnosed cases were in low- and middle-income countries. Low-income countries had the highest proportion <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> of undiagnosed cases (58.7%), followed by middle-income countries at 45.5%, and high-income countries at        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 28.9%.1 The lack of congruence between glycaemic measures impacts reported prevalence of undiagnosed diabetes.  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> An analysis of previously undiagnosed diabetes detected by an elevated FPG, HbA1c, or both reported that        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> globally 29% of individuals with screen-detected diabetes had an isolated elevated FPG, 37% had an isolated     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> elevated HbA1c, and 34% had elevated levels of both, with substantial variation across regions. In most low-    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> and middle-income regions, isolated elevated HbA1c was more common than isolated elevated FPG.12 Some of this   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> disparity may relate to ethnic variations in the FPG-HbA1c relationship.13 Intermediate hyperglycaemia          <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Intermediate hyperglycaemia, also referred to as â€œprediabetesâ€, includes impaired glucose tolerance (IGT),      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> impaired fasting glucose (IFG), and intermediate HbA1c. IGT was introduced in 1979 to describe a category of    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> increased risk of progressing to diabetes.14 IFG was introduced in 1997 to describe the FPG zone, which was     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> believed to equate to IGT.15 There are differences in the pathogenesis of IFG and IGT, with IGT associated with <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> muscle insulin resistance and defective insulin secretion, resulting in less efficient disposal of the glucose  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> load during the OGTT; IFG is associated with impaired insulin secretion and impaired suppression of hepatic     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> glucose output.16 Criteria WHO and ADA criteria are the same for IGT but are different for defining IFG (Table  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 1.2), with WHO using an FPG range of 6.1â€“6.9 mmol/L (110â€“125 mg/dL) and the ADA using an FPG range of 5.6â€“6.9   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> mmol/L (100â€“125 mg/dL). Based on an OGTT with measurement of both FPG and 2 h PG, IH can be subdivided into     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> those with isolated IFG, isolated IGT, and combined IFG/IGT. IFG and IGT are not clinical entities but rather   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> risk factors for future diabetes and adverse outcomes, and regression to normoglycaemia is common, ranging from <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 33% to 59% over 1â€“5 years of follow-up for IFG and 17% to 42% over 6â€“11 years of follow-up for IGT.17 In 2009,  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> an International Expert Committee (IEC) recommended using an HbA1c of 6.0%â€“6.4% (42â€“47 mmol/mol) to identify    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> people with IH.18 An HbA1c intermediate hyperglycaemia category termed â€œprediabetesâ€ was adopted by ADA in      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 2010, defined as an HbA1c of 5.7%â€“6.4% (39â€“47 mmol/mol).19 To date, WHO has not made a recommendation on HbA1c  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> for IH. Other groups IDF Global Clinical Practice Recommendations for Managing Type 2 Diabetes â€“ 2025 24        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> SCREENING AND PREVENTION such as the UK National Institute for Health and Care Excellence recommends an HbA1c   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> of 6.0%â€“6.4% (42â€“47 mmol/mol).20 Prevalence of intermediate hyperglycaemia In 2024, IDF estimated the global    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> prevalence of IGT was 12.0% and that of IFG was 9.2% among adults aged 20â€“79 years, with marked regional        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> differences. Age-adjusted IGT prevalence was highest in Southeast Asia region (13.8%) and lowest in Europe      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> region (5.9%). North America and the Caribbean region showed the highest IFG prevalence (13.6%) while Europe    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> had again the lowest (5.4%).1 There are significant differences in prevalence and congruence of IH identified   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> by different criteria, and overlap between the various biochemical tests is only moderate. Although IFG and     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> intermediate HbA1c were introduced to achieve alignment with IGT, individuals with IGT who also had ADA-IFG was <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 58%, WHO-IFG was 23%, and ADA-HbA1c was 32%.21 In addition, the percentage of people without IGT who have IFG   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> increases substantially with ADA-FPG versus WHO-FPG.22 The 2015â€“2016 US NHANES survey reported IH prevalences   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> ranging from 4.3% with IEC-HbA1c to 43.5% with ADA-IFG. If a combination of ADA-HbA1c, ADA-FPG, and 2 h PG was  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> used, the prevalence was 2.5% compared with 51.3% if any of the three tests was used.23 Progression to diabetes <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> All measures of IH predict progression to T2DM without intervention, and incident rates of T2DM increase with   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> longer periods of follow-up. Randomised controlled trials (RCTs) of diabetes prevention in people with IGT in   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Asia,24 Europe,25 India,26 and the United States27 reported a cumulative diabetes incidence of 23%â€“68% in the   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> control group in this high-risk group mostly defined by two abnormal OGTTs. A Cochrane review reported a        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> cumulative diabetes incidence in individuals with IGT of 13% after one year and 60% after 20 years follow-up.   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> The risk of diabetes was highest with combined IFG and IGT compared to people with normal glucose tolerance and <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> with isolated IGT. The cumulative diabetes incidence after 12 years follow-up was 31% for both ADA-IFG and      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> WHO-IFG; for ADA-HbA1c it was 31% at 10 years follow-up and 29% at 15 years follow-up for IEC-HbA1c.17 A recent <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Danish population study reported a 21% 5-year cumulative T2DM incidence for IEC-HbA1c.28 Older age is an        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> important consideration. A study of older adults with a high prevalence of ADA-FPG and ADA-HbA1c-defined IH     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> reported that regression to normoglycaemia or death was more frequent than progression to diabetes.29           <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Prediction of adverse outcomes The association between adverse outcomes and the various definitions of IH has   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> been examined in two systematic reviews. The first included 129 studies with 10,069,955 individuals30 and the   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> second included 106 prospective studies and nearly 1.85 million people from 27 countries.31 Overall, IH was     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> associated with a significantly increased risk of mortality, cardiovascular disease (CVD), stroke, and chronic  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> kidney disease compared with normoglycaemia across the different definitions of IH, albeit with some minor,     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> inconsistent differences. Summary There are considerable differences in prevalence with the various individual  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> tests for IH. Although the absolute reported prevalence varies, the pattern is consistent, with the highest     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> prevalences found with ADA-IFG, ADA-HbA1c, and IGT and the lowest with WHO-IFG and IEC-HbA1c.32, 33 Differences <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> in IH prevalences and progression to T2DM may reflect differences in pathophysiology and the myriad of          <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> ecological and external factors (e.g., environment, ecosystem, awareness, cultures, access to care, and         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> standard of care) as well as host factors (e.g., ancestry, ethnicity, sex, age, gender, genetics, life course   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> events, education, lifestyles, cognitive/psychological behaviours, coexisting risk factors, and comorbidities)  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> and their complex interactions. As such, context and phenotyping are important considerations in attempts to    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> improve the precision of risk assessment to maximise the impacts and cost-effectiveness of interventions.34, 35 <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> There are well-documented differences across ethnic groups based on OGTT, with Asians highly insulin-sensitive, <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Africans most insulin-resistant, and Caucasians in-between along the hyperbolic curve between glucose           <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> sensitivity and insulin secretion.36 Data from Uganda indicate that nearly one-third of people with incident    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> diabetes have a body mass index (BMI) &lt;25 kg/m2, with a predominant phenotype of 25 Chapter 1 reduced           <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> pancreatic secretory function.37 These differences contribute to sub-phenotypes within the spectrum of          <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> dysregulation of glucose metabolism, which may stem from interethnic differences in biological responses,       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> influenced by differences in population-specific genetic and ecological factors.38 Screening for undiagnosed    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> diabetes and intermediate hyperglycaemia Screening for undiagnosed T2DM or for IH are commonly recommended      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> strategies. Earlier diagnosis and treatment reduce the risk of adverse outcomes, and identifying people with IH <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> provides an opportunity to prevent progression to diabetes. The usual approach to screening for undiagnosed     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> T2DM or IH is based on well-recognised clinical risk factors (e.g., increasing age, family history of diabetes, <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> overweight/ obesity, previous history of gestational diabetes, ethnicity) and/or using formal risk scores       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> composed of clinical information, followed by blood testing of glucose or HbA1c.39,40 Risk scores have been     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> demonstrated to enhance the performance of biochemical testing.32 Use of local data to develop a risk score to  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> estimate absolute risk prediction for diabetes may also increase precision. Testing method and frequency of     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> screening There are considerable differences in the performance of individual tests for IH and consequently     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> differences in country and international recommendations. If a decision is made to screen, the choice of test   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> procedure and frequency of testing will need to be determined by a countryâ€™s health services, taking into       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> account available resources. Within-country differences in recommendations underscore the lack of universal     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> consensus.7, 41 While guidelines recommend repeat testing to confirm a diagnosis of diabetes in an asymptomatic <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> individual, there are no guidelines regarding repeat testing to confirm IH.42 The 1 h OGTT â€“ a proposed new     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> approach to testing for intermediate hyperglycaemia Decades ago, the 2 h OGTT was a five-sample test with       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> glucose measured at 0, 30, 60, 90, and 120 minutes. Later the 30-, 60-, and 90-min samples were eliminated,     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> leaving the modern day OGTT with only FPG and 2 h PG. Recently, the value of the 1 h PG during an OGTT has been <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> revisited in an IDF Position Statement. Epidemiological data demonstrate the value of a 1 h PG â‰¥8.6 mmol/L (155 <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> mg/dL) in predicting diabetes and associated complications, even in people with otherwise normal glucose        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> tolerance, and a 1 h PG â‰¥11.6 mmol/L (210 mg/dL) for diagnosing T2DM. The IDF Position Statement suggests the 1 <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> h PG as a more sensitive and practical method than other current biochemical tests and calls for redefining     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> current diagnostic criteria for IH and T2DM by adding the 1 h PG as a diagnostic option.43 The evidence         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> supporting the utility of the 1 h PG during an OGTT is comprehensively detailed in the IDF Position Statement   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> and is therefore not reviewed further in this Chapter. In time, the 1 h PG OGTT may be adopted for detecting    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> IH. Using a 1 h OGTT may not necessarily overcome the practical and health system challenges of the 2 h OGTT,   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> even though it is a shorter test. An additional test for detecting IH may find increased prevalence rates and   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> incongruence in classifying individuals with IH evident with currently available tests. While it is likely that <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> individuals with an elevated 1 h PG will benefit from diabetes prevention interventions similar to those with   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> IGT, there are currently no supporting clinical trial data. Diabetes prevention There are two complementary     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> approaches to reducing the incidence of type 2 diabetes: o The individual-based high-risk approach with         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> interventions in higher risk individuals o The population approach to reduce diabetes risk factors across the   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> entire population The individual-based high-risk approach This strategy involves identifying individuals at     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> higher risk of developing T2DM by screening and testing for IH, followed by offering lifestyle interventions.   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Successful randomised diabetes prevention studies have targeted individuals with IGT, and a recent review       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> reported a lack of effect of lifestyle intervention in individuals with isolated IFG.44 However, the situation  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> may be different for IDF Global Clinical Practice Recommendations for Managing Type 2 Diabetes â€“ 2025 26        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> SCREENING AND PREVENTION pharmacological interventions to prevent diabetes for glucose- or HbA1c-defined IH.45, <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 46 There are limited data on the effectiveness of lifestyle intervention in individuals with IH identified by   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> HbA1c. The US Diabetes Prevention Program (DPP) evaluated treatment effects (in participants with IH identified <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> by HbA1c) on incident diabetes, defined by HbA1c â‰¥6.5% (48 mmol/mol). Lifestyle intervention and metformin      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> reduced diabetes incidence by 49% and 44%, respectively, during the DPP, and by 29% and 38%, respectively,      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> during the 10-year follow-up. In contrast to the superiority of the lifestyle intervention on glucose-defined   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> diabetes, metformin and lifestyle interventions had similar effects in preventing HbA1c-defined diabetes.47     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Interventions to prevent or delay development of T2DM in high-risk individuals review reported a significant    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> reduction in incident T2DM in people with IGT with or without IFG (but not in isolated IFG) who received diet   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> and exercise counselling.53 The lack of effect in IFG has been confirmed in a more recent systematic review of  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> data from other studies.44 Diabetes prevention or delay persists but decreases over time as demonstrated after  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 20 years in the China Da Qing Diabetes Prevention Study, with intervention participants having 3.6 fewer years  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> with diabetes. However, residual risk of progression to diabetes was high: 80% in the intervention group and    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 93% in the control group after 20 years.54 The Finnish DPS reported an ongoing reduction in incident T2DM over  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> the 13-year follow-up. The cumulative incidence of diabetes was 44% in the intervention group and 64% in the    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> control group, with an estimated five-year delay in deterioration from IGT to overt T2DM.55 The US Diabetes     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Prevention Program Outcomes Study also showed sustained diabetes prevention in the intervention versus control  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> group after 12 years.56 Emerging data from long-term observational studies of RCTs suggest a possible           <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> beneficial effect on vascular complications,57 including a lower risk of severe retinopathy after 20 years of   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> follow-up,58 and a significant 41% risk reduction in CVD and 29% reduction in all-cause death in the            <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> intervention group after 23 years.59 Pharmacotherapy Several studies have assessed the effect of various        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> glucose-lowering medications on T2DM prevention. A Cochrane review reported the superiority of metformin in     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> reducing incident T2DM compared with standard diet and exercise but it was not different compared with          <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> intensive diet and exercise, acarbose, thiazolidinediones, or when combined with intensive lifestyle compared   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> with intensive lifestyle alone.60 However, a recent RCT reported a 17% significantly lower risk of incident     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> T2DM with metformin plus lifestyle intervention compared with lifestyle intervention alone, but with more       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> adverse gastrointestinal side effects.61 Data on long-term outcomes are limited except for the US DPP which     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> showed no difference in microvascular complications in the metformin versus the comparative group after 15      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> years follow-up.62 Other agents which significantly reduced diabetes incidence include acarbose,63              <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> thiazolidinediones,45 glucagon-like peptide-1 receptor agonists,64 and sodium-glucose cotransporter-2           <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> inhibitors.46 Several systematic reviews and meta-analyses have demonstrated an association between incident    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> T2DM and diet or dietary components, including: o High glycaemic index (GI) foods and high glycaemic load (GL)  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> diets increase risk.48 o Consumption of foods and dietary components from plant-based sources, such as whole    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> grain products, fibre, vegetable fats, and plant proteins, reduces risk.49 o A higher intake of red meat,       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> processed meat, and sugar-sweetened beverages increases risk.50 o A high intake of vegetable fat lowers T2DM    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> incidence but total fat intake is not associated with incident T2DM.50 o Substituting plant protein for animal  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> protein may decrease T2DM risk.51 o Vegetarian diets are associated with reduced T2DM incidence.52 Randomised   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> controlled studies Diet and physical activity Lifestyle changes are effective in preventing or delaying the     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> development of T2DM. A Cochrane 27 Chapter 1 Community and national programmes Several programmes have          <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> translated the high-risk individual lifestyle-based T2DM diabetes prevention RCTs into large-scale community    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> and national prevention programmes. The US National Diabetes Prevention Program (US NDPP) US NDPP is a          <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> lifestyle intervention programme to prevent T2DM in at-risk people age â‰¥18 years old identified by HbA1c, FPG,  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> or OGTT, or previous gestational diabetes, or positive ADA risk test. The programme is overseen by the Centre   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> for Disease Control (CDC) and promotes â‰¥5% weight loss over one year delivered via in-person classes, distance  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> learning, online programming, or a combination of modalities. There are a total of 26 sessions and at least 22  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> must be completed for the individual to achieve CDC recognition for completing the programme. Analysis of       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 14,747 adults enrolled in the programme reported that 36% achieved the 5% weight loss goal (average weight loss <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 4.2%). As yet, incident T2DM has not been systematically evaluated.65 The Finnish National Diabetes Prevention  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Programme (FIN-D2D) FIN-D2D is a community-based lifestyle modification T2DM prevention programme delivered in  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> primary and occupational health care, predominantly through groups.66 Individuals are screened for high risk    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> with the Finnish Diabetes Risk Score (FINDRISC) and are then referred for OGTT. Evaluation of 2,730 individuals <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> with complete follow-up data showed that in those who lost 2.5%â€“4.9% body weight and â‰¥5% during the first year, <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> risk for incident medication-treated diabetes after 7.4 years was significantly reduced by 37% and 29%,         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> respectively, compared with those with stable weight. There were no significant differences in CVD events or    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> all-cause mortality.67 The UK National Health Service Diabetes Prevention Programme (NHS DPP) This programme is <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> offered to individuals aged â‰¥18 years with an HbA1c 6.0â€“6.4% (42â€“47 mmol/mol) or FPG 5.5â€“6.9 mmol/L (100â€“125    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> mg/dL) through 13 lifestyle modification education sessions delivered by face-to-face groups or a digital       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> service. An assessment of 17,252 individuals who completed the programme demonstrated a mean weight loss of 3.3 <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> kg and an HbA1c reduction of 0.19% (2.04 mmol/mol). T2DM incident was not reported.68 Australian Victorian      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Life! Taking Action on Diabetes Program This is a community-based diabetes prevention programme with            <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> individuals at risk of developing diabetes identified by a national risk score. An evaluation of 8,412          <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> participants who commenced a Life! Program (of whom 37% completed all six education sessions) showed an average <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> weight loss of 2.4 kg (2.7%) in completers and 1.4 kg weight loss in those attending 1â€“5 sessions.69            <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Middle-income countries A review of six RCTs of community-based lifestyle interventions included three studies  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> (Chennai and Kerala, India, and one from rural China) reported diabetes incidence in 1,921 individuals. The     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> review found a non-significant reduction in diabetes incidence at 12 months compared with controls. Significant <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> reductions were observed in weight (2.3 kg) and in FPG and HbA1c.70 A lifestyle diabetes prevention programme   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> in primary care settings in Thailand in 1,093 individuals with IGT reported a significant 28% reduction in      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> incident diabetes after two years compared with the control group, accompanied by body weight reduction of 1.5  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> kg in the intervention group and a 0.4 kg increase in the control group.71 South Africa Lifestyle Africa is a   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> culturally adapted version of the US DPP with a lifestyle intervention of 17 video-based group sessions         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> delivered by trained community health workers. An assessment of 494 enrolled participants reported a mean       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> weight change of 0.6% in the intervention group, not significantly different to the 0.4% in the control group.  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> However, HbA1c was significantly lower (mean difference 0.24% [2.58 mmol/mol]).72 The population approach       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Strategies to improve the health of the entire population by reducing modifiable risk factors for NCDs are an   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> integral part of T2DM prevention. Reducing population diabetes risk factors results in a small downward shift   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> in average population levels of diabetes risk, which can lead to a significant reduction in diabetes. This can  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> be achieved by encouraging a healthy diet and regular physical activity, preventing overweight and obesity, and <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> reducing other IDF Global Clinical Practice Recommendations for Managing Type 2 Diabetes â€“ 2025 28 SCREENING    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> AND PREVENTION health risks such as smoking, excessive alcohol intake, improving sleep, and minimising          <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> climate-related health effects. Common strategies to drive population change include increasing                 <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> health-promoting environments, embedding health-promoting activities in everyday life, education and social     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> media campaigns, and reducing marketing and the promotion of unhealthy foods, especially to children. Effective <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> societal strategies include legislation (e.g., sugar tax) to reduce consumption of sugar-sweetened beverages,   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> food reformulation, improved food labelling, and changing the physical environment (e.g., reduce pollution,     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> provide living and leisure space). Broader population-based measures are also important, including improving    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> general education, reducing poverty, ensuring food security, and raising health awareness â€“ all underpinned by  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> universal health coverage and a robust primary care and health system.38 These interventions can be             <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> incorporated in diabetes prevention programmes.66 Summary Randomised controlled studies have demonstrated the   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> effective prevention of T2DM in people with IGT across different populations but a lack of effect in people     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> with isolated IFG. The effect on incident diabetes persists but declines over time. Emerging evidence suggests  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> a decline in some adverse diabetes outcomes. Several countries and settings have translated this evidence into  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> community-based programmes, with differences in target population, method of identifying high-risk individuals, <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> and the intervention content and delivery. Overall, the degree of weight loss is less than in RCTs and data on  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> incident diabetes are lacking. Including strategies to reduce population diabetes risk is an important          <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> component of diabetes prevention programmes. Implementing diabetes prevention programmes Diabetes prevention    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> programmes should ideally include both high-risk and population strategies. Encouragingly, the incidence of     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> diagnosed diabetes appears to be stabilising or declining in many higher-income countries, with a reported      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> annual estimated change in incidence ranging from â€“1.1% to â€“10.8% since 2010. Multifaceted T2DM prevention      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> activities in individuals at high risk of T2DM and population-wide approaches may be factors in this            <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> observation.73 Population strategies require lobbying and influencing national policy makers. The focus of this <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> section is implementing programmes for high-risk individuals.\\nThe essential components of programmes targeting <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> high-risk individuals are universally agreed (Figure 1.1). However, there are a number of questions which need  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> to be considered in developing and implementing a community or Figure 1.1 Overview of high-risk type 2 diabetes <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> screening and prevention programmes â€ Programme content and delivery dependent on local resources. FPG, fasting  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> plasma glucose; HbA1c, glycated haemoglobin; OGTT, oral glucose tolerance test.\\n29 Chapter 1 Programme         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> delivery Established programmes have varied widely with respect to number of education sessions (ranging from   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 4â€“22), the way the programme is delivered (face-to-face individual or group, online), and the follow-up support <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> offered. Programmes have also differed with respect to training, qualifications, and accreditation of the       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> education trainers who deliver the programme. Awareness, enrolment, and retention In Finland, 25% of men and    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 48% of women reported being aware of the FIN-D2D programme in the area where it was being rolled out, compared  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> with 20% men and 36% of women in the control area.77 Community-based programmes have consistently highlighted   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> the challenge of enrolment and retention. In the Victorian Diabetes Program, over 29,000 individuals showed     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> interest in the programme, 15,000 were referred, approximately 8,500 commenced the programme, and 3,000         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> attended all six programme sessions.69 In the UK NHS Diabetes Prevention Programme by December 2018, nearly     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 325,000 people were referred, approximately 150,000 attended the initial assessment, and approximately 95,000   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> attended at least one of 13 group-based intervention sessions with approximately half completing the            <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> intervention (attending &gt;60% of sessions).68 Attendance may be influenced by the mode of programme delivery,    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> with assessment of over 330,000 US National DPP participants showing that the average number of sessions        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> attended was highest for in-person participants (68%), online (57%), distance learning (55%), and combination   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> (49%), with a similar pattern for average weeks in the programme. Among participants who remained in the        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> programme for all sessions, average weight loss exceeded the programme goal of 5% for all delivery modes.78     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Results were similar for the South African programme â€“ average attendance across all sessions and groups was    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 54%, with 35% attending at least 75% of sessions across all groups.79 Scalability Scalability and reach remain  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> a challenge. The US National DPP has been successful in offering the programme to over 700,000 at-risk          <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> participants since it began in 2012 but there are an estimated nearly 100 million Americans with IH. One        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> approach which has been taken to improve reach is to incorporate diabetes prevention national diabetes          <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> prevention programme for high-risk individuals.\\nRisk assessment and screening Most programmes target a         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> specific age group for screening rather than offering universal screening but differ in the selected age, which <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> is decided based on local risk and resources. Many guidelines suggest initial screening with a risk score to    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> identify high-risk individuals. Developing or adapting a risk score using local data may increase predictive    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> precision. Screening for high risk is complex and challenging on a large scale. The strongest evidence for      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> successful lifestyle intervention is for people with IGT, which can only be diagnosed by an OGTT.44 However,    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> OGTT screening has practical limitations for both the health system and participants, especially if it is also  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> to be used for routine follow-up assessment. Given these practical challenges, many national programmes use     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> HbA1c or FPG to identify high-risk individuals for interventions to reduce progression to T2DM. While the US    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> DPP includes testing with any of the three tests for identifying IH, the most used tests are HbA1c and FPG      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> rather than an OGTT. The UK DPP advocates blood testing with HbA1c or FPG. The Hong Kong Chronic Co-Care Pilot  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Scheme includes screening for IH based on an HbA1c of 6.0%â€“6.4% (42â€“47 mmol/mol) or FPG 6.1â€“6.9 mmol/L (110â€“125 <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> mg/dL).74 Advances in understanding the heterogenous nature of IH and in technology may increase the precision  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> with which the highest-risk individuals can be identified for a programme based on selective use of OGTT,       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> depending on available resources. Options include stratifying levels of risk and recommending OGTT testing in   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> the younger highest-risk category.75 Another option is the 1 h OGTT PG. Screening for diabetes prevention       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> programmes requires balancing the evidence, practicalities, potential impact, and cost. A comparison of a range <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> of screening scenarios, including OGTT, FPG, and HbA1c alone or following risk score assessment explored the    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> potential impact on reducing incident diabetes and cost. Compared with OGTT testing, costs of screening and     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> prevention were substantially lower with an initial assessment with a risk score, followed by a blood test, but <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> the potential for diabetes prevention was reduced by 35% to 75%. With all scenarios, there will be some         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> lower-risk individuals who will develop diabetes.76 IDF Global Clinical Practice Recommendations for Managing   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Type 2 Diabetes â€“ 2025 30 SCREENING AND PREVENTION into broader NCD prevention initiatives. Some programmes     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> offer financial incentives to encourage risk assessment and subsidise lifestyle educational interventions.      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Implementation If a decision is made to have a diabetes prevention programme for high-risk individuals, the     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> design will need to be decided according to local practice, local resources, feasibility, and cost. Data        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> systems and evaluation are important components of the programme to facilitate quality improvement. REFERENCES  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 1. International Diabetes Federation (IDF). IDF Diabetes Atlas. 11th edition. Brussels, Belgium: International  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Diabetes Federation, 2025. Available from: http://www.diabetesatlas.org. 2. World Health Organization.          <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Assessing national capacity for the prevention and control of noncommunicable diseases: report of the 2019      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> global survey [Internet]. Geneva: WHO; 2020]. Available from: https://iris.who.int/handle/10665/331452.         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> [Accessed February 2025]. 3. PAHO/NMH/NV/21-0041 Pan American Health Organization, 2021. Country snapshot of    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> diabetes prevention and control in the Americas. Available from: https://iris.\\npaho.org/handle/10665.2/55326.  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> [Accessed February 2025]. 4. Rahim NE, Flood D, Marcus ME, et al. Diabetes risk and provision of diabetes       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> prevention activities in 44 low-income and middle-income countries: a cross-sectional analysis of nationally    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> representative, individual-level survey data. Lancet Glob Health. 2023;11(10):e1576-e1586. 5. World Health      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Organization. Definition and diagnosis of diabetes mellitus and intermediate hyperglycaemia - report of a       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> WHO/IDF consultation. World Health Organization 2006. Available from: https://                                  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> www.who.int/publications/i/item/definition-and-diagnosis-of-diabetes-mellitus-and-intermediate-hyperglycaemia.  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> [Accessed February 2025]. 6. Bonora E, Tuomilehto J. The pros and cons of diagnosing diabetes with A1C.         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Diabetes Care. 2011;34 Suppl 2(Suppl 2):S184-190. 7. American Diabetes Association Professional Practice C. 2.  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Diagnosis and Classification of Diabetes: Standards of Care in Diabetes-2025. Diabetes Care.                    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 2025;48(Supplement_1):S27-S49. 8. World Health Organization. Use of Glycated Haemoglobin (HbA1c) in the         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Diagnosis of Diabetes Mellitus. 2011. WHO/NMH/CHP/ CPM/11.1 Available from:                                     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> https://apps.who.\\nint/iris/bitstream/handle/10665/70523/WHO_ NMH_CHP_CPM_11.1_eng.pdf. [Accessed February      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 2025]. 9. Cowie CC, Rust KF, Byrd-Holt DD, et al. Prevalence of diabetes and high risk for diabetes using A1C   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> criteria in the U.S. population in 1988-2006. Diabetes Care. 2010;33(3):562-568. 10. Sun H, Saeedi P, Karuranga <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> S, et al. IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> projections for 2045. Diabetes Res Clin Pract. 2022;183:109119. 11. NCD Risk Factor Collaboration. Worldwide    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> trends in diabetes prevalence and treatment from 1990 to 2022: a pooled analysis of 1108                        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> population-representative studies with 141 million participants. Lancet. 2024;404(10467):2077-2093. 12. NCD     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Risk Factor Collaboration. Global variation in diabetes diagnosis and prevalence based on fasting glucose and   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> hemoglobin A1c. Nat Med. 2023;29(11):2885-2901. 13. Ram Y, Xu Y, Cheng A, et al. Variation in the relationship  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> between fasting glucose and HbA1c: implications for the diagnosis of diabetes in different age and ethnic       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> groups. BMJ Open Diabetes Res Care. 2024;12(2):e003470. 14. National Diabetes Data Group. Classification and    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes. 1979;28(12):1039-1057.    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 15. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care. 1997;20(7):1183-1197. 16.    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Abdul-Ghani MA, Jenkinson CP, Richardson DK, et al. Insulin secretion and action in subjects with impaired      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> fasting glucose and impaired glucose tolerance: results from the Veterans Administration Genetic Epidemiology   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Study. Diabetes. 2006;55(5):1430-1435. 17. Richter B, Hemmingsen B, Metzendorf MI, et al. Development of type 2 <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> diabetes mellitus in people with intermediate hyperglycaemia. Cochrane Database Syst Rev. 2018;10(10):CD012661. <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 31 Chapter 1 18. International Expert Committee. International Expert Committee report on the role of the A1C   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> assay in the diagnosis of diabetes. Diabetes Care. 2009;32(7):1327-1334. 19. Zhang X, Gregg EW, Williamson DF,  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> et al. A1C level and future risk of diabetes: a systematic review. Diabetes Care. 2010;33(7):1665-1673. 20.     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> National Insititue for Health and Care Excellence (NICE). Type 2 diabetes: prevention in people at high risk.   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Guidance and guidelines. Available from: https:// www.nice.org.uk/guidance/ph38/chapter/                        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Recommendations#risk-assessment. [Accessed February 2025]. 21. James C, Bullard KM, Rolka DB, et al.            <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Implications of alternative definitions of prediabetes for prevalence in U.S. adults. Diabetes Care.            <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 2011;34(2):387-391. 22. Glumer C, Jorgensen T, Borch-Johnsen K, et al. Prevalences of diabetes and impaired     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> glucose regulation in a Danish population: the Inter99 study. Diabetes Care. 2003;26(8):2335-2340. 23.          <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Echouffo-Tcheugui JB, Selvin E. Prediabetes and what it means: The epidemiological evidence. Annu Rev Public    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Health. 2021;42:59-77. 24. Pan XR, Li GW, Hu YH, et al. Effects of diet and exercise in preventing NIDDM in     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care. 1997;20(4):537-544.  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 25. Tuomilehto J, Lindstrom J, Eriksson JG, et al. Prevention of type 2 diabetes mellitus by changes in         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001;344(18):1343-1350. 26.             <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Ramachandran A, Snehalatha C, Mary S, et al. The Indian Diabetes Prevention Programme shows that lifestyle      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> (IDPP-1). Diabetologia. 2006;49(2):289-297. 27. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346(6):393-403.   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 28. Nicolaisen SK, Pedersen L, Witte DR, et al. HbA1c-defined prediabetes and progression to type 2 diabetes in <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Denmark: A population-based study based on routine clinical care laboratory data. Diabetes Res Clin Pract.      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 2023;203:110829. 29. Rooney MR, Rawlings AM, Pankow JS, et al. Risk of progression to diabetes among older      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> adults with prediabetes. JAMA Intern Med. 2021;181(4):511-519. 30. Cai X, Zhang Y, Li M, et al. Association     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> between prediabetes and risk of all cause mortality and cardiovascular disease: updated meta-analysis. BMJ.     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 2020;370:m2297. 31. Gujral UP, Jagannathan R, He S, et al. Association between varying cut-points of            <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> intermediate hyperglycemia and risk of mortality, cardiovascular events and chronic kidney disease: a           <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> systematic review and meta-analysis. BMJ Open Diabetes Res Care. 2021;9(1):e001776. 32. Schmidt MI, Bracco PA,  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Yudkin JS, et al. Intermediate hyperglycaemia to predict progression to type 2 diabetes (ELSA-Brasil): an       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> occupational cohort study in Brazil. Lancet Diabetes Endocrinol. 2019;7(4):267-277. 33. Lee CMY, Colagiuri S,   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Woodward M, et al. Comparing different definitions of prediabetes with subsequent risk of diabetes: an          <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> individual participant data meta-analysis involving 76 513 individuals and 8208 cases of incident diabetes. BMJ <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Open Diabetes Res Care. 2019;7(1):e000794. 34. Chung WK, Erion K, Florez JC, et al. Precision medicine in       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> diabetes: a Consensus Report from the American Diabetes Association (ADA) and the European Association for the  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Study of Diabetes (EASD). Diabetologia. 2020;63(9):1671-1693. 35. Herman WH, Ye W. Precision prevention of      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> diabetes. Diabetes Care. 2023;46(11):1894-1896. 36. Kodama K, Tojjar D, Yamada S, et al. Ethnic differences in  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> the relationship between insulin sensitivity and insulin response: a systematic review and meta-analysis.       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Diabetes Care. 2013;36(6):1789-1796. 37. Kibirige D, Sekitoleko I, Lumu W, et al. Understanding the             <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> pathogenesis of lean non-autoimmune diabetes in an African population with newly diagnosed diabetes.            <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Diabetologia. 2022;65(4):675-683. 38. Chan JCN, Lim LL, Wareham NJ, et al. The Lancet Commission on diabetes:   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Using data to transform diabetes care and patient lives. Lancet. 2021;396(10267):2019-2082. 39. Lindstrom J,    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Tuomilehto J. The diabetes risk score: a practical tool to predict type 2 diabetes risk. Diabetes Care.         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 2003;26(3):725-731. 40. American Diabetes Association Professional Practice Committee. 3. Prevention or Delay   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> of Diabetes and Associated Comorbidities: Standards of Care in Diabetes-2024. Diabetes Care. 2024;47(Suppl      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 1):S43-S51. IDF Global Clinical Practice Recommendations for Managing Type 2 Diabetes â€“ 2025 32 SCREENING AND   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> PREVENTION 41. Davidson KW, Barry MJ, et al., US Preventive Services Task Force. Screening for prediabetes and  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> type 2 diabetes: US Preventive Services Task Force Recommendation Statement. JAMA. 2021;326(8):736-743. 42.     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Echouffo-Tcheugui JB, Perreault L, Ji L, et al. Diagnosis and management of prediabetes: A review. JAMA.        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 2023;329(14):1206-1216. 43. Bergman M, Manco M, Satman I, et al. International Diabetes Federation Position     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Statement on the 1-hour post-load plasma glucose for the diagnosis of intermediate hyperglycaemia and type 2    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> diabetes. Diabetes Res Clin Pract. 2024;209:111589. 44. Sathish T, Khunti K, Narayan KMV, et al. Effect of      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> conventional lifestyle interventions on type 2 diabetes incidence by glucose-defined prediabetes phenotype: An  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> individual participant data meta-analysis of randomized controlled trials. Diabetes Care.                       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 2023;46(11):1903-1907. 45. Gerstein HC, Yusuf S, et al. Effect of rosiglitazone on the frequency of diabetes in <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet.    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 2006;368(9541):1096-1105. 46. Rossing P, Inzucchi SE, Vart P, et al. Dapagliflozin and new-onset type 2         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> diabetes in patients with chronic kidney disease or heart failure: pooled analysis of the DAPA-CKD and DAPA-HF  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> trials. Lancet Diabetes Endocrinol. 2022;10(1):24-34. 47. Diabetes Prevention Program Research Group. HbA1c as  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> a predictor of diabetes and as an outcome in the diabetes prevention program: a randomized clinical trial.      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Diabetes Care. 2015;38(1):51-58. 48. Jenkins DJA, Willett WC, Yusuf S, et al. Association of glycaemic index    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> and glycaemic load with type 2 diabetes, cardiovascular disease, cancer, and all-cause mortality: a             <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> meta-analysis of mega cohorts of more than 100 000 participants. Lancet Diabetes Endocrinol.                    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 2024;12(2):107-118. 49. Neuenschwander M, Ballon A, Weber KS, et al. Role of diet in type 2 diabetes incidence: <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> umbrella review of meta-analyses of prospective observational studies. BMJ. 2019;366:l2368. 50. Neuenschwander  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> M, Barbaresko J, Pischke CR, et al. Intake of dietary fats and fatty acids and the incidence of type 2          <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> diabetes: A systematic review and dose-response meta-analysis of prospective observational studies. PLoS Med.   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 2020;17(12):e1003347. 51. Li J, Glenn AJ, Yang Q, et al. Dietary protein sources, mediating biomarkers, and     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> incidence of type 2 diabetes: Findings from the Womenâ€™s Health Initiative and the UK Biobank. Diabetes Care.    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 2022;45(8):1742-1753. 52. Lee Y, Park K. Adherence to a vegetarian diet and diabetes risk: A systematic review  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> and meta-analysis of observational studies. Nutrients. 2017;9(6):603. 53. Hemmingsen B, Gimenez-Perez G,        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Mauricio D, et al. Diet, physical activity or both for prevention or delay of type 2 diabetes mellitus and its  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> associated complications in people at increased risk of developing type 2 diabetes mellitus. Cochrane Database  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Syst Rev. 2017;12(12):CD003054. 54. Li G, Zhang P, Wang J, et al. The long-term effect of lifestyle             <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20-year follow-up study.    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Lancet. 2008;371(9626):1783-1789. 55. Lindstrom J, Peltonen M, Eriksson JG, et al. Improved lifestyle and       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> decreased diabetes risk over 13 years: long-term follow-up of the randomised Finnish Diabetes Prevention Study  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> (DPS). Diabetologia. 2013;56(2):284-293. 56. Diabetes Prevention Program Research Group. Long-term effects of   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> lifestyle intervention or metformin on diabetes development and microvascular complications over 15-year        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> follow-up: the Diabetes Prevention Program Outcomes Study. Lancet Diabetes Endocrinol. 2015;3(11):866-875. 57.  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Nathan DM, Bennett PH, Crandall JP, et al. Does diabetes prevention translate into reduced long-term vascular   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> complications of diabetes? Diabetologia. 2019;62(8):1319-1328. 58. Gong Q, Gregg EW, Wang J, et al. Long-term   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> effects of a randomised trial of a 6-year lifestyle intervention in impaired glucose tolerance on               <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> diabetes-related microvascular complications: the China Da Qing Diabetes Prevention Outcome Study.              <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Diabetologia. 2011;54(2):300-307. 59. Li G, Zhang P, Wang J, et al. Cardiovascular mortality, all-cause         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> the Da Qing Diabetes Prevention Study: a 23-year follow-up study. Lancet Diabetes Endocrinol.                   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 2014;2(6):474-480. 60. Madsen KS, Chi Y, Metzendorf MI, et al. Metformin for prevention or delay of type 2      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> diabetes mellitus and its associated complications in persons at increased risk 33 Chapter 1 for the            <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> development of type 2 diabetes mellitus. Cochrane Database Syst Rev. 2019;12(12):CD008558. 61. Zhang L, Zhang   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Y, Shen S, et al. Safety and effectiveness of metformin plus lifestyle intervention compared with lifestyle     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> intervention alone in preventing progression to diabetes in a Chinese population with impaired glucose          <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> regulation: a multicentre, open-label, randomised controlled trial. Lancet Diabetes Endocrinol.                 <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 2023;11(8):567-577. 62. Diabetes Prevention Program Research Group. Long-term effects of lifestyle intervention <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> or metformin on diabetes development and microvascular complications over 15-year follow-up: the Diabetes       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Prevention Program Outcomes Study. Lancet Diabetes Endocrinol. 2015;3(11):866-75. 63. Chiasson JL, Josse RG,    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Gomis R, et al. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet.   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 2002;359(9323):2072-2077. 64. le Roux CW, Astrup A, Fujioka K, et al. 3 years of liraglutide versus placebo for <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised,             <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> double-blind trial. Lancet. 2017;389(10077):1399-1409. 65. Ely EK, Gruss SM, Luman ET, et al. A national effort <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> to prevent type 2 diabetes: Participant-level evaluation of CDCâ€™s National Diabetes Prevention Program.         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Diabetes Care. 2017;40(10):1331-1341. 66. Saaristo T, Peltonen M, Keinanen-Kiukaanniemi S, et al. National type <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 2 diabetes prevention programme in Finland: FIN-D2D. Int J Circumpolar Health. 2007;66(2):101-112. 67.          <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Rintamaki R, Rautio N, Peltonen M, et al. Long-term outcomes of lifestyle intervention to prevent type 2        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> diabetes in people at high risk in primary health care. Prim Care Diabetes. 2021;15(3):444-450. 68. Valabhji J, <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Barron E, Bradley D, et al. Early outcomes from the English National Health Service Diabetes Prevention         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Programme. Diabetes Care. 2020;43(1):152-160. 69. Dunbar JA, Jayawardena A, Johnson G, et al. Scaling up        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> diabetes prevention in Victoria, Australia: policy development, implementation, and evaluation. Diabetes Care.  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 2014;37(4):934-942. 70. Shirinzadeh M, Afshin-Pour B, Angeles R, et al. The effect of community-based programs  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> on diabetes prevention in low- and middle-income countries: a systematic review and meta-analysis. Global       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Health. 2019;15(1):10. 71. Aekplakorn W, Tantayotai V, Numsangkul S, et al. Evaluation of a community-based     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Diabetes Prevention Program in Thailand: A cluster randomized controlled trial. J Prim Care Community Health.   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 2019;10:2150132719847374. 72. Catley D, Puoane T, Tsolekile L, et al. Evaluation of an adapted version of the   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Diabetes Prevention Program for low- and middle-income countries: A cluster randomized trial to evaluate        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> â€œLifestyle Africaâ€ in South Africa. PLoS Med. 2022;19(4):e1003964. 73. Magliano DJ, Chen L, Islam RM, et al.    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Trends in the incidence of diagnosed diabetes: a multicountry analysis of aggregate data from 22 million        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> diagnoses in high-income and middle-income settings. Lancet Diabetes Endocrinol. 2021;9(4):203-211. 74.         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Government-funded healthcare programme. Available from: https://www.qhms.com/en/                                <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> services/public-private-partnership/ccdc-pilot-scheme. [Accessed February 2025]. 75. Zhang Y, Luk AOY, Chow E,  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> et al. High risk of conversion to diabetes in first-degree relatives of individuals with young-onset type 2     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> diabetes: a 12-year follow-up analysis. Diabet Med. 2017;34(12):1701-1709. 76. Lee CMY, Versace VL, Malo JA, et <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> al. Screening for diabetes prevention with diabetes risk scores - A balancing act. Diabetes Res Clin Pract.     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 2018;135:120-127. 77. Wikstrom K, Lindstrom J, Tuomilehto J, et al. National diabetes prevention program        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> (DEHKO): awareness and self-reported lifestyle changes in Finnish middle-aged population. Public Health.        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 2015;129(3):210-217. 78. Ely EK, Ng BP, Cannon MJ. Delivering the National Diabetes Prevention Program:         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Assessment of outcomes in in-person and virtual organizations. J Diabetes Res. 2023;2023:8894593. 79. Catley D, <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Puoane T, Goggin K, et al. Adapting the Diabetes Prevention Program for low- and middle-income countries:       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> preliminary implementation findings from lifestyle Africa. Transl Behav Med. 2020;10(1):46-54. 34 Glycaemic     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Control Assessment and Targets In Type 2 Diabetes Chapter 2 GLYCAEMIC TARGETS 35 Chapter 2 Optimal Care Basic   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Care Glycated haemoglobin (HbA1c) â€¢\\tMeasure HbA1c at regular intervals â€¢\\tHbA1c general target 7.0% (53        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> mmol/mol) â€¢\\tPersonalise HbA1c - higher in the elderly - lower in the newly diagnosed â€¢\\tMeasure fructosamine   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> if HbA1c cannot be measured accurately â€¢\\tMeasure HbA1c at regular intervals â€¢\\tHbA1c general target 7.0% (53   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> mmol/mol) â€¢\\tPersonalise HbA1c (especially in the elderly) â€¢\\tIf HbA1c assay not available, use any available   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> glucose measure Self-monitoring of blood glucose (SMBG) â€¢\\tRoutinely recommend SMBG to all insulin-treated      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> people with type 2 diabetes mellitus (T2DM) â€¢\\tConsider SMBG in other people with T2DM â€¢\\tProvide education in  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> structured SMBG â€¢\\tRoutinely recommend SMBG to people with T2DM treated with multiple daily insulin regimens    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> â€¢\\tConsider SMBG in other people with T2DM treated with other insulin regimens â€¢\\tProvide education in          <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> structured SMBG â€¢\\tSMBG targets: Fasting and pre-prandial glucose - 4.0â€“8.0 mmol/L (70â€“144 mg/dL) Postprandial  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> glucoseâ€  - 4.0â€“8.0 mmol/L (70â€“144 mg/dL) (preferable) - 4.0â€“9.0 mmol/L (70â€“160 mg/dL) (acceptable) Continuous   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> glucose monitoring (CGM) â€¢\\tConsider CGM in all insulin-treated people with T2DM and in others on an individual <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> basis â€¢\\tConsider short-term CGM in select people with T2DM on intensive insulin regimens or insulin pump, if   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> available and affordable â€¢\\tCGM targets (refer to Table 2.1) â€ Measure postprandial glucose 1â€“2 h after          <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> beginning a meal.\\nRECOMMENDATIONS IDF Global Clinical Practice Recommendations for Managing Type 2 Diabetes â€“  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 2025 36 GLYCAEMIC TARGETS o Glycaemic control reduces the risk of both micro- and macrovascular complications   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> in type 2 diabetes mellitus (T2DM). o Assessing and monitoring glycaemia is an essential component of guiding   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> treatment decisions to achieve and maintain target glycaemic control. o Setting glycaemic targets is based on   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> established associations with adverse outcomes. o HbA1c is the established gold standard for assessing          <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> glycaemic control in T2DM. o The general HbA1c target of &lt;7.0% (&lt;53 mmol/mol) should be personalised, balancing <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> reducing complications, minimising hypoglycaemia and an individualâ€™s characteristics. o HbA1c measurement may   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> be affected by a variety of factors â€“ in these situations, fructosamine and glycated albumin are alternatives   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> for monitoring glycaemic control. o Improving HbA1c improves diabetes outcomes in the short- and longer-term. o <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> HbA1c variability may be important but has not been definitively confirmed as an independent risk factor for    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> diabetes complications. o The contribution of fasting plasma glucose (FPG) and postprandial glucose (PPG) to    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> overall glycaemia varies according to HbA1c levels, being greater for PPG at lower HbA1c levels and greater for <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> FPG at higher HbA1c levels. o In select individuals with T2DM, HbA1c measurement may be complemented with       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> self-monitoring of blood glucose (SMBG) or continuous glucose monitoring (CGM). o SMBG and CGM may provide      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> additional useful clinical information on glycaemic metrics relevant to diabetes management, including periods  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> of hyperglycaemia and hypoglycaemia. o SMBG is recommended in insulin-treated T2DM but may be useful in other   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> situations. o SMBG use (intensity and frequency) should be structured and individualised. o The proposed SMBG   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> targets are adapted to align with CGM metrics. o CGM is currently used mainly in people with type 1 diabetes    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> mellitus (T1DM) but use is increasing in insulin-treated T2DM in high-resource health settings. Data supporting <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> its use in non-insulin treated people with T2DM are limited. o Key CGM metrics include glycaemic variability    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> and time in defined glucose ranges. o Target CGM metrics are based on international consensus. o Most of the    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> global diabetes population lives in low-income and middle-income countries (LMICs) where access and             <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> affordability to HbA1c testing, SMBG, and CGM are limited.\\nKEY POINTS 37 Chapter 2 BACKGROUND Glycaemic        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> control is a treatment pillar for reducing the risk of both micro- and macrovascular complications in type 2    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> diabetes mellitus (T2DM),1 and early and intensive glycaemic control has a legacy effect in reducing            <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> cardiovascular and kidney disease events and all-cause mortality even after 24 years.2 Assessing and monitoring <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> glycaemia are essential components of guiding treatment decisions to achieve and maintain target glycaemic      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> control. Measurement of glycated haemoglobin (HbA1c) underpins the assessment of long-term glycaemic control in <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> people with T2DM. In select individuals with T2DM, this may be complemented with self-monitoring of blood       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> glucose (SMBG) by finger-stick capillary devices or continuous glucose monitoring (CGM) devices which measure   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> interstitial glucose. SMBG and CGM may provide additional useful clinical information on other dimensions of    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> glycaemia relevant to diabetes management, including periods of hyperglycaemia and hypoglycaemia. Determining   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> glycaemic targets is based on the established association of adverse diabetes outcomes derived from             <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> epidemiological studies or post-hoc analyses of intervention studies. Observational studies have shown a        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> relationship between HbA1c and macro- and microvascular complications, and death in people with T2DM.3          <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Interventional randomised controlled trials (RCTs) examining the effect of intensive glycaemic control have     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> achieved HbA1c levels ranging from 6.5%â€“7.1% (48â€“54 mmol/mol).4-8 Identifying actual â€œthresholdsâ€ in the HbA1c/ <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> complications relationship has given differing results. For example, post-hoc analyses of the ADVANCE trial     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> suggest an HbA1c â€œthresholdâ€ of below 7.0% (53 mmol/mol) for macrovascular events and death, and 6.5% (48       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> mmol/mol) for microvascular events.9 However other analyses of observational data suggest a continuous increase <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> in risk of major adverse cardiovascular disease (CVD) outcomes down to an HbA1c of 5.7% (39 mmol/mol).10        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Setting clinical target recommendations should consider both the individual and population-level impact. The    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> global prevalence of poor glycaemic control is high, ranging from between 45% and 93% in one systematic         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> review11 and another reporting that the proportion with adequate control was 22% since 2010.12 These estimates  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> are considerably lower than the World Health Organization (WHO) goal of 80% of people with diagnosed diabetes   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> achieving good control of glycaemia.13 The greatest population impact on complications will be achieved by      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> reducing HbA1c from very high to moderate glycaemic levels. Although lowering HbA1c from 7.0% to 6.0% (53       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> mmol/mol to 42 mmol/mol) is associated with a further reduction in the risk of microvascular complications, the <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> absolute risk reductions become much smaller and numbers needed to treat to benefit an individual increase.14   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Setting lower targets has implications for the impact on health services in different resource settings.        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> General glycaemic targets (e.g., HbA1c &lt;7.0% [&lt;53 mmol/mol]) are proposed as guides that are appropriate for    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> many people but need to be personalised, balancing reducing complications and minimising hypoglycaemia and      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> taking into account a range of factors relevant to the individual with T2DM, including comorbidities, age,      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> duration of diabetes, risk of hypoglycaemia, life expectancy, individual preferences, and available             <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> resources.14,15 Setting specific glycaemic (and other) goals during consultations are also helpful in improving <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> outcomes for individuals with diabetes.16 Advances in technology, such as continuous glucose monitoring (CGM),  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> have provided more detailed information on glycaemia in both healthy individuals without diabetes and people    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> with diabetes, and these data can be used to inform glycaemic targets in people with diabetes.17 To date, CGM   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> has largely been applied to people with type 1 diabetes mellitus (T1DM) but is increasingly being considered in <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> T2DM in high-resource health settings. GLOBAL CONSIDERATIONS Approximately 80% of the global diabetes           <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> population lives in low-income and middle-income countries (LMICs) where healthcare resources are often         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> limited, which impacts access, availability, and affordability to many established evidence-based diabetes      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> interventions.18 These considerations are relevant to formulating practical clinical recommendations and        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> implementation strategies for assessment of glycaemic control in resource-limited settings. Regular periodic    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> measurement of HbA1c is the gold standard for assessing longer-term glycaemic control, and health systems       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> should IDF Global Clinical Practice Recommendations for Managing Type 2 Diabetes â€“ 2025 38 GLYCAEMIC TARGETS    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> aim to ensure that it is available throughout their services. However, at present it is not available in many   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> health services. The 2019 periodic WHO country capacity survey on non-communicable diseases (NCDs) of 160       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> countries reported that overall HbA1c testing was generally available in only 53% of primary care facilities in <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> the public and private health sectors.19 The Pan American Health Organization separately reported that 18 of 35 <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> countries (51.4%) had HbA1c testing generally available in &gt;50% primary healthcare facilities in the public     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> sector.20 In these situations, other less satisfactory methods of assessing glycaemia (e.g., fasting, random,   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> and postprandial glucose measurement) remain the only option for assessing glycaemic control. An additional     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> important consideration for HbA1c testing is that the assay is not currently well-enough standardised in many   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> countries.21 SMBG systems have been the standard method of self-assessment of glycaemia for many years in       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> well-resourced settings. However, access to SMBG in LMICs is often hindered by unavailability, high costs,      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> inadequate coverage by national health services, and even when available, usage is compromised by poor diabetes <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> education.22 Approximately 95% of SMBG expenses is attributable to testing strips. Consequently, SMBG is only   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> widely used if subsidised, but the availability of subsidised supplies varies considerably. One survey reported <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> that full provision by government of two or more blood glucose test strips per day for children with diabetes   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> aged less than 15 years occurred in 18 of 20 high-income countries (HIC), five of 15 upper MIC countries, and   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> none of 37 LMIC and LIC countries.23 Access in LMIC is further hindered because out-of-pocket prices to         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> individuals are often much higher than prices in HIC, making SMBG mostly unaffordable.24 An Indonesian study    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> reported that public sector facilities did not supply devices for self-testing and in the private sector, a     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> low-income worker required nine to 12 daysâ€™ wages to purchase a meter and a monthâ€™s supply of test strips.25    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> The 2023 WHOâ€™s Essential Diagnostics List recognised the role of blood glucose meters and test strips for SMBG  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> in home settings and added a new recommendation for glucose measurement for use in community settings â€œto       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> self-monitor type 1 and type 2 diabetes mellitus at homeâ€.26 This significant step should help increase access  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> to SMBG in LMICs. CGM has emerged as an option for self-monitoring which provides more detailed glycaemic       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> information but is considerably more expensive than SMBG systems. There are few data on the global use or       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> availability of CGM, which is at present largely restricted to well-resourced health settings. The Indonesian   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> study assessed the financial impact of CGM and reported that it would require spending 31 daysâ€™ salary of a     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> low-income worker to purchase a CGM reader, meaning no salary would remain for basic daily needs. Moreover,     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> buying a monthâ€™s supply of CGM sensors would require 61 daysâ€™ salary, effectively making access to CGM          <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> financially impossible for many individuals.25 EVIDENCE SUMMARY HbA1c (glycated haemoglobin) Measurement of     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> HbA1c is the established gold standard marker to assess glycaemic control in T2DM and has prognostic value for  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> the development of diabetes complications and is routinely used to measure glycaemia in outcome-related         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> clinical studies.27 HbA1c integrates the mean glycaemia from the past two to three months. It can be measured   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> in the laboratory or by point-of-care testing. Point-of-care technology can give HbA1c results of sufficient    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> quality to enable clinical decision-making and can be used in community and primary care settings.28 HbA1c      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> measurement may be affected by a variety of genetic, haematologic, and illness-related factors. The most common <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> worldwide important factors affecting HbA1c levels are haemoglobinopathies, certain anaemias, and disorders     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> associated with accelerated red cell turnover, such as malaria.21 Serum glycated proteins (fructosamine and     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> glycated albumin) are an alternative to monitor glycaemic control, especially in people with diabetes where     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> measurement or interpretation of HbA1c is problematic. Fructosamine reflects total glycated serum proteins and  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> glycated albumin, the proportion of total albumin that is glycated. These measures reflect glycaemia over the   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> past two to four weeks and are associated with long-term complications but lack definitive outcome data.14 39   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Chapter 2 HbA1c and diabetes complications Glycaemia measured by HbA1c is associated with increased risk of     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> microvascular and macrovascular complications in T2DM.29 Interventions to reduce HbA1c significantly reduce     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> macrovascular and microvascular complications in the short and longer-term.1,7 One meta-analysis suggested a    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 15% relative risk reduction in non-fatal myocardial infarction with every 1.0% (11 mmol/mol) reduction in       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> HbA1c30 and another that an absolute HbA1c reduction of 0.9% (10 mmol/mol) reduced the relative risk of kidney  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> events by 20% and eye events by 13%.31 HbA1c variability Serial measurements of HbA1c can be used to assess     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> long-term glycaemic variability.32,33 While HbA1c variability has not been definitively confirmed as an         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> independent risk factor for diabetes complications, observational studies34,35 and post-hoc analysis of         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> diabetes outcomes studies have reported an association between HbA1c variability and diabetes complications,    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> including macrovascular events in the ADVANCE study,36 CVD death in the EMPAREG study,37 and all-cause          <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> mortality in the ACCORD study.38 However in the VADT study, no HbA1c measures were associated with CVD.39 High  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> variability in HbA1c, even among individuals with T2DM whose average HbA1c was at target levels, has been       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> associated with an increased risk of CVD complications and other adverse outcomes.40,41 HbA1c target Setting    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> general HbA1c targets is based on observational studies and post-hoc analyses of interventional RCTs showing a  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> relationship between HbA1c levels and macrovascular and microvascular complications, and death in people with   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> T2DM. However, the nature of the relationship has varied. The UKPDS showed a curvilinear relationship between   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> HbA1c and microvascular complications.3 The ADVANCE trial showed a non-linear relationship between mean HbA1c   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> during follow-up and the risks of macrovascular events, microvascular events, and death with evidence of HbA1c  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> â€˜thresholdsâ€™ below 7.0% (53 mmol/mol) for macrovascular events and death, and 6.5% (48 mmol/mol) for            <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> microvascular events.9 An Italian registry-based study examined 251,339 newly diagnosed T2DM without CVD at     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> baseline and assessed major CVD outcomes-based mean HbA1c. After a mean follow-up of 4.6 years, compared with   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> mean HbA1c &lt;5.7% (39 mmol/mol) during the first year after diagnosis, CVD risk increased progressively to 56%   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> for individuals with HbA1c &gt;8.0% (&gt;64 mmol/mol).10 Interventional RCTs examining the effect of intensive        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> glycaemic control have achieved HbA1c targets ranging from of 6.5%â€“7.1% (48â€“54 mmol/mol).4-8 These data are the <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> basis for the general target of HbA1c &lt;7.0% (&lt;53 mmol/mol) in people with T2DM recommended by most guidelines   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> for minimising risk of diabetes complications and hypoglycaemia. This target is proposed as a guide, which is   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> appropriate for many people, but it is important to consider personalising targets, based on a range of factors <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> relevant to the individual with T2DM. These factors include the presence of comorbidities, age, duration of     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> diabetes, risk of hypoglycaemia, life expectancy, individual preferences, and available resources.14,15         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Increasing age and declining functional and cognitive capacity are particularly relevant when setting less      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> stringent goals, as treatment burden and risk of harm outweigh potential benefits.42 It is also important to    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> adjust targets as required if circumstances change. Setting glycaemic targets should consider not only the      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> impact on the individual but also the broader population-level effects. Considering the high global levels of   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> poor glycaemic control,11,12 the greatest population impact on complications will be achieved by reducing HbA1c <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> from high to moderate glycaemic levels. Although further lowering of HbA1c is associated with an additional     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> reduction in the risk of complications, the absolute risk reductions become much smaller, and number needed to  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> treat to achieve a benefit for an individual increases.14 For example, if the annual incidence of a diabetes    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> complication is 5% at an HbA1c of 9.0% (75 mmol/mol) and lowering HbA1c by 1.0% (11 mmol/mol) is associated     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> with a 50% reduction in the annual incidence of that complication, 40 people would need to have their HbA1c     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> lowered from 9.0% (75 mmol/mol) to 8.0% (64 mmol/mol) to benefit one individual. The equivalent numbers for     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> lowering HbA1c from 8.0% (64 mmol/mol) to 7.0% (53 mmol/mol) is 80 individuals and from 7.0% (53 mmol/mol) to   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 6.5% (48 mmol/mol) is 270 individuals. Therefore, setting low HbA1c population targets has implications for the <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> impact on health services in different resource settings. IDF Global Clinical Practice Recommendations for      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Managing Type 2 Diabetes â€“ 2025 40 GLYCAEMIC TARGETS Postprandial and fasting glucose The contribution of       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> fasting plasma glucose (FPG) and postprandial glucose (PPG) to overall glycaemia in people with T2DM varies     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> according to HbA1c levels. The relative contribution of PPG decreased progressively from approximately 70% in   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> the lowest to approximately 30% in the highest quintile of HbA1c, whereas the opposite is observed for the      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> relative contribution of FPG â€“ approximately 30% in the lowest compared with approximately 70% in the highest   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> quintile.43,44 A short-term study assessed the relative contribution of controlling FPG and PPG in people with  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> T2DM with an HbA1c â‰¥7.5% (58 mmol/mol). Only 64% of people achieving an FPG &lt;5.6 mmol/L (100 mg/dL) achieved an <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> HbA1c &lt;7.0% (53 mmol/mol) compared with 94% who achieved a PPG of &lt;7.8 mmol/L (140 mg/dL).45 However, the       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> contribution of FPG to HbA1c may also be influenced by the intervention to improve glycaemia with basal insulin <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> reducing the contribution of basal hyperglycaemia to approximately 35% with lowering mean FPG to 6.5 mmol/L     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> (117 mg/dL) and HbA1c to 7.0% (53 mmol/mol).46 Postprandial and fasting glucose and diabetes complications      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Atherosclerotic disease accounts for much of the increased mortality and morbidity associated with T2DM, and    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> PPG may have a direct toxic effect on the vascular endothelium, mediated by oxidative stress that is            <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> independent of other CVD risk factors.47 The HEART2D RCT in people with T2DM after acute myocardial infarction  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> compared controlling PPG with three premeal doses of insulin lispro (PRANDIAL strategy) versus a basal strategy <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> (BASAL) of twice daily NPH insulin or once daily insulin glargine. After 2.6 years, the trial was stopped due   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> to lack of efficacy.48 The Kumamoto study which used multiple daily insulin injections to control both fasting  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> and post-meal glycaemia in people with T2DM, reported a curvilinear relationship between retinopathy and        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> microalbuminuria with both FPG and two-hour PPG control with no development or progression of retinopathy or    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> nephropathy with FPG &lt;6.1 mmol/L (110 mg/dL) and two-hour post-meal PG &lt;10 mmol/L (180 mg/dL). This suggests    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> that both reduced PPG and reduced FPG are strongly associated with reductions in retinopathy and nephropathy.8  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> RCTs have examined CVD outcomes with glucose-lowering medications (GLMs) which target PPG. The NAVIGATOR trial  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> examined the effect of the short-acting insulin secretagogue, nateglinide, on risk of CVD events in 9,306       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> people with impaired glucose tolerance. CVD outcomes were not significantly reduced in the participants taking  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> nateglinide compared with placebo after a median of five years.49 Three studies have examined alpha glucosidase <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> inhibitors on CVD outcomes. The ACE (Acarbose Cardiovascular Evaluation) study examined the effect of acarbose  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> in people with coronary artery disease and impaired glucose tolerance and failed to show a difference in        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> outcomes between acarbose and placebo.50 The UKPDS randomised 1,946 people with T2DM to acarbose or placebo.    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> After three years, there was no difference in the primary aggregated outcome or microvascular disease.51 The    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> ABC study assessed the effect of voglibose on the recurrence of myocardial infarction in people with a previous <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> myocardial infarction and impaired glucose tolerance but was terminated early after an interim analysis         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> suggested a low probability of a positive outcome.52 Fasting plasma and postprandial glucose variability        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Long-term glycaemic variability can be assessed by serial measurements of HbA1c or other measures of glycaemia, <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> including FPG and PPG.32,33 Post-hoc analyses of diabetes outcomes studies have examined the relationship       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> between FPG variability and diabetes complications. In the ADVANCE study intensive treatment group, an increase <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> in visit-to-visit variation in FPG was associated with an increased risk of both macrovascular and              <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> microvascular events.36 In the DEVOTE study, higher day-to-day fasting glycaemic variability was associated     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> with increased risks of severe hypoglycaemia and all-cause mortality.53 In the VADT study, variability measures <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> of FPG were significantly associated with CVD events after adjusting for other risk factors. Considered         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> separately, this relationship was evident in the intensive treatment group but not in the standard group.39 In  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> the EMPAREG study, higher FPG variability was associated with an increased risk for CVD death in both treatment <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> arms.37 There are no equivalent in-depth data analyses examining PPG variability. 41 Chapter 2 Postprandial and <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> fasting glucose targets The Kumamoto study showed no development or progression of retinopathy or nephropathy   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> with FPG &lt;6.1 mmol/L (110 mg/dL) and two-hour post-meal PG &lt;10 mmol/L (180 mg/dL).8 Intervention RCTs on the    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> effects of glycaemic control used different glycaemic targets to intensify treatment in the intensive treatment <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> groups. The UKPDS aimed for an FPG &lt;6.0 mmol/L (108 mg/dL);7 the ACCORD study intensified treatment in the      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> intensive glycaemic control group every month if required, if HbA1c levels were â‰¥6.0% (42 mmol/mol) or if &gt;50%  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> of premeal or post-meal capillary glucose readings were &gt;5.6 mmol/L (100 mg/dL) or &gt;7.8 mmol/L (140 mg/dL),     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> respectively;54 and the VADT started or adjusted insulin based on achieving SMBG fasting glucose of 4.4 to 6.4  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> mmol/L (80 to 115 mg/dL).55 SMBG targets recommended by diabetes organisations have also differed but are       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> generally in the same range. The IDF recommended target levels for capillary plasma glucose levels of &lt;6.0      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> mmol/L (&lt;108 mg/dL) before meals, and &lt;8.0 mmol/L (&lt;144 mg/dL) one to two hours after meals;42 the ADA          <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> recommends a pre-prandial capillary plasma glucose level of 4.4â€“7.2 mmol/L (80â€“130 mg/dL) and a peak            <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> post-prandial capillary plasma glucose level of &lt;10 mmol/L (180 mg/ dL);14 and the Research Society for the     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Study of Diabetes in India recommends an FPG â‰¤6.4 mmol/L (115 mg/dL) and a postprandial glucose â‰¤8.9 mmol/L     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> (160 mg/dL).56 CGM-derived glycaemic data are also useful in informing glycaemic targets. In 153 healthy        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> children and adults, all without diabetes and not overweight, CGM showed that 96% of glucose readings were      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> between 3.9 and 7.8 mmol/L (70 and 140 mg/dL during the day [6 am to 11:59 pm]) and 99% during the night (12 am <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> to 5:59 am). No glucose levels exceeded 10 mmol/L (180 mg/dL) and 1.4% and 0.4% of readings fell below this     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> level during the day and night, respectively.17 Taking into account available data and in particular aligning   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> with CGM data, Table 2.1 shows suggested general targets for SMBG glucose levels. Algorithms based on similar   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> targets have been used to safely and successfully adjust basal insulin in people with T2DM.57 Glycaemic         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> profiles / other measures of glycaemia While measurement of HbA1c is the established gold standard biomarker    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> for assessing glycaemic control, it does not provide information on short-term glycaemic variability or         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> hypoglycaemia. The advent of CGM has enabled a more comprehensive assessment and understanding of glycaemia.27  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> A number of glycaemic metrics are recommended for assessment of CGM-derived glycaemia. Short-term glycaemic     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> variability refers to how much glucose levels fluctuate between peaks and nadirs within or between the day and  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> is usually described as the percent coefficient of variation (%CV) of glucose within-day (%CV over 24 hours)    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> and between-day (%CV over several days).34 CGM-derived time in range (TIR), time above range (TAR), and time    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> below range (TBR) of defined glycaemic levels are useful measures of glycaemic status and in clinical           <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> management. Time in a defined range is assessed using a 14-day CGM assessment with a CGM wear of 70% or         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> higher.58 While there is a correlation with HbA1c, CGM metrics provide additional information on glycaemic      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> status. For example, a retrospective analysis examined the relationship between end-of-study HbA1c levels and   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> CGM data in 530 adults with T1DM or insulin-requiring T2DM from four randomised trials. HbA1c was strongly      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> correlated with mean glucose value, TIR in the * The mg/dL and mmol/L values are not strictly identical but     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> have been rounded for ease of use, noting that SMBG-generated values have an inbuilt accuracy error. **Measure  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> post-prandial glucose 1â€“2 h after beginning a meal. SMBG, self-monitoring of blood glucose. Measure Target*     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Fasting and pre-prandial glucose 4.0â€“8.0 mmol/L 70â€“144 mg/dL Post-prandial glucose** 4.0â€“8.0 mmol/L             <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> (preferable) 4.0â€“9.0 mmol/L (acceptable) 70â€“144 mg/dL (preferable) 70â€“160 mg/dL (acceptable) Table 2.1          <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Suggested general SMBG targets IDF Global Clinical Practice Recommendations for Managing Type 2 Diabetes â€“ 2025 <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 42 GLYCAEMIC TARGETS 3.9â€“10.0 mmol/L (70â€“180 mg/dL) range, and percentage of glucose values &gt;13.9 mmol/L (250   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> mg/dL) but weakly correlated with the percentage of glucose values &lt;3.9 mmol/L (70 mg/dL) or &lt;3.0 mmol/L (54    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> mg/dL). The median percentage glucose &lt;3.0 mmol/L (70 mg/dL) was 1.2% across all HbA1c ranges while the         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> percentage of glucose values &gt;13.9 mmol/L (250 mg/dL) varied from 2.5% (0.6 h/day) to 27.8% (6.7 h/day) in the  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> lowest and highest HbA1c groups, respectively.59 CGM metrics and diabetes complications CGM-derived metrics are <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> associated with diabetes outcomes. A review of 34 publications, including 663 people with T1DM and 19,909 with  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> T2DM, reported an association of higher glycaemic variability and lower TIR with diabetes microvascular and     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> macrovascular complications. Higher TIR was associated with reduced risk of albuminuria, retinopathy,           <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> cardiovascular disease mortality, all-cause mortality, and abnormal carotid intima-media thickness. However,    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> the authors acknowledged several limitations, including 30 of the 34 papers being cross-sectional studies and   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> most studies using only a short period of CGM (48 to 72 hours).60 In prospective cohort studies in people with  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> T2DM, greater %CV was associated with increased risk for all-cause mortality even among people with seemingly   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> well-controlled diabetes (mean HbA1c of 7.3% [56 mmol/ mol]).61 Lower TIR was also associated with increased    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> risk of all-cause and CVD mortality in people with T2DM.62 A systematic review of 11 studies in 13,987 people   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> with T2DM examined the association between CGM-derived TIR and microvascular complications of diabetic          <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> retinopathy (DR) (n = 4 studies), diabetic nephropathy (DN) (n = 4 studies), and diabetic peripheral neuropathy <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> (DPN) (n = 7 studies). The majority of studies (10 of the 11) were conducted in Asia. A 10% increase in TIR was <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> associated with a reduction in albuminuria, severity of DR, and prevalence of DPN and cardiac autonomic         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> neuropathy.63 CGM metrics targets An international consensus has proposed targets for key glycaemic metrics as  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> summarised in Table 2.2.58 Table 2.2 Key metrics for assessing glycaemic status using continuous glucose        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> monitoring (CGM) in non-pregnant adults with diabetes58 Metric Interpretation Goal Number of days of CGM 14     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> days Percentage of time CGM device is active 70% data Coefficient of variation Percentage coefficient of        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> variation Intraday (i.e., within 24 h) and Interday (i.e., over multiple days) â‰¤36% Time in range 70â€“180 mg/dL  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> (3.9â€“10.0 mmol/L) Percentage readings and time in range &gt;70% (most adults) &gt;50% (older adults) Time below range <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> &lt;70 mg/dL (&lt;3.9 mmol/L) including readings &lt;54 mg/dL (&lt;3.0 mmol/L) Percentage readings and time below range &lt;4% <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> (most adults) &lt;1% (older adults) Time below range &lt;54 mg/dL (&lt;3.0 mmol/L) Percentage readings and time below    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> range &lt;1% Time above range &gt;180 mg/dL (&gt;10.0 mmol/L) including readings &gt;250 mg/dL (&gt; 13.9 mmol/L) Percentage   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> readings and time above range &lt;25% (most adults) &lt;50% (older adults) Time above range &gt;250 mg/dL (&gt; 13.9        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> mmol/L) Percentage readings and time above range &lt;5% (most adults) &lt;10% (older adults) CGM, continuous glucose  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> monitoring. 43 Chapter 2 Methods for self-assessment of glycaemia Two approaches are available for              <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> self-assessment of glycaemia. Self-monitoring of blood glucose (SMBG) Self-monitoring of capillary              <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> (finger-stick) blood glucose (SMBG) is a common component of diabetes care and is commonly recommended in       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> people treated with a multiple-daily insulin regimen or insulin pump, including those with T2DM.64              <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Recommendations for SMBG use in less intensively insulin-treated people with T2DM (e.g., on basal insulin)      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> varies, although self-measurement of fasting glucose appears helpful in adjusting basal insulin dose and        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> improving glycaemic control.65 SMBG is generally not routinely recommended in people with non-insulin-treated   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> T2DM. A 2012 Cochrane review concluded that when diabetes duration is more than one year, the overall effect of <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> SMBG on glycaemic control in people with T2DM not using insulin is small up to six months after initiation and  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> subsides after 12 months while acknowledging that more research is needed to explore the impact of SMBG on      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> hypoglycaemia and diabetes complications.66 An IDF Guideline on SMBG use in non-insulin-treated T2DM suggested  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> that in RCTs, SMBG data are only likely to be an effective self-management tool when results are reviewed and   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> acted on by healthcare providers and/or people with T2DM to actively modify behaviour and/or adjust treatment.  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> The principal IDF recommendation was that SMBG should be used only when individuals with diabetes, their        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> caregivers, and/or their healthcare providers have the knowledge, skills, and willingness to incorporate SMBG   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> monitoring and therapy adjustment into their diabetes care plan in order to attain agreed treatment goals and   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> that its use should be individualised and structured.67 RCTs have examined the effects of structured SMBG in    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> people with non-insulin-treated T2DM. In a 12-month RCT, 483 poorly controlled (HbA1c â‰¥7.5% [58 mmol/mol])      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> insulin-naÃ¯ve people with T2DM were randomised to a control enhanced usual care group or enhanced usual care    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> group with structured SMBG. After 12-months, structured SMBG significantly improved glycaemic control (HbA1c    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> reduction 0.3% [3 mmol/mol]) and facilitated more timely and aggressive treatment changes.68 Another 12-month   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> RCT randomised 1,024 people with non-insulin-treated T2DM (median baseline HbA1c 7.3% [56 mmol/mol]) to         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> intensive structured SMBG and an active control group. A small but significantly greater reduction in HbA1c     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> (0.12% [1.3 mmol/mol]) was observed over 12 months in the structured SMBG group and more participants achieved  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> clinically meaningful reductions in HbA1c (&gt;0.3% [3 mmol/mol]).69 A recent RCT examined the impact of           <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> structured SMBG, with or without TeleCare support, on glycaemic control in people with non-insulin-treated T2DM <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> that was suboptimally controlled (HbA1c â‰¥7.5% to â‰¤13% [â‰¥58 to â‰¤119 mmol/mol]) and a diabetes duration of more   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> than one year. After 12 months, HbA1c was significantly lower by 0.8% (8.9 mmol/mol) in both the structured     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> SMBG groups compared with the control group. No additional benefit to structured SMBG was observed with the     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> addition of once-monthly TeleCare support.70 SMBG protocols (intensity and frequency) should be individualised  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> to address each individualâ€™s specific educational, behavioural and clinical requirements, specific needs, and   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> goals and provider requirements for data on glycaemic patterns to monitor impact of therapeutic                 <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> decision-making. In addition to those with insulin-treated T2DM, SMBG may be considered for people using GLMs   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> who have an increased risk of hypoglycaemia, experience hypoglycaemia unawareness, have poor metabolic control  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> despite multiple medications, and/or temporarily as an aid to education in newly diagnosed people with          <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> T2DM.42,71 Continuous glucose monitoring (CGM) Personal CGM systems have evolved rapidly in recent years and    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> are increasingly used to manage diabetes. CGM systems continuously measure interstitial glucose concentrations  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> at intervals of one to five minutes, which correlate well with blood glucose levels. CGM provides the user with <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> immediate glucose information on asymptomatic hypoglycaemia or hyperglycaemia to make treatment decisions and   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> health professionals with more detailed information on glycaemia to guide therapeutic advice. CGM can also help <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> to educate and support healthier lifestyle choices. IDF Global Clinical Practice Recommendations for Managing   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Type 2 Diabetes â€“ 2025 44 GLYCAEMIC TARGETS There are currently limited data on CGM use in people with T2DM.    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> The IMMEDIATE study randomised 116 people with non-insulin-treated T2DM to isCGM with diabetes self-management  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> education (DSME) or DSME alone (which included SMBG). After 16 weeks, the isCGM and DSME group had              <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> significantly greater mean TIR, significantly less TAR, and a greater reduction in mean HbA1c by 0.3% (3        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> mmol/mol) compared with the DSME alone arm. TBR and hypoglycaemia were lower but not significantly different.   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Glucose monitoring satisfaction was higher among isCGM users.73 The RELIEF study was a retrospective analysis   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> of 74,011 people with T1DM or T2DM initiating flash glucose monitoring identified from the French national      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> claims database. After 12 months, hospitalisations for acute diabetes complications decreased by 39% in people  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> with T2DM following initiation of flash glucose monitoring, although the absolute change was small â€“ overall    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 2.67% versus 1.62%, hospitalisations for diabetic ketoacidosis 1.70% versus. 0.82%, severe hypoglycaemia 0.7%   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> versus 0.62%, and hyperglycaemia 0.12% versus 0.09%.74 These differences persisted after two years.75 CGM use   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> is currently not widely recommended or adopted as part of routine care for people with T2DM. Wider use of CGM   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> will require healthcare system adaptations, including training and education of both people with diabetes and   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> clinicians in guiding day-to-day management decisions. Further research is also needed to inform optimal CGM    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> usage guidelines and address cost-effectiveness challenges in people with T2DM. Although CGM technology offers  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> potential advantages, it is expensive and global availability and access are limited. Incorporating CGM use in  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> health systems where there are many challenges and barriers to achieving recommended standards of diabetes care <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> will test policy makers and it is likely their use will be limited to those who can privately afford them until <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> costs are substantially lower.\\nSMBG and CGM compared CGM has the potential to provide more detailed glycaemic  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> information than SMBG. However, to date, reported clinical differences in studies comparing CGM and SMBG have   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> been small. A systematic review of 12 RCTs compared SMBG and CGM in 1,248 people with T2DM. Compared with SMBG, <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> CGM use (rtCGM or isCGM) resulted in small but significantly lower HbA1c (mean difference 0.31% [3.4 mmol/mol]) <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> with the effect being similar in individuals using insulin with or without oral agents or oral agents only. A   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> larger effect was noted with rtCGM than isCGM. CGM was associated with a 6.4% increased TIR, a 0.7% decreased   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> TBR, a 5.9% decreased TAR, and a 1.5% decreased glycaemic variability. CGM was associated with a                <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> non-statistically significant difference in the incidence of severe hypoglycaemia and macrovascular             <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> complications. No trials reported data on microvascular complications.76 A systematic review of 26 RCTs         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> involving 2,783 people with T2DM compared CGM (real-time/ retrospective data analysis CGM or isCGM) versus      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> usual care (which may have included SMBG). Compared with usual care/SMBG, CGM reduced HbA1c by 0.19% (2         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> mmol/mol) and isCGM by 0.31% (3.4 mmol/mol) but increased risk of mainly device-related adverse events. Unlike  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> CGM, isCGM was associated with improved user satisfaction.77 More CGM data are expected to become available as  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> CGM is increasingly integrated into clinical trials. A recent consensus statement detailed how CGM might be     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> incorporated in diabetes RCTs, especially with new pharmaceutical agents, and could help identify treatment     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> differences related to hypoglycaemia and glycaemic metrics while minimising the potential confounding effect of <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> CGM use.78 Applying these consensus recommendations in LMICs presents challenges and may require different      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> approaches in resource-limited settings to ensure such technology does not widen the resource-driven digital    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> divide.79 There are two basic types of CGM systems: o Realtime CGM (rtCGM): automatically and continuously      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> transmits data to the user, provides alerts and active alarms and glucose data in real-time to a receiver       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> (e.g., smart watch or phone) o Intermittently scanned CGM (isCGM): provides the same type of glucose data but   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> requires the user to scan the sensor to obtain information and does not have alerts and alarms.72 45 Chapter 2  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> REFERENCES 1. Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> diabetes. N Engl J Med. 2008;359(15):1577-1589. 2. Adler AI, Coleman RL, Leal J, et al. Post-trial monitoring   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> of a randomised controlled trial of intensive glycaemic control in type 2 diabetes extended from 10 years to 24 <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> years (UKPDS 91). Lancet. 2024;404(10448):145-155. 3. Adler AI, Stratton IM, Neil HA, et al. Association of     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36):       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> prospective observational study. BMJ. 2000;321(7258):412-419. 4. Patel A, MacMahon S, Chalmers J, et al.        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med.           <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 2008;358(24):2560-2572. 5. Gerstein HC, Miller ME, Byington RP , et al. Effects of intensive glucose lowering   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> in type 2 diabetes. N Engl J Med. 2008;358(24):2545-2559. 6. Duckworth W, Abraira C, Moritz T, et al. Glucose   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360(2):129-139. 7. UK   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet.           <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 1998;352(9131):837-853. 8. Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> mellitus: A randomized prospective 6-year study. Diabetes Res Clin Pract. 1995;28(2):103-117. 9. Zoungas S,     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Chalmers J, Ninomiya T, et al. Association of HbA1c levels with vascular complications and death in patients    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> with type 2 diabetes: Evidence of glycaemic thresholds. Diabetologia. 2012;55(3):636-643. 10. Russo GT,         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Nicolucci A, Lucisano G, et al. When does metabolic memory start? Insights from the Association of Medical      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Diabetologists Annals Initiative on stringent HbA1c targets. Diabetes. 2025;74(1):75-81. 11. Bin Rakhis SA,     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Sr., AlDuwayhis NM, Aleid N, et al. Glycemic control for type 2 diabetes mellitus patients: A systematic        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> review. Cureus. 2022;14(6):e26180. 12. Shahrestanaki E, Mohammadian Khonsari N, Seif E, et al. The worldwide    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> trend in diabetes awareness, treatment, and control from 1985 to 2022: A systematic review and meta-analysis of <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 233 population-representative studies. Front Public Health. 2024;12:1305304. 13. World Health Organization.     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Guidance on global monitoring for diabetes prevention and control: Framework, indicators and application.       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Geneva: World Health Organization; 2024. Licence: CC BY-NC-SA 3.0 IGO. Available from: https://www.who.int/     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> publications/i/item/9789240102248 [Accessed November, 2024]. 14. American Diabetes Association Professional     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Practice Committee. 6. Glycemic Goals and Hypoglycemia: Standards of Care in Diabetes-2025. Diabetes Care.      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 2025;48(Suppl 1):S128-S145. 15. Cheung NW, Conn JJ, dâ€™Emden MC, et al. Position statement of the Australian     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Diabetes Society: Individualisation of glycated haemoglobin targets for adults with diabetes mellitus. Med J    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Aust. 2009;191(6):339-344. 16. Whitehead L, Glass C, Coppell K. The effectiveness of goal setting on glycaemic  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> control for people with type 2 diabetes and prediabetes: A systematic review and meta-analysis. J Adv Nurs.     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 2022;78(5):1212-1227. 17. Shah VN, DuBose SN, Li Z, et al. Continuous glucose monitoring profiles in healthy    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> nondiabetic participants: A multicenter prospective study. J Clin Endocrinol Metab. 2019;104(10):4356-4364.     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Erratum in: J Clin Endocrinol Metab. 2022;107(4):e1775-e1776. 18. International Diabetes Federation (IDF). IDF  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Diabetes Atlas, 11th edition. Brussels, Belgium: International Diabetes Federation, 2025. Available from:       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> https://diabetesatlas.org. 19. World Health Organization. Assessing national capacity for the prevention and    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> control of noncommunicable diseases: Report of the 2019 global survey. Geneva: World Health Organization; 2020. <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Licence: CC BY-NC-SA 3.0 IGO. Available from: https://www.who.int/ publications/i/item/9789240002319 [Accessed  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> November 2024]. 20. Pan American Health Organization (PAHO). Country snapshot of diabetes prevention and        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> control in the Americas. Information kit (folder, banner, brochure). PAHO; 2021. Available from:                <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> https://iris.paho.org/handle/10665.2/55326 [Accessed November 2024]. IDF Global Clinical Practice               <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Recommendations for Managing Type 2 Diabetes â€“ 2025 46 GLYCAEMIC TARGETS 21. World Health Organization. Use of  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Glycated Haemoglobin (HbA1c) in the Diagnosis of Diabetes Mellitus: Abbreviated Report of a WHO Consultation.   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Geneva: World Health Organization: 2011. Available from: https:// www.ncbi.nlm.nih.gov/books/NBK304267/         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> [Accessed November 2024]. 22. Klatman EL, Jenkins AJ, Ahmedani MY, et al. Blood glucose meters and test strips: <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Global market and challenges to access in low-resource settings. Lancet Diabetes Endocrinol. 2019;7(2):150-160. <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 23. Ogle GD, Middlehurst AC, Silink M. The IDF Life for a Child Program Index of diabetes care for children and <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> youth. Pediatr Diabetes. 2016;17(5):374-384. 24. Health Action International (HAI). Market report of diabetes   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> self-monitoring devices in LMICs - October 2021. Developed by the Clinton Health Access Initiative (CHAI).      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Available from:                                                                                                 <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> https://haiweb.org/wp-content/uploads/2021/09/Market-Report_Self-monitoring-Devices-in-LMICs.pdf [Accessed      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> November 2024]. 25. Ramadaniati HU, Anggriani Y, Lepeska M, et al. Availability, price and affordability of     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> insulin, delivery devices and self-monitoring blood glucose devices in Indonesia. PLoS One.                     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 2024;19(10):e0309350. 26. World Health Organization. The selection and use of essential in vitro diagnostics:   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Report of the fourth meeting of the WHO Strategic Advisory Group of Experts on In Vitro Diagnostics, 2022       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> (including the fourth WHO model list of essential in vitro diagnostics). Geneva: World Health Organization;     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 2023 (WHO Technical Report Series, No. 1053). Licence: CC BY-NC-SA 3.0.IGO. Available from:                     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> https://www.who.int/publications/i/ item/9789240081093 [Accessed January 2024]. 27. Ceriello A, Prattichizzo F, <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Phillip M, et al. Glycaemic management in diabetes: Old and new approaches. Lancet Diabetes Endocrinol.         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 2022;10(1):75-84. 28. Gourlay A, Sutherland C, Radley A. point-of-care testing of HbA(1)c levels in community   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> settings for people with established diabetes or people at risk of developing diabetes: A systematic review and <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> meta-analysis. Prim Care Diabetes. 2024;18(1):7-16. 29. Stratton IM, Adler AI, Neil HA, et al. Association of   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> observational study. BMJ. 2000;321(7258):405-412. 30. Turnbull FM, Abraira C, Anderson RJ, et al. Intensive     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia. 2009;52(11):2288-2298. 31. Zoungas <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> S, Arima H, Gerstein HC, et al. Effects of intensive glucose control on microvascular outcomes in patients with <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> type 2 diabetes: A meta-analysis of individual participant data from randomised controlled trials. Lancet       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Diabetes Endocrinol. 2017;5(6):431-437. 32. Monnier L, Colette C, Owens D. Glucose variability and diabetes     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> complications: Risk factor or biomarker? Can we disentangle the â€œGordian Knotâ€? Diabetes Metab.                 <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 2021;47(3):101225. 33. Monnier L, Colette C, Wojtusciszyn A, et al. Toward defining the threshold between low   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> and high glucose variability in diabetes. Diabetes Care. 2017;40(7):832-838. 34. Ceriello A, Monnier L, Owens   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> D. Glycaemic variability in diabetes: Clinical and therapeutic implications. Lancet Diabetes Endocrinol.        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 2019;7(3):221-230. 35. Li S, Nemeth I, Donnelly L, et al. Visit-to-visit HbA(1c) variability is associated with <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> cardiovascular disease and microvascular complications in patients with newly diagnosed type 2 diabetes.        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Diabetes Care. 2020;43(2):426-432. 36. Hirakawa Y, Arima H, Zoungas S, et al. Impact of visit-to-visit glycemic <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> variability on the risks of macrovascular and microvascular events and all-cause mortality in type 2 diabetes:  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> The ADVANCE trial. Diabetes Care. 2014;37(8):2359-2365. 37. Ceriello A, Ofstad AP, Zwiener I, et al.            <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Empagliflozin reduced long-term HbA1c variability and cardiovascular death: Insights from the EMPA-REG OUTCOME  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> trial. Cardiovasc Diabetol. 2020;19(1):176. 38. Sheng CS, Tian J, Miao Y, et al. Prognostic significance of     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> long-term HbA(1c) variability for all-cause mortality in the ACCORD trial. Diabetes Care. 2020;43(6):1185-1190. <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 39. Zhou JJ, Schwenke DC, Bahn G, et al. Glycemic variation and cardiovascular risk in the Veterans Affairs     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Diabetes Trial. Diabetes Care. 2018;41(10):2187-2194. 40. Sato M, Inaishi J, Saisho Y, et al. Association of    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> visit-to-visit glycemic variability with risk of cardiovascular diseases in high-risk Japanese patients with    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> type 2 diabetes: A subanalysis of the EMPATHY trial. J Diabetes Investig. 2021;12(12):2190-2196. 47 Chapter 2   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 41. Ceriello A, Lucisano G, Prattichizzo F, et al. HbA1c variability predicts cardiovascular complications in   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> type 2 diabetes regardless of being at glycemic target. Cardiovasc Diabetol. 2022;21(1):13. 42. International   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Diabetes Federation. Managing older people with type 2 diabetes - Global guideline. 2013. Available from:       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> https://idf.org/ media/uploads/2023/05/attachments-48.pdf [Accessed November 2024]. 43. Monnier L, Lapinski H,  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal           <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> hyperglycemia of type 2 diabetic patients: Variations with increasing levels of HbA(1c). Diabetes Care.         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 2003;26(3):881-885. 44. International Diabetes Federation. Guideline for management of postmeal glucose in      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> diabetes. Diabetes Res Clin Pract. 2014;103(2):256-268. 45. Woerle HJ, Neumann C, Zschau S, et al. Impact of    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> fasting and postprandial glycemia on overall glycemic control in type 2 diabetes. Importance of postprandial    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> glycemia to achieve target HbA1c levels. Diabetes Res Clin Pract. 2007;77(2):280-285. 46. Riddle M, Umpierrez   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> G, DiGenio A, et al. Contributions of basal and postprandial hyperglycemia over a wide range of A1C levels      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> before and after treatment intensification in type 2 diabetes. Diabetes Care. 2011;34(12):2508-2514. 47.        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Ceriello A, Hanefeld M, Leiter L, et al. Postprandial glucose regulation and diabetic complications. Arch       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Intern Med. 2004;164(19):2090-2095. 48. Raz I, Wilson PW, Strojek K, et al. Effects of prandial versus fasting  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> glycemia on cardiovascular outcomes in type 2 diabetes: The HEART2D trial. Diabetes Care. 2009;32(3):381-386.   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 49. Holman RR, Haffner SM, McMurray JJ, et al. Effect of nateglinide on the incidence of diabetes and           <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> cardiovascular events. N Engl J Med. 2010;362(16):1463-1476. 50. Holman RR, Coleman RL, Chan JCN, et al.        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> impaired glucose tolerance (ACE): A randomised, double-blind, placebo-controlled trial. Lancet Diabetes         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Endocrinol. 2017;5(11):877-886. 51. Holman RR, Cull CA, Turner RC. A randomized double-blind trial of acarbose  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> in type 2 diabetes shows improved glycemic control over 3 years (U.K. Prospective Diabetes Study 44). Diabetes  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Care. 1999;22(6):960-964. 52. Asakura M, Kim J, Asanuma H, et al. Does treatment of impaired glucose tolerance  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> improve cardiovascular outcomes in patients with previous myocardial infarction? Cardiovasc Drugs Ther.         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 2017;31(4):401-411. 53. Zinman B, Marso SP, Poulter NR, et al. Day-to-day fasting glycaemic variability in      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> DEVOTE: Associations with severe hypoglycaemia and cardiovascular outcomes (DEVOTE 2). Diabetologia.            <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 2018;61(1):48-57. 54. Gerstein HC, Riddle MC, Kendall DM, et al. Glycemia treatment strategies in the Action to <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol. 2007;99(12a):34i-43i. 55. Abraira C,      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Duckworth W, McCarren M, et al. Design of the cooperative study on glycemic control and complications in        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> diabetes mellitus type 2: Veterans Affairs Diabetes Trial. J Diabetes Complications. 2003;17(6):314-322. 56.    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Rao PV, Makkar BM, Kumar A, et al. RSSDI consensus on self-monitoring of blood glucose in types 1 and 2         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> diabetes mellitus in India. Int J Diabetes Dev Ctries. 2018;38(3):260-279. 57. Johnson ML, Bergenstal RM, Levy  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> BL, et al. A safe and simple algorithm for adding and adjusting mealtime insulin to basal-only therapy. Clin    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Diabetes. 2022;40(4):489-497. 58. Battelino T, Danne T, Bergenstal RM, et al. Clinical targets for continuous   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> glucose monitoring data interpretation: Recommendations from the International Consensus on Time in Range.      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Diabetes Care. 2019;42(8):1593-1603. 59. Hirsch IB, Welsh JB, Calhoun P, et al. Associations between HbA(1c)    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> and continuous glucose monitoring-derived glycaemic variables. Diabet Med. 2019;36(12):1637-1642. 60. Yapanis   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> M, James S, Craig ME, et aI. Complications of diabetes and metrics of glycemic management derived from          <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> continuous glucose monitoring. J Clin Endocrinol Metab. 2022;107(6):e2221-e2236. 61. Mo Y, Wang C, Lu J, et al. <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Impact of short-term glycemic variability on risk of all-cause mortality in type 2 diabetes patients with       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> well-controlled glucose profile by continuous glucose monitoring: A prospective cohort study. Diabetes Res Clin <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Pract. 2022;189:109940. 62. Lu J, Wang C, Shen Y, et al. Time in range IDF Global Clinical Practice             <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Recommendations for Managing Type 2 Diabetes â€“ 2025 48 GLYCAEMIC TARGETS in relation to all-cause and           <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> cardiovascular mortality in patients with type 2 diabetes: A prospective cohort study. Diabetes Care.           <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 2021;44(2):549-555. 63. Raj R, Mishra R, Jha N, et al. Time in range, as measured by continuous glucose         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> monitor, as a predictor of microvascular complications in type 2 diabetes: A systematic review. BMJ Open        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Diabetes Res Care. 2022;10(1):e002573. 64. American Diabetes Association Professional Practice Committee. 7.    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Diabetes technology: Standards of care in diabetes-2025. Diabetes Care. 2025;48(Suppl 1):S146-S166. 65. Garber  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> AJ. Treat-to-target trials: Uses, interpretation and review of concepts. Diabetes Obes Metab.                   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 2014;16(3):193-205. 66. Malanda UL, Welschen LM, Riphagen, II, et al. Self-monitoring of blood glucose in       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> patients with type 2 diabetes mellitus who are not using insulin. Cochrane Database Syst Rev. 2012;1:CD005060.  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 67. International Diabetes Federation. Guideline on self-monitoring of blood glucose in non-insulin treated     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> type 2 diabetes. 2013. Available from:                                                                          <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> https://d-net.idf.org/en/library/190-self-monitoring-of-blood-glucose-in-non-insulin-treated-type-2-diabetes.ht <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> ml [Accessed November 2024]. 68. Polonsky WH, Fisher L, Schikman CH, et al. Structured self-monitoring of blood <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> glucose significantly reduces A1C levels in poorly controlled, noninsulin-treated type 2 diabetes: Results from <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> the Structured Testing Program study. Diabetes Care. 2011;34(2):262-267. 69. Bosi E, Scavini M, Ceriello A, et  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> al. Intensive structured self-monitoring of blood glucose and glycemic control in noninsulin-treated type 2     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> diabetes: The PRISMA randomized trial. Diabetes Care. 2013;36(10):2887-2894. 70. Parsons SN, Luzio SD, Harvey   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> JN, et al. Effect of structured self-monitoring of blood glucose, with and without additional TeleCare support, <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> on overall glycaemic control in non-insulin treated Type 2 diabetes: The SMBG Study, a 12-month randomized      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> controlled trial. Diabet Med. 2019;36(5):578-590. 71. National Institute for Health and Care Excellence (NICE). <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Type 2 diabetes in adults: Management. NICE guideline [NG28]. Available from: https://www.nice.org.uk/          <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> guidance/ng28 [Accessed November 2024]. 72. Edelman SV, Argento NB, Pettus J, et al. Clinical implications of   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> real-time and intermittently scanned continuous glucose monitoring. Diabetes Care. 2018;41(11):2265-2274. 73.   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Aronson R, Brown RE, Chu L, et al. IMpact of flash glucose Monitoring in pEople with type 2 Diabetes            <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Inadequately controlled with non-insulin Antihyperglycaemic ThErapy (IMMEDIATE): A randomized controlled trial. <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Diabetes Obes Metab. 2023;25(4):1024-1031. 74. Roussel R, Riveline JP, Vicaut E, et al. Important drop in rate  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> of acute diabetes complications in people with type 1 or type 2 diabetes after initiation of flash glucose      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> monitoring in France: The RELIEF Study. Diabetes Care. 2021;44(6):1368-1376. 75. Riveline JP, Roussel R, Vicaut <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> E, et al. Reduced rate of acute diabetes events with flash glucose monitoring is sustained for 2 years after    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> initiation: Extended outcomes from the RELIEF Study. Diabetes Technol Ther. 2022;24(9):611-618. 76. Jancev M,   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Vissers T, Visseren FLJ, et al. Continuous glucose monitoring in adults with type 2 diabetes: A systematic      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> review and meta-analysis. Diabetologia. 2024;67(5):798-810. 77. Seidu S, Kunutsor SK, Ajjan RA, et al. Efficacy <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> and safety of continuous glucose monitoring and intermittently scanned continuous glucose monitoring in         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> patients with type 2 diabetes: A systematic review and meta-analysis of interventional evidence. Diabetes Care. <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 2024;47(1):169-179. 78. Battelino T, Alexander CM, Amiel SA, et al. Continuous glucose monitoring and metrics   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> for clinical trials: An international consensus statement. Lancet Diabetes Endocrinol. 2023;11(1):42-57. 79.    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Gupta Y, Goyal A, Tandon N. Implications of technology guidelines for low-income and middle-income countries.   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Lancet Diabetes Endocrinol. 2023;11(3):155. 49 Chapter 2 50 Blood Glucose-Lowering Therapies â€“ Non-Insulin      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Options for Type 2 Diabetes Chapter 3 BLOOD GLUCOSE-LOWERING THERAPIES â€“ NON-INSULIN 51 Chapter 3               <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> RECOMMENDATIONS Optimal Care Basic Care At diagnosis No complications or low cardio-renal risk In obese persons <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> â€¢\\tLifestyle modification â€¢\\tMetformin â€¢\\tCombination therapy is an option â€¢\\tConsider metformin and GLP-1RA    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> â€¢\\tLifestyle modification â€¢\\tMetformin â€¢\\tConsider metformin and SGLT2i* Risk of or with cardio-renal           <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> complications â€¢\\tLifestyle modification â€¢\\tMetformin and SGLT2i or GLP-1RA (SGLT2i preferred in HF)             <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> â€¢\\tLifestyle modification â€¢\\tMetformin and SGLT2i* On therapy and not at glycaemic target No complications or   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> low cardio-renal risk â€¢\\tReinforce lifestyle modification If only on metformin â€¢\\tAdd SGLT2i In obese persons   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> â€¢\\tAdd GLP-1RA If on combination therapy â€¢\\tAdd an SGLT2i or GLP-1RA â€¢\\tIf already taking an SGLT2i or GLP-1RA, <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> add an agent from another BGL therapy â€¢\\tReinforce lifestyle modification If only on metformin â€¢\\tAdd SGLT2i*   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> or any available BGL therapy If on combination therapy â€¢\\tAdd SGLT2i* or any available BGL therapy Risk of or   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> with cardio-renal complications â€¢\\tReinforce lifestyle modification If only on metformin: â€¢\\tAdd SGLT2i or      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> GLP-1RA In obese persons â€¢\\tAdd GLP-1RA If on combination therapy â€¢\\tAdd an SGLT2i or GLP-1RA â€¢\\tIf already     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> taking an SGLT2i or GLP-1RA, add an agent from another BGL therapy â€¢\\tReinforce lifestyle modification If only  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> on metformin: â€¢\\tAdd SGLT2i* or any available BGL therapy If on combination therapy â€¢\\tAdd SGLT2i* or any       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> available BGL therapy * SGLT2 inhibitors are increasingly available in several low- and middle-income countries <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> at generally affordable cost.\\nBGL, blood glucose- lowering; GLP-1RA, glucagon-like peptide-1 receptor agonist; <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> HF, heart failure; SGLT2i, sodium-glucose cotransporter-2 inhibitor.\\nIDF Global Clinical Practice              <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Recommendations for Managing Type 2 Diabetes â€“ 2025 52 BLOOD GLUCOSE-LOWERING THERAPIES â€“ NON-INSULIN o         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Globally, poor glycaemic control is common in people with type 2 diabetes mellitus (T2DM) and improving         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> glycaemic control remains an unmet need and a key diabetes care priority. o Early and intensive glycaemic       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> control in T2DM not only reduces micro- and macrovascular complications but also has a legacy effect that lower <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> risk for decades. o Intensive multifactorial risk management, including blood glucose, blood pressure, and      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> lipids, decreases long-term cardio-renal events and overall mortality. o Recent cardiovascular outcome trials   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> with sodium-glucose cotransporter-2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> have demonstrated significant cardio-renal protection, prompting debate about balancing the focus on glycaemic  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> control and organ protection, particularly for individuals at low risk of cardio-renal complications. o Global  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> availability, access, and affordability of blood glucose-lowering therapies (BGL) vary widely and impact        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> treatment options in lower resource settings. o The majority of cardio-renal outcome studies have added trial   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> therapies to usual care with placebo as the comparator and outcome data from head-to-head studies comparing     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> blood glucose-lowering therapies are limited. o Initiating therapy should be personalised based on individual   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> characteristics, comorbidities, and shared decision-making, with lifestyle interventions (e.g., self-management <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> education, nutrition, and exercise) as essential components. o Metformin remains the recommended first-line     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> monotherapy due to its global availability, efficacy, safety profile, low hypoglycaemia risk, and               <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> cost-effectiveness, along with demonstrated long-term cardiovascular benefits. o Emerging data support the      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> early use of SGLT2 inhibitors and GLP-1 receptor agonists, usually added to metformin, to mitigate the adverse  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> consequences of poor glycaemic control and improve cardio-renal outcomes, although evidence supporting their    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> role as first-line monotherapy is limited. o Initial combination therapy may increase durability of glycaemic   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> control compared with stepwise addition of BGL therapies. o Timely treatment intensification is crucial to      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> overcome clinical inertia, while deintensification should be considered in individuals at or near glycaemic     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> targets, especially in the elderly and those prone to hypoglycaemia. o Therapy choices should factor in         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> management of coexisting conditions such as cardio-renal complications, metabolic dysfunction-associated        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> steatotic liver disease, and weight control.\\nKEY POINTS 53 Chapter 3 BACKGROUND Early and intensive glycaemic  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> control Evidence strongly suggests that good glycaemic control is the key to decreasing the risk of both micro- <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> and macrovascular complications in type 2 diabetes mellitus (T2DM).1 Furthermore, early and intensive glycaemic <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> control has a legacy effect in decreasing the risk of developing complications even after 24 years, compared to <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> non-intensive glycaemic control.2 This legacy effect underscores the long-term benefits of early and intensive  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> glycaemic control in reducing cardiovascular and kidney disease events and all-cause mortality. Globally, poor  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> glycaemic control in people with T2DM is common, being observed in 45%â€“93% of individuals, with considerable    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> inter- and within-country variations.3 Consequently, improving glycaemic control remains an unmet need and a    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> key diabetes care priority. In addition, intensive multifactorial risk factor management (blood glucose, blood  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> pressure, lipids) reduces microvascular complications and long-term cardio-renal events and mortality.4,5       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Cardio-renal protection Several sodium-glucose cotransporter-2 (SGLT2) inhibitor and glucagon-like peptide-1    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> (GLP-1) receptor agonist cardiovascular outcome trial (CVOT) randomised controlled trials (RCTs) have           <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> demonstrated cardio-renal protection with benefits in cardiovascular disease (CVD), heart failure, and renal    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> outcomes. These findings have stimulated a paradigm shift to focusing on organ protection with less emphasis on <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> glycaemic control. As a result, there is debate about the relative importance of glycaemic control in the       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> management of T2DM and potential unintended consequences for the many individuals with poor glycaemic control   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> without or at low risk of cardio-renal complications.6 Separating an effect of intensive glucose control and    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> the cardio-renal protection of newer blood glucose-lowering (BGL) medications is limited by a lack of dedicated <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> RCTs. CVOT RCTs have been mainly performed in people with T2DM with prior cardiovascular and/or kidney disease  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> or multiple risk factors, and the majority of participants in the CVOTs of SGLT2 inhibitors and GLP-1 receptor  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> agonists were treated with conventional BGL medications and reninâ€“ angiotensinâ€“aldosterone system inhibitors,   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> statins, and antiplatelet therapy. Of note, these newer agents have no demonstrated benefits on diabetes        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> microvascular complications of retinopathy and neuropathy, which are known to be influenced by improved         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> glycaemic control. Achieving glycaemic control is a universally accepted goal. Complimenting this with specific <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> cardio-renal protection interventions in a low-resource health environment will be determined by availability,  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> accessibility, and affordability of newer BGL medications. GLOBAL CONSIDERATIONS A number of classes of         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> non-insulin BGL therapies are available and their attributes have been reviewed and summarised elsewhere.7,8    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> The global availability, access to, and affordability of BGL therapies vary widely. The World Health            <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Organization (WHO) periodically publishes an Essential Medicines List (EML).9 This includes a core list of      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> minimum medicine needs for a basic healthcare system of the most efficacious, safe, and cost-effective          <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> medicines for priority conditions, including diabetes, selected on the basis of current and estimated future    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> public health relevance, and potential for safe and cost-effective treatment. The current list for diabetes is  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> shown in Table 3.1. IDF Global Clinical Practice Recommendations for Managing Type 2 Diabetes â€“ 2025 54 BLOOD   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> GLUCOSE-LOWERING THERAPIES â€“ NON-INSULIN The WHO EML is reviewed and updated every two years, and in 2023,      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> SGLT2 inhibitors were included. In some low- and middle-income countries (LMICs), generic SGLT2 inhibitors are  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> becoming available at affordable prices. The WHO EML serves as a basis for National EMLs (NEML) with            <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> approximately 70% of the 194 WHO member states having NEMLs. The congruence of NEMLs with the WHO EML varies    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> considerably across conditions, with the median of listed diabetes drugs being 0.60.10 In another study, the    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> total number of diabetes medicines listed on NEMLs ranged from 0 to 16 across 127 countries (median: 4;         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> interquartile range: 3â€“6) and diabetes health outcome scores were associated with the number of diabetes        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> medicines on NEMLs.11 As reviewed in Chapter 2, assessment of glycaemic control is important in monitoring the  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> effectiveness of BGL medications. Global consensus is that measurement of glycated haemoglobin (HbA1c) should   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> be used to initiate and modify BGL therapy. Other tests, such as fasting and postprandial self-blood glucose,   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> glucose variability, and time in range measurements, provide additional information about glycaemic status and  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> underlying pathophysiology, and influence therapeutic choice.12 Unfortunately, HbA1c measurement and other      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> technologies are not available in many health facilities throughout the world and therefore healthcare          <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> providers should remain flexible in using alternative methods for glucose monitoring and treatment planning as  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> per local resources and capabilities. EVIDENCE SUMMARY Initiating therapy Determining the optimal timing for    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> initiating and choosing BGL therapy in drug-naÃ¯ve individuals with unsatisfactory diabetes control requires     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> assessment of individual characteristics (advanced age), personal circumstances (financial constraints, living  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> alone or in a care facility), glycaemic targets, and the presence of comorbidities and cardio-renal disease or  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> risk. Shared decision-making should include an evaluation of benefits and risks such as hypoglycaemia and is a  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> continuous process.13 Lifestyle intervention Lifestyle interventions, including diabetes self-management        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> education, medical nutrition therapy, and regular physical activity, play a pivotal role in managing T2DM       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> regardless of BGL medication,14 and contribute to improved outcomes, including quality of life,15 reduced       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> all-cause mortality,16 hospitalisation, and lower healthcare costs,17,18 emphasising their importance in        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> initial management. Individuals should be encouraged to aim for specific lifestyle goals, such as at least 150  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> minutes of moderate exercise per week and a reduction in excess body weight of 5%â€“10%. Weight loss can improve  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Table 3.1 World Health Organization Model List of Essential Medicines â€“ 23rd List (2023) Medicines for Diabetes <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Oral hypoglycaemic agents Empagliflozin Therapeutic alternatives: â€¢ canagliflozin â€¢ dapagliflozin Tablet: 10    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> mg; 25 mg.\\nGliclazide* Therapeutic alternatives: â€¢ 4th level ATC chemical subgroup (A10BB Sulfonylureas) Solid <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> oral dosage form: (controlled-release tablets) 30 mg; 60 mg; 80 mg.\\n*glibenclamide not suitable above 60       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> years.\\nMetformin Tablet: 500 mg (hydrochloride). ATC, Anatomical Therapeutic Chemical. Adapted from World      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Health Organization, 20239 55 Chapter 3 glycaemic control, induce diabetes remission, and lead to improvements  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> in various metabolic and cardiovascular risk factors (see Chapter 5). Globally, there is considerable variation <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> in local diets, influenced by tradition, local customs, religion, and the availability and affordability of     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> food. Consequently, the applicability of nutrition-related studies to a particular environment will vary,       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> although some overarching observations are relevant. Most intervention studies of different diets and dietary   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> components associated with benefits in diabetes control have been short-term. Beneficial effects diminish over  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> time and are not consistently maintained in studies with follow-up periods longer than 12 months. Carbohydrate  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> in foods comprises the major nutrient component in most diets worldwide. Many less economically secure          <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> communities rely on carbohydrate foods for their sustenance. Wealthier nations have selected types of           <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> carbohydrate foods that have contributed to obesity, diabetes, and ill health. A systematic review and          <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> meta-analysis of RCTs on varying carbohydrate quantity reported a dose-dependent effect. Each 10% decrease in   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> carbohydrate intake reduced HbA1c by 0.2% (3 mmol/mol) after six months, compared to a carbohydrate intake      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> between 55%â€“65%.19 A recent RCT compared a healthy low-carbohydrate diet with a usual diet in adults with HbA1c <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> between 6.0%â€“6.9% (42â€“52 mmol/mol) who were not taking BGL medications. After six months, the low-carbohydrate  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> diet group had a significantly lower HbA1c (0.23% [3 mmol/mol]) compared to the usual diet group.20 Diets that  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> improve carbohydrate quality by using low glycaemic index foods may help improve glycaemic control, with a      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> systematic review reporting a statistically significant reduction of HbA1c of 0.19% (2 mmol/mol) compared with  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> a range of other diets.21 The more restrictive vegan diet (low-fat, excluding all animal-based products)        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> demonstrated an HbA1c reduction of 0.41% (4 mol/mol) compared with a conventional diet.22 The diets to be       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> advised for the management of T2DM must be culturally and economically appropriate. Dietitians with local       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> experience must be part of the team. Foods such as legumes, fresh fruit and non-starchy vegetables, nuts and    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> seeds in acceptable form should be encouraged, and advice against consumption of soft drinks and sugars should  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> be given, together with reducing amounts of starchy foods, especially those that are highly processed. Such     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> diets will not only benefit people with T2DM but human health globally and reduce the environmental impact of   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> human food production. Understanding how nutrition therapy and pharmacotherapy interact in real-world diabetes  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> management remains a challenge. The lack of clear evidence of complementarity between diet quality and the      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> intensity of BGL medications highlights the challenge and need for better integration between diet and          <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> pharmacologic approaches.23 First-line monotherapy Metformin When pharmacologic intervention is necessary,      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> metformin is traditionally recommended as first-line monotherapy based on its blood glucose-lowering efficacy,  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> low hypoglycaemia risk, weight neutrality with the potential for modest weight loss, good safety profile,       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> general availability, and low cost.8,13 In addition, there is a long experience with its use, and long-term CVD <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> benefits were observed in the UKDPS.24 Metforminâ€™s safety profile extends to individuals with reduced estimated <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> glomerular filtration rates (eGFR), supporting its use in those with an eGFR â‰¥30 mL/min/1.73 mÂ². Other          <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> therapies Other therapies are also effective as first-line treatments, with some well-recognised class effect   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> differences. Reductions in HbA1c were similar across monotherapies except that dipeptidyl peptidase 4 (DPP4)    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> inhibitors had smaller effects. Body weight was reduced or maintained with metformin, DPP4 inhibitors, GLP-1    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> receptor agonists, and SGLT2 inhibitors and increased with sulfonylureas and thiazolidinediones. Hypoglycaemia  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> was more frequent with sulfonylureas. Gastrointestinal adverse events were highest with metformin and GLP-1     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> receptor agonists. Genital mycotic infections were increased with SGLT2 inhibitors.25 Within each class, there  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> are also differences between individual agents. Of particular relevance to Basic Care Recommendations where the <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> range and choice of therapeutic options are limited due to access, availability, and affordability, there are   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> well-documented differences in sulfonylureas with regard to hypoglycaemia risk and impact on weight.26 IDF      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Global Clinical Practice Recommendations for Managing Type 2 Diabetes â€“ 2025 56 BLOOD GLUCOSE-LOWERING          <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> THERAPIES â€“ NON-INSULIN SGLT2 inhibitors and GLP-1 receptor agonists T2DM significantly increases the risk of   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> cardio-renal complications. The findings of cardio-renal protection in recent RCTs with SGLT2 inhibitors and    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> GLP-1 receptor agonists have led to guidelines and consensus statements proposing the use of these agents as    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> first-line therapy in individuals with or at high risk of cardio-renal disease, either in combination with      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> metformin13 or as monotherapy.27 At present, the evidence supporting these agents as first-line monotherapy is  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> inconclusive.28 All CVOT RCTs demonstrating cardio-renal protection have added the study medication to existing <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> therapy of study participants, with the majority taking metformin. Post-hoc analyses have shown no evidence of  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> heterogeneity in the CV efficacy of the GLP-1 receptor agonist liraglutide based on background metformin29 or   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> with SGLT2 inhibitors for reductions in cardiovascular, kidney, and mortality outcomes regardless of whether    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> individuals were receiving or not receiving metformin. However, it should be noted that baseline metformin      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> users had an approximately 30% lower risk of the primary outcome than metformin non-users.30 A meta-analysis of <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> newer BGL medications in metformin-naÃ¯ve people with T2DM reported beneficial effect of GLP-1 receptor agonists <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> and SGLT2 inhibitors.31 A recent observational registry-based study using the AMD Annals Initiative assessed    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> the association between the early introduction of SGLT2 inhibitors and consequences of poor glycaemic control   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> in newly diagnosed individuals with T2DM without CVD.32 The early introduction of SGLT2 inhibitors in people    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> with T2DM, 90% of whom were also taking metformin, eliminated the association between poor glycaemic control in <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> the first two years after T2DM diagnosis and later CVD events, suggesting that SGLT2 inhibitors may attenuate   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> the consequences of poor glycaemic control after T2DM diagnosis. To date, there have not been any direct        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> comparisons of metformin versus newer agents on diabetes-related outcomes as first-line monotherapy. A          <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> registry-based randomised trial (SMARTEST) is underway to directly assess dapagliflozin versus metformin on a   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> primary composite endpoint of macro- or microvascular events in approximately 4,300 participants with early     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> T2DM.33 Combination therapy There are numerous combinations of non-insulin BGL therapies, and it is beyond the  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> scope of this document to review all potential combinations. This section highlights some aspects of            <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> combination therapy. Combination first-line therapy Metformin serves as the cornerstone for combination         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> therapy. While conventional approaches have favoured stepwise addition of therapy, some individuals may require <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> combination therapy (two BGL medications) to achieve glycaemic control early in the course of their diabetes.   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Dual initial oral therapy can be considered in those with HbA1c levels exceeding 9%â€“10% (75â€“86 mmol/mol)        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> without symptoms. In some cases, insulin may be required as part of initial pharmacotherapy, particularly in    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> those with clear symptoms and/ or signs of significant hyperglycaemia.7,34 In these situations, combination     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> therapy may be temporary. A decision to reduce hyperglycaemia quickly through combination therapy should also   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> consider potential detrimental effects such as the risk of retinopathy progression.35 The primary focus should  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> not be rapid reduction but rather reaching glycaemic goals and maintaining them over time. Initial combination  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> therapy may increase durability of glycaemic control compared with stepwise addition of BGL therapies. The      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> VERIFY trial demonstrated the superiority of initial combination therapy over sequential addition in slowing    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> the decline of glycaemic control. Participants with T2DM diagnosed within two years prior to enrolment with     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> HbA1c of 6.5%â€“7.5% (48â€“58 mmol/mol) received either combination treatment with metformin and vildagliptin or    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> initial metformin monotherapy with the subsequent addition of vildagliptin if required to improve diabetes      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> control. The endpoint, time from randomisation to initial treatment failure (HbA1c â‰¥7.0% [53 mmol/mol]),        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> occurred in 43.6% in the combination treatment group and 62.1% in the monotherapy group.36 The VERIFY study was <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> not designed or powered to assess the effect of combination treatment on cardiovascular outcomes. The effect of <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> initial triple therapy on long-term glycaemic control has also been studied. In the EDICT study, drug-naÃ¯ve     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> individuals with new-onset T2DM were randomly assigned to receive either 1) combination therapy with 57 Chapter <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 3 metformin, pioglitazone, and exenatide (triple therapy) or 2) sequential addition of metformin followed by    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> glipizide and insulin (conventional therapy) aiming to maintain HbA1c below 6.5% (48 mmol/mol). After three     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> years, HbA1c was significantly lower with initial triple therapy compared with conventional therapy (6.4% [47   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> mmol/mol] versus 6.9% [52 mmol/mol]).37 The TRIPLE-AXEL study randomised individuals with drug-naÃ¯ve T2DM to    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> triple combination therapy with metformin, dapagliflozin, and saxagliptin or conventional stepwise add-on       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> therapy (initiated with metformin, followed by glimepiride and sitagliptin). The primary outcome, the           <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> proportion who achieved an HbA1c &lt;6.5% (48 mmol/mol) without hypoglycaemia, weight gain of 5% or higher, or     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> discontinuation of drugs because of adverse events at 104 weeks, was achieved in 39.0% and 17.1%, respectively, <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> although HbA1c reduction from baseline was similar in both groups.38 However, in both triple therapy studies,   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> the treatment regimens differed between the two groups. There are no dedicated outcome studies comparing        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> treatment initiation with combinations of BGL therapies. Combination SGLT2 inhibitors and GLP-1 receptor        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> agonists Some guidance suggests combining SGLT2 inhibitor and GLP-1 receptor agonist therapies. However, this   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> combination has not been evaluated in an outcome RCT and the results of analyses of administrative datasets are <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> not convincing. Nested case-control studies of individuals with T2DM in England and Wales of primary care data  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> from the Clinical Practice Research Datalink and Secure Anonymised Information Linkage Databank reported on the <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> association of SGLT2 inhibitors, GLP-1 receptor agonists, or their combination regimens on major adverse        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> cardiac and cerebrovascular events (MACCE) and heart failure (HF) compared to other BGL regimens. Use of SGLT2  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> inhibitor was associated with an 18% lower odds of MACCE, and the odds of HF were 51% lower with SGLT2          <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> inhibitors and 18% lower with GLP-1 receptor agonists, but the combination was not superior to either agent     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> used alone.39 The addition of either SGLT2 inhibitors or sulfonylureas to baseline GLP-1 receptor agonists on   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> CVD outcomes was explored in an analysis of three US claims datasets in 12,584 people with T2DM and showed      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> significant reductions in the risk of MACCE and HF hospitalisations in the SGLT2 inhibitor/GLP-1 receptor       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> agonist combination compared to the sulfonylureas/GLP-1 receptor agonist combination.40 However, the magnitude  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> of the CVD risk reduction was comparable to the benefit seen in CVOTs of SGLT2 inhibitors versus placebo, where <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> baseline GLP-1 receptor agonist use was minimal. Treatment intensification, deintensification, or modification  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Early intervention is required in people with T2DM not reaching or maintaining their individualised glycaemia   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> targets. Clinical inertia is one of the most difficult barriers to overcome in clinical practice and has a      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> dramatic impact on the prognosis of complications and quality of life.41,42 Timely treatment intensification    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> with additional BGL therapy when required is crucial to avoid clinical inertia. Failure to reach or maintain    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> glycaemic targets should be a trigger to consider a change in therapy. The presence or emergence of             <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> comorbidities also influence this decision. Any change or intensification of therapy should be reassessed       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> within three months. Meta-analyses suggest that any drug added to an initial therapy, particularly with         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> metformin, can improve glycaemic control.43,44 Conversely, deintensification of therapy should be considered in <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> people at or near glycaemic target who are prone to hypoglycaemia, especially the elderly.45 The use of         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> sulfonylureas (and glinides) should be minimised where alternatives are available and affordable, or dose       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> should be reduced.46 Achieving glycaemic targets does not mandate treatment deintensification, especially with  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> newer agents such as GLP-1 receptor agonists and SGLT2 inhibitors, which not only manage hyperglycaemia but     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> also provide additional cardio-renal benefits in high-risk individuals without increasing hypoglycaemia, as     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> well as supporting weight control. Managing coexisting cardio-renal complications, metabolic                    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> dysfunction-associated steatotic liver disease (MASLD), and weight control are addressed in specific chapters.  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> In brief, therapies with demonstrated benefits in managing these comorbidities should be preferred considering  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> that they are also efficacious in controlling hyperglycaemia, if they are available, affordable, and            <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> accessible. IDF Global Clinical Practice Recommendations for Managing Type 2 Diabetes â€“ 2025 58 BLOOD           <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> GLUCOSE-LOWERING THERAPIES â€“ NON-INSULIN REFERENCES 1. Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359(15):1577-1589. 2. Adler AI, Coleman RL, <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Leal J, et al. Post-trial monitoring of a randomised controlled trial of intensive glycaemic control in type 2  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> diabetes extended from 10 years to 24 years (UKPDS 91). Lancet. 2024;404(10448):145-155. 3. Bin Rakhis SA, Sr., <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> AlDuwayhis NM, Aleid N, et al. Glycemic control for type 2 diabetes mellitus patients: A systematic review.     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Cureus. 2022;14(6):e26180. 4. Gaede P, Vedel P, Parving HH, et al. Intensified multifactorial intervention in   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> patients with type 2 diabetes mellitus and microalbuminuria: The Steno type 2 randomised study. Lancet.         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 1999;353(9153):617-622. 5. Gaede P, Vedel P, Larsen N, et al. Multifactorial intervention and cardiovascular    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> disease in patients with type 2 diabetes. N Engl J Med. 2003;348(5):383-393. 6. Khunti K, Zaccardi F, Amod A,   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> et al. Glycaemic control is still central in the hierarchy of priorities in type 2 diabetes management.         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Diabetologia. 2024 [Epub ahead of print]. DOI: 10.1007/s00125-024-06254-w. 7. American Diabetes Association     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Professional Practice Committee. 9. Pharmacologic approaches to glycemic treatment: Standards of care in        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> diabetes-2024. Diabetes Care. 2024;47(Suppl 1):S158-S178. 8. National Institute for Health and Care Excellence  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> (NICE). NICE guideline [NG28] Type 2 diabetes in adults: Management. Available from:                            <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> https://www.nice.org.uk/guidance/ng28 [Accessed August 2024]. 9. World Health Organization. Web Annex A. World  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Health Organization Model List of Essential Medicines - 23rd List. In: The selection and use of essential       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> medicines 2023: Executive summary of the report of the 24th WHO Expert Committee on the Selection and Use of    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Essential Medicines, 24 - 28 April 2023. Geneva: World Health Organization; 2023 (WHO/MHP/HPS/EML/2023.02).     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Licence: CC BY-NC-SA3.0 IGO. 10. Piggott T, Nowak A, Brignardello-Petersen R, et al. Global status of essential <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> medicine selection: a systematic comparison of national essential medicine lists with recommendations by WHO.   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> BMJ Open. 2022;12(2):e053349. 11. Budhram D, Benipal S, Bilimoria K, et al. Essential diabetes medicines and    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> health outcomes in 127 countries. Diabetes Obes Metab. 2021;23(5):1121-1128. 12. Ceriello A, Prattichizzo F,    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Phillip M, et al. Glycaemic management in diabetes: Old and new approaches. Lancet Diabetes Endocrinol.         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 2022;10(1):75-84. 13. Davies MJ, Aroda VR, Collins BS, et al. Management of hyperglycemia in type 2 diabetes,   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> of Diabetes (EASD). Diabetes Care. 2022;45(11):2753-2786. 14. American Diabetes Association Professional        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Practice Committee. 5. Facilitating positive health behaviors and well-being to improve health outcomes:        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Standards of care in diabetes-2024. Diabetes Care. 2024;47(Suppl 1):S77-S110. Erratum in: Diabetes Care.        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 2024;47(4):761-762. 15. Cochran J, Conn VS. Meta-analysis of quality of life outcomes following diabetes        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> self-management training. Diabetes Educ. 2008;34(5):815-823. 16. He X, Li J, Wang B, et al. Diabetes            <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> self-management education reduces risk of all-cause mortality in type 2 diabetes patients: A systematic review  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> and meta-analysis. Endocrine. 2017;55(3):712-731. 17. Robbins JM, Thatcher GE, Webb DA, et al. Nutritionist     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> visits, diabetes classes, and hospitalization rates and charges: the Urban Diabetes Study. Diabetes Care.       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 2008;31(4):655-660. 18. Strawbridge LM, Lloyd JT, Meadow A, et al. One-year outcomes of diabetes                <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> self-management training among medicare beneficiaries newly diagnosed with diabetes. Med Care.                  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 2017;55(4):391-397. 19. Jayedi A, Zeraattalab-Motlagh S, Jabbarzadeh B, et al. Dose-dependent effect of         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> carbohydrate restriction for type 2 diabetes management: A systematic review and dose-response meta-analysis of <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> randomized controlled trials. Am J Clin Nutr. 2022;116(1):40-56. 20. Dorans KS, Bazzano LA, Qi L, et al.        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Effects of a low-carbohydrate dietary intervention on hemoglobin A1c: A randomized clinical trial. JAMA Netw    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Open. 2022;5(10):e2238645. 21. Zafar MI, Mills KE, Zheng J, et al. Low-glycemic index diets as an intervention  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> for diabetes: a systematic review and meta-analysis. Am J Clin Nutr. 2019;110(4):891-902. 59 Chapter 3 22.      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Barnard ND, Cohen J, Jenkins DJ, et al. A low-fat vegan diet and a conventional diabetes diet in the treatment  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> of type 2 diabetes: A randomized, controlled, 74-wk clinical trial. Am J Clin Nutr. 2009;89(5):1588S-1596S. 23. <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Desjardins C, Leblay L, BÃ©langer A, et al. Relationship between diet quality and glucose-lowering medication    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> intensity among adults with type 2 diabetes: Results from the CARTaGENE cohort. CJC Open. 2024;6(1):20-29. 24.  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352(9131):854-865. 25.       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Maruthur NM, Tseng E, Hutfless S, et al. Diabetes medications as monotherapy or metformin-based combination     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> therapy for type 2 diabetes: A systematic review and meta-analysis. Ann Intern Med. 2016;164(11):740-751. 26.   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Kalra S, Bahendeka S, Sahay R, et al. Consensus recommendations on sulfonylurea and sulfonylurea combinations   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> in the management of type 2 diabetes mellitus - International Task Force. Indian J Endocrinol Metab.            <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 2018;22(1):132-157. 27. Marx N, Federici M, SchÃ¼tt K, et al. 2023 ESC Guidelines for the management of          <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> cardiovascular disease in patients with diabetes. Eur Heart J. 2023;44(39):4043-4140. 28. Prattichizzo F,       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Ceriello A. Is time ready for combination therapy at diagnosis of type 2â€¯diabetes? Diabetes Metab Res Rev.      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 2021;37(5):e3460. 29. Crowley MJ, McGuire DK, Alexopoulos AS, et al. Effects of liraglutide on cardiovascular   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> outcomes in type 2 diabetes patients with and without baseline metformin use: Post hoc analyses of the LEADER   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> trial. Diabetes Care. 2020;43(9):e108-e110. 30. Neuen BL, Arnott C, Perkovic V, et al. Sodium-glucose           <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> co-transporter-2 inhibitors with and without metformin: A meta-analysis of cardiovascular, kidney and mortality <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> outcomes. Diabetes Obes Metab. 2021;23(2):382-390. 31. Masson W, Lavalle-Cobo A, Lobo M, et al. Novel           <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> antidiabetic drugs and risk of cardiovascular events in patients without baseline metformin use: A              <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> meta-analysis. Eur J Prev Cardiol. 2021;28(1):69-75. 32. Ceriello A, Lucisano G, Prattichizzo F, et al. The     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> legacy effect of hyperglycemia and early use of SGLT-2 inhibitors: A cohort study with newly-diagnosed people   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> with type 2 diabetes. Lancet Reg Health Eur. 2023;31:100666. 33. SundstrÃ¶m J, KristÃ³fi R, Ã–stlund O, et al. A   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> registry-based randomised trial comparing an SGLT2 inhibitor and metformin as standard treatment of early stage <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> type 2 diabetes (SMARTEST): Rationale, design and protocol. J Diabetes Complications. 2021;35(10):107996. 34.   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Samson SL, Vellanki P, Blonde L, et al. American Association of Clinical Endocrinology Consensus Statement:     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Comprehensive Type 2 Diabetes Management Algorithm - 2023 Update. Endocr Pract. 2023;29(5):305-340. 35. Bain    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> SC, Klufas MA, Ho A, et al. Worsening of diabetic retinopathy with rapid improvement in systemic glucose        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> control: A review. Diabetes Obes Metab. 2019;21(3):454-466. 36. Matthews DR, PaldÃ¡nius PM, Proot P, et al.      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential          <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): A 5-year, multicentre, randomised,           <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> double-blind trial. Lancet. 2019;394(10208):1519-1529. 37. Abdul-Ghani M, Puckett C, Adams J, et al. Durability <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> of triple combination therapy versus stepwise addition therapy in patients with new-onset T2DM: 3-year          <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> follow-up of EDICT. Diabetes Care. 2021;44(2):433-439. 38. Kim NH, Moon JS, Lee YH, et al. Efficacy and         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> tolerability of initial triple combination therapy with metformin, dapagliflozin and saxagliptin compared with  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> stepwise add-on therapy in drug-naÃ¯ve patients with type 2 diabetes (TRIPLE-AXEL study): A multicentre,         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> randomized, 104-week, open-label, active-controlled trial. Diabetes Obes Metab. 2024;26(9):3642-3652. 39.       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Wright AK, Carr MJ, Kontopantelis E, et al. Primary prevention of cardiovascular and heart failure events with  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> SGLT2 inhibitors, GLP-1 receptor agonists, and their combination in type 2 diabetes. Diabetes Care.             <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 2022;45(4):909-918. 40. Dave CV, Kim SC, Goldfine AB, et al. Risk of cardiovascular outcomes in patients with   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> type 2 diabetes after addition of SGLT2 inhibitors versus sulfonylureas to baseline GLP-1RA therapy.            <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Circulation. 2021;143(8):770-779. 41. Chew BH, Mohd-Yusof BN, Lai PSM, Khunti K. Overcoming therapeutic inertia <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> as the Achillesâ€™ heel for improving suboptimal diabetes care: An integrative review. Endocrinol Metab (Seoul).  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 2023;38(1):34-42. IDF Global Clinical Practice Recommendations for Managing Type 2 Diabetes â€“ 2025 60 BLOOD     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> GLUCOSE-LOWERING THERAPIES â€“ NON-INSULIN 42. Reach G, Pechtner V, Gentilella R, et al. Clinical inertia and its <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> impact on treatment intensification in people with type 2 diabetes mellitus. Diabetes Metab.                    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 2017;43(6):501-511. 43. Bennett WL, Maruthur NM, Singh S, et al. Comparative effectiveness and safety of        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> medications for type 2 diabetes: an update including new drugs and 2-drug combinations. Ann Intern Med.         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 2011;154(9):602-613. 44. Maloney A, Rosenstock J, Fonseca V. A model-based meta-analysis of 24                  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> antihyperglycemic drugs for type 2 diabetes: Comparison of treatment effects at therapeutic doses. Clin         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Pharmacol Ther. 2019;105(5):1213-1223. 45. Oâ€™Neil H, Todd A, Pearce M, et al. What are the consequences of over <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> and undertreatment of type 2 diabetes mellitus in a frail population? A systematic review. Endocrinol Diabetes  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Metab. 2024;7(2):e00470. 46. Lipska KJ, Ross JS, Miao Y, et al. Potential overtreatment of diabetes mellitus in <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> older adults with tight glycemic control. JAMA Intern Med. 2015;175(3):356-362. 61 Chapter 3 62 Blood           <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Glucose-Lowering Therapies â€“ Insulin Options for Type 2 Diabetes Chapter 4 BLOOD GLUCOSE-LOWERING THERAPIES â€“   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> INSULIN 63 Chapter 4 RECOMMENDATIONS Optimal Care Basic Care Insulin initiation â€¢\\tBegin insulin therapy when   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> optimised glucose-lowering medications and lifestyle interventions do not maintain target blood glucose control <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> â€¢\\tBegin insulin therapy when optimised available glucose-lowering medications and lifestyle interventions do   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> not maintain target blood glucose control Support â€¢\\tProvide education, continuing lifestyle management, and    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> regular review, including telehealth â€¢\\tProvide education, continuing lifestyle management, and regular review  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Monitoring â€¢\\tSelf-monitoring of blood glucose â€¢\\tConsider CGM with complex insulin regimens and insulin pump   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> therapy â€¢\\tRegular HbA1c measurement â€¢\\tSelf-monitoring of blood glucose â€¢\\tRegular HbA1c measurement Insulin   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> regimen â€¢\\tSelect from a broad range of affordable insulins and insulin delivery devices â€¢\\tAccess to insulin   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> pump therapy available â€¢\\tSelect from a limited range of affordable and continuously available insulin Insulin  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> initiation â€¢\\tCommence with single daily injection of basal analogue insulin â€¢\\tContinue metformin (if          <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> tolerated and not contraindicated) â€¢\\tContinue with other blood glucose- lowering therapies if appropriate      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> â€¢\\tCommence with single daily injection of affordable human, analogue, or biosimilar insulin â€¢\\tContinue        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> metformin (if tolerated and not contraindicated) â€¢\\tContinue with other affordable and available blood          <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> glucose-lowering therapies if appropriate Insulin intensification â€¢\\tOptions include: - Basal bolus - Premixed  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> insulin - Add GLP-1RA (either separately or switch to FDC) - Insulin pump â€¢\\tOptions include: - Basal bolus -   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Premixed human insulin - Other affordable and available blood glucose-lowering therapies Insulin                <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> deintensification â€¢\\tRegularly review insulin dose, need for insulin, and complex insulin regimens, especially  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> in the elderly and individuals at target glycaemia or experiencing hypoglycaemia â€¢\\tDeintensify and simplify    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> treatment as required CGM, continuous glucose monitor; FDC, fixed-dose combination; GLP-1RA, glucagon-like      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> peptide-1 receptor agonist; HbA1c, glycated haemoglobin.\\nIDF Global Clinical Practice Recommendations for      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Managing Type 2 Diabetes â€“ 2025 64 BLOOD GLUCOSE-LOWERING THERAPIES - INSULIN o Insulin therapy is a key option <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> for type 2 diabetes mellitus (T2DM) when nonâ€insulin treatments fail to achieve glycaemic targets. o Long term  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> outcome studies confirm insulinâ€™s efficacy in improving glycaemic control and its legacy effect on reducing     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> micro- and macrovascular complications in T2DM. o The decision to use insulin should consider the individualâ€™s  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> views on safety, cultural values, social and religious influences, health literacy and language barriers. o A   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> diverse range of insulin types (human, analogue, and biosimilar) is available. o The clinical effects of these  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> insulin types in T2DM are similar except for small differences in hypoglycaemia between intermediate human and  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> long-acting analogue insulins. o Global access to insulin remains a significant challenge and only about half   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> of those with T2DM who could benefit have access to appropriate insulin therapy due to regulatory, supply       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> chain, cost, and device access barriers. o Biosimilar insulins offer the potential for cost reduction and       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> improved accessibility. o The different insulin pharmacokinetic profiles, ultra rapid-acting, rapid-acting,     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> short-acting, intermediate-acting, and long-acting, facilitate personalised and tailored treatment. o Premixed  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> insulins offer a range of fixed-dose combinations of rapid- or short-acting with intermediate- or long-acting   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> insulins aiming to control fasting and postprandial glucose. o Combining insulin with other agents such as      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> glucagon-like peptide-1 (GLP-1) receptor agonists (including fixed dose combinations) or sodium-glucose         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> cotransporter-2 (SGLT2) inhibitors has the potential to enhance glycaemic control, promote weight loss, reduce  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> insulin dosage, and lower hypoglycaemia risk. o Insulin initiation typically begins by adding once daily basal  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> insulin and continuing some oral blood glucose lowering medication(s), with treatment intensification options   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> including adding prandial insulin, switching to premixed regimens, adding a GLP-1 receptor agonist or an SGLT2  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> inhibitor, tailored to the individual glycaemic responses and preferences, and resource considerations. o       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Regular reassessment of insulin therapy is essential and insulin deintensification or simplification should be  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> regularly considered, especially in older or frail individuals, to minimise hypoglycaemia risk, reduce          <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> treatment burden, and improve quality of life. KEY POINTS 65 Chapter 4 BACKGROUND Insulin therapy is an         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> often-used therapeutic option in people with type 2 diabetes mellitus (T2DM) when glycaemic control is not      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> achieved with non-insulin blood glucose-lowering therapies. The decision to use insulin therapy should not only <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> consider glycaemic control but also take into account the individualâ€™s views on insulin safety, cultural values <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> and beliefs, social influences, religious considerations, health literacy, and language barriers. The diverse   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> landscape of insulin types allows for customisation to address specific requirements of the individual.         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Advances in the manufacture and design of commercial insulin have guaranteed supplies and led to insulins with  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> different pharmacokinetics as well as the potential for more flexible and personalised treatment regimens. The  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> emergence of biosimilar insulins provides an opportunity to decrease cost and increase global insulin access.   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> The development of fixed-dose combinations (FDCs) of basal insulin and glucagon-like peptide-1 (GLP-1) receptor <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> agonists adds to the range of insulin-related treatments. GLOBAL CONSIDERATIONS Global access to insulin        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> remains a challenge. The World Health Organization (WHO) estimated that 15% of people with T2DM require         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> insulin, but only half are appropriately treated because of barriers to insulin availability such as regulatory <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> challenges and issues with supply chains and cost.1 A range of insulins are listed in the WHO Model List of     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Essential Medicines (Table 4.1). Insulin (soluble and intermediate) has been listed since the first WHO         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Essential Medicine List in 1977. In 2021, long-acting insulin analogues (insulin glargine, detemir, degludec,   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> and their quality-assured biosimilars, as therapeutic alternatives) were added, with the WHO Expert Committee   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> on the Selection and Use of Essential Medicines noting that access to affordable human insulin remained a       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> critical global priority.1 In addition, appropriate use of insulin is hampered by a lack of access to           <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> affordable medical devices for safe administration and optimal glucose monitoring to guide insulin use.1 The    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> challenges of global access to insulin are experienced in most regions of the world.3 EVIDENCE SUMMARY Insulins <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> can be described by the method of manufacture and their pharmacokinetic characteristics. Methods of modern-day  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> insulin manufacture Human insulin In the past, insulin was obtained from pig and beef pancreas. These were      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> replaced in the 1980s Medicines for Diabetes Insulins Insulin injection (soluble)* *including quality-assured   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> biosimilars Injection: 40 IU/mL in 10 mL vial; 100 IU/mL in 10 mL vial; 100 IU/mL in 3 mL cartridge or          <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> pre-filled pen. Intermediate-acting insulin* *including quality-assured biosimilars Injection: 40 IU/mL in 10   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> mL vial; 100 IU/mL in 10 mL vial; 100 IU/mL in 3 mL cartridge or pre-filled pen (as compound insulin zinc       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> suspension or isophane insulin).\\nLong-acting insulin analogues* Therapeutic alternatives: â€¢ insulin degludec â€¢ <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> insulin detemir â€¢ insulin glargine *including quality-assured biosimilars Injection: 100 IU/mL in 3 mL          <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> cartridge or pre-filled pen.\\nTable 4.1 World Health Organization Model List of Essential Medicines â€“ 23rd List <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> (2023) Adapted from World Health Organization, 2023.2 IDF Global Clinical Practice Recommendations for Managing <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Type 2 Diabetes â€“ 2025 66 BLOOD GLUCOSE-LOWERING THERAPIES - INSULIN by genetically engineered human insulin    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> made by recombinant DNA technology using fermentation in micro-organisms (bacteria or yeast). Consequently,     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> human insulin can be produced in large quantities with a high level of purity and consistent quality at         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> relatively low cost.4 Analogue insulin The first insulin analogue (insulin Lispro rDNA) was approved for human  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> therapy in 1996. Analogue insulins are genetic modifications of human insulin, produced using recombinant DNA   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> technology, and designed to alter the absorption of subcutaneously injected insulin. Following subcutaneous     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> injection, insulin molecules form a depot from which absorption into the systemic circulation occurs. All       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> insulin molecules have a tendency to self-aggregate into hexameric complexes, and these clusters must           <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> dissociate into dimers and monomers to enter the bloodstream. The pharmacologic features of individual insulin  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> analogue preparations largely alter the rate of hexamer dissociation and insulin movement into the circulation. <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Fast-acting analogues either have less tendency to aggregate after injection or dissociate quickly and enter    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> the bloodstream faster; long-acting analogues aggregate more, remain aggregated for longer, and enter the       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> bloodstream slowly. Biosimilar insulin Biosimilar insulin is also developed through recombinant DNA technology  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> and is highly similar to an already approved reference insulin.5 Criteria for approval of a biosimilar require  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> a quality assessment; demonstration of similarity in physicochemical and biological characterisation, including <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> receptor binding, metabolic potency, and mitogenicity; pharmacokinetic/pharmacodynamic profiles in phase 1      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> studies; and assessment of safety endpoints in phase 3 clinical trials, with an emphasis on immunogenicity.6    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> The first biosimilar insulin, Abasaglar, was approved in the European Union in 2014 and in the US, the first    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> biosimilar insulin (Basaglar) was approved in 2016.6 Semglee (insulin glargine-yfgn) received FDA approval in   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> July 2021 as the first interchangeable insulin glargine biosimilar.7 Studies consistently demonstrate the       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> efficacy and safety of biosimilar insulin analogues in glycaemic control, with no notable differences in        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> insulin antibody formation compared to reference.8 Biosimilar insulins present an option for lower-priced and   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> efficacious insulin alternatives.9 Categorisation of insulin by pharmacokinetic characteristics Insulin can be  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> categorised into five groups: ultra rapid-acting analogue (URAA) insulins, rapid-acting analogue insulins       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> (RAAI), short-acting human insulins, intermediate-acting human insulins, and long-acting analogue insulins.     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Notable examples are shown in Table 4.2. The pharmacokinetic profiles of insulin analogues are significantly    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> altered by changing the amino acid sequence compared with native human insulin. Increasing the onset of action  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> is designed to better control postprandial glucose excursions, whereas the long-acting insulins are designed to <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> control fasting plasma glucose levels. The main anticipated beneficial consequences include improved glycaemic  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> control and reduced hypoglycaemia compared with human insulin. However, this has not been clearly established   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> in T2DM. A Cochrane systematic review concluded that overall, there were no clear benefits of rapid-acting      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> analogue insulin over regular short-acting human insulin in people with T2DM in change in glycated haemoglobin  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> (HbA1c) or number of non-severe hypoglycaemic episodes.10 There is limited evidence on ultra rapid-acting       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> analogue (URAA) insulins in T2DM. A recent Ultra rapid-acting analogue insulins (URAA) Rapid-acting analogue    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> insulins (RAAI) Short-acting human insulins Intermediate-acting human insulins Long-acting analogue insulins    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Faster aspart (URAsp) Insulin lispro-aabc (URLi) Insulin lispro Insulin aspart Insulin glulisine Regular human  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> insulin NPH human insulin Insulin glargine Insulin detemir Insulin degludec Insulin glargine-yfgn (Semglee)     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> NPH, neutral protamine Hagedorn.\\nTable 4.2 Types of insulins 67 Chapter 4 meta-analysis showed no difference   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> in HbA1c compared with RAAI but a small reduction in 1-hour (but not 2-hour) postprandial glucose in people     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> with T2DM, and consequently concluded that they are not routinely recommended.11 Another Cochrane systematic    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> review in people with T2DM compared long-acting analogue insulins (insulin glargine and insulin detemir) with   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> intermediate-acting human insulin (NPH insulin) and showed that while the effect on HbA1c was comparable,       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> treatment with insulin glargine and insulin detemir was associated with fewer participants experiencing         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> hypoglycaemia compared with NPH insulin. Treatment with insulin detemir also reduced the incidence of serious   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> hypoglycaemia; however, serious hypoglycaemic events were rare.12 Premixed insulins Premixed insulins (Table    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 4.3) offer a diverse array of fixed component formulations designed to address both fasting and postprandial    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> glycaemia.13,14 These formulations combine rapid or short-acting insulin with intermediate- or long-acting      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> insulin and their pharmacokinetic profile is designed to strike a balance between 24-hour efficacy and          <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> convenience for the person with T2DM.14 The efficacy of premixed insulins in improving glycaemic control is     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> well-established. Premixed analogues were found to be similar to premixed human insulin in lowering fasting     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> glucose, HbA1c, and the incidence of hypoglycaemia, but more effective in lowering postprandial glucose.        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Compared to long-acting insulin analogues, premixed analogues were superior in lowering postprandial glucose    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> and HbA1c (mean difference â€“0.39% [-4 mmol/mol]) but inferior in lowering fasting glucose, and had higher       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> incidence of hypoglycaemia.16 Premixed and basal bolus regimens (defined as any basal injection with at least a <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> single bolus injection per day) have been compared in randomised controlled trials (RCTs) and real-world        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> settings. There were no significant differences between the insulin regimens but there was a discordance        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> between real-world and RCT data. Both insulin regimens were associated with HbA1c reductions (real-world data   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> â€“0.28% [-3 mmol/mol]; RCT data, â€“1.4% [-15 mmol/mol]) and weight gain (real-world data, +0.27 kg; RCT data,     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> +2.96 kg), demonstrating greater changes in RCTs compared with real-world conditions.17 Combining insulin and a <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> GLP-1 receptor agonist Treatment can be intensified in a person with insulin-treated T2DM by adding a GLP-1     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> receptor agonist. A systematic review comparing basal plus/basal bolus and adding a GLP-1 receptor agonist to   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> insulin combinations was associated with a similar HbA1c reduction (-0.06% [-0.7 mmol/mol]) but greater weight  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> loss (-3.72 kg), a lower incidence of hypoglycaemic events (relative risk [RR] -0.46), and a reduction in       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> insulin dosage of 30.3 units/day.18 Fixed-dose combinations (FDC) of insulin and a GLP-1 receptor agonist are   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> available. IDegLira is a combination of insulin degludec (IDeg) and liraglutide with one unit of IDeg combined  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> with 0.036 mg of liraglutide. IGlarLixi is a combination of insulin glargine and lixisenatide with one unit of  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> insulin glargine combined with 0.33-to-1 Î¼g of lixisenatide. These products are administered once daily and aim <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> to optimise efficacy and minimise drawbacks associated with individual components.19 Compared with a control    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> group (mostly the individual components or another Type of premixed insulin Low-mixed formulations Mid-mixed    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> formulations High-mixed formulations Premixed human regular insulin-NPH insulin 30% regular insulin/70% NPH     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> insulin 50% regular insulin/50% NPH insulin 75% regular insulin/25% NPH insulin Premixed insulin analogues 30%  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> insulin aspart/70% insulin aspart protamine 25% insulin lispro/75% insulin lispro protamine 50% insulin         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> aspart/50% insulin aspart protamine 50% insulin lispro/50% insulin lispro protamine 75% insulin lispro/25%      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> insulin lispro protamine Coformulation 70% insulin degludec/30% insulin aspart NPH, neutral protamine Hagedorn. <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Adapted from Kalra et al. 201815 Table 4.3 Formulations of premixed insulin IDF Global Clinical Practice        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Recommendations for Managing Type 2 Diabetes â€“ 2025 68 BLOOD GLUCOSE-LOWERING THERAPIES - INSULIN insulin       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> regimen), IDegLira significantly lowered HbA1c by 0.63% (7 mmol/mol) but there was no difference in body weight <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> change. The percentage of those achieving HbA1c &lt;6.5% or &lt;7.0% (&lt;48 mmol/mol or &lt;53 mmol/mol) without weight    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> gain and hypoglycaemia episodes was higher with IDegLira.20 Similar results were reported for iGlarLixi, which  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> achieved an HbA1c reduction of 0.56% (6 mmol/mol).21 A meta-analysis of RCTs compared free or FDC combinations  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> of a GLP-1 receptor agonist plus basal insulin versus insulin intensification on glycaemic control in people    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> with T2DM. Compared with insulin uptitration, insulin and GLP-1 receptor agonist combined therapy resulted in a <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> significantly greater decrease in HbA1c (-0.53% [-6 mmol/mol]), more individuals at HbA1c target, greater       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> reduction in body weight (-1.9 kg) but similar hypoglycaemic events. Results did not differ in either the free  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> or FDC subgroups.22 Use of FDC has been associated with increased treatment persistence and improved            <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> adherence.23 Combining insulin and sodium-glucose cotransporter-2 inhibitors Insulin can also be effectively    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> combined with sodium-glucose cotransporter-2 (SGLT2) inhibitors as reported in a systematic review and          <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> meta-analysis. Compared with the control group of insulin plus placebo or insulin alone, SGLT2 inhibitor        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> reduced HbA1c by 1.4% (15 mmol/mol), body weight by 2.3 kg, and decreased the dose of insulin without           <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> increasing the risk of hypoglycaemia.24 Insulin outcome studies Numerous studies have examined the impact of    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> insulin therapy on glycaemic control in people with T2DM. However, there are limited data on clinical outcomes  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> focused specifically on insulin treatment, rather than its use as a component of an intensified glycaemic       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> control strategy in RCTs. The UKPDS is the main long-term study which assessed insulin treatment and randomised <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> people with newly diagnosed T2DM to intensive glycaemic control (with sulfonylurea or insulin, or metformin if  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> overweight) or conventional glycaemic control (primarily diet). Over 10 years, mean HbA1c was 7.0% (53          <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> mmol/mol) in the intensive group compared with 7.9% (63 mmol/mol) in the conventional group, with no            <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> differences in agents in the intensive group. Compared with the conventional group, the risk in the intensive   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> group was 12% significantly lower for any diabetes-related endpoint, driven by a significant 25% risk reduction <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> in microvascular endpoints. There was no difference in endpoints between sulfonylureas and insulin.25 In the    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 10-year post-trial follow-up study, participants randomised to the intensive group with sulfonylurea or insulin <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> showed a continued 9% risk reduction for any diabetes-related endpoint and 24% reduction in microvascular       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> disease. Risk reductions of 15% for myocardial infarction and 13% in death from any cause emerged over time,    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> despite an early loss of glycaemic differences. Outcome results for insulin and sulfonylureas were not reported <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> separately.26 The UKPDS results have recently been reported for another 14 years of follow up. The beneficial   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> effects of early intensive glycaemic control with sulfonylurea or insulin therapy, compared with conventional   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> glycaemic control, persisted with risk reductions of 10% for death from any cause, 17% for myocardial           <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> infarction, and 26% for microvascular disease.27 The ORIGIN study randomised individuals to insulin glargine to <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> normalise fasting glucose (targeting a fasting blood glucose level of â‰¤5.3 mmol/L [â‰¤95 mg/dL]) or standard care <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> to assess the impact on cardiovascular events. After a median follow up of 6.2 years, incident cardiovascular   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> outcomes were similar in the insulin glargine and standard care groups.28 The GRADE study assessed the          <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> comparative effectiveness of insulin glargine U-100, glimepiride, liraglutide, and sitagliptin added to         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> metformin in achieving and maintaining an HbA1c &lt;7.0% (&lt;53 mmol/mol) in people with T2DM. During a mean 5.0     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> years of follow up, the incidences of microvascular complications and death were not materially different among <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> the four treatment groups. There was a possible non-significant difference among the groups in the incidence of <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> any cardiovascular disease, favouring the GLP-1 receptor agonist.29 Overall, insulin is an established and safe <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> long-term treatment for improving glycaemic control in people with T2DM and is associated with a legacy effect  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> of improved micro- and macrovascular outcomes in newly diagnosed people with T2DM. Initiating and optimising    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> insulin therapy in individuals with T2DM Although insulin therapy is a treatment option at any stage of T2DM,   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> it is usually initiated after other treatments have failed to achieve 69 Chapter 4 personalised glycaemic       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> targets. It may be introduced earlier if diabetes control is poor (e.g., HbA1c &gt;10% [&gt;86 mmol/mol], blood       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> glucose consistently &gt;16.7 mmol/L [&gt;300 mg/dL]) and the person has symptomatic hyperglycaemia. For most people  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> with T2DM, insulin is usually used as a third or fourth blood glucose-lowering therapy in combination with      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> metformin and/or other blood glucose-lowering therapies, taking into account level of diabetes control,         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> diabetes duration, obesity, age, comorbidities, personal preferences, and medication attributes such as         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> efficacy, hypoglycaemia risk, adverse events, availability, and cost. An overview of insulin initiation and     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> intensification options is shown in Figure 4.1. Choice will depend on availability and affordability of         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> options, especially in resource-limited settings. The most frequently used options are basal insulin (with or   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> without prandial insulin) or premixed insulin. Insulin initiation and treatment intensification Insulin         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> treatment is usually initiated with once daily basal insulin. An alternate approach is to commence with once or <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> twice daily premixed insulin. The commencing dose for basal insulin is 10 units/day or 0.1â€“0.2 units/kg/ day    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> and increasing 2â€“4 units or by 10%â€“15% units at agreed intervals (often once weekly) to achieve target fasting  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> plasma glucose, unless hypoglycaemia occurs. Care should be taken to avoid excessive increases in the dose of   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> basal insulin (â€œoverbasalisationâ€). There is a ceiling effect of basal insulin, where increasing doses result   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> in proportionally smaller reductions in fasting blood glucose.30 The plateau effect is observed at doses around <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 0.5 units/kg/ day, with variations noted in different patient populations. Exceeding this threshold offers      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> modest glycaemic benefits and may lead to weight gain and increased hypoglycaemia.31,32 There is usually a      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> linear response to increasing basal insulin doses up to 0.3 units/kg/day, but between 0.3 and 0.5 units/kg/day, <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> the response diminishes non-linearly. Therefore, treatment intensification should be considered when basal      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> insulin doses surpass 0.3 units/kg/day.32 Basal insulin treatment should be intensified in people who are       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> taking a basal insulin dose of 0.3â€“0.5 units/kg/day or who have not attained their personalised HbA1c target    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> and fasting blood glucose is below 7.0 mmol/L (126 mg/dL). Assessment of the difference between bedtime and     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> morning blood glucose values (BeAM value) may assist in identifying individuals on basal insulin who need       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> treatment intensification, with large positive BeAM values with fasting glucose at goal suggestive of poor      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> control of postprandial glucose.33 Figure 4.1 Insulin initiation and intensification â€ either separately or as a <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> fixed dose combination GLP-1RA, glucagon-like peptide-1 receptor agonist.\\nIDF Global Clinical Practice         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Recommendations for Managing Type 2 Diabetes â€“ 2025 70 BLOOD GLUCOSE-LOWERING THERAPIES - INSULIN Adding        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> prandial insulin allows for greater flexibility for individuals with variable daily routines but requires a     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> higher level of cognitive and dexterity abilities, necessitates more frequent blood glucose monitoring, and may <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> involve more frequent injections compared to premixed insulin regimens. An alternate approach to escalating     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> basal insulin doses and avoiding additional injections is to add a blood glucose-lowering oral agent with       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> reduced hypoglycaemia and weight gain potential such as a SGLT2 inhibitor. Treatment intensification by         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> switching from a basal to a premixed insulin is a simple, safe, and effective approach, especially in           <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> resource-limited settings. For individuals on basal bolus insulin who do not achieve glycaemic targets, further <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> intensification of insulin therapy involves increasing the number of bolus injections (multiple daily           <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> injections). This typically involves a basal insulin and a prandial insulin injection before each of the main   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> meals. Other glucose-lowering medications can be continued but sulfonylurea should be discontinued. Access to   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> blood glucose monitoring is essential to guide bolus prandial insulin adjustments. Finally, insulin pump        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> therapy may be considered. This is not common in T2DM and requires access to and affordability of blood glucose <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> monitoring, preferably continuous glucose monitoring. However, the lack and cost of the required technology     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> mean that these options are usually not available in resource-limited settings. Insulin and treatment           <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> deintensification As with all therapies, the dose and the continuing need for insulin should be periodically    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> reassessed. This is particularly important in older individuals with T2DM. Deintensifying insulin treatment may <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> include insulin discontinuation, dose reduction, or changing to an alternate medication when benefits outweigh  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> harm, particularly in older people.34 Real-world single-arm clinical trials in older individuals support the    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> findings of improved quality of life, reduced stress, and fewer complications arising from hypoglycaemia.35 A   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> particularly concerning trend of overtreatment relates to individuals with HbA1c below 6.5% (48 mmol/mol) not   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> being considered or offered therapy simplification. A population-based retrospective cohort study using claims  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> database data reported that over three-quarters of frail individuals or those with multiple comorbidities did   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> not undergo therapy simplification, posing potential risks associated with polypharmacy.36 Treatment            <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> simplification should be considered for all individuals with T2DM on complex insulin regimens. Triggers for     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> simplification include poor glycaemic control, adherence difficulties, hypoglycaemic episodes, substantial      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> weight gain, comorbidities, cognitive impairments, frailty, limited life expectancy, a history of falls, and    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> negative impacts on quality of life.37 Deintensification of complex insulin regimens can be done by simplifying <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> the regimen from a basal bolus regimen or with two premixed insulins to a basal regimen with or without         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> non-insulin medications. The decision should be personalised, involving shared decision-making and continuous   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> assessments. The BEYOND trial demonstrated the feasibility of switching individuals on basal bolus insulin with <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> inadequate glycaemic control to basal insulin plus either a SGLT2 inhibitor or GLP-1 receptor agonist, which    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> resulted in fewer injections, lower insulin dose, less hypoglycaemia, and improved glycaemic control.38 In      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> individuals with proven insulinopaenia (undetectable C-peptide or history of ketoacidosis or severe             <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> decompensation after insulin reduction or withdrawal), and in those with long-standing diabetes and treatment   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> with complex insulin regimens due to proven ineffectiveness of other regimens, deintensification by reducing    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> insulin dose should be performed gradually and cautiously with regular monitoring. There are three main options <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> for intensifying treatment, with the choice depending on the personâ€™s preference, blood glucose monitoring      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> requirement, and medication availability and cost: 1. Add prandial insulin: administer one rapid-acting insulin <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> injection before the meal with the highest carbohydrate content. 2. Switch to premixed insulin: replace basal   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> insulin with a premixed insulin, usually twice daily â€“ before breakfast and before evening meal.\\n3. Add a      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> GLP-1 receptor agonist. 71 Chapter 4 REFERENCES 1. World Health Organization (WHO). Keeping the 100-year-old    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> promise: Making insulin access universal. Available from:                                                       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> https://www.\\nwho.int/publications/i/item/9789240039100 [Accessed August 2024]. 2. World Health Organization.   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Web Annex A. World Health Organization Model List of Essential Medicines â€“ 23rd List, 2023. In: The selection   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> and use of essential medicines 2023: Executive summary of the report of the 24th WHO Expert Committee on the    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Selection and Use of Essential Medicines, 24 - 28 April 2023.\\nGeneva: World Health Organization; 2023          <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> (WHO/MHP/HPS/EML/2023.02) Licence: CC BY-NC-SA 3.0 IGO. 3. Fralick M, Jenkins AJ, Khunti K, et al. Global       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> accessibility of therapeutics for diabetes mellitus. Nat Rev Endocrinol. 2022;18(4):199-204. 4. Beran D, Gale   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> EAM, Yudkin JS. The insulin market reaches 100. Diabetologia. 2022;65(6):931-935. 5. Heller S, Raposo JF, TofÃ©  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> S, et al. Breaking barriers with basal insulin biosimilars in type 2 diabetes. Clin Diabetes.                   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 2023;41(2):154-162. 6. Davies M, Dahl D, Heise T, et al. Introduction of biosimilar insulins in Europe. Diabet  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Med. 2017;34(10):1340-1353. 7. U.S. Food and Drug Administration. FDA approves first interchangeable biosimilar <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> insulin product for treatment of diabetes. Available from: https://www.fda.gov/                                 <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> news-events/press-announcements/                                                                                <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> fda-approves-first-interchangeable-biosimilar-insulin-product-treatment-diabetes#:~:text=Semglee%20(insulin%20  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> glargine%2Dyfgn)%20is%20the%20first%20 interchangeable%20biosimilar,effective%20                                <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> options%20for%20treating%20diabetes.. [Accessed August 2024]. 8. Yang LJ, Wu TW, Tang CH, et al. Efficacy and   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> immunogenicity of insulin biosimilar compared to their reference products: a systematic review and              <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> meta-analysis. BMC Endocr Disord. 2022;22(1):35. 9. Heinemann L, Fritz I, Khatami H, et al. Administration of   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> biosimilar insulin analogs: Role of devices. Diabetes Technol Ther. 2017;19(2):79-84. 10. Fullerton B,          <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Siebenhofer A, Jeitler K, et al. Short-acting insulin analogues versus regular human insulin for adult,         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> non-pregnant persons with type 2 diabetes mellitus. Cochrane Database Syst Rev. 2018;12(12):CD013228. 11.       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Villar-Taibo R, GaldÃ³n Sanz-Pastor A, FernÃ¡ndez-Rubio E, et al. Are new ultra-rapid-acting insulins associated  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> with improved glycemic control and reduced hypoglycemia in comparison to conventional rapid-acting insulins for <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> individuals with type 1 and type 2 diabetes? A systematic review and meta-analysis. Diabetes Technol Ther.      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 2024;26(8):575-586. 12. Semlitsch T, Engler J, Siebenhofer A, et al. (Ultra-)long-acting insulin analogues      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus. Cochrane Database Syst    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Rev. 2020;11(11):CD005613. 13. Mohan V, Kalra S, Kesavadev J, et al. Consensus on initiation and                <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> intensification of premix insulin in type 2 diabetes management. J Assoc Physicians India. 2017;65(4):59-73.    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 14. Silver B, Ramaiya K, Andrew SB, et al. EADSG Guidelines: Insulin therapy in diabetes. Diabetes Ther.        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 2018;9(2):449-492. 15. Kalra S, Czupryniak L, Kilov G, et al. Expert opinion: Patient selection for premixed    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> insulin formulations in diabetes care. Diabetes Ther. 2018;9(6):2185-2199. 16. Qayyum R, Bolen S, Maruthur N,   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> et al. Systematic review: Comparative effectiveness and safety of premixed insulin analogues in type 2          <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> diabetes. Ann Intern Med. 2008;149(8):549-559. 17. Anyanwagu U, Mamza J, Gordon J, et al. Premixed vs           <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> basal-bolus insulin regimen in type 2 diabetes: Comparison of clinical outcomes from randomized controlled      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> trials and real-world data. Diabet Med. 2017;34(12):1728-1736. 18. Castellana M, Cignarelli A, Brescia F, et    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> al. GLP-1 receptor agonist added to insulin versus basal-plus or basal-bolus insulin therapy in type 2          <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> diabetes: A systematic review and meta-analysis. Diabetes Metab Res Rev. 2019;35(1):e3082. 19. Nomoto H.        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Fixed-ratio combinations of basal insulin and glucagon-like peptide-1 receptor agonists as a promising strategy <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> for treating diabetes. World J Diabetes. 2023;14(3):188-197. 20. Liu Y, Li X, Zheng Y, et al. IDegLira for type <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 2 diabetes: A systematic review and meta-analysis. Endocrine. 2024;83(3):648-658. IDF Global Clinical Practice  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Recommendations for Managing Type 2 Diabetes â€“ 2025 72 BLOOD GLUCOSE-LOWERING THERAPIES - INSULIN 21. Liu Y, Li <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> C, Li X, et al. iGlarLixi for type 2 diabetes: A systematic review and meta-analysis. Endocrine. 2024. [Epub    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> ahead of print]. DOI: 10.1007/s12020-024-03868-3. 22. Maiorino MI, Chiodini P, Bellastella G, et al. Free and   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> fixed-ratio combinations of basal insulin and GLP-1 receptor agonists versus basal insulin intensification in   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials. Diabetes Obes Metab.    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 2018;20(9):2309-2313. 23. Edelman S, Cassarino D, Kayne D, et al. Treatment persistence and adherence in people <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> with type 2 diabetes switching to iGlarLixi vs free-dose combinations of basal insulin and glucagon-like        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> peptide 1 receptor agonist. J Manag Care Spec Pharm. 2022;28(9):958-968. 24. Yang Y, Chen S, Pan H, et al.      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Safety and efficiency of SGLT2 inhibitor combining with insulin in subjects with diabetes: Systematic review    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> and meta-analysis of randomized controlled trials. Medicine (Baltimore). 2017;96(21):e6944. Erratum in:         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Medicine (Baltimore). 2017;96(26):e7458. 25. UK Prospective Diabetes Study (UKPDS) Group. Intensive             <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of           <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352(9131):837-853. 26. Holman RR, Paul  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med.          <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 2008;359(15):1577-1589. 27. Adler AI, Coleman RL, Leal J, et al. Post-trial monitoring of a randomised          <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> controlled trial of intensive glycaemic control in type 2 diabetes extended from 10 years to 24 years (UKPDS    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 91). Lancet. 2024;404(10448):145-155. 28. Gerstein HC, Bosch J, Dagenais GR, et al. Basal insulin and           <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> cardiovascular and other outcomes in dysglycemia. N Engl J Med. 2012;367(4):319-328. 29. Nathan DM, Lachin JM,  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Bebu I, et al. Glycemia reduction in type 2 diabetes - microvascular and cardiovascular outcomes. N Engl J Med. <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 2022;387(12):1075-1088. 30. Cowart K. Overbasalization: Addressing hesitancy in treatment intensification       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> beyond basal insulin. Clin Diabetes. 2020;38(3):304-310. 31. Meece J. Basal insulin intensification in patients <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> with type 2 diabetes: A review. Diabetes Ther. 2018;9(3):877-890. 32. Umpierrez GE, Skolnik N, Dex T, et al.    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> When basal insulin is not enough: A dose-response relationship between insulin glargine 100 units/mL and        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> glycaemic control. Diabetes Obes Metab. 2019;21(6):1305-1310. 33. Zisman A, Morales F, Stewart J, et al. BeAM   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> value: An indicator of the need to initiate and intensify prandial therapy in patients with type 2 diabetes     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> mellitus receiving basal insulin. BMJ Open Diabetes Res Care. 2016;4(1):e000171. 34. Seidu S, Kunutsor SK,      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Topsever P, et al. Deintensification in older patients with type 2 diabetes: A systematic review of approaches, <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> rates and outcomes. Diabetes Obes Metab. 2019;21(7):1668-1679. 35. Munshi MN, Slyne C, Segal AR, et al.         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Simplification of insulin regimen in older adults and risk of hypoglycemia. JAMA Intern Med.                    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 2016;176(7):1023-1025. 36. McAlister FA, Youngson E, Eurich DT. Treatment deintensification is uncommon in      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> adults with type 2 diabetes mellitus: A retrospective cohort study. Circ Cardiovasc Qual Outcomes.              <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 2017;10(4):e003514. 37. Jude EB, Malecki MT, Gomez Huelgas R, et al. Expert panel guidance and narrative review <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> of treatment simplification of complex insulin regimens to improve outcomes in typeâ€¯2 diabetes. Diabetes Ther.  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 2022;13(4):619-634. 38. Giugliano D, Longo M, Caruso P, et al. Feasibility of simplification from a basal-bolus <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> insulin regimen to a fixed-ratio formulation of basal insulin plus a GLP-1RA or to basal insulin plus an SGLT2  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> inhibitor: BEYOND, a randomized, pragmatic trial. Diabetes Care. 2021;44(6):1353-1360.\\n73 Chapter 4 74 Weight  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Control in Type 2 Diabetes Management Chapter 5 WEIGHT CONTROL 75 Chapter 5 Optimal Care Basic Care Weight      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> reduction â€¢\\tLifestyle change â€¢\\tVLCD â€¢\\tIncretin-based therapy â€¢\\tMetabolic bariatric surgery â€¢\\tLifestyle     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> change â€¢\\tLow-calorie diet â€¢\\tUse weight-sparing BGL therapy â€¢\\tSGLT2i if available Improving diabetes control  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> â€¢\\tLifestyle change â€¢\\tIncretin-based therapy â€¢\\tMetabolic bariatric surgery â€¢\\tLifestyle change â€¢\\tMetformin   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> â€¢\\tAdd weight-sparing BGL therapy when indicated â€¢\\tSGLT2i if available Diabetes prevention â€¢\\tLifestyle change <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> â€¢\\tConsider: - Metformin - SGLT2i/incretin-based therapy - Metabolic bariatric surgery â€¢\\tLifestyle change      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> â€¢\\tConsider metformin Diabetes remission â€¢\\tLifestyle change â€¢\\tVLCD â€¢\\tMetabolic bariatric surgery             <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> â€¢\\tLifestyle change â€¢\\tLow-calorie diet â€¢\\tVLCD BGL, blood glucose-lowering; SGLT2i, sodium-glucose             <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> cotransporter-2 inhibitor; VLCD, very low-calorie diet.\\nRECOMMENDATIONS IDF Global Clinical Practice           <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Recommendations for Managing Type 2 Diabetes â€“ 2025 76 WEIGHT CONTROL o Obesity is a major driver of type 2     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> diabetes mellitus (T2DM) accounting for an estimated 43% of cases globally and a major factor in the increase   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> in childhood T2DM. o People in many Asian countries develop T2DM at a lower body weight and a high proportion   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> have an ideal body weight at diagnosis. o A complex interplay of biological, genetic, socioeconomic,            <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> educational, environmental, and commercial factors underlies both obesity and T2DM. o The health and economic   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> burden of diabetes is immense accounting for around 12% of global health expenditure (nearly US $1.015 trillion <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> annually); lower- and middle-income countries (LMICs) face the double burden of malnutrition and rising obesity <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> rates. o There is compelling evidence that strategies to reduce weight can prevent and reverse T2DM and other   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> obesity-associated comorbidities. o While several factors influence the relationship of weight and T2DM         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> control, in general a 1 kg weight loss results in a 0.1% (1.1 mmol/mol) reduction in glycated haemoglobin       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> (HbA1c). o Ethnic-specific cut-offs for BMI and waist circumference should be used. o A stratified,             <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> personalised approach to weight management, ranging from lifestyle interventions (nutrition, physical activity, <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> behavioural counselling) to pharmacotherapy and metabolic bariatric surgery, is recommended based on the        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> severity of overweight/obesity, associated comorbidities and available resources. o Intensive lifestyle         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> interventions, very low-calorie diets and metabolic bariatric surgery can result in T2DM remission but          <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> maintaining long term remission is challenging. o Incretin-based therapies (such as semaglutide, tirzepatide,   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> and retatrutide) show robust efficacy for weight loss and improved glycaemic control but their high cost and    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> limited availability restrict their use in resource-limited settings. o The choice of blood glucose-lowering    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> therapies should consider their impact on body weight - agents like sodium-glucose cotransporter-2 (SGLT2)      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> inhibitors, glucagon-like peptide-1 (GLP-1) receptor agonist and metformin promote weight loss, whereas         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> sulfonylureas and glitazones tend to increase weight. o Metabolic bariatric surgery is associated with longer   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> term diabetes remission, improved glycaemic control and benefits on microvascular and macrovascular outcomes    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> but availability and access are often restricted, especially in resource-limited settings.\\nKEY POINTS 77       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Chapter 5 BACKGROUND There is a close relationship between diabetes and obesity. Obesity is estimated to be     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> responsible for around 218 million cases of type 2 diabetes mellitus (T2DM) and is associated with a seven-fold <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> increased risk of developing T2DM compared with a healthy weight. Globally, obesity is responsible for around   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 43% of T2DM cases. However, this relationship varies across countries. In the US and UK, obesity contributes to <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> an estimated 80%â€“90% of T2DM while in many Asian countries people develop T2DM at a lower body weight, with one <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> study showing that 63% of people with T2DM diabetes in India had an ideal body weight at diagnosis. The         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> increasing rates of childhood obesity are a major factor in the increase of childhood T2DM.1 A complex          <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> interplay of common factors contributes to obesity and T2DM, including biology, genetics, food, education,      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> social deprivation, social economic status, healthcare access, stigma, and commercial determinants of health.1  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> The health and economic burden of diabetes has profound repercussions, particularly in lower- and middle-income <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> countries (LMICs),2,3 where there is the paradoxical double burden of malnutrition and soaring obesity.3        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Diabetes consumes approximately 12% of global health expenditure, translating to US $1.015 trillion annually.4  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> This cost has surged by 338% in the last 17 years and is projected to reach US $1.043 trillion by 2050.4 There  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> is now compelling evidence that strategies to reduce weight can prevent and reverse T2DM and other              <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> obesity-associated conditions and comorbidities. Overweight and obesity are commonly defined by body mass index <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> (BMI). Since this measure alone may not provide information about the health of an individual, there has been a <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> recent call to identify increased adiposity as an indicator of clinical obesity to guide management decisions.  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> T2DM is an established obesity-related disorder and an indicator of clinical obesity and consequently           <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> management of overweight and obesity is an important aspect of diabetes care.5 Since Asians manifest T2DM at    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> lower body weights, lower cut-offs are proposed for defining overweight and obesity in these populations (Table <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 5.1). Unhealthy weight can also be characterised by measurement of waist circumference and should be            <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> interpreted using published ethnic-specific cut-points.7 The routine measurement of waist circumference can     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> also be used to guide management and determine the efficacy of weight reduction interventions.7 Weight          <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> management treatment options are usually guided by the severity of overweight/ obesity assessed by weight       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> anthropometry (BMI/waist circumference) and tailored to improve person-specific cardiovascular, renal, and      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> metabolic outcomes using a personalised Table 5.1 Classification of weight category by race/ethnic-appropriate  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> body mass index (BMI)6 BMI, body mass index. General population Asian populations Obesity BMI â‰¥30 BMI â‰¥27.5     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Obesity class I BMI 30â€“34.9 BMI 27.5â€“32.4 Obesity class II BMI 35â€“39.9 BMI 32.5â€“37.4 Obesity class III BMI â‰¥40  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> BMI â‰¥37.5 Overweight BMI 25â€“29.9 BMI 23â€“27.4 Normal BMI 18.5â€“25 BMI 18.5â€“22.9 IDF Global Clinical Practice      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Recommendations for Managing Type 2 Diabetes â€“ 2025 78 WEIGHT CONTROL treatment plan (Table 5.2). Success       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> requires a combination of caring and supportive health professionals, a motivated person, and a flexible        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> programme which uses the range of available options. Treatment should always include supervised lifestyle       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> interventions, which can be intensified with reduced or low energy diet, very low-calorie diet (VLCD),          <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> pharmacotherapy, or metabolic bariatric surgery (MBS). Unfortunately, the availability and affordability of     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> weight control treatment options is limited globally. GLOBAL CONSIDERATIONS Weight control is complex and       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> requires significant health resources. The relationship between weight and T2DM varies considerably across      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> countries and many weight control recommendations have limited relevance where a significant proportion of the  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> diabetes population is not overweight or obese. Large-scale weight control programmes are particularly          <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> challenging in countries faced with the double burden of malnutrition and increasing rates of                   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> overweight/obesity. The emerging incretin-based anti-obesity medications are costly and not generally           <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> affordable or reimbursed in most countries and especially in resource-limited settings. Access is also an issue <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> with metabolic bariatric surgery. With limited availability and affordability of BGL medications with           <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> established weight loss potential in many countries throughout the world, alternate weight mitigating           <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> strategies become increasingly important including nutrition education and use of BGL medications with minimal  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> negative impact on weight. EVIDENCE SUMMARY Weight loss results in improvement of a range of parameters         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> relevant to improving outcomes in people with T2DM linked to the degree of weight loss.8 Weight loss and        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> diabetes control A number of factors influence the relationship of weight and diabetes control (glycated        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> haemoglobin [HbA1c] change) in people with T2DM, including choice of blood glucose-lowering (BGL) therapy and   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> baseline HbA1c. However, as a general guide, a 1 kg weight loss is estimated to result in a 0.1% reduction in   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> HbA1c (approximately 1.1 mmol/mol), although a higher baseline HbA1c is associated with a greater reduction in  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> HbA1c for the same degree of weight loss.9 Impact of weight loss in type 2 diabetes Preventing type 2 diabetes  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> As reviewed in Chapter 1, lifestyle interventions and pharmacotherapy can prevent progression from intermediate <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> hyperglycaemia, in particular impaired glucose tolerance (IGT), to T2DM and can also reverse intermediate       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> hyperglycaemia to normoglycaemia. * Refer to Table 5.1. T2DM, type 2 diabetes mellitus. Intervention 25.0â€“26.9  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> (or 23.0â€“24.9*) 27.0â€“29.9 (or 25.0â€“27.4*) â‰¥30.0 (or â‰¥27.5*) Nutrition, physical activity, and behavioural       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> counselling Indicated in all individuals Indicated in all individuals as an adjunct to intensifying treatment   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Indicated in all individuals as an adjunct to intensifying treatment Pharmacotherapy Preferred treatment        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> intensification option if available Initial treatment intensification option if available Metabolic bariatric   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> surgery (MBS) Consider in individuals with comorbidities Table 5.2 A stratified approach to weight management   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> in people with T2DM 79 Chapter 5 In the US Diabetes Prevention Program (DPP), an average weight loss of 6.7%    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> was associated with a 58% reduced incidence of T2DM in people with IGT.10 A subsequent analysis showed that for <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> every kilogram of weight lost there was a 16% reduction in risk for progression to diabetes, but after 10 kg    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> weight loss, there was negligible benefit of further weight loss on diabetes risk reduction.11 These data       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> illustrate that even 1â€“2 kg of weight loss in people at risk for developing T2DM can have health benefits,      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> although it is generally accepted that a weight loss of at least 2.5% or more is required, with maximal impact  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> on T2DM prevention occurring at 10% weight loss.12 Type 2 diabetes remission It has long been recognised that   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> in some people with T2DM, glucose levels can improve into the normal range either spontaneously or after        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> medical or surgical interventions, which can persist, at least temporarily, after glucose-lowering              <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> pharmacotherapy is withdrawn. This occurrence is now referred to as â€œremissionâ€ and is generally defined as an  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> HbA1c &lt;6.5% (48 mmol/mol) without blood glucose medications for a period of three months or more.13 However, it <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> should be noted that publications on diabetes remission have used various definitions and are therefore not     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> always directly comparable. Furthermore, current definitions exclude those achieving remission while taking     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> newer diabetes and weight loss glucagon-like peptide-1 (GLP-1) receptor agonists based therapies.14 Since       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> weight loss is strongly associated with diabetes remission, the introduction of these newer BGL medications     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> with significant weight-lowering potential has raised the question of revisiting the diabetes remission         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> definition to include a provision for continuing these medications, analogous to the situation of metabolic     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> bariatric surgery where remission is defined in the presence of the intervention which induced weight loss.     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Data from the National Diabetes Audit in England reported that 1.7% of 2,297,700 people underwent T2DM          <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> remission without specific intervention. The odds of remission was 2.87-fold greater in people diagnosed with   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> T2DM within one year compared to three to five years, and a BMI reduction of â‰¥10%, as compared to &lt;5%, was      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> associated with 3.57 greater odds of remission.15 A younger age, shorter duration of diabetes, lower baseline   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> weight, and detectable C-peptide levels without insulin treatment are associated with the highest diabetes      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> remission rates.16 Intensive lifestyle intervention (ILI), very low-calorie diet (VLCD), and MBS not only       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> substantially enhance glycaemic control but may also induce T2DM remission. Intensive lifestyle intervention In <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> the Look AHEAD (Action for Health in Diabetes) trial in 5,145 overweight or obese individuals with T2DM,        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> greater weight loss was achieved in the group randomised to ILI compared to diabetes education at one year      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> (-7.9%), which decreased to -3.9% at four years.17 This translated into diabetes remission in 2% in the control <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> group and 11.5% and 7.3% in ILI participants at one and four years, respectively. Very low-calorie diet VLCDs   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> are effective interventions to induce rapid weight loss and improving glycaemia. Two randomised controlled      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> trials (RCTs) of VLCD interventions in the UK (DiRECT-predominantly White European) and Qatar                   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> (DIADEM-1-predominantly Arab) reported significant reductions in body weight of 11.2%, with T2DM remission in   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 45%â€“60% at 12 months18,19 and 35% in the DiRECT study at 24 months.16 A small RCT, the South Asian Diabetes     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Remission Feasibility Trial (STANDby), of 25 South Asians in the UK, reported weight loss of 7.2% and T2DM      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> remission in 38% at four months.20 In a non-randomised, open-label primary care study from Australia            <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> (DiRECT-Aus), VLCD achieved a weight loss of 11.2% and T2DM remission in 55% of 155 participants at one year.21 <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Maintaining these remission rates for a longer period is challenging, as reported by the five-year DiRECT       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> extension study, with 13% overall remaining in remission at five years.22 In relation to weight loss required   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> for T2DM remission, the DiRECT study showed that weight loss of 5â€“10 kg (baseline weight approximately 100 kg)  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> resulted in remission rates of 34% at one year and 29% at two years. With weight losses of 10â€“15 kg, remission  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> rates were 57% and 60% and with weight loss more than 15 kg, remission rates were 86% and 70%, respectively, at <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> one and two years. After five years, remission rate was 19% for individuals maintaining a weight loss of more   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> than 10 kg.16 Metabolic bariatric surgery (MBS) MBS offers superior diabetes remission and blood glucose        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> control compared to non-surgical interventions for people with T2DM.23,24 In the IDF Global Clinical Practice   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Recommendations for Managing Type 2 Diabetes â€“ 2025 80 WEIGHT CONTROL Alliance of Randomized Trials of Medicine <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Versus Metabolic Surgery in Type 2 Diabetes (ARMMS-T2D), people with T2DM aged 20â€“65 years and BMI 27â€“45 kg/m2  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> reported diabetes remission at three years of 37.5% of participants after MBS compared with 2.6% with           <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> medical/lifestyle intervention.25 A recent systematic review included 85,473 people with T2DM, of whom 24,451   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> were in the surgical group, with followâ€up durations between five and 15 years. Data on 972 people from seven   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> studies (three cohort studies and four RCTs) were available for long-term assessment of diabetes remission.     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> There was a significant increase in diabetes remission with MBS compared with conventional medical therapy with <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> remission rates of 32% versus 6% over five to 15 years.26 The wide range of remission rates reported with MBS   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> may be due to the diversity of surgical procedures, limited numbers in the RCTs, different lengths of           <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> follow-up, different definitions of diabetes remission, and difference in reporting of remission â€“ cumulative   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> remission (counted as any individual who ever achieved remission) and/or prevalent remission (counted as only   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> individuals who were in remission at the time of measurement).27 MBS improves control of diabetes through both  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> weight-dependent and weight-independent actions. Some degree of glycaemic improvement is associated with weight <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> loss as reported in a meta-analysis of eight studies involving 1,247 participants who underwent MBS, which      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> demonstrated that percentage excess weight loss was positively associated with remission rate.28 Furthermore,   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 75% of participants who do not achieve diabetes remission had weight regain.29 Improvement in insulin           <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> sensitivity following weight loss with MBS is a likely mechanism and changes in gut microbiome may also be a    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> factor. A striking feature of MBS is the rapid improvement in glycaemic control that precedes weight loss with  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> reports of individuals being insulin-free at the time of discharge. Mechanisms driving these rapid,             <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> weight-independent improvements in glucose homeostasis may be related to alterations in gut hormones.27         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Mortality and diabetes-related complications Accumulating data demonstrate that interventions leading to weight <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> loss in people with T2DM are associated with reduced risk of premature mortality and diabetes-related           <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> microvascular and macrovascular complications. This may be the direct result of improved control of glycaemic   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> and other risk factors (hypertension, lipids), or due to periods of diabetes remission, or a direct effect of   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> pharmacotherapy used to induce weight loss. Intensive lifestyle intervention The primary aim of the LOOK AHEAD  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> study was to examine whether an intensive lifestyle weight loss intervention would decrease cardiovascular      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> morbidity and mortality in 5,145 overweight or obese people with T2DM. Despite greater weight loss in the       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> intervention group than in the control group throughout the study (6.0% versus 3.5% at study end), after a      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> median follow-up of 9.6 years, rates of cardiovascular disease (CVD) events were similar in both groups.30      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Secondary analyses showed a benefit on diabetic nephropathy31 and symptoms of neuropathy.32 Additionally, a     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> recent analysis of study participants who achieved diabetes remission at any stage during the study had a 40%   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> lower rate of CVD and 33% lower rate of chronic kidney disease after adjusting for HbA1c, lipids, blood         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> pressure, and CVD history.33 In a similar post-hoc analysis, weight loss &gt;10% was also associated with a        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> reduction in CVD by 20%.30,34 Metabolic bariatric surgery A systematic review assessed long-term outcomes in    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 84,890 people with T2DM, of whom 24,247 underwent MBS (11 studies â€“ nine retrospective cohort, one prospective  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> cohort, one small RCT [n = 150]) with follow-up durations between five and 15 years. Significant decreases were <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> observed in microvascular complications incidence (hazard ratio [HR]=0.57), macrovascular complications         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> incidence (HR=0.59), and mortality (HR=0.53).26 A recently published network meta-analysis has undertaken an    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> indirect comparison between MBS and blood glucose-lowering therapies and reported an advantage in glycaemic     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> control and weight management for MBS. However, the lack of direct head-to-head comparative trials between MBS  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> and the incretin-based therapies is a critical research gap.35 Anti-obesity pharmacotherapy Pharmacotherapeutic <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> options for the management of obesity were limited in the pre-incretin-based era. The increasing range of novel <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 81 Chapter 5 anti-obesity medications include GLP-1 receptor agonists (such as higher strength liraglutide 3.0  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> mg and semaglutide 2.4 mg), dual GLP-1 and GIP receptor agonists (such as tirzepatide), and triple GLP-1, GIP,  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> and glucagon receptor agonists (such as retatrutide). However, they are expensive and not generally available,  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> especially in resource-limited settings. Incretin-based therapies have demonstrated benefits in the management  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> of people with T2DM, as reviewed in Chapter 3. This section reviews the incretin-based therapies targeting      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> weight management and their use in people with T2DM. Semaglutide Semaglutide has been shown to effectively      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> reduce weight and improve CVD, renal, and heart failure outcomes in overweight and obese people with T2DM. The  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> weight loss efficacy of higher doses of once-weekly subcutaneous GLP-1 receptor agonist, semaglutide 2.4 mg,    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> has been established in the STEP-1 trial in people without diabetes with a BMI â‰¥30 or â‰¥27 kg/m2 with one or     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> more weight-related coexisting condition where placebo-subtracted weight loss of 12.4% was observed over 68     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> weeks.36 The STEP-2 trial assessed once-weekly subcutaneous semaglutide 2.4 mg versus 1.0 mg (approved dose for <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> diabetes management) and placebo in adults with overweight or obesity and T2DM. Semaglutide 2.4 mg achieved a   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> placebo-subtracted weight loss of 6.2% and a placebo-subtracted improvement in HbA1c of 1.4% (15 mmol/mol) over <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 68 weeks while semaglutide 1.0 mg achieved a placebo-subtracted weight loss of 3.8% and a placebo-subtracted    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> improvement in HbA1c of 1.1% (12 mmol/mol) over 68 weeks.37 The PIONEER 6 trial randomised 3,183 individuals    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> with T2DM to once-daily oral semaglutide (14 mg) or placebo for a median of 15.9 months. There was a            <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> significant reduction in body weight (â€“4.2 kg versus â€“0.8 kg) and HbA1c (â€“1.0% versus â€“0.3% [-11 mmol/mol       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> versus -3 mmol/mol]) in the oral semaglutide compared to placebo group. The primary outcome (cardiovascular     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> death, non-fatal myocardial infarction, or non-fatal stroke) was not significantly different in the oral        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> semaglutide group versus the placebo group, demonstrating non-inferiority but not superiority to placebo.38     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Among people with T2DM and obesity-related heart failure with preserved ejection fraction, semaglutide 2.4 mg   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> once-weekly resulted in a 6.4% greater placebo-subtracted weight loss at one year and was associated with       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> significantly larger reductions in heart failure-related symptoms and physical limitations.39 Tirzepatide In    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> SURPASS-2, 1,879 adults with T2DM (HbA1c 8.3% [67 mmol/mol], weight 93.7 kg) were randomised to receive         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> tirzepatide (GLP-1/ GIP dual agonist) 5 mg, 10 mg, 15 mg, or semaglutide 1.0 mg subcutaneously weekly over 40   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> weeks. The change from baseline in HbA1c was -2.01% (-17 mmol/mol), -2.24% (24.5 mmol/ mol), -2.30% (25.1       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> mmol/mol), and -1.86% (20.3 mmol/mol) and body weight loss was -7.6 kg, -9.3 kg, -11.2 kg, and -5.7 kg,         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> respectively. An HbA1c &lt;6.5% (48 mmol/mol) was achieved in 69%, 77%, 80%, and 64% and diabetes remission (HbA1c <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> &lt;5.7% [&lt;39 mmol/mol]) was achieved in 27%, 40%, 46%, and 19%, respectively.40 The SURMOUNT-2, a 72-week phase 3 <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> trial of tirzepatide in adults with obesity and T2DM, demonstrated significant weight reductions with           <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> tirzepatide 10 mg and 15 mg, with mean body weight decreases of 12.8% and 14.7%, respectively, compared to a    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 3.2% reduction in the placebo group. This study confirmed the robust effect of tirzepatide on weight loss in a  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> population with diabetes, with 79%â€“83% of tirzepatide-treated participants achieving a body weight reduction of <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 5% or higher.41 Similar to semaglutide studies, in the SURMONT-4 trial, in participants with obesity/           <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> overweight, withdrawing tirzepatide led to substantial regain of lost weight while those who continued          <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> treatment maintained and augmented the initial weight reduction.42 The SURPASS-CVOT study is currently          <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> examining the cardiovascular safety and efficacy of tirzepatide compared with the GLP-1 receptor agonist        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> dulaglutide in T2D.43 Retatrutide Retatrutide is a novel GLP-1/GIP/glucagon receptor triple agonist which is in <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> the early stages of clinical trials. In a phase 2, double-blind, randomised, placebo-controlled trial, 338      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> adults with a BMI â‰¥30 or â‰¥27 with at least one weight-related complication, excluding diabetes, were randomised <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> to retatrutide 1 mg, IDF Global Clinical Practice Recommendations for Managing Type 2 Diabetes â€“ 2025 82 WEIGHT <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> CONTROL 2 mg, 4 mg, 12 mg, or placebo administered subcutaneously once-weekly for 48 weeks. There was a         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> dose-dependent weight reduction of 8.7%, 16.3%, 21.7% and 24.2% respectively with increasing dose compared with <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 2.1% weight loss in the placebo group. At week 48, 72% of the participants with intermediate hyperglycaemia at  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> baseline had a HbA1c &lt;5.7% (&lt;39 mmol/mol) in the retatrutide groups compared to 22% in the placebo group.44 In  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> a subsequent study, adults with T2DM received once-weekly doses of retatrutide, dulaglutide, or placebo over 24 <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> weeks, with a 36-week follow-up. Retatrutide 12 mg significantly improved HbA1c levels by 2% (17 mmol/mol) and  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> achieved a 16.9% decrease in body weight compared with a 0.01% (~0.1 mmol/ mol) reduction in HbA1c and a 3%     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> reduction in body weight in the placebo group.45 Effects of other blood glucose-lowering therapies on weight    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> With the limited availability and affordability of BGL medications with established weight loss potential in    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> many countries throughout the world, particularly incretin-based therapies, a key strategy for Basic Care is to <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> preferentially use BGL therapies with minimal negative impact on weight. In these settings, nutrition education <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> at diagnosis and throughout the care process is particularly important for mitigating weight gain. The effects  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> of BGL therapies on body weight vary both between and within drug classes. Sodium-glucose cotransporter-2       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> (SGLT2) inhibitors are associated with weight loss and their global availability is improving. Metformin        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> results in a small weight loss; dipeptidyl peptidase 4 (DPP4) inhibitors and Î±-glucosidase inhibitors are       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> considered weight-neutral; and glitazones are associated with weight gain.46 As a class, sulfonylurea           <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> monotherapy is associated with a weight gain of approximately 2.0 kg.46 However, weight change has been         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> reported to be limited in other longer-term studies. In the ADVANCE study, mean body weight with gliclazide     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> during the RCT follow-up period was 0.7 kg greater in the intensive control group than in the standard control  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> group,47 but only 0.1 kg over five years in the post-trial.48 The RECORD trial showed that weight was not       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> increased in those randomised to dual therapy with metformin and a sulfonylurea.49 The TOSCA study showed that  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> dual metformin and sulfonylurea therapy was associated with an initial small weight gain in the first year,     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> returning to baseline weight over five years.50 Globally, sulfonylureas remain an important option, either as   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> monotherapy or more commonly as combination therapy. While concerns remain about the risk of hypoglycaemia and  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> weight gain with some sulfonylureas, newer agents (such as glimepiride and gliclazide) are associated with      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> better safety profiles and continue to be promoted in guidelines, especially in combination with other BGL      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> therapies.51,52 REFERENCES 1. Obesity and type 2 diabetes: a joint approach to halt the rise. A policy brief by <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> the International Diabetes Federation and the World Obesity Federation. Available from:                         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> https://www.idf.org/media/uploads/2022/11/                                                                      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> IDF-WOF-Obesity-and-type-2-diabetes_A-joint-approach-to-halt-the-rise-WEB-2.pdf [Accessed September 2024]. 2.   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> World Obesity Federation. Missing the 2025 Global Targets. Available from: https://www.\\nworldobesity.org       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> [Accessed September 2024]. 3. World Obesity Federation. World Obesity Atlas 2022. Available from:               <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> http://s3-eu-west-1.\\namazonaws.com/wof-files/World_Obesity_ Atlas_2022.pdf [Accessed September 2024]. 4.       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> International Diabetes Federation (IDF). IDF Diabetes Atlas. 11th edition. Brussels, Belgium: International     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Diabetes Federation, 2025. Available from: http://www.diabetesatlas.org. 5. Rubino F, Cummings DE, Eckel RH, et <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> al. Definition and diagnostic criteria of clinical obesity. Lancet Diabetes Endocrinol. 2025;13(3):221-262. 6.  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> World Health Organization (WHO) Expert Consultation. Appropriate body-mass index for Asian populations and its  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> implications for policy and intervention strategies. Lancet. 2004;363(9403):157-163. Erratum in: Lancet.        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 2004;363(9412):902. 7. Ross R, Neeland IJ, Yamashita S, et al. Waist circumference as a vital sign in clinical  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> practice: a Consensus Statement from the IAS and ICCR Working Group on Visceral Obesity. Nat Rev Endocrinol.    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 2020;16(3):177-189. 8. Horn DB, Almandoz JP, Look M. What is clinically relevant weight loss for your patients  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> and how can it be achieved? A narrative review. Postgrad Med. 2022;134(4):359-375. 83 Chapter 5 9. Gummesson A, <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Nyman E, Knutsson M, et al. Effect of weight reduction on glycated haemoglobin in weight loss trials in         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> patients with type 2 diabetes. Diabetes Obes Metab. 2017;19(9):1295-1305. 10. Knowler WC, Barrett-Connor E,     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Engl J Med. 2002;346(6):393-403. 11. Hamman RF, Wing RR, Edelstein SL, et al. Effect of weight loss with        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> lifestyle intervention on risk of diabetes. Diabetes Care. 2006;29(9):2102-2107. 12. Ryan DH, Yockey SR. Weight <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> loss and improvement in comorbidity: Differences at 5%, 10%, 15%, and over. Curr Obes Rep. 2017;6(2):187-194.   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 13. Riddle MC, Cefalu WT, Evans PH, et al. Consensus report: Definition and interpretation of remission in type <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 2 diabetes. Diabetes Care. 2021;44(10):2438-2444. 14. Taheri S. Type 2 diabetes remission: A new mission in     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> diabetes care. Diabetes Care. 2024;47(1):47-49. 15. Holman N, Wild SH, Khunti K, et al. Incidence and           <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> characteristics of remission of type 2 diabetes in England: A cohort study using the National Diabetes Audit.   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Diabetes Care. 2022;45(5):1151-1161. 16. Lean MEJ, Leslie WS, Barnes AC, et al. Durability of a primary         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> care-led weight-management intervention for remission of type 2 diabetes: 2-Year results of the DiRECT          <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> open-label, cluster-randomised trial. Lancet Diabetes Endocrinol. 2019;7(5):344-355. 17. Gregg EW, Chen H,      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Wagenknecht LE, et al. Association of an intensive lifestyle intervention with remission of type 2 diabetes.    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> JAMA. 2012;308(23):2489-2496. 18. Lean ME, Leslie WS, Barnes AC, et al. Primary care-led weight management for  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> remission of type 2 diabetes (DiRECT): An open-label, cluster-randomised trial. Lancet.                         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 2018;391(10120):541-551. 19. Taheri S, Zaghloul H, Chagoury O, et al. Effect of intensive lifestyle             <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> intervention on bodyweight and glycaemia in early type 2 diabetes (DIADEM-I): An open-label, parallel-group,    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> randomised controlled trial. Lancet Diabetes Endocrinol. 2020;8(6):477-489. 20. Sattar N, Welsh P, Leslie WS,   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> et al. Dietary weight-management for type 2 diabetes remissions in South Asians: The South Asian diabetes       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> remission randomised trial for proof-of-concept and feasibility (STANDby). Lancet Reg Health Southeast Asia.    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 2023;9:100111. 21. Hocking SL, Markovic TP, Lee CMY, et al. Intensive lifestyle intervention for remission of   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> early type 2 diabetes in primary care in Australia: DiRECT-Aus. Diabetes Care. 2024;47(1):66-70. 22. Lean ME,   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Leslie WS, Barnes AC, et al. 5-year follow-up of the randomised Diabetes Remission Clinical Trial (DiRECT) of   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> continued support for weight loss maintenance in the UK: an extension study. Lancet Diabetes Endocrinol.        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 2024;12(4):233-246. 23. Mingrone G, Panunzi S, De Gaetano A, et al. Bariatric surgery versus conventional       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> medical therapy for type 2 diabetes. N Engl J Med. 2012;366(17):1577-1585. 24. Schauer PR, Kashyap SR, Wolski   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> K, et al. Bariatric surgery versus intensive medical therapy in obese patients with diabetes. N Engl J Med.     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 2012;366(17):1567-1576. 25. Kirwan JP, Courcoulas AP, Cummings DE, et al. Diabetes remission in the Alliance of <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Randomized Trials of Medicine versus Metabolic Surgery in Type 2 Diabetes (ARMMS-T2D). Diabetes Care.           <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 2022;45(7):1574-1583. 26. Yang Y, Miao C, Wang Y, et al. The long-term effect of bariatric/metabolic surgery    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> versus pharmacologic therapy in type 2 diabetes mellitus patients: A systematic review and meta-analysis.       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Diabetes Metab Res Rev. 2024;40(5):e3830. 27. Affinati AH, Esfandiari NH, Oral EA, et al. Bariatric surgery in  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> the treatment of type 2 diabetes. Curr Diab Rep. 2019;19(12):156. 28. Yan YX, Wang GF, Xu N, et al. Correlation <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> between postoperative weight loss and diabetes mellitus remission: A meta-analysis. Obes Surg.                  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 2014;24(11):1862-1869. 29. Mingrone G, Panunzi S, De Gaetano A, et al. Bariatric-metabolic surgery versus       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> conventional medical treatment in obese patients with type 2 diabetes: 5 Year follow-up of an open-label,       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> single-centre, randomised controlled trial. Lancet. 2015;386(9997):964-973. 30. Wing RR, Bolin P, Brancati FL,  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> et al. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med.             <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 2013;369(2):145-154. 31. Knowler WC, Bahnson JL, Bantle JP, et al. Effect of a long-term behavioural weight     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> loss intervention on nephropathy in overweight or obese adults with type 2 diabetes: A secondary analysis of    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> the Look AHEAD IDF Global Clinical Practice Recommendations for Managing Type 2 Diabetes â€“ 2025 84 WEIGHT       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> CONTROL randomised clinical trial. Lancet Diabetes Endocrinol. 2014;2(10):801-809. 32. Look AHEAD Research      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Group. Effects of a long-term lifestyle modification programme on peripheral neuropathy in overweight or obese  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> adults with type 2 diabetes: The Look AHEAD study. Diabetologia. 2017;60(6):980-988. 33. Gregg EW, Chen H,      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Bancks MP , et al. Impact of remission from type 2 diabetes on long-term health outcomes: Findings from the     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Look AHEAD study. Diabetologia. 2024;67(3):459-469. 34. Gregg EW, Jakicic JM, Blackburn G, et al. Association   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> of the magnitude of weight loss and changes in physical fitness with long-term cardiovascular disease outcomes  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> in overweight or obese people with type 2 diabetes: A post-hoc analysis of the Look AHEAD randomised clinical   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> trial. Lancet Diabetes Endocrinol. 2016;4(11):913-921. 35. Wu T, Wong CKH, Lui DTW, et al. Bariatric surgery,   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> novel glucose-lowering agents, and insulin for type 2 diabetes and obesity: Bayesian network meta-analysis of   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> randomized controlled trials. BJS Open. 2023;7(4):zrad077. 36. Wilding JPH, Batterham RL, Calanna S, et al.     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989-1002. 37. Davies   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> M, FÃ¦rch L, Jeppesen OK, et al. Semaglutide 2Â·4 mg once a week in adults with overweight or obesity, and type 2 <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> diabetes (STEP 2): A randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet.         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 2021;397(10278):971-984. 38. Husain M, Birkenfeld AL, Donsmark M, et al. Oral semaglutide and cardiovascular    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> outcomes in patients with type 2 diabetes. N Engl J Med. 2019;381(9):841-851. 39. Kosiborod MN, Petrie MC,      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Borlaug BA, et al. Semaglutide in patients with obesity-related heart failure and type 2 diabetes. N Engl J     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Med. 2024;390(15):1394-1407. 40. FrÃ­as JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus semaglutide once  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> weekly in patients with type 2 diabetes. N Engl J Med. 2021;385(6):503-515. 41. Garvey WT, Frias JP, Jastreboff <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> AM, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): A  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2023;402(10402):613-626. 42.  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Aronne LJ, Sattar N, Horn DB, et al. Continued treatment With tirzepatide for maintenance of weight reduction   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> in adults with obesity: The SURMOUNT-4 randomized clinical trial. JAMA. 2024;331(1):38-48. 43. Nicholls SJ,     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Bhatt DL, Buse JB, et al. Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS-CVOT design and baseline  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> characteristics. Am Heart J. 2024;267:1-11. 44. Jastreboff AM, Kaplan LM, FrÃ­as JP, et al.                      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Triple-hormone-receptor agonist retatrutide for obesity - a phase 2 trial. N Engl J Med. 2023;389(6):514-526.   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 45. Rosenstock J, Frias J, Jastreboff AM, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> people with type 2 diabetes: A randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> trial conducted in the USA. Lancet. 2023;402(10401):529-544. 46. Apovian CM, Okemah J, Oâ€™Neil PM. Body weight   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> considerations in the management of type 2 diabetes. Adv Ther. 2019;36(1):44-58. 47. Patel A, MacMahon S,       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Chalmers J, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Engl J Med. 2008;358(24):2560-2572. 48. Zoungas S, Chalmers J, Kengne AP, et al. The efficacy of lowering       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> glycated haemoglobin with a gliclazide modified release-based intensive glucose lowering regimen in the ADVANCE <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> trial. Diabetes Res Clin Pract. 2010;89(2):126-133. 49. Home PD, Pocock SJ, Beck-Nielsen H, et al.              <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> (RECORD): a multicentre, randomised, open-label trial. Lancet. 2009;373(9681):2125-2135. 50. Vaccaro O, Masulli <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> M, Nicolucci A, et al. Effects on the incidence of cardiovascular events of the addition of pioglitazone versus <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): A randomised, <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> multicentre trial. Lancet Diabetes Endocrinol. 2017;5(11):887-897. 51. Kalra S, Bahendeka S, Sahay R, et al.    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Consensus recommendations on sulfonylurea and sulfonylurea combinations in the management of type 2 diabetes    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> mellitus - International Task Force. Indian J Endocrinol 85 Chapter 5 Metab. 2018;22(1):132-157. 52. Al-Saleh   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Y, Sabico S, Al-Furqani A, et al. Sulfonylureas in the current practice of type 2 diabetes management: Are they <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> all the same? Consensus from the Gulf Cooperation Council (GCC) countries advisory board on sulfonylureas.      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Diabetes Ther. 2021;12(8):2115-2132. Erratum in: Diabetes Ther. 2021;12(8):2265-2266. 86 Cardio-Renal           <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Protection in Type 2 Diabetes Chapter 6 CARDIO-RENAL PROTECTION 87 Chapter 6 RECOMMENDATIONS Optimal Care Basic <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Care Atherosclerotic Cardiovascular Disease (ASCVD) Screening/risk assessment â€¢\\tHistory of ASCVD â€¢\\tHigh-risk  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> assessment - Age plus 2 risk factors - CVD risk score Management â€¢\\tGlycaemic control â€¢\\tRisk factor control    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> â€¢\\tBlood pressure/lipid control â€¢\\tConsider aspirin â€¢\\tSGLT2i or GLP-1RA â€¢\\tConsider SGLT2i and GLP-1RA         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> â€¢\\tGlycaemic control â€¢\\tRisk factor control â€¢\\tBlood pressure/lipid control â€¢\\tConsider aspirin â€¢\\tSGLT2i*      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Heart Failure (HF) Screening/risk assessment â€¢\\tSymptoms â€¢\\tHospitalisation for HF â€¢\\tECG â€¢\\tEchocardiography   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> â€¢\\tRisk score â€¢\\tBiomarkers - BNP / NT-proBNP â€¢\\tSymptoms â€¢\\tHospitalisation for HF â€¢\\tECG â€¢\\tRisk score        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Management â€¢\\tGlycaemic control â€¢\\tRisk factor control â€¢\\tBlood pressure/lipid control â€¢\\tACEi or ARB           <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> â€¢\\tBeta-blockers â€¢\\tMetformin+SGLT2i â€¢\\tConsider adding a non-steroidal MRA â€¢\\tConsider adding                  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> GLP-1RA/tirzepatide in obese individuals â€¢\\tGlycaemic control â€¢\\tRisk factor control â€¢\\tBlood pressure/lipid    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> control â€¢\\tACEi or ARB â€¢\\tBeta-blockers â€¢\\tMetformin+SGLT2i* â€¢\\tConsider adding a steroidal MRA Chronic Kidney  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Disease (CKD) Screening/risk assessment â€¢\\teGFR â€¢\\tUACR Management â€¢\\tGlycaemic control â€¢\\tRisk factor control  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> â€¢\\tBlood pressure/lipid control â€¢\\tACEi or ARB â€¢\\tSGLT2i â€¢\\tConsider adding semaglutide â€¢\\tGlycaemic control    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> â€¢\\tRisk factor control â€¢\\tBlood pressure/lipid control â€¢\\tACEi or ARB â€¢\\tSGLT2i* * SGLT2 inhibitors are         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> increasingly available in several low- and middle-income countries at generally affordable cost.\\nACEi,         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; BNP/NT-proBNP, b-type            <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> natriuretic peptide/N- terminal pro-b-type natriuretic peptide; CVD, cardiovascular disease; ECG,               <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> electrocardiogram; eGFR, estimated glomerular filtration rate; GLP-1RA, glucagon-like peptide-1 receptor        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> agonist; HF, heart failure; MRA, mineralocorticoid receptor antagonist; SGLT2i, sodium-glucose cotransporter-2  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> inhibitor; UACR, urine albumin-to-creatinine ratio.\\nIDF Global Clinical Practice Recommendations for Managing  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Type 2 Diabetes â€“ 2025 88 CARDIO-RENAL PROTECTION o Diabetes complications result from a complex interplay of   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> hyperglycaemia, cardiometabolic risk factors (e.g., elevated blood pressure and lipids), obesity, and unhealthy <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> lifestyle behaviours. o Cardio-renal complications, including atherosclerotic cardiovascular disease (ASCVD),   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> heart failure (HF), and chronic kidney disease (CKD), are major drivers of premature mortality and morbidity in <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> type 2 diabetes mellitus (T2DM). o Cardiovascular disease (CVD) is highly prevalent in T2DM, around 30%         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> overall, with significant rates of coronary artery disease, silent myocardial infarctions, and HF; CKD affects  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> around 40% of individuals, with marked ethnic differences. o Early and regular screening for CVD (using risk    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> scores, symptom assessment, electrocardiogram, echocardiography, and biomarkers) and CKD (estimated glomerular  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> filtration rate [eGFR] and urine albumin-to-creatinine ratio) is critical for timely intervention. o A          <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> multi-pillar management approach is essential, focusing on glycaemic control, risk factor modification (blood   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> pressure and lipid management, smoking cessation, weight control), and use of proven cardio-renal protective    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> therapies. o Newer blood glucose lowering agents, especially SGLT2 inhibitors and GLP-1 receptor agonists, have <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> demonstrated robust benefits in reducing adverse cardio-renal outcomes. o SGLT2 inhibitors consistently reduce  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> risks of kidney disease progression, HF hospitalisations, and cardiovascular death across diverse groups with   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> T2DM. o GLP-1 receptor agonists reduce major adverse cardiovascular events, all-cause mortality, and composite  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> kidney outcomes. o Other glucose lowering therapies (metformin, sulfonylureas, DPP4 inhibitors, insulin)        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> generally have neutral cardio-renal effects while thiazolidinediones increase HF risk. o Non-steroidal          <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> mineralocorticoid receptor antagonists (e.g., finerenone) further expand options for reducing cardio-renal risk <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> in T2DM. o Global challenges, especially in low resource settings, limit availability and access to             <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> comprehensive screening and optimal medications to reduce cardio-renal risk. o A structured, multi-pillar       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> treatment approach that integrates both traditional and novel therapies is recommended to improve cardio-renal  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> outcomes in people with T2DM. KEY POINTS 89 Chapter 6 BACKGROUND Diabetes complications are the result of a     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> complex interplay of hyperglycaemia, cardiometabolic risk factors such as elevated blood pressure and lipids,   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> obesity, and an unhealthy lifestyle (diet, physical inactivity, smoking). In addition, some complications       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> increase the risk of other complications, with chronic kidney disease (CKD) associated with an increased risk   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> of all-cause and cardiovascular (CVD) mortality, CVD events, and hospitalisation with heart failure (HF).1 This <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Chapter focuses on cardio-renal protection, a major driver of premature mortality and significant morbidity in  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> people with type 2 diabetes mellitus (T2DM) (Figure 6.1). Minimising cardio-renal complications requires        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> effective and regular screening to detect CVD and CKD, and early comprehensive intervention, including          <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> consideration of newer blood glucose-lowering (BGL) medications with established cardio-renal protection        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> (sodium-glucose cotransporter-2 [SGLT2] inhibitors and glucagon-like peptide-1 [GLP-1] receptor agonists)1 in   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> the context of the key pillars in diabetes management (Figure 6.2). GLOBAL CONSIDERATIONS In low resource       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> settings, particularly in low- and middle-income countries, access, availability, and affordability of          <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> comprehensive Optimal Care for screening and management of cardio-renal risk is often limited. This includes    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> healthcare services, qualified healthcare professionals, diagnostic tests, and availability and affordability   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> of medications. For example, in 125 surveyed countries, fewer than one in four had facilities available for     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> routine measurements of serum creatinine or proteinuria and there was considerable interregional and            <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> intraregional variability.2 A broad range of medications is available on the World Health Organization (WHO)    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Essential Medicines List (EML) for managing cardio-renal risk, including angiotensin-converting enzyme (ACE)    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> inhibitors, angiotensin receptor blockers (ARBs), beta-blockers, diuretics, and spironolactone.3 While this     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> does not guarantee local availability, the WHO EML serves as a platform for lobbying local policy makers to     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> have these medications on the countryâ€™s national EML. As described in Chapter 3 on non-insulin glucose-lowering <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> medications, while access to these medications is limited globally, MASLD, Metabolic dysfunction-associated     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> steatotic liver disease; MASH, Metabolic dysfunction-associated steatohepatitis; PVD, peripheral vascular       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> disease.\\nFigure 6.1 Diabetes-associated complications IDF Global Clinical Practice Recommendations for         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Managing Type 2 Diabetes â€“ 2025 90 CARDIO-RENAL PROTECTION the range is increasing in many countries, including <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> generic and affordable SGLT2 inhibitors. However, if Optimal Care cannot be achieved, implementing programmes   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> to achieve Basic Care standards have the potential to significantly reduce cardio-renal risk and improve        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> outcomes for people with T2DM. EVIDENCE SUMMARY Prevalence of CVD and CKD in people with T2DM T2DM increases    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> the risk of developing atherosclerotic cardiovascular disease (ASCVD), HF, CKD, and risk of premature death     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> compared with those without T2DM.4 A recent systematic review of over four million individuals with T2DM        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> reported an overall CVD prevalence of 32.2%; 29.1% with coronary artery disease (CAD), 14.9% HF, 14.6% angina,  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 10.0% myocardial infarction (MI), and 7.6% stroke.5 CVD was the cause of death in 9.9%, representing 50.3% of   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> all deaths.5 In a real-world study in primary care of 123,261 individuals (9,616 with T2DM), 43.7% presented    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> with ASCVD and/or CKD and/or HF: 34.8% ASCVD, 4.0% HF, and 14.6% CKD.6 Asymptomatic CVD is common in T2DM with  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> approximately one in three individuals experiencing undetected ischaemic episodes.7 The UKPDS study reported a  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> prevalence of around 20% of â€œsilentâ€ MI in people with T2DM.8 Heart failure is an important but                 <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> under-recognised risk factor for adverse outcomes in people with T2DM and has often been overlooked compared    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> with prevention of ASCVD. HF represents a substantial global burden with significant unmet needs in terms of    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> morbidity and mortality. A meta-analysis of 43 studies established diabetes as a significant adverse factor     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> linked to long-term survival and hospitalisation risk in both acute and chronic HF.9 In a 2016 cross-sectional  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> study, 26.4% of US nursing home residents aged 65 or older with T2DM had HF.10 HF is not only common in T2DM    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> but is preventable and treatable. CKD affects approximately 40% of individuals with T2DM overall but prevalence <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> varies with age, ethnic background, duration of diabetes, and presence of cardiometabolic risk factors.11 CKD   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> in individuals with T2DM has remained consistently high at approximately 40% from 2007 to 2012.12 There are     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> significant ethnic disparities with higher rates among Black and Mexican-American populations. Alarmingly, one  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> in four persons under age 65 with T2DM has CKD, underscoring the need to improve early detection and            <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> management.12 The intricate relationship between T2DM, CVD, and CKD is highlighted in a cross-sectional         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> multicentre study of individuals with T2DM from the United Arab Emirates and Kuwait, in whom CKD prevalence was <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 44.3%, followed by CVD (17.3%) and CAD (15%), with a discernible male predilection. Co-prevalence of CVD and    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> CKD was common (11.7%), and a longer duration of T2DM correlated with heightened risks of CVD, CAD, and         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> peripheral artery disease.13 Individuals with T2DM without known cardio-renal disease have an 80% lifetime risk <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> of developing CVD or renal events: a 54% risk of CKD; 41% risk of CVD death; 29% risk of HF; 20% risk of        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> stroke; 19% risk of MI; and 9% risk of peripheral vascular disease (PVD). Achieving ideal CVD health could      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> potentially reduce risks by 37% if evidence-based interventions for reducing CVD associated with T2DM were more <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> widely used.14 Figure 6.2 Key pillars of diabetes management 91 Chapter 6 Screening for CVD and CKD in people   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> with T2DM The availability of effective therapeutic options to prevent and reduce adverse cardio-renal outcomes <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> underscores the importance of screening and early detection for both CVD and CKD in people with T2DM. The       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> following is an overview of approaches for assessing cardio-renal risk. While access will vary across countries <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> and health systems, it is important for each health service to develop local criteria for assessing and         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> defining cardio-renal risk and to implement management strategies. CVD screening and risk assessment (i) ASCVD  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> â€“ established event and/or high-risk a. Established ASCVD traditionally includes those who have had an MI,      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> stroke, or a revascularisation procedure. Some definitions also include a transient ischaemic attack, angina,   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> amputation, PVD. b. High CVD risk can be assessed using a formal CVD risk score or by clinical characteristics  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> (e.g., age plus 2 additional risk factors such as smoking, elevated blood pressure, dyslipidaemia).15 Screening <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> should include routine questions for symptoms of ASCVD. Risk assessment in people with T2DM should be           <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> considered from age 40 years. (ii) Heart failure a. Symptoms of HF, hospitalisation for HF b. Electrocardiogram <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> (ECG / EKG) c. Echocardiography with measurement of ejection fraction d. Biomarkers â€“ natriuretic peptides      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> (b-type natriuretic peptide [BNP] and N-terminal pro-b-type natriuretic peptide [NT-proBNP]). BNP or NT-proBNP  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> are biomarkers which are surrogates for intracardiac volumes and filling pressures. Screening protocols using   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> these biomarkers and cut-off values are not universally agreed, require further validation, and are currently   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> not widely available in routine clinical practice.16-20 Screening should include routine questions for symptoms <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> of HF. There is no consensus on routine screening for HF but some suggest formal assessment for HF should       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> commence at least from five years post-T2DM diagnosis.21 CKD screening and risk assessment Renal function       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> should be assessed by measuring the following: 1. Estimated glomerular filtration rate (eGFR) 2. Urine          <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> albumin-to-creatinine ratio (UACR) The primary biomarkers for CKD are eGFR and UACR.22 Normal albuminuria is    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> defined as less than 30 mg/g of creatinine (3 mg/mmol), 30â€“300 mg/g (3â€“30 mg/mmol) as moderately increased      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> albuminuria, and greater than 300 mg/g (30 mg/mmol) as severely increased albuminuria. An eGFR &lt;60 mL/min/1.73  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> m2 signifies impaired renal function. Figure 6.3, shown on the next page, illustrates the Kidney Disease â€“      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Improving Global Outcomes (KDIGO) classification of CKD based on eGFR and UACR and the associated level of      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> risk. Higher categories of CKD, characterised by lower GFR and greater albuminuria, independently increase risk <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> for adverse outcomes which include CKD progression, CVD, all-cause and CVD mortality, HF, kidney failure, and   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> acute kidney injury.23 Annual screening is recommended for CKD starting at diagnosis of T2DM because evidence   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> of CKD is often present already at diagnosis. Management of CVD and CKD in people with T2DM The key pillars for <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> reducing cardio-renal risk follow the same principles for diabetes complications in general (Figure 6.2),       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> adapted according to local availability and affordability of specific therapies in developing and implementing  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> a personalised treatment plan. Pillars of management to improve cardio-renal outcomes in people with T2DM 1.    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Glycaemic control The importance of early and intensive glycaemic control is considered in Chapter 3 on         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> non-insulin glucose-lowering medications; meta-analyses of randomised controlled trials (RCTs) have confirmed   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> that intensive glucose control reduces the risk of CVD, retinopathy, and nephropathy.24,25 2. Risk factor       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> control This is an essential and routine pillar of diabetes care and cardio-renal risk protection irrespective  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> of other interventions and is of IDF Global Clinical Practice Recommendations for Managing Type 2 Diabetes â€“    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 2025 92 CARDIO-RENAL PROTECTION added relevance when access and availability to newer therapies are limited.    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Modifiable risk factors include blood pressure control, lipid control, smoking cessation, and management of     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> obesity or overweight. A comprehensive review of the complete spectrum of risk factor control is outside the    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> scope of these clinical recommendations but can be found elsewhere.15,23,26 The following is a summary of key   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> points relevant to blood pressure and lipid control. (i) Blood pressure control26 â€¢ Hypertension is common      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> among people with T2DM, is a major risk factor for ASCVD, HF, and CKD, and its treatment reduces cardio-renal   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> complications. â€¢ An elevated blood pressure is defined as a systolic blood pressure (SBP) 120â€“129 mmHg and a    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> diastolic blood pressure (DBP) &lt;80 mmHg and hypertension as a SBP â‰¥130 mmHg or a DBP â‰¥80 mmHg. â€¢ Blood pressure <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> should be measured at every routine clinical visit. â€¢ The treatment goal is a blood pressure &lt;130/80 mmHg, if   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> it can be safely attained. â€¢ ACE inhibitors or ARBs are recommended first-line therapy for hypertension in      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> people with T2DM with or at risk of cardio-renal complications. â€¢ Multiple-drug therapy is often required to    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> achieve blood pressure targets. â€¢ Combinations of ACE inhibitors and ARBs and combinations of ACE inhibitors or <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> ARBs with direct renin inhibitors should not be used. â€¢ An ACE inhibitor or ARB is recommended first-line       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> treatment for hypertension in people with diabetes and elevated UACR. The benefits of tighter blood pressure    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> control were confirmed in a recent study in people with T2DM which reported a significantly lower incidence of  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> major CVD events (composite of non-fatal stroke, non-fatal MI, treatment or hospitalisation for HF, or death    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> from CVD) with intensive treatment targeting a SBP of &lt;120 mmHg compared with standard treatment targeting a    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> SBP of &lt;140 mmHg.27 (ii) Lipids26 â€¢ Lipid should be measured at T2DM diagnosis and annually. â€¢ Target           <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> low-density lipoprotein (LDL) cholesterol goals are &lt;1.8 mmol/L (70 mg/dL) for primary prevention and           <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> &lt;1.4mmol/L (55 mg/dL) for secondary prevention. â€¢ Statins are first-choice pharmacotherapy Figure 6.3 KDIGO     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> nomenclature for chronic kidney disease23 CKD, chronic kidney disease; GFR, glomerular filtration rate; KDIGO,  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Kidney Disease â€“ Improving Global Outcomes.\\n93 Chapter 6 for primary and secondary prevention with other       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> therapies considered if LDL cholesterol goal is not met on statins or if intolerant to statins. â€¢ KDIGO         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> recommends statins in adults with T2DM aged 18â€“49 years with CKD if not treated with chronic dialysis or kidney <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> transplantation.23 â€¢ Hypertriglyceridemia should be addressed as required. 3. Other standard therapies (i) ACE  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> inhibitors or ARBs KDIGO recommends starting an ACE inhibitor or ARB for people with CKD and T2DM and           <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> moderately-to-severely increased albuminuria (G1â€“G4, A2 and A3 â€“ Figure 6.3) but avoiding any combination of    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> ACE inhibitors, ARB, and direct renin inhibitor therapy.23 (ii) Beta-blockers Beta-blockers are effective in    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> reducing all-cause death and hospitalisation for HF in people with HF with reduced ejection fraction (HFrEF)    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> with diabetes.15 4. Blood glucose-lowering therapies (i) SGLT2 inhibitors and GLP-1 receptor agonists There is  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> now compelling evidence of specific cardio-renal protection with SGLT2 inhibitors and GLP-1 receptor agonists.  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Consequently, these agents should be considered as mainstream therapies for people with T2DM with or at         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> increased cardio-renal risk and their use has become a key pillar of managing cardio-renal risk.28 SGLT2        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> inhibitors SGLT2 inhibitors have clearly demonstrated benefits across the spectrum of cardio-renal outcomes.    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> The weight of current evidence favours these agents in people with T2DM at high risk or with established HF or  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> CKD. In a meta-analysis of six studies of 46,969 individuals with T2DM, including 66% with ASCVD, SGLT2         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> inhibitors were associated with a 10% reduced risk of major adverse CVD events, 32% reduced risk of             <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> hospitalisation for HF, and 38% reduction in adverse kidney outcomes. The largest benefit across the SGLT2      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> inhibitor class was risk reduction for hospitalisation for HF and adverse kidney outcomes.29 A meta-analysis of <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 13 studies with 90,409 participants (82.7% with T2DM) compared SGLT2 inhibitors with placebo. SGLT2 inhibitors  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> reduced the risk of kidney disease progression by 37% and reduced the risk of CVD death or hospitalisation for  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> HF by 23%. The risk reduction was similar in individuals with and without diabetes and irrespective of mean     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> baseline eGFR.30 A meta-analysis of 48 studies involving 58,165 people with T2DM demonstrated that SGLT2        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> inhibitors were associated with significant reductions in UACR and reduced the risk of microalbuminuria by 31%  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> and macroalbuminuria by 51% compared with placebo or active comparators.31 The EMPA KIDNEY study showed that    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> empagliflozin slowed the progression of impaired glomerular filtration in people with or without T2DM, and with <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> or without albuminuria.32 A meta-analysis of four heart failure studies (n = 15,684 participants, 42%â€“100% with <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> T2DM), four trials in people with T2DM at high ASCVD (n = 42,568), and three trials in CKD (n = 19,289          <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> participants, 68%â€“100% T2DM) reported significantly better outcomes with SGLT2 inhibitors compared with         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> placebo: 23% reduced risk of hospitalisation for HF or CVD death, 14% reduced CVD death, 36% less kidney        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> disease progression, and a 12% reduction in all-cause mortality.33 In five trials of 21,947 people with HF,     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> SGLT2 inhibitors reduced the risk of composite CVD death or hospitalisation for HF by 23%, CVD death by 13%,    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> first hospitalisation for HF by 28%, and all-cause mortality by 8%. These outcomes for each endpoint were       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> consistently observed in HF with mildly reduced or preserved ejection fraction and results were similar in      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> those with and without diabetes.34 GLP-1 receptor agonists A recent meta-analysis of 11 trials involving 67,769 <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> people with T2DM examined the cardio-renal effects of GLP-1 receptor agonists versus placebo. Composite renal   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> outcome was reduced by 18%, kidney failure by 16%, major adverse cardiovascular events (MACE) by 13%, and       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> all-cause mortality by 12%. Overall hospitalisation for HF was reduced by 13% but no baseline information was   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> available on HF status or ejection fraction. Risk of serious adverse events was similar but treatment           <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> discontinuation due to adverse events was 51% higher with GLP-1 receptor agonists.35 A meta-analysis of 13      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> cardiovascular outcome trials (CVOTs; 83,258 people with and without diabetes) examined the effects of GLP-1    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> IDF Global Clinical Practice Recommendations for Managing Type 2 Diabetes â€“ 2025 94 CARDIO-RENAL PROTECTION     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> receptor agonists versus placebo. GLP-1 receptor agonists significantly reduced MACE by 14%, all-cause          <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> mortality by 13%, CV mortality by 13%, fatal stroke by 26%, non-fatal stroke by 13%, coronary revascularisation <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> by 14%, and composite kidney outcome by 24%. These effects were independent of sex, CVD history, body mass      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> index (BMI), and eGFR. GLP-1 receptor agonists did not significantly reduce fatal or non-fatal MI,              <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> hospitalisation for unstable angina, or HF hospitalisation.36 Until recently, the renal effects of GLP-1        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> receptor agonists have been derived from secondary and post-hoc kidney outcomes analysis in clinical trials of  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> GLP-1 receptor agonists for CVD and glycaemic control studies. The FLOW study is the first dedicated study      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> comparing a GLP-1 receptor agonist (semaglutide 1.0 mg once weekly) and placebo in people with T2DM and CKD.    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> The study was ceased early after a prespecified interim analysis demonstrated a 24% reduction in the composite  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> primary outcome with semaglutide. Benefits were observed in the composite of the kidney-specific components of  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> the primary outcome (21% reduction) and CVD death (29% reduction). The results of all confirmatory secondary    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> outcomes also favoured semaglutide.37 To date, no clinical trial has specifically evaluated the efficacy of     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> GLP-1 receptor agonists on CVD outcomes in people with T2DM and heart failure. The STEP-HFpEF DM Trial          <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> randomised people with T2DM and HF with preserved ejection fraction and a BMI â‰¥30 to receive once-weekly        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> semaglutide (2.4 mg) or placebo for 52 weeks. The primary HF endpoint was change from baseline in the Kansas    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> City Cardiomyopathy Questionnaire clinical summary score. Semaglutide resulted in larger reductions in heart    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> failure-related symptoms and physical limitations.38 The cardiovascular outcome SUSTAIN-6 study noted an        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> increase in retinopathy.39 A dedicated RCT of semaglutide versus placebo (FOCUS-NCT03811561) to assess the      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> impact on retinopathy in people with T2DM is due to report in 2026.40 Combination SGLT2 inhibitors and GLP-1    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> receptor agonists No clinical trial has studied combinations of SGLT2 inhibitors and GLP-1 receptor agonists on <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> cardio-renal outcomes in people with T2DM and CKD. However, some indirect data are available. A meta-analysis   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> of 13 real-world observational studies examined combinations of SGLT2 inhibitors and GLP-1 receptor agonists in <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> people with T2DM. The combination was associated with a 51% significantly lower all-cause mortality compared    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> with individual therapies and significant reductions in weight, SBP, and HbA1c. However, the study had a number <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> of limitations, with the authors concluding that the certainty of evidence was deemed to be low-to-very low by  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> the GRADE criteria.41 In a prespecified analysis, the FLOW trial examined the overall benefits of semaglutide   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> on kidney and CVD outcomes in people with T2DM and CKD in relation to baseline users (n = 550) and non-users (n <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> = 2,983) of SGLT2 inhibitors and reported that outcomes were not influenced by the concomitant use of SGLT2     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> inhibitors. However, the power of the analysis was limited by the low use of SGLT2 inhibitors at trial entry    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> and that more participants initiated SGLT2 inhibitors in the placebo group during the trial.42 (ii) Tirzepatide <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Tirzepatide is a long-acting agonist of glucose-dependent insulinotropic polypeptide and glucagon-like          <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> peptide-1 receptors, which results in considerable weight loss. To date, clinical trial data are lacking with   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> respect to its effects on cardio-renal outcomes. The SURPASS-CVOT study is currently examining the              <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> cardiovascular safety and efficacy of tirzepatide compared with the GLP-1 receptor agonist dulaglutide in with  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> T2DM43 The SUMMIT trial randomised people with HF and preserved ejection fraction (48% with T2DM) and BMI â‰¥ 30  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> to receive tirzepatide (up to 15 mg subcutaneously once per week) or placebo. After a median follow-up 104      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> weeks, CVD death or a worsening HF event was reduced by 38% (worsening HF events by 46%) and health status was  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> improved in the tirzepatide group compared with placebo group.44 (iii) Effects of other blood glucose-lowering  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> therapies on cardio-renal outcomes The following is a brief summary of the cardio-renal effects of other BGL    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> therapies. Overall cardio-renal effects have been neutral (except for increased risk of HF with                 <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> thiazolidinediones), suggesting that these agents can be used when required to improve glycaemic control.       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Metformin The cardio-renal effects of metformin have not been studied in a dedicated CVOT. While the UKPDS      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> showed beneficial effects of metformin on long-term diabetes outcomes, the primary focus of the RCT component   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> of the UKPDS was 95 Chapter 6 on comparing intensive with less intensive diabetes control. The UKPDS included a <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> nested RCT of 753 overweight or obese people with T2DM, comparing conventional glucose targets with a policy of <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> intensive glucose lowering with metformin.45 Metformin reduced MI by 39%, coronary death by 50%, and stroke by  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 41% over a median period of 10.7 years. Post-trial follow-up after 24 years showed that early intensive         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> glycaemic control with metformin therapy compared with conventional glycaemic control resulted in 20% risk      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> reduction in all-cause mortality and a 31% reduction in MI.46 Sulfonylureas CVD outcomes with sulfonylureas has <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> been studied in two RCTs. The ADVANCE study examined gliclazide in the context of intensified glycaemic control <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> and did not show any CVD benefits or harms.47 Similarly, the post-trial follow-up ADVANCE-ON study observed no  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> differences in risk of death from any cause or major macrovascular events.48 The dedicated CAROLINA CVOT        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> compared CVD outcomes in people with T2DM randomised to the DPP4 inhibitor, linagliptin, and the sulfonylurea,  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> glimepiride, in addition to usual care. The primary outcome of time to first occurrence of CVD death, non-fatal <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> MI, or non-fatal stroke over a follow-up period of 6.3 years was not different between the two groups but       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> hypoglycaemia was more common in the sulfonylurea group.49 In the UKPDS in individuals with newly diagnosed     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> T2DM, the sulfonylureas chlorpropamide and glibenclamide/glyburide had no statistically significant effects on  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> CV outcomes and equally did not suggest adverse CVD effects of sulfonylureas.50 Alpha glucosidase inhibitors    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> There is no dedicated CVOT with an alpha glucosidase inhibitor (AGI) in people with T2DM. The ACE study         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> examined the effect of the AGI acarbose on CVD outcomes in people with CAD and impaired glucose tolerance and   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> failed to show a difference in outcomes between acarbose and placebo.51 Thiazolidinediones The RECORD study     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> assessed CV outcomes in people with T2DM after addition of rosiglitazone to either metformin or sulfonylurea    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> compared with the combination of the two. Rosiglitazone did not increase the risk of overall CVD morbidity or   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> mortality although there was a possible increase in MI compared with standard glucose-lowering therapies.52 The <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> PROACTIVE CVOT assessed the CVD effects of pioglitazone versus placebo in individuals with T2DM and ASCVD and   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> failed to show a statistically significant effect on the primary composite outcome.53 The thiazolidinediones    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> pioglitazone and rosiglitazone are associated with increased risk of HF. DPP4 inhibitors Four CVOTs in people   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> with T2DM with or at high risk of ASCVD have assessed the CVD effects of DPP4 inhibitors versus placebo and     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> demonstrated non-inferiority but not superiority of DPP4 inhibition in the primary CVD endpoint.54-57 The       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> SAVOR-TIMI 53 study showed that saxagliptin significantly increased the risk of hospitalisation for HF versus   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> placebo.58 Insulin Two basal insulins have been formally evaluated in dedicated CVOTs and did not show a        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> difference in CVD outcomes. The ORIGIN study of insulin glargine included individuals at high CVD risk with     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> impaired fasting glucose, impaired glucose tolerance, or T2DM. After a median follow-up of 6.2 years, the       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> incidence of CV outcomes did not differ between the insulin glargine and standard care groups.59 The DEVOTE     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> trial randomised individuals with T2DM with ASCVD or with a high CVD risk to once daily insulin degludec versus <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> insulin glargine. There was no significant difference in the primary composite of CVD death, non-fatal MI, or   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> non-fatal stroke between the two groups after a median 1.8 years follow-up.60 Mineralocorticoid receptor        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> antagonists a. Steroidal mineralocorticoid receptor antagonists (MRAs) spironolactone or eplerenone reduce      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> death and HF hospitalisation in people with HFrEF, with consistent results in people with or without diabetes.  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Caution is required when using MRAs in people with impaired renal function and in those with serum potassium    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> concentration &gt;5.0 mmol/L.15 The efficacy of these agents in people with HF and mildly reduced or preserved     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> ejection fraction has not been established. b. Non-steroidal MRA â€“ finerenone The placebo-controlled            <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> FIDELIO-DKD61 and IDF Global Clinical Practice Recommendations for Managing Type 2 Diabetes â€“ 2025 96           <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> CARDIO-RENAL PROTECTION FIGARO-DKD62 trials demonstrated that finerenone reduced risk of kidney failure and CVD <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> outcomes (CVD death, non-fatal MI, non-fatal stroke, or hospitalisation for HF) in people with CKD and T2DM who <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> were on maximum doses of ACE inhibitors or ARBs.63 Finerenone has also been shown to further improve renal      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> function in people with CKD and T2DM already receiving SGLT2 inhibitors at baseline64 and cardio-renal outcomes <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> in people with CKD and T2DM irrespective of SGLT2 inhibitor use.65 A recent outcome study reported that in      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> people with HF and mildly reduced or preserved ejection fraction (41% of whom had T2DM), finerenone resulted in <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> a significantly lower rate of a composite of total worsening HF events and death from CVD compared with         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> placebo.66 Summary The emergence of newer therapies has resulted in a significant paradigm shift in the         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> management of cardio-renal risk through a structured, multi-pillar treatment approach to improve outcomes. In   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> addition to the traditional pillars of improving glycaemic control and interventions for established risk       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> factors, the cardio-renal benefits of SGLT2 inhibitors, GLP-1 receptor agonists, and non-steroidal              <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> mineralocorticoid receptor antagonists are supported by robust clinical trial evidence.67 These therapies have  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> expanded standard CKD treatment with renin-angiotensin system (RAS) blockers.68 Current guidelines15,26 include <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> decision algorithms which highlight established and new pillars for managing cardio-renal risk and enhance risk <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> reduction for people with T2DM with at least one of ASCVD, HF, CKD, or those at high risk for ASCVD.26,69       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> REFERENCES 1. Ibrahim M, Ba-Essa EM, Baker J, et al. Cardio-renal-metabolic disease in primary care setting.    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Diabetes Metab Res Rev. 2024;40(3):e3755. 2. Bello AK, Levin A, Tonelli M, et al. Assessment of global kidney   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> health care status. JAMA. 2017;317(18):1864-1881. 3. World Health Organization. Web Annex A. World Health       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Organization Model List of Essential Medicines â€“ 23rd List, 2023. In: The selection and use of essential        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> medicines 2023: Executive summary of the report of the 24th WHO Expert Committee on the Selection and Use of    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Essential Medicines, 24 - 28 April 2023.\\nGeneva: World Health Organization; 2023 (WHO/MHP/HPS/EML/2023.02). 4. <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Castro Conde A, Marzal MartÃ­n D, Campuzano Ruiz R, et al. Comprehensive cardiovascular and renal protection in  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> patients with type 2 diabetes. J Clin Med. 2023;12(12):3925. 5. Einarson TR, Acs A, Ludwig C, et al. Prevalence <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> of cardiovascular disease in type 2 diabetes: A systematic literature review of scientific evidence from across <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> the world in 2007-2017. Cardiovasc Diabetol. 2018;17(1):83. 6. Goderis G, Vaes B, Mamouris P, et al. Prevalence <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> of atherosclerotic cardiovascular disease, heart failure, and chronic kidney disease in patients with type 2    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> diabetes mellitus: A primary care research network-based study. Exp Clin Endocrinol Diabetes.                   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 2022;130(7):447-453. 7. Cohn PF, Fox KM, Daly C. Silent myocardial ischemia. Circulation.                       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 2003;108(10):1263-1277. 8. Davis TM, Coleman RL, Holman RR. Prognostic significance of silent myocardial        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> infarction in newly diagnosed type 2 diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS) 79.   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Circulation. 2013;127(9):980-987. 9. Dauriz M, Mantovani A, Bonapace S, et al. Prognostic impact of diabetes on <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> long-term survival outcomes in patients with heart failure: A meta-analysis. Diabetes Care.                     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 2017;40(11):1597-1605. 10. Osundolire S, Naqvi S, Nunes AP, et al. Heart failure among US nursing home          <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> residents with diabetes mellitus. Int J Cardiol. 2022;349:138-143. 11. Skolnik NS, Style AJ. Importance of      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> early screening and diagnosis of chronic kidney disease in patients with type 2 diabetes. Diabetes Ther.        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 2021;12(6):1613-1630. 12. Wu B, Bell K, Stanford A, et al. Understanding CKD among patients with T2DM:          <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Prevalence, temporal trends, and treatment patterns-NHANES 2007-2012. BMJ Open Diabetes Res Care.               <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 2016;4(1):e000154. 13. Al-Ozairi E, Jallo MK, Hafidh K, et al. Prevalence of cardiovascular and renal           <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> co-morbidities in patients with type 2 diabetes in the Gulf, a cross-sectional observational study. Diabetes    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Ther. 2021;12(4):1193-1207. 14. Zhang R, Mamza JB, Morris T, et al. Lifetime 97 Chapter 6 risk of               <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> cardiovascular-renal disease in type 2 diabetes: A population-based study in 473,399 individuals. BMC Med.      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 2022;20(1):63. 15. Marx N, Federici M, SchÃ¼tt K, et al. 2023 ESC Guidelines for the management of               <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> cardiovascular disease in patients with diabetes. Eur Heart J. 2023;44(39):4043-4140. 16. SeferoviÄ‡ P, Farmakis <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> D, Bayes-Genis A, et al. Biomarkers for the prediction of heart failure and cardiovascular events in patients   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> with type 2 diabetes: A position statement from the Heart Failure Association of the European Society of        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Cardiology. Eur J Heart Fail. 2022;24(7):1162-1170. 17. Mueller C, McDonald K, de Boer RA, et al. Heart Failure <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Association of the European Society of Cardiology practical guidance on the use of natriuretic peptide          <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> concentrations. Eur J Heart Fail. 2019;21(6):715-731. 18. Ceriello A, Catrinoiu D, Chandramouli C, et al. Heart <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> failure in type 2 diabetes: current perspectives on screening, diagnosis and management. Cardiovasc Diabetol.   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 2021;20(1):218. 19. Pop-Busui R, Januzzi JL, Bruemmer D, et al. Heart failure: An underappreciated complication <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> of diabetes. A consensus report of the American Diabetes Association. Diabetes Care. 2022;45(7):1670-1690. 20.  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Bayes-Genis A, Docherty KF, Petrie MC, et al. Practical algorithms for early diagnosis of heart failure and     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> heart stress using NT-proBNP: A clinical consensus statement from the Heart Failure Association of the ESC. Eur <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> J Heart Fail. 2023;25(11):1891-1898. 21. Packer M. Heart failure: The most important, preventable, and          <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> treatable cardiovascular complication of type 2 diabetes. Diabetes Care. 2018;41(1):11-13. 22. ElSayed NA,      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Aleppo G, Aroda VR, et al. 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes-2023.  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Diabetes Care. 2023;46(Suppl 1):S191-S202. 23. Stevens PE, Ahmed SB, Carrero JJ, et al. KDIGO 2024 Clinical     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Practice Guideline for the evaluation and management of chronic kidney disease. Kidney Int.                     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 2024;105(4):S117-S314. 24. Turnbull FM, Abraira C, Anderson RJ, et al. Intensive glucose control and            <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> macrovascular outcomes in type 2 diabetes. Diabetologia. 2009;52(11):2288-2298. 25. Zoungas S, Arima H,         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Gerstein HC, et al. Effects of intensive glucose control on microvascular outcomes in patients with type 2      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> diabetes: A meta-analysis of individual participant data from randomised controlled trials. Lancet Diabetes     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Endocrinol. 2017;5(6):431-437. 26. ElSayed NA, Aleppo G, Bannuru RR, et al. 10. Cardiovascular Disease and Risk <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Management: Standards of Care in Diabetes-2024. Diabetes Care. 2024;47(Suppl 1):S179-S218. 27. Bi Y, Li M, Liu  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Y, et al. Intensive blood-pressure control in patients with type 2 diabetes. N Engl J Med. 2024. [Epub ahead of <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> print]. DOI: 10.1056/NEJMoa2412006. 28. Prattichizzo F, Ceriello A. Positioning newer drugs in the management   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> of type 2 diabetes. Lancet Diabetes Endocrinol. 2021;9(3):138-139. 29. McGuire DK, Shih WJ, Cosentino F, et al. <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: A     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> meta-analysis. JAMA Cardiol. 2021;6(2):148-158. 30. Nuffield Department of Population Health Renal Studies      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Group; SGLT2 inhibitor Meta-Analysis Cardio-Renal Trialistsâ€™ Consortium. Impact of diabetes on the effects of   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> sodium glucose co-transporter-2 inhibitors on kidney outcomes: Collaborative meta-analysis of large             <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> placebo-controlled trials. Lancet. 2022;400(10365):1788-1801. 31. Bae JH, Park EG, Kim S, et al. Effects of     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> sodium-glucose cotransporter 2 inhibitors on renal outcomes in patients with type 2 diabetes: A systematic      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> review and meta-analysis of randomized controlled trials. Sci Rep. 2019;9(1):13009. 32. Herrington WG, Staplin  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> N, Wanner C, et al. Empagliflozin in patients with chronic kidney disease. N Engl J Med. 2023;388(2):117-127.   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 33. Staplin N, Roddick AJ, Emberson J, et al. Net effects of sodium-glucose co-transporter-2 inhibition in      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> different patient groups: A meta-analysis of large placebo-controlled randomized trials. EClinicalMedicine.     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 2021;41:101163. 34. Vaduganathan M, Docherty KF, Claggett BL, et al. SGLT-2 inhibitors in patients with heart   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> failure: A comprehensive meta-analysis of five randomised controlled trials. Lancet. 2022;400(10354):757-767.   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 35. Badve SV, Bilal A, Lee MMY, et al. Effects of GLP-1 receptor agonists on kidney and cardiovascular disease  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> outcomes: A meta-analysis of randomised controlled trials. Lancet Diabetes Endocrinol. 2024. [Epub ahead of IDF <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Global Clinical Practice Recommendations for Managing Type 2 Diabetes â€“ 2025 98 CARDIO-RENAL PROTECTION print]. <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> DOI: 10.1016/s2213-8587(24)00271-7. 36. Rivera FB, Cruz LLA, Magalong JV, et al. Cardiovascular and renal       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> outcomes of glucagon-like peptide 1 receptor agonists among patients with and without type 2 diabetes mellitus: <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> A meta-analysis of randomized placebo-controlled trials. Am J Prev Cardiol. 2024;18:100679. 37. Perkovic V,     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Tuttle KR, Rossing P, et al. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> N Engl J Med. 2024;391(2):109-121. 38. Kosiborod MN, Petrie MC, Borlaug BA, et al. Semaglutide in patients with <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> obesity-related heart failure and type 2 diabetes. N Engl J Med. 2024;390(15):1394-1407. 39. Marso SP, Bain SC, <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med.       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 2016;375(19):1834-1844. 40. A research study to look at how semaglutide compared to placebo affects diabetic    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> eye disease in people with type 2 diabetes (FOCUS). ClinicalTrials.gov Identifier: NCT03811561. Available from: <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> https:// clinicaltrials.gov/study/NCT03811561[Accessed September 2024]. 41. Ahmad A, Sabbour H. Effectiveness   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> and safety of the combination of sodium-glucose transport protein 2 inhibitors and glucagon-like peptide-1      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> receptor agonists in patients with type 2 diabetes mellitus: A systematic review and meta-analysis of           <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> observational studies. Cardiovasc Diabetol. 2024;23(1):99. 42. Mann JFE, Rossing P, Bakris G, et al. Effects of <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> kidney disease in the FLOW trial. Nat Med. 2024;30(10):2849-2856. 43. Nicholls SJ, Bhatt DL, Buse JB, et al.    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> diabetes and atherosclerotic cardiovascular disease: SURPASS-CVOT design and baseline characteristics. Am Heart <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> J. 2024;267:1-11. 44. Packer M, Zile MR, Kramer CM, et al. Tirzepatide for heart failure with preserved         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> ejection fraction and obesity. N Engl J Med. 2024. [Epub ahead of print]. DOI: 10.1056/ NEJMoa2410027. 45. UK   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on           <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet.1998;352(9131):854-865. 46. Adler  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> AI, Coleman RL, Leal J, et al. Post-trial monitoring of a randomised controlled trial of intensive glycaemic    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> control in type 2 diabetes extended from 10 years to 24 years (UKPDS 91). Lancet. 2024;404(10448):145-155. 47.  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Patel A, MacMahon S, Chalmers J, et al. Intensive blood glucose control and vascular outcomes in patients with  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> type 2 diabetes. N Engl J Med. 2008;358(24):2560-2572. 48. Zoungas S, Chalmers J, Neal B, et al. Follow-up of   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> blood-pressure lowering and glucose control in type 2 diabetes. N Engl J Med. 2014;371(15):1392-1406. 49.       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Rosenstock J, Kahn SE, Johansen OE, et al. Effect of linagliptin vs glimepiride on major adverse cardiovascular <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> outcomes in patients with type 2 diabetes: The CAROLINA randomized clinical trial. JAMA.                        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 2019;322(12):1155-1166. 50. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 2 diabetes (UKPDS 33). Lancet. 1998;352(9131):837-853. 51. Holman RR, Coleman RL, Chan JCN, et al. Effects of   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> tolerance (ACE): A randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol.              <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 2017;5(11):877-886. 52. Home PD, Pocock SJ, Beck-Nielsen H, et al. Rosiglitazone evaluated for cardiovascular   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> outcomes in oral agent combination therapy for type 2 diabetes (RECORD): A multicentre, randomised, open-label  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> trial. Lancet. 2009;373(9681):2125-2135. 53. Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> of macrovascular events in patients with type 2 diabetes in the PROactive study (PROspective pioglitAzone       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Clinical Trial In macroVascular Events): A randomised controlled trial. Lancet. 2005;366(9493):1279-1289. 54.   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> diabetes mellitus. N Engl J Med. 2013;369(14):1317-1326. 55. White WB, Cannon CP, Heller SR, et al. Alogliptin  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> after acute coronary syndrome in 99 Chapter 6 patients with type 2 diabetes. N Engl J Med.                      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 2013;369(14):1327-1335. 56. Green JB, Bethel MA, Armstrong PW, et al. Effect of sitagliptin on cardiovascular   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> outcomes in type 2 diabetes. N Engl J Med. 2015;373(3):232-242. 57. Rosenstock J, Perkovic V, Johansen OE, et   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> al. Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> cardiovascular and renal risk: The CARMELINA randomized clinical trial. JAMA. 2019;321(1):69-79. 58. Scirica    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> BM, Braunwald E, Raz I, et al. Heart failure, saxagliptin, and diabetes mellitus: Observations from the         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> SAVOR-TIMI 53 randomized trial. Circulation. 2014;130(18):1579-1588. 59. Gerstein HC, Bosch J, Dagenais GR, et  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> al. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med. 2012;367(4):319-328. 60.  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Pratley RE, Husain M, Lingvay I, et al. Heart failure with insulin degludec versus glargine U100 in patients    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> with type 2 diabetes at high risk of cardiovascular disease: DEVOTE 14. Cardiovasc Diabetol. 2019;18(1):156.    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 61. Bakris GL, Agarwal R, Anker SD, et al. Effect of finerenone on chronic kidney disease outcomes in type 2    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> diabetes. N Engl J Med. 2020;383(23):2219-2229. 62. Pitt B, Filippatos G, Agarwal R, et al. Cardiovascular      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> events with finerenone in kidney disease and type 2 diabetes. N Engl J Med. 2021;385(24):2252-2263. 63. Agarwal <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> R, Filippatos G, Pitt B, et al. Cardiovascular and kidney outcomes with finerenone in patients with type 2      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> diabetes and chronic kidney disease: The FIDELITY pooled analysis. Eur Heart J. 2022;43(6):474-484. 64. Rossing <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> P, Filippatos G, Agarwal R, et al. Finerenone in predominantly advanced CKD and type 2 diabetes with or without <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> sodium-glucose cotransporter-2 inhibitor therapy. Kidney Int Rep. 2022;7(1):36-45. 65. Rossing P, Anker SD,     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Filippatos G, et al. Finerenone in patients with chronic kidney disease and type 2 diabetes by sodium-glucose   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> cotransporter 2 inhibitor treatment: The FIDELITY analysis. Diabetes Care. 2022;45(12):2991-2998. 66. Solomon   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> SD, McMurray JJV, Vaduganathan M, et al. Finerenone in heart failure with mildly reduced or preserved ejection  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> fraction. N Engl J Med. 2024;391(16):1475-1485. 67. Naaman SC, Bakris GL. Diabetic nephropathy: Update on       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> pillars of therapy slowing progression. Diabetes Care. 2023;46(9):1574-1586. 68. Blazek O, Bakris GL. The       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> evolution of â€œpillars of therapyâ€ to reduce heart failure risk and slow diabetic kidney disease progression. Am <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Heart J Plus. 2022;19:100187. 69. Bae J, Liu D, Chinthammit C, et al. Type 2 diabetes pharmacotherapy trends in <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> high-risk subgroups. Diabetes Obes Metab. 2022;24(6):1166-1171.\\n100 Management of Metabolic                    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Dysfunction-Associated Steatotic Liver Disease (MASLD) in Type 2 Diabetes Chapter 7 MANAGEMENT OF MASLD 101     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Chapter 7 RECOMMENDATIONS Optimal Care Basic Care Screening and risk assessment â€¢\\tSuspect MASLD in all people  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> with T2DM, especially if overweight or obese; LFTs are abnormal â€¢\\tScreen for MASLD-related fibrosis - FIB-4    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> score - Imaging if FIB-4 result elevated - VCTE - MRE â€¢\\tSuspect MASLD in all people with T2DM, especially if   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> overweight or obese; LFTs are abnormal â€¢\\tScreen for MASLD-related fibrosis - FIB-4 score - Imaging if FIB-4    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> result elevated (if available) Management of people with T2DM and at-risk MASLD â€¢\\tImplement Pillars of         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Diabetes Care (Chapter 6) â€¢\\tAt-risk MASLD determined by FIB-4 and imaging â€¢\\tPromote healthy lifestyle change  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> and at least 5% weight loss if overweight or obese â€¢\\tSpecific MASLD therapy - Resmetirom (where approved) -    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> GLP-1RAs (including semaglutide, liraglutide, and tirzepatide) â€¢\\tConsider metabolic bariatric surgery          <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> â€¢\\tImplement Pillars of Diabetes Care (Chapter 6) â€¢\\tAt-risk MASLD determined by FIB-4 alone or with imaging if <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> available â€¢\\tPromote healthy lifestyle change and at least 5% weight loss if overweight or obese â€¢\\tSpecific    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> MASLD therapy - Pioglitazone (if available and not contraindicated) - SGLT2i for weight loss and cardio-renal   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> protection Note: These recommendations also apply to people with intermediate hyperglycaemia.\\nFIB-4,           <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> fibrosis-4 index; GLP-1RA, glucagon-like peptide-1 receptor agonist; LFT, liver function test(s); MASLD,        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> metabolic dysfunction-associated steatotic liver disease; MRE, magnetic resonance elastography; SGLT2i,         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> sodium-glucose cotransporter-2 inhibitor; T2DM, type 2 diabetes mellitus; VCTE, vibration-controlled transient  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> elastography.\\nIDF Global Clinical Practice Recommendations for Managing Type 2 Diabetes â€“ 2025 102 MANAGEMENT  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> OF MASLD o Metabolic dysfunction-associated steatotic liver disease (MASLD), previously termed non-alcoholic    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> fatty liver disease (NAFLD), is steatotic liver disease without harmful alcohol intake. o MASLD is the most     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> common chronic liver disease and is closely linked with type 2 diabetes mellitus (T2DM), intermediate           <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> hyperglycaemia, and obesity. o MASLD increases risk of adverse liver and cardio-renal outcomes. o All people    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> with T2DM are at-risk of MASLD. The main objective is to identify and manage those with â€œat-risk MASLDâ€ to      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> prevent progression to cirrhosis and its complications. o Identifying and managing MASLD in resource-poor       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> settings is challenging due to the limited availability of required blood and imaging tests, access to          <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> preferred glucose-lowering medications, and the scarcity of specialised services. o The global prevalence of    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> MASLD in people with T2DM is 65% and metabolic dysfunction-associated steatohepatitis (MASH) is 32%. Thirty-six <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> per cent of people have fibrosis and 15% advanced fibrosis. MASLD is common in obesity. o Individuals with T2DM <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> and suspected MASLD should be assessed for risk of developing advanced liver disease with a blood-based risk    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> score (Fibrosis-4 index [FIB-4]) and followed up with vibration-controlled transient elastography (VCTE) or     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> magnetic resonance elastography (MRE) imaging to detect fibrosis, if available. o Liver biopsy is not required  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> for managing most people with MASLD. o MASLD-specific interventions include lifestyle modification and weight   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> loss (â‰¥5%â€“10%). o Resmetirom is the only approved (in the USA) MASH-targeted therapy. It is an oral,            <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> liver-directed, thyroid hormone beta-1 receptor agonist and is indicated for non-cirrhotic MASH and             <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> moderate-to-advanced liver fibrosis. o No blood glucose-lowering (BGL) medication for T2DM has an indication as <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> a MASLD-targeted therapy. o Some glucagon-like peptide-1 (GLP-1) receptor agonists (semaglutide, liraglutide,   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> tirzepatide) and pioglitazone improve histological features of MASH. Semaglutide has recently been demonstrated <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> to improve liver fibrosis. o Pioglitazone is not available in many countries and its side effect profile should <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> be considered in deciding whether or not to prescribe it. o Sodium-glucose cotransporter-2 (SGLT2) inhibitors   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> improve liver steatosis without affecting liver fibrosis linked to weight loss. o Insulin is the preferred      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> treatment of hyperglycaemia in T2DM with decompensated cirrhosis. o Statin therapy is safe in T2DM and MASLD,   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> including compensated cirrhosis. o Metabolic bariatric surgery is an option to treat MASLD/MASH in those with   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> severe obesity and has been associated with resolution of MASLD and MASH but not advanced fibrosis.\\nKEY POINTS <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 103 Chapter 7 BACKGROUND Metabolic dysfunction-associated steatotic liver disease (MASLD), previously termed    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> non-alcoholic fatty liver disease (NAFLD), is defined as steatotic liver disease (SLD) in the presence of one   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> or more cardiometabolic risk factors (including type 2 diabetes mellitus [T2DM] and intermediate                <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> hyperglycaemia) and the absence of harmful alcohol intake. The change in nomenclature from â€œnon-alcoholicâ€ to   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> â€œmetabolic dysfunctionâ€ reflects an evolving understanding of these conditions and their metabolic links.1      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> MASLD is the most common chronic liver disease and is closely linked with T2DM, intermediate hyperglycaemia,    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> and obesity. In addition to adverse liver outcomes, MASLD is associated with an increased risk of adverse       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> cardio-renal outcomes. Other forms of SLD include alcohol-related liver disease (ALD) (alcohol intake &gt;50 g/day <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> for females and &gt;60 g/day for males) and MASLD with moderate increased alcohol intake (MetALD) (alcohol intake  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 20â€“50 g/day for females and 30â€“60 g/day for males).1 have a high index of suspicion for MASLD in all people     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> with T2DM and to specifically identify and intervene in those with â€œat-risk MASLDâ€ to prevent progression to    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> cirrhosis and its complications. GLOBAL CONSIDERATIONS MASLD is an important, common, and increasingly          <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> recognised serious comorbidity in people with T2DM and intermediate hyperglycaemia. Identifying and managing    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> MASLD in resource-poor settings present several challenges. The blood and imaging tests required for screening  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> for at-risk individuals with MASLD may not be available. Preferred glucose-lowering medications for managing    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> people with MASLD may not be available, accessible, and affordable. The only MASLD-targeted treatment is only   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> currently approved in the United States. Specialised services are scarce. Despite these limitations, much can   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> still be done through primary care and diabetes services in resource-limited settings to improve the management <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> and outcomes for people with T2DM and MASLD. EVIDENCE SUMMARY The prevalence of MASLD, MASH, and fibrosis in    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> T2DM An estimated 30% of the global general population has MASLD with regional differences ranging from 25% in  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Western Europe to 44% in Latin America.2 The global prevalence of MASLD in people with T2DM is 56%, two-fold    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> higher than in the general population, with studies from Europe reporting the highest prevalence at 68%. The    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> reported prevalence of MASH is 37%, and 17% who had a liver biopsy had advanced fibrosis. Individuals with T2DM <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> not only have a greater prevalence of MASLD but also an increased risk of developing MASH and advanced fibrosis <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> compared with the general population.2 A more recent analysis of nearly two million individuals with T2DM       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> reported prevalence rates of MASLD of 65% and MASH of 32%, with 36% of those with MASLD having fibrosis (stage  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> F2â€“ F4) and 15% advanced fibrosis (stage F3â€“F4).3 However, it should be noted that many of the included studies <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> were from clinics and hospital settings and were not random samples. The spectrum of MASLD includes: o          <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Metabolic dysfunction-associated steatotic (fatty) liver (MASL) o Metabolic dysfunction-associated              <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> steatohepatitis (MASH) o Fibrosis o Cirrhosis o MASH-related hepatocellular carcinoma (HCC) The intricate       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> association between MASLD/MASH in individuals with T2DM and intermediate hyperglycaemia and adverse liver and   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> systematic impacts emphasises the need for proactive intervention and tailored personalised management          <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> strategies. A definitive diagnosis of hepatic steatosis requires either imaging or histology and is not         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> practical or necessary in a routine clinical setting. Adverse outcomes of MASLD relate to MASH and fibrosis.    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Consequently, the objective is to IDF Global Clinical Practice Recommendations for Managing Type 2 Diabetes â€“   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 2025 104 MANAGEMENT OF MASLD In a study involving 360 people with T2DM who underwent liver biopsies when        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> alanine aminotransferase (ALT) levels were persistently &gt;20 IU/L in females or &gt;30 IU/L in males in the absence <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> of other liver disease, the prevalence of MASH, advanced fibrosis, and cirrhosis was 58%, 38%, and 10%,         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> respectively.4 Of note and relevance to diabetes, in overweight populations the prevalence of MASLD was 70%,    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> MASL 42%, MASH 34%, fibrosis stages 2â€“4 20%, and 7% had advanced fibrosis stages 3â€“4. Prevalences were similar  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> in the obese population.5 Fibrosis progression is subject to a myriad of influences, including comorbidities,   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> genetic factors, and environmental conditions. The increased risk of major adverse liver outcomes is linked to  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> the particular manifestation of MASLD. A Swedish registry-based cohort study of 230,992 people with T2DM        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> without a history of liver disease reported a low incidence of adverse outcomes, with 3,215 (1.4%) developing   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> major adverse liver outcomes over 10 years.6 In a national matched prospective cohort study of 10,568           <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> individuals with biopsy-confirmed MASLD with a median follow-up of 14.2 years, 4,338 with MASLD died. Compared  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> with controls, individuals with MASLD had significantly increased overall mortality (16.9 versus 28.6/1000      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> person-years). Significant excess mortality risk was 8.3/1000 person-years for simple steatosis, 13.4/1000      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> person-years for non-fibrotic MASH, 18.4/1000 person-years for non-cirrhotic fibrosis, and 53.6/1000            <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> person-years for cirrhosis.7 T2DM is associated with poorer outcomes in individuals with biopsy-proven MASH and <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> compensated cirrhosis, including an increased risk of death and HCC. Compared with metabolically healthy        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> individuals, people with T2DM had the highest risk of having MASLD (odds ratio [OR] = 10.88) followed by        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> intermediate hyperglycaemia (OR = 4.19). During a median follow-up of 26.7 years, people with MASLD had         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> significantly higher age-adjusted mortality than non-MASLD (32.7% versus 28.7%) with the highest                <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> age-standardised cumulative mortality in those with T2DM (41.3%), followed by intermediate hyperglycaemia       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> (35.1%), compared with metabolically healthy individuals (21.9%).8 While the natural history of MASLD is        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> relatively well-defined, there is substantial individual variability in disease trajectories. The risk of       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> future liver-related events starts to increase at the fibrosis stage. However, it takes decades for MASLD to    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> progress to cirrhosis and hepatic decompensation.1 Screening and diagnosis of MASLD at-risk of advanced liver   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> disease in people with T2DM The association between MASLD stage and adverse outcomes underlines the need for    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> nuanced clinical approaches.1 The primary goal in the management of MASLD in people with T2DM is to identify    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> individuals at-risk of MASLD-related fibrosis, particularly those with abdominal obesity and additional         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> metabolic risk factors or abnormal liver function tests. This has become an important aspect of comprehensive   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> care for T2DM but remains challenging in resource-limited health systems. Screening and diagnosis of            <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> individuals with MASLD who are at-risk of developing advanced liver disease usually involves a two-step         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> approach of an initial blood-based score followed by imaging. Blood-based score The Fibrosis-4 index (FIB-4) is <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> the most widely used available tool. It uses a combination of blood test values and anthropometric information  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> to screen for risk of liver fibrosis. FIB-4 is calculated as age x aspartate transaminase (AST)/(platelet count <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> x âˆš ALT) (age in years, ALT and AST in U/L, and platelet count in 109/L).9 A FIB-4 score &lt;1.3 identifies        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> individuals who are not likely to have advanced fibrosis and who require ongoing periodic re-evaluation (one to <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> three years) while a FIB-4 value &gt;2.67 is associated with high-risk and ideally should be referred to a         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> hepatologist.10 The ability of FIB-4 to detect fibrosis is limited in the intermediate score range (1.30â€“2.67). <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> A lower cut-off value of 2.0 is recommended in people aged over 65 years and the test does not perform well in  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> individuals younger than 35 years, and also less well in people with diabetes.11 Automated FIB-4 score          <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> calculation followed by reminder messages in the electronic health system has been shown to increase referral   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> of individuals with increased fibrosis scores to hepatologists from 3% to 33%.12 Persistently or intermittently <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> elevated ALT levels &gt;30 U/L may indicate chronic liver injury, whereas AST levels lack sensitivity and          <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> specificity in identifying MASLD with advanced fibrosis. 105 Chapter 7 Imaging Individuals assessed as moderate <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> or high-risk of advanced disease on FIB-4 should undergo further assessment with imaging. Vibration-controlled  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> transient elastography (VCTE) is commonly used to estimate liver stiffness measurement (LSM) as an assessment   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> of degree of fibrosis and controlled attenuation parameter (CAP) as an assessment of steatosis.13 Other         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> ultrasound-based methods like acoustic radio force impulse (if available) may be preferred due to cost          <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> considerations. Some ultrasound techniques may not be reliably used to examine adults with class 2 obesity.1    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Magnetic resonance elastography (MRE) can also be used to assess liver stiffness and is more sensitive than     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> VCTE in detecting fibrosis stage â‰¥2 but requires specialised equipment to generate mechanical waves and         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> dedicated acquisition techniques, which are only available at a few sites.10 Tests of specific collagen-related <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> blood constituents (e.g., the Enhanced Liver Fibrosis test, ELF) may be an alternative to imaging to identify   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> advanced liver fibrosis in the future.1 Liver biopsy is not required for clinical management in most cases of   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> people with MASLD. Management The evolving landscape of MASLD management in T2DM requires personalised          <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> approaches based on the Key Pillars of Diabetes Management (See Chapter 6) and considering MASH-targeted        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> therapy if available, accessible, and affordable. MASLD-specific interventions Lifestyle modification and       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> weight loss Overweight and obese MASLD people with T2DM and intermediate hyperglycaemia should be recommended   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> dietary and physical activity lifestyle changes that promote weight loss to reduce liver steatosis and improve  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> cardiometabolic profile, while discouraging alcohol consumption.1 The degree of weight loss has a significant   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> impact on different MASLD manifestations. Sustained diet-induced weight loss of â‰¥5% reduces liver fat, 7%â€“10%   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> weight loss improves liver inflammation, and â‰¥10% weight loss improves fibrosis.1, 14 For example, weight loss  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> of at least 7% by lifestyle modification with a Mediterranean diet was associated with MASH resolution after 52 <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> weeks, and weight loss of more than 10% with improvement in liver fibrosis. However, histological changes with  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> lifestyle intervention are achieved in less than 20% of people.15 Pharmacotherapy 1. MASH-targeted therapy â€“    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> resmetirom Resmetirom is the first specific medication for the treatment of MASLD and received accelerated FDA  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> approval in March 2024. It is an orally active, liver-directed, thyroid hormone beta-1 receptor agonist and is  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> indicated for adults with non-cirrhotic MASH and moderate-to-advanced liver fibrosis in conjunction with diet   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> and exercise. In a phase 3 randomised controlled trial (RCT), resmetirom 80 mg resulted in resolution of MASH   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> without worsening of fibrosis in 25.9% of individuals compared with 9.7% in the placebo group, and fibrosis     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> improvement by at least one stage with no worsening of MASLD activity score in 24.2% compared with 14.2% in the <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> placebo group. Low-density lipoprotein concentrations were also significantly decreased.16 The usual daily dose <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> is 80 mg in individuals with a body weight &lt;100 kg and 100 mg with body weight â‰¥100 kg. Dose reduction should   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> be considered with moderate CYP2C8 inhibitors such as clopidogrel. Resmetirom is generally well-tolerated with  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> the most common side effects being gastrointestinal (diarrhoea, nausea, and vomiting) and pruritus.1, 14        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> However, it is not widely available. There is currently no effective MASH-targeted pharmacotherapy available    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> for people with MASH and cirrhosis. 2. Blood glucose-lowering medications Blood glucose-lowering (BGL)          <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> medications for T2DM have been reviewed in Chapters 3 and 4. BGL medications may impact MASLD directly or       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> through improved glycaemic control and/or weight loss. No currently available BGL or weight management          <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> medication is approved as a MASLD-targeted therapy. The following is a brief review of the specific effects of  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> BGL medications on MASLD. IDF Global Clinical Practice Recommendations for Managing Type 2 Diabetes â€“ 2025 106  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> MANAGEMENT OF MASLD Metformin Metformin has not been shown to improve steatohepatitis in paired-biopsy studies. <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> However, it is safe and should be continued in individuals with cirrhosis unless discontinuation is required    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> due to hepatic decompensation or renal failure. Sulfonylureas There are no RCTs with liver histological         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> endpoints which have examined the effects of sulfonylureas as a MASLD-targeted therapy. There is an increased   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> risk of hypoglycaemia in cirrhotic liver disease. Insulin Insulin reduces hepatic steatosis but its effect on   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> steatohepatitis remains unknown.17 Insulin treatment for uncontrolled T2DM in the presence of MASLD can         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> decrease liver steatosis by addressing lipotoxicity and glucotoxicity. However, it may potentially increase     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> hepatic triacylglycerol content and contribute to hepatic fat accumulation.18 Insulin is the preferred          <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> treatment of hyperglycaemia in adults with T2DM with decompensated cirrhosis. Thiazolidinediones (pioglitazone) <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Pioglitazone has been demonstrated in several phase 2 RCTs to improve histological features of MASH but has no  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> clear effect on fibrosis regression.19-21 However, there has not been a large phase 3 multicentre trial with    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> pioglitazone which has further assessed these findings. Pioglitazone is not available in many countries and its <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> side effect profile should be considered in deciding whether or not to prescribe it. SGLT2 inhibitors           <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Short-term SGLT2 inhibitor RCTs have shown reversal of liver steatosis and a reduction in plasma                <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> aminotransferase levels but no improvement in markers of liver fibrosis.22, 23 These changes seem to be         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> primarily linked to weight loss rather than specific targeted MASLD effects. SGLT2 inhibitors are safe in       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> people with T2DM and MASLD and have other well-documented cardio-renal benefits. GLP-1 receptor agonists Single <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> GLP-1 receptor agonists (liraglutide and semaglutide),18 dual GLP-1 receptor agonists (tirzepatide24, 25 and    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> survodutide26), and triple GLP-1 receptor agonists (retatrutide)27 have shown positive effects not only on      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> weight loss and hyperglycaemia but also on the reduction of liver steatosis, with some showing benefits on      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> histological parameters in people with biopsy-proven non-cirrhotic MASH.25, 27 Recently, the positive results   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> of the ESSENCE study were released. The ESSENCE study is a phase 3 RCT evaluating the effect of subcutaneous    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> semaglutide 2.4 mg in people with biopsy-proven MASH and fibrosis stage 2 or 3, which included 56% of           <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> participants with T2DM.28 After 72 weeks in the first 800 individuals (56% T2DM), endpoints were significantly  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> better with semaglutide compared with placebo. Primary endpoints showed 62.9% of people treated with            <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> semaglutide 2.4 mg achieved resolution of steatohepatitis with no worsening of liver fibrosis compared to 34.1% <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> taking placebo, and 37.0% treated with semaglutide achieved improvements in liver fibrosis with no worsening of <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> steatohepatitis compared to 22.5% taking placebo. Secondary endpoints showed 32.8% of participants treated with <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> semaglutide achieved both resolution of steatohepatitis and improvements in liver fibrosis (compared to 16.2%   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> taking placebo).29 This is the first phase 3 GLP-1 receptor agonist-related study to show significant           <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> definitive improvement in liver fibrosis in MASLD. GLP-1 receptor agonists have not been shown to be beneficial <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> in cirrhosis, with a placebo-controlled RCT in adults with biopsy-confirmed MASH-related compensated cirrhosis  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> and body mass index â‰¥27 kg/mÂ² failing to show an improvement with semaglutide 2.4 mg weekly in fibrosis or      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> achievement of MASH resolution, but there were no safety concerns.30 Cohort studies have reported that GLP-1    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> receptor agonist use in people with T2DM are associated with lower risk of progression to cirrhosis and lower   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> mortality compared with using DPP4 inhibitors but the protective association was not seen in people with        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> existing cirrhosis.31 Another cohort study which matched people with T2DM with and without cirrhosis reported   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> that GLP-1 receptor agonist use was associated with lower risk of death and major liver outcomes.32 Overall,    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> given the established cardio-renal benefits of SGLT2 inhibitors and GLP-1 receptor agonists and the weight      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> reduction effects, especially of GLP-1 receptor agonists, these agents are preferred in people with T2DM and    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> MASLD, if available, accessible, and affordable, and taking into account each individualâ€™s characteristics and  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> comorbidities. 107 Chapter 7 3. Statins Statin therapy is safe in adults with T2DM and MASLD, including in      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> those with compensated cirrhosis. Statins should be initiated or continued for cardiovascular risk reduction as <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> clinically indicated. Recent data have reported that regular use of statins was associated with a 15% lower     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> hazard ratio of new-onset liver disease and a 28% lower hazard ratio for liver-related deaths (cirrhosis and    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> HCC) compared with no statin use.33 Data on statin safety and efficacy in individuals with decompensated        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> cirrhosis are limited and therefore statin therapy should be used with caution and closely monitored. 4.        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Metabolic bariatric surgery Metabolic bariatric surgery (MBS) is an option to treat MASLD/MASH in those with    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> severe obesity given the positive effect on T2DM and cardiovascular disease and has been associated with        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> resolution of MASLD and MASH.34, 35 However, advanced fibrosis can persist for many years and is associated     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> with lesser weight loss and metabolic improvement.36 In adults with T2DM and compensated cirrhosis from MASLD,  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> MBS should be used with caution and is currently not recommended in decompensated cirrhosis. REFERENCES 1.      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> European Association for the Study of the Liver, European Association for the Study of Diabetes, European       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Association for the Study of Obesity. EASL-EASD-EASO Clinical Practice Guidelines on the management of          <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> metabolic dysfunction-associated steatotic liver disease (MASLD). J Hepatol. 2024;81(3):492-542. 2. Younossi    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> ZM, Golabi P, Paik JM, et al. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and           <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology. 2023;77(4):1335-1347. 3. En Li Cho E, Ang <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> CZ, Quek J, et al. Global prevalence of non-alcoholic fatty liver disease in type 2 diabetes mellitus: an       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> updated systematic review and meta-analysis. Gut. 2023;72(11):2138-2148. 4. Castera L, Laouenan C,              <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Vallet-Pichard A, et al. High prevalence of NASH and advanced fibrosis in type 2 diabetes: A prospective study  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> of 330 outpatients undergoing liver biopsies for elevated ALT, using a low threshold. Diabetes Care.            <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 2023;46(7):1354-1362. 5. Quek J, Chan KE, Wong ZY, et al. Global prevalence of non-alcoholic fatty liver        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> disease and non-alcoholic steatohepatitis in the overweight and obese population: a systematic review and       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> meta-analysis. Lancet Gastroenterol Hepatol. 2023;8(1):20-30. 6. Shang Y, Grip ET, Modica A, et al. Metabolic   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> syndrome traits increase the risk of major adverse liver outcomes in type 2 diabetes. Diabetes Care.            <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 2024;47(6):978-985. 7. Simon TG, Roelstraete B, Khalili H, et al. Mortality in biopsy-confirmed nonalcoholic    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> fatty liver disease: results from a nationwide cohort. Gut. 2021;70(7):1375-1382. 8. Golabi P, Paik JM, Kumar   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> A, et al. Nonalcoholic fatty liver disease (NAFLD) and associated mortality in individuals with type 2          <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> diabetes, pre-diabetes, metabolically unhealthy, and metabolically healthy individuals in the United States.    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Metabolism. 2023;146:155642. 9. Vallet-Pichard A, Mallet V, Nalpas B, et al. FIB-4: An inexpensive and accurate <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest. Hepatology. 2007;46(1):32-36.  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 10. Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, et al. AASLD Practice Guidance on the clinical assessment   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> and management of nonalcoholic fatty liver disease. Hepatology. 2023;77(5):1797-1835. 11. European Association  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> for the Study of the L. EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> severity and prognosis - 2021 update. J Hepatol. 2021;75(3):659-689. 12. Zhang X, Yip TC, Wong GL, et al.       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Clinical care pathway to detect advanced liver disease in patients with type 2 diabetes through automated       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> fibrosis score calculation and electronic reminder messages: A randomised controlled trial. Gut.                <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 2023;72(12):2364-2371. 13. Mikolasevic I, Orlic L, Franjic N, et al. Transient elastography (FibroScan(Â®)) with <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> controlled attenuation parameter in the assessment of liver steatosis and fibrosis in patients with             <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> nonalcoholic fatty liver disease - Where do we stand? World J Gastroenterol. 2016;22(32):7236-7251. 14.         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Koutoukidis DA, Koshiaris C, Henry JA, et al. The effect of the magnitude of weight loss on non-alcoholic fatty <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> liver disease: A systematic review and meta-analysis. Metabolism. 2021;115:154455. IDF Global Clinical Practice <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Recommendations for Managing Type 2 Diabetes â€“ 2025 108 MANAGEMENT OF MASLD 15. Vilar-Gomez E, Martinez-Perez   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Y, Calzadilla-Bertot L, et al. Weight loss through lifestyle modification significantly reduces features of     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> nonalcoholic steatohepatitis. Gastroenterology. 2015;149(2):367-378 e365; quiz e314-365. 16. Harrison SA,       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Bedossa P, Guy CD, et al. A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis. N  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Engl J Med. 2024;390(6):497-509. 17. Budd J, Cusi K. Role of agents for the treatment of diabetes in the        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> management of nonalcoholic fatty liver disease. Curr Diab Rep. 2020;20(11):59. 18. Gastaldelli A, Stefan N,     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Haring HU. Liver-targeting drugs and their effect on blood glucose and hepatic lipids. Diabetologia.            <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 2021;64(7):1461-1479. 19. Cusi K, Orsak B, Bril F, et al. Long-term pioglitazone treatment for patients with    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: A randomized trial. Ann Intern Med.   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 2016;165(5):305-315. 20. Aithal GP, Thomas JA, Kaye PV, et al. Randomized, placebo-controlled trial of          <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. Gastroenterology.                       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 2008;135(4):1176-1184. 21. Sanyal AJ, Chalasani N, Kowdley KV, et al. Pioglitazone, vitamin E, or placebo for   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> nonalcoholic steatohepatitis. N Engl J Med. 2010;362(18):1675-1685. 22. Abdelgani S, Khattab A, Adams J, et al. <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Empagliflozin reduces liver fat in individuals with and without diabetes. Diabetes Care. 2024;47(4):668-675.    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 23. Kahl S, Gancheva S, Strassburger K, et al. Empagliflozin effectively lowers liver fat content in            <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> well-controlled type 2 diabetes: A randomized, double-blind, phase 4, placebo-controlled trial. Diabetes Care.  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 2020;43(2):298-305. 24. Gastaldelli A, Cusi K, Fernandez Lando L, et al. Effect of tirzepatide versus insulin   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): A    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial. Lancet Diabetes Endocrinol.    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 2022;10(6):393-406. 25. Loomba R, Hartman ML, Lawitz EJ, et al. Tirzepatide for metabolic                       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> dysfunction-associated steatohepatitis with liver fibrosis. N Engl J Med. 2024;391(4):299-310. 26. Sanyal AJ,   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Bedossa P, Fraessdorf M, et al. A phase 2 randomized trial of survodutide in MASH and fibrosis. N Engl J Med.   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 2024;391(4):311-319. 27. Sanyal AJ, Kaplan LM, Frias JP, et al. Triple hormone receptor agonist retatrutide for <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> metabolic dysfunction-associated steatotic liver disease: A randomized phase 2a trial. Nat Med.                 <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 2024;30(7):2037-2048. 28. Newsome PN, Sanyal AJ, Engebretsen KA, et al. Semaglutide 2.4 mg in participants with <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> metabolic dysfunction-associated steatohepatitis: Baseline characteristics and design of the phase 3 ESSENCE    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> trial. Aliment Pharmacol Ther. 2024;60(11-12):1525-1533. 29. Newsome PN, Sanyal AJ, Kliers I. Phase 3 ESSENCE   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> trial: Semaglutide in metabolic dysfunction-associated steatohepatitis. Gastroenterol Hepatol (N Y). 2024;20(12 <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Suppl 11):6-7. 30. Loomba R, Abdelmalek MF, Armstrong MJ, et al. Semaglutide 2.4 mg once weekly in patients     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> with non-alcoholic steatohepatitis-related cirrhosis: A randomised, placebo-controlled phase 2 trial. Lancet    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Gastroenterol Hepatol. 2023;8(6):511-522. 31. Kanwal F, Kramer JR, Li L, et al. GLP-1 receptor agonists and     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> risk for cirrhosis and related complications in patients with metabolic dysfunction-associated steatotic liver  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> disease. JAMA Intern Med. 2024;184(11):1314-1323. 32. Yen FS, Hou MC, Cheng-Chung Wei J, et al. Glucagon-like   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> peptide-1 receptor agonist use in patients with liver cirrhosis and type 2 diabetes. Clin Gastroenterol         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Hepatol. 2024;22(6):1255-1264 e1218. 33. Vell MS, Loomba R, Krishnan A, et al. Association of statin use with   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> risk of liver disease, hepatocellular carcinoma, and liver-related mortality. JAMA Netw Open.                   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 2023;6(6):e2320222. 34. Verrastro O, Panunzi S, Castagneto-Gissey L, et al. Bariatric-metabolic surgery versus  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> lifestyle intervention plus best medical care in non-alcoholic steatohepatitis (BRAVES): A multicentre,         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> open-label, randomised trial. Lancet. 2023;401(10390):1786-1797. 35. Lee Y, Doumouras AG, Yu J, et al. Complete <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> resolution of nonalcoholic fatty liver disease after bariatric surgery: A systematic review and meta-analysis.  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Clin Gastroenterol Hepatol. 2019;17(6):1040-1060 e1011. 36. Pais R, Aron-Wisnewsky J, Bedossa P, et al.         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Persistence of severe liver fibrosis despite substantial weight loss with bariatric surgery. Hepatology.        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 2022;76(2):456-468.\\n109 Chapter 7 International Diabetes Federation Avenue Herrmann-Debroux 54 B-1160          <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Brussels, Belgium info@idf.org idf.org\\n\\n##Source\\nhttps://idf.org/media/uploads/2025/04/IDF_Rec_2025.pdf\",    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> \"## Title\\nThe American Diabetes Association Releases Standards of Care in ...\\n\\n## Content\\n![ADA             <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Logo](https://diabetes.org/sites/default/files/ADA85_logo_full_RGB_0.svg)\\n![prediabetes medical                <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> chart](/sites/default/files/2023-08/prediabetes-icon.svg)\\n\\nLearn your risk for type 2 and take steps to       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> prevent it\\n\\n![Diabetes Prevention](/sites/default/files/2023-08/diabetes-prevention-icon.svg)\\n\\nLearn the    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> ins and outs of diabetes and steps for better care\\n\\n![weight                                                  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> scale](/sites/default/files/2024-07/ADA_Icon_Library_scale-full.svg)\\n\\nObesity care is as unique as you are.   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Discover the different treatment and prevention                                                                 <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> options.\\n\\n![Education](/sites/default/files/2023-09/Education.svg)\\n\\nLearn what you can do to keep your      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> child with diabetes safe at school\\n\\n![Gestational](/sites/default/files/2023-09/Gestational.svg)\\n\\nWhat you  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> need to know about gestational diabetes\\n\\n![Diabetes                                                           <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Prevention](/sites/default/files/2023-08/diabetes-prevention-icon.svg)\\n\\nMake a plan to be prepared when       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> illness                                                                                                         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> strikes\\n\\n![Calculator](/sites/default/files/2023-09/Calculator.svg)\\n![Paper](/sites/default/files/2023-09/Pa <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> per.svg)\\n\\nSign up to receive timely information on topics to help you and your family live a healthy          <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> life\\n\\n![Better Choices for Life logo](/sites/default/files/2023-09/bcfl.svg)\\n\\nBringing ADA's evidence-based <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> guidelines and perspective directly to you in the store so you can make informed choices.\\n\\n![Food             <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Bowl](/sites/default/files/2023-09/Food_Bowl.svg)\\n![Milk carrot                                                <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> apple](/sites/default/files/2024-06/meal-patterns-side-nav.svg)\\n![Utensils](/sites/default/files/2023-09/Utens <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> ils.svg)\\n![checklist](/sites/default/files/2023-09/NewlyDiagnosed_checklist.svg)\\n\\nTake the 60-second test to <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> find out your                                                                                                   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> risk\\n\\n![Book](/sites/default/files/2023-09/two%20tone.svg)\\n![Location](/sites/default/files/2023-09/Location <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> .svg)\\n\\nFind help and resources in your zip code\\n\\n![Money                                                    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> hand](/sites/default/files/2023-09/Money_Hand.svg)\\n\\nChoose between a one-time donation or recurring monthly   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> gifts.\\n\\n![Handshake](/sites/default/files/2023-09/handshake.svg)\\n\\nReach out and get involved in programs    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> and events near you.\\n\\n![Transportation](/sites/default/files/2023-09/Transportation.svg)\\n\\nWe make vehicle   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> donations easy so you can help fuel our fight,                                                                  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> hassle-free.\\n\\n![People](/sites/default/files/2023-09/people.svg)\\n![Recipients](/sites/default/files/2023-09/ <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Recipients.svg)\\n![Book](/sites/default/files/2023-09/two%20tone.svg)\\n![capitol                                <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> icon](/sites/default/files/2023-10/capitol.svg)\\n\\n## Breadcrumb\\n\\n# The American Diabetes Association         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Releases Standards of Care in Diabetesâ€”2025\\n\\n![American Diabetes Association logo reversed out white on red   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> background](/sites/default/files/styles/large/public/2024-06/ada-a_comms_logo-full-crops-clean.jpg?itok=HH6Loyi <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> L)\\n\\n*New recommendations on nutrition, weight-loss medications and technology*\\n\\nToday, the American         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Diabetes AssociationÂ® released the [*Standards of Care in                                                       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Diabetesâ€”2025*](https://diabetesjournals.org/care/issue/48/Supplement_1) (*Standards of Care*) the gold         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> standard in evidence-based guidelines for diagnosing and managing diabetes and prediabetes. Based on the latest <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> scientific research and clinical trials, the *Standards of Care* includes strategies for diagnosing and         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> treating diabetes in both youth and adults, methods to prevent or delay type 2 diabetes and its associated      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> comorbidities like obesity, and care recommendations to enhance health outcomes.\\n\\nâ€œThe latest ADA guidelines  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> combine comprehensive, evidence-based recommendations for diabetes care with actionable guidance to enable      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> health care professionals provide the best care possible for those living with diabetes,â€ said Nuha El Sayed,   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> MD, MMSc, the ADAâ€™s senior vice president of health care improvement.\\n\\nNotable updates to the [*Standards of  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Care in Diabetesâ€”2025*](https://diabetesjournals.org/care/issue/48/Supplement_1) include*:*\\n\\nThe ADA annually <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> updates its *Standards of Care* through the efforts of its Professional Practice Committee (PPC). Comprising    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> global experts from diverse professional backgrounds, the PPC includes physicians, nurse practitioners,         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> certified diabetes care and education specialists, registered dietitian nutritionists, pharmacists, and         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> methodologists. Its members hold expertise in a range of related fields. The 2025 *Standards of Care* has       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> garnered endorsements from the American College of Cariology (Section 10), the American Geriatrics Society      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> (Section 13), the American Society of Bone and Mineral Research (Bone Health, Section 4), and the Obesity       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Society (Section 8).\\n\\nOther noteworthy changes include:\\n\\nâ€œImproving the lives of people affected by         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> diabetes is a key part of the ADAâ€™s mission. The *Standards of Care* offers the trusted support needed for      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> people living with diabetes and those caring for them to manage the disease and thrive until we find a cure,â€   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> said Charles â€œChuckâ€ Henderson, the ADAâ€™s chief executive officer.\\n\\n*The* [*Standards of Care in              <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Diabetesâ€”2025*](https://diabetesjournals.org/care/issue/48/Supplement_1) is now available online as a           <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> supplement to the January 2025 issue of *Diabetes CareÂ®.* In addition, a convenient [Standards of Care          <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> app](https://professional.diabetes.org/content-page/standards-care-app-1), available for iOS and Android        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> systems, offers the latest guidelines with interactive tables and algorithms for easy reference. Additional     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> resources, including a comprehensive slide deck and a webcast offering continuing education (CE) credit, are    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> available on the ADAâ€™s professional website [DiabetesPro](https://professional.diabetes.org/)Â®. A               <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> quick-reference pocket chart will soon be available for purchase on ShopDiabetes.org. For primary care          <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> providers, the Abridged Standards of Care, developed by the ADAâ€™s Primary Care Advisory Group, is planned for   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> release in Spring 2025 in *Clinical DiabetesÂ®*. Through the [â€œlivingâ€ Standards of Care                         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> process](https://professional.diabetes.org/standards-of-care/living-standards-update), the online version,      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> abridged guidelines, and all related materials will be updated in real time throughout the year to reflect the  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> latest evidence and regulatory changes.\\n\\n# # #\\n\\n**About the American Diabetes Association**Â   \\nThe         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> American Diabetes Association (ADA) is the nationâ€™s leading voluntary health organization fighting to end       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> diabetes and helping people thrive. For 84 years, the ADA has driven discovery and research to prevent, manage, <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> treat, and ultimately cure diabetes. There are 136 million Americans living with diabetes or prediabetes.       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Through advocacy, program development, and education, weâ€™re fighting for them all. To learn more or to get      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> involved, visit us at [diabetes.org](https://diabetes.org/) or call 1-800-DIABETES (800-342-2383). Join the     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> fight with us on Facebook ([American Diabetes                                                                   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Association](https://www.facebook.com/AmericanDiabetesAssociation?loc=superfooter)), Spanish Facebook           <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> ([AsociaciÃ³n Americana de la Diabetes](https://www.facebook.com/AsocAmericanaDiabetes)), LinkedIn ([American    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Diabetes Association](https://www.linkedin.com/company/american-diabetes-association/)), and Instagram          <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> ([@AmDiabetesAssn](https://www.instagram.com/AmDiabetesAssn/)). To learn more about how we are advocating for   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> everyone affected by diabetes, visit us on X ([@AmDiabetesAssn](https://x.com/AmDiabetesAssn)).\\n\\n## Contact   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Virginia Cramer for press-related                                                                               <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> questions.\\n\\n![ADA](https://diabetes.org/sites/default/files/2024-05/JoinTheFight_PopUp_1032x578.jpg)\\n\\n###   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Give Today and Change lives!\\n\\nWith your support, the American Diabetes AssociationÂ® can continue our          <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> lifesaving work to make breakthroughs in research and provide people with the resources they need to fight      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> diabetes.\\n\\n![ADA Logo](/sites/default/files/ADA85_logo_full_RGB_0.svg)\\n\\n2451 Crystal Drive, Suite           <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 900\\n\\nArlington, VA 22202\\n\\nP.O. Box 7023\\n\\nMerrifield, VA 22116-7023\\n\\n[Center for                         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Information](/about-us/center-information \\\"Center for Information\\\")\\n\\nMonday to Friday\\n\\n9:00 AMâ€“5:30 PM    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> ET\\n\\n![National Health council                                                                                 <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> logo](/sites/default/files/styles/sponsor_logo_288_180_no_crop/public/2023-09/National-Health-Council.png.png?i <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> tok=WPKlFArr)\\n![Charity navigator                                                                              <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> logo](/sites/default/files/styles/sponsor_logo_288_180_no_crop/public/2023-09/charity-navigator-g.png.png?itok= <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> pJ3CJ7R2)\\n![Accredited charity                                                                                 <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> seal](/sites/default/files/styles/sponsor_logo_288_180_no_crop/public/2023-09/accredited-charity-seal.png.png?i <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> tok=v8BJGkOD)\\n\\nCopyright 1995â€“2025. American Diabetes AssociationÂ®. All rights                                <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> reserved.\\n\\n##Source\\nhttps://diabetes.org/newsroom/press-releases/american-diabetes-association-releases-stan <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> dards-care-diabetes-2025\", \"## Title\\nSummary of Revisions: Standards of Care in Diabetesâ€”2025\\n\\n##            <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Content\\nSummary of Revisions: Standards of Care in Diabetesâ€”2025 | Diabetes Care | American Diabetes           <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Association\\n\\n===============\\n[Skip to Main                                                                   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Content](https://diabetesjournals.org/care/article/48/Supplement_1/S6/157564/Summary-of-Revisions-Standards-of- <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Care-in-Diabetes#skipNav)\\n\\n[![Image 1: American Diabetes Association                                          <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Logo](https://ada.silverchair-cdn.com/data/SiteBuilderAssetsOriginals/Live/Images/umbrella/logo-umbrella.svg)_O <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> pen Menu_](javascript:;)\\n\\n[![Image 2: American Diabetes Association                                           <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Logo](https://ada.silverchair-cdn.com/data/SiteBuilderAssetsOriginals/Live/Images/umbrella/logo-umbrella.svg)]( <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> https://diabetesjournals.org/)[Close](javascript:;)\\n\\n*   [Professional                                        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Books](https://diabetesjournals.org/books)\\n*   [Clinical Compendia](https://diabetesjournals.org/compendia)\\n* <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> [Journals _Open Menu_](javascript:;)\\n    *   [Journals Home](https://diabetesjournals.org/journals)\\n    *     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> [Diabetes](https://diabetesjournals.org/diabetes)\\n    *   [Diabetes Care](https://diabetesjournals.org/care)\\n <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> *   [Clinical Diabetes](https://diabetesjournals.org/clinical)\\n    *   [Diabetes                               <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Spectrum](https://diabetesjournals.org/spectrum)\\n    *   [Diabetes, Obesity, and Cardiometabolic               <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> CARE](https://diabetesjournals.org/docm-care)\\n    *   [BMJ Open Diabetes Research &amp; Care Open External         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Link](https://drc.bmj.com/)\\n    *   [Journal Article                                                           <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Collections](https://diabetesjournals.org/journals/pages/journals_special_collections)\\n\\n*   [ADA Standards of <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Care](https://diabetesjournals.org/care/issue/48/Supplement_1)\\n*   [ADA Meeting                                <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Abstracts](https://diabetesjournals.org/journals/pages/scientific-sessions-abstracts)\\n*   [Podcasts _Open      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Menu_](javascript:;)\\n    *   [All ADA Podcasts](https://diabetesjournals.org/journals/pages/podcasts)\\n    *   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> [DiabetesBio Open External Link](https://diabetesbio.libsyn.com/)\\n    *   [Diabetes Care On Air Open External  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Link](https://diabetescareonair.libsyn.com/site)\\n    *   [Diabetes Core Update Open External                   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Link](https://docupdate.libsyn.com/site)\\n    *   [Diabetes Core Update Special                                 <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Editions](https://diabetesjournals.org/journals/pages/diabetes-core-update-special-editions)\\n    *   [Diabetes <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Day by Day Open External Link](https://diabetesdaybyday.libsyn.com/site)\\n\\n*   [Professional News Open         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> External Link](https://professional.diabetes.org/)\\n\\n[_Search Dropdown Menu_](javascript:;)\\n\\nheader          <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> search\\n\\nsearch input Search input auto suggest \\n\\nfilter your search \\n\\n[Search](javascript:;)\\n\\n[Advanced <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Search](https://diabetesjournals.org/advanced-search)\\n\\n[_User Tools Dropdown_](javascript:;)\\n\\n[Sign In      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> _Open Menu_](javascript:;)\\n\\n[![Image 3: Diabetes                                                              <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Care](https://ada.silverchair-cdn.com/data/SiteBuilderAssets/Live/Images/care/care-header-97500660.svg)](https: <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> //diabetesjournals.org/care)\\n\\n[_Toggle Menu_ Menu](javascript:;)\\n*   [Articles &amp; Issues _Open                <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Menu_](javascript:;)\\n    *   [Current Issue](https://diabetesjournals.org/care/issue)\\n    *   [Online Ahead   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> of Print](https://diabetesjournals.org/care/online-ahead-of-print)\\n    *   [ADA Standards of                   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Care](https://diabetesjournals.org/care/issue/48/Supplement_1)\\n    *   [Issue                                  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Archive](https://diabetesjournals.org/care/issue-covers)\\n    *   [Featured Article                             <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Collections](https://diabetesjournals.org/journals/pages/diabetes_care_featured_collection)\\n    *   [All       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Article Collections](https://diabetesjournals.org/journals/collections)\\n    *   [Saved                         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Searches](https://diabetesjournals.org/my-account/saved-searches)\\n\\n*   [Review                                <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Articles](https://diabetesjournals.org/collection/2178/Review-Articles)\\n*   [Info &amp; About _Open                <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Menu_](javascript:;)\\n    *   [About the Journal](https://diabetesjournals.org/care/pages/about-the-journal)\\n  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> *   [About the Editors](https://diabetesjournals.org/care/pages/Editorial_Board)\\n    *   [ADA Journal          <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Policies](https://diabetesjournals.org/journals/pages/ada-journal-policies)\\n    *   [Reuse, Licensing, and     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Public Access](https://diabetesjournals.org/journals/pages/license)\\n    *   [Reprints and                      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Permissions](https://diabetesjournals.org/journals/pages/reprints-and-permissions)\\n    *                       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> [Advertising](https://diabetesjournals.org/journals/pages/advertising)\\n\\n*   [Podcasts _Open                   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Menu_](javascript:;)\\n    *   [All ADA Podcasts](https://diabetesjournals.org/journals/pages/podcasts)\\n    *   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> [DiabetesBio Open External Link](https://diabetesbio.libsyn.com/)\\n    *   [Diabetes Care On Air Open External  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Link](https://diabetescareonair.libsyn.com/site)\\n    *   [Diabetes Core Update Open External                   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Link](https://docupdate.libsyn.com/site)\\n    *   [Diabetes Core Update Special                                 <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Editions](https://diabetesjournals.org/journals/pages/diabetes-core-update-special-editions)\\n    *   [Diabetes <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Day by Day Open External Link](https://diabetesdaybyday.libsyn.com/site)\\n\\n*   [Submit &amp; Review _Open          <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Menu_](javascript:;)\\n    *   [Instructions for                                                                 <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Authors](https://diabetesjournals.org/care/pages/instructions-for-authors)\\n    *   [Submit a Manuscript Open   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> External Link](http://mc.manuscriptcentral.com/diabetescare)\\n    *   [Submit Cover                             <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Artwork](https://diabetesjournals.org/care/pages/submit_a_cover_image)\\n    *   [Guidance for                   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Reviewers](https://diabetesjournals.org/journals/pages/reviewers)\\n\\n*   [Subscribe _Open                       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Menu_](javascript:;)\\n    *   [Subscriptions                                                                    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Home](https://diabetesjournals.org/journals/pages/journal_subscriptions)\\n    *   [Individual                   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Subscriptions](https://diabetesjournals.org/journals/pages/individual_subscriptions)\\n    *   [Institutional    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Subscriptions](https://diabetesjournals.org/journals/pages/institutional_journal_subscriptions)\\n    *   [Site  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Licensing](https://diabetesjournals.org/journals/pages/site_licensing)\\n    *   [Access Institutional Usage     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Reports](https://diabetesjournals.org/journals/pages/access-institutional-usage-reports)\\n    *   [Sign Up for  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Email Alerts](https://diabetesjournals.org/my-account/alerts)\\n\\n[Skip Nav                                      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Destination](https://diabetesjournals.org/care/article/48/Supplement_1/S6/157564/Summary-of-Revisions-Standards <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> -of-Care-in-Diabetes#)\\n\\nClose navigation menu\\n\\nArticle navigation\\n\\n[Volume 48, Issue                      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Supplement_1](https://diabetesjournals.org/care/issue/48/Supplement_1)\\n\\n January 2025 \\n\\n[![Image 4:         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Diabetes Care Cover Image for Volume 48, Issue                                                                  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Supplement_1](https://ada.silverchair-cdn.com/ada/content_public/journal/care/issue/48/supplement_1/7/m_diacare <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> _48_supplement_1_cover.png?Expires=1765621439&amp;Signature=kpBXHYiNj~-5SAPfzmcft5iXOlw2MQsyxjf8g2DRlDFgeuWxA9yeTll <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> zjgPTvuAf0XVVktjE4PCG8761SHu-5P3DffgyJDroTJs6Ac-9gyzwTyU0ffeZukjU3eGr41DbJggTN6XfkbYKnrtQ89Txb8pZm2PSVYGqL06GEV <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 8TlyVg2VWEu1zeNlbLxIk-ZNFgaFZ4QY8-qdNJb~OU0TflpiZZaDrMHyVD4~6xeshPECZEdFMwPu1u-aY5~S~uj-o7q3nRmIA8C3yr5QHsIC86M <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Z6WuIhYQ7OWbMkpcJmYD5c0k~kRe9kzDm~06Bww6fw9EJy9SuBloNnyPbEP2BxwyA__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)](https:// <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> diabetesjournals.org/care/issue/48/Supplement_1)\\n\\n*   [Previous                                               <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Article](https://diabetesjournals.org/care/article/48/Supplement_1/S1/157562/Introduction-and-Methodology-Stand <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> ards-of-Care-in)\\n*   [Next                                                                                     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Article](https://diabetesjournals.org/care/article/48/Supplement_1/S14/157553/1-Improving-Care-and-Promoting-He <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> alth-in)\\n\\nArticle Contents\\n\\n*   [General                                                                    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Changes](https://diabetesjournals.org/care/article/48/Supplement_1/S6/157564/Summary-of-Revisions-Standards-of- <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Care-in-Diabetes#5310725) \\n*   [Section                                                                        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Changes](https://diabetesjournals.org/care/article/48/Supplement_1/S6/157564/Summary-of-Revisions-Standards-of- <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Care-in-Diabetes#5310729) \\n\\nArticle Navigation\\n\\nSummary of Revisions|December 09 2024\\n\\nSummary of         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Revisions: Standards of Care in Diabetesâ€”2025                                                                   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> _Free_\\n===============================================================\\n\\n[American Diabetes Association       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Professional Practice Committee](javascript:;)\\n\\n American Diabetes Association Professional Practice          <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Committee \\n\\n Search for other works by this author on: \\n\\n[This                                              <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Site](https://diabetesjournals.org/care/search-results?f_AllAuthors=American+Diabetes+Association+Professional+ <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Practice+Committee+)\\n\\n[PubMed](http://www.ncbi.nlm.nih.gov/pubmed?cmd=search&amp;term=American%20Diabetes%20Assoc <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> iation%20Professional%20Practice%20Committee)\\n\\n[Google                                                        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Scholar](http://scholar.google.com/scholar?q=author:%22%20%22)\\n\\n[![Image 5: Crossmark: Check for              <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Updates](https://crossmark-cdn.crossref.org/widget/v2.0/logos/CROSSMARK_Color_horizontal.svg)](javascript:;)\\n\\ <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> n_Diabetes Care_                                                                                                <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 2025;48(Supplement_1):S6â€“S13\\n\\n[https://doi.org/10.2337/dc25-SREV](https://doi.org/10.2337/dc25-SREV)\\n\\nPubMe <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> d:\\n\\n[39651984](https://pubmed.ncbi.nlm.nih.gov/39651984)\\n\\n*                                                 <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> [Split-Screen](https://diabetesjournals.org/care/article-split/48/Supplement_1/S6/157564/Summary-of-Revisions-S <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> tandards-of-Care-in-Diabetes)\\n*   [_Views Icon_ Views _Open Menu_](javascript:;)\\n    *   [Article             <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> contents](javascript:;)\\n\\n*   [Open the PDF for in another                                                     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> window](https://diabetesjournals.org/care/article-pdf/48/Supplement_1/S6/791587/dc25srev.pdf)\\n*   [_Share      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Icon_ Share](javascript:;)\\n    *   [Facebook](javascript:;)\\n    *   [X](javascript:;)\\n    *                  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> [LinkedIn](javascript:;)\\n    *   [Email](javascript:;)\\n\\n*   [_Cite Icon_ Cite](javascript:;) \\n*   [Get      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Permissions](http://s100.copyright.com/AppDispatchServlet?publisherName=Wiley&amp;publication=0149-5992&amp;title=Summa <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> ry%20of%20Revisions%3A%20Standards%20of%20Care%20in%20Diabetes%E2%80%942025&amp;publicationDate=2024-12-09&amp;volumeNu <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> m=48&amp;issueNum=Supplement_1&amp;author=American%20Diabetes%20Association%20Professional%20Practice%20Committee%3B%20 <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> ElSayed%2C%20Nuha%20A.&amp;startPage=S6&amp;endPage=S13&amp;contentId=10.2337%2Fdc25-SREV&amp;oa=&amp;orderBeanReset=True)          <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> \\n\\nCitation\\n\\nAmerican Diabetes Association Professional Practice Committee; Summary of Revisions: Standards  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> of Care in Diabetesâ€”2025. _\\\\_Diabetes Care\\\\__ 1 January 2025; 48 (Supplement_1): S6â€“S13.                      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> [https://doi.org/10.2337/dc25-SREV](https://doi.org/10.2337/dc25-SREV)\\n\\nDownload citation file:\\n\\n*   [Ris   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> (Zotero)](https://diabetesjournals.org/Citation/Download?resourceId=157564&amp;resourceType=3&amp;citationFormat=0)\\n*  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> [Reference                                                                                                      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Manager](https://diabetesjournals.org/Citation/Download?resourceId=157564&amp;resourceType=3&amp;citationFormat=0)\\n*   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> [EasyBib](https://diabetesjournals.org/Citation/Download?resourceId=157564&amp;resourceType=3&amp;citationFormat=0)\\n*  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> [Bookends](https://diabetesjournals.org/Citation/Download?resourceId=157564&amp;resourceType=3&amp;citationFormat=0)\\n* <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> [Mendeley](https://diabetesjournals.org/Citation/Download?resourceId=157564&amp;resourceType=3&amp;citationFormat=0)\\n* <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> [Papers](https://diabetesjournals.org/Citation/Download?resourceId=157564&amp;resourceType=3&amp;citationFormat=0)\\n*   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> [EndNote](https://diabetesjournals.org/Citation/Download?resourceId=157564&amp;resourceType=3&amp;citationFormat=1)\\n*  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> [RefWorks](https://diabetesjournals.org/Citation/Download?resourceId=157564&amp;resourceType=3&amp;citationFormat=3)\\n* <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> [BibTex](https://diabetesjournals.org/Citation/Download?resourceId=157564&amp;resourceType=3&amp;citationFormat=2)\\n\\nt <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> oolbar search\\n\\n[_Search Dropdown Menu_](javascript:;)\\n\\ntoolbar search\\n\\nsearch input Search input auto     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> suggest \\n\\nfilter your search \\n\\n[Search](javascript:;)\\n\\n[Advanced                                          <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Search](https://diabetesjournals.org/advanced-search)\\n\\nGeneral Changes\\n---------------\\n\\nThe field of       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> diabetes care is rapidly changing as new research, technology, and treatments that can improve the health and   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> well-being of people with diabetes continue to emerge. With annual updates since 1989, the American Diabetes    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Association has long been a leader in producing guidelines that capture the most current state of the           <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> field.\\n\\nThe 2025 â€œStandards of Care in Diabetesâ€ has continued to incorporate person-first and inclusive      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> language. Efforts were made to consistently apply terminology that empowers people with diabetes and recognizes <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> the individual at the center of diabetes care.\\n\\nAlthough levels of evidence for several recommendations have  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> been updated, these changes are not outlined below where the clinical recommendation has remained the same.     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> That is, changes in evidence level from, for example, **E** to **C**, are not noted below. The 2025 Standards   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> of Care contains, in addition to many minor changes that clarify recommendations or reflect new evidence, more  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> substantive revisions detailed below.\\n\\nSection Changes\\n---------------\\n\\n### Endorsements\\n\\nFor the second <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> consecutive year, the â€œBone Heathâ€ subsection in Section 4, â€œComprehensive Medical Evaluation and Assessment of <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Comorbidities,â€ received endorsement from the American Society for Bone and Mineral Research and Section 8,     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> â€œObesity and Weight Management for the Prevention of Type 2 Diabetes,â€ received endorsement from The Obesity    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Society. For the seventh consecutive year, Section 10, â€œCardiovascular Disease and Risk Management,â€ received   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> endorsement from the American College of Cardiology. For the first time, Section 13, â€œOlder Adults,â€ received   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> endorsement from the American Geriatrics Society.\\n\\n### Section 1. Improving Care and Promoting Health in      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Populations\\n\\n([https://doi.org/10.2337/dc25-S001](https://doi.org/10.2337/dc25-S001))\\n\\nRecommendation 1.1   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> was expanded to include people at risk for diabetes in addition to those with diabetes.\\n\\nRecommendation 1.2   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> was revised to include, in addition to the Chronic Care Model, other evidence-based care delivery models and    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> frameworks that have been demonstrated to improve diabetes care delivery and health outcomes. These include the <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Patient-Centered Medical Home model, Accountable Care Organizations, and value-based payment models and are     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> discussed in the text.\\n\\nRecommendation 1.5 was added to emphasize the importance of quality improvement       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> initiatives and interprofessional teams for supporting sustainable and scalable process changes that improve    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> quality of care and health outcomes. Implementation concepts were added throughout the section to provide       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> actionable guidance on how to implement and sustain interventions that improve care delivery and population     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> health.\\n\\nRecommendation 1.6 was added to emphasize the importance of assessing and addressing disparities in  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> diabetes care and health outcomes. The text includes actionable guidance on measuring health disparities and    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> engaging interprofessional teams and community partners to address them.\\n\\nRecommendation 1.7 was revised to   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> emphasize the importance of screening for and addressing multiple social determinants of health that impact     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> diabetes management, health outcomes, and quality of life.\\n\\nThe narrative text now includes an expanded       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> discussion of cost and affordability considerations as well as health disparities and social determinants of    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> health.\\n\\n[**Table 1.1**](https://doi.org/10.2337/dc25-S001) was added to highlight the importance of engaging <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> an interprofessional team approach to person-centered care for people with diabetes across the life             <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> span.\\n\\n### Section 2. Diagnosis and Classification of                                                         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Diabetes\\n\\n([https://doi.org/10.2337/dc25-S002](https://doi.org/10.2337/dc25-S002))\\n\\n[**Table                <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 2.3**](https://doi.org/10.2337/dc25-S002) was added to provide considerations related to the use and            <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> interpretation of laboratory measurement of glucose and A1C.\\n\\nThe â€œClassificationâ€ subsection has been        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> updated to provide a pragmatic approach to management of individuals who have features of both type 1 and type  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 2 diabetes.\\n\\nIn the â€œType 1 Diabetesâ€ subsection, Recommendation 2.7 was added to emphasize the importance of <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> antibody-based screening for presymptomatic type 1 diabetes in individuals with a family history of type 1      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> diabetes or otherwise known elevated genetic risk. The associated text was also updated and expanded to reflect <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> these changes.\\n\\nThe â€œGestational Diabetes Mellitusâ€ subsection was completely updated to facilitate           <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> understanding and implementation of the current various approaches to screening for and diagnosis of            <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> gestational diabetes mellitus (GDM).\\n\\nThe text in various other subsections, including those that discuss     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> diabetes and immune checkpoint inhibitors, the role of the gut microbiome in diabetes risk, and monogenic       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> diabetes, was updated.\\n\\n### Section 3. Prevention or Delay of Diabetes and Associated                         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Comorbidities\\n\\n([https://doi.org/10.2337/dc25-S003](https://doi.org/10.2337/dc25-S003))\\n\\nIn the â€œLifestyle  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Behavior Change for Type 2 Diabetes Preventionâ€ subsection, text pertaining to sleep health in relation to risk <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> of type 2 diabetes was added. This addition highlights sleep as a central component in the management of        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> prediabetes and type 2 diabetes, placing it on a level playing field with other lifestyle behaviors (e.g.,      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> physical activity and eating patterns).\\n\\nIn the â€œPharmacologic Interventions to Delay Type 2 Diabetesâ€        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> subsection, the text on the proposed use of vitamin D therapy to prevent type 2 diabetes was extensively        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> updated. The text related to long-term metformin therapy and associated vitamin B12 deficiency was also         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> updated.\\n\\nThe language in Recommendation 3.15 was strengthened to facilitate discussion with selected         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> individuals aged â‰¥8 years with stage 2 type 1 diabetes about the role of teplizumab-mzwv infusion to delay the  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> onset of symptomatic type 1 diabetes (stage 3).\\n\\n### Section 4. Comprehensive Medical Evaluation and          <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Assessment of                                                                                                   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Comorbidities\\n\\n([https://doi.org/10.2337/dc25-S004](https://doi.org/10.2337/dc25-S004))\\n\\nLanguage in        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> [**Fig. 4.1**](https://doi.org/10.2337/dc25-S004) was updated, and [**Table                                     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 4.1**](https://doi.org/10.2337/dc25-S004) was modified to include changes made throughout Section               <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 4.\\n\\nRecommendation 4.3 was changed to include assessment for glycemic status and previous treatment at the    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> initial visit and follow-up visits as appropriate.\\n\\n[**Table 4.2**](https://doi.org/10.2337/dc25-S004) was    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> amended to include essential components for assessment, planning, and referral as appropriate.\\n\\nChanges were  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> made in the â€œImmunizationsâ€ subsection to reflect updates for COVID-19, pneumococcal pneumonia, influenza, and  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> respiratory syncytial virus. [**Table 4.3**](https://doi.org/10.2337/dc25-S004) was revised to include          <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> important vaccination updates.\\n\\nRecommendation 4.6 was modified to specify initial and repeat screening for   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> autoimmune thyroid disease.\\n\\nRecommendation 4.10 was updated to specify avoiding medications with known       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> association with higher fracture risk.\\n\\nRecommendation 4.12 was revised to include the recommended intake of  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> calcium for people with diabetes.\\n\\nRecommendation 4.13 was updated to specify when antiresorptive medications <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> and osteoanabolic agents should be considered.\\n\\n[**Table 4.4**](https://doi.org/10.2337/dc25-S004) was        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> updated to specify when bone mineral density testing should be performed.\\n\\nA new subsection, â€œDental Care,â€   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> was added and includes two new recommendations. Recommendation 4.15 was added to state people with diabetes     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> should be referred for a dental exam at least once per year. Recommendation 4.16 was added to state that        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> efforts between medical and dental teams should be coordinated so that glucose-lowering medications can be      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> appropriately adjusted prior to and in the postâ€“dental procedure period as needed.\\n\\nRecommendation 4.17 was   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> updated to reflect that an assessment for disability should be performed at the initial visit and an assessment <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> for decline in function should be performed at each subsequent visit.\\n\\nRecommendation 4.18 was modified to    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> include inquiring about sexual health in men and to screen with a morning serum total testosterone if symptoms  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> and/or signs of hypogonadism are present.\\n\\nRecommendation 4.19 was added to specifically state that men with  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> diabetes or prediabetes should be screened for erectile dysfunction, and new text was added on erectile         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> dysfunction.\\n\\nA new subsection, â€œFemale Sexual Dysfunction,â€ was added and includes two new recommendations.  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Recommendation 4.20 states that health care professionals should inquire about sexual health, particularly in   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> women who experience depression and/or anxiety and those with recurrent urinary tract infections.               <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Recommendation 4.21 was added to state that health care professionals should screen for symptoms and/or signs   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> of genitourinary syndrome of menopause.\\n\\nThe terminology for nonalcoholic fatty liver disease (NAFLD) and     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> nonalcoholic steatohepatitis (NASH) was updated to metabolic dysfunctionâ€“associated steatotic liver disease     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> (MASLD) and metabolic dysfunctionâ€“associated steatohepatitis (MASH), respectively. This updated nomenclature    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> was incorporated throughout the section.\\n\\nRecommendation 4.22a was revised to specify when to screen for the  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> risk of having or developing cirrhosis related to MASH using the calculated fibrosis-4 index                    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> (FIB-4).\\n\\nRecommendation 4.23 was amended to state that adults with type 2 diabetes or prediabetes and a      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> FIB-4 &gt;1.3 should have additional risk stratification performed.\\n\\nRecommendation 4.24 was revised to state    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> that individuals with a higher risk for significant liver fibrosis should be referred to a gastroenterologist   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> or hepatologist.\\n\\nRecommendation 4.25 was revised to include an interprofessional team approach when          <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> promoting weight loss, particularly with a structured nutrition plan and physical activity program for          <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> cardiometabolic benefits and histological improvement.\\n\\nRecommendation 4.26 was revised to include a dual     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> glucose-dependent insulinotropic polypeptide (GIP) and glucagon like peptide 1 (GLP-1) receptor agonist (RA)    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> with potential benefits in MASH as an adjunctive therapy to lifestyle interventions for weight loss in adults   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> with type 2 diabetes, MASLD, and overweight or obesity.\\n\\nRecommendation 4.27a was revised to state that in    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> adults with type 2 diabetes and biopsy-proven MASH or those at high risk for liver fibrosis, use of             <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> pioglitazone or a GLP-1 RA or a dual GIP and GLP-1 RA is preferred for glycemic management due to potential     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> beneficial effects on MASH.\\n\\nRecommendation 4.27b was added to state that combination therapy with            <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> pioglitazone and a GLP-1 RA can be considered for treatment of hyperglycemia in adults with type 2 diabetes     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> with biopsy-proven MASH or those at high risk of liver fibrosis because of potential beneficial effects of such <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> a combination on MASH.\\n\\nRecommendation 4.28 was added to state that treatment with a thyroid hormone          <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> receptor-Î² agonist in adults with type 2 diabetes or prediabetes with MASLD with moderate (F2) or advanced (F3) <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> liver fibrosis may be considered and that the individual should be referred to a gastroenterologist or          <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> hepatologist with expertise in MASLD management for the initiation and monitoring of this                       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> therapy.\\n\\nRecommendation 4.29 was added to emphasize that treatment initiation and monitoring should be       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> individualized and within the context of an interprofessional team for MASLD and MASH management.\\n\\n[**Figure  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 4.2**](https://doi.org/10.2337/dc25-S004) was revised to reflect important updates to the diagnostic algorithm  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> for risk stratification and the prevention of cirrhosis in individuals MASLD, and new [**Fig.                   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 4.3**](https://doi.org/10.2337/dc25-S004) includes the MASLD treatment algorithm.\\n\\n### Section 5.             <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Facilitating Positive Health Behaviors and Well-being to Improve Health                                         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Outcomes\\n\\n([https://doi.org/10.2337/dc25-S005](https://doi.org/10.2337/dc25-S005))\\n\\nIn the â€œDiabetes        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Self-Management Education and Supportâ€ subsection, Recommendation 5.1 was updated to emphasize that all people  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> with diabetes should be advised to participate in diabetes self-management education and support (DSMES) rather <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> than being just encouraged to participate.\\n\\nRecommendation 5.2 was updated to clarify when to provide         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> DSMES.\\n\\nRecommendation 5.3 was revised to be more succinct and action-oriented, placing emphasis on routine   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> assessment of key goals of DSMES.\\n\\nRecommendation 5.4 was added to emphasize the importance of screening for  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> behavioral health concerns at the same time points as evaluating the need for DSMES.\\n\\nLanguage in             <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Recommendation 5.5 was updated to state that DSMES should be culturally appropriate and responsive to           <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> individual preferences, needs, and values.\\n\\nRecommendation 5.6 was updated to reflect the now-common practice <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> of remote-delivery of DSMES and reimbursement for remotely delivered modalities.\\n\\nRecommendation 5.9 was      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> updated to reinforce the importance of screening for and including social determinants of health in guiding the <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> design and delivery of DSMES.\\n\\nIn the â€œMedical Nutrition Therapyâ€ subsection, Recommendation 5.12 was updated <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> to emphasize the importance of providing treatment based on nutrition, physical activity, and behavioral        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> therapy for individuals with overweight or obesity, aiming for at least 3â€“7% weight loss.\\n\\nRecommendation     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 5.14 on eating patterns now has revised verbiage to include processed foods, lean proteins, and nondairy        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> alternatives.\\n\\nRecommendation 5.16 was updated to include actionable language and clarity regarding the use   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> of dietary supplements for glycemic benefits.\\n\\nRecommendations 5.17 and 5.18 were updated to have revised and <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> actionable language, respectively.\\n\\nRecommendation 5.19 was updated to use actionable                         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> language.\\n\\nRecommendation 5.20 was revised to recommend limiting sodium as clinically appropriate, which can  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> be done, in part, by limiting consumption of processed foods.\\n\\nRecommendation 5.21 was modified to recommend  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> water over nutritive and nonnutritive sweetened beverages, and Recommendation 5.22 was added to state that      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> nonnutritive sweeteners can be used instead of sugar-sweetened products in moderation and for short term to     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> reduce overall calorie and carbohydrate intake.\\n\\nRecommendation 5.23 was added to emphasize the screening for <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> malnutrition, especially for those who have undergone metabolic surgery and for those being treated with weight <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> management pharmacological therapies.\\n\\nRecommendation 5.25 was revised to use actionable                      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> language.\\n\\nRecommendation 5.26 was added to address the issue of sodiumâ€“glucose cotransporter (SGLT)          <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> inhibition being associated with ketoacidosis under certain conditions. It provides guidance on awareness,      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> prevention, risk mitigation, and dietary adjustments.\\n\\nRecommendation 5.29 was added to encourage intake of   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> plant-based proteins and fiber, and Recommendation 5.31 was added to encourage limiting foods high in saturated <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> fats to reduce cardiovascular disease risk.\\n\\nTwo new recommendations were added for religious fasting.        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Recommendation 5.32 states to use the Diabetes and Ramadan International Alliance comprehensive prefasting risk <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> assessment for risk stratification of people with diabetes prior to engaging in religious fasting.              <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Recommendation 5.33 was created to provide guidance to health care professionals caring for people with         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> diabetes who participate in religious fasting.\\n\\nAdditionally, newly added [**Fig.                             <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 5.1**](https://doi.org/10.2337/dc25-S005) illustrates differences and similarities between religious and        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> intermittent fasting for people with diabetes. [**Table 5.4**](https://doi.org/10.2337/dc25-S005) includes a    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> risk calculation and suggested risk score for people with diabetes who seek to fast during Ramadan, and         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> [**Table 5.5**](https://doi.org/10.2337/dc25-S005) includes information about medication changes during         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> fasting.\\n\\nIn the â€œPhysical Activityâ€ subsection, Recommendation 5.34 was updated to include a statement about <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> limiting the amount of time spent sedentary, which includes recreational screen time.\\n\\nRecommendation 5.38    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> was modified to state that prolonged sitting should be interrupted at least every 30 min for glycemic           <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> benefits.\\n\\nRecommendation 5.39 was added to counsel adults and youth receiving weight management              <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> pharmacotherapy or metabolic surgery to meet physical activity recommendations. The accompanying text addresses <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> the concern of sarcopenic obesity with use of incretin therapies and metabolic surgery.\\n\\nIn the â€œSmoking      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Cessation: Tobacco, E-cigarettes, and Cannabisâ€ subsection, Recommendation 5.42 was added to advise people with <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> type 1 diabetes and those with other forms of diabetes at risk for diabetic ketoacidosis (DKA) to not use       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> recreational cannabis in any form due to the risk of cannabis hyperemesis syndrome. The accompanying text       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> describes cannabis hyperemesis syndrome and its diagnostic criteria.\\n\\nRecommendation 5.43 in â€œSupporting      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Positive Health Behaviorsâ€ was updated to include health-related quality of life as an outcome when using       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> behavioral health strategies to support self-management and healthy behaviors.\\n\\nRecommendation 5.45 in        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> â€œPsychosocial Careâ€ was revised to state the specific psychosocial concerns health care professionals should    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> screen for including diabetes distress, depression, anxiety, fear of hypoglycemia, and disordered eating        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> behaviors.\\n\\nRecommendation 5.48 in â€œDiabetes Distressâ€ was updated to recommend the frequency of at least     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> annual screening for diabetes distress in people with diabetes, caregivers, and family                          <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> members.\\n\\nRecommendation 5.49 in â€œAnxietyâ€ was updated to recommend screening for anxiety, which is in        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> accordance with the U.S. Preventive Services Task Force recommendation for screening for                        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> anxiety.\\n\\nRecommendation 5.50 in â€œAnxietyâ€ was added to include a recommendation for screening for fear of    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> hypoglycemia in people with diabetes at risk for hypoglycemia or fear of hypoglycemia.\\n\\nRecommendation 5.51   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> in â€œDepressionâ€ was modified to have more actionable language for the importance of depression                  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> rescreening.\\n\\nRecommendation 5.54 in â€œDisordered Eating Behaviorâ€ was updated to recommend screening for      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> disordered or disrupted eating using validated screening measures. The accompanying text describes the          <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> disordered or disrupted eating behaviors commonly reported in people with diabetes.\\n\\n[**Tables                <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 5.7**](https://doi.org/10.2337/dc25-S005) and [**5.8**](https://doi.org/10.2337/dc25-S005) were added to        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> illustrate psychosocial concerns and their association with diabetes-related outcomes in adults with type 1 and <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> type 2 diabetes, respectively.\\n\\n### Section 6. Glycemic Goals and                                             <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Hypoglycemia\\n\\n([https://doi.org/10.2337/dc25-S006](https://doi.org/10.2337/dc25-S006))\\n\\nRecommendation 6.12 <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> was added to promote routine screening for fear of hypoglycemia in individuals at risk for hypoglycemia.\\n\\nA   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> new subsection entitled â€œHyperglycemic Crises: Diagnosis, Management, and Preventionâ€ was added to cover the    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> epidemiology, diagnostic criteria, and outpatient prevention of DKA and the hyperglycemic hyperosmolar state    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> (HHS).\\n\\nNew recommendations on routine assessment of history of DKA and HHS (recommendation 6.20) and         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> providing structured prevention education (Recommendation 6.21) in the outpatient setting were                  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> added.\\n\\n[**Tables 6.9**](https://doi.org/10.2337/dc25-S006) and [**6.10**](https://doi.org/10.2337/dc25-S006) <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> were added and include risk factors for hyperglycemic crises as well as clinical presentation of DKA and HHS in <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> people with diabetes, respectively.\\n\\n[**Figure 6.2**](https://doi.org/10.2337/dc25-S006) was revised to       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> provide a specific and actionable approach to selecting individual glycemic goals, accounting for health status <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> and other person- and treatment-specific factors favoring more or less stringent goals.\\n\\n### Section 7.       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Diabetes                                                                                                        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Technology\\n\\n([https://doi.org/10.2337/dc25-S007](https://doi.org/10.2337/dc25-S007))\\n\\nRecommendation 7.8    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> was modified to emphasize consideration for starting diabetes technology early, even at                         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> diagnosis.\\n\\nRecommendation 7.9 was added to emphasize that reports for all continuous glucose monitoring      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> (CGM) devices, connected insulin devices, and continuous subcutaneous insulin infusion and automated insulin    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> delivery (AID) systems should be standardized with at a minimum the ambulatory glucose profile and weekly       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> summary. In addition, there should be options for raw data or daily and weekly reports available to the health  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> care professionals.\\n\\nRecommendation 7.14 was modified to make the clinician aware of potential interference   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> of medications and other substances on glucose levels measured by blood glucose meters.\\n\\n[**Table             <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 7.2**](https://doi.org/10.2337/dc25-S007) was modified to include the various potential substances or medical   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> conditions that may affect glucose levels when measured by blood glucose meters.\\n\\n[**Table                    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 7.3**](https://doi.org/10.2337/dc25-S007) was modified to include the description of over-the-counter CGM       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> devices.\\n\\nRecommendation 7.15 was modified to support the use of real-time CGM (rtCGM) and intermittently     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> scanned CGM (isCGM) for youth and adults with diabetes (type 1 or type 2) on any type of insulin therapy based  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> on the most recent literature.\\n\\nRecommendation 7.16 was added to consider the use of rtCGM or isCGM in adults <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> with type 2 diabetes on glucose-lowering agents other than insulin to achieve and maintain individualized       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> glycemic goals.\\n\\nRecommendation 7.18 was modified to align with Section 15, â€œManagement of Diabetes in        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Pregnancy,â€ and reflect the update of CGM benefits in type 1 diabetes and pregnancy and other types of diabetes <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> in pregnancy.\\n\\nThe text on CGM was expanded to include the updated sensors integrated with AID systems and to <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> update the most recent literature evidence supporting the benefits of CGM in individuals with type 2 diabetes   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> on glucose-lowering agents other than insulin from clinical trials and real-world studies. Furthermore, the CGM <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> section was expanded to include the need to standardize any diabetes technology device reports and to provide   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> clinicians not only with single page summaries but also with access to detailed reports and even raw data from  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> devices, especially those reporting insulin dose modifications, such as AID systems.\\n\\nThe text on insulin     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> pumps and AID systems was greatly expanded to discuss the features of the various AID systems and their data    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> from pivotal trials and real-world studies in type 1 and type 2 diabetes.\\n\\nRecommendation 7.29 was modified   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> to include provision of support and diabetes management advice in people with diabetes using open-source        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> closed-loop systems.\\n\\nThe text for open-source closed-loop systems was also expanded to include the most      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> recent published evidence on the safety and effectiveness of these systems in people with type 1                <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> diabetes.\\n\\nRecommendation 7.30 was expanded to include the benefits of combining technology with online or    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> virtual coaching to improve glycemic outcomes in individuals with diabetes and prediabetes.\\n\\nRecommendation   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 7.32 was refined to emphasize the importance of continuing the use of insulin pumps or AID in people with       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> diabetes while hospitalized when clinically appropriate and with confirmatory point-of-care blood glucose       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> measurements for insulin dose adjustments and hypoglycemia assessment and treatment. The use of these devices   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> in the inpatient setting should be contingent on the availability of infrastructure support and institutional   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> diabetes technology protocols.\\n\\n### Section 8. Obesity and Weight Management for the Prevention and Treatment <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> of Type 2                                                                                                       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Diabetes\\n\\n([https://doi.org/10.2337/dc25-S008](https://doi.org/10.2337/dc25-S008))\\n\\nRecommendation 8.2a was <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> updated to clarify that additional measurements of body fat distribution are warranted if BMI is                <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> indeterminant.\\n\\nRecommendation 8.2b was revised to recommend monitoring of obesity-related anthropometric     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> measurements at least every 3 months during active weight management treatment.\\n\\nDiscussion of weight stigma  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> and bias toward people living in larger bodies was added to the text.\\n\\nRecommendation 8.11 was enhanced to    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> reflect the importance of continued monitoring, support, and interventions for individuals who have achieved    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> weight loss goals to support the maintenance of these goals long term.\\n\\nRecommendation 8.18 was added to      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> recommend screening for malnutrition for people with diabetes and obesity who have lost significant             <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> weight.\\n\\nRecommendation 8.19 was added to recommend continuing weight management pharmacotherapy, as          <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> indicated, beyond reaching weight loss goals to maintain health benefits and avoid weight regain and worsening  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> of cardiometabolic abnormalities that often result from sudden discontinuation of weight management             <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> pharmacotherapy.\\n\\nRecommendation 8.25 was revised to emphasize use of a CGM device to improve safety in       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> individuals with postâ€“metabolic surgery hypoglycemia.\\n\\nUpdated [**Tables                                      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 8.1**](https://doi.org/10.2337/dc25-S008) and [**8.2**](https://doi.org/10.2337/dc25-S008) provide detailed     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> information on the efficacy, common side effects, safety considerations, and costs of approved weight           <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> management pharmacotherapy options.\\n\\nDiscussion of medication cost and access barriers was added to the text, <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> including suggestions to members of the interprofessional diabetes care team on mitigating financial            <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> barriers.\\n\\n### Section 9. Pharmacologic Approaches to Glycemic                                                <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Treatment\\n\\n([https://doi.org/10.2337/dc25-S009](https://doi.org/10.2337/dc25-S009))\\n\\nThis section was       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> reorganized and expanded with two new subsections: _1_) a subsection titled â€œAdditional Recommendations for All <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Individuals With Diabetesâ€ that includes new recommendations as well as recommendations previously listed with  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> those for individuals with type 1 or type 2 diabetes if pertinent to individuals regardless of their type of    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> diabetes, and _2_) a subsection titled â€œSpecial Circumstances and Populations.â€\\n\\n[**Figure                    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 9.1**](https://doi.org/10.2337/dc25-S009) was revised for clarity, and a general statement was added to         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> [**Table 9.1**](https://doi.org/10.2337/dc25-S009) on dose adjustments when using AID systems.\\n\\nThe           <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> subsection on insulin administration technique was expanded to address inhaled insulin and use of insulin bolus <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> patches.\\n\\nRecommendation 9.8 was revised to emphasize the importance of selecting glucose-lowering            <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> medications that provide sufficient effectiveness and achieve and maintain multiple treatment goals             <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> simultaneously, including improving cardiovascular, kidney, weight, and other relevant outcomes, reducing       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> hypoglycemia risk, and considering cost, access, risk for adverse reactions, and individual                     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> preferences.\\n\\nRecommendations were revised to explicitly advise on choice of pharmacotherapy for individuals  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> with type 2 diabetes and established or high risk of atherosclerotic cardiovascular disease (ASCVD)             <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> (Recommendation 9.10), heart failure (Recommendation 9.11), and chronic kidney disease (CKD) (Recommendation    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 9.12) to improve health outcomes for individuals with these conditions irrespective of A1C.\\n\\nRecommendation   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 9.12 was added to recommend use of GLP-1 RA with demonstrated benefits in individuals with type 2 diabetes,     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> symptomatic heart failure with preserved ejection fraction, and obesity.\\n\\nRecommendation 9.13 was revised to  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> recommend use of either SGLT2 inhibitor or GLP-1 RA with demonstrated benefits in individuals with type 2       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> diabetes and CKD.\\n\\nRecommendations 9.15 and 9.16 were added to recommend treatment of individuals with type 2 <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> diabetes and MASLD or MASH with GLP-1 RA, dual GIP and GLP-1 RA, pioglitazone, or a combination of GLP-1 RA and <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> pioglitazone based on the staging of liver disease risk and need for weight management.\\n\\n[**Figure            <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 9.3**](https://doi.org/10.2337/dc25-S009) and the text discussing choice of glucose-lowering therapy in adults  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> with type 2 diabetes were extensively revised to facilitate evidence-based selection of glucose-lowering        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> therapies based on individualized treatment goals. Considerations of glucose-lowering medication effects on     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> MASLD and MASH were added to [**Fig. 9.3**](https://doi.org/10.2337/dc25-S009).\\n\\n[**Table                     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 9.2**](https://doi.org/10.2337/dc25-S009) was simplified and revised to better highlight important              <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> considerations when choosing medications for lowering glucose in type 2 diabetes.\\n\\nRecommendation 9.20 was    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> clarified to recommend reassessing the need for and/or dose of medications with higher hypoglycemia risk (i.e., <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> sulfonylureas, meglitinides, and insulin) when initiating a new glucose-lowering medication to minimize the     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> risk of hypoglycemia and treatment burden.\\n\\nRecommendation 9.21 was added to advise against concurrent use of <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> a dipeptidyl peptidase 4 inhibitor with a GLP-1 RA due to lack of additional glucose lowering beyond that of a  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> GLP-1 RA alone.\\n\\nRecommendation 9.24 was clarified by specifying that a GLP-1 RA or a dual GIP and GLP-1 RA   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> is preferred to insulin in adults with type 2 diabetes only in the absence of evidence of insulin               <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> deficiency.\\n\\nText in the â€œBasal Insulinâ€ section was revised to provide guidance on switching between         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> different basal insulin formulations.\\n\\n[**Figure 9.4**](https://doi.org/10.2337/dc25-S009) was revised for    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> clarity, and the list of options for prandial insulin was expanded.\\n\\nRecommendation 9.27 was revised to       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> remove consideration of basal insulin doses exceeding 0.5 units/kg/day as evidence of overbasalization.         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Instead, signs of overbasalization including significant bedtime-to-morning or postprandial-to-preprandial      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> glucose differential, occurrences of hypoglycemia (aware or unaware), and high glycemic variability should be   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> used.\\n\\n[**Tables 9.3**](https://doi.org/10.2337/dc25-S009) and [**9.4**](https://doi.org/10.2337/dc25-S009)   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> were updated with glucose-lowering medication and insulin costs as of 1 July 2024, and an expanded discussion   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> on medication costs and affordability was added to the text.\\n\\nIn the new subsection â€œSpecial Circumstances    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> and Populations,â€ Recommendations 9.31a, 9.31b, and 9.31c were added to advise on actions to take when          <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> medications are not available (such as medication shortages); Recommendations 9.32a and 9.32b were added to     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> address care considerations for individuals of childbearing potential; and Recommendation 9.33 was added to     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> provide guidance on mitigating risk of ketoacidosis when individuals at risk for ketoacidosis or who follow a   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> ketogenic eating pattern are treated with SGLT inhibition. Additional text in this subsection discusses         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> considerations for glucose-lowering pharmacotherapy for individuals with diabetes secondary to chemotherapy and <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> with other types of diabetes (i.e., pancreatogenic diabetes, cystic fibrosisâ€“related diabetes, posttransplant   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> diabetes, maturity-onset diabetes of the young, and neonatal diabetes).\\n\\n### Section 10. Cardiovascular       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Disease and Risk                                                                                                <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Management\\n\\n([https://doi.org/10.2337/dc25-S010](https://doi.org/10.2337/dc25-S010))\\n\\nRecommendation 10.1   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> was updated with details on the frequency of recommended blood pressure monitoring.\\n\\n[**Figure                <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 10.2**](https://doi.org/10.2337/dc25-S010) was updated to provide clarity on medication classes for the         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> treatment of confirmed hypertension in nonpregnant people with diabetes.\\n\\nRecommendation 10.12 was modified   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> to specify appropriate monitoring for increased serum creatinine levels, serum potassium levels, and            <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> hypokalemia when ACE inhibitors, angiotensin receptor blockers (ARBs), or mineralocorticoid receptor            <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> antagonists are used.\\n\\nRecommendation 10.13 was added to specify hypertension treatment options that should   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> be avoided during pregnancy and in sexually active individuals of childbearing potential not using reliable     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> contraception.\\n\\nRecommendation 10.26 was added to recommend that in most cases lipid-lowering agents should   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> be discontinued prior to conception and avoided in sexually active individuals of childbearing potential not    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> using reliable contraception, unless the benefits may outweigh the risk.\\n\\n[**Figures                          <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 10.3**](https://doi.org/10.2337/dc25-S010) and [**10.4**](https://doi.org/10.2337/dc25-S010) were added to      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> illustrate recommendations for primary prevention and secondary prevention of ASCVD, respectively, in people    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> with diabetes using cholesterol-lowering therapy.\\n\\nTriglyceride thresholds were updated in Recommendations    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 10.31 and 10.32.\\n\\nThe criteria for coronary artery disease investigations in Recommendation 10.39b were       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> revised to include signs or symptoms of cardiac or associated vascular disease or electrocardiogram             <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> abnormalities.\\n\\nRecommendation 10.41 was modified to include screening for peripheral artery disease (PAD)    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> with ankle-brachial index testing in asymptomatic people with diabetes aged â‰¥65 years, microvascular disease in <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> any location, or foot complications or any end-organ damage from diabetes if a PAD diagnosis would change       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> management. PAD screening should also be considered in individuals with diabetes duration â‰¥10 years and high    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> cardiovascular risk.\\n\\nFor individuals with type 2 diabetes, obesity, and symptomatic heart failure with       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> preserved ejection fraction, Recommendation 10.46d was added to recommend treatment with a GLP-1 RA with        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> demonstrated benefit in this population to reduce heart failureâ€“related symptoms, reduce physical limitations,  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> and improve exercise function.\\n\\n[**Figure 10.5**](https://doi.org/10.2337/dc25-S010) was added to illustrate  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> recommendations for screening for asymptomatic and undiagnosed cardiovascular disease, and [**Fig.              <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 10.6**](https://doi.org/10.2337/dc25-S010) was added to provide an overview of recommendations for the          <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> prevention of the development of symptomatic heart failure in people with diabetes.\\n\\n### Section 11. Chronic  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Kidney Disease and Risk                                                                                         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Management\\n\\n([https://doi.org/10.2337/dc25-S011](https://doi.org/10.2337/dc25-S011))\\n\\nRecommendation 11.3   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> was amended for clarity about optimizing blood pressure management goals.\\n\\nRecommendation 11.4a was revised   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> to clarify that ACE inhibitors or ARBs should be titrated to the maximally tolerated dose to prevent the        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> progression of CKD and reduce cardiovascular events in nonpregnant individuals with diabetes and                <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> hypertension.\\n\\nRecommendation 11.4b was modified to specify appropriate monitoring for increased serum        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> creatinine levels, serum potassium levels, and hypokalemia when ACE inhibitors, ARBs, or mineralocorticoid      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> receptor antagonists are used.\\n\\nRecommendation 11.5b was updated to state that for people with type 2         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> diabetes and CKD, a GLP-1 RA with demonstrated benefit in this population should be used to reduce              <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> cardiovascular risk and kidney disease progression.\\n\\nRecommendation 11.6 was added to state that potentially  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> harmful antihypertensive medications in pregnancy should be avoided in sexually active individuals of           <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> childbearing potential not using reliable contraception and to switch to options considered safer prior to      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> conception and during pregnancy.\\n\\nRecommendation 11.7 was updated to specify reducing urinary albumin by â‰¥30% <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> to slow progression of CKD.\\n\\nRecommendation 11.8 was updated to specify protein goals for individuals with    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> stage 3 or higher CKD and those who are treated with dialysis.\\n\\n[**Table                                      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 11.1**](https://doi.org/10.2337/dc25-S011) was added to include reasons to consider nonâ€“diabetes-related kidney <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> diseases in a person with CKD and diabetes, and [**Table 11.3**](https://doi.org/10.2337/dc25-S011) was added   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> to include suggestions for interventions that lower albuminuria.\\n\\n### Section 12. Retinopathy, Neuropathy,    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> and Foot Care\\n\\n([https://doi.org/10.2337/dc25-S012](https://doi.org/10.2337/dc25-S012))\\n\\nRecommendation     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 12.5 was updated to specify involvement of an ophthalmologist for more frequent examinations if retinopathy is  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> progressing or sight threatening.\\n\\nRecommendation 12.8 wording was changed to reflect that a dilated eye exam <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> should be performed before and in the first trimester, rather than one or the other.\\n\\nRecommendation 12.19    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> was modified to include additional screening criteria for symptoms and signs of autonomic                       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> neuropathy.\\n\\nRecommendation 12.22 was updated to recommend against opioid use for neuropathic pain treatment  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> due to the potential for adverse events, and the narrative text was updated to expand on this.\\n\\nA short       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> discussion on the role of weight management and neuropathy was added to the narrative text.\\n\\nRecommendation   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 12.24 was updated to include the Ipswich touch test as an option for neurological assessment.\\n\\nRecommendation <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 12.29 was expanded to include the importance of smoke cessation and referral for counseling for individuals who <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> smoke and have a prior history of lower-extremity complications, loss of protective sensation, structural       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> abnormalities, or PAD.\\n\\nIncreasing role of surgery in diabetic foot management was added to the narrative     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> text of foot care section.\\n\\n### Section 13. Older                                                             <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Adults\\n\\n([https://doi.org/10.2337/dc25-S013](https://doi.org/10.2337/dc25-S013))\\n\\nThe 4Ms framework of      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> age-friendly health systems (Mentation, Medications, Mobility, and What Matters Most) as it applies to diabetes <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> management in older adults was introduced and illustrated in the new [**Fig.                                    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 13.1**](https://doi.org/10.2337/dc25-S013).\\n\\nRecommendation 13.8a was modified to include time in range and   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> time below range in addition to A1C treatment goals for older adults who are otherwise healthy with few and     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> stable chronic conditions and intact cognitive functional status.\\n\\nRecommendation 13.8b was modified to       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> include time in range and time below range in addition to A1C treatment goals for older adults who have         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> intermediate or complex health who are clinically heterogeneous with variable life expectancy.\\n\\n[**Table      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 13.1**](https://doi.org/10.2337/dc25-S013) was modified to include a column on reasonable CGM goals for each    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> health status category.\\n\\nIn the â€œTreatmentâ€ section, the appropriate selection and use of SGLT2 inhibitors in <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> older adults was expanded.\\n\\n### Section 14. Children and                                                      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Adolescents\\n\\n([https://doi.org/10.2337/dc25-S014](https://doi.org/10.2337/dc25-S014))\\n\\nRecommendation 14.4  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> in the â€œType 1 Diabetesâ€ section was added to emphasize key nutrition principles.\\n\\nRecommendation 14.10 was   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> altered to emphasize limits on sedentary activity.\\n\\nRecommendation 14.21 was changed to state that insulin    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> pumps should be offered to anyone with type 1 diabetes who can use the devices safely.\\n\\nRecommendation 14.24  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> was modified to remove lack of access as a reason for less stringent A1C goals.\\n\\nRecommendation 14.26 was     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> altered to include weight gain as a balancing measure for more stringent A1C goals.\\n\\nRecommendation 14.36 was <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> changed to exclude secondary causes of hypertension.\\n\\nRecommendation 14.41 was updated to include the use of  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> age-approved statins.\\n\\nRecommendation 14.50 was modified to state that screening should be repeated at a      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> minimum of 2-year intervals or more frequently if screening is normal and BMI is increasing.\\n\\nRecommendation  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 14.57 was revised to include the key nutritional principles and provide specific examples of healthy food       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> choices and what foods should be avoided.\\n\\nRecommendation 14.60 was changed to recommend an A1C goal of &lt;6.5% <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> (&lt;48 mmol/mol) for most children and adolescents with type 2 diabetes who have a low risk of hypoglycemia and a <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> higher risk of complications.\\n\\nRecommendation 14.65 was revised to change the terminology from â€œhyperglycemic <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> hyperosmolar nonketotic syndromeâ€ to â€œhyperglycemic hyperosmolar stateâ€ and include intravenous fluid as the    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> initial step to treat severe hyperglycemia (blood glucose â‰¥600 mg/dL) once the diagnosis is confirmed.\\n\\nThe   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> narrative was updated to reinforce the benefits and safety of GLP-1 RAs in decreasing A1C, weight, blood        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> pressure, and insulin dose reduction. [**Figure 14.1**](https://doi.org/10.2337/dc25-S014) was updated to       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> reflect the revision in this recommendation.\\n\\nRecommendation 14.73 was modified to reflect that excluding     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> secondary hypertension is an essential step in hypertension management.\\n\\nRecommendation 14.104 was revised to <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> state that vaping and electronic cigarettes are both discouraged.\\n\\nRecommendation 14.105 in the â€œSubstance    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Use in Pediatric Diabetesâ€ section was added to state that all youth with diabetes should be advised not to use <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> cannabis recreationally in any form.\\n\\nRecommendation 14.108 was modified to encourage pediatric diabetes      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> specialists to partner with youth with diabetes and their caregivers to engage in shared                        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> decision-making.\\n\\n[**Tables 14.1 _A_**](https://doi.org/10.2337/dc25-S014) and [**14.1                        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> _B_**](https://doi.org/10.2337/dc25-S014) were modified to include changes made throughout Section 14.\\n\\n###   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Section 15. Management of Diabetes in                                                                           <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Pregnancy\\n\\n([https://doi.org/10.2337/dc25-S015](https://doi.org/10.2337/dc25-S015))\\n\\nSection 15 was         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> restructured to discuss the care of pregnant individuals with type 1 diabetes, type 2 diabetes, and GDM in all  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> sections and to discuss aspects of management in each relevant subsection (e.g., preconception care and         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> pharmacotherapy); consequently, the order of appearance of some of the recommendations                          <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> changed.\\n\\nRecommendation 15.7 wording was changed to reflect that a dilated eye exam should be performed      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> before and in the first trimester, rather than one or the other.\\n\\n[**Table                                    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 15.1**](https://doi.org/10.2337/dc25-S015) was updated with a folic acid supplement recommendation of 400â€“800   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Î¼g/day and clarification for which checklist items are only for individuals with preexisting diabetes and not   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> for individuals with prediabetes or a history of GDM, and specific immunizations were omitted and               <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> referenced.\\n\\nIn Recommendation 15.10, the benefits of CGM use in type 1 diabetes and pregnancy were           <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> clarified, and an addition of its potential to be beneficial in other types of diabetes in pregnancy was        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> added.\\n\\nRecommendation 15.12 no longer states that CGM metrics should not be used as a substitute for blood   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> glucose monitoring; the recommendation now states that CGM may be used in conjunction with blood glucose        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> monitoring to achieve glycemic goals.\\n\\nGlucose goals for preexisting diabetes, GDM treated with insulin, and  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> GDM not treated with insulin are consolidated into a new [**Table                                               <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 15.2**](https://doi.org/10.2337/dc25-S015).\\n\\nâ€œManagement of Gestational Diabetes Mellitusâ€ and â€œManagement of <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Preexisting Type 1 Diabetes and Type 2 Diabetes Pregnancyâ€ were merged into one subsection, titled â€œManagement  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> of Diabetes in Pregnancy,â€ which includes all aspects of management for all types of diabetes (e.g., nutrition, <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> physical activity, and pharmacotherapy).\\n\\nRecommendation 15.14 provides more clarification on the recommended <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> eating pattern in pregnancy.\\n\\nInsulin recommendations that were previously split into separate                <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> recommendations for preexisting diabetes and GDM were merged.\\n\\nThere are two new recommendations regarding    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> AID use in type 1 diabetes and pregnancy. Recommendation 15.19 states that AID systems are recommended if the   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> system has a pregnancy-specific glucose goal. Recommendation 15.20 states that AID systems may be considered    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> for select individuals with an experienced health care team if the system does not have a pregnancy-specific    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> glucose goal or algorithm.\\n\\nRecommendation 15.21 provides more clarification for why metformin and glyburide  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> should not be first-line agents for management of diabetes in pregnancy.\\n\\nThe narrative for subsection        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> â€œPhysical Activityâ€ includes recommended activity levels for pregnancy, as these pertain to individuals with    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> any type of diabetes in pregnancy.\\n\\nThe â€œInsulinâ€ subsection includes information on different insulin        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> delivery modalities used during labor and delivery or postpartum.\\n\\nThe recommendation to explicitly measure   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> blood pressure during pregnancy is now mentioned in the narrative of the â€œPreeclampsia and Aspirinâ€ subsection  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> per the recent guidelines of the U.S. Preventive Services Task Force.\\n\\nRecommendation 15.25 was split into    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> two recommendations. Recommendation 15.25a provides more examples of potentially harmful medications in         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> pregnancy. Recommendation 15.25b recommends that lipid-lowering medications be avoided in most circumstances in <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> pregnancy but that statins may be considered for use in high-risk individuals (such as those with prior ASCVD   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> and familial hypercholesterolemia) when benefits outweigh risks. The narrative discusses Recommendation 15.25b  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> in more detail and includes discussion of studies of pravastatin use in pregnancy.\\n\\n### Section 16. Diabetes  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Care in the Hospital\\n\\n([https://doi.org/10.2337/dc25-S016](https://doi.org/10.2337/dc25-S016))\\n\\nDiabetes    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> care in the hospital stresses identification and treatment of dysglycemia and provides glycemic goals. For the  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> treatment of persistent hyperglycemia starting at a threshold of â‰¥180 mg/dL (â‰¥10.0 mmol/L), Recommendation      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 16.4a was amended to reflect that insulin should be initiated or intensified for the majority of critically ill <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> individuals, and Recommendation 16.4b was added to state that insulin and/or other glucose-lowering therapies   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> should be initiated or intensified for the majority of noncritically ill individuals.\\n\\nRecommendation 16.5a   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> was updated to state that a glycemic goal of 140â€“180 mg/dL (7.8â€“10.0 mmol/L) is recommended for most critically <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> ill individuals, but more stringent individualized glycemic goals may be appropriate if they can be achieved    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> without significant hypoglycemia. Recommendation 16.5b was updated to recommend a glycemic goal of 100â€“180      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> mg/dL (5.6â€“10.0 mmol/L) for most noncritically ill individuals if it can be achieved without significant        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> hypoglycemia.\\n\\nRecommendation 16.7 was amended for clarity on the use of insulin pump or AID continuation and <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> their use in people with diabetes who are hospitalized, when clinically appropriate.\\n\\nRecommendation 16.8a    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> was added to state that continuous intravenous insulin infusion is recommended for achieving glycemic goals and <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> avoiding hypoglycemia in critically ill individuals.\\n\\nThe language regarding a hypoglycemia management        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> surveillance protocol for health systems was updated for clarity in Recommendation 16.12.\\n\\nGuidance regarding <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> use of GLP-1 RA and dual GIP and GLP-1 RA medications in the perioperative setting and regarding instructions   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> in preparation for procedures or surgery has been added to the narrative text.\\n\\nRecommendations 16.14 and     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 16.15 were added for DKA and HHS management; transition to maintenance subcutaneous insulin administration and  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> discharge planning were added. Additionally, the newly added [**Fig. 16.1**](https://doi.org/10.2337/dc25-S016) <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> includes treatment pathways for DKA and HHS.\\n\\n### Section 17. Diabetes                                        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Advocacy\\n\\n([https://doi.org/10.2337/dc25-S017](https://doi.org/10.2337/dc25-S017))\\n\\nThe subsections         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> â€œDiabetes Care in the School Settingâ€ and â€œDiabetes and Drivingâ€ were updated with information from recently    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> published advocacy statements. The subsection â€œDiabetes Management in Detention Facilitiesâ€ was added with      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> information from a recently published advocacy statement.\\n\\n*A complete list of members of the American        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Diabetes Association Professional Practice Committee can be found at                                            <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> [https://doi.org/10.2337/dc25-SINT](https://doi.org/10.2337/dc25-SINT).\\n\\nDuality of interest information for  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> each author is available at [10.2337/dc25-SDIS](https://doi.org/10.2337/dc25-SDIS).\\n\\nSuggested citation:      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> American Diabetes Association Professional Practice Committee. Summary of revisions: Standards of Care in       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Diabetesâ€”2025. Diabetes Care 2025;48(Suppl. 1):S6â€“S13\\n\\nÂ© 2024 by the American Diabetes                        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Association\\n\\n2024\\n\\nReaders may use this article as long as the work is properly cited, the use is           <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> educational and not for profit, and the work is not altered. More information is available at                   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> [https://www.diabetesjournals.org/journals/pages/license](https://www.diabetesjournals.org/journals/pages/licen <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> se).\\n\\n[](https://diabetesjournals.org/care/article/48/Supplement_1/S6/157564/Summary-of-Revisions-Standards-o <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> f-Care-in-Diabetes)\\n\\n417,299                                                                                  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Views\\n\\n[29](https://www.webofscience.com/api/gateway?GWVersion=2&amp;SrcApp=silverchair&amp;SrcAuth=WosAPI&amp;KeyUT=WOS: <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 001378283000018&amp;DestLinkType=CitingArticles&amp;DestApp=WOS_CPL)Web of Science\\n\\n[![Image 6: Article has an        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> altmetric score of                                                                                              <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 32](https://badges.altmetric.com/?size=128&amp;score=32&amp;types=mttttttu)](https://www.altmetric.com/details.php?doma <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> in=diabetesjournals.org&amp;citation_id=171817539)\\n\\n[View Metrics](javascript:;)\\n\\n[Ã—Close                       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Modal](javascript:;)\\n\\n### Email alerts\\n\\n[Article Activity Alert](javascript:;)\\n\\n[Online Ahead of Print    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Alert](javascript:;)\\n\\n[Latest Issue Alert](javascript:;)\\n\\n[Close Modal](javascript:;)\\n\\n*   Online ISSN    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 1935-5548\\n*   Print ISSN 0149-5992\\n\\n### Journals\\n\\n*   [Diabetes](https://diabetesjournals.org/diabetes)\\n* <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> [Diabetes Care](https://diabetesjournals.org/care)\\n*   [Diabetes, Obesity, and Cardiometabolic                 <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> CARE](https://diabetesjournals.org/docm-care)\\n*   [Clinical                                                    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Diabetes](https://diabetesjournals.org/clinical)\\n*   [Diabetes                                                 <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Spectrum](https://diabetesjournals.org/spectrum)\\n*   [Standards of Medical Care in                             <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Diabetes](https://diabetesjournals.org/care/issue/48/Supplement_1)\\n*   [Scientific Sessions                    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Abstracts](https://diabetesjournals.org/journals/pages/scientific-sessions-abstracts)\\n*   [BMJ Open Diabetes   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Research &amp; Care](https://drc.bmj.com/)\\n\\n### Books\\n\\n*                                                        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> [ShopDiabetes.org](https://shopdiabetes.org/collections/professional-books)\\n*   [ADA Professional              <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Books](https://diabetesjournals.org/books)\\n\\n### Clinical Compendia\\n\\n*   [Clinical Compendia                 <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Home](https://diabetesjournals.org/compendia)\\n\\n### News\\n\\n*   [Latest                                        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> News](https://www.diabetes.org/newsroom)\\n*   [DiabetesPro                                                      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> SmartBrief](https://www2.smartbrief.com/signupSystem/subscribe.action?pageSequence=1&amp;briefName=diabetespro)\\n\\n <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> ### Podcasts\\n\\n*   [Diabetes Core                                                                              <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Update](https://diabetesjournals.org/journals/pages/diabetes-core-update-podcasts)\\n*   [Diabetes Care \\\"On     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Air\\\"](https://sites.libsyn.com/453336/site)\\n*   [DiabetesBio](https://sites.libsyn.com/499063/site)\\n*        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> [Diabetes Day by Day](https://sites.libsyn.com/435096/site)\\n*   [Diabetes Core Update: Special                 <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Editions](https://diabetesjournals.org/journals/pages/diabetes-core-update-special-editions)\\n\\n### Other\\n\\n*  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> [Special Collections](https://diabetesjournals.org/journals/pages/journals_special_collections)\\n*              <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> [DiabetesProÂ®](https://professional.diabetes.org/)\\n*   [Diabetes Food                                          <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Hubâ„¢](https://www.diabetesfoodhub.org/)\\n*   [Insulin Affordability](https://doi.org/10.2337/dci18-0019)\\n*     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> [Know Diabetes By Heartâ„¢](https://www.knowdiabetesbyheart.org/)\\n\\n### About\\n\\n*   [About the                  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> ADA](https://www.diabetes.org/about-us)\\n*   [Journal                                                           <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Policies](https://diabetesjournals.org/journals/pages/ada-journal-policies)\\n*   [For                           <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Reviewers](https://diabetesjournals.org/journals/pages/reviewers)\\n*   [Advertising in ADA                      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Journals](https://diabetesjournals.org/journals/pages/advertising)\\n*   [Reprints and Permission for            <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Reuse](https://diabetesjournals.org/journals/pages/reprints-and-permissions)\\n*   [Copyright Notice/Public      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Access Policy](https://diabetesjournals.org/journals/pages/license)\\n*   [Privacy                               <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Policy](https://diabetes.org/about-us/policies/privacy-policy)\\n\\n### Resources\\n\\n*   [ADA Professional        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Membership](https://professional.diabetes.org/membership)\\n*   [ADA Member                                      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Directory](http://professional.diabetes.org/directory)\\n*                                                       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> [Diabetes.org](http://www.diabetes.org/)\\n\\n[![Image                                                            <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 7](https://ada.silverchair-cdn.com/data/SiteBuilderAssetsOriginals/Live/images/umbrella/logo-umbrella-footer.sv <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> g?versionId=6439)](https://diabetes.org/)\\n\\n*   [Bluesky](https://bsky.app/profile/adapubs.bsky.social)\\n*     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> [X (Twitter)](https://twitter.com/ADA_Pubs)\\n*   [Facebook](https://www.facebook.com/adaPublications)\\n*        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> [LinkedIn](https://www.linkedin.com/company/american-diabetes-association/)\\n\\n*   [Contact                     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Us](https://diabetesjournals.org/contact-us)\\n*   [Cookie                                                       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Policy](https://diabetesjournals.org/journals/pages/Policies)\\n*                                                <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> [Accessibility](https://diabetesjournals.org/pages/Accessibility)\\n*   [Terms &amp;                                 <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Conditions](https://diabetes.org/about-us/policies/terms-of-use)\\n*   [Get Adobe Acrobat                        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Reader](https://get.adobe.com/reader/)\\n*   Â© Copyright American Diabetes Association\\n\\n[_Close                <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Modal_](javascript:;)\\n\\n[Close Modal](javascript:;)\\n\\n##### This Feature Is Available To Subscribers          <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Only\\n\\n[Sign                                                                                                   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> In](https://diabetesjournals.org/sign-in?returnUrl=%2fcare%2farticle%2f48%2fSupplement_1%2fS6%2f157564%2fSummar <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> y-of-Revisions-Standards-of-Care-in-Diabetes) or [Create an                                                     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Account](https://diabetesjournals.org/my-account/register?siteId=1000003&amp;returnUrl=%2fcare%2farticle%2f48%2fSup <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> plement_1%2fS6%2f157564%2fSummary-of-Revisions-Standards-of-Care-in-Diabetes)\\n\\n[_Close                        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Modal_](javascript:;)\\n\\n[_Close Modal_](javascript:;)\\n\\n This site uses cookies. By continuing to use our     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> website, you are agreeing to [our privacy                                                                       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> policy.](https://www.diabetesjournals.org/content/privacy-policy-american-diabetes-association-journals)\\n\\n[Ac <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> cept](javascript:;)\\n\\nclose                                                                                    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> advertisement\\n\\n##Source\\nhttps://diabetesjournals.org/care/article/48/Supplement_1/S6/157564/Summary-of-Revis <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> ions-Standards-of-Care-in-Diabetes\"]                                                                            <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â•°â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â•¯</span>\n",
              "</pre>\n"
            ]
          },
          "metadata": {}
        },
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "\u001b[33mâ•­â”€\u001b[0m\u001b[33mâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€\u001b[0m\u001b[33m ðŸ”§ Tool Output \u001b[0m\u001b[33mâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€\u001b[0m\u001b[33mâ”€â•®\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m {'recommended_doctor': AIMessage(content='{\\n  \"name\": \"Dr. Janet Dyne\",\\n  \"specialization\": \"Endocrinology    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m (Diabetes Care)\",\\n  \"available_timings\": \"10:00 AM - 1:00 PM\",\\n  \"location\": \"City Health Clinic\",\\n          \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m \"contact\": \"janet.dyne@healthclinic.com\"\\n}', additional_kwargs={'refusal': None},                              \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m response_metadata={'token_usage': {'completion_tokens': 69, 'prompt_tokens': 387, 'total_tokens': 456,          \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 'completion_tokens_details': {'accepted_prediction_tokens': 0, 'audio_tokens': 0, 'reasoning_tokens': 0,        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 'rejected_prediction_tokens': 0}, 'prompt_tokens_details': {'audio_tokens': 0, 'cached_tokens': 0}},            \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 'model_provider': 'openai', 'model_name': 'gpt-4o-mini-2024-07-18', 'system_fingerprint': 'fp_560af6e559',      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 'id': 'chatcmpl-CZagubdp8I4HAmEaxeWCHMHunN4ST', 'service_tier': 'default', 'finish_reason': 'stop', 'logprobs': \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m None}, id='lc_run--9b801946-9fed-48bd-8fea-d170d63a3ca2-0', usage_metadata={'input_tokens': 387,                \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 'output_tokens': 69, 'total_tokens': 456, 'input_token_details': {'audio': 0, 'cache_read': 0},                 \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 'output_token_details': {'audio': 0, 'reasoning': 0}})}                                                         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ•°â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â•¯\u001b[0m\n"
            ],
            "text/html": [
              "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #808000; text-decoration-color: #808000\">â•­â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€ ðŸ”§ Tool Output â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â•®</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> {'recommended_doctor': AIMessage(content='{\\n  \"name\": \"Dr. Janet Dyne\",\\n  \"specialization\": \"Endocrinology    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> (Diabetes Care)\",\\n  \"available_timings\": \"10:00 AM - 1:00 PM\",\\n  \"location\": \"City Health Clinic\",\\n          <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> \"contact\": \"janet.dyne@healthclinic.com\"\\n}', additional_kwargs={'refusal': None},                              <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> response_metadata={'token_usage': {'completion_tokens': 69, 'prompt_tokens': 387, 'total_tokens': 456,          <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 'completion_tokens_details': {'accepted_prediction_tokens': 0, 'audio_tokens': 0, 'reasoning_tokens': 0,        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 'rejected_prediction_tokens': 0}, 'prompt_tokens_details': {'audio_tokens': 0, 'cached_tokens': 0}},            <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 'model_provider': 'openai', 'model_name': 'gpt-4o-mini-2024-07-18', 'system_fingerprint': 'fp_560af6e559',      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 'id': 'chatcmpl-CZagubdp8I4HAmEaxeWCHMHunN4ST', 'service_tier': 'default', 'finish_reason': 'stop', 'logprobs': <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> None}, id='lc_run--9b801946-9fed-48bd-8fea-d170d63a3ca2-0', usage_metadata={'input_tokens': 387,                <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 'output_tokens': 69, 'total_tokens': 456, 'input_token_details': {'audio': 0, 'cache_read': 0},                 <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 'output_token_details': {'audio': 0, 'reasoning': 0}})}                                                         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â•°â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â•¯</span>\n",
              "</pre>\n"
            ]
          },
          "metadata": {}
        },
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "\u001b[32mâ•­â”€\u001b[0m\u001b[32mâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€\u001b[0m\u001b[32m ðŸ¤– Assistant \u001b[0m\u001b[32mâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€\u001b[0m\u001b[32mâ”€â•®\u001b[0m\n",
              "\u001b[32mâ”‚\u001b[0m ### Latest Methods for Diabetes Management                                                                      \u001b[32mâ”‚\u001b[0m\n",
              "\u001b[32mâ”‚\u001b[0m                                                                                                                 \u001b[32mâ”‚\u001b[0m\n",
              "\u001b[32mâ”‚\u001b[0m The management of diabetes, particularly type 2 diabetes, has seen significant advancements, especially in the  \u001b[32mâ”‚\u001b[0m\n",
              "\u001b[32mâ”‚\u001b[0m areas of treatment, lifestyle intervention, and monitoring. Key updates in diabetes management as of 2025       \u001b[32mâ”‚\u001b[0m\n",
              "\u001b[32mâ”‚\u001b[0m include:                                                                                                        \u001b[32mâ”‚\u001b[0m\n",
              "\u001b[32mâ”‚\u001b[0m                                                                                                                 \u001b[32mâ”‚\u001b[0m\n",
              "\u001b[32mâ”‚\u001b[0m 1. **Lifestyle Interventions**:                                                                                 \u001b[32mâ”‚\u001b[0m\n",
              "\u001b[32mâ”‚\u001b[0m    - Lifestyle changes remain foundational in diabetes management, emphasizing diet and physical activity.      \u001b[32mâ”‚\u001b[0m\n",
              "\u001b[32mâ”‚\u001b[0m    - Intensive lifestyle interventions (ILI) can lead to significant improvements in glycemic control.          \u001b[32mâ”‚\u001b[0m\n",
              "\u001b[32mâ”‚\u001b[0m                                                                                                                 \u001b[32mâ”‚\u001b[0m\n",
              "\u001b[32mâ”‚\u001b[0m 2. **Medications**:                                                                                             \u001b[32mâ”‚\u001b[0m\n",
              "\u001b[32mâ”‚\u001b[0m    - **SGLT2 Inhibitors**: These drugs (e.g., empagliflozin) have shown substantial benefits in reducing        \u001b[32mâ”‚\u001b[0m\n",
              "\u001b[32mâ”‚\u001b[0m cardiovascular and kidney-related risks in patients with diabetes.                                              \u001b[32mâ”‚\u001b[0m\n",
              "\u001b[32mâ”‚\u001b[0m    - **GLP-1 Receptor Agonists**: Medications like semaglutide and tirzepatide not only help in glycemic        \u001b[32mâ”‚\u001b[0m\n",
              "\u001b[32mâ”‚\u001b[0m control but also promote weight loss and improve cardiovascular health.                                         \u001b[32mâ”‚\u001b[0m\n",
              "\u001b[32mâ”‚\u001b[0m    - **Resmetirom**: Recently approved for metabolic dysfunction-associated steatohepatitis (MASH), showcasing  \u001b[32mâ”‚\u001b[0m\n",
              "\u001b[32mâ”‚\u001b[0m a novel approach for liver health in diabetes patients.                                                         \u001b[32mâ”‚\u001b[0m\n",
              "\u001b[32mâ”‚\u001b[0m                                                                                                                 \u001b[32mâ”‚\u001b[0m\n",
              "\u001b[32mâ”‚\u001b[0m 3. **Technology in Care**:                                                                                      \u001b[32mâ”‚\u001b[0m\n",
              "\u001b[32mâ”‚\u001b[0m    - Continuous Glucose Monitoring (CGM) systems have enhanced the ability to manage blood glucose levels       \u001b[32mâ”‚\u001b[0m\n",
              "\u001b[32mâ”‚\u001b[0m effectively, facilitating timely interventions.                                                                 \u001b[32mâ”‚\u001b[0m\n",
              "\u001b[32mâ”‚\u001b[0m                                                                                                                 \u001b[32mâ”‚\u001b[0m\n",
              "\u001b[32mâ”‚\u001b[0m 4. **Screening and Management of Complications**:                                                               \u001b[32mâ”‚\u001b[0m\n",
              "\u001b[32mâ”‚\u001b[0m    - Regular screening for cardiovascular disease (CVD) and chronic kidney disease (CKD) is now recommended due \u001b[32mâ”‚\u001b[0m\n",
              "\u001b[32mâ”‚\u001b[0m to the intertwining relationships these conditions have with diabetes.                                          \u001b[32mâ”‚\u001b[0m\n",
              "\u001b[32mâ”‚\u001b[0m    - Enhanced understanding of the need for early intervention to prevent complications has led to more         \u001b[32mâ”‚\u001b[0m\n",
              "\u001b[32mâ”‚\u001b[0m comprehensive guideline recommendations.                                                                        \u001b[32mâ”‚\u001b[0m\n",
              "\u001b[32mâ”‚\u001b[0m                                                                                                                 \u001b[32mâ”‚\u001b[0m\n",
              "\u001b[32mâ”‚\u001b[0m 5. **Focus on Mental Health**:                                                                                  \u001b[32mâ”‚\u001b[0m\n",
              "\u001b[32mâ”‚\u001b[0m    - Increased acknowledgment of the psychological aspects of diabetes management, including routine screening  \u001b[32mâ”‚\u001b[0m\n",
              "\u001b[32mâ”‚\u001b[0m for diabetes distress and anxiety, emphasizing holistic patient care.                                           \u001b[32mâ”‚\u001b[0m\n",
              "\u001b[32mâ”‚\u001b[0m                                                                                                                 \u001b[32mâ”‚\u001b[0m\n",
              "\u001b[32mâ”‚\u001b[0m For a more detailed account of these methods, the [International Diabetes Federation (IDF) Recommendations for  \u001b[32mâ”‚\u001b[0m\n",
              "\u001b[32mâ”‚\u001b[0m Managing Type 2 Diabetes 2025](https://idf.org/media/uploads/2025/04/IDF_Rec_2025.pdf) and the [American        \u001b[32mâ”‚\u001b[0m\n",
              "\u001b[32mâ”‚\u001b[0m Diabetes Association Standards of Care 2025](https://diabetesjournals.org/care/issue/48/Supplement_1) provide   \u001b[32mâ”‚\u001b[0m\n",
              "\u001b[32mâ”‚\u001b[0m extensive insights.                                                                                             \u001b[32mâ”‚\u001b[0m\n",
              "\u001b[32mâ”‚\u001b[0m                                                                                                                 \u001b[32mâ”‚\u001b[0m\n",
              "\u001b[32mâ”‚\u001b[0m ### Recommended Doctor                                                                                          \u001b[32mâ”‚\u001b[0m\n",
              "\u001b[32mâ”‚\u001b[0m                                                                                                                 \u001b[32mâ”‚\u001b[0m\n",
              "\u001b[32mâ”‚\u001b[0m For diabetes management, I recommend the following healthcare professional:                                     \u001b[32mâ”‚\u001b[0m\n",
              "\u001b[32mâ”‚\u001b[0m                                                                                                                 \u001b[32mâ”‚\u001b[0m\n",
              "\u001b[32mâ”‚\u001b[0m #### Dr. Janet Dyne                                                                                             \u001b[32mâ”‚\u001b[0m\n",
              "\u001b[32mâ”‚\u001b[0m - **Specialization**: Endocrinology (Diabetes Care)                                                             \u001b[32mâ”‚\u001b[0m\n",
              "\u001b[32mâ”‚\u001b[0m - **Location**: City Health Clinic                                                                              \u001b[32mâ”‚\u001b[0m\n",
              "\u001b[32mâ”‚\u001b[0m - **Available Timings**: 10:00 AM - 1:00 PM                                                                     \u001b[32mâ”‚\u001b[0m\n",
              "\u001b[32mâ”‚\u001b[0m - **Contact**: [janet.dyne@healthclinic.com](mailto:janet.dyne@healthclinic.com)                                \u001b[32mâ”‚\u001b[0m\n",
              "\u001b[32mâ”‚\u001b[0m                                                                                                                 \u001b[32mâ”‚\u001b[0m\n",
              "\u001b[32mâ”‚\u001b[0m If you would like to book an appointment, please reach out to Dr. Dyne's office via the provided email address. \u001b[32mâ”‚\u001b[0m\n",
              "\u001b[32mâ•°â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â•¯\u001b[0m\n"
            ],
            "text/html": [
              "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #008000; text-decoration-color: #008000\">â•­â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€ ðŸ¤– Assistant â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â•®</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span> ### Latest Methods for Diabetes Management                                                                      <span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>                                                                                                                 <span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span> The management of diabetes, particularly type 2 diabetes, has seen significant advancements, especially in the  <span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span> areas of treatment, lifestyle intervention, and monitoring. Key updates in diabetes management as of 2025       <span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span> include:                                                                                                        <span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>                                                                                                                 <span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span> 1. **Lifestyle Interventions**:                                                                                 <span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>    - Lifestyle changes remain foundational in diabetes management, emphasizing diet and physical activity.      <span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>    - Intensive lifestyle interventions (ILI) can lead to significant improvements in glycemic control.          <span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>                                                                                                                 <span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span> 2. **Medications**:                                                                                             <span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>    - **SGLT2 Inhibitors**: These drugs (e.g., empagliflozin) have shown substantial benefits in reducing        <span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span> cardiovascular and kidney-related risks in patients with diabetes.                                              <span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>    - **GLP-1 Receptor Agonists**: Medications like semaglutide and tirzepatide not only help in glycemic        <span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span> control but also promote weight loss and improve cardiovascular health.                                         <span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>    - **Resmetirom**: Recently approved for metabolic dysfunction-associated steatohepatitis (MASH), showcasing  <span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span> a novel approach for liver health in diabetes patients.                                                         <span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>                                                                                                                 <span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span> 3. **Technology in Care**:                                                                                      <span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>    - Continuous Glucose Monitoring (CGM) systems have enhanced the ability to manage blood glucose levels       <span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span> effectively, facilitating timely interventions.                                                                 <span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>                                                                                                                 <span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span> 4. **Screening and Management of Complications**:                                                               <span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>    - Regular screening for cardiovascular disease (CVD) and chronic kidney disease (CKD) is now recommended due <span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span> to the intertwining relationships these conditions have with diabetes.                                          <span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>    - Enhanced understanding of the need for early intervention to prevent complications has led to more         <span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span> comprehensive guideline recommendations.                                                                        <span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>                                                                                                                 <span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span> 5. **Focus on Mental Health**:                                                                                  <span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>    - Increased acknowledgment of the psychological aspects of diabetes management, including routine screening  <span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span> for diabetes distress and anxiety, emphasizing holistic patient care.                                           <span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>                                                                                                                 <span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span> For a more detailed account of these methods, the [International Diabetes Federation (IDF) Recommendations for  <span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span> Managing Type 2 Diabetes 2025](https://idf.org/media/uploads/2025/04/IDF_Rec_2025.pdf) and the [American        <span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span> Diabetes Association Standards of Care 2025](https://diabetesjournals.org/care/issue/48/Supplement_1) provide   <span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span> extensive insights.                                                                                             <span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>                                                                                                                 <span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span> ### Recommended Doctor                                                                                          <span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>                                                                                                                 <span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span> For diabetes management, I recommend the following healthcare professional:                                     <span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>                                                                                                                 <span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span> #### Dr. Janet Dyne                                                                                             <span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span> - **Specialization**: Endocrinology (Diabetes Care)                                                             <span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span> - **Location**: City Health Clinic                                                                              <span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span> - **Available Timings**: 10:00 AM - 1:00 PM                                                                     <span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span> - **Contact**: [janet.dyne@healthclinic.com](mailto:janet.dyne@healthclinic.com)                                <span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>                                                                                                                 <span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span> If you would like to book an appointment, please reach out to Dr. Dyne's office via the provided email address. <span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">â•°â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â•¯</span>\n",
              "</pre>\n"
            ]
          },
          "metadata": {}
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "# Example usage\n",
        "query = \"I am having panic attacks, what could I do? get detailed comprehensive information please\"\n",
        "result = call_agent(healthbuddy_agent, query, verbose=True)"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 1000
        },
        "id": "UwcGu13kgqJs",
        "outputId": "0183432b-5e8b-45c5-a4a1-839d6ba3a493"
      },
      "id": "UwcGu13kgqJs",
      "execution_count": null,
      "outputs": [
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "\u001b[34mâ•­â”€\u001b[0m\u001b[34mâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€\u001b[0m\u001b[34m ðŸ§‘ Human \u001b[0m\u001b[34mâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€\u001b[0m\u001b[34mâ”€â•®\u001b[0m\n",
              "\u001b[34mâ”‚\u001b[0m I am having panic attacks, what could I do? get detailed comprehensive information please                       \u001b[34mâ”‚\u001b[0m\n",
              "\u001b[34mâ•°â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â•¯\u001b[0m\n"
            ],
            "text/html": [
              "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #000080; text-decoration-color: #000080\">â•­â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€ ðŸ§‘ Human â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â•®</span>\n",
              "<span style=\"color: #000080; text-decoration-color: #000080\">â”‚</span> I am having panic attacks, what could I do? get detailed comprehensive information please                       <span style=\"color: #000080; text-decoration-color: #000080\">â”‚</span>\n",
              "<span style=\"color: #000080; text-decoration-color: #000080\">â•°â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â•¯</span>\n",
              "</pre>\n"
            ]
          },
          "metadata": {}
        },
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "\u001b[31mâ•­â”€\u001b[0m\u001b[31mâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€\u001b[0m\u001b[31m âš™ï¸ Tool Request \u001b[0m\u001b[31mâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€\u001b[0m\u001b[31mâ”€â•®\u001b[0m\n",
              "\u001b[31mâ”‚\u001b[0m                                                                                                                 \u001b[31mâ”‚\u001b[0m\n",
              "\u001b[31mâ”‚\u001b[0m ðŸ”§ Tool Call: search_web                                                                                        \u001b[31mâ”‚\u001b[0m\n",
              "\u001b[31mâ”‚\u001b[0m    Args: {                                                                                                      \u001b[31mâ”‚\u001b[0m\n",
              "\u001b[31mâ”‚\u001b[0m   \"query\": \"panic attacks symptoms and treatment options 2025\"                                                  \u001b[31mâ”‚\u001b[0m\n",
              "\u001b[31mâ”‚\u001b[0m }                                                                                                               \u001b[31mâ”‚\u001b[0m\n",
              "\u001b[31mâ”‚\u001b[0m    ID: call_wnCS5JqJgsqNbNDb3rTSjLrh                                                                            \u001b[31mâ”‚\u001b[0m\n",
              "\u001b[31mâ”‚\u001b[0m                                                                                                                 \u001b[31mâ”‚\u001b[0m\n",
              "\u001b[31mâ”‚\u001b[0m ðŸ”§ Tool Call: search_arxiv                                                                                      \u001b[31mâ”‚\u001b[0m\n",
              "\u001b[31mâ”‚\u001b[0m    Args: {                                                                                                      \u001b[31mâ”‚\u001b[0m\n",
              "\u001b[31mâ”‚\u001b[0m   \"query\": \"panic attacks psychological treatment\"                                                              \u001b[31mâ”‚\u001b[0m\n",
              "\u001b[31mâ”‚\u001b[0m }                                                                                                               \u001b[31mâ”‚\u001b[0m\n",
              "\u001b[31mâ”‚\u001b[0m    ID: call_Ers0oRVCtJQe8mZiJ4nMnhEK                                                                            \u001b[31mâ”‚\u001b[0m\n",
              "\u001b[31mâ•°â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â•¯\u001b[0m\n"
            ],
            "text/html": [
              "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #800000; text-decoration-color: #800000\">â•­â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€ âš™ï¸ Tool Request â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â•®</span>\n",
              "<span style=\"color: #800000; text-decoration-color: #800000\">â”‚</span>                                                                                                                 <span style=\"color: #800000; text-decoration-color: #800000\">â”‚</span>\n",
              "<span style=\"color: #800000; text-decoration-color: #800000\">â”‚</span> ðŸ”§ Tool Call: search_web                                                                                        <span style=\"color: #800000; text-decoration-color: #800000\">â”‚</span>\n",
              "<span style=\"color: #800000; text-decoration-color: #800000\">â”‚</span>    Args: {                                                                                                      <span style=\"color: #800000; text-decoration-color: #800000\">â”‚</span>\n",
              "<span style=\"color: #800000; text-decoration-color: #800000\">â”‚</span>   \"query\": \"panic attacks symptoms and treatment options 2025\"                                                  <span style=\"color: #800000; text-decoration-color: #800000\">â”‚</span>\n",
              "<span style=\"color: #800000; text-decoration-color: #800000\">â”‚</span> }                                                                                                               <span style=\"color: #800000; text-decoration-color: #800000\">â”‚</span>\n",
              "<span style=\"color: #800000; text-decoration-color: #800000\">â”‚</span>    ID: call_wnCS5JqJgsqNbNDb3rTSjLrh                                                                            <span style=\"color: #800000; text-decoration-color: #800000\">â”‚</span>\n",
              "<span style=\"color: #800000; text-decoration-color: #800000\">â”‚</span>                                                                                                                 <span style=\"color: #800000; text-decoration-color: #800000\">â”‚</span>\n",
              "<span style=\"color: #800000; text-decoration-color: #800000\">â”‚</span> ðŸ”§ Tool Call: search_arxiv                                                                                      <span style=\"color: #800000; text-decoration-color: #800000\">â”‚</span>\n",
              "<span style=\"color: #800000; text-decoration-color: #800000\">â”‚</span>    Args: {                                                                                                      <span style=\"color: #800000; text-decoration-color: #800000\">â”‚</span>\n",
              "<span style=\"color: #800000; text-decoration-color: #800000\">â”‚</span>   \"query\": \"panic attacks psychological treatment\"                                                              <span style=\"color: #800000; text-decoration-color: #800000\">â”‚</span>\n",
              "<span style=\"color: #800000; text-decoration-color: #800000\">â”‚</span> }                                                                                                               <span style=\"color: #800000; text-decoration-color: #800000\">â”‚</span>\n",
              "<span style=\"color: #800000; text-decoration-color: #800000\">â”‚</span>    ID: call_Ers0oRVCtJQe8mZiJ4nMnhEK                                                                            <span style=\"color: #800000; text-decoration-color: #800000\">â”‚</span>\n",
              "<span style=\"color: #800000; text-decoration-color: #800000\">â•°â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â•¯</span>\n",
              "</pre>\n"
            ]
          },
          "metadata": {}
        },
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "\u001b[33mâ•­â”€\u001b[0m\u001b[33mâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€\u001b[0m\u001b[33m ðŸ”§ Tool Output \u001b[0m\u001b[33mâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€\u001b[0m\u001b[33mâ”€â•®\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m [\"## Title\\nPanicToCalm: A Proactive Counseling Agent for Panic Attacks\\n\\n## Summary\\nPanic attacks are acute  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m episodes of fear and distress, in which timely,\\nappropriate intervention can significantly help individuals    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m regain stability.\\nHowever, suitable datasets for training such models remain scarce due to\\nethical and        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m logistical issues. To address this, we introduce PACE, which is a\\ndataset that includes high-distress episodes \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m constructed from first-person\\nnarratives, and structured around the principles of Psychological First          \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Aid\\n(PFA). Using this data, we train PACER, a counseling model designed to provide\\nboth empathetic and        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m directive support, which is optimized through supervised\\nlearning and simulated preference alignment. To       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m assess its effectiveness, we\\npropose PanicEval, a multi-dimensional framework covering general                 \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m counseling\\nquality and crisis-specific strategies. Experimental results show that PACER\\noutperforms strong    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m baselines in both counselor-side metrics and client affect\\nimprovement. Human evaluations further confirm its  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m practical value, with PACER\\nconsistently preferred over general, CBT-based, and GPT-4-powered models in\\npanic \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m scenarios (Code is available at https://github.com/JihyunLee1/PanicToCalm\\n).\\n\\n##Content\\nPanicToCalm: A      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Proactive Counseling Agent for Panic Attacks\\nJihyun Lee â™£, Yejin Min â™£, San Kim â™£, Yejin Jeon â™£, SungJun       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Yangâ™¢,\\nHyounghun Kimâ™£, â™¢, Gary Geunbae Leeâ™£, â™¢\\nâ™£Graduate School of Artificial Intelligence,                   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m POSTECH\\nâ™¢Department of Computer Science and Engineering, POSTECH\\n{jihyunlee, yeajinmin, sankm, jeonyj0612,    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m sjyang114, h.kim, gblee}@postech.ac.kr\\nAbstract\\nPanic attacks are acute episodes of fear and\\ndistress, in    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m which timely, appropriate interven-\\ntion can significantly help individuals regain\\nstability. However,        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m suitable datasets for train-\\ning such models remain scarce due to ethical\\nand logistical issues. To address   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m this, we in-\\ntroduce PACE, which is a dataset that includes\\nhigh-distress episodes constructed from           \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m first-\\nperson narratives, and structured around the\\nprinciples of Psychological First Aid (PFA).\\nUsing this  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m data, we train PACER, a counseling\\nmodel designed to provide both empathetic and\\ndirective support, which is  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m optimized through\\nsupervised learning and simulated preference\\nalignment. To assess its effectiveness, we     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m pro-\\npose PANICEVAL, a multi-dimensional frame-\\nwork covering general counseling quality and\\ncrisis-specific \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m strategies. Experimental results\\nshow that PACER outperforms strong baselines\\nin both counselor-side metrics  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m and client af-\\nfect improvement. Human evaluations further\\nconfirm its practical value, with PACER            \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m consis-\\ntently preferred over general, CBT-based, and\\nGPT-4-powered models in panic scenarios                 \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 1.\\n1\\nIntroduction\\nPanic attacks are sudden episodes of intense fear\\naccompanied by physical symptoms such   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m as rapid\\nheartbeat, shortness of breath, and dizziness. These\\nepisodes often occur without warning, leaving   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m indi-\\nviduals in acute distress and unable to self-regulate\\n(Hoppe et al., 2012; American Psychiatric         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Associa-\\ntion, 2013; Kolek et al., 2020). Immediate interven-\\ntion from a trained professional through        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m grounding,\\nbox-breathing, or relocation to a safe environment,\\ncan be highly effective (Chalmers et al.,      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 2022; John-\\nston, 2023). However, professional support is not\\nalways accessible due to time, cost, and        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m availability\\nconstraints, which increases the demand for AI sys-\\ntems that are capable of timely assistance.  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Despite\\n1Code\\nis\\navailable\\nat\\nhttps://github.com/\\nJihyunLee1/PanicToCalm\\nIâ€™m,,, at a shopping mall, and  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m there are so many people \\ntalking,,,,,. Itâ€™s... overwhelming. I... I canâ€™t breathe.\\nPanic                     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m \\nAttack\\nClient\\n(Empathy: \\n, Directive : \\n)\\nI can understand how you feel, this feeling must be very       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m \\nfrightening for you.\\nCounseling\\nModel\\nSample Conversation in Panic Scenario\\nI'm sorry to hear that you're \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m feeling this way. \\nWhen you're in a place like a coffee shop, what thoughts \\nusually go through your          \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m mind?\\nCBT\\n Counseling\\nModel\\n(Empathy: \\n, Directive : \\n)\\nI understand this is really overwhelming right   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m now. \\nCan you find a quiet corner, or step outside for a moment? \\nPACER\\n(Empathy: \\n, Directive :\\n)\\nFigure \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 1: Conversation between a client and different\\ncounseling models. PACER delivers both appropriate\\nempathy and \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m clear, directive guidance to support imme-\\ndiate stabilization.\\nthis need, the unpredictable and deeply       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m personal\\nnature of panic attacks makes it nearly impossi-\\nble to collect authentic, in-the-moment             \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m counseling\\ninteractions for model training.\\nMeanwhile, synthetic dialogue datasets with\\nlarge language       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m models (LLMs) have emerged as a\\npromising alternative in environments where data\\ncollection is challenging,   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m given their strong con-\\nversational abilities (Lee et al., 2022; Kim et al.,\\n2023a; Kulkarni et al., 2024;    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Lee et al., 2024b; Jang\\net al., 2024; Lee et al., 2025). In the counseling do-\\nmain, identifying authentic    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m and diverse sources for\\ndialogue construction such as crowd sourcing (Na,\\n2024; Qiu et al., 2024), web Q&A    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m (Xiao et al.,\\n2024), and augmenting from real counseling di-\\nalogues (Liu et al., 2023), and applying         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m suitable\\ntherapeutic theory (Na, 2024; Lee et al., 2024a;\\nKim et al., 2025) are key challenges in             \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m building\\neffective synthetic datasets. However, prior efforts\\nhave predominantly focused on general           \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m psycholog-\\nical concerns and employed cognitively demanding\\ncounseling procedures, assuming that clients are  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m in\\nrelatively stable emotional states. This assumption\\nlimits the applicability to high-distress              \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m situations\\nlike panic attacks, where clients require immediate,\\ndirective, and low-cognitive-burden           \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m support.\\narXiv:2510.21143v2  [cs.AI]  28 Oct 2025\\nTo address this, we introduce PACE (Panic-to-\\nAid          \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Counseling with Emergency) dataset, that is\\nfocused on immediate intervention during acute\\npanic attacks      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m (Figure 1). We begin by collecting\\nfirst-person narratives from individuals who de-\\nscribe their panic        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m episodes. From these narratives,\\nwe identify key components of a panic attack, in-\\ncluding environmental      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m context, physical symptoms,\\nemotional responses, and cognitive patterns. As the\\nunderlying therapeutic        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m framework, we adopt Psy-\\nchological First Aid (PFA; Brymer et al. (2006)),\\nwhich is designed to provide       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m immediate stabiliza-\\ntion for individuals experiencing high-distress situ-\\nations such as trauma, PTSD, or    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m panic attacks.\\nBuilding on our PACE dataset, we train PACER\\n(Panic-to-Aid Counseling with Emergency           \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Re-\\nsponse), which is a counseling model that is de-\\nsigned to stabilize acute panic episodes through\\nrapid  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m interventions. To further enhance the modelâ€™s\\nability to cope with a broad spectrum of panic cases,\\nwe run    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m simulations using a client agent, exposing\\nit to unpredictable and diverse scenarios. From\\nthese simulations, \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m we collect preference feedback\\nfrom the client agent and perform alignment train-\\ning to guide the modelâ€™s    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m behavior toward greater\\ndirectiveness and empathy.\\nFinally, we introduce PANICEVAL, a novel eval-\\nuation     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m framework designed to assess counseling\\nmodels in the context of acute panic interventions.\\nWhile existing    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m evaluation methods primarily focus\\non general therapeutic quality, they often fail to cap-\\nture the urgency   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m and stabilization demands inherent\\nto panic attack scenarios (Aarons et al., 2012; Li\\net al., 2024; Lee et    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m al., 2024a). To address this\\ngap, PANICEVAL incorporates core principles from\\nPFA, which enables the          \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m evaluation of both general\\ncounseling competencies and first-aid-oriented in-\\ntervention                      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m effectiveness.\\nDuring evaluation, we examine two aspects: the\\ncounselorâ€™s effectiveness and the clientâ€™s      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m emotional\\nimprovement. PACER demonstrates strong perfor-\\nmance in both general and first-aid-specific         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m skills,\\nparticularly in the clarity of its responses. Signif-\\nicant emotional improvement can also be seen    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m in\\nclients through increased self-esteem and reduced\\nfear. In human evaluations involving both clini-\\ncal    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m experts and individuals with lived experience,\\nPACER was consistently preferred over the general,\\nCognitive   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Behavioral Therapy (CBT) based, and\\neven closed models like GPT-4o (OpenAI, 2024b).\\n2\\nRelated                \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Work\\n2.1\\nData Challenges in Mental Health\\nBuilding counseling systems requires high-quality\\ndialogue data,  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m but privacy and ethical concerns hin-\\nder real-world collection. As such, recent work\\nuse closed-source LLMs: \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m HealMe (Xiao et al.,\\n2024) generates short CBT-based dialogues from\\ncrowdsourced profiles; Cactus (Lee et     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m al., 2024a)\\nadds scripted planning for longer sessions; CPsy-\\nCoun (Zhang et al., 2024) reconstructs          \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m profiles\\nfrom anonymized transcripts; and Psych8k (Liu\\net al., 2023), SMILEChat (Qiu et al., 2024),           \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m and\\nCBT-LLM (Na, 2024) utilize online mental health\\nforums. Yet, these approaches target generalized\\nissues  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m with calm, reflective users. In contrast, we\\nfocus on the acute phase of panic attacks, simulat-\\ning          \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m real-time stabilization grounded in PFA.\\n2.2\\nSynthetic Preference Pairs for Value\\nAlignment\\nHuman-annotated \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m preference datasets have been\\nkey to aligning LLMs for better performance and\\nsafety (Bai et al., 2022;       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Stiennon et al., 2020;\\nNakano et al., 2021), but they are costly and hard\\nto scale. To overcome this, recent  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m studies use syn-\\nthetic preference data generated by LLMs. Meth-\\nods like R-DPO (Gallego, 2024) and Selfee    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m (Kim\\net al., 2023b) apply self-critique or model-based\\nscoring, while AutoPM (Kim et al., 2024)               \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m and\\nSAFER-Instruct (Shi et al., 2024) guide models\\ntoward helpfulness, honesty, and harmlessness\\n(HHH) using \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m GPT-4 (Achiam et al., 2023). Build-\\ning on these, we apply model-based scoring in a\\nnovel setting; outputs    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m are aligned with therapeutic\\nvalues like empathy and directiveness via interac-\\ntion with a simulated patient \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m in panic counseling.\\n3\\nPsychological First Aid\\nPFA is a modular intervention developed by the\\nNational      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Child Traumatic Stress Network and the\\nNational Center for PTSD to provide support fol-\\nlowing traumatic      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m events (Brymer et al., 2006). It is\\norganized around three sequential actionsâ€”Look,\\nListen, and Linkâ€”which    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m guides responders in as-\\nsessing the situation and ensuring safety (Look),\\nstabilizes individuals and offers  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m emotional sup-\\nport (Listen), and connects them to further ser-\\nvices and resources (Link) (World Health      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Organi-\\nzation, 2013). Unlike long-term therapies like CBT\\nor Emotion-Focused Therapy (EFT;                   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Greenberg\\n(2017)), which require reflective engagement over\\nmultiple sessions, PFA is designed for acute      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m psy-\\nchological crises as it prioritizes directive, action-\\noriented strategies and immediate stabilization.  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Its\\neffectiveness in managing panic episodes has been\\nhighlighted in prior studies (Chalmers et al.,          \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 2022).\\n4\\nPACE: Panic Episode Dataset with\\nPFA Counseling\\nIn this section, we introduce PACE, the first      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m coun-\\nseling dataset that is designed to address acute\\npanic episodes. We hypothesize that a                  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m high-quality\\ndataset should satisfy three key criteria: (1) the\\nclientâ€™s episode must be plausible and        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m reflective\\nof real-world panic scenarios; (2) the counselor\\nmust successfully guide the client toward         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m stabiliza-\\ntion; and (3) the dialogue must maintain general\\ntherapeutic standards.\\nTo meet these             \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m requirements, our data generation\\npipeline consists of three stages: (1) collecting au-\\nthentic panic         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m narratives, (2) generating multi-staged\\ndialogue scripts based on the PFA guideline, and (3)\\napplying         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m meticulous filtering to ensure counseling\\nquality. We use GPT-4O-MINI (OpenAI, 2024a)\\nas the primary          \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m generation model. An overview is\\nprovided in Figure 2, and corresponding details and\\nprompts are provided in  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Appendix B, H and I.\\n4.1\\nCollecting Client Panic Profiles\\nAs the first step, we model the panic episode      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m pro-\\nfile, which is a structured representation of a panic\\nepisode consisting of three key components:        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m the\\ncontextual Environment, Trigger Type, and Vi-\\ncious Cycle that is defined as the interlinked phys-\\nical, \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m emotional, and cognitive responses that rein-\\nforce one another, thereby intensifying the sever-\\nity of the   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m episode (Clark, 1986).\\nThe Trigger\\nType represents the initial stimulus that activates\\nthis self-reinforcing \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m cycle. To construct these pro-\\nfiles, we sourced first-person narratives of panic\\nepisodes from publicly      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m available social media post\\nand prompted an LLM to extract the relevant com-\\nponents. Given the sensitivity   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m of the data, we ap-\\nplied a meticulous personally identifiable informa-\\ntion (PII) removal process using      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m automated detec-\\ntion and manual review (Appendix B.2), resulting\\nin 1,226 verified profiles.\\nTo enhance the \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m diversity of contextual settings in\\nthe panic profiles, we augmented the Environment\\nand Trigger Type         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m components using an external\\npersona dataset (Zhang et al., 2018). Specifically,\\nwe randomly selected a       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Trigger Type (physical,\\nemotional, or cognitive) and a persona from the\\nexternal persona dataset, then        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m prompted an LLM\\nto generate a plausible environment conditioned on\\nthese two factors. The generated           \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Environment and\\nnew Trigger Type were then attached to the original\\nVicious Cycle to form an augmented        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m profile. For\\nexample, given a Trigger Type (e.g., physical) and\\na persona (e.g., a big fan of live music),    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m the LLM\\ngenerated a realistic Environment such as â€œa tightly\\npacked concert venue.â€ (further examples in      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Ap-\\npendix B.3). Through this process, we constructed\\na total of 9,997 panic profiles.\\n4.2\\nDefining         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Counselor Goals\\nOn the counselor side, we define the modelâ€™s goals\\nbased on the principles of PFA. Since the  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m original\\nPFA guidelines include actions that are not feasi-\\nble for dialogue models (e.g., providing          \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m physical\\nresources like water), we restructure the goals to fo-\\ncus on interventions that can be delivered    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m through\\nconversation. Specifically, we define the goals for\\neach PFA stage as follows: LOOK identifies        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m the\\nclientâ€™s panic profile and guides them to a safe envi-\\nronment; LISTEN focuses on stabilization           \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m through\\nbreathing, grounding and reassurance; and LINK\\nencourages follow-up with a human counselor, end-\\ning \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m with on a positive note. The goals for each\\nstage are summarized in Figure 2 (right) and Ap-\\npendix B.4, and  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m are denoted as goalstage.\\n4.3\\nStructured Dialogue Generation with PFA\\nGiven a panic profile and the          \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m goalstage, we gener-\\nate a complete counseling session that consists of\\nthree sequential stages. Our session  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m generation pro-\\ncess is guided by two key design choices to ensure\\nalignment with each stageâ€™s therapeutic    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m objective.\\nFirst, each stage is generated independently and\\nthen concatenated to form the full session.       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m This\\nmodular structure facilitates alignment with the\\nobjective of each stage. For each stage, we             \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m first\\ngenerate a plan to outline the dialogue flow, and\\nthen generate the dialogue turns corresponding        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m to\\nplan and goalstage. Second, rather than simulat-\\ning turn-by-turn interactions between client              \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m and\\ncounselor agents, we adopt a script-style genera-\\ntion approach. In this setup, the model generates\\nthe  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m entire dialogue for a stage in a single inference\\npass, enabling more coherent and goal-aligned out-\\nputs     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m within each therapeutic phase. Each stage is\\nrepresented as:\\nStage = {plan, [(st0, s0, u0), . . . , (stk, sk, \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m uk)]}\\nPsychological First Aid Counselor\\nStage A. LOOK\\nGoal : Focuses on assessing the clientâ€™s condition,    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m \\nensuring their safety.\\nâ€¢\\nIdentify Physical Symptoms, Emotional States, \\nThinking, Ensure                   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Safety\\nr/MentalHealth â€¢2 days ago\\nRunningBlueBird\\n[Serious] My First Panic Attack â€“ Terrifying               \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Experience\\nHey everyone,\\nI just had my first panic attack at the mall.. My \\nheart was racing and I was so    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m dizzy, I couldnâ€™t \\nbreathe, and my hands went numb. I thought Iâ€™m \\ndying.  I was so scared and I had no idea  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m what was \\nhappening, and I was this close to calling 911. \\nI went to the doctor today, and they said it was   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m \\njust a panic attack.\\nShare\\n2\\n3\\nPanic Attack Episode\\nBig fan of Band\\nLawyer\\nHave two kids\\nExternal     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Source\\nTrigger\\ntype\\nPhysical\\nEmotional\\nCognitive\\nPanic Profile\\nEnvironment\\nTrigger Type\\nPhysical       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Reaction\\nEmotional Reaction\\nCognitive Reaction\\nA packed concert venue\\nPhysical\\nHeart Racing,               \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Dizzy\\nScared\\nI might Die!\\nProfile Augmentation (Env, Trigger)\\nI feel dizzyâ€¦ My heart is racingâ€¦ I think Iâ€™m \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m about to faint!\\nAlright, letâ€™s try some grounding now. \\nCan you feel the texture of the chair? How does it    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m feel?\\nThanks for the suggestion. Iâ€™ll try to find the right support.\\nIf this condition persists, I recommend  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m seeking professional support.\\nâ€¦\\nI hear you. Youâ€™re feeling really uncomfortable right now. \\nAre you in safe  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m place now?\\nLOOK Stage\\nLISTEN Stage\\nThis is Panic Attack First Aid Center.  \\nThere are so many people around \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m me â€” Iâ€™m at this packed concert \\nand I canâ€™t catch my breath. It really hurts.\\nStage Planning                 \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m \\nStrategy\\nUtterance Generation\\nCan you move slightly to the side or find a wall or barrier to lean           \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m against?\\nStrategy\\nUtterance Generation\\nâ€¦\\nI think I can feel it... Itâ€™s a bit rough under my fingers.\\nLINK  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Stage\\nRemember, this symptom is temporary and will pass soon. \\nYou have the strength to control it.\\nPACE     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Psychological First Aid for acute panic attack\\nPFA guidelines\\nStage B. LISTEN\\nGoal : Providing emotional     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m support, Stabilization.\\nâ€¢\\nStabilization by breathing or grounding, Helping the \\nclient shift from irrational \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m fear \\nStage C. LINK\\nGoal : Focuses on assessing the clientâ€™s condition, \\nensuring their                      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m safety.\\nâ€¢\\nEncourage the client to seek further professional help, \\nEnd the session with a positive           \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m message.\\nStage Planning \\nStrategy\\nClient shows high distress, in this step, \\nI will assess the client's     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m physical, emotional, \\nand cognitive state, and guide them to a safe \\nplace\\nThe client's condition hasn't     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m been assessed \\nyet, and their safety is still uncertain. KEEP\\nStage Planning \\nStrategy\\nUtterance            \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Generation\\nStrategy\\nUtterance Generation\\nStage Planning \\nStrategy\\nUtterance Generation\\nFigure 2: An       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m overview of the automatic pipeline for generating the PACE dataset.\\nwhere ui is the client utterance, si is    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m the counselorâ€™s\\nresponse, and sti is the counselorâ€™s strategy for\\ngenerating si. Strategy sti reflects the    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m decision of\\nwhether the counselor should move on to the next\\nstage or not, based on the current dialogue      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m history\\nand goalstage. If sti = keep, the model generates\\nsi, and corresponding ui continues within the       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m same\\nstage. If sti = next, both si and ui are left empty,\\nand the session transitions to the next             \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m stage.\\nOverall,\\nthe\\nLOOK\\nphase\\nis\\ngenerated\\ngiven\\nthe\\npanic\\nprofile\\nand\\na\\ngoalstage:\\nLOOK\\n=\\nLLM \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m (Profile, goalstage).\\nThe\\nsub-\\nsequent\\nLISTEN\\nand\\nLINK\\nstages\\nare\\ngenerated based on the previous      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m stage dia-\\nlogues,\\nprofile,\\nand\\ntheir\\nrespective\\ngoals:\\nLISTEN, LINK = LLM(History, Profile,             \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m goalstage).\\nThe\\nfinal\\ndialogue\\nis\\nformed\\nby\\nconcate-\\nnating\\nthe\\noutputs\\nof\\nthe\\nthree\\nphases:\\nDia \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m logue = LOOK âŠ•LISTEN âŠ•LINK.\\n4.4\\nDialogue Quality Filtering\\nTo ensure structural consistency and              \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m counseling\\nquality of the PACE dataset, we applied a multi-\\nstep filtering process. First, we removed         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m dialogues\\nwith abnormal formatting or excessively long ut-\\nterances (over 100 words), eliminating 5.92%       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m of\\nthe data. Second, CTRS (Aarons et al., 2012) is\\nused to assess alignment with general                      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m therapeutic\\nstandards; five relevant dimensions of Empathy,\\nClarity, Emotional Alignment, Directive           \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Support,\\nand Encouragement, were rated on a scale from 1\\n(poor) to 5 (excellent) by prompting GPT-4o.         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Di-\\nalogues that received a score equal to or less than\\n3 for any dimension were removed (2.42%),             \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m ulti-\\nmately resulting in 8,263 dialogues and 106,433\\nturns. Additional validation of CTRS filtering          \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m with\\nhuman agreement is provided in Appendix B.5.\\n4.5\\nExpert Review of\\nPACE\\nCategory\\nVery                 \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Poor\\nPoor\\nFair\\nGood\\nExcellent\\nEmpathy\\n0.0%\\n1.0%\\n18.0%\\n57.0%\\n24.0%\\nClarity\\n0.0%\\n1.0%\\n29.0%\\n50.7%\\ \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m n19.3%\\nEmotional                                                                                               \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m App.\\n0.0%\\n2.7%\\n34.3%\\n48.7%\\n14.3%\\nDirective\\n0.0%\\n0.0%\\n9.7%\\n64.0%\\n26.3%\\nEncouragement\\n0.0%\\n0.0%\\n19 \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m .7%\\n56.0%\\n24.3%\\nTable 1: Expert evaluation of generated dialogues using\\nthe CTRS rubric. Scores range from  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 1 (very poor) to 5\\n(excellent).\\nWe conducted an expert evaluation with three\\nmental health professionals, to \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m validate the clinical\\nappropriateness and quality of the generated dia-\\nlogues We randomly sampled 100        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m dialogues from\\nthe training set and asked the experts to rate each\\nresponse using the CTRS rubric on a        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 5-point scale\\n(from 1 = very poor to 5 = excellent). The results\\n(Table 1) show that most dialogues fall      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m within the\\nfair to excellent range, supporting the overall valid-\\nity of the generated data. Specifically,    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m the average\\nscores were 4.04 for Empathy, 3.88 for Clarity, 3.75\\nfor Emotional Appropriateness, 4.17 for      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Directive\\nSupport, and 4.05 for Encouragement.\\n4.6\\nComparison\\nPACE with Existing\\nCounseling Datasets\\nIn   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Table 2, we compare our dataset PACE with other\\nexisting synthetic counseling datasets. While prior\\ndatasets  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m primarily address general mental health\\nDataset\\nCounseling Theory\\nProfile Source\\nIssue                      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Type\\nIn-Crisis\\nLanguage\\n# of Dialogues\\nMulti Turn\\nPsyCon (Mishra et al., 2023)\\nNot Specified\\nRecords,    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Crowed Sourcing\\n7 psychological issues\\nNo\\nEnglish\\n1,020\\n24.58\\nPsych8k (Liu et al., 2023)\\nNot             \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Specified\\nCounseling Records\\nAnx, Dep, Relation, Minority\\nNo\\nEnglish\\n8,187\\n1.00\\nSmileChat (Qiu et al.,   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 2024)\\nNot Specified\\nSocial Media\\nNot Specified\\nNo\\nChinese\\n55,165\\n10.4\\nHealMe (Xiao et al.,              \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 2024)\\nCognitive Behavioral Therapy\\nCrowed Sourcing\\nNot Specified\", \"## Title\\nPsychology-driven LLM Agents   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m for Explainable Panic Prediction on Social Media during Sudden Disaster Events\\n\\n## Summary\\nDuring sudden     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m disaster events, accurately predicting public panic sentiment\\non social media is crucial for proactive         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m governance and crisis management.\\nCurrent efforts on this problem face three main challenges: lack of          \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m finely\\nannotated data hinders emotion prediction studies, unmodeled risk perception\\ncauses prediction         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m inaccuracies, and insufficient interpretability of panic\\nformation mechanisms. We address these issues by      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m proposing a Psychology-driven\\ngenerative Agent framework (PsychoAgent) for explainable panic prediction        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m based\\non emotion arousal theory. Specifically, we first construct a fine-grained open\\npanic emotion dataset   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m (namely COPE) via human-large language models (LLMs)\\ncollaboration to mitigate semantic bias. Then, we develop \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m a framework\\nintegrating cross-domain heterogeneous data grounded in psychological\\nmechanisms to model risk    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m perception and cognitive differences in emotion\\ngeneration. To enhance interpretability, we design an          \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m LLM-based role-playing\\nagent that simulates individual psychological chains through dedicatedly\\ndesigned      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m prompts. Experimental results on our annotated dataset show that\\nPsychoAgent improves panic emotion prediction \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m performance by 12.6% to 21.7%\\ncompared to baseline models. Furthermore, the explainability and                 \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m generalization\\nof our approach is validated. Crucially, this represents a paradigm shift from\\nopaque          \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m \\\"data-driven fitting\\\" to transparent \\\"role-based simulation with\\nmechanistic interpretation\\\" for panic     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m emotion prediction during emergencies.\\nOur implementation is publicly available                                \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m at:\\nhttps://anonymous.4open.science/r/PsychoAgent-19DD.\\n\\n##Content\\nPsychology-driven LLM Agents for         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Explainable Panic Prediction on Social\\nMedia during Sudden Disaster Events\\nMengzhu Liu*1, Zhengqiu Zhu*1,     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Chuan Ai1, Chen Gao2,\\nXinghong Li1, Lingnan He3, Kaisheng Lai4, Yingfeng Chen 2, Xin Lu1, Yong Li2, Quanjun    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Yin1\\n1National University of Defense Technology, 2Tsinghua University,\\n3Sun Yat-sen University, 4Jinan        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m University\\n*Equal contribution\\nEvent characteristics\\nï¼ˆPhysical                                              \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m domainï¼‰\\n-------------------------------------\\nDisaster occurrence time\\nCurrent location of the              \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m disaster\\nCurrent intensity of the disaster\\nRisk perception\\nï¼ˆCognitive                                       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m domainï¼‰\\n---------------------------------------\\nScope of disaster threat\\nSeverity of the disaster\\nDegree   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m of disaster hazard\\nIndividual characteristics\\nï¼ˆCognitive                                                     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m domainï¼‰\\n-------------------------------------\\nTopic attention\\nTone characteristics\\nEmotional               \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m trends\\nPersonality traits\\nPanic emotion arousal\\n(Cognitive                                                   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m domain)\\n---------------------------------------\\nRisk awareness\\nEvent uncertainty\\nCoping effectiveness \\nand \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m sense of control\\nSituational novelty\\nPsychological State\\n(Social                                             \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m domain)\\n-----------------------------------------\\nThank you for \\nyour hard work.\\nThatâ€™s \\noutrageous!\\nHope \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m the disaster \\nwill end soon!\\nThatâ€™s \\nterribleï¼\\nRisk communication\\n(Information                            \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m domain)\\n-------------------------------------\\nGeographical \\ncoordinates\\nSocial media \\ncharacteristics      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m \\nAverage number\\nof posts\\nHistorical posts\\nRestrictive \\neffect\\nConcrete \\nrepresentation\\nAffective        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m \\nstate\\nConcrete \\nrepresentation\\nPsychological state \\ntransformation\\nFigure 1: Path of panic formation.    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m The physical domain supplies an objective benchmark, while the information\\ndomain dynamically adjusts          \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m cognitive inputs. The cognitive domain processes these inputs through individual\\nconstraints and risk          \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m perception, triggering panic emotions that ultimately materialize as observable social media\\nbehaviors through \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m the social domain.\\nAbstract\\nAccurately predicting public panic sentiment\\non social media is crucial for      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m proactive gover-\\nnance and crisis management. Current efforts\\non this problem face three main                 \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m challenges:\\nlack of finely annotated data hinders emotion\\nprediction studies, unmodeled risk                  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m perception\\ncauses prediction inaccuracies, and insufficient\\ninterpretability of panic formation               \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m mechanisms.\\nWe address these issues by proposing a Psy-\\nchology-driven generative Agent                       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m framework\\n(PsychoAgent) for explainable panic prediction\\nbased on emotion arousal theory. Specifically,\\nwe   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m first construct a fine-grained panic emotion\\ndataset (namely COPE) via human-large lan-\\nguage models (LLMs)   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m collaboration, combin-\\ning scalable LLM-based labeling with human\\nannotators for accuracy and bias            \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m mitigation.\\nThen, we construct PsychoAgent integrating\\ncross-domain heterogeneous data grounded               \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m in\\npsychological mechanisms to model risk per-\\nception and cognitive differences in emotion\\ngeneration. To   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m enhance interpretability, we de-\\nsign an LLM-based role-playing agent that sim-\\nulates individual             \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m psychological chains through\\ndedicatedly designed prompts. Experimental\\nresults on our annotated dataset show \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m that Psy-\\nchoAgent improves panic emotion prediction\\nperformance by 12.6% to 21.7% compared to\\nbaseline      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m models. Furthermore, the explainabil-\\nity and generalization of our approach is val-\\nidated. Crucially, this  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m represents a paradigm\\nshift from opaque \\\"data-driven fitting\\\" to trans-\\nparent \\\"role-based simulation with \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m mechanis-\\ntic interpretation\\\" for panic emotion prediction\\nduring emergencies. Our implementation            \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m is\\npublicly available at: https://anonymous.4o\\npen.science/r/PsychoAgent-19DD.\\n1\\nIntroduction\\nSocial media \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m accelerates the spread of extreme\\nemotions during sudden events (Organization et al.,\\n2020), yet its          \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m real-time nature, rich information con-\\ntent, and spatiotemporal granularity offer unique\\nopportunities for   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m emotion prediction and manage-\\nment. Among various negative emotions, uncon-\\n1\\narXiv:2505.16455v1  [cs.AI]   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 22 May 2025\\ntrolled panic can exhaust emergency resources, trig-\\nger secondary disasters, even escalate       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m isolated haz-\\nards into complex societal crises (Rune and Keech,\\n2023). For instance, during the 2011 Japan   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m earth-\\nquake, panic-driven mass salt-buying in China ex-\\nacerbated price surges and supply shortages          \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m (Pier-\\nson, 2011). Hence, timely prediction and moni-\\ntoring of panic enable proactive interventions          \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m to\\nmitigate its spread and impact (Wu et al., 2025).\\nCurrent research focuses on coarse-grained               \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m ret-\\nrospective emotion classification using single-\\nmodality textual data (MitroviÂ´c et al., 2024;\\nWeigang  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m et al., 2024; Mitrovic and Kanjirangat,\\n2022), while dedicated studies on panic emotion\\nprediction remain     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m scarce. More details about emo-\\ntion prediction research are in Appendix A.1. Due\\nto the limitations of       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m dataset annotation quality and\\ninherent methodological constraints, precisely pre-\\ndicting public panic       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m remains significant challenges.\\nFirstly, current panic emotion annotation\\nmethods have semantic               \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m deviations.\\nExisting\\ndatasets rely on static annotations and lack normal-\\nstate behavioral data, impeding    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m predictive model-\\ning of panic evolution and causing: (1) oversim-\\nplified categorization of panic as fear    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m (Yang et al.,\\n2022), ignoring disaster-specific risk perception;\\n(2) semantic drift in keyword-based          \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m detection due\\nto variations in linguistic nuances and expressive\\nconventions (MitroviÂ´c et al., 2024; Weigang \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m et al.,\\n2024), weakening cognition-semantics alignment.\\nSecondly, current prediction models                   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m have\\ncross-domain feature fusion and dynamic model-\\ning limitations. Psychological studies indicate           \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m that\\npublic emotions are influenced by multi-domain\\nheterogeneous features. While current models at-\\ntempt   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m to incorporate such features (Regan et al.,\\n2024), they remain limited to simplistic combina-\\ntions of text   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m with single factors. Moreover, existing\\nmodels often use static temporal modeling, fail to\\ncapture evolving   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m feature interactions, significantly\\nreduce predictive efficacy (MitroviÂ´c et al., 2024).\\nLastly, current      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m studies have explainability gap\\nin panic formation mechanism. Current stud-\\nies focus on surface emotion      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m detection and sta-\\ntistical correlations (MitroviÂ´c et al., 2024), ne-\\nglecting psychological drivers like    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m risk perception,\\ncognitive appraisal mechanisms (Hariharan et al.,\\n2017). Though cognitive-emotion            \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m interactions are\\nvalidated in psychological studies, existing works\\nfail to computationally map the risk      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m perception-to-\\narousal chain (Regan et al., 2024; Houlihan et al.,\\n2023), leaving emotional evolution         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m pathways unex-\\nplained.\\nTo address the above challenges, we propose a\\nPsychology-driven generative Agent     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m framework\\n(PsychoAgent) for panic emotion prediction dur-\\ning sudden disasters. Specifically, we first        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m adopt\\na human-LLM collaborative annotation method\\nto construct a fine-grained panic emotion                   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m dataset\\n(Collaborative Fine-grained Open Panic Emotions\\nDataset, COPE), resolving semantic deviation          \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m and\\ncross-cultural annotation biases. Secondly, we de-\\nvelop a mental framework to fuse                       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m multi-domain\\nfeatures through the psychological mechanisms of\\npanic formation (as illustrated in Figure 1).   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Fi-\\nnally, guided by theoretical lenses of risk percep-\\ntion and emotion arousal, we design a                 \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m chain-of-\\nthought (CoT)-driven LLM-based agent to simulate\\nthe full psychological chain of \\\"disaster         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m perception,\\nrisk cognition, panic emotion arousal, and posting\\nbehavior response\\\". Our work shows            \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m significant\\nimplications for developing explainable AI systems\\ncapable of providing deeper insights into      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m collective\\nemotional dynamics during sudden disaster events.\\nOur contributions are summarized as:\\nâ€¢ To       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m support panic prediction, we pioneer a novel\\ndual-phase panic emotion annotation dataset. We\\nalso fine-tune a \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m discriminator to detect panic sig-\\nnals in generated texts.\\nâ€¢ We innovatively propose a                       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m psychology-driven,\\nmulti-domain fusion mental model for public\\npanic prediction during disasters. Our         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m approach\\nintegrates multi-domain data via an LLM-based\\nrole-playing agent for interpretable psycholog-\\nical  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m modeling of panic formation mechanisms.\\nâ€¢ Experimental results show that the proposed\\nframework achieves an   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m accuracy of 86% (â†‘at\\nleast 13% versus SOTA) in panic emotion pre-\\ndiction task. Moreover, scalability studies \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m and\\ncase studies further validate the explainability\\nand generalization of our approach.\\n2\\nProblem          \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Definition and Dataset\\nConstruction\\nIn this section, we first formalize the problem defi-\\nnition, then       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m detail the methods for building a fine-\\ngrained panic emotion dataset and finally fine-tune\\na BERT-based      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m model for panic recognition.\\n2.1\\nProblem Definition\\nThe sentiment prediction task can be defined             \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m as:\\nÏƒi\\nt+1 = F\\n\\u0000Ii\\nt\\n\\u0001\\n,\\n(1)\\n2\\nwhere Ïƒi\\nt+1 is the sentiment label of user i at fu-\\nture   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m time t + 1, and Ii\\nt is post contents that user i\\npublishes on social media at time t.\\nThis study aims to    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m predict usersâ€™ panic emotion\\nlabels after disaster occurrence through deep fusion\\nof multi-domain features    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m from their pre-disaster\\nsocial media posts, integrated with psychological\\ntheories. Formally, this task can   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m be formulated as:\\nÏƒi\\nt+1 = F\\n\\u0000Ii\\nt, Pt+1, Ci\\nt\\n\\u0001\\n,\\n(2)\\nwhere t + 1 is the time after the     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m sudden disaster,\\nt is the time before the disaster, Ïƒi\\nt+1 is the post-\\ndisaster sentiment label of user i,  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Pt+1 is the post-\\ndisaster physical features, and Ci\\nt is the personal\\ntraits of user i from pre-disaster    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m analysis.\\n2.2\\nCOPE Dataset Benchmark\\nTo address the gap in high-quality panic emotion\\nresources, we develop \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m the first fine-grained dataset\\nCOPE, spanning pre- and post-disaster phases,\\nwhich fills the gap in           \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m standardized panic emotion\\ndatasets and provides a foundation for advancing\\nresearch in emotion prediction    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m and related fields.\\nIts core innovation is the standardized human-LLM\\ncollaborative annotation process,       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m structured as fol-\\nlows. More details are in Appendix A.2.\\nâ€¢ Multi-source data collection: Focusing on        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Hur-\\nricane Sandy (2012), we used 52.25 million\\ntweets from 13.75 million users (Oct. 15- Nov.\\n12)           \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m (Kryvasheyeu et al., 2015). After preprocess-\\ning (detailed in Appendix A.2.1), the dataset\\nincludes 9,065    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m users, including user IDs, fol-\\nlower/followee counts, timestamps, locations,\\nand ternary emotion labels.\\nâ€¢  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Panic annotation framework: Targeting post-\\ndisaster texts, we adopt a LLM-human hybrid\\nannotation pipeline:  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m (1) LLM generates initial\\nlabels via semantic parsing; (2) 100 annotators\\nconducted three rounds of           \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m cross-validation to en-\\nsure robustness; (3) Fine-tuned BERT model au-\\ntomates remaining annotations.\\nâ€¢      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m User-level panic identification: We identify pan-\\nicked users via a \\\"one-veto\\\" rule (â‰¥1 panic                \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m text).\\n3\\nPsychology-Driven LLM Agent\\nFramework\\nWe first delineate the architecture of PsychoAgent.\\nThen we \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m describe the methodology for individ-\\nual feature extraction. Finally, we introduce the\\npsychology-driven     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m LLM-based agent to simulate\\nposting behavior for predicting panic emotions.\\n3.1\\nOverview of                  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m PsycoAgent\\nBased on the studies of risk perception and emotion\\narousal in psychology, we summarize the        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m panic\\nemotion formation pathway as follows (Figure 1):\\nâ€¢ In the physical domain, we transform                 \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m spatiotem-\\nporal disaster intensity into interpretable data\\nthrough risk communication;\\nâ€¢ In the information \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m domain, we amplify disaster\\nseverity through communication channels, mod-\\nulating risk perception and         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m refining physical data\\ninterpretation, establishing via physical-cognitive\\nbidirectional feedback loops;\\nâ€¢   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m In the cognitive domain, we utilize individual\\ntraits to mediate risk interpretation biases, trigger-\\ning     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m panic through emotional arousal to achieve\\nthe transformation from data to emotion;\\nâ€¢ In the social domain,   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m we materialize individual\\npanic into collective psychological states through\\nsocial media behavior            \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m patterns.\\nBased on this, we propose PsychoAgent (Fig-\\nure 2), a multi-domain fusion-driven LLM                \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m agent\\nframework for panic emotion prediction, which\\ncomprises four main parts: (1) In the informa-\\ntion      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m domain, we focus on collecting social media\\ntexts and risk communication channel features; (2)\\nIn the         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m physical domain, we extract disaster char-\\nacteristics via geospatial platforms, gathering key\\nindicators to  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m convert physical features into disas-\\nter information; (3) In the cognitive domain, we\\nextract individual     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m traits from pre-disaster social me-\\ndia posts. Then, we construct user profiles to drive\\nthe LLM agents,      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m aiming at simulating \\\"disaster per-\\nception, risk perception, panic arousal, and posting\\nbehavior\\\"          \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m psychological chain; (4) In the social do-\\nmain, we use the fine-tuned BERT model to verify\\nthe generated     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m text. Then, we enforce a \\\"one-vote\\\"\\nveto rule for user-level prediction. Subsequent sec-\\ntions detail       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m cognitive domain implementations.\\n3.2\\nPsychological and Behavioral Features\\nExtraction\\nPsychological        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m studies establish that personality\\ntraits, sentiment dynamics, topical concerns, and\\nlinguistic patterns      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m critically shape risk perception\\nand emotional responses (Gross and John, 2003;\\nBrosch et al., 2013; Syrdal   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m and Briggs, 2018; Davis\\net al., 2020). We accordingly extract four main\\nfeatures from usersâ€™ pre-disaster     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m posts.\\nBig Five Personality Traits\\nWe employ the pub-\\nlicly available model bert-base-personality            \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m (Devlin\\n3\\nCognition domain\\nCoT-driven LLM-based agent\\nInformation domain\\nOnline social media post          \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m text\\nThat's \\noutrageous!\\nPhysical domain\\nSudden disaster \\ndescription\\n\\\"Linguistics expert\\\"\\nMoE         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m System\\nCommon \\ntweet\\nExtraction\\nIndividual feature extraction\\nCognitive domain\\nGeographical               \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m \\ncoordinates\\nSocial media \\ncharacteristics \\nAverage number \\nof posts\\nHistorical \\nposts\\nDisaster         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m \\nlocation\\nDisaster \\nintensity index\\nNetwork characteristics\\nEmotion \\ntrends\\nTopics of \\ninterest\\nBig    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m five \\npersonality traits\\nLanguage \\nstyle\\nPersonalized \\ncharacter profile\\nPrior \\nknowledge\\nPersonalized  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m \\nuser agent\\nPPDTS\\nRisk perception \\nEmotion arousal\\nGenerated \\npost prediction\\n\\\"Psychology expert\\\"      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m \\nFactual verification Emotion arousal\\nverification\\nSocial domain\\nFinal text \\npassed verification\\nFailed,  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m \\nregenerate\\nPanic emotion \\ndiscrimination model\\nOnline social media \\nemotion prediction\\nPanic emotion     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m \\nprediction\\nThank you for \\nyour hard work.\\nHope the disaster \\nwill end soon!\\nThatâ€˜s terribleï¼\\nFigure 2: \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Overview of the proposed panic emotion prediction frameworkâ€”â€”PsychoAgent.\\net al., 2019) to analyze the userâ€™s  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m personality traits.\\nThis process can be formally expressed as:\\nÏi = Ïˆpersonality(Ii\\nt),\\n(3)\\nwhere Ïi is    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m the personality vector of the i-th user,\\nand Ïˆpersonality is the model. More details are pro-\\nvided in        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Appendix A.3.1.\\nSentiment\\nTrend\\nFeatures\\nWe\\nuse\\nthe\\nBERTweet model (Nguyen et al., 2020) to              \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m perform\\nternary sentiment analysis on pre-disaster posts,\\naggregating results to generate an emotional        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m trend\\nprofile. This is formalized as:\\nÎ³i = Ïˆsentiment(Ii\\nt),\\n(4)\\nwhere Î³i is the sentiment trend vector of \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m the i-th\\nuser; Ïˆsentiment is the sentiment model.\\nTopic-Aware Characteristic Features\\nUsing\\nLDA model       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m clustering and LLM-guided merging,\\nwe extract topic features by analyzing usersâ€™ histor-\\nical posts. The      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m process is expressed as:\\nÏ„ i = Î“ Â· Î˜i,\\n(5)\\nwhere Î˜i is the LDA-clustered topic vector of the\\ni-th user; Î“   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m is the membership relationships; Ï„ i is\\nthe consolidated thematic focus vector summarized\\nby LLM. Appendix    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m A.3.2 offers additional details.\\nLinguistic Features\\nWe design prompts to cap-\\nture usersâ€™ tone features via \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m LLM. The process is\\nformalized as:\\nvi = LLMlanguage(Ii\\nt, pv),\\n(6)\\nwhere vi is the tone features of the    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m i-th user;\\nLLMlanguage is the tone feature extraction model;\\npÎ½ is the prompt for LLM to extract tone         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m features.\\nMore details can be referred to Appendix A.3.3.\\n3.3\\nBuilding LLM Agent with                        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Psychological\\nTheories\\nWe design a CoT-driven LLM-based agent to simu-\\nlate usersâ€™ perception and            \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m responsiveness through\\nfour stages, with key stages centering on risk per-\\nception and emotional arousal (see \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m in Figure 3):\\nâ€¢ Disaster perception stage (physical-information\\ndomain): We integrate psychological           \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m knowledge,\\ndisaster features, and user profiles to form agentâ€™s\\nlong-term memory;\\nâ€¢ Risk perception stage    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m (cognitive domain): We\\nprompt the agent to engage with the psycho-\\nlogical preparedness for disaster threats  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m scale\\n(PPDTS) (McLennan et al., 2020);\\nâ€¢ Panic arousal stage (cognitive domain): We\\nprompt the agent to      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m quantify panic probability\\nthrough multi-dimensional analysis;\\nâ€¢ Posting response stage (social domain): We   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m gen-\\nerate tweets with MoE-based consistency verifi-\\ncation mechanism.\\nDisaster Perception Stage\\nThis stage \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m equips the\\nagent with essential prior knowledge by integrating\\npsychological knowledge, disaster data, and    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m user\\nfeatures into its long-term memory via structured\\nprompts. The process is expressed as:\\nLLMi\\nU =       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m LLMRP(K, D, Ui, pu),\\n(7)\\nwhere LLMi\\nU denotes the user feature learning\\nagent for user i; LLMRP is the      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m role-playing LLM-\\nbased agent; K is psychological knowledge con-\\nstraints; D is disaster data; Ui is features \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m of user\\ni, encompassing both static traits and risk commu-\\nnication patterns; pu is the initialization        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m prompt.\\nDetailed implementation is in Appendix A.4.1.\\n4\\nPersonalization \\nfeatures\\nLLM-based \\nrole-playing \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m agent\\nLLM-based \\nrole-playing \\nagent\\nGenerate \\ntext \\ndocument\\nGenerate \\ntext document\\nMoE              \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m \\nsystem\\nExpert \\nverification results\\nMoE system\\nRisk perception\\nEmotion arousal\\nImprove the \\ngenerated  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m text\\nLLM-based \\nrole-playing \\nagent\\nMoE \\nsystem\\nGenerate \\ntext document\\nExpert \\nverification           \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m \\nresults\\nFinal text \\ndocument approved\\nPsychological \\nprior knowledge\\nIncident                            \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m \\ndescription\\nGeneral-\\npurpose\\nLLM\\nPsychological \\nprior knowledge\\nLearn \\npsychological                   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m \\nknowledge\\nIncident \\ndescription\\nEvent \\ndata \\nanalysis\\nUser  features\\nDisaster event \\nperception       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m stage\\nEmotion \\ntrigger\\nPanic emotion \\ngeneration\\nRisk \\nperception\\nPanic emotion \\narousal stage\\nFinal   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m text \\ndocument approved\\nRegenerate text \\nnot approved\\nReview approved\\nOutput text\\nPosting \\nresponse      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m stage\\nUser Role \\nInitialization \\nAgent\\nPPDTS\\nRisk cognition \\nformation stage\\nGenerate \\ntext             \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m document\\nEmotional arousal \\nprobability\\nPosting \\nresponse stage\\nLLM-based role-playing agent\\nMoE          \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m system\\nMoE system\\nInformation input\\nFeedback loop\\nResult output\\nFigure 3: Detailed stages for building     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m LLM-based agent driven by CoT in the cognitive domain module.\\nRisk Perception Stage\\nWe construct a            \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m dynamic\\nrisk perception framework using disaster per-\\nception stageâ€™s memory and PPDTS (see Ap-\\npendix       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m A.4.2), emulating usersâ€™ risk perception\\nprocesses via structured psychological assessment.\\nBy leveraging     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m LLMâ€™s reasoning capabilities with\\na human cognitive-inspired stepwise CoT prompt-\\ning mechanism: question     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m comprehension, mem-\\nory retrieval, option mapping, and summary judg-\\nment, we prompt the agent to output risk \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m perception\\nscores (1-4 levels) for each question, formalized\\nas:\\nSi = LLMi\\nU(Q, pperception),\\n(8)\\nwhere   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Si is the PPDTS evaluation scores for user\\ni; Q is the question set comprising the PPDTS;\\npperception is the  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m PPDTS assessment prompt.\\nPanic Arousal Stage\\nTo bridge risk perception\\nand emotion arousal, we               \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m reparameterize the dis-\\ncrete PPDTS scores into panic propensity drivers.\\nSpecifically, we prompt the agent   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m to analyze four\\ncore factors (Risk awareness, coping effectiveness,\\nevent uncertainty, and situational        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m novelty) through\\na cognitive chain reasoning mechanism, and in-\\nfer the panic propensity probability based on \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m prior\\noutputs. This process can be represented as:\\nCi = LLMi\\nU(Si, pc),\\n(9)\\nP i\\npanic = LLMi\\nU(Si, Ci,   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m ppanic),\\n(10)\\nwhere Ci is the summary of four factors for user\\ni; P i\\npanic is the panic propensity         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m probability; PC is\\nthe prompt directing the agent in summarizing the\\nfour factors; ppanic is the prompt       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m guiding the agent\\nto evaluate userâ€™s panic probability.\\nPosting Response Stage\\nIn this stage, we prompt\\nthe \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m agent to integrate knowledge across stages (see\\nAppendix A.4.3 for details) and predict the post\\ncontent the  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m user is most likely to generate under the\\ndisaster event. This process can be represented as:\\nT i =           \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m LLMi\\nU(Si, Ci, P i\\npanic, pT ),\\n(11)\\nwhere T i is the set of tweets most likely published\\nby the i-th      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m user; PT is \", \"## Title\\nRisk Psychology & Cyber-Attack Tactics\\n\\n## Summary\\nWe examine whether measured     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m cognitive processes predict cyber-attack\\nbehavior. We analyzed data that included psychometric scale responses \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m and\\nlabeled attack behaviors from cybersecurity professionals who conducted\\nred-team operations against a     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m simulated enterprise network. We employed\\nmultilevel mixed-effects Poisson regression with technique counts    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m nested within\\nparticipants to test whether cognitive processes predicted technique-specific\\nusage. The scales \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m significantly predicted technique use, but effects varied by\\ntechnique rather than operating uniformly.        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Neither expertise level nor\\nexperimental treatment condition significantly predicted technique                 \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m patterns,\\nindicating that cognitive processes may be stronger drivers of technique\\nselection than training or \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m experience. These findings demonstrate that\\nindividual cognitive differences shape cyber-attack behavior and   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m support the\\ndevelopment of psychology-informed defense strategies.\\n\\n##Content\\n \\nRisk Psychology &          \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Cyber-Attack Tactics \\nRubens Kim1, Stephan Carney2, Yvonne Fonken3, Soham Hans1, \\nSofia Hirschmann4, Stacy    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Marsella4, Peggy Wu3, and Nikolos \\nGurney1 \\n1Institute for Creative Technologies, University of Southern      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m California, Playa Vista, CA  \\n2Marshall School of Business, University of Southern California, Los Angeles, CA \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m \\n3Raytheon Technologies, Farmington, CT  \\n4Khoury College of Computer Sciences, Northeastern University,      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Boston, MA  \\nABSTRACT \\nWe examine whether measured cognitive processes predict cyber-attack behavior. We      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m \\nanalyzed data that included psychometric scale responses and labeled attack behaviors \\nfrom cybersecurity    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m professionals who conducted red-team operations against a simulated \\nenterprise network. We employed           \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m multilevel mixed-effects Poisson regression with \\ntechnique counts nested within participants to test whether  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m cognitive processes predicted \\ntechnique-specific usage. The scales significantly predicted technique use, but \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m effects \\nvaried by technique rather than operating uniformly. Neither expertise level nor experimental         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m \\ntreatment condition significantly predicted technique patterns, indicating that cognitive \\nprocesses may be  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m stronger drivers of technique selection than training or experience. These \\nfindings demonstrate that          \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m individual cognitive differences shape cyber-attack behavior and \\nsupport the development of                   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m psychology-informed defense strategies. \\nKeywords: Cyberpsychology, Cognitive Biases, Adversary Behavior,      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Decision-Making \\nINTRODUCTION \\nCybersecurity defenses typically focus on technical vulnerabilitiesâ€”patching   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m \\nsoftware, configuring firewalls, and detecting malicious signatures. However, \\nhuman attackers remain the    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m ultimate threat, and humans are subject, or vulnerable, \\nto cognitive processes (e.g., biases) that            \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m systematically influence decision-making. \\nThe IARPA Reimagining Security with Cyberpsychology-Informed        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Network \\nDefences (ReSCIND) program sought to shift focus from technical \\ncountermeasures to exploiting these \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m vulnerabilities to impede attackers. As part of \\nReSCIND, the Guarding Against Malicious Biased Threats        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m (GAMBiT) project \\ncollected multi-modal data from skilled professionals attacking simulated \\nenterprise       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m networks, including responses to psychometric inventories and network \\nactivity that was later annotated using \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m a standardized taxonomy of adversarial \\ntactics. Using multilevel modeling, we tested whether differences in   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m cognitive \\nvulnerability predict which tactics individuals employed during the operation. \\nPSYCHOLOGICAL      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m VULNERABILITIES AND CYBERSECURITY \\nThe study of cyber attackersâ€™ cognitive states, particularly their biases,  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m during an \\nattack is a young field of research. Biases, as studied in judgment and decision \\nmaking (Tversky  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m & Kahneman, 1974) and occasionally referred to as cognitive \\nvulnerabilities, however, are linked to a         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m multitude of adverse decision outcomes. \\n2  \\nKim et al. \\nExamples are as diverse as under-saving for         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m retirement (Benartzi & Thaler, 2013) \\nand misjudging how charged emotional states will alter your own decision \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m making \\n(Loewenstein & Lerner, 2002). Historically, cybersecurity researchers have \\nfocussed on studying the  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m impact of attackers' skills during capture the flag tasks \\nand similar activitiesâ€”a focus that underweights    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m the cognitive states of cyber \\nattackers (Fergusonâ€‘Walter et al., 2019). Early contributions to the research   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m area, \\nsuch as Ferguson-Walter et al.â€™s Tularosa Study (Fergusonâ€‘Walter et al., 2019), \\nestablished some pros \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m and cons of experimentally studying attackersâ€™ mental states \\nalong with exploratory insights into their       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m biases (Gutzwiller et al., 2024). These \\nefforts, along with a related project that pulled together expert     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m opinions on the \\nlikely biases experienced by cyber attackers (Johnson et al., 2021) motivated the             \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m \\ndevelopment of the IARPA ReSCIND program (IARPA, 2025). ReSCIND sought \\nto, â€œ[leverage] well-established     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m cognitive vulnerabilities and human limitations to \\nimpede cyber attackers.â€ Accomplishing that meant directly \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m studying attackersâ€™ \\ncognitive states, including through the administration of psychological inventories       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m \\ndesigned to measure cognitive vulnerabilities. \\nThe GAMBiT project conducted experiments in which skilled    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m attackers \\nundertook two eight-hour days of attacking a simulated enterprise network (Beltz \\net al. 2025).    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m The researchers captured multi-modal data, ranging from self-reports \\n(e.g., participantsâ€™ hacking skills,     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m demographics, and responses to inventories) to \\nalert data (e.g., Suricata (White et al., 2013)). Full         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m experimental details are \\navailable in the Beltz et al. paper, but participants started from a Kali Linux      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m virtual \\nmachine (Denis et al., 2016) and pursued objectives laid out in a dossier. Critically, \\nbefore       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m beginning their attacks, all participants completed four scales designed to \\nmeasure different aspects of      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m their cognitive tendencies: the Cognitive Reflection \\nTest (CRT, (Frederick, 2005)), the General Risk          \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Propensity Scale (GRiPS, (Zhang \\net al., 2019)), and two subscales from the Adult Decision Making Competence   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m \\nscale that measure resistance to positive and negative framing (ADMC-RC1 and \\nADMC-RC2, respectively,        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m (Bruine de Bruin et al., 2007)). Interestingly, the \\nattackersâ€™ responses to these scales and their measured   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m attack skills were \\nstatistically linked (Oh et al., 2025). \\nThe GAMBiT project also developed an approach    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m for annotating the Suricata \\nlogs (Hans, Hirschmann, et al., 2025). This pipeline, which has a large language  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m \\nmodel (LLM) at its core, was initially developed to understand the notes kept by \\nthe attackers (Hans,       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Gurney, et al., 2025). The annotations are based on the \\nMITRE ATT&CK framework, which is â€œa                   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m globally-accessible knowledge base of \\nadversary tactics and techniques based on real-world observationsâ€ used \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m to model \\nthreats and provides a clear attack taxonomy (Strom et al. 2020). The effort sought \\nto identify    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m when the attackers 1) noted that they used MITRE ATT&CK \\npersistence techniques and 2) correlate those         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m annotations with the different \\npsychometric scales. The researchers found a statistically significant         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m negative \\nrelationship between GRiPS scores and persistence usage, suggesting that attackers \\nwith a lower    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m risk propensity relied more on risk-mitigating techniques. We use the \\nSuricata log annotations in our         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m modeling efforts. \\nRisk Psychology and Cyber-Attack Tactics 3 \\nHYPOTHESIS \\nWe hypothesized that the cyber    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m attackersâ€™ cognitive processes, as measured by the \\nscales, would predict the MITRE ATT&CK techniques that     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m attackers use. In other \\nwords, the count of each MITRE ATT&CK technique annotated in the individual           \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m \\nSuricata logs serve as the dependent variable and the cyber attackersâ€™ responses to \\nthe various scales      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m (along with experimental controls and demographics) as the \\nindependent variables in the modeled relationship. \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m \\nMETHODS \\nWe analyzed data from two experiments, GAMBiT Experiments 2 (HSR2, \\nâ€œcontrol,â€ N=17) and 3 (HSR3,  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m â€œtriggers,â€ N=16), conducted under the IARPA \\nReSCIND program. Data were from cybersecurity professionals who  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m completed \\ndatasets a red-team cyber operations in a simulated enterprise network (SimSpace \\nCyber Force      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Platform). We excluded data from 31 additional participants due to \\nincomplete data and HSR1 because of        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m changes in the experimental design. \\nOur data structure consisted of technique counts nested within            \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m participants, \\nwhich are the main dependent variables. The classification of participant's network \\nactivity  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m into 11 MITRE ATT&CK technique categories resulted in 363 \\nobservations (33 participants Ã— 11 techniques). The \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 11 MITRE ATT&CK \\ntechnique categories, derived from Suricata IDS alerts using an LLM annotation \\npipeline,    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m are: Reconnaissance, Execution, Initial Access, Lateral Movement, \\nCredential Access, Privilege Escalation,    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Collection, Discovery, Command and \\nControl, Exfiltration, Persistence. Because multiple technique counts from \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m the \\nsame individual are not independent, we used multilevel mixed-effects modeling \\nto account for           \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m within-participant correlation while testing whether psychometric \\nmeasures predict technique-specific use     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m patterns. \\nAll 33 participants completed the four psychometric scales, our main \\nindependent variables, as    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m part of the experiment prior to engaging in the hackathon. \\nWe also rely on other covariates to control for    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m experimental design features, \\nindividual differences, and demographic anomalies: Treatment condition          \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m (triggers \\nvs. control), Division (Expert vs. Open), age, gender, country (USA vs. other), \\nnative English    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m speaker.  \\nWe selected Reconnaissance as the reference technique because it had the \\nhighest observed         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m frequency (N = 1399, 71.2 % of observations), thus providing the \\nmost stable baseline for contrast estimates. \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Theoretically, reconnaissance \\nrepresents ongoing information-gathering throughout penetration testing,        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m whereas \\nother techniques (e.g., Initial Access, Lateral Movement) are more discrete events. \\nAll             \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m coefficients therefore represent effects relative to reconnaissance use.  \\nAt Level 1, we modeled technique    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m counts using Poisson regression, appropriate \\nfor non-negative count data. The model included main effects for \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m technique \\ncategories (with Reconnaissance as the reference due to its high frequency), \\npsychometric Ã—       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m technique interactions to test whether cognitive processes predict \\ntechniques differentially, and             \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m participant-level covariates (treatment condition, \\nexpertise level, demographics). At Level 2, we included    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m participant-level \\npredictors: psychometric scores (ADMC RC1, ADMC RC2, CRT, GRiPS), \\ntreatment condition     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m (Triggers vs. Control), expertise level (Expert vs. Open \\nDivision), and demographic controls (age, gender,    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m country, native English \\n4  \\nKim et al. \\nspeaker). All continuous predictors were standardized (M=0, SD=1)   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m prior to \\nanalysis to improve numerical stability and facilitate interpretation. We included \\nrandom          \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m intercepts for participants to account for individual differences in overall \\ntechnique use, allowing each     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m participant to have their own baseline level of \\nactivity. This accounts for stable individual differences     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m (e.g., general activity level, \\noverall technical proficiency) while testing technique-specific psychometric   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m \\neffects. Sample size constraints prevented use of random slopes. \\nThe psychometric Ã— technique interactions  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m are the critical feature of our \\nanalysis. These interactions test whether specific cognitive processes        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m predict \\ntechnique use differentially, for example, whether higher reflective thinking (CRT \\nscore) predicts  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m more use of some techniques but less use of others.  \\nWe fit the models using the lme4 package (version 1.1-37 \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m (Bates et al., 2025)) \\nin R (version 4.5.0) with maximum likelihood estimation and the BOBYQA \\noptimizer      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m (Powell, 2009). Likelihood ratio tests (Type II Wald chi-square) \\nassessed the significance of fixed effects.  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m The model converged with a warning \\nabout large eigenvalue ratios, reflecting correlation between the ADMC     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m scales \\n(r=.74) and model complexity. The dispersion ratio (3.64) indicated moderate \\noverdispersion,         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m suggesting unexplained variance beyond that expected under the \\nPoisson distribution. This inflates standard   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m errors (making individual coefficient \\ntests more conservative) but does not invalidate our inference given    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m the strong \\neffects observed (all p < .002). + \\nWe report both omnibus likelihood ratio tests for each        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m psychometric Ã— technique \\ninteraction and individual coefficient tests for specific technique contrasts. The   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m \\nomnibus tests (one per psychometric measure) control family-wise error rate at \\nÎ±=.05. Individual            \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m coefficients are reported for interpretation but should be \\nconsidered exploratory given the large number of   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m contrasts. Model coefficients \\nrepresent log rate ratios. For main effects, exp(Î²) gives the rate ratio for    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m that \\ntechnique relative to reconnaissance. For interaction terms, exp(Î²) gives the \\nmultiplicative change in \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m the rate ratio associated with a one SD increase in the \\nmeasure. For example, a coefficient of 0.82 for CRT Ã— \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Lateral Movement indicates \\nthat a one SD increase in reflective thinking is associated with a 2.3-fold        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m increase \\n(exp(0.82)=2.27) in lateral movement relative to reconnaissance. \\nRESULTS \\nPsychometric measures   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m did not differ significantly between Expert and Open \\nDivision groups (all p > .20). Across all participants,  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 1,964 technique uses were \\nidentified from network logs, classified into 11 MITRE ATT&CK categories.           \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m \\nReconnaissance dominated (N=1,399, 71%), with all but one participantâ€™s Suricata \\nlogs showing evidence of   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m this technique. Other frequently used techniques \\nincluded Lateral Movement (N=206, 13 participants),          \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Execution (N=175, 24 \\nparticipants), and Initial Access (N=53, 19 participants). Three techniques were         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m \\nrarely observed: Command and Control (3 participants), Exfiltration (3 \\nparticipants), and Persistence (1    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m participant).  \\nThe intraclass correlation coefficient (ICC) was 0.255, indicating that 25.5% of \\nvariance in \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m technique counts was attributable to stable between-person differences, \\nwith the remaining 74.5% due to       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m within-person variation across techniques. This \\nsubstantial between-person variance justified the multilevel  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m modeling approach \\nRisk Psychology and Cyber-Attack Tactics 5 \\nand indicated meaningful individual            \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m differences in overall technique use beyond \\ntechnique-specific patterns. The model fit the data well          \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m (AIC=1797.9, \\nBIC=2039.3). The random intercept standard deviation was 1.06, reflecting \\nconsiderable         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m heterogeneity in participants' baseline activity levels. Moderate \\noverdispersion was detected (dispersion     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m ratio=3.64), suggesting additional \\nunexplained variance; however, this does not invalidate inference given    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m the \\nextremely strong effects observed (all p < .002). \\nLikelihood ratio tests (Table 1) revealed that all    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m four psychometric measures \\nsignificantly predicted technique use, but effects varied by technique (see        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m \\nsignificant psychometric Ã— technique interactions in Table 1). We interpret this as \\nindicating that         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m cognitive processes predict technique preferences differentially \\nrather than uniformly. \\nTable 1. Likelihood \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Ratio Tests \\nEffect \\nChi-square \\ndf \\np-value \\ntechnique \\n2137.09 \\n10 \\n< .001 \\ntreatment \\n1.73 \\n1     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m \\n0.189 \\nDivision \\n0.30 \\n1 \\n0.584 \\nage_z \\n0.16 \\n1 \\n0.692 \\ngender \\n0.78 \\n1 \\n0.377 \\ncountry_usa      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m \\n1.27 \\n1 \\n0.260 \\nenglish_native \\n1.65 \\n1 \\n0.200 \\ntechnique:ADMC_RC1_z \\n122.76 \\n11 \\n< .001            \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m \\ntechnique:ADMC_RC2_z \\n48.42 \\n11 \\n< .001 \\ntechnique:CRT_z \\n198.92 \\n11 \\n< .001 \\ntechnique:GRiPS_z       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m \\n30.72 \\n11 \\n0.001 \\nIn contrast, treatment condition (Triggers vs. Control), expertise level (Expert \\nvs.   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Open Division), and demographic variables did not significantly predict \\ntechnique use patterns. This          \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m indicates that individual cognition, rather than \\nexperimental manipulation or experience level, may have been \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m the primary drivers \\nof technique selection in this sample. \\nTo understand these interactions, we examined    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m individual technique-specific \\neffects (See Table 2 for all significant effects with coefficients and          \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m confidence \\nintervals. Figures 1 and 2 graphically display the results.). Twelve psychometric Ã— \\ntechnique    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m combinations showed significant effects at Î±=.05. Higher scores on the \\nresistance to positive framing scale   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m (ADMC RC1) were associated with increased \\nReconnaissance use, indicating that such individuals engaged in     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m more information-\\ngathering. Conversely, it was negatively associated with Command and Control \\ntechnique     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m use, though this latter finding should be interpreted cautiously given the \\nrarity of this technique (N=7      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m total uses). \\nHigher scores on the resistence to negative framing scale (ADMC RC2) were \\nassociated with      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m reduced Reconnaissance use, suggesting that individuals with \\ngreater such resistance engaged in less broad    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m information-gathering. It also \\nnegatively predicted Lateral Movement, indicating less network traversal among \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m \\nhigh resistance to negative framing individuals. \\n6  \\nKim et al. \\nReflective thinking (CRT) showed the     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m most extensive effects, significantly \\npredicting six techniques. Higher CRT was associated with reduced       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m \\nReconnaissance, Collection, Credential Access, Initial Access, and Privilege \\nEscalation. Notably, CRT       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m showed the opposite effect for Lateral Movement, where \\nmore reflective thinkers used this technique           \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m significantly more. This suggests that \\nindividuals high in reflective thinking employed a qualitatively       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m different tactical \\napproach: less broad reconnaissance and vulnerability scanning, but more strategic         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m \\nnetwork traversal once initial access was achieved. \\nRisk seeking propensity (GRiPS) positively predicted    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m both Collection and \\nInitial Access techniques. This suggests that individuals who self-reported a higher      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m \\npropensity to accept or seek risks were more likely to engage in data gathering \\noperations and gain system  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m access.  \\nTable 2: Significant Psychometric Ã— Technique Effects \\nPredictor \\nTechnique \\nCoefficient \\nSE \\nz \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m \\np-value \\nADMC_RC1 \\nReconnaissance \\n1.040 \\n0.337 \\n3.09 \\n0.002 \\nADMC_RC1 \\nCommand and \\nControl         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m \\n-2.136 \\n0.968 \\n-2.21 \\n0.027 \\nADMC_RC2 \\nReconnaissance \\n-0.798 \\n0.302 \\n-2.64 \\n0.008 \\nADMC_RC2        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m \\nLateral Movement \\n-0.760 \\n0.325 \\n-2.34 \\n0.019 \\nCRT \\nReconnaissance \\n-0.605 \\n0.208 \\n-2.91 \\n0.004     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m \\nCRT \\nCollection \\n-0.685 \\n0.315 \\n-2.17 \\n0.030 \\nCRT \\nCredential Access \\n-0.861 \\n0.240 \\n-3.59 \\n< .001 \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m \\nCRT \\nInitial Access \\n-0.548 \\n0.244 \\n-2.25 \\n0.025 \\nCRT \\nLateral Movement \\n0.824 \\n0.238 \\n3.47 \\n<     \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m .001 \\nCRT \\nPrivilege \\nEscalation \\n-0.646 \\n0.298 \\n-2.17 \\n0.030 \\nGRiPS \\nCollection \\n1.117 \\n0.441       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m \\n2.54 \\n0.011 \\nGRiPS \\nInitial Access \\n1.095 \\n0.335 \\n3.26 \\n0.001 \\nNote: Coefficients for 1 SD increase   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m in predictor. \\nIn summary, the multilevel analysis revealed robust technique-specific effects \\nof the         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m measured cognitive processes on hacking behavior. Reflective thinking \\n(CRT) showed the most pervasive         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m influence, affecting six different techniques with \\na consistent pattern: negative effects on reconnaissance   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m and vulnerability \\nexploitation techniques, but a strong positive effect on strategic network traversal.       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m \\nRisk propensity consistently facilitated information gathering and access \\noperations. These differential    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m effects may explain why previous analyses found \\nnull results: psychometric effects do not operate uniformly   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m across all techniques \\nbut rather shape specific tactical choices within the broader attack process. \\nWe      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m translated selected coefficients into rate ratios to aid interpretation. For \\nexample, the CRT Ã— Lateral       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Movement effect (Î²=0.82) indicates that a one SD \\nincrease in reflective thinking was associated with a        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 2.3-fold increase in Lateral \\nMovement use relative to Reconnaissance (exp(0.82)=2.27). Similarly, the strong  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m \\nnegative effect of CRT on Credential Access (Î²=-0.86) suggests that high reflective \\nthinkers use this       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m technique at only 42% the rate of low reflective thinkers (exp(-\\nRisk Psychology and Cyber-Attack Tactics 7    \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m \\n0.86)=0.42), relative to Reconnaissance. These rate differences indicate that \\ncognitive processes can       \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m meaningfully influence tactical decisions. \\n \\nFigure 1: A heatmap of all psychometric Ã— technique             \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m coefficients. The concentration of \\nnegative CRT effects and positive GRiPS effects on specific techniques is  \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m visually apparent, \\nas is the relative scarcity of significant effects for rare techniques. \\n \\nFigure 2: The \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m 12 significant effects with 95% confidence intervals. Effect sizes varied \\nconsiderably, with the largest      \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m effects observed for CRT Ã— Lateral Movement (Î²=0.82) and \\nADMC RC1 Ã— Command and Control (Î²=-2.14). The        \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m predominantly negative CRT effects \\nand positive GRiPS effects represent the most consistent patterns across   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m techniques. \\nDespite the significant psychometric effects, the random intercept variance \\n(SD=1.06) indicated \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m substantial individual differences in technique use beyond \\nthose explained by measured cognitive processes.   \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ”‚\u001b[0m Some individuals showed \\nconsistently high technique\"]                                                         \u001b[33mâ”‚\u001b[0m\n",
              "\u001b[33mâ•°â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â•¯\u001b[0m\n"
            ],
            "text/html": [
              "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #808000; text-decoration-color: #808000\">â•­â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€ ðŸ”§ Tool Output â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â•®</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> [\"## Title\\nPanicToCalm: A Proactive Counseling Agent for Panic Attacks\\n\\n## Summary\\nPanic attacks are acute  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> episodes of fear and distress, in which timely,\\nappropriate intervention can significantly help individuals    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> regain stability.\\nHowever, suitable datasets for training such models remain scarce due to\\nethical and        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> logistical issues. To address this, we introduce PACE, which is a\\ndataset that includes high-distress episodes <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> constructed from first-person\\nnarratives, and structured around the principles of Psychological First          <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Aid\\n(PFA). Using this data, we train PACER, a counseling model designed to provide\\nboth empathetic and        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> directive support, which is optimized through supervised\\nlearning and simulated preference alignment. To       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> assess its effectiveness, we\\npropose PanicEval, a multi-dimensional framework covering general                 <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> counseling\\nquality and crisis-specific strategies. Experimental results show that PACER\\noutperforms strong    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> baselines in both counselor-side metrics and client affect\\nimprovement. Human evaluations further confirm its  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> practical value, with PACER\\nconsistently preferred over general, CBT-based, and GPT-4-powered models in\\npanic <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> scenarios (Code is available at https://github.com/JihyunLee1/PanicToCalm\\n).\\n\\n##Content\\nPanicToCalm: A      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Proactive Counseling Agent for Panic Attacks\\nJihyun Lee â™£, Yejin Min â™£, San Kim â™£, Yejin Jeon â™£, SungJun       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Yangâ™¢,\\nHyounghun Kimâ™£, â™¢, Gary Geunbae Leeâ™£, â™¢\\nâ™£Graduate School of Artificial Intelligence,                   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> POSTECH\\nâ™¢Department of Computer Science and Engineering, POSTECH\\n{jihyunlee, yeajinmin, sankm, jeonyj0612,    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> sjyang114, h.kim, gblee}@postech.ac.kr\\nAbstract\\nPanic attacks are acute episodes of fear and\\ndistress, in    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> which timely, appropriate interven-\\ntion can significantly help individuals regain\\nstability. However,        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> suitable datasets for train-\\ning such models remain scarce due to ethical\\nand logistical issues. To address   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> this, we in-\\ntroduce PACE, which is a dataset that includes\\nhigh-distress episodes constructed from           <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> first-\\nperson narratives, and structured around the\\nprinciples of Psychological First Aid (PFA).\\nUsing this  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> data, we train PACER, a counseling\\nmodel designed to provide both empathetic and\\ndirective support, which is  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> optimized through\\nsupervised learning and simulated preference\\nalignment. To assess its effectiveness, we     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> pro-\\npose PANICEVAL, a multi-dimensional frame-\\nwork covering general counseling quality and\\ncrisis-specific <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> strategies. Experimental results\\nshow that PACER outperforms strong baselines\\nin both counselor-side metrics  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> and client af-\\nfect improvement. Human evaluations further\\nconfirm its practical value, with PACER            <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> consis-\\ntently preferred over general, CBT-based, and\\nGPT-4-powered models in panic scenarios                 <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 1.\\n1\\nIntroduction\\nPanic attacks are sudden episodes of intense fear\\naccompanied by physical symptoms such   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> as rapid\\nheartbeat, shortness of breath, and dizziness. These\\nepisodes often occur without warning, leaving   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> indi-\\nviduals in acute distress and unable to self-regulate\\n(Hoppe et al., 2012; American Psychiatric         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Associa-\\ntion, 2013; Kolek et al., 2020). Immediate interven-\\ntion from a trained professional through        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> grounding,\\nbox-breathing, or relocation to a safe environment,\\ncan be highly effective (Chalmers et al.,      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 2022; John-\\nston, 2023). However, professional support is not\\nalways accessible due to time, cost, and        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> availability\\nconstraints, which increases the demand for AI sys-\\ntems that are capable of timely assistance.  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Despite\\n1Code\\nis\\navailable\\nat\\nhttps://github.com/\\nJihyunLee1/PanicToCalm\\nIâ€™m,,, at a shopping mall, and  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> there are so many people \\ntalking,,,,,. Itâ€™s... overwhelming. I... I canâ€™t breathe.\\nPanic                     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> \\nAttack\\nClient\\n(Empathy: \\n, Directive : \\n)\\nI can understand how you feel, this feeling must be very       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> \\nfrightening for you.\\nCounseling\\nModel\\nSample Conversation in Panic Scenario\\nI'm sorry to hear that you're <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> feeling this way. \\nWhen you're in a place like a coffee shop, what thoughts \\nusually go through your          <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> mind?\\nCBT\\n Counseling\\nModel\\n(Empathy: \\n, Directive : \\n)\\nI understand this is really overwhelming right   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> now. \\nCan you find a quiet corner, or step outside for a moment? \\nPACER\\n(Empathy: \\n, Directive :\\n)\\nFigure <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 1: Conversation between a client and different\\ncounseling models. PACER delivers both appropriate\\nempathy and <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> clear, directive guidance to support imme-\\ndiate stabilization.\\nthis need, the unpredictable and deeply       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> personal\\nnature of panic attacks makes it nearly impossi-\\nble to collect authentic, in-the-moment             <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> counseling\\ninteractions for model training.\\nMeanwhile, synthetic dialogue datasets with\\nlarge language       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> models (LLMs) have emerged as a\\npromising alternative in environments where data\\ncollection is challenging,   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> given their strong con-\\nversational abilities (Lee et al., 2022; Kim et al.,\\n2023a; Kulkarni et al., 2024;    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Lee et al., 2024b; Jang\\net al., 2024; Lee et al., 2025). In the counseling do-\\nmain, identifying authentic    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> and diverse sources for\\ndialogue construction such as crowd sourcing (Na,\\n2024; Qiu et al., 2024), web Q&amp;A    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> (Xiao et al.,\\n2024), and augmenting from real counseling di-\\nalogues (Liu et al., 2023), and applying         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> suitable\\ntherapeutic theory (Na, 2024; Lee et al., 2024a;\\nKim et al., 2025) are key challenges in             <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> building\\neffective synthetic datasets. However, prior efforts\\nhave predominantly focused on general           <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> psycholog-\\nical concerns and employed cognitively demanding\\ncounseling procedures, assuming that clients are  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> in\\nrelatively stable emotional states. This assumption\\nlimits the applicability to high-distress              <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> situations\\nlike panic attacks, where clients require immediate,\\ndirective, and low-cognitive-burden           <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> support.\\narXiv:2510.21143v2  [cs.AI]  28 Oct 2025\\nTo address this, we introduce PACE (Panic-to-\\nAid          <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Counseling with Emergency) dataset, that is\\nfocused on immediate intervention during acute\\npanic attacks      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> (Figure 1). We begin by collecting\\nfirst-person narratives from individuals who de-\\nscribe their panic        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> episodes. From these narratives,\\nwe identify key components of a panic attack, in-\\ncluding environmental      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> context, physical symptoms,\\nemotional responses, and cognitive patterns. As the\\nunderlying therapeutic        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> framework, we adopt Psy-\\nchological First Aid (PFA; Brymer et al. (2006)),\\nwhich is designed to provide       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> immediate stabiliza-\\ntion for individuals experiencing high-distress situ-\\nations such as trauma, PTSD, or    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> panic attacks.\\nBuilding on our PACE dataset, we train PACER\\n(Panic-to-Aid Counseling with Emergency           <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Re-\\nsponse), which is a counseling model that is de-\\nsigned to stabilize acute panic episodes through\\nrapid  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> interventions. To further enhance the modelâ€™s\\nability to cope with a broad spectrum of panic cases,\\nwe run    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> simulations using a client agent, exposing\\nit to unpredictable and diverse scenarios. From\\nthese simulations, <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> we collect preference feedback\\nfrom the client agent and perform alignment train-\\ning to guide the modelâ€™s    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> behavior toward greater\\ndirectiveness and empathy.\\nFinally, we introduce PANICEVAL, a novel eval-\\nuation     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> framework designed to assess counseling\\nmodels in the context of acute panic interventions.\\nWhile existing    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> evaluation methods primarily focus\\non general therapeutic quality, they often fail to cap-\\nture the urgency   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> and stabilization demands inherent\\nto panic attack scenarios (Aarons et al., 2012; Li\\net al., 2024; Lee et    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> al., 2024a). To address this\\ngap, PANICEVAL incorporates core principles from\\nPFA, which enables the          <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> evaluation of both general\\ncounseling competencies and first-aid-oriented in-\\ntervention                      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> effectiveness.\\nDuring evaluation, we examine two aspects: the\\ncounselorâ€™s effectiveness and the clientâ€™s      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> emotional\\nimprovement. PACER demonstrates strong perfor-\\nmance in both general and first-aid-specific         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> skills,\\nparticularly in the clarity of its responses. Signif-\\nicant emotional improvement can also be seen    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> in\\nclients through increased self-esteem and reduced\\nfear. In human evaluations involving both clini-\\ncal    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> experts and individuals with lived experience,\\nPACER was consistently preferred over the general,\\nCognitive   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Behavioral Therapy (CBT) based, and\\neven closed models like GPT-4o (OpenAI, 2024b).\\n2\\nRelated                <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Work\\n2.1\\nData Challenges in Mental Health\\nBuilding counseling systems requires high-quality\\ndialogue data,  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> but privacy and ethical concerns hin-\\nder real-world collection. As such, recent work\\nuse closed-source LLMs: <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> HealMe (Xiao et al.,\\n2024) generates short CBT-based dialogues from\\ncrowdsourced profiles; Cactus (Lee et     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> al., 2024a)\\nadds scripted planning for longer sessions; CPsy-\\nCoun (Zhang et al., 2024) reconstructs          <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> profiles\\nfrom anonymized transcripts; and Psych8k (Liu\\net al., 2023), SMILEChat (Qiu et al., 2024),           <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> and\\nCBT-LLM (Na, 2024) utilize online mental health\\nforums. Yet, these approaches target generalized\\nissues  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> with calm, reflective users. In contrast, we\\nfocus on the acute phase of panic attacks, simulat-\\ning          <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> real-time stabilization grounded in PFA.\\n2.2\\nSynthetic Preference Pairs for Value\\nAlignment\\nHuman-annotated <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> preference datasets have been\\nkey to aligning LLMs for better performance and\\nsafety (Bai et al., 2022;       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Stiennon et al., 2020;\\nNakano et al., 2021), but they are costly and hard\\nto scale. To overcome this, recent  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> studies use syn-\\nthetic preference data generated by LLMs. Meth-\\nods like R-DPO (Gallego, 2024) and Selfee    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> (Kim\\net al., 2023b) apply self-critique or model-based\\nscoring, while AutoPM (Kim et al., 2024)               <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> and\\nSAFER-Instruct (Shi et al., 2024) guide models\\ntoward helpfulness, honesty, and harmlessness\\n(HHH) using <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> GPT-4 (Achiam et al., 2023). Build-\\ning on these, we apply model-based scoring in a\\nnovel setting; outputs    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> are aligned with therapeutic\\nvalues like empathy and directiveness via interac-\\ntion with a simulated patient <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> in panic counseling.\\n3\\nPsychological First Aid\\nPFA is a modular intervention developed by the\\nNational      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Child Traumatic Stress Network and the\\nNational Center for PTSD to provide support fol-\\nlowing traumatic      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> events (Brymer et al., 2006). It is\\norganized around three sequential actionsâ€”Look,\\nListen, and Linkâ€”which    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> guides responders in as-\\nsessing the situation and ensuring safety (Look),\\nstabilizes individuals and offers  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> emotional sup-\\nport (Listen), and connects them to further ser-\\nvices and resources (Link) (World Health      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Organi-\\nzation, 2013). Unlike long-term therapies like CBT\\nor Emotion-Focused Therapy (EFT;                   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Greenberg\\n(2017)), which require reflective engagement over\\nmultiple sessions, PFA is designed for acute      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> psy-\\nchological crises as it prioritizes directive, action-\\noriented strategies and immediate stabilization.  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Its\\neffectiveness in managing panic episodes has been\\nhighlighted in prior studies (Chalmers et al.,          <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 2022).\\n4\\nPACE: Panic Episode Dataset with\\nPFA Counseling\\nIn this section, we introduce PACE, the first      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> coun-\\nseling dataset that is designed to address acute\\npanic episodes. We hypothesize that a                  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> high-quality\\ndataset should satisfy three key criteria: (1) the\\nclientâ€™s episode must be plausible and        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> reflective\\nof real-world panic scenarios; (2) the counselor\\nmust successfully guide the client toward         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> stabiliza-\\ntion; and (3) the dialogue must maintain general\\ntherapeutic standards.\\nTo meet these             <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> requirements, our data generation\\npipeline consists of three stages: (1) collecting au-\\nthentic panic         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> narratives, (2) generating multi-staged\\ndialogue scripts based on the PFA guideline, and (3)\\napplying         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> meticulous filtering to ensure counseling\\nquality. We use GPT-4O-MINI (OpenAI, 2024a)\\nas the primary          <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> generation model. An overview is\\nprovided in Figure 2, and corresponding details and\\nprompts are provided in  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Appendix B, H and I.\\n4.1\\nCollecting Client Panic Profiles\\nAs the first step, we model the panic episode      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> pro-\\nfile, which is a structured representation of a panic\\nepisode consisting of three key components:        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> the\\ncontextual Environment, Trigger Type, and Vi-\\ncious Cycle that is defined as the interlinked phys-\\nical, <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> emotional, and cognitive responses that rein-\\nforce one another, thereby intensifying the sever-\\nity of the   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> episode (Clark, 1986).\\nThe Trigger\\nType represents the initial stimulus that activates\\nthis self-reinforcing <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> cycle. To construct these pro-\\nfiles, we sourced first-person narratives of panic\\nepisodes from publicly      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> available social media post\\nand prompted an LLM to extract the relevant com-\\nponents. Given the sensitivity   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> of the data, we ap-\\nplied a meticulous personally identifiable informa-\\ntion (PII) removal process using      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> automated detec-\\ntion and manual review (Appendix B.2), resulting\\nin 1,226 verified profiles.\\nTo enhance the <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> diversity of contextual settings in\\nthe panic profiles, we augmented the Environment\\nand Trigger Type         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> components using an external\\npersona dataset (Zhang et al., 2018). Specifically,\\nwe randomly selected a       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Trigger Type (physical,\\nemotional, or cognitive) and a persona from the\\nexternal persona dataset, then        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> prompted an LLM\\nto generate a plausible environment conditioned on\\nthese two factors. The generated           <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Environment and\\nnew Trigger Type were then attached to the original\\nVicious Cycle to form an augmented        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> profile. For\\nexample, given a Trigger Type (e.g., physical) and\\na persona (e.g., a big fan of live music),    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> the LLM\\ngenerated a realistic Environment such as â€œa tightly\\npacked concert venue.â€ (further examples in      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Ap-\\npendix B.3). Through this process, we constructed\\na total of 9,997 panic profiles.\\n4.2\\nDefining         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Counselor Goals\\nOn the counselor side, we define the modelâ€™s goals\\nbased on the principles of PFA. Since the  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> original\\nPFA guidelines include actions that are not feasi-\\nble for dialogue models (e.g., providing          <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> physical\\nresources like water), we restructure the goals to fo-\\ncus on interventions that can be delivered    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> through\\nconversation. Specifically, we define the goals for\\neach PFA stage as follows: LOOK identifies        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> the\\nclientâ€™s panic profile and guides them to a safe envi-\\nronment; LISTEN focuses on stabilization           <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> through\\nbreathing, grounding and reassurance; and LINK\\nencourages follow-up with a human counselor, end-\\ning <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> with on a positive note. The goals for each\\nstage are summarized in Figure 2 (right) and Ap-\\npendix B.4, and  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> are denoted as goalstage.\\n4.3\\nStructured Dialogue Generation with PFA\\nGiven a panic profile and the          <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> goalstage, we gener-\\nate a complete counseling session that consists of\\nthree sequential stages. Our session  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> generation pro-\\ncess is guided by two key design choices to ensure\\nalignment with each stageâ€™s therapeutic    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> objective.\\nFirst, each stage is generated independently and\\nthen concatenated to form the full session.       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> This\\nmodular structure facilitates alignment with the\\nobjective of each stage. For each stage, we             <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> first\\ngenerate a plan to outline the dialogue flow, and\\nthen generate the dialogue turns corresponding        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> to\\nplan and goalstage. Second, rather than simulat-\\ning turn-by-turn interactions between client              <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> and\\ncounselor agents, we adopt a script-style genera-\\ntion approach. In this setup, the model generates\\nthe  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> entire dialogue for a stage in a single inference\\npass, enabling more coherent and goal-aligned out-\\nputs     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> within each therapeutic phase. Each stage is\\nrepresented as:\\nStage = {plan, [(st0, s0, u0), . . . , (stk, sk, <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> uk)]}\\nPsychological First Aid Counselor\\nStage A. LOOK\\nGoal : Focuses on assessing the clientâ€™s condition,    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> \\nensuring their safety.\\nâ€¢\\nIdentify Physical Symptoms, Emotional States, \\nThinking, Ensure                   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Safety\\nr/MentalHealth â€¢2 days ago\\nRunningBlueBird\\n[Serious] My First Panic Attack â€“ Terrifying               <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Experience\\nHey everyone,\\nI just had my first panic attack at the mall.. My \\nheart was racing and I was so    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> dizzy, I couldnâ€™t \\nbreathe, and my hands went numb. I thought Iâ€™m \\ndying.  I was so scared and I had no idea  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> what was \\nhappening, and I was this close to calling 911. \\nI went to the doctor today, and they said it was   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> \\njust a panic attack.\\nShare\\n2\\n3\\nPanic Attack Episode\\nBig fan of Band\\nLawyer\\nHave two kids\\nExternal     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Source\\nTrigger\\ntype\\nPhysical\\nEmotional\\nCognitive\\nPanic Profile\\nEnvironment\\nTrigger Type\\nPhysical       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Reaction\\nEmotional Reaction\\nCognitive Reaction\\nA packed concert venue\\nPhysical\\nHeart Racing,               <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Dizzy\\nScared\\nI might Die!\\nProfile Augmentation (Env, Trigger)\\nI feel dizzyâ€¦ My heart is racingâ€¦ I think Iâ€™m <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> about to faint!\\nAlright, letâ€™s try some grounding now. \\nCan you feel the texture of the chair? How does it    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> feel?\\nThanks for the suggestion. Iâ€™ll try to find the right support.\\nIf this condition persists, I recommend  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> seeking professional support.\\nâ€¦\\nI hear you. Youâ€™re feeling really uncomfortable right now. \\nAre you in safe  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> place now?\\nLOOK Stage\\nLISTEN Stage\\nThis is Panic Attack First Aid Center.  \\nThere are so many people around <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> me â€” Iâ€™m at this packed concert \\nand I canâ€™t catch my breath. It really hurts.\\nStage Planning                 <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> \\nStrategy\\nUtterance Generation\\nCan you move slightly to the side or find a wall or barrier to lean           <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> against?\\nStrategy\\nUtterance Generation\\nâ€¦\\nI think I can feel it... Itâ€™s a bit rough under my fingers.\\nLINK  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Stage\\nRemember, this symptom is temporary and will pass soon. \\nYou have the strength to control it.\\nPACE     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Psychological First Aid for acute panic attack\\nPFA guidelines\\nStage B. LISTEN\\nGoal : Providing emotional     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> support, Stabilization.\\nâ€¢\\nStabilization by breathing or grounding, Helping the \\nclient shift from irrational <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> fear \\nStage C. LINK\\nGoal : Focuses on assessing the clientâ€™s condition, \\nensuring their                      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> safety.\\nâ€¢\\nEncourage the client to seek further professional help, \\nEnd the session with a positive           <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> message.\\nStage Planning \\nStrategy\\nClient shows high distress, in this step, \\nI will assess the client's     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> physical, emotional, \\nand cognitive state, and guide them to a safe \\nplace\\nThe client's condition hasn't     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> been assessed \\nyet, and their safety is still uncertain. KEEP\\nStage Planning \\nStrategy\\nUtterance            <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Generation\\nStrategy\\nUtterance Generation\\nStage Planning \\nStrategy\\nUtterance Generation\\nFigure 2: An       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> overview of the automatic pipeline for generating the PACE dataset.\\nwhere ui is the client utterance, si is    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> the counselorâ€™s\\nresponse, and sti is the counselorâ€™s strategy for\\ngenerating si. Strategy sti reflects the    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> decision of\\nwhether the counselor should move on to the next\\nstage or not, based on the current dialogue      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> history\\nand goalstage. If sti = keep, the model generates\\nsi, and corresponding ui continues within the       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> same\\nstage. If sti = next, both si and ui are left empty,\\nand the session transitions to the next             <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> stage.\\nOverall,\\nthe\\nLOOK\\nphase\\nis\\ngenerated\\ngiven\\nthe\\npanic\\nprofile\\nand\\na\\ngoalstage:\\nLOOK\\n=\\nLLM <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> (Profile, goalstage).\\nThe\\nsub-\\nsequent\\nLISTEN\\nand\\nLINK\\nstages\\nare\\ngenerated based on the previous      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> stage dia-\\nlogues,\\nprofile,\\nand\\ntheir\\nrespective\\ngoals:\\nLISTEN, LINK = LLM(History, Profile,             <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> goalstage).\\nThe\\nfinal\\ndialogue\\nis\\nformed\\nby\\nconcate-\\nnating\\nthe\\noutputs\\nof\\nthe\\nthree\\nphases:\\nDia <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> logue = LOOK âŠ•LISTEN âŠ•LINK.\\n4.4\\nDialogue Quality Filtering\\nTo ensure structural consistency and              <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> counseling\\nquality of the PACE dataset, we applied a multi-\\nstep filtering process. First, we removed         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> dialogues\\nwith abnormal formatting or excessively long ut-\\nterances (over 100 words), eliminating 5.92%       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> of\\nthe data. Second, CTRS (Aarons et al., 2012) is\\nused to assess alignment with general                      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> therapeutic\\nstandards; five relevant dimensions of Empathy,\\nClarity, Emotional Alignment, Directive           <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Support,\\nand Encouragement, were rated on a scale from 1\\n(poor) to 5 (excellent) by prompting GPT-4o.         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Di-\\nalogues that received a score equal to or less than\\n3 for any dimension were removed (2.42%),             <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> ulti-\\nmately resulting in 8,263 dialogues and 106,433\\nturns. Additional validation of CTRS filtering          <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> with\\nhuman agreement is provided in Appendix B.5.\\n4.5\\nExpert Review of\\nPACE\\nCategory\\nVery                 <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Poor\\nPoor\\nFair\\nGood\\nExcellent\\nEmpathy\\n0.0%\\n1.0%\\n18.0%\\n57.0%\\n24.0%\\nClarity\\n0.0%\\n1.0%\\n29.0%\\n50.7%\\ <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> n19.3%\\nEmotional                                                                                               <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> App.\\n0.0%\\n2.7%\\n34.3%\\n48.7%\\n14.3%\\nDirective\\n0.0%\\n0.0%\\n9.7%\\n64.0%\\n26.3%\\nEncouragement\\n0.0%\\n0.0%\\n19 <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> .7%\\n56.0%\\n24.3%\\nTable 1: Expert evaluation of generated dialogues using\\nthe CTRS rubric. Scores range from  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 1 (very poor) to 5\\n(excellent).\\nWe conducted an expert evaluation with three\\nmental health professionals, to <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> validate the clinical\\nappropriateness and quality of the generated dia-\\nlogues We randomly sampled 100        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> dialogues from\\nthe training set and asked the experts to rate each\\nresponse using the CTRS rubric on a        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 5-point scale\\n(from 1 = very poor to 5 = excellent). The results\\n(Table 1) show that most dialogues fall      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> within the\\nfair to excellent range, supporting the overall valid-\\nity of the generated data. Specifically,    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> the average\\nscores were 4.04 for Empathy, 3.88 for Clarity, 3.75\\nfor Emotional Appropriateness, 4.17 for      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Directive\\nSupport, and 4.05 for Encouragement.\\n4.6\\nComparison\\nPACE with Existing\\nCounseling Datasets\\nIn   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Table 2, we compare our dataset PACE with other\\nexisting synthetic counseling datasets. While prior\\ndatasets  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> primarily address general mental health\\nDataset\\nCounseling Theory\\nProfile Source\\nIssue                      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Type\\nIn-Crisis\\nLanguage\\n# of Dialogues\\nMulti Turn\\nPsyCon (Mishra et al., 2023)\\nNot Specified\\nRecords,    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Crowed Sourcing\\n7 psychological issues\\nNo\\nEnglish\\n1,020\\n24.58\\nPsych8k (Liu et al., 2023)\\nNot             <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Specified\\nCounseling Records\\nAnx, Dep, Relation, Minority\\nNo\\nEnglish\\n8,187\\n1.00\\nSmileChat (Qiu et al.,   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 2024)\\nNot Specified\\nSocial Media\\nNot Specified\\nNo\\nChinese\\n55,165\\n10.4\\nHealMe (Xiao et al.,              <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 2024)\\nCognitive Behavioral Therapy\\nCrowed Sourcing\\nNot Specified\", \"## Title\\nPsychology-driven LLM Agents   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> for Explainable Panic Prediction on Social Media during Sudden Disaster Events\\n\\n## Summary\\nDuring sudden     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> disaster events, accurately predicting public panic sentiment\\non social media is crucial for proactive         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> governance and crisis management.\\nCurrent efforts on this problem face three main challenges: lack of          <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> finely\\nannotated data hinders emotion prediction studies, unmodeled risk perception\\ncauses prediction         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> inaccuracies, and insufficient interpretability of panic\\nformation mechanisms. We address these issues by      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> proposing a Psychology-driven\\ngenerative Agent framework (PsychoAgent) for explainable panic prediction        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> based\\non emotion arousal theory. Specifically, we first construct a fine-grained open\\npanic emotion dataset   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> (namely COPE) via human-large language models (LLMs)\\ncollaboration to mitigate semantic bias. Then, we develop <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> a framework\\nintegrating cross-domain heterogeneous data grounded in psychological\\nmechanisms to model risk    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> perception and cognitive differences in emotion\\ngeneration. To enhance interpretability, we design an          <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> LLM-based role-playing\\nagent that simulates individual psychological chains through dedicatedly\\ndesigned      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> prompts. Experimental results on our annotated dataset show that\\nPsychoAgent improves panic emotion prediction <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> performance by 12.6% to 21.7%\\ncompared to baseline models. Furthermore, the explainability and                 <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> generalization\\nof our approach is validated. Crucially, this represents a paradigm shift from\\nopaque          <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> \\\"data-driven fitting\\\" to transparent \\\"role-based simulation with\\nmechanistic interpretation\\\" for panic     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> emotion prediction during emergencies.\\nOur implementation is publicly available                                <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> at:\\nhttps://anonymous.4open.science/r/PsychoAgent-19DD.\\n\\n##Content\\nPsychology-driven LLM Agents for         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Explainable Panic Prediction on Social\\nMedia during Sudden Disaster Events\\nMengzhu Liu*1, Zhengqiu Zhu*1,     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Chuan Ai1, Chen Gao2,\\nXinghong Li1, Lingnan He3, Kaisheng Lai4, Yingfeng Chen 2, Xin Lu1, Yong Li2, Quanjun    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Yin1\\n1National University of Defense Technology, 2Tsinghua University,\\n3Sun Yat-sen University, 4Jinan        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> University\\n*Equal contribution\\nEvent characteristics\\nï¼ˆPhysical                                              <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> domainï¼‰\\n-------------------------------------\\nDisaster occurrence time\\nCurrent location of the              <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> disaster\\nCurrent intensity of the disaster\\nRisk perception\\nï¼ˆCognitive                                       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> domainï¼‰\\n---------------------------------------\\nScope of disaster threat\\nSeverity of the disaster\\nDegree   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> of disaster hazard\\nIndividual characteristics\\nï¼ˆCognitive                                                     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> domainï¼‰\\n-------------------------------------\\nTopic attention\\nTone characteristics\\nEmotional               <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> trends\\nPersonality traits\\nPanic emotion arousal\\n(Cognitive                                                   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> domain)\\n---------------------------------------\\nRisk awareness\\nEvent uncertainty\\nCoping effectiveness \\nand <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> sense of control\\nSituational novelty\\nPsychological State\\n(Social                                             <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> domain)\\n-----------------------------------------\\nThank you for \\nyour hard work.\\nThatâ€™s \\noutrageous!\\nHope <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> the disaster \\nwill end soon!\\nThatâ€™s \\nterribleï¼\\nRisk communication\\n(Information                            <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> domain)\\n-------------------------------------\\nGeographical \\ncoordinates\\nSocial media \\ncharacteristics      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> \\nAverage number\\nof posts\\nHistorical posts\\nRestrictive \\neffect\\nConcrete \\nrepresentation\\nAffective        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> \\nstate\\nConcrete \\nrepresentation\\nPsychological state \\ntransformation\\nFigure 1: Path of panic formation.    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> The physical domain supplies an objective benchmark, while the information\\ndomain dynamically adjusts          <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> cognitive inputs. The cognitive domain processes these inputs through individual\\nconstraints and risk          <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> perception, triggering panic emotions that ultimately materialize as observable social media\\nbehaviors through <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> the social domain.\\nAbstract\\nAccurately predicting public panic sentiment\\non social media is crucial for      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> proactive gover-\\nnance and crisis management. Current efforts\\non this problem face three main                 <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> challenges:\\nlack of finely annotated data hinders emotion\\nprediction studies, unmodeled risk                  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> perception\\ncauses prediction inaccuracies, and insufficient\\ninterpretability of panic formation               <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> mechanisms.\\nWe address these issues by proposing a Psy-\\nchology-driven generative Agent                       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> framework\\n(PsychoAgent) for explainable panic prediction\\nbased on emotion arousal theory. Specifically,\\nwe   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> first construct a fine-grained panic emotion\\ndataset (namely COPE) via human-large lan-\\nguage models (LLMs)   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> collaboration, combin-\\ning scalable LLM-based labeling with human\\nannotators for accuracy and bias            <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> mitigation.\\nThen, we construct PsychoAgent integrating\\ncross-domain heterogeneous data grounded               <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> in\\npsychological mechanisms to model risk per-\\nception and cognitive differences in emotion\\ngeneration. To   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> enhance interpretability, we de-\\nsign an LLM-based role-playing agent that sim-\\nulates individual             <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> psychological chains through\\ndedicatedly designed prompts. Experimental\\nresults on our annotated dataset show <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> that Psy-\\nchoAgent improves panic emotion prediction\\nperformance by 12.6% to 21.7% compared to\\nbaseline      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> models. Furthermore, the explainabil-\\nity and generalization of our approach is val-\\nidated. Crucially, this  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> represents a paradigm\\nshift from opaque \\\"data-driven fitting\\\" to trans-\\nparent \\\"role-based simulation with <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> mechanis-\\ntic interpretation\\\" for panic emotion prediction\\nduring emergencies. Our implementation            <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> is\\npublicly available at: https://anonymous.4o\\npen.science/r/PsychoAgent-19DD.\\n1\\nIntroduction\\nSocial media <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> accelerates the spread of extreme\\nemotions during sudden events (Organization et al.,\\n2020), yet its          <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> real-time nature, rich information con-\\ntent, and spatiotemporal granularity offer unique\\nopportunities for   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> emotion prediction and manage-\\nment. Among various negative emotions, uncon-\\n1\\narXiv:2505.16455v1  [cs.AI]   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 22 May 2025\\ntrolled panic can exhaust emergency resources, trig-\\nger secondary disasters, even escalate       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> isolated haz-\\nards into complex societal crises (Rune and Keech,\\n2023). For instance, during the 2011 Japan   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> earth-\\nquake, panic-driven mass salt-buying in China ex-\\nacerbated price surges and supply shortages          <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> (Pier-\\nson, 2011). Hence, timely prediction and moni-\\ntoring of panic enable proactive interventions          <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> to\\nmitigate its spread and impact (Wu et al., 2025).\\nCurrent research focuses on coarse-grained               <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> ret-\\nrospective emotion classification using single-\\nmodality textual data (MitroviÂ´c et al., 2024;\\nWeigang  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> et al., 2024; Mitrovic and Kanjirangat,\\n2022), while dedicated studies on panic emotion\\nprediction remain     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> scarce. More details about emo-\\ntion prediction research are in Appendix A.1. Due\\nto the limitations of       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> dataset annotation quality and\\ninherent methodological constraints, precisely pre-\\ndicting public panic       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> remains significant challenges.\\nFirstly, current panic emotion annotation\\nmethods have semantic               <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> deviations.\\nExisting\\ndatasets rely on static annotations and lack normal-\\nstate behavioral data, impeding    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> predictive model-\\ning of panic evolution and causing: (1) oversim-\\nplified categorization of panic as fear    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> (Yang et al.,\\n2022), ignoring disaster-specific risk perception;\\n(2) semantic drift in keyword-based          <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> detection due\\nto variations in linguistic nuances and expressive\\nconventions (MitroviÂ´c et al., 2024; Weigang <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> et al.,\\n2024), weakening cognition-semantics alignment.\\nSecondly, current prediction models                   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> have\\ncross-domain feature fusion and dynamic model-\\ning limitations. Psychological studies indicate           <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> that\\npublic emotions are influenced by multi-domain\\nheterogeneous features. While current models at-\\ntempt   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> to incorporate such features (Regan et al.,\\n2024), they remain limited to simplistic combina-\\ntions of text   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> with single factors. Moreover, existing\\nmodels often use static temporal modeling, fail to\\ncapture evolving   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> feature interactions, significantly\\nreduce predictive efficacy (MitroviÂ´c et al., 2024).\\nLastly, current      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> studies have explainability gap\\nin panic formation mechanism. Current stud-\\nies focus on surface emotion      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> detection and sta-\\ntistical correlations (MitroviÂ´c et al., 2024), ne-\\nglecting psychological drivers like    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> risk perception,\\ncognitive appraisal mechanisms (Hariharan et al.,\\n2017). Though cognitive-emotion            <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> interactions are\\nvalidated in psychological studies, existing works\\nfail to computationally map the risk      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> perception-to-\\narousal chain (Regan et al., 2024; Houlihan et al.,\\n2023), leaving emotional evolution         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> pathways unex-\\nplained.\\nTo address the above challenges, we propose a\\nPsychology-driven generative Agent     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> framework\\n(PsychoAgent) for panic emotion prediction dur-\\ning sudden disasters. Specifically, we first        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> adopt\\na human-LLM collaborative annotation method\\nto construct a fine-grained panic emotion                   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> dataset\\n(Collaborative Fine-grained Open Panic Emotions\\nDataset, COPE), resolving semantic deviation          <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> and\\ncross-cultural annotation biases. Secondly, we de-\\nvelop a mental framework to fuse                       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> multi-domain\\nfeatures through the psychological mechanisms of\\npanic formation (as illustrated in Figure 1).   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Fi-\\nnally, guided by theoretical lenses of risk percep-\\ntion and emotion arousal, we design a                 <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> chain-of-\\nthought (CoT)-driven LLM-based agent to simulate\\nthe full psychological chain of \\\"disaster         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> perception,\\nrisk cognition, panic emotion arousal, and posting\\nbehavior response\\\". Our work shows            <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> significant\\nimplications for developing explainable AI systems\\ncapable of providing deeper insights into      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> collective\\nemotional dynamics during sudden disaster events.\\nOur contributions are summarized as:\\nâ€¢ To       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> support panic prediction, we pioneer a novel\\ndual-phase panic emotion annotation dataset. We\\nalso fine-tune a <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> discriminator to detect panic sig-\\nnals in generated texts.\\nâ€¢ We innovatively propose a                       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> psychology-driven,\\nmulti-domain fusion mental model for public\\npanic prediction during disasters. Our         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> approach\\nintegrates multi-domain data via an LLM-based\\nrole-playing agent for interpretable psycholog-\\nical  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> modeling of panic formation mechanisms.\\nâ€¢ Experimental results show that the proposed\\nframework achieves an   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> accuracy of 86% (â†‘at\\nleast 13% versus SOTA) in panic emotion pre-\\ndiction task. Moreover, scalability studies <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> and\\ncase studies further validate the explainability\\nand generalization of our approach.\\n2\\nProblem          <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Definition and Dataset\\nConstruction\\nIn this section, we first formalize the problem defi-\\nnition, then       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> detail the methods for building a fine-\\ngrained panic emotion dataset and finally fine-tune\\na BERT-based      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> model for panic recognition.\\n2.1\\nProblem Definition\\nThe sentiment prediction task can be defined             <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> as:\\nÏƒi\\nt+1 = F\\n\\u0000Ii\\nt\\n\\u0001\\n,\\n(1)\\n2\\nwhere Ïƒi\\nt+1 is the sentiment label of user i at fu-\\nture   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> time t + 1, and Ii\\nt is post contents that user i\\npublishes on social media at time t.\\nThis study aims to    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> predict usersâ€™ panic emotion\\nlabels after disaster occurrence through deep fusion\\nof multi-domain features    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> from their pre-disaster\\nsocial media posts, integrated with psychological\\ntheories. Formally, this task can   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> be formulated as:\\nÏƒi\\nt+1 = F\\n\\u0000Ii\\nt, Pt+1, Ci\\nt\\n\\u0001\\n,\\n(2)\\nwhere t + 1 is the time after the     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> sudden disaster,\\nt is the time before the disaster, Ïƒi\\nt+1 is the post-\\ndisaster sentiment label of user i,  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Pt+1 is the post-\\ndisaster physical features, and Ci\\nt is the personal\\ntraits of user i from pre-disaster    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> analysis.\\n2.2\\nCOPE Dataset Benchmark\\nTo address the gap in high-quality panic emotion\\nresources, we develop <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> the first fine-grained dataset\\nCOPE, spanning pre- and post-disaster phases,\\nwhich fills the gap in           <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> standardized panic emotion\\ndatasets and provides a foundation for advancing\\nresearch in emotion prediction    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> and related fields.\\nIts core innovation is the standardized human-LLM\\ncollaborative annotation process,       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> structured as fol-\\nlows. More details are in Appendix A.2.\\nâ€¢ Multi-source data collection: Focusing on        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Hur-\\nricane Sandy (2012), we used 52.25 million\\ntweets from 13.75 million users (Oct. 15- Nov.\\n12)           <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> (Kryvasheyeu et al., 2015). After preprocess-\\ning (detailed in Appendix A.2.1), the dataset\\nincludes 9,065    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> users, including user IDs, fol-\\nlower/followee counts, timestamps, locations,\\nand ternary emotion labels.\\nâ€¢  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Panic annotation framework: Targeting post-\\ndisaster texts, we adopt a LLM-human hybrid\\nannotation pipeline:  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> (1) LLM generates initial\\nlabels via semantic parsing; (2) 100 annotators\\nconducted three rounds of           <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> cross-validation to en-\\nsure robustness; (3) Fine-tuned BERT model au-\\ntomates remaining annotations.\\nâ€¢      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> User-level panic identification: We identify pan-\\nicked users via a \\\"one-veto\\\" rule (â‰¥1 panic                <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> text).\\n3\\nPsychology-Driven LLM Agent\\nFramework\\nWe first delineate the architecture of PsychoAgent.\\nThen we <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> describe the methodology for individ-\\nual feature extraction. Finally, we introduce the\\npsychology-driven     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> LLM-based agent to simulate\\nposting behavior for predicting panic emotions.\\n3.1\\nOverview of                  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> PsycoAgent\\nBased on the studies of risk perception and emotion\\narousal in psychology, we summarize the        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> panic\\nemotion formation pathway as follows (Figure 1):\\nâ€¢ In the physical domain, we transform                 <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> spatiotem-\\nporal disaster intensity into interpretable data\\nthrough risk communication;\\nâ€¢ In the information <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> domain, we amplify disaster\\nseverity through communication channels, mod-\\nulating risk perception and         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> refining physical data\\ninterpretation, establishing via physical-cognitive\\nbidirectional feedback loops;\\nâ€¢   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> In the cognitive domain, we utilize individual\\ntraits to mediate risk interpretation biases, trigger-\\ning     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> panic through emotional arousal to achieve\\nthe transformation from data to emotion;\\nâ€¢ In the social domain,   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> we materialize individual\\npanic into collective psychological states through\\nsocial media behavior            <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> patterns.\\nBased on this, we propose PsychoAgent (Fig-\\nure 2), a multi-domain fusion-driven LLM                <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> agent\\nframework for panic emotion prediction, which\\ncomprises four main parts: (1) In the informa-\\ntion      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> domain, we focus on collecting social media\\ntexts and risk communication channel features; (2)\\nIn the         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> physical domain, we extract disaster char-\\nacteristics via geospatial platforms, gathering key\\nindicators to  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> convert physical features into disas-\\nter information; (3) In the cognitive domain, we\\nextract individual     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> traits from pre-disaster social me-\\ndia posts. Then, we construct user profiles to drive\\nthe LLM agents,      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> aiming at simulating \\\"disaster per-\\nception, risk perception, panic arousal, and posting\\nbehavior\\\"          <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> psychological chain; (4) In the social do-\\nmain, we use the fine-tuned BERT model to verify\\nthe generated     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> text. Then, we enforce a \\\"one-vote\\\"\\nveto rule for user-level prediction. Subsequent sec-\\ntions detail       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> cognitive domain implementations.\\n3.2\\nPsychological and Behavioral Features\\nExtraction\\nPsychological        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> studies establish that personality\\ntraits, sentiment dynamics, topical concerns, and\\nlinguistic patterns      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> critically shape risk perception\\nand emotional responses (Gross and John, 2003;\\nBrosch et al., 2013; Syrdal   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> and Briggs, 2018; Davis\\net al., 2020). We accordingly extract four main\\nfeatures from usersâ€™ pre-disaster     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> posts.\\nBig Five Personality Traits\\nWe employ the pub-\\nlicly available model bert-base-personality            <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> (Devlin\\n3\\nCognition domain\\nCoT-driven LLM-based agent\\nInformation domain\\nOnline social media post          <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> text\\nThat's \\noutrageous!\\nPhysical domain\\nSudden disaster \\ndescription\\n\\\"Linguistics expert\\\"\\nMoE         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> System\\nCommon \\ntweet\\nExtraction\\nIndividual feature extraction\\nCognitive domain\\nGeographical               <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> \\ncoordinates\\nSocial media \\ncharacteristics \\nAverage number \\nof posts\\nHistorical \\nposts\\nDisaster         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> \\nlocation\\nDisaster \\nintensity index\\nNetwork characteristics\\nEmotion \\ntrends\\nTopics of \\ninterest\\nBig    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> five \\npersonality traits\\nLanguage \\nstyle\\nPersonalized \\ncharacter profile\\nPrior \\nknowledge\\nPersonalized  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> \\nuser agent\\nPPDTS\\nRisk perception \\nEmotion arousal\\nGenerated \\npost prediction\\n\\\"Psychology expert\\\"      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> \\nFactual verification Emotion arousal\\nverification\\nSocial domain\\nFinal text \\npassed verification\\nFailed,  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> \\nregenerate\\nPanic emotion \\ndiscrimination model\\nOnline social media \\nemotion prediction\\nPanic emotion     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> \\nprediction\\nThank you for \\nyour hard work.\\nHope the disaster \\nwill end soon!\\nThatâ€˜s terribleï¼\\nFigure 2: <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Overview of the proposed panic emotion prediction frameworkâ€”â€”PsychoAgent.\\net al., 2019) to analyze the userâ€™s  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> personality traits.\\nThis process can be formally expressed as:\\nÏi = Ïˆpersonality(Ii\\nt),\\n(3)\\nwhere Ïi is    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> the personality vector of the i-th user,\\nand Ïˆpersonality is the model. More details are pro-\\nvided in        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Appendix A.3.1.\\nSentiment\\nTrend\\nFeatures\\nWe\\nuse\\nthe\\nBERTweet model (Nguyen et al., 2020) to              <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> perform\\nternary sentiment analysis on pre-disaster posts,\\naggregating results to generate an emotional        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> trend\\nprofile. This is formalized as:\\nÎ³i = Ïˆsentiment(Ii\\nt),\\n(4)\\nwhere Î³i is the sentiment trend vector of <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> the i-th\\nuser; Ïˆsentiment is the sentiment model.\\nTopic-Aware Characteristic Features\\nUsing\\nLDA model       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> clustering and LLM-guided merging,\\nwe extract topic features by analyzing usersâ€™ histor-\\nical posts. The      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> process is expressed as:\\nÏ„ i = Î“ Â· Î˜i,\\n(5)\\nwhere Î˜i is the LDA-clustered topic vector of the\\ni-th user; Î“   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> is the membership relationships; Ï„ i is\\nthe consolidated thematic focus vector summarized\\nby LLM. Appendix    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> A.3.2 offers additional details.\\nLinguistic Features\\nWe design prompts to cap-\\nture usersâ€™ tone features via <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> LLM. The process is\\nformalized as:\\nvi = LLMlanguage(Ii\\nt, pv),\\n(6)\\nwhere vi is the tone features of the    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> i-th user;\\nLLMlanguage is the tone feature extraction model;\\npÎ½ is the prompt for LLM to extract tone         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> features.\\nMore details can be referred to Appendix A.3.3.\\n3.3\\nBuilding LLM Agent with                        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Psychological\\nTheories\\nWe design a CoT-driven LLM-based agent to simu-\\nlate usersâ€™ perception and            <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> responsiveness through\\nfour stages, with key stages centering on risk per-\\nception and emotional arousal (see <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> in Figure 3):\\nâ€¢ Disaster perception stage (physical-information\\ndomain): We integrate psychological           <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> knowledge,\\ndisaster features, and user profiles to form agentâ€™s\\nlong-term memory;\\nâ€¢ Risk perception stage    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> (cognitive domain): We\\nprompt the agent to engage with the psycho-\\nlogical preparedness for disaster threats  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> scale\\n(PPDTS) (McLennan et al., 2020);\\nâ€¢ Panic arousal stage (cognitive domain): We\\nprompt the agent to      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> quantify panic probability\\nthrough multi-dimensional analysis;\\nâ€¢ Posting response stage (social domain): We   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> gen-\\nerate tweets with MoE-based consistency verifi-\\ncation mechanism.\\nDisaster Perception Stage\\nThis stage <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> equips the\\nagent with essential prior knowledge by integrating\\npsychological knowledge, disaster data, and    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> user\\nfeatures into its long-term memory via structured\\nprompts. The process is expressed as:\\nLLMi\\nU =       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> LLMRP(K, D, Ui, pu),\\n(7)\\nwhere LLMi\\nU denotes the user feature learning\\nagent for user i; LLMRP is the      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> role-playing LLM-\\nbased agent; K is psychological knowledge con-\\nstraints; D is disaster data; Ui is features <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> of user\\ni, encompassing both static traits and risk commu-\\nnication patterns; pu is the initialization        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> prompt.\\nDetailed implementation is in Appendix A.4.1.\\n4\\nPersonalization \\nfeatures\\nLLM-based \\nrole-playing <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> agent\\nLLM-based \\nrole-playing \\nagent\\nGenerate \\ntext \\ndocument\\nGenerate \\ntext document\\nMoE              <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> \\nsystem\\nExpert \\nverification results\\nMoE system\\nRisk perception\\nEmotion arousal\\nImprove the \\ngenerated  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> text\\nLLM-based \\nrole-playing \\nagent\\nMoE \\nsystem\\nGenerate \\ntext document\\nExpert \\nverification           <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> \\nresults\\nFinal text \\ndocument approved\\nPsychological \\nprior knowledge\\nIncident                            <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> \\ndescription\\nGeneral-\\npurpose\\nLLM\\nPsychological \\nprior knowledge\\nLearn \\npsychological                   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> \\nknowledge\\nIncident \\ndescription\\nEvent \\ndata \\nanalysis\\nUser  features\\nDisaster event \\nperception       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> stage\\nEmotion \\ntrigger\\nPanic emotion \\ngeneration\\nRisk \\nperception\\nPanic emotion \\narousal stage\\nFinal   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> text \\ndocument approved\\nRegenerate text \\nnot approved\\nReview approved\\nOutput text\\nPosting \\nresponse      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> stage\\nUser Role \\nInitialization \\nAgent\\nPPDTS\\nRisk cognition \\nformation stage\\nGenerate \\ntext             <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> document\\nEmotional arousal \\nprobability\\nPosting \\nresponse stage\\nLLM-based role-playing agent\\nMoE          <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> system\\nMoE system\\nInformation input\\nFeedback loop\\nResult output\\nFigure 3: Detailed stages for building     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> LLM-based agent driven by CoT in the cognitive domain module.\\nRisk Perception Stage\\nWe construct a            <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> dynamic\\nrisk perception framework using disaster per-\\nception stageâ€™s memory and PPDTS (see Ap-\\npendix       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> A.4.2), emulating usersâ€™ risk perception\\nprocesses via structured psychological assessment.\\nBy leveraging     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> LLMâ€™s reasoning capabilities with\\na human cognitive-inspired stepwise CoT prompt-\\ning mechanism: question     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> comprehension, mem-\\nory retrieval, option mapping, and summary judg-\\nment, we prompt the agent to output risk <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> perception\\nscores (1-4 levels) for each question, formalized\\nas:\\nSi = LLMi\\nU(Q, pperception),\\n(8)\\nwhere   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Si is the PPDTS evaluation scores for user\\ni; Q is the question set comprising the PPDTS;\\npperception is the  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> PPDTS assessment prompt.\\nPanic Arousal Stage\\nTo bridge risk perception\\nand emotion arousal, we               <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> reparameterize the dis-\\ncrete PPDTS scores into panic propensity drivers.\\nSpecifically, we prompt the agent   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> to analyze four\\ncore factors (Risk awareness, coping effectiveness,\\nevent uncertainty, and situational        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> novelty) through\\na cognitive chain reasoning mechanism, and in-\\nfer the panic propensity probability based on <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> prior\\noutputs. This process can be represented as:\\nCi = LLMi\\nU(Si, pc),\\n(9)\\nP i\\npanic = LLMi\\nU(Si, Ci,   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> ppanic),\\n(10)\\nwhere Ci is the summary of four factors for user\\ni; P i\\npanic is the panic propensity         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> probability; PC is\\nthe prompt directing the agent in summarizing the\\nfour factors; ppanic is the prompt       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> guiding the agent\\nto evaluate userâ€™s panic probability.\\nPosting Response Stage\\nIn this stage, we prompt\\nthe <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> agent to integrate knowledge across stages (see\\nAppendix A.4.3 for details) and predict the post\\ncontent the  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> user is most likely to generate under the\\ndisaster event. This process can be represented as:\\nT i =           <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> LLMi\\nU(Si, Ci, P i\\npanic, pT ),\\n(11)\\nwhere T i is the set of tweets most likely published\\nby the i-th      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> user; PT is \", \"## Title\\nRisk Psychology &amp; Cyber-Attack Tactics\\n\\n## Summary\\nWe examine whether measured     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> cognitive processes predict cyber-attack\\nbehavior. We analyzed data that included psychometric scale responses <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> and\\nlabeled attack behaviors from cybersecurity professionals who conducted\\nred-team operations against a     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> simulated enterprise network. We employed\\nmultilevel mixed-effects Poisson regression with technique counts    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> nested within\\nparticipants to test whether cognitive processes predicted technique-specific\\nusage. The scales <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> significantly predicted technique use, but effects varied by\\ntechnique rather than operating uniformly.        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Neither expertise level nor\\nexperimental treatment condition significantly predicted technique                 <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> patterns,\\nindicating that cognitive processes may be stronger drivers of technique\\nselection than training or <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> experience. These findings demonstrate that\\nindividual cognitive differences shape cyber-attack behavior and   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> support the\\ndevelopment of psychology-informed defense strategies.\\n\\n##Content\\n \\nRisk Psychology &amp;          <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Cyber-Attack Tactics \\nRubens Kim1, Stephan Carney2, Yvonne Fonken3, Soham Hans1, \\nSofia Hirschmann4, Stacy    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Marsella4, Peggy Wu3, and Nikolos \\nGurney1 \\n1Institute for Creative Technologies, University of Southern      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> California, Playa Vista, CA  \\n2Marshall School of Business, University of Southern California, Los Angeles, CA <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> \\n3Raytheon Technologies, Farmington, CT  \\n4Khoury College of Computer Sciences, Northeastern University,      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Boston, MA  \\nABSTRACT \\nWe examine whether measured cognitive processes predict cyber-attack behavior. We      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> \\nanalyzed data that included psychometric scale responses and labeled attack behaviors \\nfrom cybersecurity    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> professionals who conducted red-team operations against a simulated \\nenterprise network. We employed           <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> multilevel mixed-effects Poisson regression with \\ntechnique counts nested within participants to test whether  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> cognitive processes predicted \\ntechnique-specific usage. The scales significantly predicted technique use, but <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> effects \\nvaried by technique rather than operating uniformly. Neither expertise level nor experimental         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> \\ntreatment condition significantly predicted technique patterns, indicating that cognitive \\nprocesses may be  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> stronger drivers of technique selection than training or experience. These \\nfindings demonstrate that          <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> individual cognitive differences shape cyber-attack behavior and \\nsupport the development of                   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> psychology-informed defense strategies. \\nKeywords: Cyberpsychology, Cognitive Biases, Adversary Behavior,      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Decision-Making \\nINTRODUCTION \\nCybersecurity defenses typically focus on technical vulnerabilitiesâ€”patching   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> \\nsoftware, configuring firewalls, and detecting malicious signatures. However, \\nhuman attackers remain the    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> ultimate threat, and humans are subject, or vulnerable, \\nto cognitive processes (e.g., biases) that            <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> systematically influence decision-making. \\nThe IARPA Reimagining Security with Cyberpsychology-Informed        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Network \\nDefences (ReSCIND) program sought to shift focus from technical \\ncountermeasures to exploiting these <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> vulnerabilities to impede attackers. As part of \\nReSCIND, the Guarding Against Malicious Biased Threats        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> (GAMBiT) project \\ncollected multi-modal data from skilled professionals attacking simulated \\nenterprise       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> networks, including responses to psychometric inventories and network \\nactivity that was later annotated using <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> a standardized taxonomy of adversarial \\ntactics. Using multilevel modeling, we tested whether differences in   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> cognitive \\nvulnerability predict which tactics individuals employed during the operation. \\nPSYCHOLOGICAL      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> VULNERABILITIES AND CYBERSECURITY \\nThe study of cyber attackersâ€™ cognitive states, particularly their biases,  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> during an \\nattack is a young field of research. Biases, as studied in judgment and decision \\nmaking (Tversky  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> &amp; Kahneman, 1974) and occasionally referred to as cognitive \\nvulnerabilities, however, are linked to a         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> multitude of adverse decision outcomes. \\n2  \\nKim et al. \\nExamples are as diverse as under-saving for         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> retirement (Benartzi &amp; Thaler, 2013) \\nand misjudging how charged emotional states will alter your own decision <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> making \\n(Loewenstein &amp; Lerner, 2002). Historically, cybersecurity researchers have \\nfocussed on studying the  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> impact of attackers' skills during capture the flag tasks \\nand similar activitiesâ€”a focus that underweights    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> the cognitive states of cyber \\nattackers (Fergusonâ€‘Walter et al., 2019). Early contributions to the research   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> area, \\nsuch as Ferguson-Walter et al.â€™s Tularosa Study (Fergusonâ€‘Walter et al., 2019), \\nestablished some pros <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> and cons of experimentally studying attackersâ€™ mental states \\nalong with exploratory insights into their       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> biases (Gutzwiller et al., 2024). These \\nefforts, along with a related project that pulled together expert     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> opinions on the \\nlikely biases experienced by cyber attackers (Johnson et al., 2021) motivated the             <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> \\ndevelopment of the IARPA ReSCIND program (IARPA, 2025). ReSCIND sought \\nto, â€œ[leverage] well-established     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> cognitive vulnerabilities and human limitations to \\nimpede cyber attackers.â€ Accomplishing that meant directly <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> studying attackersâ€™ \\ncognitive states, including through the administration of psychological inventories       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> \\ndesigned to measure cognitive vulnerabilities. \\nThe GAMBiT project conducted experiments in which skilled    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> attackers \\nundertook two eight-hour days of attacking a simulated enterprise network (Beltz \\net al. 2025).    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> The researchers captured multi-modal data, ranging from self-reports \\n(e.g., participantsâ€™ hacking skills,     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> demographics, and responses to inventories) to \\nalert data (e.g., Suricata (White et al., 2013)). Full         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> experimental details are \\navailable in the Beltz et al. paper, but participants started from a Kali Linux      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> virtual \\nmachine (Denis et al., 2016) and pursued objectives laid out in a dossier. Critically, \\nbefore       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> beginning their attacks, all participants completed four scales designed to \\nmeasure different aspects of      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> their cognitive tendencies: the Cognitive Reflection \\nTest (CRT, (Frederick, 2005)), the General Risk          <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Propensity Scale (GRiPS, (Zhang \\net al., 2019)), and two subscales from the Adult Decision Making Competence   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> \\nscale that measure resistance to positive and negative framing (ADMC-RC1 and \\nADMC-RC2, respectively,        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> (Bruine de Bruin et al., 2007)). Interestingly, the \\nattackersâ€™ responses to these scales and their measured   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> attack skills were \\nstatistically linked (Oh et al., 2025). \\nThe GAMBiT project also developed an approach    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> for annotating the Suricata \\nlogs (Hans, Hirschmann, et al., 2025). This pipeline, which has a large language  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> \\nmodel (LLM) at its core, was initially developed to understand the notes kept by \\nthe attackers (Hans,       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Gurney, et al., 2025). The annotations are based on the \\nMITRE ATT&amp;CK framework, which is â€œa                   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> globally-accessible knowledge base of \\nadversary tactics and techniques based on real-world observationsâ€ used <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> to model \\nthreats and provides a clear attack taxonomy (Strom et al. 2020). The effort sought \\nto identify    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> when the attackers 1) noted that they used MITRE ATT&amp;CK \\npersistence techniques and 2) correlate those         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> annotations with the different \\npsychometric scales. The researchers found a statistically significant         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> negative \\nrelationship between GRiPS scores and persistence usage, suggesting that attackers \\nwith a lower    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> risk propensity relied more on risk-mitigating techniques. We use the \\nSuricata log annotations in our         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> modeling efforts. \\nRisk Psychology and Cyber-Attack Tactics 3 \\nHYPOTHESIS \\nWe hypothesized that the cyber    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> attackersâ€™ cognitive processes, as measured by the \\nscales, would predict the MITRE ATT&amp;CK techniques that     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> attackers use. In other \\nwords, the count of each MITRE ATT&amp;CK technique annotated in the individual           <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> \\nSuricata logs serve as the dependent variable and the cyber attackersâ€™ responses to \\nthe various scales      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> (along with experimental controls and demographics) as the \\nindependent variables in the modeled relationship. <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> \\nMETHODS \\nWe analyzed data from two experiments, GAMBiT Experiments 2 (HSR2, \\nâ€œcontrol,â€ N=17) and 3 (HSR3,  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> â€œtriggers,â€ N=16), conducted under the IARPA \\nReSCIND program. Data were from cybersecurity professionals who  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> completed \\ndatasets a red-team cyber operations in a simulated enterprise network (SimSpace \\nCyber Force      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Platform). We excluded data from 31 additional participants due to \\nincomplete data and HSR1 because of        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> changes in the experimental design. \\nOur data structure consisted of technique counts nested within            <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> participants, \\nwhich are the main dependent variables. The classification of participant's network \\nactivity  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> into 11 MITRE ATT&amp;CK technique categories resulted in 363 \\nobservations (33 participants Ã— 11 techniques). The <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 11 MITRE ATT&amp;CK \\ntechnique categories, derived from Suricata IDS alerts using an LLM annotation \\npipeline,    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> are: Reconnaissance, Execution, Initial Access, Lateral Movement, \\nCredential Access, Privilege Escalation,    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Collection, Discovery, Command and \\nControl, Exfiltration, Persistence. Because multiple technique counts from <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> the \\nsame individual are not independent, we used multilevel mixed-effects modeling \\nto account for           <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> within-participant correlation while testing whether psychometric \\nmeasures predict technique-specific use     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> patterns. \\nAll 33 participants completed the four psychometric scales, our main \\nindependent variables, as    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> part of the experiment prior to engaging in the hackathon. \\nWe also rely on other covariates to control for    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> experimental design features, \\nindividual differences, and demographic anomalies: Treatment condition          <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> (triggers \\nvs. control), Division (Expert vs. Open), age, gender, country (USA vs. other), \\nnative English    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> speaker.  \\nWe selected Reconnaissance as the reference technique because it had the \\nhighest observed         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> frequency (N = 1399, 71.2 % of observations), thus providing the \\nmost stable baseline for contrast estimates. <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Theoretically, reconnaissance \\nrepresents ongoing information-gathering throughout penetration testing,        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> whereas \\nother techniques (e.g., Initial Access, Lateral Movement) are more discrete events. \\nAll             <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> coefficients therefore represent effects relative to reconnaissance use.  \\nAt Level 1, we modeled technique    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> counts using Poisson regression, appropriate \\nfor non-negative count data. The model included main effects for <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> technique \\ncategories (with Reconnaissance as the reference due to its high frequency), \\npsychometric Ã—       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> technique interactions to test whether cognitive processes predict \\ntechniques differentially, and             <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> participant-level covariates (treatment condition, \\nexpertise level, demographics). At Level 2, we included    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> participant-level \\npredictors: psychometric scores (ADMC RC1, ADMC RC2, CRT, GRiPS), \\ntreatment condition     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> (Triggers vs. Control), expertise level (Expert vs. Open \\nDivision), and demographic controls (age, gender,    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> country, native English \\n4  \\nKim et al. \\nspeaker). All continuous predictors were standardized (M=0, SD=1)   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> prior to \\nanalysis to improve numerical stability and facilitate interpretation. We included \\nrandom          <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> intercepts for participants to account for individual differences in overall \\ntechnique use, allowing each     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> participant to have their own baseline level of \\nactivity. This accounts for stable individual differences     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> (e.g., general activity level, \\noverall technical proficiency) while testing technique-specific psychometric   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> \\neffects. Sample size constraints prevented use of random slopes. \\nThe psychometric Ã— technique interactions  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> are the critical feature of our \\nanalysis. These interactions test whether specific cognitive processes        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> predict \\ntechnique use differentially, for example, whether higher reflective thinking (CRT \\nscore) predicts  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> more use of some techniques but less use of others.  \\nWe fit the models using the lme4 package (version 1.1-37 <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> (Bates et al., 2025)) \\nin R (version 4.5.0) with maximum likelihood estimation and the BOBYQA \\noptimizer      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> (Powell, 2009). Likelihood ratio tests (Type II Wald chi-square) \\nassessed the significance of fixed effects.  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> The model converged with a warning \\nabout large eigenvalue ratios, reflecting correlation between the ADMC     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> scales \\n(r=.74) and model complexity. The dispersion ratio (3.64) indicated moderate \\noverdispersion,         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> suggesting unexplained variance beyond that expected under the \\nPoisson distribution. This inflates standard   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> errors (making individual coefficient \\ntests more conservative) but does not invalidate our inference given    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> the strong \\neffects observed (all p &lt; .002). + \\nWe report both omnibus likelihood ratio tests for each        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> psychometric Ã— technique \\ninteraction and individual coefficient tests for specific technique contrasts. The   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> \\nomnibus tests (one per psychometric measure) control family-wise error rate at \\nÎ±=.05. Individual            <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> coefficients are reported for interpretation but should be \\nconsidered exploratory given the large number of   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> contrasts. Model coefficients \\nrepresent log rate ratios. For main effects, exp(Î²) gives the rate ratio for    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> that \\ntechnique relative to reconnaissance. For interaction terms, exp(Î²) gives the \\nmultiplicative change in <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> the rate ratio associated with a one SD increase in the \\nmeasure. For example, a coefficient of 0.82 for CRT Ã— <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Lateral Movement indicates \\nthat a one SD increase in reflective thinking is associated with a 2.3-fold        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> increase \\n(exp(0.82)=2.27) in lateral movement relative to reconnaissance. \\nRESULTS \\nPsychometric measures   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> did not differ significantly between Expert and Open \\nDivision groups (all p &gt; .20). Across all participants,  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 1,964 technique uses were \\nidentified from network logs, classified into 11 MITRE ATT&amp;CK categories.           <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> \\nReconnaissance dominated (N=1,399, 71%), with all but one participantâ€™s Suricata \\nlogs showing evidence of   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> this technique. Other frequently used techniques \\nincluded Lateral Movement (N=206, 13 participants),          <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Execution (N=175, 24 \\nparticipants), and Initial Access (N=53, 19 participants). Three techniques were         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> \\nrarely observed: Command and Control (3 participants), Exfiltration (3 \\nparticipants), and Persistence (1    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> participant).  \\nThe intraclass correlation coefficient (ICC) was 0.255, indicating that 25.5% of \\nvariance in <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> technique counts was attributable to stable between-person differences, \\nwith the remaining 74.5% due to       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> within-person variation across techniques. This \\nsubstantial between-person variance justified the multilevel  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> modeling approach \\nRisk Psychology and Cyber-Attack Tactics 5 \\nand indicated meaningful individual            <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> differences in overall technique use beyond \\ntechnique-specific patterns. The model fit the data well          <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> (AIC=1797.9, \\nBIC=2039.3). The random intercept standard deviation was 1.06, reflecting \\nconsiderable         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> heterogeneity in participants' baseline activity levels. Moderate \\noverdispersion was detected (dispersion     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> ratio=3.64), suggesting additional \\nunexplained variance; however, this does not invalidate inference given    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> the \\nextremely strong effects observed (all p &lt; .002). \\nLikelihood ratio tests (Table 1) revealed that all    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> four psychometric measures \\nsignificantly predicted technique use, but effects varied by technique (see        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> \\nsignificant psychometric Ã— technique interactions in Table 1). We interpret this as \\nindicating that         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> cognitive processes predict technique preferences differentially \\nrather than uniformly. \\nTable 1. Likelihood <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Ratio Tests \\nEffect \\nChi-square \\ndf \\np-value \\ntechnique \\n2137.09 \\n10 \\n&lt; .001 \\ntreatment \\n1.73 \\n1     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> \\n0.189 \\nDivision \\n0.30 \\n1 \\n0.584 \\nage_z \\n0.16 \\n1 \\n0.692 \\ngender \\n0.78 \\n1 \\n0.377 \\ncountry_usa      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> \\n1.27 \\n1 \\n0.260 \\nenglish_native \\n1.65 \\n1 \\n0.200 \\ntechnique:ADMC_RC1_z \\n122.76 \\n11 \\n&lt; .001            <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> \\ntechnique:ADMC_RC2_z \\n48.42 \\n11 \\n&lt; .001 \\ntechnique:CRT_z \\n198.92 \\n11 \\n&lt; .001 \\ntechnique:GRiPS_z       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> \\n30.72 \\n11 \\n0.001 \\nIn contrast, treatment condition (Triggers vs. Control), expertise level (Expert \\nvs.   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Open Division), and demographic variables did not significantly predict \\ntechnique use patterns. This          <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> indicates that individual cognition, rather than \\nexperimental manipulation or experience level, may have been <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> the primary drivers \\nof technique selection in this sample. \\nTo understand these interactions, we examined    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> individual technique-specific \\neffects (See Table 2 for all significant effects with coefficients and          <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> confidence \\nintervals. Figures 1 and 2 graphically display the results.). Twelve psychometric Ã— \\ntechnique    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> combinations showed significant effects at Î±=.05. Higher scores on the \\nresistance to positive framing scale   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> (ADMC RC1) were associated with increased \\nReconnaissance use, indicating that such individuals engaged in     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> more information-\\ngathering. Conversely, it was negatively associated with Command and Control \\ntechnique     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> use, though this latter finding should be interpreted cautiously given the \\nrarity of this technique (N=7      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> total uses). \\nHigher scores on the resistence to negative framing scale (ADMC RC2) were \\nassociated with      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> reduced Reconnaissance use, suggesting that individuals with \\ngreater such resistance engaged in less broad    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> information-gathering. It also \\nnegatively predicted Lateral Movement, indicating less network traversal among <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> \\nhigh resistance to negative framing individuals. \\n6  \\nKim et al. \\nReflective thinking (CRT) showed the     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> most extensive effects, significantly \\npredicting six techniques. Higher CRT was associated with reduced       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> \\nReconnaissance, Collection, Credential Access, Initial Access, and Privilege \\nEscalation. Notably, CRT       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> showed the opposite effect for Lateral Movement, where \\nmore reflective thinkers used this technique           <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> significantly more. This suggests that \\nindividuals high in reflective thinking employed a qualitatively       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> different tactical \\napproach: less broad reconnaissance and vulnerability scanning, but more strategic         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> \\nnetwork traversal once initial access was achieved. \\nRisk seeking propensity (GRiPS) positively predicted    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> both Collection and \\nInitial Access techniques. This suggests that individuals who self-reported a higher      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> \\npropensity to accept or seek risks were more likely to engage in data gathering \\noperations and gain system  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> access.  \\nTable 2: Significant Psychometric Ã— Technique Effects \\nPredictor \\nTechnique \\nCoefficient \\nSE \\nz <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> \\np-value \\nADMC_RC1 \\nReconnaissance \\n1.040 \\n0.337 \\n3.09 \\n0.002 \\nADMC_RC1 \\nCommand and \\nControl         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> \\n-2.136 \\n0.968 \\n-2.21 \\n0.027 \\nADMC_RC2 \\nReconnaissance \\n-0.798 \\n0.302 \\n-2.64 \\n0.008 \\nADMC_RC2        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> \\nLateral Movement \\n-0.760 \\n0.325 \\n-2.34 \\n0.019 \\nCRT \\nReconnaissance \\n-0.605 \\n0.208 \\n-2.91 \\n0.004     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> \\nCRT \\nCollection \\n-0.685 \\n0.315 \\n-2.17 \\n0.030 \\nCRT \\nCredential Access \\n-0.861 \\n0.240 \\n-3.59 \\n&lt; .001 <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> \\nCRT \\nInitial Access \\n-0.548 \\n0.244 \\n-2.25 \\n0.025 \\nCRT \\nLateral Movement \\n0.824 \\n0.238 \\n3.47 \\n&lt;     <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> .001 \\nCRT \\nPrivilege \\nEscalation \\n-0.646 \\n0.298 \\n-2.17 \\n0.030 \\nGRiPS \\nCollection \\n1.117 \\n0.441       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> \\n2.54 \\n0.011 \\nGRiPS \\nInitial Access \\n1.095 \\n0.335 \\n3.26 \\n0.001 \\nNote: Coefficients for 1 SD increase   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> in predictor. \\nIn summary, the multilevel analysis revealed robust technique-specific effects \\nof the         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> measured cognitive processes on hacking behavior. Reflective thinking \\n(CRT) showed the most pervasive         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> influence, affecting six different techniques with \\na consistent pattern: negative effects on reconnaissance   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> and vulnerability \\nexploitation techniques, but a strong positive effect on strategic network traversal.       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> \\nRisk propensity consistently facilitated information gathering and access \\noperations. These differential    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> effects may explain why previous analyses found \\nnull results: psychometric effects do not operate uniformly   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> across all techniques \\nbut rather shape specific tactical choices within the broader attack process. \\nWe      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> translated selected coefficients into rate ratios to aid interpretation. For \\nexample, the CRT Ã— Lateral       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Movement effect (Î²=0.82) indicates that a one SD \\nincrease in reflective thinking was associated with a        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 2.3-fold increase in Lateral \\nMovement use relative to Reconnaissance (exp(0.82)=2.27). Similarly, the strong  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> \\nnegative effect of CRT on Credential Access (Î²=-0.86) suggests that high reflective \\nthinkers use this       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> technique at only 42% the rate of low reflective thinkers (exp(-\\nRisk Psychology and Cyber-Attack Tactics 7    <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> \\n0.86)=0.42), relative to Reconnaissance. These rate differences indicate that \\ncognitive processes can       <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> meaningfully influence tactical decisions. \\n \\nFigure 1: A heatmap of all psychometric Ã— technique             <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> coefficients. The concentration of \\nnegative CRT effects and positive GRiPS effects on specific techniques is  <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> visually apparent, \\nas is the relative scarcity of significant effects for rare techniques. \\n \\nFigure 2: The <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> 12 significant effects with 95% confidence intervals. Effect sizes varied \\nconsiderably, with the largest      <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> effects observed for CRT Ã— Lateral Movement (Î²=0.82) and \\nADMC RC1 Ã— Command and Control (Î²=-2.14). The        <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> predominantly negative CRT effects \\nand positive GRiPS effects represent the most consistent patterns across   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> techniques. \\nDespite the significant psychometric effects, the random intercept variance \\n(SD=1.06) indicated <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> substantial individual differences in technique use beyond \\nthose explained by measured cognitive processes.   <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span> Some individuals showed \\nconsistently high technique\"]                                                         <span style=\"color: #808000; text-decoration-color: #808000\">â”‚</span>\n",
              "<span style=\"color: #808000; text-decoration-color: #808000\">â•°â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â•¯</span>\n",
              "</pre>\n"
            ]
          },
          "metadata": {}
        },
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "\u001b[32mâ•­â”€\u001b[0m\u001b[32mâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€\u001b[0m\u001b[32m ðŸ¤– Assistant \u001b[0m\u001b[32mâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€\u001b[0m\u001b[32mâ”€â•®\u001b[0m\n",
              "\u001b[32mâ”‚\u001b[0m ### Detailed Information on Panic Attacks                                                                       \u001b[32mâ”‚\u001b[0m\n",
              "\u001b[32mâ”‚\u001b[0m                                                                                                                 \u001b[32mâ”‚\u001b[0m\n",
              "\u001b[32mâ”‚\u001b[0m **Overview**                                                                                                    \u001b[32mâ”‚\u001b[0m\n",
              "\u001b[32mâ”‚\u001b[0m Panic attacks are sudden episodes of intense fear or anxiety that come on quickly, often without any clear      \u001b[32mâ”‚\u001b[0m\n",
              "\u001b[32mâ”‚\u001b[0m reason. They can be extremely distressing and may lead individuals to believe they are experiencing a           \u001b[32mâ”‚\u001b[0m\n",
              "\u001b[32mâ”‚\u001b[0m life-threatening emergency.                                                                                     \u001b[32mâ”‚\u001b[0m\n",
              "\u001b[32mâ”‚\u001b[0m                                                                                                                 \u001b[32mâ”‚\u001b[0m\n",
              "\u001b[32mâ”‚\u001b[0m **Symptoms of Panic Attacks**                                                                                   \u001b[32mâ”‚\u001b[0m\n",
              "\u001b[32mâ”‚\u001b[0m Common symptoms include:                                                                                        \u001b[32mâ”‚\u001b[0m\n",
              "\u001b[32mâ”‚\u001b[0m - Racing heartbeat                                                                                              \u001b[32mâ”‚\u001b[0m\n",
              "\u001b[32mâ”‚\u001b[0m - Shortness of breath                                                                                           \u001b[32mâ”‚\u001b[0m\n",
              "\u001b[32mâ”‚\u001b[0m - Chest pain or discomfort                                                                                      \u001b[32mâ”‚\u001b[0m\n",
              "\u001b[32mâ”‚\u001b[0m - Trembling or shaking                                                                                          \u001b[32mâ”‚\u001b[0m\n",
              "\u001b[32mâ”‚\u001b[0m - Feelings of choking                                                                                           \u001b[32mâ”‚\u001b[0m\n",
              "\u001b[32mâ”‚\u001b[0m - Sweating                                                                                                      \u001b[32mâ”‚\u001b[0m\n",
              "\u001b[32mâ”‚\u001b[0m - Nausea or abdominal distress                                                                                  \u001b[32mâ”‚\u001b[0m\n",
              "\u001b[32mâ”‚\u001b[0m - Dizziness, lightheadedness, or feeling faint                                                                  \u001b[32mâ”‚\u001b[0m\n",
              "\u001b[32mâ”‚\u001b[0m - Numbness or tingling sensations                                                                               \u001b[32mâ”‚\u001b[0m\n",
              "\u001b[32mâ”‚\u001b[0m - Feeling of unreality or detachment                                                                            \u001b[32mâ”‚\u001b[0m\n",
              "\u001b[32mâ”‚\u001b[0m - Fear of losing control or \"going crazy\"                                                                       \u001b[32mâ”‚\u001b[0m\n",
              "\u001b[32mâ”‚\u001b[0m - Fear of dying                                                                                                 \u001b[32mâ”‚\u001b[0m\n",
              "\u001b[32mâ”‚\u001b[0m                                                                                                                 \u001b[32mâ”‚\u001b[0m\n",
              "\u001b[32mâ”‚\u001b[0m Most panic attacks last between 5 and 20 minutes, but some may continue for an hour or more.                    \u001b[32mâ”‚\u001b[0m\n",
              "\u001b[32mâ”‚\u001b[0m                                                                                                                 \u001b[32mâ”‚\u001b[0m\n",
              "\u001b[32mâ”‚\u001b[0m **When to Seek Help**                                                                                           \u001b[32mâ”‚\u001b[0m\n",
              "\u001b[32mâ”‚\u001b[0m If you experience recurrent and unexpected panic attacks along with a month (or more) of persistent concern     \u001b[32mâ”‚\u001b[0m\n",
              "\u001b[32mâ”‚\u001b[0m about having another attack, itâ€™s advisable to contact a healthcare professional. A general practitioner (GP)   \u001b[32mâ”‚\u001b[0m\n",
              "\u001b[32mâ”‚\u001b[0m can conduct a thorough assessment to rule out other health conditions and provide a diagnosis.                  \u001b[32mâ”‚\u001b[0m\n",
              "\u001b[32mâ”‚\u001b[0m                                                                                                                 \u001b[32mâ”‚\u001b[0m\n",
              "\u001b[32mâ”‚\u001b[0m ### Treatment Options                                                                                           \u001b[32mâ”‚\u001b[0m\n",
              "\u001b[32mâ”‚\u001b[0m 1. **Psychotherapy**                                                                                            \u001b[32mâ”‚\u001b[0m\n",
              "\u001b[32mâ”‚\u001b[0m    - **Cognitive Behavioral Therapy (CBT)**: This is the most common type of psychotherapy used for panic       \u001b[32mâ”‚\u001b[0m\n",
              "\u001b[32mâ”‚\u001b[0m disorder. CBT helps individuals understand and change their thoughts and behaviors that contribute to panic     \u001b[32mâ”‚\u001b[0m\n",
              "\u001b[32mâ”‚\u001b[0m attacks.                                                                                                        \u001b[32mâ”‚\u001b[0m\n",
              "\u001b[32mâ”‚\u001b[0m    - **Exposure Therapy**: Involves gradual exposure to the situations that trigger panic attacks.              \u001b[32mâ”‚\u001b[0m\n",
              "\u001b[32mâ”‚\u001b[0m                                                                                                                 \u001b[32mâ”‚\u001b[0m\n",
              "\u001b[32mâ”‚\u001b[0m 2. **Medications**                                                                                              \u001b[32mâ”‚\u001b[0m\n",
              "\u001b[32mâ”‚\u001b[0m    - **Selective Serotonin Reuptake Inhibitors (SSRIs)**: Such as fluoxetine (Prozac), sertraline (Zoloft), and \u001b[32mâ”‚\u001b[0m\n",
              "\u001b[32mâ”‚\u001b[0m paroxetine (Paxil). SSRIs are often the first-line treatment.                                                   \u001b[32mâ”‚\u001b[0m\n",
              "\u001b[32mâ”‚\u001b[0m    - **Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs)**: Like venlafaxine (Effexor XR).               \u001b[32mâ”‚\u001b[0m\n",
              "\u001b[32mâ”‚\u001b[0m    - **Benzodiazepines**: These can provide rapid relief but are typically not recommended for long-term use    \u001b[32mâ”‚\u001b[0m\n",
              "\u001b[32mâ”‚\u001b[0m due to the risk of dependence.                                                                                  \u001b[32mâ”‚\u001b[0m\n",
              "\u001b[32mâ”‚\u001b[0m                                                                                                                 \u001b[32mâ”‚\u001b[0m\n",
              "\u001b[32mâ”‚\u001b[0m 3. **Lifestyle Changes**                                                                                        \u001b[32mâ”‚\u001b[0m\n",
              "\u001b[32mâ”‚\u001b[0m    - **Regular Physical Activity**: Exercise can help reduce anxiety and improve overall mental health.         \u001b[32mâ”‚\u001b[0m\n",
              "\u001b[32mâ”‚\u001b[0m    - **Avoiding Triggers**: This includes caffeine, alcohol, and recreational drugs that may worsen symptoms.   \u001b[32mâ”‚\u001b[0m\n",
              "\u001b[32mâ”‚\u001b[0m    - **Breathing and Relaxation Techniques**: Such as yoga, mindfulness meditation, and deep breathing          \u001b[32mâ”‚\u001b[0m\n",
              "\u001b[32mâ”‚\u001b[0m exercises.                                                                                                      \u001b[32mâ”‚\u001b[0m\n",
              "\u001b[32mâ”‚\u001b[0m                                                                                                                 \u001b[32mâ”‚\u001b[0m\n",
              "\u001b[32mâ”‚\u001b[0m 4. **Self-Help Strategies**                                                                                     \u001b[32mâ”‚\u001b[0m\n",
              "\u001b[32mâ”‚\u001b[0m    - **Stay Calm During an Attack**: Remind yourself that panic attacks are not life-threatening, practice slow \u001b[32mâ”‚\u001b[0m\n",
              "\u001b[32mâ”‚\u001b[0m breathing, and focus on your surroundings.                                                                      \u001b[32mâ”‚\u001b[0m\n",
              "\u001b[32mâ”‚\u001b[0m    - **Prepare for Attacks**: Learn and practice coping strategies in environments where attacks may occur or   \u001b[32mâ”‚\u001b[0m\n",
              "\u001b[32mâ”‚\u001b[0m when you begin to feel anxious.                                                                                 \u001b[32mâ”‚\u001b[0m\n",
              "\u001b[32mâ”‚\u001b[0m                                                                                                                 \u001b[32mâ”‚\u001b[0m\n",
              "\u001b[32mâ”‚\u001b[0m ### Support Resources                                                                                           \u001b[32mâ”‚\u001b[0m\n",
              "\u001b[32mâ”‚\u001b[0m - Joining support groups can be beneficial for individuals dealing with panic attacks or panic disorder.        \u001b[32mâ”‚\u001b[0m\n",
              "\u001b[32mâ”‚\u001b[0m Connecting with others can provide additional strategies and emotional support.                                 \u001b[32mâ”‚\u001b[0m\n",
              "\u001b[32mâ”‚\u001b[0m - Many organizations, like **Anxiety UK** and **Mind**, offer resources and support specific to anxiety and     \u001b[32mâ”‚\u001b[0m\n",
              "\u001b[32mâ”‚\u001b[0m panic disorders.                                                                                                \u001b[32mâ”‚\u001b[0m\n",
              "\u001b[32mâ”‚\u001b[0m                                                                                                                 \u001b[32mâ”‚\u001b[0m\n",
              "\u001b[32mâ”‚\u001b[0m ### Recommended Action                                                                                          \u001b[32mâ”‚\u001b[0m\n",
              "\u001b[32mâ”‚\u001b[0m It's highly advisable to consult a healthcare provider if you're experiencing panic attacks. They can provide a \u001b[32mâ”‚\u001b[0m\n",
              "\u001b[32mâ”‚\u001b[0m diagnosis and work with you to develop a treatment plan that suits your needs.                                  \u001b[32mâ”‚\u001b[0m\n",
              "\u001b[32mâ”‚\u001b[0m                                                                                                                 \u001b[32mâ”‚\u001b[0m\n",
              "\u001b[32mâ”‚\u001b[0m ### Helpful Links                                                                                               \u001b[32mâ”‚\u001b[0m\n",
              "\u001b[32mâ”‚\u001b[0m - [NHS - Panic Disorder](https://www.nhs.uk/mental-health/conditions/panic-disorder/)                           \u001b[32mâ”‚\u001b[0m\n",
              "\u001b[32mâ”‚\u001b[0m - [Mayo Clinic - Panic Attacks and Panic                                                                        \u001b[32mâ”‚\u001b[0m\n",
              "\u001b[32mâ”‚\u001b[0m Disorder](https://www.mayoclinic.org/diseases-conditions/panic-attacks/diagnosis-treatment/drc-20376027)        \u001b[32mâ”‚\u001b[0m\n",
              "\u001b[32mâ”‚\u001b[0m - [American Academy of Family                                                                                   \u001b[32mâ”‚\u001b[0m\n",
              "\u001b[32mâ”‚\u001b[0m Physicians](https://www.aafp.org/pubs/afp/issues/2022/0800/generalized-anxiety-disorder-panic-disorder.html)    \u001b[32mâ”‚\u001b[0m\n",
              "\u001b[32mâ”‚\u001b[0m                                                                                                                 \u001b[32mâ”‚\u001b[0m\n",
              "\u001b[32mâ”‚\u001b[0m If you'd like to book an appointment with a mental health specialist or a general practitioner, let me know,    \u001b[32mâ”‚\u001b[0m\n",
              "\u001b[32mâ”‚\u001b[0m and I can assist with recommendations!                                                                          \u001b[32mâ”‚\u001b[0m\n",
              "\u001b[32mâ•°â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â•¯\u001b[0m\n"
            ],
            "text/html": [
              "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #008000; text-decoration-color: #008000\">â•­â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€ ðŸ¤– Assistant â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â•®</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span> ### Detailed Information on Panic Attacks                                                                       <span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>                                                                                                                 <span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span> **Overview**                                                                                                    <span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span> Panic attacks are sudden episodes of intense fear or anxiety that come on quickly, often without any clear      <span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span> reason. They can be extremely distressing and may lead individuals to believe they are experiencing a           <span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span> life-threatening emergency.                                                                                     <span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>                                                                                                                 <span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span> **Symptoms of Panic Attacks**                                                                                   <span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span> Common symptoms include:                                                                                        <span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span> - Racing heartbeat                                                                                              <span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span> - Shortness of breath                                                                                           <span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span> - Chest pain or discomfort                                                                                      <span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span> - Trembling or shaking                                                                                          <span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span> - Feelings of choking                                                                                           <span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span> - Sweating                                                                                                      <span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span> - Nausea or abdominal distress                                                                                  <span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span> - Dizziness, lightheadedness, or feeling faint                                                                  <span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span> - Numbness or tingling sensations                                                                               <span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span> - Feeling of unreality or detachment                                                                            <span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span> - Fear of losing control or \"going crazy\"                                                                       <span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span> - Fear of dying                                                                                                 <span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>                                                                                                                 <span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span> Most panic attacks last between 5 and 20 minutes, but some may continue for an hour or more.                    <span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>                                                                                                                 <span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span> **When to Seek Help**                                                                                           <span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span> If you experience recurrent and unexpected panic attacks along with a month (or more) of persistent concern     <span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span> about having another attack, itâ€™s advisable to contact a healthcare professional. A general practitioner (GP)   <span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span> can conduct a thorough assessment to rule out other health conditions and provide a diagnosis.                  <span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>                                                                                                                 <span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span> ### Treatment Options                                                                                           <span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span> 1. **Psychotherapy**                                                                                            <span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>    - **Cognitive Behavioral Therapy (CBT)**: This is the most common type of psychotherapy used for panic       <span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span> disorder. CBT helps individuals understand and change their thoughts and behaviors that contribute to panic     <span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span> attacks.                                                                                                        <span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>    - **Exposure Therapy**: Involves gradual exposure to the situations that trigger panic attacks.              <span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>                                                                                                                 <span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span> 2. **Medications**                                                                                              <span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>    - **Selective Serotonin Reuptake Inhibitors (SSRIs)**: Such as fluoxetine (Prozac), sertraline (Zoloft), and <span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span> paroxetine (Paxil). SSRIs are often the first-line treatment.                                                   <span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>    - **Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs)**: Like venlafaxine (Effexor XR).               <span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>    - **Benzodiazepines**: These can provide rapid relief but are typically not recommended for long-term use    <span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span> due to the risk of dependence.                                                                                  <span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>                                                                                                                 <span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span> 3. **Lifestyle Changes**                                                                                        <span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>    - **Regular Physical Activity**: Exercise can help reduce anxiety and improve overall mental health.         <span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>    - **Avoiding Triggers**: This includes caffeine, alcohol, and recreational drugs that may worsen symptoms.   <span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>    - **Breathing and Relaxation Techniques**: Such as yoga, mindfulness meditation, and deep breathing          <span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span> exercises.                                                                                                      <span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>                                                                                                                 <span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span> 4. **Self-Help Strategies**                                                                                     <span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>    - **Stay Calm During an Attack**: Remind yourself that panic attacks are not life-threatening, practice slow <span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span> breathing, and focus on your surroundings.                                                                      <span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>    - **Prepare for Attacks**: Learn and practice coping strategies in environments where attacks may occur or   <span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span> when you begin to feel anxious.                                                                                 <span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>                                                                                                                 <span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span> ### Support Resources                                                                                           <span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span> - Joining support groups can be beneficial for individuals dealing with panic attacks or panic disorder.        <span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span> Connecting with others can provide additional strategies and emotional support.                                 <span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span> - Many organizations, like **Anxiety UK** and **Mind**, offer resources and support specific to anxiety and     <span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span> panic disorders.                                                                                                <span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>                                                                                                                 <span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span> ### Recommended Action                                                                                          <span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span> It's highly advisable to consult a healthcare provider if you're experiencing panic attacks. They can provide a <span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span> diagnosis and work with you to develop a treatment plan that suits your needs.                                  <span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>                                                                                                                 <span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span> ### Helpful Links                                                                                               <span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span> - [NHS - Panic Disorder](https://www.nhs.uk/mental-health/conditions/panic-disorder/)                           <span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span> - [Mayo Clinic - Panic Attacks and Panic                                                                        <span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span> Disorder](https://www.mayoclinic.org/diseases-conditions/panic-attacks/diagnosis-treatment/drc-20376027)        <span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span> - [American Academy of Family                                                                                   <span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span> Physicians](https://www.aafp.org/pubs/afp/issues/2022/0800/generalized-anxiety-disorder-panic-disorder.html)    <span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>                                                                                                                 <span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span> If you'd like to book an appointment with a mental health specialist or a general practitioner, let me know,    <span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span> and I can assist with recommendations!                                                                          <span style=\"color: #008000; text-decoration-color: #008000\">â”‚</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">â•°â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â•¯</span>\n",
              "</pre>\n"
            ]
          },
          "metadata": {}
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "\n",
            "\n",
            "Final Response:\n",
            "\n"
          ]
        },
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<IPython.core.display.Markdown object>"
            ],
            "text/markdown": "### Detailed Information on Panic Attacks\n\n**Overview**\nPanic attacks are sudden episodes of intense fear or anxiety that come on quickly, often without any clear reason. They can be extremely distressing and may lead individuals to believe they are experiencing a life-threatening emergency.\n\n**Symptoms of Panic Attacks**\nCommon symptoms include:\n- Racing heartbeat\n- Shortness of breath\n- Chest pain or discomfort\n- Trembling or shaking\n- Feelings of choking\n- Sweating\n- Nausea or abdominal distress\n- Dizziness, lightheadedness, or feeling faint\n- Numbness or tingling sensations\n- Feeling of unreality or detachment\n- Fear of losing control or \"going crazy\"\n- Fear of dying\n\nMost panic attacks last between 5 and 20 minutes, but some may continue for an hour or more. \n\n**When to Seek Help**\nIf you experience recurrent and unexpected panic attacks along with a month (or more) of persistent concern about having another attack, itâ€™s advisable to contact a healthcare professional. A general practitioner (GP) can conduct a thorough assessment to rule out other health conditions and provide a diagnosis.\n\n### Treatment Options\n1. **Psychotherapy**\n   - **Cognitive Behavioral Therapy (CBT)**: This is the most common type of psychotherapy used for panic disorder. CBT helps individuals understand and change their thoughts and behaviors that contribute to panic attacks.\n   - **Exposure Therapy**: Involves gradual exposure to the situations that trigger panic attacks.\n\n2. **Medications**\n   - **Selective Serotonin Reuptake Inhibitors (SSRIs)**: Such as fluoxetine (Prozac), sertraline (Zoloft), and paroxetine (Paxil). SSRIs are often the first-line treatment.\n   - **Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs)**: Like venlafaxine (Effexor XR).\n   - **Benzodiazepines**: These can provide rapid relief but are typically not recommended for long-term use due to the risk of dependence.\n\n3. **Lifestyle Changes**\n   - **Regular Physical Activity**: Exercise can help reduce anxiety and improve overall mental health.\n   - **Avoiding Triggers**: This includes caffeine, alcohol, and recreational drugs that may worsen symptoms.\n   - **Breathing and Relaxation Techniques**: Such as yoga, mindfulness meditation, and deep breathing exercises.\n\n4. **Self-Help Strategies**\n   - **Stay Calm During an Attack**: Remind yourself that panic attacks are not life-threatening, practice slow breathing, and focus on your surroundings.\n   - **Prepare for Attacks**: Learn and practice coping strategies in environments where attacks may occur or when you begin to feel anxious.\n\n### Support Resources\n- Joining support groups can be beneficial for individuals dealing with panic attacks or panic disorder. Connecting with others can provide additional strategies and emotional support.\n- Many organizations, like **Anxiety UK** and **Mind**, offer resources and support specific to anxiety and panic disorders.\n\n### Recommended Action\nIt's highly advisable to consult a healthcare provider if you're experiencing panic attacks. They can provide a diagnosis and work with you to develop a treatment plan that suits your needs.\n\n### Helpful Links\n- [NHS - Panic Disorder](https://www.nhs.uk/mental-health/conditions/panic-disorder/)\n- [Mayo Clinic - Panic Attacks and Panic Disorder](https://www.mayoclinic.org/diseases-conditions/panic-attacks/diagnosis-treatment/drc-20376027)\n- [American Academy of Family Physicians](https://www.aafp.org/pubs/afp/issues/2022/0800/generalized-anxiety-disorder-panic-disorder.html)\n\nIf you'd like to book an appointment with a mental health specialist or a general practitioner, let me know, and I can assist with recommendations!"
          },
          "metadata": {}
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "# Example usage without printing detailed log messages\n",
        "query = \"I am having panic attacks, please recommend a right doctor\"\n",
        "result = call_agent(healthbuddy_agent, query, verbose=False)"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 215
        },
        "id": "2BkQdNUTfw0H",
        "outputId": "3cded86f-4247-45f5-aa74-77981c067b67"
      },
      "id": "2BkQdNUTfw0H",
      "execution_count": null,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "\n",
            "\n",
            "Final Response:\n",
            "\n"
          ]
        },
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<IPython.core.display.Markdown object>"
            ],
            "text/markdown": "I recommend you see **Dr. Matt Murdock**, a specialist in Psychiatry focused on mental health. Here are the details:\n\n- **Specialization**: Psychiatry (Mental Health)\n- **Available Timings**: 4:00 PM - 7:00 PM\n- **Location**: Mind Care Center\n- **Contact**: [matt.murdock@mindcare.com](mailto:matt.murdock@mindcare.com)\n\nFeel free to reach out to him for an appointment regarding your panic attacks."
          },
          "metadata": {}
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "queries = [\n",
        "    'Patient 001: Reported panic attacks - please assign doctor',\n",
        "    'Patient 003: Diabetes checkup - please assign doctor',\n",
        "    'Patien 004: Has the flu - please assign doctor'\n",
        "]"
      ],
      "metadata": {
        "id": "qgEtBwAmsCAh"
      },
      "id": "qgEtBwAmsCAh",
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "results = [call_agent(healthbuddy_agent, query, verbose=False) for query in queries]"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 720
        },
        "id": "4ekAJQZlsSme",
        "outputId": "4150e6ee-0208-4f70-8242-416fb2276d52"
      },
      "id": "4ekAJQZlsSme",
      "execution_count": null,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "\n",
            "\n",
            "Final Response:\n",
            "\n"
          ]
        },
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<IPython.core.display.Markdown object>"
            ],
            "text/markdown": "I recommend booking an appointment with the following specialist for panic attacks:\n\n### Dr. Matt Murdock\n- **Specialization:** Psychiatry (Mental Health)\n- **Available Timings:** 4:00 PM - 7:00 PM\n- **Location:** Mind Care Center\n- **Contact:** [matt.murdock@mindcare.com](mailto:matt.murdock@mindcare.com)\n\nPlease reach out to Dr. Murdock via email to book an appointment."
          },
          "metadata": {}
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "\n",
            "\n",
            "Final Response:\n",
            "\n"
          ]
        },
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<IPython.core.display.Markdown object>"
            ],
            "text/markdown": "I recommend the following doctor for your diabetes checkup:\n\n### Dr. Janet Dyne\n- **Specialization:** Endocrinology (Diabetes Care)\n- **Available Timings:** 10:00 AM - 1:00 PM\n- **Location:** City Health Clinic\n- **Contact Email:** [janet.dyne@healthclinic.com](mailto:janet.dyne@healthclinic.com)\n\nPlease feel free to reach out via email to book an appointment."
          },
          "metadata": {}
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "\n",
            "\n",
            "Final Response:\n",
            "\n"
          ]
        },
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<IPython.core.display.Markdown object>"
            ],
            "text/markdown": "I recommend the following doctor for your flu symptoms:\n\n### Dr. Dinah Lance\n- **Specialization:** General Physician\n- **Available Timings:** 9:00 AM - 12:00 PM\n- **Location:** Downtown Medical Center\n- **Contact:** [dinah.lance@downtownmed.com](mailto:dinah.lance@downtownmed.com)\n\nPlease book an appointment via the provided email."
          },
          "metadata": {}
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "import pandas as pd\n",
        "pd.set_option('display.max_colwidth', None)\n",
        "res_df = pd.DataFrame({'query': queries,\n",
        "                       'response': [item[-1].content for item in results]})\n",
        "res_df"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 247
        },
        "id": "Pxy_hmFgsY4r",
        "outputId": "9f2c1f8f-0e61-4881-a1c0-937a3e6f6302"
      },
      "id": "Pxy_hmFgsY4r",
      "execution_count": null,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "                                                        query  \\\n",
              "0  Patient 001: Reported panic attacks - please assign doctor   \n",
              "1        Patient 003: Diabetes checkup - please assign doctor   \n",
              "2              Patien 004: Has the flu - please assign doctor   \n",
              "\n",
              "                                                                                                                                                                                                                                                                                                                                                                                         response  \n",
              "0  I recommend booking an appointment with the following specialist for panic attacks:\\n\\n### Dr. Matt Murdock\\n- **Specialization:** Psychiatry (Mental Health)\\n- **Available Timings:** 4:00 PM - 7:00 PM\\n- **Location:** Mind Care Center\\n- **Contact:** [matt.murdock@mindcare.com](mailto:matt.murdock@mindcare.com)\\n\\nPlease reach out to Dr. Murdock via email to book an appointment.  \n",
              "1              I recommend the following doctor for your diabetes checkup:\\n\\n### Dr. Janet Dyne\\n- **Specialization:** Endocrinology (Diabetes Care)\\n- **Available Timings:** 10:00 AM - 1:00 PM\\n- **Location:** City Health Clinic\\n- **Contact Email:** [janet.dyne@healthclinic.com](mailto:janet.dyne@healthclinic.com)\\n\\nPlease feel free to reach out via email to book an appointment.  \n",
              "2                                           I recommend the following doctor for your flu symptoms:\\n\\n### Dr. Dinah Lance\\n- **Specialization:** General Physician\\n- **Available Timings:** 9:00 AM - 12:00 PM\\n- **Location:** Downtown Medical Center\\n- **Contact:** [dinah.lance@downtownmed.com](mailto:dinah.lance@downtownmed.com)\\n\\nPlease book an appointment via the provided email.  "
            ],
            "text/html": [
              "\n",
              "  <div id=\"df-c6dc5a6a-902a-40a6-bf26-cb8135065f61\" class=\"colab-df-container\">\n",
              "    <div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>query</th>\n",
              "      <th>response</th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>0</th>\n",
              "      <td>Patient 001: Reported panic attacks - please assign doctor</td>\n",
              "      <td>I recommend booking an appointment with the following specialist for panic attacks:\\n\\n### Dr. Matt Murdock\\n- **Specialization:** Psychiatry (Mental Health)\\n- **Available Timings:** 4:00 PM - 7:00 PM\\n- **Location:** Mind Care Center\\n- **Contact:** [matt.murdock@mindcare.com](mailto:matt.murdock@mindcare.com)\\n\\nPlease reach out to Dr. Murdock via email to book an appointment.</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1</th>\n",
              "      <td>Patient 003: Diabetes checkup - please assign doctor</td>\n",
              "      <td>I recommend the following doctor for your diabetes checkup:\\n\\n### Dr. Janet Dyne\\n- **Specialization:** Endocrinology (Diabetes Care)\\n- **Available Timings:** 10:00 AM - 1:00 PM\\n- **Location:** City Health Clinic\\n- **Contact Email:** [janet.dyne@healthclinic.com](mailto:janet.dyne@healthclinic.com)\\n\\nPlease feel free to reach out via email to book an appointment.</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>2</th>\n",
              "      <td>Patien 004: Has the flu - please assign doctor</td>\n",
              "      <td>I recommend the following doctor for your flu symptoms:\\n\\n### Dr. Dinah Lance\\n- **Specialization:** General Physician\\n- **Available Timings:** 9:00 AM - 12:00 PM\\n- **Location:** Downtown Medical Center\\n- **Contact:** [dinah.lance@downtownmed.com](mailto:dinah.lance@downtownmed.com)\\n\\nPlease book an appointment via the provided email.</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "</div>\n",
              "    <div class=\"colab-df-buttons\">\n",
              "\n",
              "  <div class=\"colab-df-container\">\n",
              "    <button class=\"colab-df-convert\" onclick=\"convertToInteractive('df-c6dc5a6a-902a-40a6-bf26-cb8135065f61')\"\n",
              "            title=\"Convert this dataframe to an interactive table.\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "  <svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\" viewBox=\"0 -960 960 960\">\n",
              "    <path d=\"M120-120v-720h720v720H120Zm60-500h600v-160H180v160Zm220 220h160v-160H400v160Zm0 220h160v-160H400v160ZM180-400h160v-160H180v160Zm440 0h160v-160H620v160ZM180-180h160v-160H180v160Zm440 0h160v-160H620v160Z\"/>\n",
              "  </svg>\n",
              "    </button>\n",
              "\n",
              "  <style>\n",
              "    .colab-df-container {\n",
              "      display:flex;\n",
              "      gap: 12px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert {\n",
              "      background-color: #E8F0FE;\n",
              "      border: none;\n",
              "      border-radius: 50%;\n",
              "      cursor: pointer;\n",
              "      display: none;\n",
              "      fill: #1967D2;\n",
              "      height: 32px;\n",
              "      padding: 0 0 0 0;\n",
              "      width: 32px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert:hover {\n",
              "      background-color: #E2EBFA;\n",
              "      box-shadow: 0px 1px 2px rgba(60, 64, 67, 0.3), 0px 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "      fill: #174EA6;\n",
              "    }\n",
              "\n",
              "    .colab-df-buttons div {\n",
              "      margin-bottom: 4px;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert {\n",
              "      background-color: #3B4455;\n",
              "      fill: #D2E3FC;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert:hover {\n",
              "      background-color: #434B5C;\n",
              "      box-shadow: 0px 1px 3px 1px rgba(0, 0, 0, 0.15);\n",
              "      filter: drop-shadow(0px 1px 2px rgba(0, 0, 0, 0.3));\n",
              "      fill: #FFFFFF;\n",
              "    }\n",
              "  </style>\n",
              "\n",
              "    <script>\n",
              "      const buttonEl =\n",
              "        document.querySelector('#df-c6dc5a6a-902a-40a6-bf26-cb8135065f61 button.colab-df-convert');\n",
              "      buttonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "\n",
              "      async function convertToInteractive(key) {\n",
              "        const element = document.querySelector('#df-c6dc5a6a-902a-40a6-bf26-cb8135065f61');\n",
              "        const dataTable =\n",
              "          await google.colab.kernel.invokeFunction('convertToInteractive',\n",
              "                                                    [key], {});\n",
              "        if (!dataTable) return;\n",
              "\n",
              "        const docLinkHtml = 'Like what you see? Visit the ' +\n",
              "          '<a target=\"_blank\" href=https://colab.research.google.com/notebooks/data_table.ipynb>data table notebook</a>'\n",
              "          + ' to learn more about interactive tables.';\n",
              "        element.innerHTML = '';\n",
              "        dataTable['output_type'] = 'display_data';\n",
              "        await google.colab.output.renderOutput(dataTable, element);\n",
              "        const docLink = document.createElement('div');\n",
              "        docLink.innerHTML = docLinkHtml;\n",
              "        element.appendChild(docLink);\n",
              "      }\n",
              "    </script>\n",
              "  </div>\n",
              "\n",
              "\n",
              "    <div id=\"df-93bbf753-f608-4e51-86a9-5dc5040a6ded\">\n",
              "      <button class=\"colab-df-quickchart\" onclick=\"quickchart('df-93bbf753-f608-4e51-86a9-5dc5040a6ded')\"\n",
              "                title=\"Suggest charts\"\n",
              "                style=\"display:none;\">\n",
              "\n",
              "<svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\"viewBox=\"0 0 24 24\"\n",
              "     width=\"24px\">\n",
              "    <g>\n",
              "        <path d=\"M19 3H5c-1.1 0-2 .9-2 2v14c0 1.1.9 2 2 2h14c1.1 0 2-.9 2-2V5c0-1.1-.9-2-2-2zM9 17H7v-7h2v7zm4 0h-2V7h2v10zm4 0h-2v-4h2v4z\"/>\n",
              "    </g>\n",
              "</svg>\n",
              "      </button>\n",
              "\n",
              "<style>\n",
              "  .colab-df-quickchart {\n",
              "      --bg-color: #E8F0FE;\n",
              "      --fill-color: #1967D2;\n",
              "      --hover-bg-color: #E2EBFA;\n",
              "      --hover-fill-color: #174EA6;\n",
              "      --disabled-fill-color: #AAA;\n",
              "      --disabled-bg-color: #DDD;\n",
              "  }\n",
              "\n",
              "  [theme=dark] .colab-df-quickchart {\n",
              "      --bg-color: #3B4455;\n",
              "      --fill-color: #D2E3FC;\n",
              "      --hover-bg-color: #434B5C;\n",
              "      --hover-fill-color: #FFFFFF;\n",
              "      --disabled-bg-color: #3B4455;\n",
              "      --disabled-fill-color: #666;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart {\n",
              "    background-color: var(--bg-color);\n",
              "    border: none;\n",
              "    border-radius: 50%;\n",
              "    cursor: pointer;\n",
              "    display: none;\n",
              "    fill: var(--fill-color);\n",
              "    height: 32px;\n",
              "    padding: 0;\n",
              "    width: 32px;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart:hover {\n",
              "    background-color: var(--hover-bg-color);\n",
              "    box-shadow: 0 1px 2px rgba(60, 64, 67, 0.3), 0 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "    fill: var(--button-hover-fill-color);\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart-complete:disabled,\n",
              "  .colab-df-quickchart-complete:disabled:hover {\n",
              "    background-color: var(--disabled-bg-color);\n",
              "    fill: var(--disabled-fill-color);\n",
              "    box-shadow: none;\n",
              "  }\n",
              "\n",
              "  .colab-df-spinner {\n",
              "    border: 2px solid var(--fill-color);\n",
              "    border-color: transparent;\n",
              "    border-bottom-color: var(--fill-color);\n",
              "    animation:\n",
              "      spin 1s steps(1) infinite;\n",
              "  }\n",
              "\n",
              "  @keyframes spin {\n",
              "    0% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "      border-left-color: var(--fill-color);\n",
              "    }\n",
              "    20% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    30% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    40% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    60% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    80% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "    90% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "  }\n",
              "</style>\n",
              "\n",
              "      <script>\n",
              "        async function quickchart(key) {\n",
              "          const quickchartButtonEl =\n",
              "            document.querySelector('#' + key + ' button');\n",
              "          quickchartButtonEl.disabled = true;  // To prevent multiple clicks.\n",
              "          quickchartButtonEl.classList.add('colab-df-spinner');\n",
              "          try {\n",
              "            const charts = await google.colab.kernel.invokeFunction(\n",
              "                'suggestCharts', [key], {});\n",
              "          } catch (error) {\n",
              "            console.error('Error during call to suggestCharts:', error);\n",
              "          }\n",
              "          quickchartButtonEl.classList.remove('colab-df-spinner');\n",
              "          quickchartButtonEl.classList.add('colab-df-quickchart-complete');\n",
              "        }\n",
              "        (() => {\n",
              "          let quickchartButtonEl =\n",
              "            document.querySelector('#df-93bbf753-f608-4e51-86a9-5dc5040a6ded button');\n",
              "          quickchartButtonEl.style.display =\n",
              "            google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "        })();\n",
              "      </script>\n",
              "    </div>\n",
              "\n",
              "  <div id=\"id_112dc778-6c27-48a6-aef7-06c6e794d947\">\n",
              "    <style>\n",
              "      .colab-df-generate {\n",
              "        background-color: #E8F0FE;\n",
              "        border: none;\n",
              "        border-radius: 50%;\n",
              "        cursor: pointer;\n",
              "        display: none;\n",
              "        fill: #1967D2;\n",
              "        height: 32px;\n",
              "        padding: 0 0 0 0;\n",
              "        width: 32px;\n",
              "      }\n",
              "\n",
              "      .colab-df-generate:hover {\n",
              "        background-color: #E2EBFA;\n",
              "        box-shadow: 0px 1px 2px rgba(60, 64, 67, 0.3), 0px 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "        fill: #174EA6;\n",
              "      }\n",
              "\n",
              "      [theme=dark] .colab-df-generate {\n",
              "        background-color: #3B4455;\n",
              "        fill: #D2E3FC;\n",
              "      }\n",
              "\n",
              "      [theme=dark] .colab-df-generate:hover {\n",
              "        background-color: #434B5C;\n",
              "        box-shadow: 0px 1px 3px 1px rgba(0, 0, 0, 0.15);\n",
              "        filter: drop-shadow(0px 1px 2px rgba(0, 0, 0, 0.3));\n",
              "        fill: #FFFFFF;\n",
              "      }\n",
              "    </style>\n",
              "    <button class=\"colab-df-generate\" onclick=\"generateWithVariable('res_df')\"\n",
              "            title=\"Generate code using this dataframe.\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "  <svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\"viewBox=\"0 0 24 24\"\n",
              "       width=\"24px\">\n",
              "    <path d=\"M7,19H8.4L18.45,9,17,7.55,7,17.6ZM5,21V16.75L18.45,3.32a2,2,0,0,1,2.83,0l1.4,1.43a1.91,1.91,0,0,1,.58,1.4,1.91,1.91,0,0,1-.58,1.4L9.25,21ZM18.45,9,17,7.55Zm-12,3A5.31,5.31,0,0,0,4.9,8.1,5.31,5.31,0,0,0,1,6.5,5.31,5.31,0,0,0,4.9,4.9,5.31,5.31,0,0,0,6.5,1,5.31,5.31,0,0,0,8.1,4.9,5.31,5.31,0,0,0,12,6.5,5.46,5.46,0,0,0,6.5,12Z\"/>\n",
              "  </svg>\n",
              "    </button>\n",
              "    <script>\n",
              "      (() => {\n",
              "      const buttonEl =\n",
              "        document.querySelector('#id_112dc778-6c27-48a6-aef7-06c6e794d947 button.colab-df-generate');\n",
              "      buttonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "\n",
              "      buttonEl.onclick = () => {\n",
              "        google.colab.notebook.generateWithVariable('res_df');\n",
              "      }\n",
              "      })();\n",
              "    </script>\n",
              "  </div>\n",
              "\n",
              "    </div>\n",
              "  </div>\n"
            ],
            "application/vnd.google.colaboratory.intrinsic+json": {
              "type": "dataframe",
              "variable_name": "res_df",
              "summary": "{\n  \"name\": \"res_df\",\n  \"rows\": 3,\n  \"fields\": [\n    {\n      \"column\": \"query\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 3,\n        \"samples\": [\n          \"Patient 001: Reported panic attacks - please assign doctor\",\n          \"Patient 003: Diabetes checkup - please assign doctor\",\n          \"Patien 004: Has the flu - please assign doctor\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"response\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 3,\n        \"samples\": [\n          \"I recommend booking an appointment with the following specialist for panic attacks:\\n\\n### Dr. Matt Murdock\\n- **Specialization:** Psychiatry (Mental Health)\\n- **Available Timings:** 4:00 PM - 7:00 PM\\n- **Location:** Mind Care Center\\n- **Contact:** [matt.murdock@mindcare.com](mailto:matt.murdock@mindcare.com)\\n\\nPlease reach out to Dr. Murdock via email to book an appointment.\",\n          \"I recommend the following doctor for your diabetes checkup:\\n\\n### Dr. Janet Dyne\\n- **Specialization:** Endocrinology (Diabetes Care)\\n- **Available Timings:** 10:00 AM - 1:00 PM\\n- **Location:** City Health Clinic\\n- **Contact Email:** [janet.dyne@healthclinic.com](mailto:janet.dyne@healthclinic.com)\\n\\nPlease feel free to reach out via email to book an appointment.\",\n          \"I recommend the following doctor for your flu symptoms:\\n\\n### Dr. Dinah Lance\\n- **Specialization:** General Physician\\n- **Available Timings:** 9:00 AM - 12:00 PM\\n- **Location:** Downtown Medical Center\\n- **Contact:** [dinah.lance@downtownmed.com](mailto:dinah.lance@downtownmed.com)\\n\\nPlease book an appointment via the provided email.\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    }\n  ]\n}"
            }
          },
          "metadata": {},
          "execution_count": 25
        }
      ]
    }
  ],
  "metadata": {
    "colab": {
      "provenance": []
    },
    "language_info": {
      "name": "python"
    },
    "kernelspec": {
      "name": "python3",
      "display_name": "Python 3"
    }
  },
  "nbformat": 4,
  "nbformat_minor": 5
}